<SEC-DOCUMENT>0001411690-23-000024.txt : 20230509
<SEC-HEADER>0001411690-23-000024.hdr.sgml : 20230509
<ACCEPTANCE-DATETIME>20230509160822
ACCESSION NUMBER:		0001411690-23-000024
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		70
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230509
DATE AS OF CHANGE:		20230509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bionano Genomics, Inc.
		CENTRAL INDEX KEY:			0001411690
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				261756290
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38613
		FILM NUMBER:		23902003

	BUSINESS ADDRESS:	
		STREET 1:		9540 TOWNE CENTRE DRIVE
		STREET 2:		SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(858) 888-7600

	MAIL ADDRESS:	
		STREET 1:		9540 TOWNE CENTRE DRIVE
		STREET 2:		SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bionano Genomics, Inc
		DATE OF NAME CHANGE:	20190308

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioNano Genomics, Inc
		DATE OF NAME CHANGE:	20120703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioNanomatrix Inc
		DATE OF NAME CHANGE:	20070906
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>bngo-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:89c9e3f0-6ddf-4644-8fed-0d858e04a501,g:e99df848-92d3-4a5f-ae11-c380aa17bbd2,d:561259e69fbb4552820b7ec56e5dea3a--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:bngo="http://bionanogenomics.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bngo-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80L2ZyYWc6NjRmM2QxZDE4NWRiNDA0ZDk0NTdiNDk4MDA4ODU2MDIvdGFibGU6ZTQzOWI4ZDNhNmEzNGUxOGJjOGIyMjlkMjY1Mzc4MzIvdGFibGVyYW5nZTplNDM5YjhkM2E2YTM0ZTE4YmM4YjIyOWQyNjUzNzgzMl8xLTEtMS0xLTEwNDExOQ_61000f64-2cb4-4c9b-bbcb-9d97cf4daa12">false</ix:nonNumeric><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80L2ZyYWc6NjRmM2QxZDE4NWRiNDA0ZDk0NTdiNDk4MDA4ODU2MDIvdGFibGU6ZTQzOWI4ZDNhNmEzNGUxOGJjOGIyMjlkMjY1Mzc4MzIvdGFibGVyYW5nZTplNDM5YjhkM2E2YTM0ZTE4YmM4YjIyOWQyNjUzNzgzMl8yLTEtMS0xLTEwNDExOQ_fa704205-dfcb-4d11-9cee-5b3543dd7a0f">2023</ix:nonNumeric><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80L2ZyYWc6NjRmM2QxZDE4NWRiNDA0ZDk0NTdiNDk4MDA4ODU2MDIvdGFibGU6ZTQzOWI4ZDNhNmEzNGUxOGJjOGIyMjlkMjY1Mzc4MzIvdGFibGVyYW5nZTplNDM5YjhkM2E2YTM0ZTE4YmM4YjIyOWQyNjUzNzgzMl8zLTEtMS0xLTEwNDExOQ_491aa12e-bd5b-469f-b1f7-1208b8982437">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80L2ZyYWc6NjRmM2QxZDE4NWRiNDA0ZDk0NTdiNDk4MDA4ODU2MDIvdGFibGU6ZTQzOWI4ZDNhNmEzNGUxOGJjOGIyMjlkMjY1Mzc4MzIvdGFibGVyYW5nZTplNDM5YjhkM2E2YTM0ZTE4YmM4YjIyOWQyNjUzNzgzMl80LTEtMS0xLTEwNDExOQ_056fdb3b-b55b-4b44-a5e4-8a4fa731ea50">0001411690</ix:nonNumeric><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80L2ZyYWc6NjRmM2QxZDE4NWRiNDA0ZDk0NTdiNDk4MDA4ODU2MDIvdGFibGU6ZTQzOWI4ZDNhNmEzNGUxOGJjOGIyMjlkMjY1Mzc4MzIvdGFibGVyYW5nZTplNDM5YjhkM2E2YTM0ZTE4YmM4YjIyOWQyNjUzNzgzMl81LTEtMS0xLTEwNDExOQ_9ff4e03a-b6e9-4b5a-8e0d-01b094af59d9">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i303c93e0678640749a33b09eedfdd18e_I20230331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80My9mcmFnOjEzMThiNmNiNTI0ODQ4NzNhMmNhNjVmOWY5YmQ2NzgyL3RhYmxlOjE2MmZhYjljNjNhNDRlMjQ4YTM3ZWZjY2VkNjI4ZDYxL3RhYmxlcmFuZ2U6MTYyZmFiOWM2M2E0NGUyNDhhMzdlZmNjZWQ2MjhkNjFfMS0xLTEtMS0xMDQxMTk_fd29a88b-a70f-4e22-b59b-5448178ece6f">9</ix:nonNumeric><ix:nonNumeric contextRef="i91fc38e2fd89410d85c4aaa28c03aa5a_I20230331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80My9mcmFnOjEzMThiNmNiNTI0ODQ4NzNhMmNhNjVmOWY5YmQ2NzgyL3RhYmxlOjE2MmZhYjljNjNhNDRlMjQ4YTM3ZWZjY2VkNjI4ZDYxL3RhYmxlcmFuZ2U6MTYyZmFiOWM2M2E0NGUyNDhhMzdlZmNjZWQ2MjhkNjFfMi0xLTEtMS0xMDQxMTk_88f82a8a-4079-4b02-abee-ff6c0ae4b97d">1</ix:nonNumeric><ix:nonNumeric contextRef="i678356c830584df394c07359661df8fe_I20230331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80My9mcmFnOjEzMThiNmNiNTI0ODQ4NzNhMmNhNjVmOWY5YmQ2NzgyL3RhYmxlOjE2MmZhYjljNjNhNDRlMjQ4YTM3ZWZjY2VkNjI4ZDYxL3RhYmxlcmFuZ2U6MTYyZmFiOWM2M2E0NGUyNDhhMzdlZmNjZWQ2MjhkNjFfMy0xLTEtMS0xMDgxNTU_b7b9adb6-1813-4d23-8ddb-4d1bb1f4cdf2">1</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i6dc9970304de496b885ae5a58e7fedba_D20211001-20211031" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81NS9mcmFnOjk4ODM0MzdlOGU4NjRjMTBhOTA4YzdlMTg2ZWZkMDNhL3RhYmxlOjQxYmFmMDc2NzYwNDQ1NGRiOTA4NWE3ZGU4YzVhNmFmL3RhYmxlcmFuZ2U6NDFiYWYwNzY3NjA0NDU0ZGI5MDg1YTdkZThjNWE2YWZfMC0xLTEtMS0xMDQxMTk_20fb25ee-20e7-4924-b66c-7321167e7608">0.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i210ababbb09845abadbcacdcd33eb108_D20211001-20211031" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81NS9mcmFnOjk4ODM0MzdlOGU4NjRjMTBhOTA4YzdlMTg2ZWZkMDNhL3RhYmxlOjQxYmFmMDc2NzYwNDQ1NGRiOTA4NWE3ZGU4YzVhNmFmL3RhYmxlcmFuZ2U6NDFiYWYwNzY3NjA0NDU0ZGI5MDg1YTdkZThjNWE2YWZfMS0xLTEtMS0xMDQxMTk_f3e615dc-e222-41d2-a3a0-2552088587c9">0.08</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="if1b97395b892463d82ebcc58b1fd3f08_I20230413" decimals="2" name="bngo:StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81NS9mcmFnOjk4ODM0MzdlOGU4NjRjMTBhOTA4YzdlMTg2ZWZkMDNhL3RhYmxlOjQxYmFmMDc2NzYwNDQ1NGRiOTA4NWE3ZGU4YzVhNmFmL3RhYmxlcmFuZ2U6NDFiYWYwNzY3NjA0NDU0ZGI5MDg1YTdkZThjNWE2YWZfMi0xLTEtMS0xMTQ5NDY_bb5867f5-8ee8-498b-b493-3e0ce98e0979">0.33</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bngo-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib13a94b835db433b868b1047f2e0d08c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad7fb23a31ff4cebb8ed73e94c311b74_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dffd8e896cf4da18e2a7981e161bfa7_I20230504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i62aa37a9d1f149238d68dcecec48dda4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i2491644bc39e40a3a0147bbb28e81a57_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16a495a5dc5b4d72a5d69105c54ed1d5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i7ae84972110b4c82abdd96887a8dc98b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22c603917ec343e5b40cf1377f2dd0fa_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i103e1f66718e42e092ef57cf65cbad93_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1fe061275f84c0db4bc966cec7ea694_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifebd115420624a60b9827cd166e72988_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc1dfa094b4c4c1fa40f179234ec50e6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa3c9898447244ed80a321d3bb3f00b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cca8398bdff4ba383ffbba2ea3b7387_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d8e7646f2804373ac2db3a030f1359c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cfe18ad0d8e4978ada52e1560b4b9dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58b67d95244b409ab6ee9c70973a72be_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i081d4286b8024fc38cd6cc1cfb880bac_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib545fe18002040049f1dd40e745063cf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26505e829d91462f95377df48fcf6c59_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35bd51c6773a4f30bc0cda985ac95b56_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ba62f46aa8044098043951d2b4e437f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20e6f07f9ffb41f3b64c9ac35f75d302_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17b0d4ea6adf427eb9d4b02037d2964a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i955cc10e676a434da3908ec8ee79b5a0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e39a84040944ede8fdaa4d1b105ad7a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49cef66a2bf8465c9be9162628f1973b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39f18943e70e4009b385fa4e3abd198f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5409b1552b72472894786a349c3cf6ab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i368dfe51ced845ce9ce881dbe02ac125_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b2f680c76ee497394f0b63f4a9b399a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4838c75f09847d6962eaee26a7817f1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85aa7ee73fd04055b335ec2d997a0f0c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b9c8029a5394f4bafac617b2deb2c22_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c6f1ced20ec4e9aa8a3fb4827f7be65_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib90ef8426ec84d859ee8b194da09c4eb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic370404fbb3041c6a839fd87ac238005_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i235c6220aed04a31be7cf68dde5f7075_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ee348f6918a4dccb9a11bb16deb4771_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80cbed6d5ffd48e39df9647e8b69fd38_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i990b58e8540b402f9deabf1b1e8d0d7a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5f34adecdf04ebca8394a17d3e26a73_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ea78ca938894da3a2c044b50e0ecd12_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fa1ec9e299d43dea83ee07700d9f2e8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4db80e7428124ae89fef6d38056d80eb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e41522832874c03827a502c55e81ea1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93dc12a23ca743058cc875c7385cba95_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2e2589f149c48c98dbde0d23aeb1c9c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:InstrumentRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09f8c8fdda344e15915c6c62c7945dcc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:InstrumentRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6b13878be8b45768ae8ee86b23ec8b8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:ConsumableRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d3a177eaaa94180a39abb73b6e894d5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:ConsumableRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5c588f3ec9a49a9926f153fcb7f5e22_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:SoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1dda61a7dbc48e3acfd918b47fcb93b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:SoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6669836447414cf385db5ed716981bad_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b1a8735b85a466297034ff9a73884a0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i6f04d40d0a8a454f84a321e4acea14d8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc3e1023716e476aab35caddbed89579_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6f8e39f135240fd97ecb419976b9597_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie92600da576c4047864e9f7117cc5fdf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72bd82e51a92475595d3e02336fdfb2d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf59dab4a829447b87dd7cfb6e935afc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i917de2a823d54fc7a1e5c49a7ec6d043_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e339b6ff4f0444a9fc421813ed7f9fc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if817cc0631b9461ca84a6ce880217661_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16ed69d918584dbcb3ba99cd2e78d70d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec1a90f2c7e6457d9c6916e2e00a8d96_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4e04fca88824c018823bdc8633103aa_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b3236b899344cfc8b2fdf441232a276_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida637f06483b4c35bd6bc6a61abb2280_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i303c93e0678640749a33b09eedfdd18e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91fc38e2fd89410d85c4aaa28c03aa5a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i678356c830584df394c07359661df8fe_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29d038c26e154c959a4f83462f9a3b3d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic21009a40b5d4f3a9d49db39e85d0352_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b57f1747a864d48806216f6ebcb9b52_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id18ec7102f5243eead2eb22c65c27ed0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d06ccbd81864c1aa7ab64abb42f4f5c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30a742016d854b90bc517ceec127c4da_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5a9db6b0ffb4fe28ef89805f31f26bc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafccbaea24c04903bdeb891f986857c7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25be08a217074beba4e4c3f2222e4263_D20210323-20210323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bngo:CowenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-23</xbrli:startDate><xbrli:endDate>2021-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97754e6d8ba6487d87fcb2566157286b_D20230309-20230309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bngo:CowenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93b42a0d7db1482cba91fd543f66a9ba_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99f3f173943c45748c287bda013eed0c_I20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4be8520461cc4836b2bf1279c0c49b2a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic493e64bbaa14b51affea368a758865b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bngo:CostOfProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80b89abf30d44e039ce4fc8aeb1da4ae_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bngo:CostOfProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29ed40c40dab442291465632e6882e02_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bngo:CostOfServiceAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i144c849f01554b1a993c3b250ed79d33_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bngo:CostOfServiceAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f330defb5aa4fb081aecf68faa28812_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94ccbf7f373d449baf5526bf6037b3f3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7a2e48e810643a8b0e555a9c8954d9f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f37993d3f264fb1b3d0691e711f9da5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45ddfb39b1e74f6dad0c0bf181cf9a21_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i649fe5ed0003466fbb184c5508561d25_I20221004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9253ac3721c14085873be006d0cf4172_D20221004-20221004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-04</xbrli:startDate><xbrli:endDate>2022-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9d74a66fe4c4a139d49dde0ca471851_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d6b4ade60694ff6bfb130ce265977e6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80c9f5e585bc49d69df5c0b0bc90a1dc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0787e57ce57b4647b096721e6444f9b9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bngo:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i230745a88815483fa50ae23b1a6526e9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bngo:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia333c3d4c489480f91a0918cb06c6e33_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bngo:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecac66c4d00049b992c7f860853fdc4b_D20230215-20230215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-15</xbrli:startDate><xbrli:endDate>2023-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb4acb3d6c734dba8bac4bebe9c2b85d_D20230215-20230215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-15</xbrli:startDate><xbrli:endDate>2023-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i759bd048bf3e4098b83b5604fbce9f26_D20230215-20230215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-15</xbrli:startDate><xbrli:endDate>2023-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22680561557b45ba98cf2f10a2456635_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38b1d6628a394f1fbbbfd993ec043869_I20230215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>bngo:installment</xbrli:measure></xbrli:unit><xbrli:context id="ib50b0f103ebb406f8f4f5c1eef93d1bd_D20230413-20230413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-13</xbrli:startDate><xbrli:endDate>2023-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6be39fe53974c5089ff9986b857d774_I20230413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffc1f718b13b4c9abe1418bc8c792699_I20230413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>bngo:vote</xbrli:measure></xbrli:unit><xbrli:context id="i6dc9970304de496b885ae5a58e7fedba_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i210ababbb09845abadbcacdcd33eb108_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1b97395b892463d82ebcc58b1fd3f08_I20230413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d2c0cf7229242a88304bb4f867c0c9d_D20221101-20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91fff28e789d4fdc80fbfa9100a620b7_I20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic97685b2136f4353b8df0de2a7e10ad3_I20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i295a9a13609e47d0bbdd3fe79bcb04e1_I20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i925ef02d711544878675a77e949a4453_I20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e35fc0471424eaeb1aa538040aea91e_D20221101-20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1dc3f6d0e094c2196112c84227fe802_D20221101-20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3a2c1a4485a471c820ca4842e5c1c64_D20221101-20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6925d4a44b4d4f8ab1473a6ec01745a1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15907a4c560a493d87c23e62f68ec83c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7a4d7a1847949aca50c56b25a88bd21_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i310d4215052d4ca0a49959195011a0ca_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93d2a3e0250e47bcb4b130e733307695_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i647cc339b7ba4424aa0eb336ee4b0a30_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f5ab08df5bf405bb9bf921da040bd2d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice1331001dd149aab4965f0b8b08572c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75520dd1a92c4e7f98c4a30068aa125f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7617b2529de45d9b88866d405c216e8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52aa8a7998954d46afe56844fc671bed_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c44b89669c84b58ac68a7d82a6f060f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7b8d23c3c2d432086d989ce0d5b3510_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i773ffb9b71e74f0fbb5045402bab92e2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfdbb8c8377342dba83719c152d876ca_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91aa339ce2224ab2b4c95c616a46b05a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c30654b099944fe816f08038b543686_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21767da9f078468aaa8154704501d4ef_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if31d69e265f548ce81614232c6d0622e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dfdfcb6eabc4fdf95b79cf9538f70c7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62d84f69387345d4810fabcf98a5a295_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i541c9938b3c74107adcc551aaa42ea63_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98f19aa7ddf044ea8bec0a50eb8c00be_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b14269404374b769581777b4169a1f0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic18218c1e1fa4ecba456ceeee9c63aff_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6627384d34dc4218abc8ef93db117f35_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i999a70848ee64e86a9903a8300ea18ae_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ab3ed3cf5644f68a916db4cc62581fe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic17b4d26f18349fbb811e5538089dabe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id843769ea0ce4178b71b8b98c986b0ee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c33d6de7efe40e2a08f973235f91b19_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d60828b8d294052882c3b89d2fd9265_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6001106820441dbaa8649a391b20f27_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9394339fa2c426f9dac1c7946f4249c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9019ad460da54067a92ced4519dbc280_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cff04acd40b44bb97ada25f13cf507d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i971953b96b7546e2b31d70534f703931_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica6f16598c254520b8de2a1aba7fd14f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04186447695d45da87b4e76c39d70450_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i229abcae1df149319098554f196c3b4a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d182bb719e0486b93ba7f98d8b1537b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0903ef6ff3f94b54a15562d6f61e5049_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e330387d6c34591aca484734572ae7d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i042557760bda403e9553e36b701f1ab8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c398cac425e49a5a91b7758fa11343b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadf82eab802a4fc0a2d085cc0c3baeae_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieabf435d9321492eb0f1862ccf31dc71_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d5aec6d9ea84d38855de750ab9fd43e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01b4a9caaa104277aa2c4a4bb45c1c91_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6c6c5c8311f41aa99327db95ebffefc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i764a624557c84d788711b6db863a88fa_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bngo:MeasurementInputProbabilityFactorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf80aacd0d8b4d49bda88deb4fe34f82_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bngo:MeasurementInputProbabilityFactorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0516c6ac8dd4d63874b612f0c8e9150_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i775844669d9443f18408dc91c0ed82e0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92407742ad83484e8413c0f98a6ddb72_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bngo:MeasurementInputProbabilityFactorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i026227378deb46939c6b0b7015b7862c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bngo:MeasurementInputProbabilityFactorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b30d459d41d4643a4ff9a4e0f57f5f7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie44567efb5fb4e42820714c15bc00b89_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i110925712b904ad2ad4771d5056f1576_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>bngo:security</xbrli:measure></xbrli:unit><xbrli:context id="i1becd5a6f0af415fae96defb606a1b8b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae48309cf5ff43dda82b169b4c36444e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4118894962b9424d92128e02a9adf2bc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i206731c08e11447b8873b07b61772810_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2908d99b8fe4704bcd189727c191080_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i561259e69fbb4552820b7ec56e5dea3a_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.431%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="15" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________________________________________</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGV4dHJlZ2lvbjo3ODkxNDRkZGE0Y2Q0NTM0YmY1OWM2NjU1NzBlNDk1Y18yMTgy_733965a0-88d5-44d9-9030-a46fd81f275c">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6MWE2OWM3NDg4OWQzNGJmYTk5OTFlMWFkY2YwOTIwMDkvdGFibGVyYW5nZToxYTY5Yzc0ODg5ZDM0YmZhOTk5MWUxYWRjZjA5MjAwOV8wLTAtMS0xLTEwNDExOQ_865e09a2-433b-417a-a7a6-9520f6da4308">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE QUARTERLY PERIOD ENDED <ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGV4dHJlZ2lvbjo3ODkxNDRkZGE0Y2Q0NTM0YmY1OWM2NjU1NzBlNDk1Y18yNDk_1d030a01-5af2-4d13-b0d8-106ad617ee7e">MARCH&#160;31, 2023</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6ZDI0NWE4NzFkYWI4NGQyN2I2NGY2MGRiNzhkMjEwNGMvdGFibGVyYW5nZTpkMjQ1YTg3MWRhYjg0ZDI3YjY0ZjYwZGI3OGQyMTA0Y18wLTAtMS0xLTEwNDExOQ_5e4da987-ab28-44f9-9e77-e5da3500af19">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TO</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGV4dHJlZ2lvbjo3ODkxNDRkZGE0Y2Q0NTM0YmY1OWM2NjU1NzBlNDk1Y18yMTg2_415b3a18-1225-4252-ab1f-545e53779bc7">001-38613</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGV4dHJlZ2lvbjo3ODkxNDRkZGE0Y2Q0NTM0YmY1OWM2NjU1NzBlNDk1Y18yMTc4_abadb48f-b319-44a8-9f65-6088873a0de8">Bionano Genomics, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.071%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6NWM0MWE3M2NhYTU0NDY5ZDliYTM2ZDBiYTIzYjk2ZjUvdGFibGVyYW5nZTo1YzQxYTczY2FhNTQ0NjlkOWJhMzZkMGJhMjNiOTZmNV8wLTAtMS0xLTEwNDExOQ_449550e7-0aa7-41eb-92e1-ba5836cfd901">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6NWM0MWE3M2NhYTU0NDY5ZDliYTM2ZDBiYTIzYjk2ZjUvdGFibGVyYW5nZTo1YzQxYTczY2FhNTQ0NjlkOWJhMzZkMGJhMjNiOTZmNV8wLTItMS0xLTEwNDExOQ_f415659f-7689-4b3b-aa8e-cc0e5cdf077e">26-1756290</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6NWM0MWE3M2NhYTU0NDY5ZDliYTM2ZDBiYTIzYjk2ZjUvdGFibGVyYW5nZTo1YzQxYTczY2FhNTQ0NjlkOWJhMzZkMGJhMjNiOTZmNV8zLTAtMS0xLTEwNDExOS90ZXh0cmVnaW9uOmE4NTQ2MDJhMmYyZjRiNTE5NjA1ODI3MDk0ZmU5Mzg2XzQ_25470da6-3c68-4fca-9318-0526b99ef8d6">9540 Towne Centre Drive, Suite 100</ix:nonNumeric>,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6NWM0MWE3M2NhYTU0NDY5ZDliYTM2ZDBiYTIzYjk2ZjUvdGFibGVyYW5nZTo1YzQxYTczY2FhNTQ0NjlkOWJhMzZkMGJhMjNiOTZmNV8zLTAtMS0xLTEwNDExOS90ZXh0cmVnaW9uOmE4NTQ2MDJhMmYyZjRiNTE5NjA1ODI3MDk0ZmU5Mzg2Xzg_34bd8179-8085-43af-bb02-27ee784128a8">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6NWM0MWE3M2NhYTU0NDY5ZDliYTM2ZDBiYTIzYjk2ZjUvdGFibGVyYW5nZTo1YzQxYTczY2FhNTQ0NjlkOWJhMzZkMGJhMjNiOTZmNV8zLTAtMS0xLTEwNDExOS90ZXh0cmVnaW9uOmE4NTQ2MDJhMmYyZjRiNTE5NjA1ODI3MDk0ZmU5Mzg2XzEy_8a7db2c9-6b9d-4f1e-8b7d-2c56c2af8bc9">CA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6NWM0MWE3M2NhYTU0NDY5ZDliYTM2ZDBiYTIzYjk2ZjUvdGFibGVyYW5nZTo1YzQxYTczY2FhNTQ0NjlkOWJhMzZkMGJhMjNiOTZmNV8zLTItMS0xLTEwNDExOQ_4238961a-ff50-460b-9ef8-dd5c094fe364">92121</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGV4dHJlZ2lvbjo3ODkxNDRkZGE0Y2Q0NTM0YmY1OWM2NjU1NzBlNDk1Y18yMTg3_dd46718a-0845-4909-8a93-53c5a9f28b38">858</ix:nonNumeric>) <ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGV4dHJlZ2lvbjo3ODkxNDRkZGE0Y2Q0NTM0YmY1OWM2NjU1NzBlNDk1Y18yMTg0_1b365d1e-8080-4f48-99db-931288f0f498">888-7600</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________________________________________</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:36.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.771%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib13a94b835db433b868b1047f2e0d08c_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6Y2E0NzU2ZTY4YzYwNDM2NDk3YWM0YTg0NmM1M2U1MjUvdGFibGVyYW5nZTpjYTQ3NTZlNjhjNjA0MzY0OTdhYzRhODQ2YzUzZTUyNV8xLTAtMS0xLTEwNDExOQ_0fed4ee9-9791-4bed-8a2b-904625543ebb">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib13a94b835db433b868b1047f2e0d08c_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6Y2E0NzU2ZTY4YzYwNDM2NDk3YWM0YTg0NmM1M2U1MjUvdGFibGVyYW5nZTpjYTQ3NTZlNjhjNjA0MzY0OTdhYzRhODQ2YzUzZTUyNV8xLTItMS0xLTEwNDExOQ_6d07523a-b55b-4fff-be97-a79f34d5a068">BNGO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib13a94b835db433b868b1047f2e0d08c_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6Y2E0NzU2ZTY4YzYwNDM2NDk3YWM0YTg0NmM1M2U1MjUvdGFibGVyYW5nZTpjYTQ3NTZlNjhjNjA0MzY0OTdhYzRhODQ2YzUzZTUyNV8xLTQtMS0xLTEwNDExOQ_2043db07-26e9-4c8c-a9e0-2f7397d3d965">The Nasdaq Stock Market, LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iad7fb23a31ff4cebb8ed73e94c311b74_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6Y2E0NzU2ZTY4YzYwNDM2NDk3YWM0YTg0NmM1M2U1MjUvdGFibGVyYW5nZTpjYTQ3NTZlNjhjNjA0MzY0OTdhYzRhODQ2YzUzZTUyNV8yLTAtMS0xLTEwNDExOQ_2a3882b2-542e-4def-bd18-aa12dc730945">Warrants to purchase Common Stock</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iad7fb23a31ff4cebb8ed73e94c311b74_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6Y2E0NzU2ZTY4YzYwNDM2NDk3YWM0YTg0NmM1M2U1MjUvdGFibGVyYW5nZTpjYTQ3NTZlNjhjNjA0MzY0OTdhYzRhODQ2YzUzZTUyNV8yLTItMS0xLTEwNDExOQ_4d6c5344-827d-4e17-a452-a742459cdd71">BNGOW</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iad7fb23a31ff4cebb8ed73e94c311b74_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6Y2E0NzU2ZTY4YzYwNDM2NDk3YWM0YTg0NmM1M2U1MjUvdGFibGVyYW5nZTpjYTQ3NTZlNjhjNjA0MzY0OTdhYzRhODQ2YzUzZTUyNV8yLTQtMS0xLTEwNDExOQ_a74585d4-7f92-43bd-bbcc-54c427e4dcc6">The Nasdaq Stock Market, LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;<ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGV4dHJlZ2lvbjo3ODkxNDRkZGE0Y2Q0NTM0YmY1OWM2NjU1NzBlNDk1Y18yMTc5_89bf60a1-3407-46b2-ba51-42083e54fd62">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:140%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:140%">   No&#160;&#160;&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGV4dHJlZ2lvbjo3ODkxNDRkZGE0Y2Q0NTM0YmY1OWM2NjU1NzBlNDk1Y18yMTgw_c299ebbc-b43b-4f9c-a85f-9fb26355b072">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:140%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8216;&#8216;emerging growth company&#8217;&#8217; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:20.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6YWM1OTZjZDBkYmRhNGU4OWI2OGJmOTZjMjVhMDBiMmIvdGFibGVyYW5nZTphYzU5NmNkMGRiZGE0ZTg5YjY4YmY5NmMyNWEwMGIyYl8xLTAtMS0xLTEwNzY0Nw_b650adc4-d62c-438a-aa7a-fb5af4ac114b">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6YWM1OTZjZDBkYmRhNGU4OWI2OGJmOTZjMjVhMDBiMmIvdGFibGVyYW5nZTphYzU5NmNkMGRiZGE0ZTg5YjY4YmY5NmMyNWEwMGIyYl8xLTQtMS0xLTEwNDExOQ_1a494c83-942e-44e4-8186-316008790dcd">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6YWM1OTZjZDBkYmRhNGU4OWI2OGJmOTZjMjVhMDBiMmIvdGFibGVyYW5nZTphYzU5NmNkMGRiZGE0ZTg5YjY4YmY5NmMyNWEwMGIyYl8yLTQtMS0xLTEwNDExOQ_26e1ab56-8093-4f8f-b74e-36e8abe3f60c">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:140%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;   Yes&#160;&#160;<ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGV4dHJlZ2lvbjo3ODkxNDRkZGE0Y2Q0NTM0YmY1OWM2NjU1NzBlNDk1Y18yMTgx_e53e3efc-2a4c-4999-b837-ff944eadce17">&#9744;</ix:nonNumeric>  No  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:140%">x</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As of May&#160;4, 2023, the registrant had <ix:nonFraction unitRef="shares" contextRef="i5dffd8e896cf4da18e2a7981e161bfa7_I20230504" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGV4dHJlZ2lvbjo3ODkxNDRkZGE0Y2Q0NTM0YmY1OWM2NjU1NzBlNDk1Y18yMTE3_f6a46532-fac8-49df-b1ef-707723c5c156">306,790,214</ix:nonFraction> shares of Common Stock ($0.0001 par value) outstanding.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.431%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="15" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i561259e69fbb4552820b7ec56e5dea3a_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIONANO GENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:3.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_10">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_10">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_13">Item&#160;1. Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_16">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_16">March 31</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_16">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_16">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_16"> and December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_16">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_16"> (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_19">Condensed Consolidated Statements of Operations for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_19">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_19">March 31</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_19">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_19">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_19"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_19">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_19">  (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_22">Condensed Consolidated Statements of Comprehensive Loss for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_22">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_22">March 31</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_22">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_22">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_22"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_22">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_22"> (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_25">Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit) for the three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_25"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_25">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_25"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_25">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_25">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_25">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_25"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_25">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_25"> (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_28">Condensed Consolidated Statements of Cash Flows for the three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_28"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_28">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_28"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_28">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_28">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_28">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_28"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_28">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_28"> (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_31">Notes to Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_31">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_70">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_70">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_97">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_97">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_100">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_100">30</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_103">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_103">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_106">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_106">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_109">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_109">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_136">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_136">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_139">Item&#160;3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_139">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_142">Item&#160;4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_142">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_145">Item&#160;5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_145">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_148">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_148">74</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_151">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_151">76</a></span></div></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i561259e69fbb4552820b7ec56e5dea3a_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_13"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1. FINANCIAL STATEMENTS</span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_16"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIONANO GENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNC0xLTEtMS0xMDQxMTk_61d44e34-766a-4455-ab02-717d1d474515">4,104,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNC0zLTEtMS0xMDQxMTk_82c734ae-7db9-46b9-a468-fdf102703dc3">5,091,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNS0xLTEtMS0xMDQxMTk_9affae1a-d6a2-4f63-a031-3853d87b5ac1">91,704,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNS0zLTEtMS0xMDQxMTk_a2f3bdfc-134d-4afe-947a-bd3b588d7073">108,095,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNi0xLTEtMS0xMDQxMTk_3b4d9a67-6a56-423e-b0ed-d1deca65241f">6,780,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNi0zLTEtMS0xMDQxMTk_53be7f54-5f84-4cbc-a9dc-62220bcd7f29">7,022,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNy0xLTEtMS0xMDQxMTk_c8a12eb9-5da2-47ce-a036-2836e286706e">33,113,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNy0zLTEtMS0xMDQxMTk_efcd008d-28a2-4879-be60-07c3ffbb43ec">29,761,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfOC0xLTEtMS0xMDQxMTk_5efa63d8-f3b3-4769-ad3b-f3699858ec83">6,856,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfOC0zLTEtMS0xMDQxMTk_e5e94b00-050c-49b6-9136-f519459c028e">7,329,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfOS0xLTEtMS0xMDQxMTk_18e6b583-9add-4db8-9105-7c7c9733c946">142,557,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfOS0zLTEtMS0xMDQxMTk_55302fe7-360e-45bb-b582-b7f2803b67be">157,298,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTAtMS0xLTEtMTA0ODQ3_8c69dfb0-b631-48c4-abbd-1ff4f26245c6">400,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTAtMy0xLTEtMTA0ODQw_c6bd7785-5ce2-44b5-8ab4-3544138e6ca1">400,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTAtMS0xLTEtMTA0MTE5_163cd5f1-06b0-4e05-a541-b61fe7346ee4">19,050,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTAtMy0xLTEtMTA0MTE5_6007f50c-2d3f-4d33-9757-b60f6396ca38">18,029,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTEtMS0xLTEtMTA0MTE5_58bfc0cc-0259-4da1-9c38-6860b7ab4b06">7,062,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTEtMy0xLTEtMTA0MTE5_ddd01b0b-fcfc-4525-9161-27260e13cb70">7,222,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTItMS0xLTEtMTA0MTE5_d28e2169-5226-4d54-9e4a-b75a24304906">3,657,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTItMy0xLTEtMTA0MTE5_d4357e95-fe03-4a3f-8950-329e6989e122">3,707,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTMtMS0xLTEtMTA0MTE5_fc670850-b190-4e59-b100-a8e253d47679">39,351,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTMtMy0xLTEtMTA0MTE5_f59ba500-c10a-49a8-88d0-2b5f1513c4d5">41,143,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTQtMS0xLTEtMTA0MTE5_bd62dc01-6895-4c88-a677-091239f52b7c">77,289,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTQtMy0xLTEtMTA0MTE5_afb3b4e8-5268-44e2-8893-c3558d005478">77,289,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTUtMS0xLTEtMTA0MTE5_ab50a950-1060-40bb-a880-859904b885ba">2,785,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTUtMy0xLTEtMTA0MTE5_0dcca78d-0af4-4413-b12c-59a4ce3f2f66">2,414,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTYtMS0xLTEtMTA0MTE5_a90d6607-506e-42e5-90d7-4a660f4be109">292,151,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTYtMy0xLTEtMTA0MTE5_4e9a04d7-be91-402f-aad0-13e9916393cc">307,502,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjAtMS0xLTEtMTA0MTE5_1d448941-9574-493a-9034-b62f494dbb89">15,780,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjAtMy0xLTEtMTA0MTE5_a904dd0b-4055-4706-bd5e-069fa1567275">12,534,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjEtMS0xLTEtMTA0MTE5_6950166d-5ac6-465b-b31b-9201437b9f8e">9,250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjEtMy0xLTEtMTA0MTE5_14ba3272-52e9-4151-9c7e-eedd45cde9bf">10,552,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjItMS0xLTEtMTA0MTE5_d6cee479-8e17-4a87-8b6b-94a7c0bf56fd">1,127,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjItMy0xLTEtMTA0MTE5_50bad892-61b3-4430-8dee-a88e549ca12e">871,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjQtMS0xLTEtMTA0MTE5_ade55ac2-2137-4f27-adff-176c0a3b3b98">2,235,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjQtMy0xLTEtMTA0MTE5_1bc73140-9278-4258-aa31-367f2b23ae01">2,260,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjUtMS0xLTEtMTA0MTE5_d5e316af-6e33-444b-8674-b8818103e485">282,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjUtMy0xLTEtMTA0MTE5_2e06372f-c8ab-4fb3-8974-46e98e752f7c">285,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjYtMS0xLTEtMTA0MTE5_aca63530-cd16-41c0-84fb-d26659edb32e">9,461,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjYtMy0xLTEtMTA0MTE5_fa9adde1-4344-49af-859b-667b8b46450a">9,382,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjctMS0xLTEtMTA0MTE5_aaf19441-8399-411b-962b-c3de2875b946">38,135,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjctMy0xLTEtMTA0MTE5_46d9d5cd-9937-4f55-8401-193104fa2c5c">35,884,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjgtMS0xLTEtMTA0MTE5_dd86d7e8-69b5-4575-967b-68772dab4b80">5,043,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjgtMy0xLTEtMTA0MTE5_e1eaf2cc-0b76-4ab0-8f62-3dfe46f81ead">5,504,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liability, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjktMS0xLTEtMTA0MTE5_5fdd6872-3ee1-4544-abd6-518b904a8810">3,612,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjktMy0xLTEtMTA0MTE5_69df39a2-4029-4391-b181-c3a12163d79a">3,619,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMzAtMS0xLTEtMTA0MTE5_264613d8-8b91-42c0-9a26-0992937f924f">13,680,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMzAtMy0xLTEtMTA0MTE5_c877c976-b3d6-40e3-bc0a-a86fb0be7c40">12,970,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMzItMS0xLTEtMTA0MTE5_d51e85f9-3157-4b26-b60c-a07bb2fc33c5">194,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMzItMy0xLTEtMTA0MTE5_31c59a0b-4400-46d4-990a-a3fdc00215d8">127,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMzQtMS0xLTEtMTA0MTE5_9ff913c5-9e92-4542-b598-b696e037ae36">60,664,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMzQtMy0xLTEtMTA0MTE5_aebeb20f-ad86-4d42-bb75-680a706d061b">58,104,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMzUtMS0xLTEtMTA0MTE5_8692d9fe-30ce-482e-b4bd-7f16522d50a4"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMzUtMy0xLTEtMTA0MTE5_23859748-73ba-4894-9de1-dbbc33aef79f"></ix:nonFraction></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i16a495a5dc5b4d72a5d69105c54ed1d5_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDMtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246NDYzMzU4YzhkOTczNGIzYTgzNDIwNjRhOTQwMTMwZjVfMjI_943b55b9-1de6-4d91-9607-ed93a316da90"><ix:nonFraction unitRef="usdPerShare" contextRef="i7ae84972110b4c82abdd96887a8dc98b_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDMtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246NDYzMzU4YzhkOTczNGIzYTgzNDIwNjRhOTQwMTMwZjVfMjI_a8b560c7-cc2f-4d4f-8627-3154a377a804">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDMtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246NDYzMzU4YzhkOTczNGIzYTgzNDIwNjRhOTQwMTMwZjVfMzY_061c402a-6a33-434a-9ea8-c3806e070971"><ix:nonFraction unitRef="shares" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDMtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246NDYzMzU4YzhkOTczNGIzYTgzNDIwNjRhOTQwMTMwZjVfMzY_38d49c24-e0d8-460d-bfea-acebebdd06df">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDMtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246NDYzMzU4YzhkOTczNGIzYTgzNDIwNjRhOTQwMTMwZjVfNjE_34f3aaa3-8ba9-4dc0-af84-4de6557c2200"><ix:nonFraction unitRef="shares" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDMtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246NDYzMzU4YzhkOTczNGIzYTgzNDIwNjRhOTQwMTMwZjVfNjE_ace255fd-8565-448c-a188-a969cc7c7579"><ix:nonFraction unitRef="shares" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDMtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246NDYzMzU4YzhkOTczNGIzYTgzNDIwNjRhOTQwMTMwZjVfNjE_b2255d4d-09dd-4ce0-aeea-86c7c94758d8"><ix:nonFraction unitRef="shares" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDMtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246NDYzMzU4YzhkOTczNGIzYTgzNDIwNjRhOTQwMTMwZjVfNjE_c8548c4e-43f9-4fcb-b3a6-744baca7745c">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding as of March&#160;31, 2023 and December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDMtMS0xLTEtMTA0MTE5_44b861db-fd25-49e4-8bc3-ccf40a717bfe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDMtMy0xLTEtMTA0MTE5_7dc6a2d6-9632-43c2-9e0b-908743dde704">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDQtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246ZjM4Y2NiMjc0NDI1NGQ0MzgyMTllN2ZjNjFjM2MxYTVfMTg_9d5bd003-1fe6-4638-8668-a8c1266b9c59"><ix:nonFraction unitRef="usdPerShare" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDQtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246ZjM4Y2NiMjc0NDI1NGQ0MzgyMTllN2ZjNjFjM2MxYTVfMTg_ba71d0a1-6f99-45d0-9f06-e51a69b6de81">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDQtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246ZjM4Y2NiMjc0NDI1NGQ0MzgyMTllN2ZjNjFjM2MxYTVfMzI_01313144-fe76-4aae-8451-ea3b40c2c838"><ix:nonFraction unitRef="shares" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDQtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246ZjM4Y2NiMjc0NDI1NGQ0MzgyMTllN2ZjNjFjM2MxYTVfMzI_ac174c58-c0c8-4bfe-8ced-1237104a5d05">400,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31, 2023 and December&#160;31, 2022; <ix:nonFraction unitRef="shares" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDQtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246ZjM4Y2NiMjc0NDI1NGQ0MzgyMTllN2ZjNjFjM2MxYTVfNjc_014f57fa-4d5e-48fc-a66c-117d5505c51e"><ix:nonFraction unitRef="shares" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDQtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246ZjM4Y2NiMjc0NDI1NGQ0MzgyMTllN2ZjNjFjM2MxYTVfNjc_f7249bdb-ef4c-461d-b77e-5fb6d939a3ec">306,790,000</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDQtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246ZjM4Y2NiMjc0NDI1NGQ0MzgyMTllN2ZjNjFjM2MxYTVfNzQ_3d5e9f53-a648-461e-b6bb-7038e2f6452f"><ix:nonFraction unitRef="shares" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDQtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246ZjM4Y2NiMjc0NDI1NGQ0MzgyMTllN2ZjNjFjM2MxYTVfNzQ_b250958d-e38d-4ad6-a13e-93f853486722">297,183,000</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDQtMS0xLTEtMTA0MTE5_e7161c77-d7d3-439e-8cba-8352ab4b8a1b">31,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDQtMy0xLTEtMTA0MTE5_7ea3d474-e08b-4637-a980-0e37ada1e9b1">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDUtMS0xLTEtMTA0MTE5_950150d2-122f-4e4b-a63e-4c772a3db93d">617,960,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDUtMy0xLTEtMTA0MTE5_f24f9fba-71a5-4f4d-9db8-82bdcad5f39d">599,207,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDYtMS0xLTEtMTA0MTE5_4f759be9-8930-4018-bbf9-6cb15bd87139">385,839,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDYtMy0xLTEtMTA0MTE5_3b1e844c-9254-4528-99c4-85e27c7d37eb">348,715,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDctMS0xLTEtMTA0MTE5_7411d118-aba8-4f41-85b3-92b463365621">665,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDctMy0xLTEtMTA0MTE5_6300c14b-2ea3-4a80-90ba-f73e62a187f3">1,124,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDgtMS0xLTEtMTA0MTE5_f8c10a38-0e26-4d83-addd-c1739814c42f">231,487,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDgtMy0xLTEtMTA0MTE5_4a6d0f16-d5c3-424e-a34d-58bede4456eb">249,398,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDktMS0xLTEtMTA0MTE5_d48570a5-7023-48ea-bc63-a61438f1d7af">292,151,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDktMy0xLTEtMTA0MTE5_65351b0e-c6f5-4dab-92e1-7943809654b7">307,502,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed consolidated financial statements</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i561259e69fbb4552820b7ec56e5dea3a_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIONANO GENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:74.888%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22c603917ec343e5b40cf1377f2dd0fa_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMy05LTEtMS0xMDQxMTk_e98e4b0b-6cbb-4b7a-8a59-208a5030900e">5,447,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i103e1f66718e42e092ef57cf65cbad93_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMy03LTEtMS0xMDU0MzU_b78ab7f8-9302-46b1-be43-59ffa4f46494">4,206,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service and other revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1fe061275f84c0db4bc966cec7ea694_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfNC05LTEtMS0xMDQxMTk_722cc110-2a97-48d4-b8c3-e314e8869b52">1,968,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifebd115420624a60b9827cd166e72988_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfNC03LTEtMS0xMDU0MzU_576c871d-efbc-4795-abe2-2eaa20a9846d">1,490,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfNS05LTEtMS0xMDQxMTk_fdc4d68c-546b-4eb8-8cfd-29324d48c6f7">7,415,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfNS0xMS0xLTEtMTA0MTE5_0d4b30a9-be47-4790-9877-195b4d848214">5,696,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22c603917ec343e5b40cf1377f2dd0fa_D20230101-20230331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfNy05LTEtMS0xMDQxMTk_cbcad507-ab44-4d99-9f8a-8413941bb4cd">3,858,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i103e1f66718e42e092ef57cf65cbad93_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfNy03LTEtMS0xMDU0Mzg_c85266b3-320f-4d1f-8466-e3706f6c7b80">3,576,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of service and other revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1fe061275f84c0db4bc966cec7ea694_D20230101-20230331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfOC05LTEtMS0xMDQxMTk_5829ca04-a251-48a6-a8c9-cbaee4b9b8b7">1,487,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifebd115420624a60b9827cd166e72988_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfOC03LTEtMS0xMDU0Mzg_c550ccbe-f3b5-4989-b760-002785a79e5b">1,259,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cost of revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfOS05LTEtMS0xMDQxMTk_4fb287c5-f062-4d25-b135-ce8a7f07c5c3">5,345,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfOS0xMS0xLTEtMTA0MTE5_bd99d4bb-633f-4b8a-ad30-87c01732db82">4,835,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTEtOS0xLTEtMTA0MTE5_bb320709-b94d-4575-ba57-55bf8b33a375">13,937,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTEtNy0xLTEtMTA1NDQx_47fbcbe4-1d6c-4391-98ea-2d1425cef3b4">10,527,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTItOS0xLTEtMTA0MTE5_3108cc48-2e86-46c4-8f84-6fef55ec805d">25,976,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTItNy0xLTEtMTA1NDQx_28d35e5a-c95b-4bfc-aaa8-a196c5a00e59">20,277,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTMtOS0xLTEtMTA0MTE5_0f24aa18-52b4-4b11-bb98-3a9ae055dff5">39,913,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTMtMTEtMS0xLTEwNDExOQ_3bbeb88a-2ce8-4a15-abd4-225f121bf3af">30,804,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTQtOS0xLTEtMTA0MTE5_524dc2b0-01d6-460b-b40b-f11a94eee336">37,843,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTQtMTEtMS0xLTEwNDExOQ_2f15408c-b894-4810-90a0-f28381eaa795">29,943,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTYtNS0xLTEtMTA1NDE5_43a4f058-2f5d-4f73-8b40-443eb140baca">704,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTYtNy0xLTEtMTA1NDQ0_dae011f0-1099-4930-a42d-4d7f81e0d4bf">110,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTctOS0xLTEtMTA0MTE5_745bf3fd-c6ab-47a3-8ff2-b2496395521d">76,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTctNy0xLTEtMTA1NDQ0_8dbe628e-a811-402c-bb18-148adeee5768">77,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjAtOS0xLTEtMTA0MTE5_0f0c621f-5785-4673-9ab1-8640a1718290">117,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTgtNy0xLTEtMTA1NDQ0_64417253-27ad-448e-b704-c0ec400cf269">33,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjEtOS0xLTEtMTA0MTE5_16c62ef8-caaf-4326-b0fe-ecb8fcd65094">745,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjEtMTEtMS0xLTEwNDExOQ_61e24136-1235-4855-b165-b12401d470c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjItOS0xLTEtMTA0MTE5_22e4ed4d-253b-4c97-8ae5-2395c9173a35">37,098,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjItMTEtMS0xLTEwNDExOQ_c33c007b-3f4a-4496-9abe-20b54605aa1a">29,943,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit (provision) for income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjMtOS0xLTEtMTA0MTE5_e50846fb-1620-43c5-9c88-835e6f287970">26,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjEtNy0xLTEtMTA1NDQ3_7e7ab820-df13-4144-938d-b01d8c48305e">9,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjQtOS0xLTEtMTA0MTE5_a330b78a-ba32-40a7-a87b-d2356db353fe">37,124,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjQtMTEtMS0xLTEwNDExOQ_53cb1095-63e3-44a6-9db2-2ac9b019179e">29,952,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjUtOS0xLTEtMTA0MTE5_87f399f3-e168-4371-a004-1688787f7e58"><ix:nonFraction unitRef="usdPerShare" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjUtOS0xLTEtMTA0MTE5_f5efeea1-77e5-4755-a087-64feabf1bd5d">0.12</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjUtMTEtMS0xLTEwNDExOQ_554ed464-9091-420c-8065-3a59e302eba7"><ix:nonFraction unitRef="usdPerShare" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjUtMTEtMS0xLTEwNDExOQ_d7230d1c-c799-4bdb-ae6d-9b650a14e193">0.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjYtOS0xLTEtMTA0MTE5_498defcb-5622-4751-81c9-96514034b3cc"><ix:nonFraction unitRef="shares" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjYtOS0xLTEtMTA0MTE5_e4a29437-16ed-4ce3-af68-31c0283ee519">302,045,000</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjQtNy0xLTEtMTA3Nzg0_1b694634-c1f7-476d-b3a7-80905ed44805"><ix:nonFraction unitRef="shares" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjQtNy0xLTEtMTA3Nzg0_278805e1-4ce5-4aa2-a006-835e35d11a7f"><ix:nonFraction unitRef="shares" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjQtNy0xLTEtMTA3Nzg0_2db6429b-0561-487f-a069-3416a4bea6a8"><ix:nonFraction unitRef="shares" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjQtNy0xLTEtMTA3Nzg0_59b23c08-d50f-40e9-97e4-e89d16d6909b">284,613,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i561259e69fbb4552820b7ec56e5dea3a_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIONANO GENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yMi9mcmFnOjRhNGUzMDY3MGM3MTQxNmE4MmU0ZGZhMjRhOWQ0MzZjL3RhYmxlOmMyNWQzYjhkMmI5MjQ2YWZiNGZhNGNlZGY2MzM1NWRjL3RhYmxlcmFuZ2U6YzI1ZDNiOGQyYjkyNDZhZmI0ZmE0Y2VkZjYzMzU1ZGNfMi0xLTEtMS0xMDQxMTk_3ee1c1bd-e4b6-4ef6-8a8d-fc884c1fd2d2">37,124,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yMi9mcmFnOjRhNGUzMDY3MGM3MTQxNmE4MmU0ZGZhMjRhOWQ0MzZjL3RhYmxlOmMyNWQzYjhkMmI5MjQ2YWZiNGZhNGNlZGY2MzM1NWRjL3RhYmxlcmFuZ2U6YzI1ZDNiOGQyYjkyNDZhZmI0ZmE0Y2VkZjYzMzU1ZGNfMi0zLTEtMS0xMDQxMTk_7bf758c0-da0a-49dd-bf25-280530b52f76">29,952,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investment securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yMi9mcmFnOjRhNGUzMDY3MGM3MTQxNmE4MmU0ZGZhMjRhOWQ0MzZjL3RhYmxlOmMyNWQzYjhkMmI5MjQ2YWZiNGZhNGNlZGY2MzM1NWRjL3RhYmxlcmFuZ2U6YzI1ZDNiOGQyYjkyNDZhZmI0ZmE0Y2VkZjYzMzU1ZGNfNC0xLTEtMS0xMDQxMTk_0fe88fc6-719e-4e5b-921f-26ef0e27bf82">423,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yMi9mcmFnOjRhNGUzMDY3MGM3MTQxNmE4MmU0ZGZhMjRhOWQ0MzZjL3RhYmxlOmMyNWQzYjhkMmI5MjQ2YWZiNGZhNGNlZGY2MzM1NWRjL3RhYmxlcmFuZ2U6YzI1ZDNiOGQyYjkyNDZhZmI0ZmE0Y2VkZjYzMzU1ZGNfNC0zLTEtMS0xMDQxMTk_34d037ef-a7bc-479d-b675-8fe3b0ec59e3">1,098,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yMi9mcmFnOjRhNGUzMDY3MGM3MTQxNmE4MmU0ZGZhMjRhOWQ0MzZjL3RhYmxlOmMyNWQzYjhkMmI5MjQ2YWZiNGZhNGNlZGY2MzM1NWRjL3RhYmxlcmFuZ2U6YzI1ZDNiOGQyYjkyNDZhZmI0ZmE0Y2VkZjYzMzU1ZGNfNS0xLTEtMS0xMDQxMTk_a47949da-e34a-415e-ad3e-eff9ab8b00b8">36,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yMi9mcmFnOjRhNGUzMDY3MGM3MTQxNmE4MmU0ZGZhMjRhOWQ0MzZjL3RhYmxlOmMyNWQzYjhkMmI5MjQ2YWZiNGZhNGNlZGY2MzM1NWRjL3RhYmxlcmFuZ2U6YzI1ZDNiOGQyYjkyNDZhZmI0ZmE0Y2VkZjYzMzU1ZGNfNS0zLTEtMS0xMDQxMTk_c3d60090-5573-4ee6-9c10-f81ed9c7a08a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yMi9mcmFnOjRhNGUzMDY3MGM3MTQxNmE4MmU0ZGZhMjRhOWQ0MzZjL3RhYmxlOmMyNWQzYjhkMmI5MjQ2YWZiNGZhNGNlZGY2MzM1NWRjL3RhYmxlcmFuZ2U6YzI1ZDNiOGQyYjkyNDZhZmI0ZmE0Y2VkZjYzMzU1ZGNfNi0xLTEtMS0xMDQxMTk_cb006580-5306-481d-a4e9-89c045724b4b">459,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yMi9mcmFnOjRhNGUzMDY3MGM3MTQxNmE4MmU0ZGZhMjRhOWQ0MzZjL3RhYmxlOmMyNWQzYjhkMmI5MjQ2YWZiNGZhNGNlZGY2MzM1NWRjL3RhYmxlcmFuZ2U6YzI1ZDNiOGQyYjkyNDZhZmI0ZmE0Y2VkZjYzMzU1ZGNfNi0zLTEtMS0xMDQxMTk_db9bd104-3307-445e-b6f6-fbc98662fc08">1,098,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yMi9mcmFnOjRhNGUzMDY3MGM3MTQxNmE4MmU0ZGZhMjRhOWQ0MzZjL3RhYmxlOmMyNWQzYjhkMmI5MjQ2YWZiNGZhNGNlZGY2MzM1NWRjL3RhYmxlcmFuZ2U6YzI1ZDNiOGQyYjkyNDZhZmI0ZmE0Y2VkZjYzMzU1ZGNfNy0xLTEtMS0xMDQxMTk_040db713-1ba4-45e7-88ce-fba3c7d4d99e">36,665,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yMi9mcmFnOjRhNGUzMDY3MGM3MTQxNmE4MmU0ZGZhMjRhOWQ0MzZjL3RhYmxlOmMyNWQzYjhkMmI5MjQ2YWZiNGZhNGNlZGY2MzM1NWRjL3RhYmxlcmFuZ2U6YzI1ZDNiOGQyYjkyNDZhZmI0ZmE0Y2VkZjYzMzU1ZGNfNy0zLTEtMS0xMDQxMTk_7bfdba58-7a6d-45f7-b614-33f4757706be">31,050,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i561259e69fbb4552820b7ec56e5dea3a_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIONANO GENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit) (Unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.607%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity (Deficit)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc1dfa094b4c4c1fa40f179234ec50e6_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMi0yLTEtMS0xMDQxMTk_095fa2a9-44e6-4940-b1dc-a91a7e47396a">289,602,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc1dfa094b4c4c1fa40f179234ec50e6_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMi00LTEtMS0xMDQxMTk_5c931121-4cb4-48d2-9031-3fd51c77cb21">29,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3c9898447244ed80a321d3bb3f00b1_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMi02LTEtMS0xMDQxMTk_70f6879d-70ad-43f7-8324-94036d0e5a6c">553,747,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1cca8398bdff4ba383ffbba2ea3b7387_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMi04LTEtMS0xMDQxMTk_81cf30d0-6b1e-4c79-81af-b7ebd1a7bbfa">216,119,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d8e7646f2804373ac2db3a030f1359c_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMi0xMC0xLTEtMTA0MTE5_460e2281-f2fe-45df-bfad-9128ce286b8d">539,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cfe18ad0d8e4978ada52e1560b4b9dd_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMi0xMi0xLTEtMTA0MTE5_225c962b-8305-4851-96b8-7c4901c5e76a">337,118,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option exercises</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i58b67d95244b409ab6ee9c70973a72be_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMy0yLTEtMS0xMDQxMTk_3b16e891-447f-4ea0-a386-220575fbc1ab">21,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i081d4286b8024fc38cd6cc1cfb880bac_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMy02LTEtMS0xMDQxMTk_22983a31-8107-4e27-8b2f-329c84fbbb28">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMy0xMi0xLTEtMTA0MTE5_f3794908-049f-4010-b41c-2ee35fa59634">15,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i081d4286b8024fc38cd6cc1cfb880bac_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfNC02LTEtMS0xMDQxMTk_240d995d-abe8-4e1f-83c6-6c6ae42088df">5,102,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfNC0xMi0xLTEtMTA0MTE5_dceffe98-5dd4-48c3-b3c2-6d291ff6f86c">5,102,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock due to the vesting of restricted stock units, net of shares withheld to cover taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i58b67d95244b409ab6ee9c70973a72be_D20220101-20220331" decimals="-3" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfNS0yLTEtMS0xMDU2MTk_e0f9d0ce-84b2-4922-adba-6ed10c834ff6">65,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib545fe18002040049f1dd40e745063cf_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfNy04LTEtMS0xMDQxMTk_ed3c0db4-d33a-4440-a5d1-ff9245aec039">29,952,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfNy0xMi0xLTEtMTA0MTE5_59efb701-46c9-49c5-a04d-7d091449d3c7">29,952,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26505e829d91462f95377df48fcf6c59_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfNy0xMC0xLTEtMTA1NjI2_95200ae5-239c-43bb-a370-05a547953d69">1,098,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfNy0xMi0xLTEtMTA3Nzk0_8835d8b3-1222-430a-a1ba-3287ddcb92d2">1,098,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i35bd51c6773a4f30bc0cda985ac95b56_I20220331" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfOC0yLTEtMS0xMDQxMTk_ddf6294b-2d0d-4003-8469-c48a3846d24a">289,688,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35bd51c6773a4f30bc0cda985ac95b56_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfOC00LTEtMS0xMDQxMTk_78a5c217-7947-4c9a-b2e5-dbf900d1ce69">29,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba62f46aa8044098043951d2b4e437f_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfOC02LTEtMS0xMDQxMTk_f4163595-022f-4aa5-aaf5-2895eb784405">558,864,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e6f07f9ffb41f3b64c9ac35f75d302_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfOC04LTEtMS0xMDQxMTk_6beeeeb6-09b4-43b1-ac20-4565f4f621e8">246,071,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17b0d4ea6adf427eb9d4b02037d2964a_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfOC0xMC0xLTEtMTA0MTE5_085a149a-100b-4d20-853c-d305393e7760">1,637,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955cc10e676a434da3908ec8ee79b5a0_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfOC0xMi0xLTEtMTA0MTE5_cb3e5f5f-9a9d-4e7a-9f5b-5a70c3951c38">311,185,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e39a84040944ede8fdaa4d1b105ad7a_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzEtMi0xLTEtMTA0MTE5_5fd24835-092f-4503-89ad-3e47bb5f3429">297,183,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e39a84040944ede8fdaa4d1b105ad7a_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzEtNC0xLTEtMTA0MTE5_7c35d271-20b9-4216-a4f0-c457cadd3155">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49cef66a2bf8465c9be9162628f1973b_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzEtNi0xLTEtMTA0MTE5_f9839aef-3fed-45b9-9353-28d3de1c6764">599,207,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39f18943e70e4009b385fa4e3abd198f_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzEtOC0xLTEtMTA0MTE5_c2a59899-c84b-4b50-ae05-e6c91ecc2b4f">348,715,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5409b1552b72472894786a349c3cf6ab_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzEtMTAtMS0xLTEwNDExOQ_1ff0bd98-3d08-4d8a-96b3-4f88fc2f5339">1,124,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzEtMTItMS0xLTEwNDExOQ_3b1d39eb-3d6a-4117-8ca7-316714fac105">249,398,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option exercises</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i368dfe51ced845ce9ce881dbe02ac125_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzItMi0xLTEtMTA0MTE5_07beca0b-13b1-454d-b5b5-c00c21fc33bb">42,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b2f680c76ee497394f0b63f4a9b399a_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzItNi0xLTEtMTA0MTE5_7db51d11-f63c-4d64-8ace-ba9a70025d6c">23,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzItMTItMS0xLTEwNDExOQ_a246ff21-b811-4590-91cd-88f70f88cc78">23,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b2f680c76ee497394f0b63f4a9b399a_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzMtNi0xLTEtMTA0MTE5_444c9ffa-f3f0-412e-b4a5-d66c65471d21">3,882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzMtMTItMS0xLTEwNDExOQ_c37a88a7-8822-413a-b965-83a3c0409706">3,882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issue common stock, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i368dfe51ced845ce9ce881dbe02ac125_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMTMtMi0xLTEtMTA5MjU3_d52c2cb8-f95a-453f-801e-7c75bb18fd58">9,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i368dfe51ced845ce9ce881dbe02ac125_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMTMtNC0xLTEtMTA5MjU3_ca20d57a-6eb4-4aa7-b61e-e658ba4d1d40">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b2f680c76ee497394f0b63f4a9b399a_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMTMtNi0xLTEtMTA5MjU3_2e4934ba-839c-4344-842c-434349be668b">14,848,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMTMtMTItMS0xLTEwOTI1Nw_c3011331-e1f0-44ad-ae2f-9ddf781699d7">14,849,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock due to the vesting of restricted stock units, net of shares withheld to cover taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i368dfe51ced845ce9ce881dbe02ac125_D20230101-20230331" decimals="-3" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzQtMi0xLTEtMTA0MTE5_2b39efd9-4258-474e-9586-e27e0c82b800">65,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4838c75f09847d6962eaee26a7817f1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzUtOC0xLTEtMTA0MTE5_8043a7cd-7674-4892-a8cb-3f2b8dd91d65">37,124,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzUtMTItMS0xLTEwNDExOQ_fcef1d21-ef6c-40e1-9e8b-3a011dd0842b">37,124,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85aa7ee73fd04055b335ec2d997a0f0c_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzYtMTAtMS0xLTEwNDExOQ_94d1509f-4498-41d8-aaea-787cc5c6e59b">459,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzYtMTItMS0xLTEwNDExOQ_62a01a1c-9b64-4eed-93e9-80de7eb6d0d8">459,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b9c8029a5394f4bafac617b2deb2c22_I20230331" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzctMi0xLTEtMTA0MTE5_bdea912e-1baf-4424-bdf8-73ca60a5f16e">306,790,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b9c8029a5394f4bafac617b2deb2c22_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzctNC0xLTEtMTA0MTE5_c26afcae-e5bb-41f8-ac02-867475c12cb6">31,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6f1ced20ec4e9aa8a3fb4827f7be65_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzctNi0xLTEtMTA0MTE5_2d717647-1220-4041-9940-8628643d5b00">617,960,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib90ef8426ec84d859ee8b194da09c4eb_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzctOC0xLTEtMTA0MTE5_c7b1da3d-6d7f-4238-933b-8616d3fc5c8a">385,839,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic370404fbb3041c6a839fd87ac238005_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzctMTAtMS0xLTEwNDExOQ_91def79a-2056-45a6-9444-9c7f5c6ffd27">665,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzctMTItMS0xLTEwNDExOQ_6a75d5e8-02b3-4420-a30e-a5ddf9773b9e">231,487,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed consolidated financial statements</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i561259e69fbb4552820b7ec56e5dea3a_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIONANO GENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMy0xLTEtMS0xMDQxMTk_c6707c28-9b3a-4b53-9bed-99da55086e49">37,124,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMy0zLTEtMS0xMDQxMTk_67762b58-4f13-45e2-8388-3887beaa4ffa">29,952,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNS0xLTEtMS0xMDQxMTk_5a8252e7-5053-4e72-8616-4983d4133ecb">3,190,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNS0zLTEtMS0xMDQxMTk_f9200311-272d-43c8-9ce5-739d160bd072">2,210,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of financing lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNi0xLTEtMS0xMDQxMTk_b713662c-77bb-4b72-9ab7-181eb5ea28bd">51,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNi0zLTEtMS0xMDQxMTk_a1f45e3b-25e6-40f8-a533-33cf5cd78ceb">29,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization (accretion) of interest on securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNy0xLTEtMS0xMDQxMTk_64391950-9a4b-44d1-87c6-13bf01b80111">82,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNy0zLTEtMS0xMDQxMTk_88e00a09-ef36-4838-a32e-c4b5feb46732">299,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="bngo:NonCashLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfOC0xLTEtMS0xMDQxMTk_2d2f0135-971c-48ca-8035-f5d8401b3427">113,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="bngo:NonCashLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfOC0zLTEtMS0xMDQxMTk_c48d6dc9-0d47-49a2-8303-1e8b86d084b9">299,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net realized loss (gain) on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTAtMS0xLTEtMTA4NDQz_9aa3f213-dd8f-461a-b771-ec96b66c595f">7,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:RealizedInvestmentGainsLosses" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTAtMy0xLTEtMTA4NDUw_9c6a415c-2408-469c-947e-c7c932e34fa6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTAtMS0xLTEtMTA0MTE5_cb70c4db-57cd-4ca1-9e41-fd52485b3ede">3,882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTAtMy0xLTEtMTA0MTE5_77238790-8f8b-430e-b036-35e90100293f">5,102,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTItMS0xLTEtMTA0MTE5_7f7dbd54-0807-44a3-b51d-de03134d17cf">789,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTItMy0xLTEtMTA0MTE5_b6e14f94-a261-4dc3-851c-720cf3121ea4">79,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of leased equipment sold to customer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="bngo:CostOfLeasedEquipmentSoldToCustomer" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTUtMS0xLTEtMTA0MTE5_62cd2b50-bb1f-4e89-b783-0741aa2a7ce6">88,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="bngo:CostOfLeasedEquipmentSoldToCustomer" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTUtMy0xLTEtMTA0MTE5_5a9961ea-b16e-4ae3-80f5-0d5dedb085fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTctMS0xLTEtMTA0MTE5_1cf7f2c6-98bd-4bed-b77c-abca17cc2fc2">242,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTctMy0xLTEtMTA0MTE5_30a0de9a-6e24-4013-9a2c-7c64f71e3284">640,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTgtMS0xLTEtMTA0MTE5_e322074c-633d-4bd6-afb4-5bb8919af976">5,707,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTgtMy0xLTEtMTA0MTE5_d16d8561-4d98-4b6e-bb6d-71c6db6b1b49">5,938,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTktMS0xLTEtMTA0MTE5_3e31d5f9-8edd-4ea8-adc1-d6d88852af6e">471,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTktMy0xLTEtMTA0MTE5_7c9fbf2d-fde6-451b-9455-1c8f83892a30">323,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTctMS0xLTEtMTE0ODE5_82751b40-5635-47f0-afe6-337c45f15937">372,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTctMy0xLTEtMTE0ODQ5_d35c46f1-25b0-449c-8f3e-5e2859e955bd">48,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjAtMS0xLTEtMTA0MTE5_15fa362c-aefb-4582-9e1e-2723df030a75">3,017,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjAtMy0xLTEtMTA0MTE5_51fbcf7e-64c9-443f-b294-b7df6dd9f582">3,168,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjEtMS0xLTEtMTA0MTE5_24b4c601-6e7a-4be7-a231-daede4e9f93a">978,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjEtMy0xLTEtMTA0MTE5_6a155513-c296-4069-a3bf-43b5d31aca9f">443,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjItMS0xLTEtMTA0MTE5_fd3bd244-f2e3-44fe-82d2-b43cb988a7c9">32,413,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjItMy0xLTEtMTA0MTE5_c46af176-9b63-4be3-a620-619f992282f2">32,494,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BioDiscovery acquisition, return of purchase consideration from escrow</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="bngo:ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjUtMS0xLTEtMTA0MTE5_cd8e1db4-112e-4894-ac0b-71902ed95b77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="bngo:ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjUtMy0xLTEtMTA0MTE5_d2e2b148-6367-4506-83af-467deaa09106">694,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="bngo:PaymentsForPropertyAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjYtMS0xLTEtMTA0MTE5_8c042868-d643-4e84-a7d6-1bebac999002">360,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="bngo:PaymentsForPropertyAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjYtMy0xLTEtMTA0MTE5_5c0c6577-6d5c-4916-bc2c-bc779f9ec2b4">150,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of available for sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjctMS0xLTEtMTA0MTE5_b551298d-ade1-4857-96d6-dd5e77361bdf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjctMy0xLTEtMTA0MTE5_f7b5180d-125a-4df9-9fd6-b5361b75a6ba">14,954,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sale and maturity of available for sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjgtMS0xLTEtMTA0MTE5_3aa441b3-33c0-405f-8c56-16c75f6350db">16,888,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjgtMy0xLTEtMTA0MTE5_c141c894-4a7a-4064-b52f-44556c304366">47,179,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsForConstructionInProcess" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjktMS0xLTEtMTA0MTE5_c046d85f-f76f-415d-86d9-b598b0d79dad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsForConstructionInProcess" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjktMy0xLTEtMTA0MTE5_2bd8bd5e-d5e9-4558-b82b-618828c191ec">832,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sale of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMzAtMS0xLTEtMTA0MTE5_866e0bd5-803b-4ff5-b827-78065e921a2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMzAtMy0xLTEtMTA0MTE5_e8b32369-ec3e-477d-ab37-f204445a439d">27,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMzEtMS0xLTEtMTA0MTE5_847f19c9-b69f-42ce-adc4-28bc5eaef60b">16,528,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMzEtMy0xLTEtMTA0MTE5_69bd55e4-69d1-479c-9c9d-681a8c6ee973">31,964,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal payments on financing lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMzgtMS0xLTEtMTA0MTE5_bc017366-06fa-4669-99ff-aeb5fa4e314b">10,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMzgtMy0xLTEtMTA0MTE5_304a208e-402f-4001-a2f5-ea0297f0c5ff">8,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMzktMS0xLTEtMTA0MTE5_96cc9422-a879-4509-8edd-55b5fe5b7d72">15,229,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMzktMy0xLTEtMTA0MTE5_31ae0cd9-1d95-4a99-b3e4-43f05d13f744">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Offering expenses on sale of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDAtMS0xLTEtMTA0MTE5_1138ff5f-c1eb-44e8-a225-a1618fa0758e">380,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDAtMy0xLTEtMTA0MTE5_06b33002-5851-414f-b4ab-9655f735c8a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from warrant and option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDItMS0xLTEtMTA0MTE5_ee3e3b2b-2b8f-4bf4-87d0-f61f9cc1c92b">23,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDItMy0xLTEtMTA0MTE5_66c4cccd-6e46-49ce-98ef-6ac89e0f0a80">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDMtMS0xLTEtMTA0MTE5_94473f28-b346-4942-9480-e46127898172">14,862,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDMtMy0xLTEtMTA0MTE5_5866e220-b139-4295-903d-89c1f388975c">7,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rates on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDQtMS0xLTEtMTA0MTE5_4187d9a0-1ff6-4947-a443-696677d40989">36,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDQtMy0xLTEtMTA0MTE5_afa46534-4048-4115-a8eb-87e73d44c29d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDUtMS0xLTEtMTA0MTE5_a2930984-c2a3-44f5-a8ff-9777839e3ffe">987,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDUtMy0xLTEtMTA0MTE5_6a0575cb-629e-478f-b7ef-9e2d45afdd72">523,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDYtMS0xLTEtMTA0MTE5_70bb7b33-0278-4f9b-95fa-bc7111bc35c4">5,491,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cfe18ad0d8e4978ada52e1560b4b9dd_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDYtMy0xLTEtMTA0MTE5_6f5d7de0-ecca-4284-8372-1097d180cc80">24,571,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDctMS0xLTEtMTA0MTE5_aedae8f0-c23b-4bad-8488-21ecda6f7d8f">4,504,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955cc10e676a434da3908ec8ee79b5a0_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDctMy0xLTEtMTA0MTE5_c19991f0-1a88-4348-bb76-e3e68d730559">24,048,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reconciliation of cash, cash equivalents and restricted cash reported within the unaudited condensed consolidated balance sheets to the total amounts reported on the unaudited condensed consolidated statements of cash flows</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDktMS0xLTEtMTA3ODA2_e7e0f993-f2c9-456a-8fb1-4ea24f80d64f">4,104,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955cc10e676a434da3908ec8ee79b5a0_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDktMy0xLTEtMTA2Nzgz_6601d822-1d3c-4e65-af54-eba5bc3741fe">24,048,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTAtMS0xLTEtMTA3ODA4_f631175f-6121-45d2-a6eb-9f610eb0833a">400,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955cc10e676a434da3908ec8ee79b5a0_I20220331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTAtMy0xLTEtMTA2Nzgz_a024f340-4e2b-4ca5-bb33-213dc939f8e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTEtMS0xLTEtMTA3ODEx_52c38c04-bc7d-40f8-bd6e-378aee520633">4,504,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955cc10e676a434da3908ec8ee79b5a0_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTEtMy0xLTEtMTA3ODE0_f12a5586-08cb-4799-a05d-4cc9874b0a81">24,048,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTAtMS0xLTEtMTA0MTE5_26297521-df0a-47c7-9505-59213ec2cc8d">76,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTAtMy0xLTEtMTA0MTE5_8626004f-40e3-4540-acbd-6043b921e2a4">70,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTEtMS0xLTEtMTA0MTE5_2c979e17-7c11-4cdc-ba03-d832f7e467ae">644,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTEtMy0xLTEtMTA0MTE5_23a78e24-9c4a-431d-9e64-068d7315cec4">217,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer of instruments and servers from property and equipment into inventory</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="bngo:TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTQtMS0xLTEtMTEyODY1_8c2848c1-a06d-4a25-a752-79f6db8b40cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="bngo:TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTQtMy0xLTEtMTEyODY2_3a7914ae-f180-408f-96bc-cd548ad1e593">544,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer of instruments and servers from inventory to property and equipment, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="bngo:TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTctMS0xLTEtMTA0MTE5_4e10fb99-9c0d-42f9-9223-83ec1b0b23a3">2,356,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="bngo:TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTctMy0xLTEtMTA0MTE5_55ddd3ff-8a33-4796-8b8d-2a17520215be">2,056,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment included in accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTgtMS0xLTEtMTA0MTE5_21aa558a-be67-4b35-ad7a-6cddf5254c6a">230,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTgtMy0xLTEtMTA0MTE5_88f58045-dba2-494d-b1ed-d6636ef7b039">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities resulting from obtaining right-of-use assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNjAtMS0xLTEtMTEyNzg2_bd70da1f-9c0f-4838-83f8-9ad0bef5fdc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNjAtMy0xLTEtMTEyNzg2_3b769e18-797e-471f-8389-05b1b5524abe">513,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed consolidated financial statements</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i561259e69fbb4552820b7ec56e5dea3a_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIONANO GENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_34"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNC9mcmFnOmJlNGM2MDUwNGY2MDRlZmQ5Y2M2YjIwNmZmYjRkMjUzL3RleHRyZWdpb246YmU0YzYwNTA0ZjYwNGVmZDljYzZiMjA2ZmZiNGQyNTNfMTI2NjU_4d5e382b-50f6-4d96-9f53-19dd8347b970" continuedAt="i3681d1a538454780b94eb00357678ad7" escape="true">Organization and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="i3681d1a538454780b94eb00357678ad7" continuedAt="i780547eac9484e4fa84d5ba1e10524ce"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bionano Genomics, Inc. (collectively, with its consolidated subsidiaries, the &#8220;Company&#8221;) is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company offers optical genome mapping (&#8220;OGM&#8221;) solutions for applications across basic, translational and clinical research, and for other applications including bioprocessing. Through its Lineagen, Inc. (doing business as Bionano Laboratories, &#8220;Bionano Laboratories&#8221;) business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery, LLC (&#8220;BioDiscovery&#8221;) business, the Company also offers platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. Through our Purigen Biosystems Inc. (&#8220;Purigen&#8221;) business, we offer nucleic acid extraction and purification solutions using proprietary isotachophoresis (&#8220;ITP&#8221;) technology.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNC9mcmFnOmJlNGM2MDUwNGY2MDRlZmQ5Y2M2YjIwNmZmYjRkMjUzL3RleHRyZWdpb246YmU0YzYwNTA0ZjYwNGVmZDljYzZiMjA2ZmZiNGQyNTNfMTI2NzA_9287c70c-1226-443c-b341-aa76b32649fd" continuedAt="i56f7cb97f1c34ec09ecec1ecc52bdbba" escape="true">Basis of Presentation</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i56f7cb97f1c34ec09ecec1ecc52bdbba">The accompanying financial information has been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for interim reporting purposes. The condensed consolidated financial statements are unaudited. The unaudited condensed consolidated financial statements reflect, in the opinion of the Company&#8217;s management, all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of financial position, results of operations, changes in equity, and comprehensive loss and cash flows for each period presented in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). All intercompany transactions and balances have been eliminated. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022.</ix:continuation> </span></div><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNC9mcmFnOmJlNGM2MDUwNGY2MDRlZmQ5Y2M2YjIwNmZmYjRkMjUzL3RleHRyZWdpb246YmU0YzYwNTA0ZjYwNGVmZDljYzZiMjA2ZmZiNGQyNTNfMTI2NzE_cd45c5cc-fc59-4046-b36b-3f435a42294a" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts reported in prior years have been reclassified to conform with the presentation in the current year. These reclassifications had no effect on the reported results of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="bngo:LiquidityAndGoingConcernPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNC9mcmFnOmJlNGM2MDUwNGY2MDRlZmQ5Y2M2YjIwNmZmYjRkMjUzL3RleHRyZWdpb246YmU0YzYwNTA0ZjYwNGVmZDljYzZiMjA2ZmZiNGQyNTNfMzI5ODUzNDkxMTc3Mw_4e2f4468-36f7-49f9-ba64-a06d7ae6608d" continuedAt="i9081e709508341df9b0bed6c90df21b9" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has experienced recurring net losses from operations, negative cash flows from operating activities, and accumulated deficit since its inception and expects to continue to incur net losses into the foreseeable future. As of March&#160;31, 2023, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNC9mcmFnOmJlNGM2MDUwNGY2MDRlZmQ5Y2M2YjIwNmZmYjRkMjUzL3RleHRyZWdpb246YmU0YzYwNTA0ZjYwNGVmZDljYzZiMjA2ZmZiNGQyNTNfMTY0OTI2NzQ3MDExMw_f4fa35a2-8c8d-4edc-9417-1a1248606e78">4.1</ix:nonFraction> million in cash and cash equivalents, $<ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNC9mcmFnOmJlNGM2MDUwNGY2MDRlZmQ5Y2M2YjIwNmZmYjRkMjUzL3RleHRyZWdpb246YmU0YzYwNTA0ZjYwNGVmZDljYzZiMjA2ZmZiNGQyNTNfMTY0OTI2NzQ3MDEyMA_a3de5bce-7e75-428e-8101-5f4fba879bc4">91.7</ix:nonFraction> million in short term investments, and working capital of $<ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-5" name="bngo:WorkingCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNC9mcmFnOmJlNGM2MDUwNGY2MDRlZmQ5Y2M2YjIwNmZmYjRkMjUzL3RleHRyZWdpb246YmU0YzYwNTA0ZjYwNGVmZDljYzZiMjA2ZmZiNGQyNTNfNTQ5NzU1ODQyMjk3_7793c21c-f5b0-4284-ba9c-c5de913221ee">104.4</ix:nonFraction> million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNC9mcmFnOmJlNGM2MDUwNGY2MDRlZmQ5Y2M2YjIwNmZmYjRkMjUzL3RleHRyZWdpb246YmU0YzYwNTA0ZjYwNGVmZDljYzZiMjA2ZmZiNGQyNTNfMTY0OTI2NzQ3MDEyNw_bf5fe4cd-df92-4f1c-a562-86986849e352">385.8</ix:nonFraction> million as of March&#160;31, 2023. During the three months ended March&#160;31, 2023, the Company used $<ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNC9mcmFnOmJlNGM2MDUwNGY2MDRlZmQ5Y2M2YjIwNmZmYjRkMjUzL3RleHRyZWdpb246YmU0YzYwNTA0ZjYwNGVmZDljYzZiMjA2ZmZiNGQyNTNfMTA5OTUxMTY1NjIxOQ_a8dadc8e-a642-46b3-9027-93a7c2b49e7e">32.4</ix:nonFraction> million cash in operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management expects operating losses and negative cash flows to continue for at least the next year as the Company continues to incur costs related to research and commercialization efforts. Management has prepared cash flows forecasts which indicate that based on the Company&#8217;s expected operating losses and negative cash flows, there is substantial doubt about the Company&#8217;s ability to continue as a going concern within twelve months after the date that the unaudited condensed consolidated financial statements for the three months ended March&#160;31, 2023, are issued. Management&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional funding. Management&#8217;s plans to raise additional capital to fulfill its operating and </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><ix:continuation id="i780547eac9484e4fa84d5ba1e10524ce" continuedAt="i3157e720d6a44a44b9dc3d8986b18f73"><ix:continuation id="i9081e709508341df9b0bed6c90df21b9"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital requirements for at least 12 months include public or private equity or debt financings. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company&#8217;s existing stockholders. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the outcome of this uncertainty.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, there were no changes to the Company&#8217;s significant accounting policies as described in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022. </span></div><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNC9mcmFnOmJlNGM2MDUwNGY2MDRlZmQ5Y2M2YjIwNmZmYjRkMjUzL3RleHRyZWdpb246YmU0YzYwNTA0ZjYwNGVmZDljYzZiMjA2ZmZiNGQyNTNfMTI2NzM_c125128e-8122-4d47-8bd1-1514082add07" continuedAt="if998c08e0c714a9faa79e9dae0c49ddc" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which amends the impairment model by requiring entities to use a forward looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. For trade receivables and other instruments, entities will be required to use a new forward-looking expected loss model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. The Company adopted ASU 2016-13 as of January 1, 2023. </span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3157e720d6a44a44b9dc3d8986b18f73"><ix:continuation id="if998c08e0c714a9faa79e9dae0c49ddc">The cumulative effect of applying the new credit loss standard was not material and, therefore, did not result in an adjustment to retained earnings. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements or related financial statement disclosures. In accordance with ASU 2016-13, the Company no longer evaluates whether its available-for-sale debt securities in an unrealized loss position are other than temporarily impaired. Instead, the Company assesses whether such unrealized loss positions are credit-related. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in other income through an allowance account. Unrealized gains and losses that are not credit-related are included in accumulated other comprehensive income.</ix:continuation></ix:continuation> </span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_37"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RleHRyZWdpb246Y2ZiMzNjYmU2MTcxNGVkMWJjM2M0MGU4NDE3YWI0MDJfMTMxMg_d2f43cb3-b7a0-49f3-9adf-165dc8b997c5" continuedAt="ia443927cbe2e49c69d28a267d9d37f27" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="ia443927cbe2e49c69d28a267d9d37f27"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common share equivalents are only included when their effect is dilutive. The Company&#8217;s potentially dilutive securities which include outstanding warrants to purchase stock, restricted stock units (&#8220;RSUs&#8221;), performance stock units (&#8220;PSUs&#8221;), and outstanding stock options under the Company&#8217;s equity incentive plans have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. Restricted stock is treated as outstanding for accounting purposes. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding because all potentially dilutive securities were anti-dilutive.</span></div><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RleHRyZWdpb246Y2ZiMzNjYmU2MTcxNGVkMWJjM2M0MGU4NDE3YWI0MDJfMTMxMw_5a092318-0fd4-4550-ba26-ee568d49f7e5" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:72.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i235c6220aed04a31be7cf68dde5f7075_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RhYmxlOmFkOTA1NWI4MTRmNTRhY2RhNTFlMzE0ZDNjOGRlOTA4L3RhYmxlcmFuZ2U6YWQ5MDU1YjgxNGY1NGFjZGE1MWUzMTRkM2M4ZGU5MDhfMS0xLTEtMS0xMDQxMTk_2c18f385-48ac-4f72-8c70-7befa8ff673c">32,013,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ee348f6918a4dccb9a11bb16deb4771_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RhYmxlOmFkOTA1NWI4MTRmNTRhY2RhNTFlMzE0ZDNjOGRlOTA4L3RhYmxlcmFuZ2U6YWQ5MDU1YjgxNGY1NGFjZGE1MWUzMTRkM2M4ZGU5MDhfMS0zLTEtMS0xMDQxMTk_93d41803-e1a3-43f7-ae87-e4853ec58e9c">21,531,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i80cbed6d5ffd48e39df9647e8b69fd38_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RhYmxlOmFkOTA1NWI4MTRmNTRhY2RhNTFlMzE0ZDNjOGRlOTA4L3RhYmxlcmFuZ2U6YWQ5MDU1YjgxNGY1NGFjZGE1MWUzMTRkM2M4ZGU5MDhfMi0xLTEtMS0xMDQxMTk_5d92df09-7a3b-477d-b291-8ad21cd590e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i990b58e8540b402f9deabf1b1e8d0d7a_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RhYmxlOmFkOTA1NWI4MTRmNTRhY2RhNTFlMzE0ZDNjOGRlOTA4L3RhYmxlcmFuZ2U6YWQ5MDU1YjgxNGY1NGFjZGE1MWUzMTRkM2M4ZGU5MDhfMi0zLTEtMS0xMDQxMTk_dff8dbe2-21f9-4554-b8da-91c5b259271b">4,257,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia5f34adecdf04ebca8394a17d3e26a73_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RhYmxlOmFkOTA1NWI4MTRmNTRhY2RhNTFlMzE0ZDNjOGRlOTA4L3RhYmxlcmFuZ2U6YWQ5MDU1YjgxNGY1NGFjZGE1MWUzMTRkM2M4ZGU5MDhfMy0xLTEtMS0xMDQxMTk_8773e8d4-e196-40bc-a3c5-a54c1af456f8">4,356,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ea78ca938894da3a2c044b50e0ecd12_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RhYmxlOmFkOTA1NWI4MTRmNTRhY2RhNTFlMzE0ZDNjOGRlOTA4L3RhYmxlcmFuZ2U6YWQ5MDU1YjgxNGY1NGFjZGE1MWUzMTRkM2M4ZGU5MDhfMy0zLTEtMS0xMDQxMTk_db9883c0-5a92-4cf9-a2d5-7439ba0a85b5">4,356,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6fa1ec9e299d43dea83ee07700d9f2e8_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RhYmxlOmFkOTA1NWI4MTRmNTRhY2RhNTFlMzE0ZDNjOGRlOTA4L3RhYmxlcmFuZ2U6YWQ5MDU1YjgxNGY1NGFjZGE1MWUzMTRkM2M4ZGU5MDhfNC0xLTEtMS0xMDQxMTk_05ac8f98-2997-4c13-a7ef-8d7fa44cfc0b">2,457,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4db80e7428124ae89fef6d38056d80eb_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RhYmxlOmFkOTA1NWI4MTRmNTRhY2RhNTFlMzE0ZDNjOGRlOTA4L3RhYmxlcmFuZ2U6YWQ5MDU1YjgxNGY1NGFjZGE1MWUzMTRkM2M4ZGU5MDhfNC0zLTEtMS0xMDQxMTk_4de44ebd-1068-4374-b23f-8626bc6444f5">296,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e41522832874c03827a502c55e81ea1_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RhYmxlOmFkOTA1NWI4MTRmNTRhY2RhNTFlMzE0ZDNjOGRlOTA4L3RhYmxlcmFuZ2U6YWQ5MDU1YjgxNGY1NGFjZGE1MWUzMTRkM2M4ZGU5MDhfNS0xLTEtMS0xMDQxMTk_a0a6c159-d197-486b-b9f9-7999785c1003">290,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93dc12a23ca743058cc875c7385cba95_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RhYmxlOmFkOTA1NWI4MTRmNTRhY2RhNTFlMzE0ZDNjOGRlOTA4L3RhYmxlcmFuZ2U6YWQ5MDU1YjgxNGY1NGFjZGE1MWUzMTRkM2M4ZGU5MDhfNS0zLTEtMS0xMDQxMTk_c0278200-3bd4-41b6-ba0b-7456afa399d9">290,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RhYmxlOmFkOTA1NWI4MTRmNTRhY2RhNTFlMzE0ZDNjOGRlOTA4L3RhYmxlcmFuZ2U6YWQ5MDU1YjgxNGY1NGFjZGE1MWUzMTRkM2M4ZGU5MDhfNi0xLTEtMS0xMDQxMTk_da088923-8e0e-47ab-95ff-e6089280ac7f">39,116,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RhYmxlOmFkOTA1NWI4MTRmNTRhY2RhNTFlMzE0ZDNjOGRlOTA4L3RhYmxlcmFuZ2U6YWQ5MDU1YjgxNGY1NGFjZGE1MWUzMTRkM2M4ZGU5MDhfNi0zLTEtMS0xMDQxMTk_dbbe29e8-2d9f-456b-b27f-f57b8a219818">30,730,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i561259e69fbb4552820b7ec56e5dea3a_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RleHRyZWdpb246OWQzYzk4ZGEwMmM5NGZlZDk3NGJmMTBmOTU0YmU3OWVfMjE0Mw_3ebbb2d7-194e-4d28-9bdc-336fee7e4ab1" continuedAt="i793d7d8cdcab4399940687d75aaed5db" escape="true">Revenue Recognition</ix:nonNumeric></span></div><ix:continuation id="i793d7d8cdcab4399940687d75aaed5db"><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RleHRyZWdpb246OWQzYzk4ZGEwMmM5NGZlZDk3NGJmMTBmOTU0YmU3OWVfMjE0Ng_b0a98ec6-e0aa-44a1-b250-9e7359aa94cf" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by Source</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Instruments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e2589f149c48c98dbde0d23aeb1c9c_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOmEwYzY4ZTkyNjQ3YjRmOTFhMzc1MGExYWZkM2IyMjViL3RhYmxlcmFuZ2U6YTBjNjhlOTI2NDdiNGY5MWEzNzUwYTFhZmQzYjIyNWJfMi0xLTEtMS0xMDQxMTk_00e3440e-1e50-403b-bac4-5a0021a1116f">1,896,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09f8c8fdda344e15915c6c62c7945dcc_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOmEwYzY4ZTkyNjQ3YjRmOTFhMzc1MGExYWZkM2IyMjViL3RhYmxlcmFuZ2U6YTBjNjhlOTI2NDdiNGY5MWEzNzUwYTFhZmQzYjIyNWJfMi0zLTEtMS0xMDQxMTk_9d71284a-fdab-49ec-b053-da035f7fe2d2">1,596,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6b13878be8b45768ae8ee86b23ec8b8_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOmEwYzY4ZTkyNjQ3YjRmOTFhMzc1MGExYWZkM2IyMjViL3RhYmxlcmFuZ2U6YTBjNjhlOTI2NDdiNGY5MWEzNzUwYTFhZmQzYjIyNWJfMy0xLTEtMS0xMDQxMTk_1623f3ea-0ddb-4cb4-8d0f-80e3ad66b26a">2,235,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d3a177eaaa94180a39abb73b6e894d5_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOmEwYzY4ZTkyNjQ3YjRmOTFhMzc1MGExYWZkM2IyMjViL3RhYmxlcmFuZ2U6YTBjNjhlOTI2NDdiNGY5MWEzNzUwYTFhZmQzYjIyNWJfMy0zLTEtMS0xMDQxMTk_056395b2-c7ad-4537-b974-d238d968f630">1,520,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c588f3ec9a49a9926f153fcb7f5e22_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOmEwYzY4ZTkyNjQ3YjRmOTFhMzc1MGExYWZkM2IyMjViL3RhYmxlcmFuZ2U6YTBjNjhlOTI2NDdiNGY5MWEzNzUwYTFhZmQzYjIyNWJfNC0xLTEtMS0xMDQ2ODU_08e5a98b-c485-4060-99e1-18bdc1ec2fa3">1,316,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1dda61a7dbc48e3acfd918b47fcb93b_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOmEwYzY4ZTkyNjQ3YjRmOTFhMzc1MGExYWZkM2IyMjViL3RhYmxlcmFuZ2U6YTBjNjhlOTI2NDdiNGY5MWEzNzUwYTFhZmQzYjIyNWJfNC0zLTEtMS0xMDQ2OTI_8d374fa4-4860-4951-8aef-f21464db7b0b">1,090,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22c603917ec343e5b40cf1377f2dd0fa_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOmEwYzY4ZTkyNjQ3YjRmOTFhMzc1MGExYWZkM2IyMjViL3RhYmxlcmFuZ2U6YTBjNjhlOTI2NDdiNGY5MWEzNzUwYTFhZmQzYjIyNWJfNC0xLTEtMS0xMDQxMTk_3790dd9a-8892-490f-90ea-5bdd5f7edb2b">5,447,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i103e1f66718e42e092ef57cf65cbad93_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOmEwYzY4ZTkyNjQ3YjRmOTFhMzc1MGExYWZkM2IyMjViL3RhYmxlcmFuZ2U6YTBjNjhlOTI2NDdiNGY5MWEzNzUwYTFhZmQzYjIyNWJfNC0zLTEtMS0xMDQxMTk_db90560b-9136-4a05-ae0e-fd3b338c6dfa">4,206,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service and other</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1fe061275f84c0db4bc966cec7ea694_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOmEwYzY4ZTkyNjQ3YjRmOTFhMzc1MGExYWZkM2IyMjViL3RhYmxlcmFuZ2U6YTBjNjhlOTI2NDdiNGY5MWEzNzUwYTFhZmQzYjIyNWJfNS0xLTEtMS0xMDQxMTk_522ca6ca-5a41-498a-a93a-84b090bf5006">1,968,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifebd115420624a60b9827cd166e72988_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOmEwYzY4ZTkyNjQ3YjRmOTFhMzc1MGExYWZkM2IyMjViL3RhYmxlcmFuZ2U6YTBjNjhlOTI2NDdiNGY5MWEzNzUwYTFhZmQzYjIyNWJfNS0zLTEtMS0xMDQxMTk_24483e33-7d36-441e-a186-215e29c1e1e4">1,490,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOmEwYzY4ZTkyNjQ3YjRmOTFhMzc1MGExYWZkM2IyMjViL3RhYmxlcmFuZ2U6YTBjNjhlOTI2NDdiNGY5MWEzNzUwYTFhZmQzYjIyNWJfNi0xLTEtMS0xMDQxMTk_bdefea21-92ae-4e17-bcaa-13e18fc2f1b0">7,415,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOmEwYzY4ZTkyNjQ3YjRmOTFhMzc1MGExYWZkM2IyMjViL3RhYmxlcmFuZ2U6YTBjNjhlOTI2NDdiNGY5MWEzNzUwYTFhZmQzYjIyNWJfNi0zLTEtMS0xMDQxMTk_9b94f88a-03bf-483d-8487-8e37d8071b6e">5,696,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has revised the classification of its revenue between the categories in the table above for the March 31, 2022 statement of operations. In the March 31, 2022 statement of operations, &#8220;software&#8221; was included in &#8220;service and other.&#8221;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by Geographic Location</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.284%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Americas</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6669836447414cf385db5ed716981bad_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfMy0xLTEtMS0xMDQxMTk_971d5b43-0133-4f5f-b190-f5b20136a098">3,444,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b1a8735b85a466297034ff9a73884a0_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfMy0zLTEtMS0xMDQxMTk_2bf1dee7-6eeb-4b83-b939-f4daccb11675">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f04d40d0a8a454f84a321e4acea14d8_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfMy01LTEtMS0xMDQxMTk_a2e1b007-8f63-4af0-877f-ade93fcf444c">3,328,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc3e1023716e476aab35caddbed89579_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfMy03LTEtMS0xMDQxMTk_6a5fe116-fbcc-4ca5-af64-d772e08526c1">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f8e39f135240fd97ecb419976b9597_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfNC0xLTEtMS0xMDQxMTk_6cdb092c-fac5-4309-9f4c-9209df8a6645">2,992,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie92600da576c4047864e9f7117cc5fdf_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfNC0zLTEtMS0xMDQxMTk_b5c3dd74-49bb-4b81-84eb-e5fe2e0dc26e">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72bd82e51a92475595d3e02336fdfb2d_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfNC01LTEtMS0xMDQxMTk_d78929cc-44b2-4497-8ab4-52aeb114e086">1,739,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibf59dab4a829447b87dd7cfb6e935afc_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfNC03LTEtMS0xMDQxMTk_fec441ff-371f-4745-8f62-abf36a6eab3d">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i917de2a823d54fc7a1e5c49a7ec6d043_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfNS0xLTEtMS0xMDQxMTk_9a4cb7d0-525b-49ff-9c60-c294e1e9790b">979,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e339b6ff4f0444a9fc421813ed7f9fc_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfNS0zLTEtMS0xMDQxMTk_86c26ad4-0ea0-4716-be56-70dd56bfc6bd">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if817cc0631b9461ca84a6ce880217661_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfNS01LTEtMS0xMDQxMTk_faf7fc10-9bdf-4c3b-aece-77844529740b">629,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i16ed69d918584dbcb3ba99cd2e78d70d_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfNS03LTEtMS0xMDQxMTk_afb50801-19b8-4896-9375-159ee59a8af6">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfNi0xLTEtMS0xMDQxMTk_0b248c88-0c18-4562-8c54-f24e404a67e2">7,415,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iec1a90f2c7e6457d9c6916e2e00a8d96_D20230101-20230331" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfNi0zLTEtMS0xMDQxMTk_6fb56937-97bb-406e-a17f-bddb57e6e3df">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfNi01LTEtMS0xMDQxMTk_ddef8e1e-5239-488b-b161-a3e6d043cf19">5,696,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if4e04fca88824c018823bdc8633103aa_D20220101-20220331" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfNi03LTEtMS0xMDQxMTk_26cf8e6a-fba0-49ee-ace8-d7142cc93ce7">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table above provides revenue from contracts with customers by source and geographic region (based on the customer&#8217;s billing address) on a disaggregated basis. Americas consists of North America and South America. EMEA consists of Europe, the Middle East, and Africa. Asia Pacific includes China, Japan, South Korea, Singapore, India and Australia. During the three months ended September 30, 2022, the Company changed the presentation of its revenues from India to be included in the Asia Pacific geographic region. Prior to the three months ended September 30, 2022, the Company had presented revenues from India in the EMEA geographic region. The impact of this change on prior period disclosures is immaterial. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023 and 2022, the United States represented <ix:nonFraction unitRef="number" contextRef="i4b3236b899344cfc8b2fdf441232a276_D20230101-20230331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RleHRyZWdpb246OWQzYzk4ZGEwMmM5NGZlZDk3NGJmMTBmOTU0YmU3OWVfODM3_f5e2c0cd-03a8-4acd-aacc-68452f9c3653">41.2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ida637f06483b4c35bd6bc6a61abb2280_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RleHRyZWdpb246OWQzYzk4ZGEwMmM5NGZlZDk3NGJmMTBmOTU0YmU3OWVfODQ0_86cb7db8-cccf-486f-90bd-65d144f09d49">45.0</ix:nonFraction>% of total revenue, respectively. No other countries represented greater than 10% of revenue during the three months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remaining Performance Obligations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was approximately $<ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RleHRyZWdpb246OWQzYzk4ZGEwMmM5NGZlZDk3NGJmMTBmOTU0YmU3OWVfMTUyNA_6b98a67b-421f-49c5-9008-01799b63ff7e">1.3</ix:nonFraction> million. These remaining performance obligations primarily relate to extended warranty and support and maintenance obligations. The Company expects to recognize approximately&#160;<ix:nonFraction unitRef="number" contextRef="i303c93e0678640749a33b09eedfdd18e_I20230331" decimals="3" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RleHRyZWdpb246OWQzYzk4ZGEwMmM5NGZlZDk3NGJmMTBmOTU0YmU3OWVfMTY5NA_69def23d-0a6d-48b9-ad74-131544c9eb10">74.9</ix:nonFraction>% of this amount as revenue during the remainder of 2023,&#160;<ix:nonFraction unitRef="number" contextRef="i91fc38e2fd89410d85c4aaa28c03aa5a_I20230331" decimals="3" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RleHRyZWdpb246OWQzYzk4ZGEwMmM5NGZlZDk3NGJmMTBmOTU0YmU3OWVfMTc1Mw_0837da0d-3b64-4024-b678-c8c65d5b76c0">20.5</ix:nonFraction>%&#160;in 2024, and <ix:nonFraction unitRef="number" contextRef="i678356c830584df394c07359661df8fe_I20230331" decimals="3" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RleHRyZWdpb246OWQzYzk4ZGEwMmM5NGZlZDk3NGJmMTBmOTU0YmU3OWVfMTc2OQ_a05c0f16-6b8c-40ab-96a6-2793b69d1976">4.6</ix:nonFraction>%&#160;in 2025 and thereafter. Warranty revenue is included in service and other revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue of approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RleHRyZWdpb246OWQzYzk4ZGEwMmM5NGZlZDk3NGJmMTBmOTU0YmU3OWVfMTkwMw_0b06e993-f02e-4326-bbdb-39a322eaf54c">0.7</ix:nonFraction> million&#160;and $<ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RleHRyZWdpb246OWQzYzk4ZGEwMmM5NGZlZDk3NGJmMTBmOTU0YmU3OWVfMTkxMA_94d0f5fb-fd8d-4784-ad90-eef57a8cf5ab">0.3</ix:nonFraction> million during the three months ended March&#160;31, 2023 and 2022, respectively, which was included in the contract liability balance at the end of the previous year.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i561259e69fbb4552820b7ec56e5dea3a_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RleHRyZWdpb246MWNmOThmMDQyMzU2NDEzNTk2YzM2ZjE4NGE1MDJmZGZfNTY2_d6d7d9fe-5dba-408e-966f-d7eca7337189" continuedAt="id0c705f2e9e14938bfeba78d43b0bd22" escape="true">Balance Sheet Account Details</ix:nonNumeric></span></div><ix:continuation id="id0c705f2e9e14938bfeba78d43b0bd22" continuedAt="i1c39f77d22d246b1a2d9cd0542bd38fd"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses</span></div><div style="margin-top:6pt;text-align:justify"><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RleHRyZWdpb246MWNmOThmMDQyMzU2NDEzNTk2YzM2ZjE4NGE1MDJmZGZfNTYx_ce11ec3d-15f0-4589-b386-b42d573cb563" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, trade</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjkzOTcxMjJmZmUyYTQ3MjE4NGJhMTM4YTdlMzRmN2RkL3RhYmxlcmFuZ2U6OTM5NzEyMmZmZTJhNDcyMTg0YmExMzhhN2UzNGY3ZGRfMi0xLTEtMS0xMDQxMTk_216931b5-4e73-4a54-8e17-f3caa4597ac5">7,030,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjkzOTcxMjJmZmUyYTQ3MjE4NGJhMTM4YTdlMzRmN2RkL3RhYmxlcmFuZ2U6OTM5NzEyMmZmZTJhNDcyMTg0YmExMzhhN2UzNGY3ZGRfMi00LTEtMS0xMDQxMTk_70a441ae-b07c-47d5-a096-94d41edbbea5">7,315,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allowance for credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjkzOTcxMjJmZmUyYTQ3MjE4NGJhMTM4YTdlMzRmN2RkL3RhYmxlcmFuZ2U6OTM5NzEyMmZmZTJhNDcyMTg0YmExMzhhN2UzNGY3ZGRfMy0xLTEtMS0xMDQxMTk_1b510d8b-8643-4062-8b8d-e55c36c53598">250,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjkzOTcxMjJmZmUyYTQ3MjE4NGJhMTM4YTdlMzRmN2RkL3RhYmxlcmFuZ2U6OTM5NzEyMmZmZTJhNDcyMTg0YmExMzhhN2UzNGY3ZGRfMy00LTEtMS0xMDQxMTk_c1a325b8-42aa-4ca3-924a-b2c066567253">293,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjkzOTcxMjJmZmUyYTQ3MjE4NGJhMTM4YTdlMzRmN2RkL3RhYmxlcmFuZ2U6OTM5NzEyMmZmZTJhNDcyMTg0YmExMzhhN2UzNGY3ZGRfNC0xLTEtMS0xMDQxMTk_01708d36-a2d9-4922-91ef-eaf13764f75b">6,780,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjkzOTcxMjJmZmUyYTQ3MjE4NGJhMTM4YTdlMzRmN2RkL3RhYmxlcmFuZ2U6OTM5NzEyMmZmZTJhNDcyMTg0YmExMzhhN2UzNGY3ZGRfNC00LTEtMS0xMDQxMTk_f914c7a8-aec8-402d-92d5-1fbc7c6fda0a">7,022,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RleHRyZWdpb246MWNmOThmMDQyMzU2NDEzNTk2YzM2ZjE4NGE1MDJmZGZfNDk0NzgwMjMyNzEzMQ_d69da13b-883a-4f78-b7e1-f760d06cb1b9" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the allowance for credit losses during the three months ended March&#160;31, 2023 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of January 1, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjllYWIyZGQyOWM2YzQ1N2ZiZDI3NzkxNDA2MGY5NjI0L3RhYmxlcmFuZ2U6OWVhYjJkZDI5YzZjNDU3ZmJkMjc3OTE0MDYwZjk2MjRfMS0xLTEtMS0xMTMxODA_f3d8430c-98c0-4524-876a-f16e1f85153f">293,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for expected credit loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjllYWIyZGQyOWM2YzQ1N2ZiZDI3NzkxNDA2MGY5NjI0L3RhYmxlcmFuZ2U6OWVhYjJkZDI5YzZjNDU3ZmJkMjc3OTE0MDYwZjk2MjRfMi0xLTEtMS0xMTMxODA_95fc3ca3-2c21-4db7-8547-13714d4dcd1c">5,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-offs and payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjllYWIyZGQyOWM2YzQ1N2ZiZDI3NzkxNDA2MGY5NjI0L3RhYmxlcmFuZ2U6OWVhYjJkZDI5YzZjNDU3ZmJkMjc3OTE0MDYwZjk2MjRfMy0xLTEtMS0xMTMxODA_650adaf8-f1bc-45c0-bae8-ad78d90fcda9">48,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjllYWIyZGQyOWM2YzQ1N2ZiZDI3NzkxNDA2MGY5NjI0L3RhYmxlcmFuZ2U6OWVhYjJkZDI5YzZjNDU3ZmJkMjc3OTE0MDYwZjk2MjRfNC0xLTEtMS0xMTMxODA_1e65b130-ae3d-4dd9-bb43-72ea04dc29a1">250,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's adoption of ASU No. 2016-13, Financial Instruments - Credit Losses, included an assessment of our aged trade receivables balances and their underlying credit risk characteristics. Our evaluation of past events, current conditions, and reasonable and supportable forecasts about the future resulted in an expectation of immaterial credit losses.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><ix:continuation id="i1c39f77d22d246b1a2d9cd0542bd38fd"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory </span></div><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RleHRyZWdpb246MWNmOThmMDQyMzU2NDEzNTk2YzM2ZjE4NGE1MDJmZGZfNTY3_f86bbcf1-35e3-4230-b595-ddd366acb11c" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventories are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjFlZmMwZTQxNmVkZDQxYWViNTY3NGI4YzZjMDAxNGEyL3RhYmxlcmFuZ2U6MWVmYzBlNDE2ZWRkNDFhZWI1Njc0YjhjNmMwMDE0YTJfMi0xLTEtMS0xMDQxMTk_1327865b-af1f-482d-96c5-b4b1b9cd9915">5,800,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjFlZmMwZTQxNmVkZDQxYWViNTY3NGI4YzZjMDAxNGEyL3RhYmxlcmFuZ2U6MWVmYzBlNDE2ZWRkNDFhZWI1Njc0YjhjNmMwMDE0YTJfMi0zLTEtMS0xMDQxMTk_c393b2e8-b694-4cb6-8ee8-dd24e7e57321">5,319,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Work in process</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjFlZmMwZTQxNmVkZDQxYWViNTY3NGI4YzZjMDAxNGEyL3RhYmxlcmFuZ2U6MWVmYzBlNDE2ZWRkNDFhZWI1Njc0YjhjNmMwMDE0YTJfMy0xLTEtMS0xMDQxMTk_4898dc80-3108-4367-a661-d6be6158777e">10,003,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjFlZmMwZTQxNmVkZDQxYWViNTY3NGI4YzZjMDAxNGEyL3RhYmxlcmFuZ2U6MWVmYzBlNDE2ZWRkNDFhZWI1Njc0YjhjNmMwMDE0YTJfMy0zLTEtMS0xMDQxMTk_14094897-2037-42c8-b63f-c20e2c2439e5">7,055,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjFlZmMwZTQxNmVkZDQxYWViNTY3NGI4YzZjMDAxNGEyL3RhYmxlcmFuZ2U6MWVmYzBlNDE2ZWRkNDFhZWI1Njc0YjhjNmMwMDE0YTJfNC0xLTEtMS0xMDQxMTk_70612b59-d5db-4057-96b8-9dcb3f8f96ae">17,310,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjFlZmMwZTQxNmVkZDQxYWViNTY3NGI4YzZjMDAxNGEyL3RhYmxlcmFuZ2U6MWVmYzBlNDE2ZWRkNDFhZWI1Njc0YjhjNmMwMDE0YTJfNC0zLTEtMS0xMDQxMTk_51a015c0-3fe9-4b2d-8973-aa6130ec67fc">17,387,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjFlZmMwZTQxNmVkZDQxYWViNTY3NGI4YzZjMDAxNGEyL3RhYmxlcmFuZ2U6MWVmYzBlNDE2ZWRkNDFhZWI1Njc0YjhjNmMwMDE0YTJfNS0xLTEtMS0xMDQxMTk_956f09a2-bcad-4e55-9ce1-1c740dd97c1a">33,113,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjFlZmMwZTQxNmVkZDQxYWViNTY3NGI4YzZjMDAxNGEyL3RhYmxlcmFuZ2U6MWVmYzBlNDE2ZWRkNDFhZWI1Njc0YjhjNmMwMDE0YTJfNS0zLTEtMS0xMDQxMTk_fa25d76b-30f0-47a0-a2c9-0a1e4ae19f5f">29,761,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RleHRyZWdpb246MWNmOThmMDQyMzU2NDEzNTk2YzM2ZjE4NGE1MDJmZGZfNTY1_79bc9a8c-f3cf-4c0c-aeaa-5a16bc886731" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that are subject to amortization consisted of the following for the periods presented:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d038c26e154c959a4f83462f9a3b3d_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfMi0yLTEtMS0xMDQxMTk_83f2609d-d35c-421f-b3a2-9ab8651269f5">2,630,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29d038c26e154c959a4f83462f9a3b3d_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfMi00LTEtMS0xMDQxMTk_ee1f3191-c504-491f-ba17-8e24d4a0f69b">684,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d038c26e154c959a4f83462f9a3b3d_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfMi02LTEtMS0xMDQxMTk_e3898b83-40a0-4a61-8f05-9924bf08b050">1,946,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21009a40b5d4f3a9d49db39e85d0352_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfMi04LTEtMS0xMDQxMTk_03464035-de84-4a8b-8831-1bfddab809c8">2,630,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic21009a40b5d4f3a9d49db39e85d0352_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfMi0xMC0xLTEtMTA0MTE5_742522d2-4786-468b-bd7e-40e7e8619965">552,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21009a40b5d4f3a9d49db39e85d0352_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfMi0xMi0xLTEtMTA0MTE5_46bed165-96d5-4f9d-b708-ecea6e805c9d">2,078,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b57f1747a864d48806216f6ebcb9b52_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfMy0yLTEtMS0xMDQxMTk_c231dafe-cddb-42fe-aacc-0b0be8f15426">4,150,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b57f1747a864d48806216f6ebcb9b52_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfMy00LTEtMS0xMDQxMTk_c2956e2f-fec2-43be-bddb-7ae9dc91813d">1,379,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b57f1747a864d48806216f6ebcb9b52_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfMy02LTEtMS0xMDQxMTk_5b730831-2f19-425d-b08c-93f573f9a2b8">2,771,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id18ec7102f5243eead2eb22c65c27ed0_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfMy04LTEtMS0xMDQxMTk_b136d2f4-9614-4f22-927d-992622e51810">4,150,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id18ec7102f5243eead2eb22c65c27ed0_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfMy0xMC0xLTEtMTA0MTE5_493cd3b8-f3a7-4fe4-baf6-d63bc09baf83">1,172,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id18ec7102f5243eead2eb22c65c27ed0_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfMy0xMi0xLTEtMTA0MTE5_119b2ed1-ce9f-4bea-ba09-7efd9e7ed031">2,978,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d06ccbd81864c1aa7ab64abb42f4f5c_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfNC0yLTEtMS0xMDQxMTk_a821e874-24d3-459c-adc1-83e6974dab99">41,600,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d06ccbd81864c1aa7ab64abb42f4f5c_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfNC00LTEtMS0xMDQxMTk_accc917d-9535-472c-b711-14aa40b931df">7,068,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d06ccbd81864c1aa7ab64abb42f4f5c_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfNC02LTEtMS0xMDQxMTk_53a032a6-081b-4759-8837-ad8be41753fc">34,532,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a742016d854b90bc517ceec127c4da_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfNC04LTEtMS0xMDQxMTk_26d8d653-3c57-4dec-85ea-afbf176908dd">41,600,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30a742016d854b90bc517ceec127c4da_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfNC0xMC0xLTEtMTA0MTE5_b3eb3a60-eea5-4f3e-ac37-bba397614631">5,615,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a742016d854b90bc517ceec127c4da_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfNC0xMi0xLTEtMTA0MTE5_64548433-1d91-4306-b21d-6b92c425e667">35,985,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfNS0yLTEtMS0xMDQxMTk_d882121f-f5f3-4c0a-8c2d-c6b02312ff56">48,380,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfNS00LTEtMS0xMDQxMTk_7f866c55-5591-4c0c-ac12-77260bd472a3">9,131,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfNS02LTEtMS0xMDQxMTk_fc7f4680-465c-481c-9ce9-4847221e1f20">39,249,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfNS04LTEtMS0xMDQxMTk_27688311-31a3-46b2-958a-5164fa257962">48,380,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfNS0xMC0xLTEtMTA0MTE5_fcab77dd-8e05-4d53-9410-1734d071d73f">7,339,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfNS0xMi0xLTEtMTA0MTE5_fe85f327-253e-4a59-bb14-d6562c00df91">41,041,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets not subject to amortization totaled $<ix:nonFraction unitRef="usd" contextRef="ib5a9db6b0ffb4fe28ef89805f31f26bc_I20221231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RleHRyZWdpb246MWNmOThmMDQyMzU2NDEzNTk2YzM2ZjE4NGE1MDJmZGZfNTQ5NzU1ODE1MDEz_22d8fdc4-fbb5-4c35-96b5-c033f37cdadd"><ix:nonFraction unitRef="usd" contextRef="iafccbaea24c04903bdeb891f986857c7_I20230331" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RleHRyZWdpb246MWNmOThmMDQyMzU2NDEzNTk2YzM2ZjE4NGE1MDJmZGZfNTQ5NzU1ODE1MDEz_f99ae2e3-7bac-4224-be5e-aeeb1f39e25b">0.1</ix:nonFraction></ix:nonFraction>&#160;million at March&#160;31, 2023 and December&#160;31, 2022, and related to the Company&#8217;s domain name. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RleHRyZWdpb246MWNmOThmMDQyMzU2NDEzNTk2YzM2ZjE4NGE1MDJmZGZfNTY0_b4788c8d-c726-4d86-9f78-fd56b45f3079" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following: </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfMS0xLTEtMS0xMDQxMTk_f404352a-d5a1-4b0d-9629-108c4719038d">6,349,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfMS0zLTEtMS0xMDQxMTk_d12c7c8c-144a-4705-bb45-d5bf47d814a3">7,002,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:DepositLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfMy0xLTEtMS0xMDQxMTk_07030618-fba4-4c33-9988-16cd01f8cf56">17,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:DepositLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfMy0zLTEtMS0xMDQxMTk_68a1ef1f-9e6e-4996-9f7a-31dac1e34665">17,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfNC0xLTEtMS0xMDQxMTk_a9b9f72b-eb64-4292-b8ae-d4997d2996e4">848,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfNC0zLTEtMS0xMDQxMTk_c4da87c6-a364-4960-b5ea-b7c177a654f2">825,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:AccruedInsuranceCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfNS0xLTEtMS0xMDQxMTk_6405141f-0690-4681-b6dc-69600dc5515b">326,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:AccruedInsuranceCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfNS0zLTEtMS0xMDQxMTk_eb9c4335-058c-457e-a853-ad74f1b32eed">613,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional fees and royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="bngo:ProfessionalFeesAndRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfNi0xLTEtMS0xMDQxMTk_7de4d4a0-f343-45a1-8579-09cbe9366a58">96,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="bngo:ProfessionalFeesAndRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfNi0zLTEtMS0xMDQxMTk_9a8f716b-fec8-495b-8131-f385e61808db">210,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warranty liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfNy0xLTEtMS0xMDQxMTk_2a012f02-4a74-43b7-8e91-2947ec381e34">591,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfNy0zLTEtMS0xMDQxMTk_a0a567d7-cb7c-471f-aa7e-411aafa9a485">489,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical study fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="bngo:AccruedClinicalStudyFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfOC0xLTEtMS0xMDQxMTk_1ae5118b-d08c-46d7-b003-f8941eff7145">174,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="bngo:AccruedClinicalStudyFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfOC0zLTEtMS0xMDQxMTk_0f154643-9cc2-4c16-8950-77b8a7a76db4">250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfOS0xLTEtMS0xMDQxMTk_a7cb503d-353e-4154-ab6b-1bf045ef0b20">849,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfOS0zLTEtMS0xMDQxMTk_0d4c9f32-594a-402f-bade-1f2aef604f15">1,146,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfMTAtMS0xLTEtMTA0MTE5_3d450668-26da-4c81-b07c-a7e12e249acd">9,250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfMTAtMy0xLTEtMTA0MTE5_46ebd4a5-d388-4e2b-bdc6-2786ac0691e0">10,552,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i561259e69fbb4552820b7ec56e5dea3a_52"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNjM0NQ_7526821b-5fff-4732-a68c-2b4b9261efee" continuedAt="id879d2b23d374f6385558b63d2163f89" escape="true">Stockholders&#8217; Equity and Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="id879d2b23d374f6385558b63d2163f89" continuedAt="i1bb56e37d1464340bfaaf1d5901f0778"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cowen At-the-Market Facility</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2021, the Company entered into a Sales Agreement with Cowen and Company, LLC (&#8220;Cowen&#8221;) which provides for the sale, in the Company&#8217;s sole discretion, of shares of common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i25be08a217074beba4e4c3f2222e4263_D20210323-20210323" decimals="-5" name="bngo:SaleOfStockValueSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMjU3OQ_d070c395-f0f4-4d18-ae3b-b4dec7e8f684">350.0</ix:nonFraction>&#160;million through or to Cowen, acting as sales agent or principal, which was amended on March 9, 2023 to decrease the maximum aggregate offering price to $<ix:nonFraction unitRef="usd" contextRef="i97754e6d8ba6487d87fcb2566157286b_D20230309-20230309" decimals="-5" name="bngo:SaleOfStockValueSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNDk0NzgwMjM0MTQ2Mw_ae8ca176-03c8-42c0-8c26-b69fcc20b17f">200.0</ix:nonFraction>&#160;million for sales made on and after the date of the amendment (the &#8220;Cowen ATM&#8221;). The Company agreed to pay Cowen a commission of up to <ix:nonFraction unitRef="number" contextRef="i25be08a217074beba4e4c3f2222e4263_D20210323-20210323" decimals="3" name="bngo:CommissionFeeMaximumPercentageOfGrossProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMjcxMQ_e8351f54-c947-4f86-985c-6883da8e232a">3.0</ix:nonFraction>% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. In August 2022, the Company sold approximately <ix:nonFraction unitRef="shares" contextRef="i93b42a0d7db1482cba91fd543f66a9ba_D20220801-20220831" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMzE2OQ_525610c0-b77f-4174-8d0a-72b1dff6daa2">6.6</ix:nonFraction>&#160;million shares of common stock under the Cowen ATM at an average share price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i99f3f173943c45748c287bda013eed0c_I20220831" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMzI0NA_60a1820e-adc9-4fda-95dd-382452369e7e">3.46</ix:nonFraction> per share, and received gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i93b42a0d7db1482cba91fd543f66a9ba_D20220801-20220831" decimals="-5" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMzMwMw_65a3fe6e-0fe6-4311-810c-242596b9e98c">23.1</ix:nonFraction> million before deducting offering costs of $<ix:nonFraction unitRef="usd" contextRef="i99f3f173943c45748c287bda013eed0c_I20220831" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMzM0MQ_53af180b-db71-40ff-8942-b12b763ac7d7">0.6</ix:nonFraction> million. During the first quarter of 2023, the Company sold approximately <ix:nonFraction unitRef="shares" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMTA5OTUxMTY0MTUyMw_25d9bfa8-a02f-49aa-88d3-a9db9ae2df9d">9.5</ix:nonFraction>&#160;million shares of common stock under the Cowen ATM at an average share price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMTA5OTUxMTY0MTUyNw_c7c011d2-329b-43cf-b28e-27e3cdb0e080">1.60</ix:nonFraction> per share, and received gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMTA5OTUxMTY0MTUzMQ_bd00fc6e-0799-45db-a345-018cff6e2b47">15.2</ix:nonFraction> million before deducting offering costs of $<ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMTA5OTUxMTY0MTUzNQ_fe435273-1880-4d43-b4e7-013369174ce8">0.4</ix:nonFraction> million. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><ix:continuation id="i1bb56e37d1464340bfaaf1d5901f0778" continuedAt="ib4b8d55ee6db43f7ad250a23f8f3e0cd"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Warrants</span></div><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNjM0Ng_80e022e1-9c29-41fe-8f3e-02744766b931" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s warrant activity during the three months ended March&#160;31, 2023 was as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares of Stock under Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjU4NTJlZmU0NWVhMjRkZjBhZDJjYjY4Y2IxNjAzOWVjL3RhYmxlcmFuZ2U6NTg1MmVmZTQ1ZWEyNGRmMGFkMmNiNjhjYjE2MDM5ZWNfMS0xLTEtMS0xMDQxMTk_a9201b96-393e-44f1-8eb1-d4ba1edf7a6c">4,356,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjU4NTJlZmU0NWVhMjRkZjBhZDJjYjY4Y2IxNjAzOWVjL3RhYmxlcmFuZ2U6NTg1MmVmZTQ1ZWEyNGRmMGFkMmNiNjhjYjE2MDM5ZWNfMS0zLTEtMS0xMDQxMTk_d529c2d3-f2a6-4140-81dc-4b5fd79f5de4">5.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4be8520461cc4836b2bf1279c0c49b2a_D20220101-20221231" name="bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjU4NTJlZmU0NWVhMjRkZjBhZDJjYjY4Y2IxNjAzOWVjL3RhYmxlcmFuZ2U6NTg1MmVmZTQ1ZWEyNGRmMGFkMmNiNjhjYjE2MDM5ZWNfMS01LTEtMS0xMDQxMTk_d7ebd10a-bc9f-40dc-987f-3652a207a0c4">0.76</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="bngo:ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjU4NTJlZmU0NWVhMjRkZjBhZDJjYjY4Y2IxNjAzOWVjL3RhYmxlcmFuZ2U6NTg1MmVmZTQ1ZWEyNGRmMGFkMmNiNjhjYjE2MDM5ZWNfMS03LTEtMS0xMDQxMTk_ea386e91-7dbd-4521-b35f-b7e7c2ede0e2">273,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="bngo:ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjU4NTJlZmU0NWVhMjRkZjBhZDJjYjY4Y2IxNjAzOWVjL3RhYmxlcmFuZ2U6NTg1MmVmZTQ1ZWEyNGRmMGFkMmNiNjhjYjE2MDM5ZWNfMi0xLTEtMS0xMDQxMTk_e77b606b-e4e7-4a8f-82b1-2d46ef9e4970">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="bngo:ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjU4NTJlZmU0NWVhMjRkZjBhZDJjYjY4Y2IxNjAzOWVjL3RhYmxlcmFuZ2U6NTg1MmVmZTQ1ZWEyNGRmMGFkMmNiNjhjYjE2MDM5ZWNfMy0xLTEtMS0xMDQxMTk_857f30ec-4f75-4109-904c-882f8baf8b1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="bngo:ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjU4NTJlZmU0NWVhMjRkZjBhZDJjYjY4Y2IxNjAzOWVjL3RhYmxlcmFuZ2U6NTg1MmVmZTQ1ZWEyNGRmMGFkMmNiNjhjYjE2MDM5ZWNfNC0xLTEtMS0xMDQxMTk_e0d93e7c-05b0-44a5-a075-44b9b592400a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjU4NTJlZmU0NWVhMjRkZjBhZDJjYjY4Y2IxNjAzOWVjL3RhYmxlcmFuZ2U6NTg1MmVmZTQ1ZWEyNGRmMGFkMmNiNjhjYjE2MDM5ZWNfNS0xLTEtMS0xMDQxMTk_14607b8f-c494-4ed7-a6e9-0d35d93ac6e6">4,356,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjU4NTJlZmU0NWVhMjRkZjBhZDJjYjY4Y2IxNjAzOWVjL3RhYmxlcmFuZ2U6NTg1MmVmZTQ1ZWEyNGRmMGFkMmNiNjhjYjE2MDM5ZWNfNS0zLTEtMS0xMDQxMTk_63877a03-a5a5-49f0-8a67-5c29b539aaa3">5.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjU4NTJlZmU0NWVhMjRkZjBhZDJjYjY4Y2IxNjAzOWVjL3RhYmxlcmFuZ2U6NTg1MmVmZTQ1ZWEyNGRmMGFkMmNiNjhjYjE2MDM5ZWNfNS01LTEtMS0xMDQxMTk_d46d5f32-b86b-4d23-959c-02ce70723f05">0.52</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="bngo:ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjU4NTJlZmU0NWVhMjRkZjBhZDJjYjY4Y2IxNjAzOWVjL3RhYmxlcmFuZ2U6NTg1MmVmZTQ1ZWEyNGRmMGFkMmNiNjhjYjE2MDM5ZWNfNS03LTEtMS0xMDQxMTk_c1fb5abb-99d7-40ed-836d-277cedaf45e3">156,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNjMzOQ_252dc0c3-3928-41af-b8c9-8b1047a503d6" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity during the three months ended March&#160;31, 2023 was as follows: &#160;&#160;</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares of Stock under Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfMS0xLTEtMS0xMDQxMTk_42c98c8c-0412-425b-acb5-dfced1339dc1">24,022,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfMS0zLTEtMS0xMDQxMTk_8039c53a-2dee-4a3f-bb20-4d6aafc8fb5f">3.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4be8520461cc4836b2bf1279c0c49b2a_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfMS01LTEtMS0xMDQxMTk_fec03270-f8b2-40e9-8c2d-a5f1e730c9c2">8.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfMS03LTEtMS0xMDQxMTk_305585d6-c138-4b02-bbc4-69922e904f3f">2,068,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfMi0xLTEtMS0xMDQxMTk_7a5b769f-861e-4b63-bc25-27f58535f18c">9,121,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfMi0zLTEtMS0xMDQxMTk_6dc72305-082c-4491-81af-c0a77d80bf4a">1.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfMy0xLTEtMS0xMDQxMTk_17fa4715-2b3d-4da7-ac70-ed9fbae65162">42,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfMy0zLTEtMS0xMDQxMTk_ed220795-1602-479e-8cda-23e64e52e01c">0.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfMy03LTEtMS0xMDQxMTk_015e1ba6-987e-458d-86df-9a70446ec6f5">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfNC0xLTEtMS0xMDQxMTk_629ed354-7a5f-4cfd-872b-c87a89c24867">1,088,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfNC0zLTEtMS0xMDQxMTk_028c1730-3376-4bf5-8aa3-62e6c5bdbd3a">3.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfNS0xLTEtMS0xMDQxMTk_dbad613d-2444-42ce-b0b3-f2b194102ce8">32,013,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfNS0zLTEtMS0xMDQxMTk_08247c9d-a326-431b-9680-751e73849033">2.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfNS01LTEtMS0xMDQxMTk_b4587f7c-e78c-4c12-b136-ba2f20666694">8.84</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfNS03LTEtMS0xMDQxMTk_300e999c-6e17-4535-ad75-2127d05b4af6">1,147,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfNi0xLTEtMS0xMDQxMTk_a7f9f00a-5431-44d1-9be1-20b8ff52fac5">9,149,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfNi0zLTEtMS0xMDQxMTk_fd71fcca-6c17-4398-9bfa-71b04f42f4ae">3.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfNi01LTEtMS0xMDQxMTk_330152c9-1fcc-4806-bb9b-e25429b7cfaa">7.89</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfNi03LTEtMS0xMDQxMTk_3e5c8c92-1744-4823-a357-aac6bdca2e08">892,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023, the weighted-average grant date fair value of stock options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTQ5NzU1ODI5NzM2_6979a6e6-0566-4557-a589-addcf00d7eeb">1.07</ix:nonFraction> per share.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNjM0MA_d472bfad-ec89-4404-b483-10d7d1cf4f6c" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation expense for the periods presented as follows:&#160;</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic493e64bbaa14b51affea368a758865b_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjcxOTcxYmNhNjNiYjQ4MWU4OTFiYWRkYTc4ODNjODU4L3RhYmxlcmFuZ2U6NzE5NzFiY2E2M2JiNDgxZTg5MWJhZGRhNzg4M2M4NThfMi0xLTEtMS0xMDUwMTk_23c26aaf-4696-4195-8ba4-66cdc0e5d545">102,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b89abf30d44e039ce4fc8aeb1da4ae_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjcxOTcxYmNhNjNiYjQ4MWU4OTFiYWRkYTc4ODNjODU4L3RhYmxlcmFuZ2U6NzE5NzFiY2E2M2JiNDgxZTg5MWJhZGRhNzg4M2M4NThfMi0zLTEtMS0xMDUwMjY_c2ba1186-6fbd-473f-9fac-61b946864fea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29ed40c40dab442291465632e6882e02_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjcxOTcxYmNhNjNiYjQ4MWU4OTFiYWRkYTc4ODNjODU4L3RhYmxlcmFuZ2U6NzE5NzFiY2E2M2JiNDgxZTg5MWJhZGRhNzg4M2M4NThfMy0xLTEtMS0xMDUwMTk_66b6f569-d2a1-4526-9764-9049642df87c">44,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144c849f01554b1a993c3b250ed79d33_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjcxOTcxYmNhNjNiYjQ4MWU4OTFiYWRkYTc4ODNjODU4L3RhYmxlcmFuZ2U6NzE5NzFiY2E2M2JiNDgxZTg5MWJhZGRhNzg4M2M4NThfMy0zLTEtMS0xMDUwMjY_95d3e066-6e85-460a-8c1a-3c1214ecf0f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f330defb5aa4fb081aecf68faa28812_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjcxOTcxYmNhNjNiYjQ4MWU4OTFiYWRkYTc4ODNjODU4L3RhYmxlcmFuZ2U6NzE5NzFiY2E2M2JiNDgxZTg5MWJhZGRhNzg4M2M4NThfMi0xLTEtMS0xMDQxMTk_da58b151-cf0c-4f7c-9eee-7bdfc32bdc26">1,357,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94ccbf7f373d449baf5526bf6037b3f3_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjcxOTcxYmNhNjNiYjQ4MWU4OTFiYWRkYTc4ODNjODU4L3RhYmxlcmFuZ2U6NzE5NzFiY2E2M2JiNDgxZTg5MWJhZGRhNzg4M2M4NThfMi0zLTEtMS0xMDQxMTk_4c901ee6-ed37-4f50-801b-a8185b790b44">3,328,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7a2e48e810643a8b0e555a9c8954d9f_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjcxOTcxYmNhNjNiYjQ4MWU4OTFiYWRkYTc4ODNjODU4L3RhYmxlcmFuZ2U6NzE5NzFiY2E2M2JiNDgxZTg5MWJhZGRhNzg4M2M4NThfMy0xLTEtMS0xMDQxMTk_720386d2-206f-43dc-a6a1-5880e1756690">2,379,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f37993d3f264fb1b3d0691e711f9da5_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjcxOTcxYmNhNjNiYjQ4MWU4OTFiYWRkYTc4ODNjODU4L3RhYmxlcmFuZ2U6NzE5NzFiY2E2M2JiNDgxZTg5MWJhZGRhNzg4M2M4NThfMy0zLTEtMS0xMDQxMTk_def491ea-57ab-4677-9aad-3c0f66119075">1,774,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjcxOTcxYmNhNjNiYjQ4MWU4OTFiYWRkYTc4ODNjODU4L3RhYmxlcmFuZ2U6NzE5NzFiY2E2M2JiNDgxZTg5MWJhZGRhNzg4M2M4NThfNC0xLTEtMS0xMDQxMTk_80831bf9-f695-425a-892d-879d6830f5a0">3,882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjcxOTcxYmNhNjNiYjQ4MWU4OTFiYWRkYTc4ODNjODU4L3RhYmxlcmFuZ2U6NzE5NzFiY2E2M2JiNDgxZTg5MWJhZGRhNzg4M2M4NThfNC0zLTEtMS0xMDQxMTk_75a550a4-6205-449f-9f8f-df033e3306d4">5,102,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNjM0NA_4690d503-bd0d-41db-9dd6-29d2351a474d" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants during the periods presented were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjEzNTNkODFhNTg1MTRjZGU5OTQ2MGZmOWI2ODk5NTk2L3RhYmxlcmFuZ2U6MTM1M2Q4MWE1ODUxNGNkZTk5NDYwZmY5YjY4OTk1OTZfMi0xLTEtMS0xMDQxMTk_3d89fa63-21f7-4adb-9cf9-2c68fd771f1a">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjEzNTNkODFhNTg1MTRjZGU5OTQ2MGZmOWI2ODk5NTk2L3RhYmxlcmFuZ2U6MTM1M2Q4MWE1ODUxNGNkZTk5NDYwZmY5YjY4OTk1OTZfMi0zLTEtMS0xMDQxMTk_8c06bfba-7eaa-4a9a-b513-cfcc7ae12bcd">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjEzNTNkODFhNTg1MTRjZGU5OTQ2MGZmOWI2ODk5NTk2L3RhYmxlcmFuZ2U6MTM1M2Q4MWE1ODUxNGNkZTk5NDYwZmY5YjY4OTk1OTZfMy0xLTEtMS0xMDQxMTk_45356908-7e32-42f2-85e3-9731cc71d25a">72.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjEzNTNkODFhNTg1MTRjZGU5OTQ2MGZmOWI2ODk5NTk2L3RhYmxlcmFuZ2U6MTM1M2Q4MWE1ODUxNGNkZTk5NDYwZmY5YjY4OTk1OTZfMy0zLTEtMS0xMDQxMTk_5caeef45-95d8-4028-857a-7d5191c58417">70.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjEzNTNkODFhNTg1MTRjZGU5OTQ2MGZmOWI2ODk5NTk2L3RhYmxlcmFuZ2U6MTM1M2Q4MWE1ODUxNGNkZTk5NDYwZmY5YjY4OTk1OTZfNC0xLTEtMS0xMDQxMTk_398cd627-644f-45e4-a690-240cb2561d98">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjEzNTNkODFhNTg1MTRjZGU5OTQ2MGZmOWI2ODk5NTk2L3RhYmxlcmFuZ2U6MTM1M2Q4MWE1ODUxNGNkZTk5NDYwZmY5YjY4OTk1OTZfNC0zLTEtMS0xMDQxMTk_c5b43850-11bd-4be4-b502-72f92fbcc01a">6.0</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjEzNTNkODFhNTg1MTRjZGU5OTQ2MGZmOWI2ODk5NTk2L3RhYmxlcmFuZ2U6MTM1M2Q4MWE1ODUxNGNkZTk5NDYwZmY5YjY4OTk1OTZfNS0xLTEtMS0xMDQxMTk_91157733-c362-4b64-95e9-d3ba887f538c">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjEzNTNkODFhNTg1MTRjZGU5OTQ2MGZmOWI2ODk5NTk2L3RhYmxlcmFuZ2U6MTM1M2Q4MWE1ODUxNGNkZTk5NDYwZmY5YjY4OTk1OTZfNS0zLTEtMS0xMDQxMTk_00dde8d1-1ffc-4e18-a05b-0fafbc32e6a4">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><ix:continuation id="ib4b8d55ee6db43f7ad250a23f8f3e0cd" continuedAt="if9408d8d6fcd4c21ab490c90685fa5ac"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A restricted stock award in the amount of <ix:nonFraction unitRef="shares" contextRef="i45ddfb39b1e74f6dad0c0bf181cf9a21_D20211001-20211031" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTQ5NzU1ODI3NjA5_8212d695-ba7b-4381-a2fb-c2d81771347f">5.0</ix:nonFraction> million shares with a grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i45ddfb39b1e74f6dad0c0bf181cf9a21_D20211001-20211031" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTQ5NzU1ODI3NjEz_778f5ae5-b265-49e1-9549-cafad5bb6910">5.20</ix:nonFraction> a share was granted as part of the acquisition of BioDiscovery. One-third of the Restricted Shares was scheduled to vest on October 18, 2022 and one-twelfth of the Restricted Shares was scheduled to vest every three months following October 18, 2022, subject to continuous service of the key employee. The fair value of the restricted stock award was based on the market value of common stock as of the date of grant and was amortized to stock-based compensation expense over the service period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 4, 2022, the restricted stock award was modified due to the change in employment status of the key employee from full time to emeritus. As a result of the modification, the restricted stock award vested in full on October 4, 2022. The award was revalued on the modification date, resulting in a modified grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i649fe5ed0003466fbb184c5508561d25_I20221004" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTQ5NzU1ODI3NjE3_554b44c1-adaf-4864-9c87-c928540475a7">2.04</ix:nonFraction> a share ($<ix:nonFraction unitRef="usd" contextRef="i9253ac3721c14085873be006d0cf4172_D20221004-20221004" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTQ5NzU1ODI3NjIx_5f539252-cf29-4b9e-8a23-d7936f04353f">15.8</ix:nonFraction>&#160;million less than the initial grant date fair value of the award). The fair value of the modified restricted stock award was based on the market value of common stock as of the modification date. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units and Performance Stock Units</span></div><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNjM0Mw_cdd34d8a-19b2-4cd3-9504-3213bec44330" continuedAt="i0778f907b86749a49cd81b8b86e266a9" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the three months ended March&#160;31, 2023:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9d74a66fe4c4a139d49dde0ca471851_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjIxN2I4MWY0NzY4YTQxNjc5ZGZmZTY5NzRjYmE5ODU2L3RhYmxlcmFuZ2U6MjE3YjgxZjQ3NjhhNDE2NzlkZmZlNjk3NGNiYTk4NTZfMS0xLTEtMS0xMDQxMTk_c7de3e1a-9dc4-4cdd-aa9a-4acdd894e008">96,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib9d74a66fe4c4a139d49dde0ca471851_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjIxN2I4MWY0NzY4YTQxNjc5ZGZmZTY5NzRjYmE5ODU2L3RhYmxlcmFuZ2U6MjE3YjgxZjQ3NjhhNDE2NzlkZmZlNjk3NGNiYTk4NTZfMS0zLTEtMS0xMDQxMTk_0b22a118-4803-4ee9-9e42-cc48249388b5">4.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d6b4ade60694ff6bfb130ce265977e6_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjIxN2I4MWY0NzY4YTQxNjc5ZGZmZTY5NzRjYmE5ODU2L3RhYmxlcmFuZ2U6MjE3YjgxZjQ3NjhhNDE2NzlkZmZlNjk3NGNiYTk4NTZfMi0xLTEtMS0xMDQxMTk_f3c9bdc1-b54b-4956-8354-753af8a7dccd">2,461,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0d6b4ade60694ff6bfb130ce265977e6_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjIxN2I4MWY0NzY4YTQxNjc5ZGZmZTY5NzRjYmE5ODU2L3RhYmxlcmFuZ2U6MjE3YjgxZjQ3NjhhNDE2NzlkZmZlNjk3NGNiYTk4NTZfMi0zLTEtMS0xMDQxMTk_e5c59c5a-9bc8-4a56-b0b5-5f4d320b453b">1.63</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0d6b4ade60694ff6bfb130ce265977e6_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjIxN2I4MWY0NzY4YTQxNjc5ZGZmZTY5NzRjYmE5ODU2L3RhYmxlcmFuZ2U6MjE3YjgxZjQ3NjhhNDE2NzlkZmZlNjk3NGNiYTk4NTZfMy0xLTEtMS0xMDQxMTk_39afa251-e128-4519-a24b-e2315a090992">65,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0d6b4ade60694ff6bfb130ce265977e6_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjIxN2I4MWY0NzY4YTQxNjc5ZGZmZTY5NzRjYmE5ODU2L3RhYmxlcmFuZ2U6MjE3YjgxZjQ3NjhhNDE2NzlkZmZlNjk3NGNiYTk4NTZfMy0zLTEtMS0xMDQxMTk_44376b2a-d462-41c7-adbb-8f9a5d725ada">4.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0d6b4ade60694ff6bfb130ce265977e6_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjIxN2I4MWY0NzY4YTQxNjc5ZGZmZTY5NzRjYmE5ODU2L3RhYmxlcmFuZ2U6MjE3YjgxZjQ3NjhhNDE2NzlkZmZlNjk3NGNiYTk4NTZfNC0xLTEtMS0xMDQxMTk_acfc6bc5-4357-4149-8224-74ce041166ba">35,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0d6b4ade60694ff6bfb130ce265977e6_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjIxN2I4MWY0NzY4YTQxNjc5ZGZmZTY5NzRjYmE5ODU2L3RhYmxlcmFuZ2U6MjE3YjgxZjQ3NjhhNDE2NzlkZmZlNjk3NGNiYTk4NTZfNC0zLTEtMS0xMDQxMTk_e38ab0e5-3928-466b-a0a1-533176a73846">1.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i80c9f5e585bc49d69df5c0b0bc90a1dc_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjIxN2I4MWY0NzY4YTQxNjc5ZGZmZTY5NzRjYmE5ODU2L3RhYmxlcmFuZ2U6MjE3YjgxZjQ3NjhhNDE2NzlkZmZlNjk3NGNiYTk4NTZfNS0xLTEtMS0xMDQxMTk_6e58e887-8669-4f1b-8a97-e0ac2a4963bf">2,457,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i80c9f5e585bc49d69df5c0b0bc90a1dc_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjIxN2I4MWY0NzY4YTQxNjc5ZGZmZTY5NzRjYmE5ODU2L3RhYmxlcmFuZ2U6MjE3YjgxZjQ3NjhhNDE2NzlkZmZlNjk3NGNiYTk4NTZfNS0zLTEtMS0xMDQxMTk_2e1a8f8d-3add-4fea-b710-bf4630ac321b">1.67</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of the RSUs that vested during the three months ended March&#160;31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="i0d6b4ade60694ff6bfb130ce265977e6_D20230101-20230331" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTM5MA_9ca8e3cb-cc14-481c-a78f-c95fe152b7c8">0.3</ix:nonFraction>&#160;million, determined as of the date of vesting. The weighted average remaining contractual term for the RSUs is <ix:nonNumeric contextRef="i0d6b4ade60694ff6bfb130ce265977e6_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTQ5Ng_30460989-5297-46f3-9462-76aa7828d3e6">3.5</ix:nonNumeric> years as of March&#160;31, 2023.</span></div><ix:continuation id="i0778f907b86749a49cd81b8b86e266a9"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes PSU activity during the three months ended March&#160;31, 2023:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0787e57ce57b4647b096721e6444f9b9_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjA2ZTRjZDBhYTYyMDQxNDVhMDdlMzVjYmM4M2Q0ZWY4L3RhYmxlcmFuZ2U6MDZlNGNkMGFhNjIwNDE0NWEwN2UzNWNiYzgzZDRlZjhfMS0xLTEtMS0xMDQxMTk_d137f351-9052-4601-9368-bd5c731230b8">290,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0787e57ce57b4647b096721e6444f9b9_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjA2ZTRjZDBhYTYyMDQxNDVhMDdlMzVjYmM4M2Q0ZWY4L3RhYmxlcmFuZ2U6MDZlNGNkMGFhNjIwNDE0NWEwN2UzNWNiYzgzZDRlZjhfMS0zLTEtMS0xMDQxMTk_e39eb22c-8cdc-4aa5-8051-c012e55045f1">4.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i230745a88815483fa50ae23b1a6526e9_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjA2ZTRjZDBhYTYyMDQxNDVhMDdlMzVjYmM4M2Q0ZWY4L3RhYmxlcmFuZ2U6MDZlNGNkMGFhNjIwNDE0NWEwN2UzNWNiYzgzZDRlZjhfMi0xLTEtMS0xMDQxMTk_232ebd46-b39f-4e6a-9521-73d3cf9ddcfe">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i230745a88815483fa50ae23b1a6526e9_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjA2ZTRjZDBhYTYyMDQxNDVhMDdlMzVjYmM4M2Q0ZWY4L3RhYmxlcmFuZ2U6MDZlNGNkMGFhNjIwNDE0NWEwN2UzNWNiYzgzZDRlZjhfMi0zLTEtMS0xMDQxMTk_087d3fac-d22e-495b-a53c-ef099301f78a">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i230745a88815483fa50ae23b1a6526e9_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjA2ZTRjZDBhYTYyMDQxNDVhMDdlMzVjYmM4M2Q0ZWY4L3RhYmxlcmFuZ2U6MDZlNGNkMGFhNjIwNDE0NWEwN2UzNWNiYzgzZDRlZjhfMy0xLTEtMS0xMDQxMTk_69d090f8-7751-46e8-ad92-571f29fa1367">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i230745a88815483fa50ae23b1a6526e9_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjA2ZTRjZDBhYTYyMDQxNDVhMDdlMzVjYmM4M2Q0ZWY4L3RhYmxlcmFuZ2U6MDZlNGNkMGFhNjIwNDE0NWEwN2UzNWNiYzgzZDRlZjhfMy0zLTEtMS0xMDQxMTk_e7feaeab-2fb0-45a6-9da7-a07b8f52db9c">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i230745a88815483fa50ae23b1a6526e9_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjA2ZTRjZDBhYTYyMDQxNDVhMDdlMzVjYmM4M2Q0ZWY4L3RhYmxlcmFuZ2U6MDZlNGNkMGFhNjIwNDE0NWEwN2UzNWNiYzgzZDRlZjhfNC0xLTEtMS0xMDQxMTk_d572be84-bbe0-4087-9cdc-70734fe13eed">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i230745a88815483fa50ae23b1a6526e9_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjA2ZTRjZDBhYTYyMDQxNDVhMDdlMzVjYmM4M2Q0ZWY4L3RhYmxlcmFuZ2U6MDZlNGNkMGFhNjIwNDE0NWEwN2UzNWNiYzgzZDRlZjhfNC0zLTEtMS0xMDQxMTk_1f202998-9493-4a2a-bc07-6d8e42dffeb4">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia333c3d4c489480f91a0918cb06c6e33_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjA2ZTRjZDBhYTYyMDQxNDVhMDdlMzVjYmM4M2Q0ZWY4L3RhYmxlcmFuZ2U6MDZlNGNkMGFhNjIwNDE0NWEwN2UzNWNiYzgzZDRlZjhfNS0xLTEtMS0xMDQxMTk_2c0c31b2-b5b8-4ef8-af89-1867f5e0f822">290,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia333c3d4c489480f91a0918cb06c6e33_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjA2ZTRjZDBhYTYyMDQxNDVhMDdlMzVjYmM4M2Q0ZWY4L3RhYmxlcmFuZ2U6MDZlNGNkMGFhNjIwNDE0NWEwN2UzNWNiYzgzZDRlZjhfNS0zLTEtMS0xMDQxMTk_7ba11770-0477-4527-8110-4eb40279e1fc">4.74</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining contractual term for the PSUs is <ix:nonNumeric contextRef="i230745a88815483fa50ae23b1a6526e9_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTY3Nw_9579ecb4-aa41-4c0f-b15a-3d9cf9d245c0">2.1</ix:nonNumeric> years as of March&#160;31, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Option Grants and RSUs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2023, the compensation committee of the Company&#8217;s board of directors granted various executive officers stock options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="iecac66c4d00049b992c7f860853fdc4b_D20230215-20230215" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTQ5NzU1ODI5NjA2_be516495-90df-45bb-b921-a1e28b2f2356">3.3</ix:nonFraction> million shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iecac66c4d00049b992c7f860853fdc4b_D20230215-20230215" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTQ5NzU1ODI5NjAy_3d8a1f6e-181e-4823-b4bd-f9be61cee53c">1.63</ix:nonFraction> per share, and RSUs amounting to <ix:nonFraction unitRef="shares" contextRef="ibb4acb3d6c734dba8bac4bebe9c2b85d_D20230215-20230215" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTQ5NzU1ODI5NjEz_460062d4-d71e-47c9-b31b-09405f87103f">0.7</ix:nonFraction> million shares of common stock at a grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="iecac66c4d00049b992c7f860853fdc4b_D20230215-20230215" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTQ5NzU1ODI5NjIy_3d8a1f6e-181e-4823-b4bd-f9be61cee53c">1.63</ix:nonFraction> per share, in each case with an effective grant date and vesting commencement date of February 15, 2023 (the &#8220;Grant Date&#8221;). These stock option grants and RSUs were issued from the 2018 Plan. The shares subject to the option shall vest monthly over <ix:nonNumeric contextRef="i759bd048bf3e4098b83b5604fbce9f26_D20230215-20230215" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNDk0NzgwMjM0MDgwOQ_66c982e3-380b-4c7f-a85c-7936c1d3e525">48</ix:nonNumeric> months beginning on the one-month anniversary of the Grant Date, such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. The RSUs shall vest annually over <ix:nonNumeric contextRef="i22680561557b45ba98cf2f10a2456635_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMTY0OTI2NzQ4MjY2Mw_70f3e7b4-6dfd-4997-9916-6bbeadf960d1">four years</ix:nonNumeric> beginning one year after the Grant Date, and the balance of the shares vest in a series of <ix:nonFraction unitRef="installment" contextRef="i38b1d6628a394f1fbbbfd993ec043869_I20230215" decimals="INF" name="bngo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNDk0NzgwMjM0MDgxNg_cb89c96f-0b90-4503-b426-44613c430539">three</ix:nonFraction> successive equal annual installments measured from the first anniversary of the Grant Date, such that the RSU shall be fully vested on the four-year anniversary of the Grant Date.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><ix:continuation id="if9408d8d6fcd4c21ab490c90685fa5ac"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series A Preferred Stock</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 13, 2023, the Company entered into an agreement with David Barker, the Chair of the Company&#8217;s board of directors, pursuant to which the Company agreed to issue and sell <ix:nonFraction unitRef="shares" contextRef="ib50b0f103ebb406f8f4f5c1eef93d1bd_D20230413-20230413" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMTY0OTI2NzQ1NzUyNA_d7995989-980a-4c14-b024-3b2d5d4dd544">one</ix:nonFraction> share of the Company&#8217;s Series A Preferred Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ib6be39fe53974c5089ff9986b857d774_I20230413" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMTY0OTI2NzQ1NzUzNg_9bf76a32-7574-47c3-b675-4a9051cb3b1d">0.0001</ix:nonFraction> per share for a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib6be39fe53974c5089ff9986b857d774_I20230413" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTQ5NzU1ODI5NjI2_c7df646b-faf4-42c3-9eae-fd0b7dcba6f4">100.00</ix:nonFraction>. The closing of the sale and purchase of the share of Series A Preferred was completed on April 13, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The share of Series A Preferred will have <ix:nonFraction unitRef="vote" contextRef="iffc1f718b13b4c9abe1418bc8c792699_I20230413" decimals="INF" name="bngo:PreferredStockNumberOfVotes" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTQ5NzU1ODMzMDIy_b7573845-a3f6-4131-aac7-a6c2c7e4548e">3.0</ix:nonFraction> billion votes, but has the right to vote only on a proposal submitted to the stockholders of the Company to adopt an amendment, or a series of alternate amendments, to the Company&#8217;s Amended and Restated Certificate of Incorporation, as amended, to combine the outstanding shares of Common Stock into a smaller number of shares of Common Stock at a ratio specified in or determined in accordance with the terms of such amendment or series of alternate amendments (&#8220;Reverse Stock Split Proposal&#8221;), and will have no voting rights (i) except with respect to a Reverse Stock Split Proposal and the votes of the share of Series A Preferred are required to be cast for and against such Reverse Stock Split Proposal in the same proportion as shares of Common Stock are voted for and against such Reverse Stock Split Proposal (with any shares of Common Stock that are not voted, whether due to abstentions, broker non-votes or otherwise not counted as votes for or against a Reverse Stock Split Proposal) and (ii) unless the holders of one-third (1/3rd) of the outstanding shares of Common Stock are present and vote, in person or by proxy, at the meeting of stockholders at which a Reverse Stock Split Proposal is submitted for stockholder approval (or any adjournment thereof). The share of Series A Preferred will vote together with the Common Stock as a single class on a Reverse Stock Split Proposal. The Series A Preferred has no other voting rights, except as may be required by the General Corporation Law of the State of Delaware. The outstanding share of Series A Preferred will be redeemed in whole, but not in part, for a redemption price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iffc1f718b13b4c9abe1418bc8c792699_I20230413" decimals="2" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNDk0NzgwMjM3NjkyNA_cf202ff7-a2b0-44c1-aae7-c269e31a4fbf">100.00</ix:nonFraction>, payable out of funds lawfully available therefor, (i) if such redemption is ordered by the Company&#8217;s Board of Directors in its sole discretion, automatically and effective on such time and date specified by the Board of Directors in its sole discretion, or (ii) automatically immediately following the approval by the stockholders of a Reverse Stock Split Proposal.</span></div></ix:continuation><div id="i561259e69fbb4552820b7ec56e5dea3a_58"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RleHRyZWdpb246NWI2NmE1ZGQyYmJiNGJhYmFmYzc0MTY5Y2YzOThjN2ZfMTk0Nw_6d5766e9-15bd-4c57-a9c5-98a306940382" continuedAt="if13ba483706944c4b5cfae6b61de6671" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="if13ba483706944c4b5cfae6b61de6671" continuedAt="i917afe11398d48909c0a7c02b6446322"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various operating lease agreements and a finance lease agreement, primarily relating to our office, laboratory, and manufacturing space. See Note 11 &#8211; Commitments and Contingencies, subsection titled &#8220;Leases&#8221;, in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December 31, 2022 for information regarding the Company&#8217;s lease agreements. </span></div><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RleHRyZWdpb246NWI2NmE1ZGQyYmJiNGJhYmFmYzc0MTY5Y2YzOThjN2ZfMTk0NQ_3b3287ae-5e55-4003-a46d-4794aa45ae55" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future minimum payments under non-cancellable operating and finance leases as of March&#160;31, 2023, are as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfMS0xLTEtMS0xMDQxMTk_f1b00986-1c7f-4d14-bc5d-8d2623cc93c9">1,942,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfMS0zLTEtMS0xMDQxMTk_a9b7c935-83a6-4c44-8e4a-730c069fe36b">242,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfMi0xLTEtMS0xMDQxMTk_0558f172-70a0-4edc-9d3e-c6a4db8bb12d">2,684,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfMi0zLTEtMS0xMDQxMTk_5dea9ddc-bb2f-4460-9204-4684198ed9f0">330,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfMy0xLTEtMS0xMDQxMTk_4c9c989e-5b67-465f-9c6d-7e16e14f8702">2,788,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfMy0zLTEtMS0xMDQxMTk_467ada5d-e367-46d7-948c-acee446aa73e">338,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfNC0xLTEtMS0xMDQxMTk_221a977e-0c07-47a8-afb3-117a3494a7fb">729,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfNC0zLTEtMS0xMDQxMTk_69cdea38-cc0a-4b2b-bcdf-df4b6c12ffbc">347,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfNS0xLTEtMS0xMDQxMTk_9c609186-c1fa-4ac9-9d93-fb21daa085bf">255,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfNS0zLTEtMS0xMDQxMTk_833b8d5e-8910-49b9-bbb0-aafc767a8946">356,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="bngo:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfNi0xLTEtMS0xMDQxMTk_cad6a552-8d23-4ffd-8d53-272c54b6093c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="bngo:FinanceLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfNi0zLTEtMS0xMDQxMTk_ec8afd41-e8ea-4c1e-afd4-a40083a21743">5,594,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfNy0xLTEtMS0xMDQxMTk_2cbc94ac-c509-4ebd-bafe-02c9cc945592">8,398,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfNy0zLTEtMS0xMDQxMTk_6d691eb4-db18-42d8-aefd-22b821b7e2f4">7,207,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfOC0xLTEtMS0xMDQxMTk_eb031512-51ee-4821-850f-552d1e4b3c63">1,120,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfOC0zLTEtMS0xMDQxMTk_a7d11123-36c1-43a0-b71f-c4de43ab19c7">3,313,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfOS0xLTEtMS0xMDQxMTk_58b03fd7-f8cb-4e1c-aa80-5687a5108fd8">7,278,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfOS0zLTEtMS0xMDQxMTk_24a8f34e-b460-482f-9f50-21a71682710c">3,894,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to potential liabilities under various claims and legal actions that are pending or may be asserted. These matters arise in the ordinary course and conduct of the business. The Company regularly assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in the unaudited condensed consolidated financial statements. An estimated loss contingency is accrued in the unaudited condensed consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on the Company&#8217;s assessment, it currently does not have any material loss exposure as it is not a defendant in any claims or legal actions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i917afe11398d48909c0a7c02b6446322">See Note 8 to our unaudited condensed consolidated financial statements for a discussion of the contingent consideration liability.</ix:continuation> </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i561259e69fbb4552820b7ec56e5dea3a_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RleHRyZWdpb246YjRmYTQ3OWVkNzVhNDg4ODg5N2RiYjFlZmQyMDkxZjNfMzQ5MA_4382f356-3ca9-4c39-af39-b89e71bcfd54" continuedAt="i0e3e5cc1e17c48228c783a4852feb8ba" escape="true">Acquisitions</ix:nonNumeric></span></div><ix:continuation id="i0e3e5cc1e17c48228c783a4852feb8ba" continuedAt="i95f841efcef947918c1ed6254abce891"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purigen Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company completed the acquisition of Purigen Biosystems, Inc. for approximately $<ix:nonFraction unitRef="usd" contextRef="i7d2c0cf7229242a88304bb4f867c0c9d_D20221101-20221130" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RleHRyZWdpb246YjRmYTQ3OWVkNzVhNDg4ODg5N2RiYjFlZmQyMDkxZjNfMTA5OTUxMTY0MDE3Ng_8a6457e2-eaa1-4609-8837-67c9b4242bdf">32.0</ix:nonFraction>&#160;million in cash and up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RleHRyZWdpb246YjRmYTQ3OWVkNzVhNDg4ODg5N2RiYjFlZmQyMDkxZjNfMTA5OTUxMTY0MDE4MA_e773d7a1-fbc7-491f-905b-be802f981c4e">32.0</ix:nonFraction>&#160;million in cash payable based on the achievement of certain milestones. Cash of $<ix:nonFraction unitRef="usd" contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130" decimals="-5" name="bngo:BusinessAcquisitionCashHeldInEscrowFund" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RleHRyZWdpb246YjRmYTQ3OWVkNzVhNDg4ODg5N2RiYjFlZmQyMDkxZjNfMTA5OTUxMTY0MDE4OQ_0cbb9718-7e79-472d-93ae-b621700a70d8">1.2</ix:nonFraction>&#160;million will be held in an escrow fund for purposes of satisfying any post-closing purchase price adjustments and indemnification claims under the Purigen Merger Agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The purchase price allocation for the acquisition of Purigen is preliminary and subject to revision as additional information about the fair value of assets and liabilities becomes available. As permitted under ASC 805, the Company is allowed a measurement period, which may not exceed one year, in which to complete its accounting for the acquisition. Per the terms of the Purigen Merger Agreement, the purchase price is still subject to adjustment for the final determination of cash, unpaid indebtedness, unpaid transaction expenses and working capital, as well for deferred and current tax assets and liabilities.</span></div><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RleHRyZWdpb246YjRmYTQ3OWVkNzVhNDg4ODg5N2RiYjFlZmQyMDkxZjNfMzg0ODI5MDcwOTY0OA_c50210cc-7d9c-4471-9189-02607fde9aea" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the estimated purchase price for the acquisition of Purigen:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d2c0cf7229242a88304bb4f867c0c9d_D20221101-20221130" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOjdmYWUxNTk4ZTQ4ZDRmY2ViNWM4ODU0MmU1NzFhMzhiL3RhYmxlcmFuZ2U6N2ZhZTE1OThlNDhkNGZjZWI1Yzg4NTQyZTU3MWEzOGJfMC0yLTEtMS0xMDQ1Njg_10d6d510-2b70-44de-845d-5ab772d23060">32,034,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Estimated fair value of milestone consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOjdmYWUxNTk4ZTQ4ZDRmY2ViNWM4ODU0MmU1NzFhMzhiL3RhYmxlcmFuZ2U6N2ZhZTE1OThlNDhkNGZjZWI1Yzg4NTQyZTU3MWEzOGJfMS0yLTEtMS0xMDQ1Njg_f4f35d48-f5a3-4d6f-931e-eae4efeb20f0">12,970,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Estimated return of cash to buyer from escrow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130" decimals="-3" name="bngo:BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOjdmYWUxNTk4ZTQ4ZDRmY2ViNWM4ODU0MmU1NzFhMzhiL3RhYmxlcmFuZ2U6N2ZhZTE1OThlNDhkNGZjZWI1Yzg4NTQyZTU3MWEzOGJfMi0yLTEtMS0xMDQ1Njg_b48b0c3d-08aa-421b-bd97-ad2776f3d40c">90,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total estimated purchase price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d2c0cf7229242a88304bb4f867c0c9d_D20221101-20221130" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOjdmYWUxNTk4ZTQ4ZDRmY2ViNWM4ODU0MmU1NzFhMzhiL3RhYmxlcmFuZ2U6N2ZhZTE1OThlNDhkNGZjZWI1Yzg4NTQyZTU3MWEzOGJfMy0yLTEtMS0xMDYwODU_0ee1f3c6-1e75-4688-a15f-c2ea5bd7b7a4">44,914,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RleHRyZWdpb246YjRmYTQ3OWVkNzVhNDg4ODg5N2RiYjFlZmQyMDkxZjNfMzg0ODI5MDcwOTY0OQ_f23d48aa-617b-4250-9fad-c5bda0427753" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated purchase price was allocated to Purigen&#8217;s tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date, with the excess recorded as goodwill, as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash &amp; cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfMC0yLTEtMS0xMDQ1Njg_e47bf23b-3d7e-445d-ac90-02e6a42f4034">290,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfMS0yLTEtMS0xMDQ1Njg_36e0d503-1f42-444b-96b5-497a12aeebda">259,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfMi0yLTEtMS0xMDQ1Njg_07757069-3269-4dd3-8b1d-24d982ec93fc">944,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfMy0yLTEtMS0xMDQ1Njg_c6ab3905-ee42-4273-9b87-3ebd9cc17787">184,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfNC0yLTEtMS0xMDQ1Njg_0ea10ec7-ee89-4f9b-a260-757f0be42b24">805,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130" decimals="-3" name="bngo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfNS0yLTEtMS0xMDQ1Njg_782bb8b5-5aea-41c8-87ee-6ecff349ba02">400,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130" decimals="-3" name="bngo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfNi0yLTEtMS0xMDQ1Njg_10e900a5-6aff-47f2-9aa4-2f69fe75025e">1,636,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfNy0yLTEtMS0xMDQ1Njg_bafaaf3d-15dc-49ef-9ff2-253783bd6a79">533,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfOC0yLTEtMS0xMDQ1Njg_ecb53a97-40d6-4163-9fc1-896b27535bac">20,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfOS0yLTEtMS0xMDQ1Njg_1e4a83a9-e9e5-4b1c-8a8f-ec68025caf6a">22,651,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounts payable and other accrued liabilities </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130" decimals="-3" name="bngo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfMTAtMi0xLTEtMTA0NTY4_71fbf7d1-40f5-4a2b-bc03-471f5464db35">1,152,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Operating lease liability (short-term and long-term)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130" decimals="-3" name="bngo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfMTEtMi0xLTEtMTA0NTY4_4eeb58de-0432-4f87-be14-93129dbe1d37">1,636,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfMTItMi0xLTEtMTA3ODU3_3175bfee-c9f6-4a4a-9d9d-a668403d1bd0">44,914,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RleHRyZWdpb246YjRmYTQ3OWVkNzVhNDg4ODg5N2RiYjFlZmQyMDkxZjNfMzg0ODI5MDcwOTY1MA_fb726260-1819-4471-b0ba-f8ae7b6b9528" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair values of identifiable intangible assets acquired are as following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ic97685b2136f4353b8df0de2a7e10ad3_I20221130" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOjE1ODEzMmQ2NGJjYjRmN2JiNzBhYTFhZjI5NTc4NzM1L3RhYmxlcmFuZ2U6MTU4MTMyZDY0YmNiNGY3YmI3MGFhMWFmMjk1Nzg3MzVfMC0yLTEtMS0xMDQ1Njg_6b3ef418-b615-4625-8280-f2eadc344221">18,800,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i295a9a13609e47d0bbdd3fe79bcb04e1_I20221130" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOjE1ODEzMmQ2NGJjYjRmN2JiNzBhYTFhZjI5NTc4NzM1L3RhYmxlcmFuZ2U6MTU4MTMyZDY0YmNiNGY3YmI3MGFhMWFmMjk1Nzg3MzVfMS0yLTEtMS0xMDQ1Njg_dae891e9-d38a-4c97-919a-ef501f2300ad">200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Tradename</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i925ef02d711544878675a77e949a4453_I20221130" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOjE1ODEzMmQ2NGJjYjRmN2JiNzBhYTFhZjI5NTc4NzM1L3RhYmxlcmFuZ2U6MTU4MTMyZDY0YmNiNGY3YmI3MGFhMWFmMjk1Nzg3MzVfMi0yLTEtMS0xMDQ1Njg_21c49587-2015-4cab-8024-d456054699d5">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Fair value of identifiable intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOjE1ODEzMmQ2NGJjYjRmN2JiNzBhYTFhZjI5NTc4NzM1L3RhYmxlcmFuZ2U6MTU4MTMyZDY0YmNiNGY3YmI3MGFhMWFmMjk1Nzg3MzVfMy0yLTEtMS0xMDYxMzA_5cfa20fa-ad98-4d4b-a77f-1a968e666858">20,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the income approach to derive the fair value of the identified intangible assets acquired. This approach calculates fair value by estimating future cash flows attributable to the assets and then discounting these cash flows to a present value using a risk-adjusted discount rate. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The customer relationships and trade name intangibles are being amortized on a straight-line basis over their estimated useful lives of <ix:nonNumeric contextRef="i6e35fc0471424eaeb1aa538040aea91e_D20221101-20221130" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RleHRyZWdpb246YjRmYTQ3OWVkNzVhNDg4ODg5N2RiYjFlZmQyMDkxZjNfMTA5OTUxMTY0MDE5Ng_31ee4d48-a3cd-4d23-8654-9d7e2d550588"><ix:nonNumeric contextRef="if1dc3f6d0e094c2196112c84227fe802_D20221101-20221130" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RleHRyZWdpb246YjRmYTQ3OWVkNzVhNDg4ODg5N2RiYjFlZmQyMDkxZjNfMTA5OTUxMTY0MDE5Ng_f4f15e03-c2ba-46c6-aafa-a7bb3a7cd923">5</ix:nonNumeric></ix:nonNumeric> years. The developed technology intangible is being amortized on a straight-line basis over its estimated useful live of <ix:nonNumeric contextRef="if3a2c1a4485a471c820ca4842e5c1c64_D20221101-20221130" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RleHRyZWdpb246YjRmYTQ3OWVkNzVhNDg4ODg5N2RiYjFlZmQyMDkxZjNfMTA5OTUxMTY0MDIwMw_6dfd7791-a3fa-4b0e-94f6-668390b5d8d5">15</ix:nonNumeric> years. Straight-line amortization was determined to be materially consistent with the pattern of expected use of the intangible assets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company began integrating Purigen&#8217;s operations with its existing operations during the fourth quarter of 2022, it is not practical or meaningful to distinguish Purigen&#8217;s expenses or net income or loss from that of the combined operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pro forma Financial Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma financial information in the table below summarizes the combined results of operations for the Company and Purigen as if the companies had been combined as of the beginning of the year prior to the acquisition. These amounts have been calculated after applying the Company&#8217;s accounting policies and adjusting the results of Purigen to reflect </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><ix:continuation id="i95f841efcef947918c1ed6254abce891"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the additional amortization that would have been charged assuming the fair value adjustments to intangible assets had been applied at the beginning of the year prior to the acquisition. <ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RleHRyZWdpb246YjRmYTQ3OWVkNzVhNDg4ODg5N2RiYjFlZmQyMDkxZjNfMzQ5NA_dce0ddfd-8cbc-4279-8516-c1db7dd005c1" continuedAt="ic5ef0227008b47e1b5c066413450b959" escape="true">The following unaudited pro forma financial information is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved as if the acquisition had taken place as of January 1, 2021.</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="ic5ef0227008b47e1b5c066413450b959"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.392%"></td><td style="width:0.1%"></td></tr><tr style="height:29pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6925d4a44b4d4f8ab1473a6ec01745a1_D20220101-20220331" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOjRhMGFkOTA2ZGRkYjRlYjc4YWUyMTg2ZTZhYjhlZDU4L3RhYmxlcmFuZ2U6NGEwYWQ5MDZkZGRiNGViNzhhZTIxODZlNmFiOGVkNThfMi00LTEtMS0xMDQxMTk_7412b978-0122-404b-943d-4922cf85beb7">6,220,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6925d4a44b4d4f8ab1473a6ec01745a1_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOjRhMGFkOTA2ZGRkYjRlYjc4YWUyMTg2ZTZhYjhlZDU4L3RhYmxlcmFuZ2U6NGEwYWQ5MDZkZGRiNGViNzhhZTIxODZlNmFiOGVkNThfMy00LTEtMS0xMDQxMTk_607b4603-d1e8-4d6c-a971-f566812f63ce">32,048,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Basic and diluted net loss per share</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6925d4a44b4d4f8ab1473a6ec01745a1_D20220101-20220331" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOjRhMGFkOTA2ZGRkYjRlYjc4YWUyMTg2ZTZhYjhlZDU4L3RhYmxlcmFuZ2U6NGEwYWQ5MDZkZGRiNGViNzhhZTIxODZlNmFiOGVkNThfNC00LTEtMS0xMDQxMTk_f1249d0e-6bce-47be-b41e-dd3b38974f93"><ix:nonFraction unitRef="usdPerShare" contextRef="i6925d4a44b4d4f8ab1473a6ec01745a1_D20220101-20220331" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOjRhMGFkOTA2ZGRkYjRlYjc4YWUyMTg2ZTZhYjhlZDU4L3RhYmxlcmFuZ2U6NGEwYWQ5MDZkZGRiNGViNzhhZTIxODZlNmFiOGVkNThfNC00LTEtMS0xMDQxMTk_fa5333f4-5805-480a-9dfb-b1a08e387576">0.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i561259e69fbb4552820b7ec56e5dea3a_64"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfNDE0OQ_76445f4d-0f7c-4e48-a68b-b006a9529bd1" continuedAt="iffa4f2faf895420fbfb08d453b697e6a" escape="true">Investments and Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="iffa4f2faf895420fbfb08d453b697e6a" continuedAt="i68c5899c3be3450db013cf67f37d64c4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds investment securities that consist of highly liquid, investment grade debt securities. The Company determines the fair value of its investment securities based upon one or more valuations reported by its investment accounting and reporting service provider. The investment service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curves, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, and broker and dealer quotes, as well as other relevant economic measures.</span></div><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfNDE1MA_f7905c39-a84d-42aa-b467-9cffe731c55b" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis as of March&#160;31, 2023 and December&#160;31, 2022: </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March&#160;31, 2023</span></div></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Fair Value and Carrying Value on Balance Sheet</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurement&#160;Category</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15907a4c560a493d87c23e62f68ec83c_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNC0xLTEtMS0xMDQxMTk_59ba22fa-2d2f-414b-9234-daf1ef4f8322">15,216,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a4d7a1847949aca50c56b25a88bd21_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNC0zLTEtMS0xMDQxMTk_bd3af6e1-73e7-491c-854a-23a52f7c9acc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i310d4215052d4ca0a49959195011a0ca_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNC01LTEtMS0xMDQxMTk_beee7614-036e-41dc-9a98-ba2e0903eadb">15,216,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93d2a3e0250e47bcb4b130e733307695_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNC03LTEtMS0xMDQxMTk_47797af1-40b3-411f-a677-b830d1e4f5c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i647cc339b7ba4424aa0eb336ee4b0a30_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNS0xLTEtMS0xMDQxMTk_a5d62169-9902-4dc5-aafc-0c71e2b28434">74,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f5ab08df5bf405bb9bf921da040bd2d_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNS0zLTEtMS0xMDQxMTk_b6b0ede2-87a4-45a0-9922-2a57a7ae973f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1331001dd149aab4965f0b8b08572c_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNS01LTEtMS0xMDQxMTk_ce0bbf3f-2598-4050-8996-c4a662350fd3">74,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75520dd1a92c4e7f98c4a30068aa125f_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNS03LTEtMS0xMDQxMTk_4f2d5d2d-70a3-4885-902b-2cbb1fb155fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government sponsored entities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7617b2529de45d9b88866d405c216e8_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNi0xLTEtMS0xMDQxMTk_5e6b6cad-eb7e-4b5f-aadd-1837202e847c">1,988,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52aa8a7998954d46afe56844fc671bed_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNi0zLTEtMS0xMDQxMTk_c585bfe1-95ae-4123-95d7-714aeb883f45">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c44b89669c84b58ac68a7d82a6f060f_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNi01LTEtMS0xMDQxMTk_bf924d96-ceb1-4da6-b43b-41cbafd3aed6">1,988,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7b8d23c3c2d432086d989ce0d5b3510_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNi03LTEtMS0xMDQxMTk_91579c8e-154c-47fd-81de-5070e3ceddf2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i773ffb9b71e74f0fbb5045402bab92e2_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNy0xLTEtMS0xMDQxMTk_529180be-7ad5-4556-910b-f714a5862822">91,704,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfdbb8c8377342dba83719c152d876ca_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNy0zLTEtMS0xMDQxMTk_46eb1eeb-0045-4a01-8ffb-346bfbbb256e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91aa339ce2224ab2b4c95c616a46b05a_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNy01LTEtMS0xMDQxMTk_9e25d72d-715b-40d7-b9d3-6f7bdba2d9f7">91,704,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c30654b099944fe816f08038b543686_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNy03LTEtMS0xMDQxMTk_e420ec7b-35d4-4dca-b4a8-992b61b2055d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21767da9f078468aaa8154704501d4ef_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfOC0xLTEtMS0xMDQxMTk_7987a1ac-9f16-47b3-9828-aef0a8236e02">252,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if31d69e265f548ce81614232c6d0622e_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfOC0zLTEtMS0xMDQxMTk_2908d771-f6ae-497f-9e0e-1ee1f89837f4">252,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dfdfcb6eabc4fdf95b79cf9538f70c7_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfOC01LTEtMS0xMDQxMTk_3485854b-e65e-4a54-9df4-aead9b34720b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d84f69387345d4810fabcf98a5a295_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfOC03LTEtMS0xMDQxMTk_a2db50a2-caeb-4400-8df5-08a771c6ef52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541c9938b3c74107adcc551aaa42ea63_I20230331" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfMTAtMS0xLTEtMTA0MTE5_fef46185-0b61-449a-972d-a8d104b7ebfb">23,141,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f19aa7ddf044ea8bec0a50eb8c00be_I20230331" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfMTAtMy0xLTEtMTA0MTE5_2ab52d51-fa37-4752-b8b6-e02f58909901">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b14269404374b769581777b4169a1f0_I20230331" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfMTAtNS0xLTEtMTA0MTE5_8031cd24-5fa8-4a02-8fc3-1bfd1f2df6c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic18218c1e1fa4ecba456ceeee9c63aff_I20230331" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfMTAtNy0xLTEtMTA0MTE5_50dcbc3b-e11e-46bc-a0f0-a625cd566ddc">23,141,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2022</span></div></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Fair Value and Carrying Value on Balance Sheet</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurement&#160;Category</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6627384d34dc4218abc8ef93db117f35_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNC0xLTEtMS0xMDQxMTk_9e1716a3-5654-4988-8211-dc2acec09a55">20,020,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i999a70848ee64e86a9903a8300ea18ae_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNC0zLTEtMS0xMDQxMTk_d5f8ed3c-9e57-454e-bfe5-9f9d62310024">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ab3ed3cf5644f68a916db4cc62581fe_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNC01LTEtMS0xMDQxMTk_9128a832-d191-4f0c-9ab3-6dba52d821da">20,020,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic17b4d26f18349fbb811e5538089dabe_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNC03LTEtMS0xMDQxMTk_1264cb72-4bb2-40a2-8a13-8c11281258a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id843769ea0ce4178b71b8b98c986b0ee_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNS0xLTEtMS0xMDQxMTk_e9d9ac50-374e-44aa-aa8b-f777b659a52f">86,094,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c33d6de7efe40e2a08f973235f91b19_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNS0zLTEtMS0xMDQxMTk_6a39a81d-f6cc-4d17-8a81-4605f3e2bb96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d60828b8d294052882c3b89d2fd9265_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNS01LTEtMS0xMDQxMTk_c66dd54b-efd4-4394-9c1b-a801f164cbe7">86,094,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6001106820441dbaa8649a391b20f27_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNS03LTEtMS0xMDQxMTk_edbdb9fe-d549-4a57-9bd6-fc7ee301d309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government sponsored entities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9394339fa2c426f9dac1c7946f4249c_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNi0xLTEtMS0xMTE4MzY_d5d7600b-4690-4a23-bd21-be8b057251e6">1,981,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i9019ad460da54067a92ced4519dbc280_I20221231" xsi:nil="true" name="us-gaap:InvestmentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNi0zLTEtMS0xMTI4ODE_88928cf4-0f22-4ced-a105-ea1465f4bcb9"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cff04acd40b44bb97ada25f13cf507d_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNi01LTEtMS0xMTE4NDM_3e1d2b8f-a527-4024-bf9b-9a60af31da6b">1,981,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i971953b96b7546e2b31d70534f703931_I20221231" xsi:nil="true" name="us-gaap:InvestmentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNi03LTEtMS0xMTI4ODc_97eba81e-5223-45c6-9a80-355fc52c9803"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6f16598c254520b8de2a1aba7fd14f_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNi0xLTEtMS0xMDQxMTk_621aff8b-d2fa-4d14-abcc-bef9d21e61b6">108,095,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04186447695d45da87b4e76c39d70450_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNi0zLTEtMS0xMDQxMTk_1b9cd9ce-2d59-43d4-8a47-8eac3edaa406">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i229abcae1df149319098554f196c3b4a_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNi01LTEtMS0xMDQxMTk_21e8318b-94ca-4b52-a6a7-5258dd31d0f9">108,095,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d182bb719e0486b93ba7f98d8b1537b_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNi03LTEtMS0xMDQxMTk_2ea82527-237b-4ddb-9a73-87c940a8f44f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0903ef6ff3f94b54a15562d6f61e5049_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNy0xLTEtMS0xMDQxMTk_ebd86529-9e29-4e03-b717-39d06eb43b25">1,868,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e330387d6c34591aca484734572ae7d_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNy0zLTEtMS0xMDQxMTk_e9e9a0fe-e2c8-4e68-8f29-785716656682">1,868,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i042557760bda403e9553e36b701f1ab8_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNy01LTEtMS0xMDQxMTk_11ea3725-2b0e-49af-b625-565e38f8fe9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c398cac425e49a5a91b7758fa11343b_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNy03LTEtMS0xMDQxMTk_46705662-0afb-43aa-bf54-62cc0ca1ea14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf82eab802a4fc0a2d085cc0c3baeae_I20221231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfOS0xLTEtMS0xMDQxMTk_698fd813-eee0-4182-ae18-59aceee6b66b">22,352,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieabf435d9321492eb0f1862ccf31dc71_I20221231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfOS0zLTEtMS0xMDQxMTk_947597ce-b7de-49b1-bd78-2f1a2f560570">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d5aec6d9ea84d38855de750ab9fd43e_I20221231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfOS01LTEtMS0xMDQxMTk_f1ef49bf-798b-4196-8eee-bb0dc69ab463">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01b4a9caaa104277aa2c4a4bb45c1c91_I20221231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfOS03LTEtMS0xMDQxMTk_84ba9861-43e5-4e56-9ab6-b53db620dd91">22,352,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds are classified as cash equivalents on the unaudited condensed consolidated balance sheet. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><ix:continuation id="i68c5899c3be3450db013cf67f37d64c4" continuedAt="i82108964c8c848779da9c274752a093e"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration relates to the acquisitions of BioDiscovery and Purigen. The outcome of the milestone consideration for all contingent consideration liabilities is binary, meaning the milestones are either achieved or not achieved, and the only other variable factor is the timing of when the milestones are achieved. The fair value measurement of the contingent consideration liabilities is based on significant inputs not observed in the market (Level 3 inputs). These unobservable inputs represent a Level 3 measurement because they are supported by little or no market activity and reflect the Company&#8217;s assumptions in measuring fair value.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the BioDiscovery contingent consideration liability is reassessed on a quarterly basis using a probability weighted model. Assumptions used to estimate the acquisition date fair value of the contingent consideration related to the acquisition of BioDiscovery include the probability of achieving, or changes in timing, of certain milestones, and a discount rate. As of March&#160;31, 2023 a discount rate of <ix:nonFraction unitRef="number" contextRef="ia6c6c5c8311f41aa99327db95ebffefc_I20230331" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfMTA5OTUxMTY1NTczMQ_95dc91f6-395b-4dd4-9735-aa833f49fc4c">3</ix:nonFraction>% was used. The Company determined the fair value of the BioDiscovery milestone consideration using a scenario-based technique, as the trigger for payment is event driven. The Company determined it is highly likely that the milestone related to the BioDiscovery acquisition will be achieved and therefore used a <ix:nonFraction unitRef="number" contextRef="i764a624557c84d788711b6db863a88fa_I20230331" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfMTA5OTUxMTY1NTczNQ_92e65263-01bb-4dbf-8dde-c40c6b47c75e">95</ix:nonFraction>% probability factor which is applied to the $<ix:nonFraction unitRef="usd" contextRef="idf80aacd0d8b4d49bda88deb4fe34f82_D20230101-20230331" decimals="-5" name="bngo:BusinessCombinationContingentConsiderationMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfMTA5OTUxMTY1NTczOQ_e015453a-6084-49cc-8bcb-99e804d2cbc4">10.0</ix:nonFraction> million milestone consideration. The change in fair value of the contingent consideration during the three months ended March&#160;31, 2023 was due to the passage of time. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liabilities related to the Purigen milestones are related to the achievement of two independent milestones with aggregate possible milestone payments totaling $<ix:nonFraction unitRef="usd" contextRef="id0516c6ac8dd4d63874b612f0c8e9150_D20230101-20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfNTQ5NzU1ODQxNzYx_76f2594f-e8fa-4ba4-a437-16836cc84399">32.0</ix:nonFraction> million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Purigen milestones are reassessed on a quarterly basis using a probability weighted model and a Monte Carlo Simulation. Assumptions used to estimate the acquisition date fair value of the milestones using a probability weighted model include the probability of achieving, or changes in timing, of independent milestones, and a discount rate of <ix:nonFraction unitRef="number" contextRef="i775844669d9443f18408dc91c0ed82e0_I20230331" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfNTQ5NzU1ODQxNzc1_ab6250bf-5635-4077-8ba7-7d1680669b64">15</ix:nonFraction>%. The Company determined the fair value of this milestone consideration using a scenario-based technique, as the trigger for payment is event driven. The Company determined the likelihood of each independent milestone and used probability factors ranging from <ix:nonFraction unitRef="number" contextRef="i92407742ad83484e8413c0f98a6ddb72_I20230331" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfNTQ5NzU1ODQxNzY1_2b9bd43f-a71c-4ca4-a190-876dd2fe4cae">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i026227378deb46939c6b0b7015b7862c_I20230331" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfNTQ5NzU1ODQxNzcx_7b6d6a53-4dc1-42f1-a7ac-b081c8df31c4">80</ix:nonFraction>% which were applied to the individual payments. A Monte Carlo Simulation was performed to determine the likelihood that the milestone will be achieved and was applied to the milestone consideration payment. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfNDE1MQ_fefc3929-9434-4062-bead-887cf8149517" continuedAt="i1dcc385ec8504f6d83958e523d2824bc" escape="true">Changes in estimated fair value of contingent consideration liability in the three months ended March&#160;31, 2023 is as follows: </ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i1dcc385ec8504f6d83958e523d2824bc"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Contingent</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Consideration</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Liability</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(Level 3</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Measurement)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of January 1, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b30d459d41d4643a4ff9a4e0f57f5f7_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjJlY2M3YmYwMjMyMDRiODViZmJkMjNkZTMwOTVjNWMyL3RhYmxlcmFuZ2U6MmVjYzdiZjAyMzIwNGI4NWJmYmQyM2RlMzA5NWM1YzJfMS0xLTEtMS0xMDQxMTk_aa83aec0-f4e8-441d-80fb-fa3e35039df8">22,352,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liability recorded as a result of current period acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44567efb5fb4e42820714c15bc00b89_D20230101-20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjJlY2M3YmYwMjMyMDRiODViZmJkMjNkZTMwOTVjNWMyL3RhYmxlcmFuZ2U6MmVjYzdiZjAyMzIwNGI4NWJmYmQyM2RlMzA5NWM1YzJfMi0xLTEtMS0xMDQxMTk_7848df45-7013-4dca-b613-d114cdc1478a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in estimated fair value, recorded in selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44567efb5fb4e42820714c15bc00b89_D20230101-20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjJlY2M3YmYwMjMyMDRiODViZmJkMjNkZTMwOTVjNWMyL3RhYmxlcmFuZ2U6MmVjYzdiZjAyMzIwNGI4NWJmYmQyM2RlMzA5NWM1YzJfMy0xLTEtMS0xMDQxMTk_7cab4a81-2ae3-4f20-8db0-c3d1c9d7add3">789,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44567efb5fb4e42820714c15bc00b89_D20230101-20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjJlY2M3YmYwMjMyMDRiODViZmJkMjNkZTMwOTVjNWMyL3RhYmxlcmFuZ2U6MmVjYzdiZjAyMzIwNGI4NWJmYmQyM2RlMzA5NWM1YzJfNC0xLTEtMS0xMDQxMTk_f94fd0d9-ac0a-4483-ad4f-23c558b3c23c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110925712b904ad2ad4771d5056f1576_I20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjJlY2M3YmYwMjMyMDRiODViZmJkMjNkZTMwOTVjNWMyL3RhYmxlcmFuZ2U6MmVjYzdiZjAyMzIwNGI4NWJmYmQyM2RlMzA5NWM1YzJfNS0xLTEtMS0xMDQxMTk_8e364709-cbf7-4860-9463-7f8badfd3585">23,141,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available for Sale Investments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in U.S. Treasury and agency securities, corporate debt securities, and commercial paper, which are classified as available-for-sale investments. These investments are carried at fair value and are included in the tables below. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. At each reporting date, the Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. The Company evaluates, among others, whether the Company has the intention to sell any of these investments and whether it is not more likely than not that the Company will be required to sell any of them before recovery of the amortized cost basis. Neither of these criteria were met in any period presented. The credit ratings of the securities held remain of the highest quality. Moreover, the Company continues to receive payments of interest and principal as they become due, and our expectation is that those payments will continue to be received timely. Based on this evaluation, as of March&#160;31, 2023 and December&#160;31, 2022, the Company determined that unrealized losses of the below securities were primarily attributable to changes in interest rates and non-credit related factors. As such, no allowances for credit losses were recorded during these periods. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, the Company held <ix:nonFraction unitRef="security" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfMTA5OTUxMTY1NjUwMA_be48a18f-97a8-4e40-9576-10ab484e67ae">17</ix:nonFraction> and <ix:nonFraction unitRef="security" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfMTA5OTUxMTY1NjQzNg_c07b5e79-5ff6-4dbe-b781-6b088f72d59a">16</ix:nonFraction> securities, respectively, which have been in an unrealized loss position for a period of less than 12 months. As of March&#160;31, 2023 and December&#160;31, 2022, the Company held <ix:nonFraction unitRef="security" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfMTA5OTUxMTY1NjUyMw_41397ba2-6550-4faf-8b05-dd76d89a6b5a">19</ix:nonFraction> and <ix:nonFraction unitRef="security" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfMTA5OTUxMTY1NjUyNw_a4218b56-7eae-446a-8cf8-ec45de643965">24</ix:nonFraction> securities, respectively, which have been in an unrealized loss position for a period of greater than 12 months.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><ix:continuation id="i82108964c8c848779da9c274752a093e" continuedAt="i1e706193afcc4475b8020d839ebe5c8a"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses are calculated using the specific identification method and recorded in other income (expense) in the Company&#8217;s unaudited condensed consolidated statements of operations and comprehensive loss. The Company has the ability, if necessary, to liquidate any of its cash equivalents and marketable securities to meet its liquidity needs in the next 12 months.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable as of March&#160;31, 2023 and December&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-5" name="us-gaap:InterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfNTQ5NzU1ODQxODM5_2deb62ca-24c4-46e4-a6c5-c0f95ea6bf0d">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-5" name="us-gaap:InterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfMTA5OTUxMTY1NTc0OQ_2c844d88-3ffa-420f-8a21-86f650248640">0.5</ix:nonFraction> million, respectively, and is recorded as a component of prepaid expenses and other current assets on the unaudited condensed consolidated balance sheets.</span></div><ix:nonNumeric contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfNDE1Mg_5b0239c1-c2e5-4af4-a7ff-07935e1e4e29" continuedAt="ifa9f37952e1b4089ab9b9dcb8889b020" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the following table summarizes the amortized cost and the unrealized gains/losses of the available for sale securities:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Contractual Maturity (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1becd5a6f0af415fae96defb606a1b8b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfMi0zLTEtMS0xMDQxMTk_1691df40-71bd-4cde-ba21-394ded72b414">15,259,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1becd5a6f0af415fae96defb606a1b8b_I20230331" decimals="-3" name="bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfMi01LTEtMS0xMDQxMTk_a1f46ec8-a237-4cea-9141-51ed89c8efee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1becd5a6f0af415fae96defb606a1b8b_I20230331" decimals="-3" name="bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfMi03LTEtMS0xMDQxMTk_84e13e5b-97d1-4f03-827f-ec636122934a">43,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1becd5a6f0af415fae96defb606a1b8b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfMi05LTEtMS0xMDQxMTk_ad6091c5-0443-4947-a1e1-f4729ef66180">15,216,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfMy0zLTEtMS0xMDQxMTk_5fd82603-7d86-43d5-9b7e-64db9307e8f6">68,739,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331" decimals="-3" name="bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfMy01LTEtMS0xMDQxMTk_d5aded91-824c-4136-a5a2-3ebc1ec45835">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331" decimals="-3" name="bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfMy03LTEtMS0xMDQxMTk_fa95a302-9fec-4d1a-8913-b8a1a6c7a493">561,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfMy05LTEtMS0xMDQxMTk_af750b7b-6b6b-4c99-a2ca-3d7cbdf2aa4c">68,178,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae48309cf5ff43dda82b169b4c36444e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfNC0zLTEtMS0xMDQxMTk_b11b176c-62cd-4293-aa17-13da4a4221d4">1,998,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae48309cf5ff43dda82b169b4c36444e_I20230331" decimals="-3" name="bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfNC01LTEtMS0xMDQxMTk_c97fdfc3-261f-491f-9972-9ab63849aa96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae48309cf5ff43dda82b169b4c36444e_I20230331" decimals="-3" name="bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfNC03LTEtMS0xMDQxMTk_9d83c563-018d-49f4-949c-0a4236d72a4a">10,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae48309cf5ff43dda82b169b4c36444e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfNC05LTEtMS0xMDQxMTk_2d48e993-4f4e-4c91-8b7c-066a0952db69">1,988,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total maturity less than 1 year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfNC0zLTEtMS0xMDcxNjA_fb5eb4e0-5da3-4bcd-a53d-51085654de4f">85,996,000</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfNC01LTEtMS0xMDcxNjE_dcdc1528-373d-40ed-a1ce-194473d38455">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfNC03LTEtMS0xMDc5NDQ_67388ee1-15d0-4e59-91cc-a2440e2f4c3c">614,000</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfNC05LTEtMS0xMDc5NDc_65c1224d-5b5b-40b3-be8b-6d1af4feabf0">85,382,000</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfNS0zLTEtMS0xMDcxNTA_a0aaf9bb-46c9-4841-8300-df61e54d0123">6,372,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331" decimals="-3" name="bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfNS01LTEtMS0xMDcxNTA_3d38bc24-dee1-4254-806b-d962a49dc133">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331" decimals="-3" name="bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfNS03LTEtMS0xMDcxNTA_fe1f38bf-8eb3-47be-a452-99bc57f14147">50,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfNS05LTEtMS0xMDcxNTA_b194f749-e187-40d6-b258-fae86fa05edf">6,322,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfOC0zLTEtMS0xMDc5NjQ_0d3b932a-ed69-4044-9efa-9f1645c143b2">92,368,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="bngo:DebtSecuritiesAvailableForSaleUnrealizedGains" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfOC01LTEtMS0xMDc5NjY_8c0b5cfd-1c5c-4172-a563-2428611d029e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="bngo:DebtSecuritiesAvailableForSaleUnrealizedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfOC03LTEtMS0xMDc5Njk_746e5476-cb4c-434f-844b-39a605922e24">664,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfOC05LTEtMS0xMDc5NzE_6897dc13-cc81-4c1e-aafc-ed3d2fe9f516">91,704,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the following table summarizes the amortized cost and the unrealized gains/losses of the available for sale securities:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Contractual Maturity (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4118894962b9424d92128e02a9adf2bc_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfMS0zLTEtMS0xMDUyNzg_d2aa190b-e2ca-4ffa-9233-a5d1fb07b46c">20,093,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4118894962b9424d92128e02a9adf2bc_I20221231" decimals="-3" name="bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfMS01LTEtMS0xMDUyNzg_319675f7-2a0d-4256-aea5-64e27cb5416d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4118894962b9424d92128e02a9adf2bc_I20221231" decimals="-3" name="bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfMS03LTEtMS0xMDUyNzg_d391eac5-59e3-40ee-8ee9-7b97fabc5687">73,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4118894962b9424d92128e02a9adf2bc_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfMS05LTEtMS0xMDUyNzg_e7d2efdb-5ed8-40fb-a36e-e889dcdf6103">20,020,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i206731c08e11447b8873b07b61772810_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfMi0zLTEtMS0xMDUyNzg_325b250c-537b-43e0-9742-2dd94f5e9fa3">72,823,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i206731c08e11447b8873b07b61772810_I20221231" decimals="-3" name="bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfMi01LTEtMS0xMDUyNzg_f7be9fb2-672a-4e65-86c3-1c003ad155ea">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i206731c08e11447b8873b07b61772810_I20221231" decimals="-3" name="bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfMi03LTEtMS0xMDUyNzg_278a9608-6b3d-4ef7-ba14-9c2f8dbbd92a">911,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i206731c08e11447b8873b07b61772810_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfMi05LTEtMS0xMDUyNzg_80ed5727-f157-45a8-9edd-206062652f1a">71,913,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2908d99b8fe4704bcd189727c191080_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfMy0zLTEtMS0xMDUyNzg_bb749a29-83de-4232-8e71-da96b428313c">1,998,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2908d99b8fe4704bcd189727c191080_I20221231" decimals="-3" name="bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfMy01LTEtMS0xMDUyNzg_fdcb6005-2eba-499f-ae29-83168c4e8eed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2908d99b8fe4704bcd189727c191080_I20221231" decimals="-3" name="bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfMy03LTEtMS0xMDUyNzg_1212dcde-dee6-4ec4-8b98-fb8e0d166835">16,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2908d99b8fe4704bcd189727c191080_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfMy05LTEtMS0xMDUyNzg_0f7b998e-d322-4c5e-98c5-2ff8d6bb5d11">1,982,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total maturity less than 1 year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfNC0zLTEtMS0xMDcyMDY_56a090e9-65ca-48c9-ae24-2647eb43b638">94,914,000</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfNC01LTEtMS0xMDcyMDc_a0545224-94cb-4122-bde5-5f6714965e95">1,000</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfNC03LTEtMS0xMDc5OTI_bd0d988f-6fd4-486d-9c80-5ff3c4f595ce">1,000,000</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfNC05LTEtMS0xMDc5OTQ_30db0c64-4b22-4c87-89fe-c9228c28d255">93,915,000</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i206731c08e11447b8873b07b61772810_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfNS0zLTEtMS0xMDcxOTY_e7fa9299-513f-4123-9676-9b661ad42256">14,268,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i206731c08e11447b8873b07b61772810_I20221231" decimals="-3" name="bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfNS01LTEtMS0xMDcxOTY_4d0bb85b-6232-441c-9de3-8b01709c3579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i206731c08e11447b8873b07b61772810_I20221231" decimals="-3" name="bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfNS03LTEtMS0xMDcxOTY_8e6fb93a-35b9-4163-b639-43bbcc8b68c2">88,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i206731c08e11447b8873b07b61772810_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfNS05LTEtMS0xMDcxOTY_617012ec-4bf9-48c9-8148-442b085d5f40">14,180,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfOC0zLTEtMS0xMDgwNzE_e21ee451-0e9a-4cd5-a924-77fc819bdbbf">109,182,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="bngo:DebtSecuritiesAvailableForSaleUnrealizedGains" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfOC01LTEtMS0xMDgwNzM_b7f3f3c5-a28b-4ef4-b1b4-7ca7708c60e2">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="bngo:DebtSecuritiesAvailableForSaleUnrealizedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfOC03LTEtMS0xMDgwNzQ_73cd685f-56a7-4ff8-a699-1dd175d9fe33">1,088,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfOC05LTEtMS0xMDgwNzc_d5e15d50-9716-4451-9b38-4898d5c1d4b3">108,095,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the following table summarizes available-for-sale securities in an unrealized loss position with no credit losses reported:</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><ix:continuation id="i1e706193afcc4475b8020d839ebe5c8a"><ix:continuation id="ifa9f37952e1b4089ab9b9dcb8889b020"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Gross Unrealized Loss</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Gross Unrealized Loss</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Gross Unrealized Loss</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1becd5a6f0af415fae96defb606a1b8b_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfMi0xLTEtMS0xMDUwOTU_ee337f0f-61f8-48a8-8ba1-ea621284602e">15,216,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1becd5a6f0af415fae96defb606a1b8b_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfMi0zLTEtMS0xMDUwOTU_e53bcc52-2be1-4307-b073-bf5792be5152">43,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1becd5a6f0af415fae96defb606a1b8b_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfMi01LTEtMS0xMDUwOTU_64ffe2a4-d84b-4b40-b690-a51f7500a494">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1becd5a6f0af415fae96defb606a1b8b_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfMi03LTEtMS0xMDUwOTU_892d99d1-8992-4058-a0f7-3835f44324fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1becd5a6f0af415fae96defb606a1b8b_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfMi05LTEtMS0xMDUwOTU_dca8467f-45a3-49c4-9c74-49bcd2267d9e">15,216,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1becd5a6f0af415fae96defb606a1b8b_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfMi0xMS0xLTEtMTA1MDk1_c3caa15e-50a2-4522-a6cb-67124ac6e369">43,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfMy0xLTEtMS0xMDUwOTU_16428f53-7b29-468f-8db9-f300478aec21">11,687,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfMy0zLTEtMS0xMDUwOTU_6b3e0888-9c67-4bad-a9e1-170f5be0911f">40,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfMy01LTEtMS0xMDUwOTU_85ed65a3-29ae-40e2-a970-85d4691783b3">62,813,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfMy03LTEtMS0xMDUwOTU_0c362921-bba2-4917-bc8d-0144c11f10fa">571,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfMy05LTEtMS0xMDUwOTU_9499cc3f-e7ce-4fd4-84a6-7b3d4c4d6cdd">74,500,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfMy0xMS0xLTEtMTA1MDk1_5664e948-9bc4-45f8-b8ee-e2de34468b78">611,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of Government Sponsored Entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae48309cf5ff43dda82b169b4c36444e_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfNC0xLTEtMS0xMDUwOTU_fd88ca56-980c-456f-ab44-d2605556022a">1,988,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae48309cf5ff43dda82b169b4c36444e_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfNC0zLTEtMS0xMDUwOTU_ca487e36-3f96-44fe-b91d-7505e740192d">10,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae48309cf5ff43dda82b169b4c36444e_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfNC01LTEtMS0xMDUwOTU_292e88b2-d308-4a44-aeba-9e40431c4498">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae48309cf5ff43dda82b169b4c36444e_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfNC03LTEtMS0xMDUwOTU_a9bc5cbc-1555-4198-8bf9-01eac5d406c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae48309cf5ff43dda82b169b4c36444e_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfNC05LTEtMS0xMDUwOTU_0b2eca12-269f-4dff-b667-963f0c6d6abb">1,988,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae48309cf5ff43dda82b169b4c36444e_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfNC0xMS0xLTEtMTA1MDk1_e272803f-863c-4205-a7cf-45fc4ae6320b">10,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfNS0xLTEtMS0xMDYzOTU_50120c30-602e-4c98-8daf-496f3459b66a">28,891,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfNS0zLTEtMS0xMDYzOTU_7ff5cf59-a8bf-4ee5-8832-9a02a5d76177">93,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfNS01LTEtMS0xMDYzOTU_7aa4d86e-fc00-489e-8070-a4be786a07a2">62,813,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfNS03LTEtMS0xMDYzOTU_119efebc-2d8b-4966-884b-e9afd15471d8">571,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfNS05LTEtMS0xMDYzOTU_ad83dfdc-6e21-4e35-bdb0-64de97e1e9d7">91,704,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfNS0xMS0xLTEtMTA2Mzk1_c429ef47-5b8a-44ef-a541-fb892bb1f1cd">664,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the following table summarizes available-for-sale securities in an unrealized loss position with no credit losses reported:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Gross Unrealized Loss</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Gross Unrealized Loss</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Gross Unrealized Loss</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4118894962b9424d92128e02a9adf2bc_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfMi0xLTEtMS0xMDUwOTU_c039e03f-979a-44cd-9760-a8656403fd97">20,020,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4118894962b9424d92128e02a9adf2bc_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfMi0zLTEtMS0xMDUwOTU_fc02cbf5-cda4-4125-a9d4-4af0f5c69485">73,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4118894962b9424d92128e02a9adf2bc_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfMi01LTEtMS0xMDUwOTU_1c7470c6-c94d-4977-8ce6-12161f012d64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4118894962b9424d92128e02a9adf2bc_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfMi03LTEtMS0xMDUwOTU_ef238eb7-07ab-4409-83d6-a83e337bf748">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4118894962b9424d92128e02a9adf2bc_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfMi05LTEtMS0xMDUwOTU_c6ca3c63-706e-433a-9d7e-c48386d6606f">20,020,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4118894962b9424d92128e02a9adf2bc_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfMi0xMS0xLTEtMTA1MDk1_573e3ba3-5642-4860-95b3-b5eb10d54dbb">73,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i206731c08e11447b8873b07b61772810_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfMy0xLTEtMS0xMDUwOTU_194a71ba-5175-45b8-bad4-e6066c2e4ca0">9,661,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i206731c08e11447b8873b07b61772810_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfMy0zLTEtMS0xMDUwOTU_0bff36ca-e16a-485f-8a42-496e3d7a8f41">27,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i206731c08e11447b8873b07b61772810_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfMy01LTEtMS0xMDUwOTU_16524261-c9fa-4a57-9e7c-03b6fbc6eb5b">74,452,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i206731c08e11447b8873b07b61772810_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfMy03LTEtMS0xMDUwOTU_e1cbba61-74d9-4035-8d1b-bb82dbd9286a">972,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i206731c08e11447b8873b07b61772810_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfMy05LTEtMS0xMDUwOTU_e7aa34c3-25ee-4a7c-be90-59c3804c17ce">84,113,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i206731c08e11447b8873b07b61772810_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfMy0xMS0xLTEtMTA1MDk1_12d8af4c-dd29-4774-b1cd-9857637b6297">999,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of Government Sponsored Entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2908d99b8fe4704bcd189727c191080_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfNC0xLTEtMS0xMDUwOTU_5fc0286e-fe4f-4af9-aabd-347213fae1c4">1,981,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2908d99b8fe4704bcd189727c191080_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfNC0zLTEtMS0xMDUwOTU_87217d36-e54a-4dae-999e-0e17b4183b3c">16,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2908d99b8fe4704bcd189727c191080_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfNC01LTEtMS0xMDUwOTU_d6b9c991-e406-41ca-a3ff-d9f99b64c85b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2908d99b8fe4704bcd189727c191080_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfNC03LTEtMS0xMDUwOTU_08d29f64-ea3e-4ea3-b039-3b64f6e475c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2908d99b8fe4704bcd189727c191080_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfNC05LTEtMS0xMDUwOTU_9f1456c3-dd17-4eca-8884-24c6584b9237">1,981,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2908d99b8fe4704bcd189727c191080_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfNC0xMS0xLTEtMTA1MDk1_31d5293d-877e-4e4f-9c0b-fb8f3d3199b3">16,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfNS0xLTEtMS0xMDgwMDY_4820772e-7cd9-42a4-827e-efcffe3e8c70">31,662,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfNS0zLTEtMS0xMDgwMjY_aa963801-f4c6-4495-879c-22936ada6e3a">116,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfNS01LTEtMS0xMDgwMjg_82b53908-1aae-43d3-ad2a-8e62f0bdaa51">74,452,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfNS03LTEtMS0xMDgwMzA_8b7faaa1-c983-49f7-997d-a6914c390d82">972,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfNS05LTEtMS0xMDgwMzI_1aa2b736-28c3-4c5e-979f-12b2fc0a850a">106,114,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfNS0xMS0xLTEtMTA4MDM0_7b9f7e40-36e2-4827-add3-ff05e2d55a83">1,088,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div id="i561259e69fbb4552820b7ec56e5dea3a_70"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto as of and for the year ended December&#160;31, 2022 and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K, or our Annual Report, filed with the Securities and Exchange Commission, or the SEC, on March 9, 2023. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Bionano Genomics, Inc. and its subsidiaries or, as the context may require, Bionano Genomics, Inc. only.</span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_73"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The information in this Quarterly Report on Form 10-Q contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the &#8220;safe harbor&#8221; created by those sections. These forward-looking statements include, but are not limited to any statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management. The words &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;projects,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in our filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements.</span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_76"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. Our mission is to transform the way the world sees the genome through optical genome mapping (&#8220;OGM&#8221;) solutions, diagnostic services and software. We offer OGM solutions for applications across basic, translational and clinical research, and for other applications including bioprocessing. Through our Bionano Laboratories business, we also provide diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through our BioDiscovery business, we offer an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. Through our Purigen business, we offer nucleic acid extraction and purification solutions using proprietary ITP technology. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Highlights</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial Adoption of Offerings for Saphyr</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In executing on our commercialization strategy, we expanded the utilization of our Saphyr</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> system and:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Grew our installed base to 259 as of March&#160;31, 2023, an increase of approximately 47% from a total installed base of 176 as of March&#160;31, 2022. Installed base represents the global number of Saphyr instruments installed at end-customer locations and therefore having the technology to process OGM.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sold 5,226 flowcells in the three-month period ended March&#160;31, 2023, an increase of approximately 62% from 3,225 flowcells sold in the same quarter of 2022. The Saphyr cartridge is the consumable that packages nanochannel arrays for DNA linearization. In its current form, the Saphyr cartridge has two configurations - one with two flowcells per cartridge and the other with three flowcells per cartridge. Flowcells sold refers to the units of genome mapping consumables used for analyzing one genome, purchased by customers to process optical genome mapping. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Macroeconomic and Geopolitical Developments </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to additional risks and uncertainties as a result of adverse geopolitical and macroeconomic developments, such as recent and potential future bank failures, the ongoing conflict between Ukraine and Russia and related sanctions, any lingering effects of COVID-19 and uncertain market conditions, including inflation and supply chain disruptions, which could continue to have a material impact on our business and financial results. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We closely monitor and comply with various applicable guidelines and legal requirements in the jurisdictions in which we operate. The future effects of the COVID-19 pandemic, if any, are unknown and our financial results may be negatively affected as a result. We may also experience long-term effects on the nature of the office environment and remote working, which may present strategy, operational, talent recruiting and retention and workplace culture challenges that may adversely affect our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we experienced supply chain challenges, which we largely attribute to the COVID-19 pandemic. While the COVID-19 pandemic did not prevent us from operating our business during the three months ended March&#160;31, 2023 and 2022, we experienced increased costs to secure certain component parts in our products and to produce our products at our contract manufacturers. We expect these increased costs to remain high for the foreseeable future. As global economic conditions recover, business activity may not recover as quickly as anticipated, and it is not possible at this time to estimate the long-term impact that these and related events could have on our business, as the impact will depend on future developments, which are highly uncertain and cannot be predicted. For instance, product demand may be reduced due to an economic recession, a decrease in corporate capital expenditures, prolonged unemployment, rising inflation rates, labor shortages, reduction in consumer confidence, adverse geopolitical and macroeconomic developments, or any similar negative economic condition. These negative effects could have a material impact on our operations, business, earnings, and liquidity.</span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_79"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate product revenue from sales of our systems and consumables, which includes our instruments, and our NxClinical&#8482; software. We currently sell our systems for research use only applications and our customers are primarily laboratories associated with academic and governmental research institutions, academic and commercial clinical laboratories, as well as pharmaceutical, biotechnology and contract research companies. In addition, we provide instruments to certain customers under our reagent rental program, under which we provide an instrument to customers at no cost and the customers agree to purchase minimum quantities of consumables. Consumable revenue consists of sales of reagents and chips necessary to process a sample. Sales of our NxClinical&#8482; software, which provides customers with solutions for analysis, interpretation and reporting of genomics data, are made on a subscription basis. We generate service revenue from the sale of diagnostic testing services for those with autism spectrum disorder and other neurodevelopmental disabilities through Bionano Laboratories, as well as services performed related to customer sample evaluations using the Saphyr system. Other revenue consists of warranty and other service-based revenue, including support, repair and maintenance services. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our revenue for the periods indicated:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,447,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,206,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,968,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,490,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,415,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,696,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects total revenue by geography and as a percentage of total revenue, based on the billing address of our customers. Americas consists of North America and South America. EMEA consists of Europe, the Middle East, and Africa. Asia Pacific includes China, Japan, South Korea, Singapore, India and Australia. </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Americas</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,444,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,328,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,992,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">979,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">629,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,415,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,696,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenue for our systems and consumables includes raw material parts costs and associated freight, shipping and handling costs, contract manufacturing costs, salaries and other personnel costs, equipment depreciation, overhead and other direct costs related to those sales recognized as product revenue in the period. Cost of service and other revenue consists of third-party laboratory costs to process the diagnostic samples, salaries of our clinical technicians who interpret and deliver the results to patients, warranty services, and other costs of servicing equipment at customer sites.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of salaries and other personnel costs, stock-based compensation, research supplies, third-party development costs for new products, materials for prototypes, equipment depreciation, and allocated overhead costs that include facility and other overhead costs. We have made substantial investments in research and development since our inception, and plan to continue to make investments in the future. Our research and development efforts have focused primarily on the tasks required to support development and commercialization of new and existing products. We believe that our continued investment in research and development is essential to our long-term competitive position. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of salaries and other personnel costs, amortization expense related to acquired intangibles, and stock-based compensation for our sales and marketing, finance, legal, human resources and general management, as well as professional services, such as legal and accounting services. </span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_82"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred losses in each year since our inception. Our net loss was $37.1 million for the three months ended March&#160;31, 2023. As of March&#160;31, 2023, we had an accumulated deficit of $385.8 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and operating losses as we:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expand our sales and marketing efforts to further commercialize our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continue research and development efforts to improve our existing products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">hire additional personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">enter into collaboration arrangements, if any;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">add operational, financial and management information systems; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">incur increased costs as a result of operating as a public company.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, based on recurring losses from operations incurred since inception, the expectation of continued operating losses, and the need to raise additional capital to finance our future operations, we determined that there is substantial doubt about our ability to continue as a going concern within 12 months of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended March 31, 2023 and 2022 </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our results of operations for the three months ended March&#160;31, 2023 and 2022:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Period-to-Period Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,447,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,206,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,241,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service and other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,968,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,490,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">478,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,415,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,696,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,719,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,858,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,576,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of service and other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,487,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,259,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cost of revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,345,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,835,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">510,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,937,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,527,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,410,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,976,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,277,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,699,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,913,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,804,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,109,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37,843,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,943,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,900,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expenses):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">704,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">594,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expenses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(455)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expenses)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">745,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">745,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37,098,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,943,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,155,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,000)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,000)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,000)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37,124,000)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,952,000)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,172,000)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have revised the classification of our revenue between the categories in the table above for the March 31, 2022 statement of operations to present software revenue within &#8220;product revenue&#8221;. In our March 31, 2022 statement of operations, &#8220;software&#8221; was included in &#8220;service and other revenue.&#8221;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue increased by $1.2 million, or 30%, to $5.4 million for the three months ended March&#160;31, 2023 compared to $4.2 million for the same period in 2022. The increase in product revenue was driven by increased demand for our Saphyr OGM solutions, including an increase in instrument installed base (47%) when compared to the same period last year. The increased demand for our reagent rental program continues to drive a significant portion of the increase in consumable sales. We believe increased demand for our OGM systems was primarily driven by increased market awareness and additional published data demonstrating the utility of OGM. We expect revenue to increase as market awareness and published data of OGM utility increases, along with continued efficiencies gained in the OGM workflow through research and development, and the acquisitions of BioDiscovery and Purigen. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service and other revenue increased by $0.5 million, or 32%, to $2.0 million for the three months ended March 31, 2023 compared to $1.5 million for the same period in 2022. The increase in service and other revenue was primarily driven by increased volume through the Bionano Laboratories sample analysis business.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue, Gross Profit, and Gross Margin</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Period-to-Period&#160;Change</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Period-to-Period&#160;Percentage Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023 to 2022</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023 to 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit (loss):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 5.5pt 0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,589,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">630,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">959,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">481,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross profit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,070,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">861,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,209,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 5.5pt 0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross margin:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 5.5pt 0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 5.5pt 0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 5.5pt 0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenue increased by $0.3 million, or 8%, to $3.9 million for the three months ended March&#160;31, 2023, compared to $3.6 million for the three months ended March&#160;31, 2022. The increase in cost of product revenue was due to higher sales of instruments and consumables. We anticipate similar increases in future periods as sales of our instruments and consumables grow.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of service and other revenue increased $0.2 million, or 18%, to $1.5 million for the three months ended March&#160;31, 2023, compared to $1.3 million for the three months ended March&#160;31, 2022. The increase in cost of service and other revenue is primarily due to increased service costs on our growing installed base as well as increased costs to support the service offerings from Bionano Laboratories. We anticipate similar increases in future periods as our installed base and the number of Bionano Laboratories services grow.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross profit increased $1.0 million, or 152%, to $1.6 million for the three months ended March&#160;31, 2023, compared to $0.6 million for the three months ended March&#160;31, 2022. The increase in gross profit was primarily due to higher sales of instruments and consumables, improvements in chip yield, and reduced scrap and quality control costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service and other gross profit increased by $0.3 million, or 108%, to $0.5 million for the three months ended March&#160;31, 2023, compared to $0.2 million for the three months ended March&#160;31, 2022. The increase in service and other gross profit is primarily due to increased sales of services &#8211; primarily those offered by Bionano Laboratories &#8211; offset by increased costs incurred to maintain our growing installed base.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (&#8220;R&amp;D&#8221;) expenses increased by $3.4 million, or 32%, to $13.9 million for the three months ended March&#160;31, 2023 compared to $10.5 million for the same period in 2022. The increase is primarily due to an increase of $2.2 million in product development costs, an increase of $0.8 million in professional services related to research activities, and $0.6 million in software and information technology costs. Compensation costs tied to headcount, excluding stock-based compensation, increased by $1.5 million. Stock-based compensation expense decreased by $2.0 million due to the vesting of stock issued as consideration in the BioDiscovery acquisition in 2022, which primarily rolled up into R&amp;D expense and vested in full in 2022. We anticipate that our previously planned R&amp;D expenses will decrease for the remainder of 2023 as we implement our cash savings initiative announced May 9, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses increased by $5.7 million, or 28%, to $26.0 million for the three months ended March&#160;31, 2023 compared to $20.3 million for the same period in 2022. The increase is primarily due to a $2.9 million increase in compensation expenses, of which $0.6 million relates to stock-based compensation, a $0.5 million increase in amortization of intangibles related to the acquisition of Purigen, a $1.3 million increase in professional services, a $0.6 million increase in marketing expenses, and a $0.7 million increase in the estimated fair value of the contingent consideration liabilities primarily related to the acquisition of Purigen, which rolls into SG&amp;A expense. The increase in compensation expense is driven primarily by increased headcount. This was due to growth in our global sales, service, and back-office teams to facilitate the expanding customer base, as well as headcount additions attributed to the acquisition of Purigen. We anticipate that our previously planned SG&amp;A expenses will decrease for the remainder of 2023 as we implement our cash savings initiative announced May 9, 2023. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income was $0.7 million for the three months ended March&#160;31, 2023, as compared to $0.1 million for the same period in 2022 resulting from positive returns on investments due to higher interest rates in 2023. Our total available for sale securities balance was $91.7 million as of March&#160;31, 2023.</span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_85"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred net losses and negative cash flows from operations. We have primarily generated cash flows from sales of equity securities and debt financings. We anticipate that future sources of liquidity will principally come from sales of common stock and other equity instruments, borrowings from credit facilities and revenue from our commercial operations. Revenue from our commercial operations has increased due to increased demand for our product offerings and our acquisition of revenue-positive BioDiscovery and Purigen. See Note 6 to our unaudited condensed consolidated financial statements for a discussion of our recent equity activity included elsewhere in this Quarterly Report on Form 10-Q for more information. We incurred net losses of $37.1 million and $29.9 million for the three months ended March&#160;31, 2023 and 2022, respectively. As of March&#160;31, 2023, we had an accumulated deficit of $385.8 million, cash and cash equivalents of $4.1 million, and available for sale investment securities of $91.7 million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Capital Requirements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our near and longer-term liquidity requirements will consist of working capital and general corporate expenses associated with the growth of our business, including, without limitation, expenses associated with scaling up our operations and continuing to increase our manufacturing capacity, sales and marketing expense, increasing market awareness of our products and services to target customers, instrument placements with customers via the reagent rental sales strategy, additional research and development expenses associated with expanding and proving the utility of our offerings, expenses associated with continuing to build out our corporate infrastructure, enhancements to information technology, and expenses associated with being a public company. We expect such expenditures to continue throughout the remainder of 2023 and over the next few years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have generally incurred significant losses and negative cash flows. Based on our $4.1 million in cash and cash equivalents and $91.7 million in available for sale securities as of March&#160;31, 2023, we anticipate our available cash balance will not be sufficient for the next twelve months from the issuance of this report. Accordingly, based on recurring losses from operations incurred since inception, our expectation of continued operating losses, our current business plan, and the need to raise additional capital to finance our future operations, we determined that there is substantial doubt about our ability to continue as a going concern within 12 months after the date that the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q are issued. We plan to continue to fund our losses from operations through revenues, cash and cash equivalents on hand, sale of marketable securities and equity or debt financings. As a result, in order to continue to operate our business beyond that time, we will need to raise additional funds. Accordingly, we are actively evaluating debt and equity financing sources available to us as well as cost reduction strategies, but there can be no assurance that financing will be available on terms acceptable to us, on a timely basis, or at all, or that we are able to effectively reduce our operating expenses. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. Any disruptions to, or volatility in, the credit and financial markets or any deterioration in overall economic conditions may make any necessary debt or equity financing more difficult to obtain, more costly and/or more dilutive. If we are unable to raise additional funds through debt or equity financing or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research and development activities or future commercialization efforts. Even if we raise additional capital, we may also be required to modify, delay or abandon some of our plans which could have a material adverse effect on our business, operating results and financial condition and our ability to achieve our intended business objectives. In addition, our estimate as to the sufficiency of our current cash, cash equivalents and available for sale securities, and our current operating plan are based on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we currently anticipate. See Note 1 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for more information.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the cash flow from operating, investing and financing activities for the periods presented:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:23pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by (used in):</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32,413,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32,494,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,528,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,964,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,862,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive cash flows from operations primarily from the sale of our products and services. Our cash flows from operating activities are also significantly influenced by our use of cash for operating expenses to support our business. We have historically experienced negative cash flows from operating activities as we have developed our technology, expanded our business and built our infrastructure, and this may continue in the future. As discussed above, we anticipate our available cash balance will not be sufficient for the next twelve months from the issuance of this report. We plan to raise additional capital to fulfill our operating and capital requirements for at least 12 months through equity or debt financings, however, we may not be able to secure such financing in a timely manner or on favorable terms, if it all. We anticipate that our cash used in operating activities will decrease over the next 12 to 24 months; however, we may observe fluctuations in the cash used in operating activities on a quarterly basis to sustain the expansion of our commercial offerings.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $32.4 million during the three months ended March&#160;31, 2023 as compared to $32.5 million during the same period in 2022. The decrease in cash used in operating activities of $0.1 million was primarily attributed to increased headcount-related expenses offset by timing of invoice payments in accounts payable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our primary investing activities have consisted of capital expenditures for the purchase of capital equipment to support our expanding infrastructure, as well as the acquisitions of Lineagen, BioDiscovery and Purigen to grow our business. We expect to continue to incur additional costs for capital expenditures related to these efforts in future periods. During the three months ended March&#160;31, 2023, cash provided by investing activities was $16.5 million, as compared to $32.0 million provided by investing activities during the same period in 2022. The decrease in cash provided by investing activities of $15.4 million was primarily attributed to the maturity of $16.9 million in available for sale securities during the three months ended March&#160;31, 2023, compared to the maturity of $47.2 million in available for sale securities during the same period in 2022, which was partially offset by a purchase of $15.0 million of available for sale securities during the same period. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $14.9 million during the three months ended March&#160;31, 2023 as compared to the same period in 2022 where we had net cash provided by financing activities of $7,000, an increase of $14.9 million. During the three months ended March&#160;31, 2023, we raised approximately $15.2 million in gross proceeds from executing sales under our at-the-market facility with Cowen and Company, LLC (&#8220;Cowen&#8221;). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Resources</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had approximately $4.1 million in cash and cash equivalents, available for sale securities of $91.7 million, and working capital of $104.4 million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in place a Sales Agreement with Cowen (the &#8220;Cowen ATM&#8221;), as amended, pursuant to which we may offer and sell from time to time up to $200.0 million of shares from the date of the amendment going forward through or to Cowen, acting as sales agent or principal. During the three months ended March&#160;31, 2023, we sold approximately 9.5 million shares of common </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock under the Cowen ATM and received gross proceeds of approximately $15.2&#160;million before deducting offering costs of $0.4&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the merger agreement related to the acquisition of BioDiscovery, we agreed to pay a milestone payment of $10.0 million in cash contingent on the achievement of a commercial milestone as set forth in the BioDiscovery agreement and plan of merger, as amended. We determined the fair value of the milestone consideration using a scenario-based technique, as the trigger for payment is event driven. The outcome of the milestone consideration is binary, meaning the milestone is either achieved or not achieved, and the only other variable factor is the timing of when the milestone is achieved. We determined it is highly likely that the milestone will be achieved and therefore used a 95% probability factor which is applied to the $10.0 million milestone consideration. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the merger agreement related to the acquisition of Purigen, we agreed to pay two independent milestone payments up to an aggregate of $32.0 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Purigen milestones are reassessed on a quarterly basis using a probability weighted model and a Monte Carlo Simulation. We determined the fair value of this milestone consideration using a scenario-based technique, as the trigger for payment is event driven. We determined the likelihood of each independent milestone and used probability factors ranging from 20% to 80% which were applied to the individual payments. At March&#160;31, 2023 and December&#160;31, 2022, a Monte Carlo Simulation was performed to determine the likelihood that the milestone will be achieved and was applied to the milestone consideration payment. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on these valuation assumptions, the fair value of the contingent consideration liabilities was determined to be $23.1 million as of March&#160;31, 2023, $9.5 million of which is current as of March&#160;31, 2023.</span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_88"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material changes to our contractual obligations from those disclosed in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_91"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. These accounting principles require us to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities as of the date of the unaudited condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We have discussed the development, selection and disclosure of the accounting estimates with our audit committee. We believe that the estimates, judgments and assumptions are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. To the extent there are material differences between these estimates, judgments or assumptions and actual results, our financial statements will be affected. Historically, revisions to our estimates have not resulted in a material change to our financial statements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we performed a qualitative assessment of goodwill impairment which included an evaluation of changes in industry, market and macroeconomic conditions as well as consideration of our financial performance and any significant trends. Our qualitative assessment indicated that it was not more likely than not that goodwill is impaired as of March&#160;31, 2023.  However, our stock price has significantly declined after March&#160;31, 2023. A sustained decline in our stock price or other material changes in the significant assumptions that affect the determination of the fair value of the Company&#8217;s single reporting unit may result in a goodwill impairment charge in future periods, and such charge may be material.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, there have been no changes to our critical accounting policies and estimates as described in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022. </span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_94"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 1 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for information concerning recent accounting pronouncements.</span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_97"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operations both within the United States and internationally, and we are exposed to market risks in the ordinary course of business. These risks primarily relate to interest rates, foreign currency exchange rates and inflation.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had approximately $4.1 million in cash and cash equivalents and $91.7 million in available for sale securities as of March&#160;31, 2023, which include highly liquid, investment grade debt securities. Such interest-bearing instruments are exposed to a certain degree of interest rate risk. The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. We do not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate risk exposure. To achieve this objective, we invest in highly liquid and high-quality government and other debt securities. To minimize our exposure due to adverse shifts in interest rates, we invest primarily in short-term securities. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are seeing, and expect to continue to see, increased interest rates, due to our investment in highly liquid and high quality government and other debt securities as well as short-term securities, as of the date of this Quarterly Report on Form 10-Q, we do not expect anticipated changes in interest rates to have a material effect on our interest rate risk in future reporting periods. Due to the short holding period of our investments and the nature of our investments, a hypothetical change of 100 basis points would have approximately a $0.2 million impact on our investments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our liabilities for acquisition-related contingent consideration, which is adjusted to fair value each reporting period, is also impacted by changes in interest rates. The risk-free interest rate used to estimate our weighted average cost of capital is a component of the discount rate used to calculate the present value of future cash flows due upon the achievement of certain milestones. As a result, any changes in the underlying risk-free interest rate could result in material changes to the fair value of such liabilities and could materially impact the amount of non-cash expense (or income) recorded each reporting period. As a consequence of the U.S. Federal Reserve raising interest rates, the underlying risk-free interest rate we use for purposes of calculating fair value of our liabilities for acquisition-related contingent consideration has increased from our prior reporting periods, but such increase did not have a material impact on our financial statements, and we currently do not expect anticipated future changes to have a material effect in future reporting periods.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Exchange Rate Risk</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct a portion of our business in currencies other than our U.S. dollar functional currency. Transactional exposure arises where transactions occur in currencies other than the functional currency. Transactions in foreign currencies are recorded at the exchange rate prevailing at the date of the transaction. The resulting monetary assets and liabilities are translated into the appropriate functional currency at exchange rates prevailing at the balance sheet date and the resulting gains and losses are reported in foreign currency translation adjustments in the unaudited condensed consolidated statements of comprehensive loss. Our foreign currency exposures are primarily concentrated in the British Pound, Chinese Renminbi, Euro, and Canadian dollar. We do not currently participate in material foreign exchange hedging activities. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have operations outside of the United States. The functional currency of each foreign subsidiary is generally the local currency. We are exposed to foreign currency exchange risk as the functional currency financial statements of foreign subsidiaries are translated to U.S. dollars. The assets and liabilities of our foreign subsidiaries having a functional currency other than the U.S. dollar are translated into U.S. dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of accumulated other comprehensive loss in shareholders&#8217; equity. The reported results of our foreign subsidiaries will be influenced by their translation into U.S. dollars by currency movements against the U.S. dollar. As of March&#160;31, 2023 and December&#160;31, 2022, we had minimal assets and liabilities denominated in foreign currencies and expect similar levels of foreign currency denomination in the next 12 months. We believe a hypothetical 10% change in foreign exchange rates as of March&#160;31, 2023 would not have a material impact on our business, financial condition, or results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inflation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Geopolitical and macroeconomic events, including the conflict between Ukraine and Russia and related sanctions and the recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures have contributed to supply chain challenges, which we believe have resulted in inflation headwinds, particularly increased logistical costs and raw material prices. During the three months ended March&#160;31, 2023, we experienced increased costs to secure certain component parts in our products and to produce our products at our contract manufacturers. However we do not believe that inflation has had a material effect on our business, financial condition or results of operations, other than its impact on the general economy, as our cost of revenue for the three months ended March&#160;31, 2023 was not significantly impacted by the cost increases we experienced. While the effects of geopolitical and macroeconomic events, as well as other inflationary pressures, are highly uncertain, as of the date of this Quarterly Report on Form 10-Q, we do not expect anticipated changes in inflation to have a material effect on our business, financial condition or results of operations for future reporting periods other than the general impacts on companies due to general economic and market conditions. If our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases. Our inability or failure to do so could harm our business, financial condition or results of operations.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i561259e69fbb4552820b7ec56e5dea3a_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain &#8220;disclosure controls and procedures,&#8221; as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act. Disclosure controls and procedures are controls and other procedures designed to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this assessment, our management, including our principal executive officer and principal financial officer, has concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, we carried out an evaluation of any potential changes in our internal control over financial reporting during the fiscal quarter covered by this Quarterly Report on Form 10-Q. Except as described below, there were no changes in our internal control over financial reporting during the quarter ended March&#160;31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we acquired Purigen Biosystems, Inc. We are in the process of integrating the internal controls of the acquired business into our overall system of internal control over financial reporting.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i561259e69fbb4552820b7ec56e5dea3a_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_106"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1. LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_109"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A. RISK FACTORS</span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_112"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTOR SUMMARY</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Below is a summary of the principal factors that make an investment in our securities speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks and uncertainties summarized in this risk factor summary, and other risks and uncertainties that we face, are set forth below under the heading &#8220;Risk Factors&#8221; and should be carefully considered, together with other information in this Quarterly Report and our other filings with the SEC before making investment decisions regarding our securities.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are an early commercial-stage company and have a limited commercial history, which may make it difficult to evaluate our current business and predict our future performance;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred recurring net losses since we were formed and expect to incur losses in the future. We cannot be certain that we will achieve or sustain profitability;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our quarterly and annual operating results and cash flows have fluctuated in the past and might continue to fluctuate, which makes our future operating results difficult to predict and could cause the market price of our securities to decline substantially;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future capital needs are uncertain and we may require additional funding in the future to advance the commercialization of our Saphyr system, Ionic Purification system, NxClinical software, and our other products, technologies and services, as well as continue our research and development efforts. If we fail to obtain additional funding, we will be forced to delay, reduce or eliminate our commercialization and development efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unfavorable geopolitical and macroeconomic developments could adversely affect our business, financial condition or results of operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The COVID-19 pandemic has materially affected and could continue to materially affect our operations globally, including at our headquarters in San Diego, California, as well as the business or operations of our research partners, customers and other third parties with whom we conduct business; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acquisitions, joint ventures and other strategic transactions could disrupt or otherwise harm our business and may cause dilution to our stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our products or technologies fail to achieve and sustain sufficient market acceptance, our revenue will be adversely affected;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the near term, sales of our Saphyr system, Ionic Purification system, NxClinical software, consumables and genome analysis services will depend on levels of research and development spending by clinical research laboratories, academic and governmental research institutions and biopharmaceutical companies, a reduction in which could limit demand for our technologies and products and adversely affect our business and operating results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not successfully manage the development and launch of new products and technologies, our financial results could be adversely affected;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to stringent and changing obligations related to data privacy and security. Actual or perceived failure by us or the third-party service providers upon which we rely to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future success is dependent upon our ability to further penetrate our existing customer base, attract new customers and retain the customers of our acquired businesses;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The size of the markets for our products and technologies may be smaller than we estimate, and new markets may not develop as quickly as we expect, or at all, limiting our ability to successfully sell our products and technologies.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are currently limited to &#8220;research use only,&#8221; or RUO, with respect to many of the materials and components used in our consumable products including our assays;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the FDA determines that our RUO products are medical devices or if we seek to market our RUO products for clinical diagnostic or health screening use, we will be required to obtain regulatory clearance(s) or approval(s), and may be required to cease or limit sales of our then marketed products, which could materially and adversely affect our </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business, financial condition and results of operations. Any such regulatory process would be expensive, time-consuming and uncertain both in timing and in outcome;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to protect our intellectual property, it may reduce our ability to maintain any technological or competitive advantage over our competitors and potential competitors, and our business may be harmed; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The price of our securities has been and may in the future be volatile or may decline regardless of our operating performance, and you could lose all or part of your investment.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i561259e69fbb4552820b7ec56e5dea3a_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider the following risk factors, together with other information in this Quarterly Report on Form 10-Q and our other filings with the SEC, before making investment decisions regarding our securities. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. The risks described below are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results. We have marked with an asterisk (*) those risk factors that reflect changes from the risk factors previously disclosed in Item 1A of our Annual Report on Form 10-K.</span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_118"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our financial condition and need for additional capital</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an early commercial-stage company and have a limited commercial history, which may make it difficult to evaluate our current business and predict our future performance. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an early commercial-stage company and have a limited commercial history. Our limited commercial history may make it difficult to evaluate our current business and, especially when combined with the other risk factors listed in this section, makes predictions about our future success or viability subject to significant uncertainty. In particular, we have significantly increased our headcount through recent acquisitions of other businesses and the expansion of our sales, marketing and research and development teams, which has increased our operating costs in a manner not historically reflected in our unaudited consolidated financial statements, and in the long-term, plan to further increase headcount as we expand our operations. Because our business model has evolved over time, and combined with our recent acquisitions, this has impacted the composition and concentration of our revenues, which we expect to continue to change with any future acquisitions and further expansion of our operations. These changes, among others, may make it difficult to evaluate our current business, assess our future performance relative to prior performance and accurately predict our future performance. We have encountered in the past, and will continue to encounter in the future, risks and difficulties frequently experienced by early commercial-stage companies, including those associated with scaling up our infrastructure, increasing the size of our organization and integrating acquired businesses. If we do not address these risks successfully, or if our assumptions regarding these risks and uncertainties are incorrect or change over time, our results of operations could differ materially from our expectations and our business, financial condition and results of operations could be materially and adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred recurring net losses since we were formed and expect to incur losses in the future. We cannot be certain that we will achieve or sustain profitability.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred recurring net losses. We incurred net losses of $37.1&#160;million and $29.9&#160;million, and used cash in operations of $32.4&#160;million and $32.5&#160;million for the three months ended March&#160;31, 2023 and 2022, respectively. As of March&#160;31, 2023, we had an accumulated deficit of $385.8&#160;million. We cannot predict if we will be profitable in the near future or at all. We expect that our losses will continue for the foreseeable future as we plan to invest significant additional funds toward the expansion of our commercial organization, research and development efforts and capital expenditures, among other things. Our recent acquisitions have increased our expenses and we expect that any future acquisitions of businesses, assets, products or technologies will further increase our expenses, which may result in additional losses. We also expect significant increases in our stock-based compensation expense in future periods, reflecting higher stock option valuations as a public company and the issuance of additional equity awards should we increase our headcount in future periods. In addition, we incur significant legal, accounting and other expenses as a result of being a public company, especially as we no longer qualify as an emerging growth company and are therefore required to comply with additional disclosure and compliance requirements. These factors, among others, will make it hard for us to achieve and sustain profitability. We may also incur significant losses in the future for a number of other reasons, many of which are beyond our control, including the level of market acceptance of our products, the introduction of competitive products and technologies, our future product development efforts, our market penetration and our margins, as well as the other risks described below.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly and annual operating results and cash flows have fluctuated in the past and might continue to fluctuate, which makes our future operating results difficult to predict and could cause the market price of our securities to decline substantially.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous factors, many of which are outside our control, may cause or contribute to significant fluctuations in our quarterly and annual operating results. These fluctuations may make financial planning and forecasting uncertain and may result in unanticipated decreases in our available cash, which could negatively affect our business and prospects. In addition, one or more of such factors may cause our revenue or operating expenses in one period to be disproportionately higher or lower relative to the other periods. As a result, comparing our operating results on a period-to-period basis might not be meaningful. You should not rely on our past results as indicative of our future performance. Moreover, our stock price might be based on </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expectations of future performance that are unrealistic or that we might not meet and, if our revenue or operating results fall below the expectations of investors or securities analysts, the price of our securities could decline substantially. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results have varied in the past. In addition to other risk factors listed in this section, some of the important factors that, alone or together, may cause fluctuations in our quarterly and annual operating results include: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adoption of our OGM solutions on our Saphyr system, Ionic Purification system or successor systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our successful creation of an end-to-end solution for OGM;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the successful integration of our BioDiscovery and Purigen businesses;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">execution on our commercial and reimbursement strategy involving Bionano Laboratories;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">customer demand for current BioDiscovery software solutions, including NxClinical software, and future software solutions developed through BioDiscovery&#8217;s platform; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the position of our Purigen business in the DNA isolation space of genome analysis and customer demand for our Ionic Purification system; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of customer orders and payments and our ability to recognize revenue;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate of utilization of consumables by our customers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reductions in or other difficulties relating to staffing, capacity, shutdowns or slowdowns of laboratories and other institutions in our customer base, such as reduced or delayed investment in new technologies or spending on products, technologies or consumables; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differences in purchasing patterns across our customer base, including potential differences in consumables spending between earlier adopters of our technologies and more recent customers and variances in rates of increase of consumables spending following new technology purchases; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">geopolitical and macroeconomic developments, such as the conflict between Ukraine and Russia and related sanctions, recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures, the COVID-19 pandemic, inflation, increased cost of goods, supply chain issues, and global financial market conditions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully integrate new personnel, technology and other assets that we may acquire into our company;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of the introduction of new systems, products, technologies, system and product enhancements and services; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in governmental funding of life sciences research and development or other changes that impact budgets, budget cycles or seasonal or other spending patterns of our customers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future accounting pronouncements or changes in our accounting policies; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of any current or future litigation or governmental investigations involving us or other third parties with whom we do business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a significant portion of our operating expenses are relatively fixed in nature, including our existing and recently acquired leases, and planned expenditures are based in part on expectations regarding future revenue. Accordingly, unexpected revenue shortfalls could decrease our gross margins and cause significant changes in our operating results from quarter to quarter. If this occurs, the trading price of our securities could fall substantially. This variability and unpredictability caused by factors such as those described above and elsewhere in this section could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any guidance we may provide, or if the guidance we provide is below the expectations of analysts or investors, the price of our securities could decline substantially. Such a stock price decline could occur even when we have met or exceeded any previously publicly stated guidance or expectations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain adequate revenue growth or do not successfully manage such growth, our business and growth prospects will be harmed. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not achieve substantial growth rates in future periods. Investors should not rely on our operating results for any prior periods as an indication of our future operating performance. To effectively manage our anticipated future growth, we must continue to maintain and enhance our financial, accounting, manufacturing, customer support and sales administration systems, processes and controls, and to integrate such systems, processes and controls into our newly acquired businesses. Failure to effectively manage our anticipated growth could lead us to over-invest or under-invest in development, operational and administrative infrastructure; result in weaknesses in our infrastructure, systems, or controls; give rise to operational mistakes, losses, loss of customers, productivity or business opportunities; and result in loss of employees and reduced productivity of remaining employees. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our continued growth could require significant capital expenditures and might divert financial resources from other projects such as the development or integration of new products, technologies and services. As additional products and technologies are commercialized, we may need to incorporate new equipment, implement new technology systems, or hire new personnel with different qualifications. Failure to manage this growth or transition could result in turnaround time delays, higher product costs, declining product quality, deteriorating customer service, and slower responses to competitive challenges. A failure in any one of these areas could make it difficult for us to meet market expectations for our products and technologies, and could damage our reputation and the prospects for our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our management is unable to effectively manage our anticipated growth, our expenses may increase more than expected, our revenue could decline or grow more slowly than expected and we may be unable to implement our business strategy. The quality of our products, technologies and services may suffer, which could negatively affect our reputation and harm our ability to retain and attract customers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future capital needs are uncertain and we may require additional funding in the future to advance the commercialization of our Saphyr system, Ionic Purification system, NxClinical software, and our other products, technologies and services, as well as continue our research and development efforts. If we fail to obtain additional funding, we will be forced to delay, reduce or eliminate our commercialization and development efforts.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have consumed substantial amounts of cash since our inception. We expect to continue to spend substantial amounts of cash in order to continue the commercialization of our products and technologies, fund our research and development programs, expand headcount in future periods and execute potential strategic transactions. In connection with the preparation of our financial statements for the fiscal year ended December 31, 2022, we performed an analysis of our ability to continue as a going concern. We believe, based on our current business plan, that our existing cash and cash equivalents will not be sufficient for the next twelve months from the issuance of this report. Our ability to execute our operating plan depends on our ability to generate sales and obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. For example, we will likely need to raise substantial additional capital to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our sales and marketing efforts to further commercialize our products, technologies and services and address competitive developments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our research and development efforts to improve our existing products, technologies and services and develop and launch new products, technologies and services, particularly if any of our products, technologies and services are deemed by the U.S. Food and Drug Administration, or FDA, to be medical devices or otherwise subject to additional regulation by the FDA;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pursue a regulatory path with the FDA, or a regulatory body outside the United States, to market our existing RUO products or new products utilized for diagnostic purposes;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lease additional facilities or build-out existing facilities as we continue to grow our employee headcount in future periods, inventory and research and development;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further expand our operations outside the United States;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into collaboration arrangements, if any, or in-license products and technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire or invest in complimentary businesses or assets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add operational, financial and management information systems; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cover increased costs incurred as a result of continued operation as a public company, including costs resulting from our no longer qualifying as an emerging growth company and, if applicable, in the future, loss of our status as a smaller reporting company or changes in our status from a non-accelerated filer to an accelerated filer or large accelerated filer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements will be influenced by many factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of integrating our newly acquired businesses or of acquiring future businesses;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market acceptance of our products, technologies and services, and the variability in costs to achieve such acceptance;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of establishing additional sales, marketing and distribution capabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of our research and development activities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to satisfy any outstanding or future debt obligations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increasing interest rates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">supply chain disruptions;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our existing distribution and marketing arrangements and our ability to enter into additional arrangements in the future;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effects of geopolitical or macroeconomic developments, such as the ongoing military conflict between Russia and Ukraine, related sanctions, recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures and the COVID-19 pandemic; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The various ways we could raise additional capital carry potential risks. We cannot assure you that we will be able to obtain additional funds on acceptable terms, or at all. If we raise additional funds by issuing equity or equity-linked securities, our stockholders may experience dilution. Any equity or debt securities we issue could provide for rights, preferences, or privileges senior to those of holders of our common stock. Future debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. Any debt or equity financing may contain terms that are not favorable to us or our stockholders. If we raise additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish some rights to our technologies or our products, or grant licenses on terms that are not favorable to us. In addition, we may not be able to access a portion of our existing cash, cash equivalents and investments due to market conditions such as recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global economic conditions have been worsening, with disruptions to, and volatility in, the credit and financial markets in the U.S. and worldwide resulting from the effects of ongoing geopolitical or macroeconomic developments. If these conditions persist or worsen, we could experience an inability to access additional capital. If we do not have, or are not able to obtain, sufficient funds, we may have to delay development or commercialization of our technologies and products. We also may have to reduce marketing, customer support or other resources devoted to our products or technologies or cease operations. Any of these factors could have a material adverse effect on our financial condition, operating results and business. Any of the foregoing could significantly harm our business, prospects, financial condition and results of operation and could cause the price of our securities to decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to increase the number of authorized shares of our common stock or our trading price does not increase, we may be limited in our ability to issue and sell our shares, and, as a result, our operations and financial condition may be materially and adversely affected. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to seek the additional capital necessary to fund our operations through public or private equity offerings, debt financings, and collaborative and licensing arrangements. We have limited shares of our common stock currently available and authorized for issuance. Investors in prior transactions have purchased our shares of common stock or our convertible securities, such as warrants, for which we must reserve unissued shares of our common stock. If the reverse split proposal for consideration at our 2023 Annual Meeting of Stockholders is not approved, we would likely need to increase the number of authorized shares of our common stock, which requires stockholder approval, in order to issue shares of our common stock or securities convertible, exercisable or exchangeable into shares of our common stock to investors and other strategic partners, in capital raising transactions. If our trading price does not increase or if we are unable to increase the authorized shares of our common stock, we will be limited in our efforts to raise additional capital. As a result, our operations and financial condition may be materially and adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable geopolitical and macroeconomic developments could adversely affect our business, financial condition or results of operations.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the global economy, the global financial markets and adverse geopolitical and macroeconomic developments, including without limitation inflation, recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures, slowing growth, rising interest rates and recession. A severe or prolonged global economic downturn could result in a variety of risks to our business. For example, inflation rates, particularly in the United States, have increased recently to levels not seen in years, and increased inflation may result in decreased demand for our products and services, increases in our operating costs (including our labor costs), prolonged unemployment, reduced liquidity and limits on our ability to access credit or otherwise raise capital on acceptable terms, if at all. In addition, the Federal Reserve has raised, and may again raise, interest rates in response to concerns about inflation, which coupled with reduced government spending and volatility in financial markets may have the effect of further increasing economic uncertainty and heightening these risks. Risks of a prolonged global economic downturn are particularly true in Europe, which is undergoing a continued severe economic crisis. A weak or declining economy, regardless of the reason for the decline, could also strain our suppliers, possibly resulting in supply disruption. For example, higher energy prices in Europe are causing an increase in cloud computing expenses, which impacts the cost for us and our partners. Any actual or perceived disruption in our product distribution channel could alter customer buying decisions, prompting customers to delay or cancel their orders, which would negatively impact our sales revenue and could harm our reputation. For example, during the COVID-19 pandemic, customers that committed to order minimum quantities of consumables or to purchase our Saphyr </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">instrument delayed such commitments. In addition, we anticipate that ongoing disruptions in our supply chain due to lingering COVID-19 and general macroeconomic effects may cause shortages in the materials required to operate our instruments, therefore limiting our ability to process customer samples and the ability of users of our systems to operate our system. We have experienced supply chain disruptions, some of which have delayed shipment of products to our customers. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, following the invasion of Ukraine by Russia, financial markets around the world experienced volatility. In response to the invasion, the United States, United Kingdom and European Union, along with others, imposed significant new sanctions and export controls against Russia, Russian banks and certain Russian individuals and may implement additional sanctions or take further punitive actions in the future. The full economic and social impact of the sanctions imposed on Russia (as well as possible future punitive measures that may be implemented), as well as the counter measures imposed by Russia, in addition to the ongoing military conflict between Ukraine and Russia, which could conceivably expand into the surrounding region, remains uncertain; however, both the conflict and related sanctions have resulted, and could continue to result in disruptions to trade, commerce, pricing stability, credit availability, supply chain continuity and reduced access to liquidity, in both Europe and globally, and has introduced significant uncertainty into global markets. In particular, the Russia-Ukraine conflict has contributed to rapidly rising costs of living (driven largely by higher energy prices) in Europe and other advanced economies. As the adverse effects of this conflict continue to develop and potentially spread, both in Europe and throughout the rest of the world, our customers may be negatively impacted, which in turn may cause them to delay purchasing decisions and otherwise depress the level of spend conducted by such customers for our products, technologies and services. Further, a weak or declining economy could strain our suppliers, possibly resulting in additional supply disruption. As a result, our business and results of operations may be adversely affected by the ongoing conflict between Ukraine and Russia and related sanctions, particularly to the extent it escalates to involve additional countries, further economic sanctions or wider military conflict. We have operations, as well as current and potential new customers throughout Europe. If economic conditions in Europe and other key markets for our products and technologies continue to remain uncertain or deteriorate further, we could experience adverse effects on our business, supply chain, partners or customers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 pandemic has materially affected and could continue to materially affect our operations globally, including at our headquarters in San Diego, California, as well as the business or operations of our research partners, customers and other third parties with whom we conduct business.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely affected by health crises in regions where we have operations, concentrations of sales and marketing teams, contractors, distributors or other business operations. Such health crises could also affect the business or operations of our research partners, customers and other third parties with whom we conduct business. In particular, the evolving effects of the COVID-19 pandemic and government measures taken in response have had significant impacts, both direct and indirect, on businesses and commerce, as significant reductions in business-related activities have occurred, supply chains have been disrupted, manufacturing and clinical development activities have been curtailed or suspended and enrollment in studies has been limited or made more difficult. Continued remote work policies, quarantines, shelter-in-place and similar government orders, shutdowns or other restrictions, or the perception of such orders, shutdowns, or other restrictions have materially affected and may continue to materially affect how we, our customers, and our suppliers are operating our businesses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As public health directives surrounding the pandemic have relaxed, we have modified our work-from-home policies for certain employees and certain of our business practices, including reopening our offices and permitting travel and in-person events, taking into consideration government restrictions, employee safety and health risks. Our approach may vary among geographies depending on appropriate health protocols, and may change at any time. Additionally, our efforts to reopen our offices safely may not be successful, could expose our employees to health risks, and could involve additional costs or liability. To the extent our employees are exposed to or become ill with COVID-19, our ability to conduct our global and domestic operations may be impaired from time to time. For example, we experienced at various times during the pandemic the inability to visit certain customer sites to support installation of, training on or service to our OGM systems. As a result, in the past, we have had to delay instrument installations or service related visits. The COVID-19 pandemic may also have long-term effects on the nature of the office environment and remote working, which may present strategy, operational, talent recruiting and retention, worker productivity and efficiency, and workplace culture challenges that may adversely affect our business. Furthermore, our remote workforce poses increased risks to our information technology systems and data as more of our personnel leverage resources not necessarily within our control.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our Bionano Laboratories diagnostic services, COVID-19 poses the risk that we or our employees, contractors, suppliers, courier delivery services and other partners may be prevented from conducting business activities, including due to, among other things, spread of the disease within these groups or shutdowns that may be requested or mandated by governmental authorities. The continued spread of COVID-19 and the measures taken by the governments of countries affected could disrupt the supply chain of materials needed for our diagnostic tests, interrupt our ability to receive specimens, impair our ability to perform or deliver the results from our tests, impede patient movement or interrupt healthcare </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services causing a decrease in test volumes, delay coverage decisions from Medicare and third-party payors, delay ongoing and planned clinical studies involving our tests, negatively affect enrollment in our ongoing or future studies, cause us to make strategic determinations regarding, among other things, the cost and quality of the components and supplies we acquire, and have a material adverse effect on our business, financial condition and results of operations. For example, COVID-19 related disruptions to the global supply chain created challenges in getting sufficient components and raw materials for production of our OGM systems and consumables, as well as resulted, at least in part, in unfavorable flowcell yields in 2021 and part of 2022 and 2023. If the pandemic persists, these disruptions could reoccur.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As global economic conditions recover, business activity may not recover as quickly as anticipated or at all, and it is not possible at this time to estimate the long-term impacts that these factors could have on our business, or the global economy as a whole, as the impact will depend on future developments, which are highly uncertain and cannot be predicted. Conditions will be subject to the effectiveness of government policies, including vaccine mandates, vaccine shortages and administration rates, the emergence of new strains or variants of the virus in markets and communities where we, our customers, and our suppliers are operating our business and other factors that are not foreseeable. Any of the foregoing could adversely affect our business, financial condition and results of operations. In addition, these factors may also have the effect of heightening many of the other risks and uncertainties described in this Quarterly Report on Form 10-Q. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New income, sales, use, excise or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, legislation informally titled the Tax Cuts and Jobs Act; the Coronavirus Aid, Relief, and Economic Security Act; and the Inflation Reduction Act enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to such legislation may affect us, and certain aspects of such legislation could be repealed or modified in future legislation. These developments, along with any other future changes in U.S. tax laws could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense. In addition, it is uncertain if and to what extent various states will conform to federal tax legislation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, should the scale of our international business activities expand, any changes in the U.S. taxation of such activities or any other changes in applicable non-U.S. tax laws could increase our worldwide effective tax rate and harm our future financial position and results of operations. Limitations on the ability of taxpayers to claim and utilize foreign tax credits and the deferral of certain tax deductions until earnings outside of the U.S. are repatriated to the U.S., as well as changes to United States tax laws that may be enacted in the future, could impact the tax treatment of future foreign earnings. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, effective January 1, 2022, the Tax Cuts and Jobs Act eliminated the option to deduct research and development expenses for tax purposes in the year incurred and requires taxpayers to capitalize and subsequently amortize such expenses over five years for research activities conducted in the United States and over 15 years for research activities conducted outside the United States. Unless the United States Department of the Treasury issues regulations that narrow the application of this provision to a smaller subset of our research and development expenses or the provision is deferred, modified, or repealed by Congress, it could harm our future operating results by effectively increasing our future tax obligations. The actual impact of this provision will depend on multiple factors, including the amount of research and development expenses we will incur, whether we achieve sufficient income to fully utilize such deductions and whether we conduct our research and development activities inside or outside the United States.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating losses and certain other tax attributes to offset future taxable income and taxes may be subject to limitations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had federal and state tax net operating loss carryforwards of $463.8 million and $197.6 million, respectively. The federal tax loss carryforwards include $282.9 million that do not expire, but utilization of such tax loss carryforwards is limited to 80% of our taxable income. The remaining federal tax loss carryforwards of $180.9 million and state tax loss carryforwards begin to expire in 2027 and 2023, respectively, unless previously utilized. As of December&#160;31, 2022, we also had federal and California research credit carryforwards of $9.4 million and $8.8 million, respectively. The federal research credit carryforwards begin to expire in 2027 unless previously utilized. The California research credits carry forward indefinitely.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, utilization of our net operating losses and research and development credit carryforwards may be subject to limitations due to ownership changes that have occurred or that could occur in the future in accordance with applicable provisions of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law. We may have experienced one or more ownership changes in the past and we may also experience additional ownership changes in the future as a result of subsequent changes in our stock ownership, some of which may be outside of our control. If an ownership change occurs and our ability to use our net operating loss or research and development credit carryforwards is materially limited, it </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">would harm our future operating results by increasing our future tax obligations. In addition, at the state level, there may be periods during which the use of net operating loss carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our results of operation could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles in the United States, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in our financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. If our assumptions underlying our estimates and judgements relating to our critical accounting policies change or if actual circumstances differ from our assumptions, estimates or judgements, our operating results may be adversely affected and could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our corporate cash saving initiative and the associated headcount reduction we announced in May 2023 may not result in anticipated savings, could result in total costs and expenses that are greater than expected, could disrupt our business, and may not achieve our intended objectives.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, we undertook a cash savings initiative that included a reduction in force. We may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from our initiative due to unforeseen difficulties, delays or unexpected costs. Our initiative may also be disruptive to our operations. For example, our headcount reductions could yield unanticipated consequences and costs, such as increased difficulties in implementing our business strategy due to the loss of institutional knowledge and expertise, reduced strength of our sales force and marketing efforts, attrition beyond the intended number of employees, decreased morale among our remaining employees, and the risk that we may not achieve the anticipated benefits of the reduction in force. In addition, while certain positions have been eliminated, certain functions necessary to our operations remain, and we may be unsuccessful in distributing the duties and obligations of departed employees among our remaining employees. The reduction in workforce could also make it difficult for us to pursue, or prevent us from pursuing, new opportunities and initiatives, including restricting the strength of our sales force and marketing efforts, due to insufficient personnel, or require us to incur additional and unanticipated costs to hire new personnel to pursue such opportunities or initiatives. Moreover, employee litigation related to the headcount reduction could be costly and prevent management from fully concentrating on the business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to develop our product candidates or additional assets will depend, in part, on our ability to effectively manage future growth or restructuring, as the case may be. In addition, if we are unable to realize the anticipated benefits from our cash savings initiative, or if we experience significant adverse consequences of such initiative, our business, financial condition, and results of operations may be materially adversely affected.</span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_121"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our business operations </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions, joint ventures and other strategic transactions could disrupt or otherwise harm our business and may cause dilution to our stockholders.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our growth strategy, we have acquired and may continue to acquire other businesses, products or technologies as well as pursue strategic alliances, joint ventures, technology licenses or investments in complementary businesses or assets. We may not be able to locate or make suitable acquisitions on acceptable terms, and future acquisitions may not be effectively and profitably integrated into our business. Our failure to successfully complete the integration of any business or assets that we acquire could have an adverse effect on our prospects, business activities, cash flow, financial condition, results of operations and stock price. Integration challenges may include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption in our relationships with our pre-acquisition customers, distributors or suppliers, or in the relationships of our acquired businesses with their pre-acquisition customers, distributors or suppliers, as a result of such a transaction;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated expenses and liabilities related to acquired companies or assets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes with the seller(s) of any acquired companies or assets or litigation with the seller(s) or third parties resulting from acquired companies or assets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties integrating acquired personnel, technologies, operations and legal compliance obligations into our existing business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management time and focus from operating our business to acquisition integration challenges;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases in our expenses and reductions in our cash available for operations and other uses;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">possible write-offs or impairment charges relating to acquired businesses or assets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties developing and marketing new products, technologies and services or integrating new products, technologies and services into our commercial plan;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">entering markets in which we have limited or no prior experience; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">coordinating our efforts throughout various localities and time zones.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign acquisitions involve unique risks in addition to those mentioned above, including those related to integration of operations across different cultures and languages, currency risks and the particular economic, political and regulatory risks associated with specific countries. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with any such transactions, we may also issue equity securities in a dilutive manner, incur additional debt, assume contractual obligations or liabilities or expend significant cash. Such transactions could harm our operating results and cash position, negatively affect the price of our stock and cause dilution to our current stockholders. For example, in connection with our acquisition of Lineagen, a U.S.-based provider of proprietary molecular diagnostics services for individuals presenting with certain neurodevelopmental disorders, we issued 6.2 million shares of our common stock, in our acquisition of BioDiscovery, a U.S.-based software company with solutions for analysis, interpretation and reporting of genomics data, we paid upfront consideration consisting of a combination of approximately $52.3 million in cash and 2.7 million shares of our common stock, and in our acquisition of Purigen, a U.S-based DNA and RNA extraction company, we paid upfront consideration of approximately $32.0 million in cash. In connection with the acquisition of BioDiscovery, we issued an additional 5.0 million shares of our common stock subject to vesting based on continued service of a key employee. These shares vested in full on October 4, 2022. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuances of shares in connection with the Lineagen and BioDiscovery acquisitions resulted in dilution to our existing stockholders, the payment of cash in the BioDiscovery acquisition reduced our cash by approximately $52.3 million, the payment of cash in the Purigen acquisition reduced our cash by approximately $32.0 million, our headcount increased by more than 75 employees as a result of all three acquisitions, and we acquired new leases in each acquisition. Accordingly, in addition to transaction costs, these acquisitions have increased our operating expenses, further increasing our net losses. We cannot predict the number, timing or size of any future strategic transactions, or the effect that any such transactions might have on our operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we conducted extensive business, financial and legal due diligence in connection with our evaluation of our recent acquisitions, our due diligence investigations may not have identified every matter that could adversely affect our business, operating results and financial condition, and such investigations may have identified matters that, in the opinion of our management based on information available at the time, bore an acceptable level of risk that they, individually or in the aggregate, might or might not adversely affect our business, operating results or financial condition. We may be unable to adequately address the financial, legal and operational risks introduced by our recent acquisitions and may have difficulty developing experience with the industries in which Lineagen, BioDiscovery and/or Purigen operate. Accordingly, we cannot guarantee that our recent acquisitions will yield the results we have anticipated and unforeseen complexities and expenses may arise. In addition, we may not achieve the revenues, growth prospects and synergies expected from these recent acquisitions, and any such benefits we do achieve may not offset our increased costs, resulting in a potential impairment of goodwill or other assets that were acquired. For any future acquisitions, we may similarly be unable to achieve revenue, growth prospects and synergies in a manner consistent with our expectations. Our failure to do so could adversely affect our business, operating results and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our products or technologies fail to achieve and sustain sufficient market acceptance, our revenue will be adversely affected.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on our ability to develop and market products and technologies that are recognized and accepted as reliable, enabling and cost-effective. Most of the potential customers for our products and technologies already use expensive research systems in their laboratories that they have used for many years and may be reluctant to replace those systems with ours. Market acceptance of our systems will depend on many factors, including our ability to demonstrate to potential customers that our technology is an attractive alternative to existing technologies. Compared to some competing technologies, our technology is new and complex, and many potential customers have limited knowledge of, or experience with, our products and technologies. Prior to adopting our systems, some potential customers may need to devote time and effort to testing and validating our systems. Any failure of our systems to meet these customer benchmarks could result in potential customers choosing to retain their existing systems or to purchase systems other than ours. In addition, it is important that our gene mapping and DNA isolation systems be perceived as accurate and reliable by the scientific and medical research community as a whole. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scientific community is comprised of a small number of early adopters and key opinion leaders who significantly influence the rest of the community. Historically, a significant part of our sales and marketing efforts has been directed at demonstrating the advantages of our technology to industry leaders, including those key opinion leaders, and encouraging such leaders to publish or present the results of their evaluation of our system. If we are unable to continue to motivate leading researchers to use our technology, or if such researchers are unable to achieve or unwilling to publish or present significant experimental results using our systems, acceptance and adoption of our systems will be slowed and our ability to increase our revenue would be adversely affected. We also run the risk that researchers may produce publications or presentations with findings that are negative about our technologies or systems, and that such findings may be due to factors outside of our control, which may also slow acceptance and adoption of our systems and adversely affect our ability to increase our revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity issuances in connection with strategic transactions or raising additional capital may cause dilution to our stockholders or restrict our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we expect to finance our strategic transactions or cash needs through a combination of equity and debt financings. To the extent that we finance our strategic transactions or raise additional capital through the sale of equity or convertible debt securities, your ownership interest could be diluted and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may be secured by all or a portion of our assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in January 2021, we completed two underwritten public offerings pursuant to which we issued an aggregate of approximately 71.7&#160;million shares of our common stock for gross proceeds, before deducting underwriting discounts and commissions and offering expenses, of approximately $331.8 million. In March 2021, we entered into an at-the-market facility with Cowen and Company, LLC, or Cowen, which provides for the sale, in our sole discretion, of shares of our common stock having an aggregate offering price of up to $350.0 million through or to Cowen, acting as sales agent or principal, which we amended in March 2023 to provide for sales of up to $200.0 million going forward. In August and September 2021, we sold 2.3&#160;million shares of common stock through Cowen for gross proceeds of approximately $13.9 million before deducting offering costs. In the fiscal year ended December 31, 2022, we sold 6.6&#160;million shares of common stock under the Cowen ATM for gross proceeds of approximately $23.1 million before deducting offering costs. In January and February 2023, we sold approximately 9.5&#160;million shares of common stock under the Cowen ATM for gross proceeds of approximately $15.2 million before deducting offering costs. In addition, we issued shares of our common stock in connection with our acquisitions of Lineagen and BioDiscovery. Any future significant sales of our capital stock or strategic transactions in which we use equity as consideration would result in further dilution to our current stockholders. As a result of these issuances, our investors experienced dilution of their ownership interests.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The issuance of shares under awards granted under existing or future employee equity benefit plans may</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">cause immediate and substantial dilution to our existing stockholders.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to provide persons who have a responsibility for our management and/or growth with additional incentive, to increase their proprietary interest in our success, and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to support and increase our ability to attract and retain individuals of exceptional talent, we maintain multiple equity incentive plans. The total number of shares of our common stock available for the grant of awards under these plans is 12.9 million, 0.4 million and 2.2 million for our 2018 Equity Incentive Plan, as amended, 2018 Employee Stock Purchase Plan and 2020 Inducement Plan, as amended, respectively, subject to adjustment, including pursuant to automatic &#8220;evergreen&#8221; increases in certain of our plans. As of March&#160;31, 2023, we had outstanding equity awards underlying those plans accounting for 32.0 million underlying shares. We may also adopt one or more additional employee equity benefit plans in the future. The issuance of shares under an employee equity benefit plan may result in substantial dilution to the interests of other stockholders. For example on February 15, 2023, our board of directors granted our executive officers options to purchase an aggregate of 3.3 million shares of our common stock, and 0.7 million restricted stock units (&#8220;RSUs&#8221;), which represented approximately 1% of our outstanding shares of common stock based on the 306.8 million shares of common stock outstanding as of May&#160;4, 2023. Accordingly, the issuance of shares under current or future employee equity benefit plans will have the effect of further diluting the proportionate equity interest and voting power of holders of our common stock. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to execute our sales and marketing strategy for our Bionano Laboratories products and services, including diagnostic assays, and are unable to gain acceptance in the market, we may be unable to generate sufficient revenue to sustain our Bionano Laboratories business.*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Bionano Laboratories business provides molecular diagnostics services and has engaged in only limited sales and marketing activities for the diagnostic assays currently offered through our CLIA-certified laboratory. To date, the revenue generated by our Bionano Laboratories business has been insufficient to fund operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that our current assays and our planned future assays represent a promising commercial opportunity, our products or assays may never gain significant acceptance in the marketplace and therefore may never generate substantial revenue or profits for us. We will need to further establish a market for our products and diagnostic assays and build that market </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through physician education, awareness programs and the publication of clinical trial results. Gaining acceptance in medical communities requires, among other things, publications in leading peer-reviewed journals of results from studies using our current products, assays and services and/or our planned future products, assays and services. The process of publication in leading medical journals is subject to a peer review process and peer reviewers may not consider the results of our studies sufficiently novel or worthy of publication. Failure to have our studies published in peer-reviewed journals would limit the adoption of our current products, assays and services and our planned future products, assays and services. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to successfully market the products and diagnostic assays that we have developed, and may develop in the future, will depend on numerous factors, including: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conducting clinical utility studies of such assays in collaboration with key thought leaders to demonstrate their use and value in important medical decisions such as treatment selection;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether our current or future partners, vigorously support our offerings;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our sales force;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether healthcare providers believe such diagnostic assays provide clinical utility;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether the medical community accepts that such diagnostic assays are sufficiently sensitive and specific to be meaningful in patient care and treatment decisions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to continually source raw materials, shipping kits and other products that we sell or consume in our manufacturing process that are of sufficient quality and supply;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to continue to fund planned sales and marketing activities; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether private health insurers, government health programs and other third-party payors will adopt our current and future assays in their guidelines, or cover such diagnostic assays and, if so, whether they will adequately reimburse us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Geopolitical and macroeconomic developments, such as recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures, may also increase the risk and uncertainty of the events described above and delay our development timelines. Failure to achieve widespread market acceptance of our current products, assays and services, as well as our planned future products, assays and services, would materially harm our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In the near term, sales of our Saphyr system, Ionic Purification system, NxClinical software, consumables and genome analysis services will depend on levels of research and development spending by clinical research laboratories, academic and governmental research institutions and biopharmaceutical companies, a reduction in which could limit demand for our technologies and products and adversely affect our business and operating results.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the near term, we expect that our revenue from sales of our Saphyr system, Ionic Purification system, NxClinical software, consumables and OGM services will be derived primarily from sales to academic and governmental research institutions, and academic and commercial clinical laboratories, as well as biopharmaceutical and contract research companies worldwide for research applications. The demand for our products and technologies will depend in part upon the research and development budgets of these customers, which are impacted by factors beyond our control, such as:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in government programs that provide funding to research institutions and companies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the regulatory environment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scientists&#8217; and customers&#8217; opinions of the utility of new products, technologies or services;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reductions in or other difficulties relating to, among other things, staffing, capacity, shutdowns or slowdowns of laboratories and other institutions as well as other impacts stemming from various geopolitical and macroeconomic developments, such as the conflict between Ukraine and Russia, related sanctions, recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures and the COVID-19 pandemic;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differences in budgetary cycles; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market acceptance of relatively new technologies, such as ours.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our operating results may fluctuate substantially due to reductions and delays in research and development expenditures by our customers. Any decrease in customers&#8217; budgets or expenditures, including impacts stemming from various geopolitical and macroeconomic developments, or in the size, scope or frequency of capital or operating expenditures, could materially and adversely affect our business, operating results and financial condition.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The sales cycle for our systems can be lengthy and variable, which makes it difficult for us to forecast revenue and other operating results. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sales process for our systems generally involves numerous interactions with multiple individuals within an organization, and often includes in-depth analysis by potential customers of our technology and products and a lengthy review process. Our customers&#8217; evaluation processes often involve a number of factors, many of which are beyond our control. As a result of these factors, the capital investment required to purchase our systems and the budget cycles of our customers, the time from initial contact with a customer to our receipt of a purchase order can vary significantly. Given the length and uncertainty of our sales cycle, we have in the past experienced, and expect to in the future experience, fluctuations in our sales on a period-to-period basis. In addition, any failure to meet customer expectations could result in customers choosing to retain their existing systems, use existing assays not requiring capital equipment or purchase systems other than ours.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our long-term results depend upon our ability to improve existing products and technologies and introduce and market new products and technologies successfully.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is dependent on the continued improvement of our existing products and technologies and our development of new products and technologies utilizing our current or other potential future technology. As we introduce new products or technologies or refine, improve or upgrade versions of existing products or technologies, we cannot predict the level of market acceptance or the amount of market share these products or technologies will achieve, if any. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with our strategy of offering new products and product refinements, we expect to continue to use a substantial amount of capital for product development and refinement. We may need additional capital for product development and refinement than is available on terms favorable to us, if at all, which could adversely affect our business, financial condition or results of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally sell our products and technologies in industries that are characterized by rapid technological changes, frequent new product and technology introductions and changing industry standards. If we do not develop new products and technologies and product and technology enhancements based on technological innovation on a timely basis, our products and technologies may become obsolete over time and our revenues, cash flow, profitability and competitive position will suffer. Our success will depend on several factors, including our ability to: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">correctly identify customer needs and preferences and predict future needs and preferences;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allocate our research and development funding to products and technologies with higher growth prospects;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anticipate and respond to our competitors&#8217; development of new products and technological innovations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">innovate and develop new technologies and applications, including software applications through our BioDiscovery subsidiary, and acquire or obtain rights to third-party technologies that may have valuable applications in the markets we serve;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully market our Ionic Purification system through our Purigen business, and to integrate that technology in our existing ecosystem of technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully commercialize new technologies in a timely manner, price them competitively and manufacture and deliver sufficient volumes of new products of appropriate quality on time; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">customers&#8217; willingness to adopt new technologies. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we fail to accurately predict future customer needs and preferences or fail to produce viable technologies, we may invest heavily in research and development of products and technologies that do not lead to significant revenue. For example, we completed the BioDiscovery acquisition in October 2021 and the Purigen acquisition in November 2022 and will need to devote time and resources in order to further develop and integrate BioDiscovery&#8217;s software and technology solutions and Purigen&#8217;s Ionic Purification system for our current and anticipated product offerings. We may be unsuccessful in achieving our desired results or in marketing such solutions to our future customers. Even if we successfully innovate and develop new products and technologies and product and technological enhancements, we may incur substantial costs in doing so, and our profitability may suffer. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to develop new products and technologies based on innovation can affect our competitive position and often requires the investment of significant resources. Difficulties or delays in research, development or production of new products, technologies and services or failure to gain market acceptance of new products and technologies may reduce future revenues and adversely affect our competitive position.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not successfully manage the development and launch of new products and technologies, our financial results could be adversely affected.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks associated with launching new products and technologies. If we encounter development or manufacturing challenges or discover errors during our product or technology development cycle, the launch dates of new products and technologies may be delayed. The expenses or losses associated with unsuccessful product and technology development or launch activities or lack of market acceptance of our new products and technologies could adversely affect our business or financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success is dependent upon our ability to further penetrate our existing customer base, attract new customers and retain the customers of our acquired businesses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current customer base for our products and technologies is primarily composed of academic and governmental research institutions and biopharmaceutical and contract research companies and, for our Bionano Laboratories diagnostic services, physicians and their patients. Our success will depend upon our ability to respond to the evolving needs of, and increase our market share among, existing customers and additional potential customers, marketing new products, technologies and services as we develop them. Our successes will also depend on our ability to maintain relationships with the customers of our acquired businesses. Identifying, engaging and marketing to customers who are unfamiliar with our current products and technologies requires substantial time, expertise and expense and involves a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract, retain and manage the sales, marketing and service personnel necessary to expand market acceptance for our technology;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and cost of maintaining and growing a specialized sales, marketing and service force; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the fact that our sales, marketing and service force may be unable to execute successful commercial activities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have utilized third parties to assist with sales, distribution and customer support in certain regions of the world. We may be unsuccessful in attracting desirable sales and distribution partners. We may also be unable to enter into arrangements with such partners on favorable terms. Any failure of our sales and marketing efforts, or those of any third-party sales and distribution partners, could adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The size of the markets for our products and technologies may be smaller than we estimate, and new markets may not develop as quickly as we expect, or at all, limiting our ability to successfully sell our products and technologies.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for our OGM-based products and technologies is evolving, making it difficult to predict with any accuracy the market opportunity for our current and future products and technologies. Our estimates of the total addressable market for our current and future products and technologies are based on a number of internal and third-party estimates and assumptions. Both our current market opportunity estimates for cytogenomics and discovery research and our potential future market opportunity estimates, including newborn screening, population genomics, neurological and cardiological risk assessment, and cell bioprocessing quality control, are forward-looking statements and are subject to significant risks and uncertainties. While these were prepared in good faith, we cannot provide assurances as to future results or events because these estimates are dependent in part on, among other things, anticipated demand for OGM instruments, complementary capabilities of OGM and NGS, and expected consumption of chips and sample prep and labeling kits. In particular, these estimates are based on current and projected selling prices for instruments and consumables, each of which is subject to change over time and may be drastically affected without warning due to matters outside of our control, including geopolitical and macroeconomic developments. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimates and assumptions underlying our addressable market opportunities also involve significant judgments with respect to, among other things, future economic, competitive, regulatory, market and financial conditions, as well as future customer demand, business decisions and corporate opportunities that may not be realized, and that are inherently subject to significant business, economic, competitive and regulatory risks and uncertainties, all of which are difficult to predict and many of which are outside of our control. For example, as interest rates continue to rise, our customers may be unable to deploy additional capital to purchase, or may re-prioritize their budget away from, our products and technologies. In addition, our underlying assumptions and estimates may prove to be inaccurate and our financial objectives may not be realized, and therefore our actual results may differ materially from our estimated addressable market opportunities. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any addressable market opportunities identified in this Quarterly Report on Form 10-Q should not be construed as financial guidance and should not otherwise be relied upon as being necessarily indicative of future results, and you are cautioned not to place undue reliance on our estimated addressable opportunities. In preparing our estimated addressable opportunities, we have relied upon and assumed, without independent verification, the accuracy and completeness of certain industry and market information provided to us by third parties or through publicly available sources, which information involves assumptions and limitations, and you should not give undue weight to such information.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently limited to RUO with respect to many of the materials and components used in our consumable products including our assays.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our instruments, consumable products and assays are purchased from suppliers with a restriction that they be used for RUO. While we have focused initially on the life sciences research market and RUO products only, part of our business strategy is to expand our product line to encompass products that are intended to be used for the diagnosis of disease and precision healthcare, either alone or in collaboration with third parties. The use of our RUO products for any such diagnostic purposes would require that we obtain regulatory clearance or approval to market our products for those purposes and also that we acquire the materials and components used in such products from suppliers without an RUO restriction. There can be no assurance that we will be able to acquire these materials and components for use in diagnostic products on acceptable terms, if at all. If we are unable to do so, we would not be able to expand our non-Bionano Laboratories product offerings beyond RUO, and our business and prospects would suffer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA Guidance on &#8220;Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only&#8221;, or, the RUO/IUO Labeling Guidance, emphasizes that the FDA will review the totality of the circumstances when evaluating whether equipment and testing components are properly labeled as RUO. It further states that merely including a labeling statement that a product is intended for RUO will not necessarily render the device exempt from the FDA&#8217;s 510(k) clearance, PMA, or other requirements, if the circumstances surrounding the distribution of the product indicate that the manufacturer intends for its product to be offered for clinical diagnostic use. These circumstances may include written or verbal marketing claims or links to articles regarding a product&#8217;s performance in clinical applications, a manufacturer&#8217;s provision of technical support for clinical validation or clinical applications, or solicitation of business from clinical laboratories, all of which could be considered evidence of intended uses that conflict with RUO labeling. If the FDA were to determine that our RUO products were intended for use in clinical investigation, diagnosis or treatment decisions, or that express or implied clinical or diagnostic claims were made for our RUO products, those products could be considered misbranded or adulterated under the Federal Food, Drug, and Cosmetic Act. If the FDA determines that our RUO products are being marketed for clinical diagnostic use without the required PMA or 510(k) clearance, we may be required to cease marketing our products as planned, recall the products from customers, revise our marketing plans, and/or suspend or delay the commercialization of our products until we obtain the required authorization. We also may be subject to a range of enforcement actions by the FDA, including warning or untitled letters, injunctions, civil monetary penalties, criminal prosecution, and recall and/or seizure of products, as well as significant adverse publicity.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If, in the future, we choose to commercialize our RUO products for clinical diagnostic use, we will be required to comply with the FDA&#8217;s premarket review and post-market control requirements for in-vitro diagnostics, or IVDs, products, as may be applicable. Complying with the FDA&#8217;s PMA and/or 510(k) clearance requirements may be expensive, time-consuming, and subject us to significant and/or unanticipated delays. Our efforts may never result in an approved PMA or 510(k) clearance for our products. Even if we obtain a PMA or 510(k) clearance, where required, such authorization may not be for the use or uses we believe are commercially attractive and/or are critical to the commercial success of our products. As a result, being subject to the FDA&#8217;s premarket review and/or post-market control requirements for our products could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited experience in marketing and selling our products and technologies, and if we are unable to successfully commercialize our products and technologies, our business and operating results will be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited experience marketing and selling our products and technologies. We currently sell our Saphyr system and Ionic Purification system for RUO through our direct field sales and support organizations located in North America and Europe and through a combination of our own sales force and third-party distributors in additional major markets such as Australia, China, Japan and South Korea.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future sales of our products and technologies will depend in large part on our ability to effectively market and sell our products and technologies, successfully manage and expand our sales force, and increase the scope of our marketing efforts. We may also enter into additional distribution arrangements in the future. Because we have limited experience in marketing and selling our products and technologies, our ability to forecast demand, the infrastructure required to support such demand and the sales cycle to customers is unproven. If we do not build an efficient and effective sales force, our business and operating results will be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on a single contract manufacturer for our optical genome mapping systems and a single contract manufacturer for our chip consumables. If either of these manufacturers should fail or not perform satisfactorily, our ability to supply these products would be negatively and adversely affected.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on a single contract manufacturer to manufacture and supply all of our OGM-based instruments, including our new Ionic Purification instruments. See the section titled &#8220;Business &#8212; Key Agreements&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2022. In addition, we rely on a single contract manufacturer based in the United States to manufacture and supply all of our chip consumables. Since our contracts with these manufacturers do not commit them to </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">supply quantities beyond the amounts included in our purchase orders, and do not commit them to carry inventory or make available any particular quantities, these contract manufacturers may give other customers&#8217; needs higher priority than ours, and we may not be able to obtain adequate supplies in a timely manner or on commercially reasonable terms. If either of these manufacturers were to be unable to supply instruments or chip consumables, our business would be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event it becomes necessary to utilize different contract manufacturers for our OGM-based instruments or chip consumables, we would experience additional costs, delays and difficulties in doing so as a result of identifying and entering into an agreement with a new supplier as well as preparing such new supplier to meet the logistical requirements associated with manufacturing our units, and our business would suffer. We may also experience additional costs and delays in the event we need access to or rights under any intellectual property of these current manufacturers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have experienced manufacturing problems or delays that could limit the growth of our revenue or increase our losses.* </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have encountered situations that resulted in delays or shortfalls caused by our outsourced manufacturing suppliers and by other third-party suppliers who manufacture components for our products. We have been negatively impacted by unfavorable flowcell yields in the production cycle. If the same or a similar issue were to occur, it could lead to lower gross margins in future periods. If we are unable to keep up with demand for our products, our revenue could be impaired, market acceptance for our products and systems could be adversely affected and our customers might instead purchase our competitors&#8217; products and systems. Our inability to successfully manufacture our products would have a material adverse effect on our operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our laboratory facilities become damaged or inoperable or we are required to vacate our existing facilities, our ability to conduct our laboratory analysis and pursue our research and development efforts may be jeopardized.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently perform all research and development activities and most of our OGM services at a single laboratory facility in San Diego, California with the remaining genome analysis services at a facility we occupy at a customer&#8217;s lab in Clermont-Ferrand, France. All of our molecular diagnostics services are processed at a single laboratory facility in Salt Lake City, Utah. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facilities and equipment could be harmed or rendered inoperable by natural or man-made disasters, including war, fire, earthquake, power loss, communications failure, terrorism, burglary, public health crises (including restrictions that may result from various geopolitical and macroeconomic developments, such as the ongoing conflict between Ukraine and Russia or the COVID-19 pandemic) or other events, which may make it difficult or impossible for us to perform our testing services for some period of time or to receive and store samples. The inability to perform tests or to reduce the backlog of sample analysis that could develop if one or both of our facilities become inoperable, for even a short period of time, may result in the loss of revenue, loss of customers or harm to our reputation, and we may be unable to regain that revenue, those customers or repair our reputation in the future. Furthermore, integral parties in our supply chain are operating from single sites, increasing their vulnerability to natural disasters and man-made disasters or other sudden, unforeseen and severe adverse events.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the loss of our samples due to such events could limit or prevent our ability to conduct research and development analysis on existing tests as well as tests in development.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facilities and the equipment we use to perform our testing and research and development could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming and expensive to rebuild our facilities, to locate and qualify a new facility with applicable regulatory authorities, replace certain pieces of equipment or license or transfer our proprietary technology to a third party, particularly in light of licensure and accreditation requirements. Even in the unlikely event that we are able to find a third party with such qualifications to enable us to resume our operations, we may be unable to negotiate commercially reasonable terms. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carry insurance for damage to our property and the disruption of our business, but this insurance may not cover all of the risks associated with damage or disruption to our business, may not provide coverage in amounts sufficient to cover our potential losses and may not continue to be available to us on acceptable terms, if at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on a limited number of suppliers or, in some cases, one supplier, for some of our materials and components used in our products, and may not be able to find replacements or immediately transition to alternative suppliers, which could have a material adverse effect on our business, financial condition, results of operations and reputation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on limited or sole suppliers for certain reagents and other materials and components that are used in our products. While we periodically forecast our needs for such materials and enter into standard purchase orders with our suppliers, we do not have long-term contracts with many of these suppliers. If we were to lose such suppliers, there can be no assurance that we will be able to identify or enter into agreements with alternative suppliers on a timely basis on acceptable terms, if at all. An interruption in our operations, including our laboratory operations, could occur if we encounter delays or difficulties in securing these materials, or if the quality of the materials supplied do not meet our requirements, or if we cannot then obtain an acceptable substitute. The time and effort required to qualify a new supplier and ensure that the new materials provide the same or better quality results could result in significant additional costs. Any such interruption could significantly affect our business, financial condition, results of operations and reputation.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain of the components used in our instruments are sourced from limited or sole suppliers. If we were to lose such suppliers, there can be no assurance that we will be able to identify or enter into agreements with alternative suppliers on a timely basis on acceptable terms, if at all. An interruption in our ability to sell and deliver instruments to customers could occur if we encounter delays or difficulties in securing these components, or if the quality of the components supplied do not meet specifications, or if we cannot then obtain an acceptable substitute. If any of these events occur, our business and operating results could be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in order to mitigate these risks, we maintain inventories of certain supplies at higher levels than would be the case if multiple sources of supply were available. If our sales or testing volume decreases or we switch suppliers, we may hold excess supplies with expiration dates that occur before use which would adversely affect our losses and cash flow position. As we introduce any new products, we may experience supply issues as we ramp up our sales or test volume. If we should encounter delays or difficulties in securing, reconfiguring or revalidating the equipment, reagents or other materials we require for our products, our business, financial condition, results of operations and reputation could be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Undetected errors or defects in our products or technologies could harm our reputation, decrease market acceptance of our products or technologies or expose us to product liability claims or recalls. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products or technologies may contain undetected errors or defects when first introduced or as new versions or new products or technologies are released. Disruptions affecting the introduction or release of, or other performance problems with, our products or technologies may damage our customers&#8217; businesses and could harm their and our reputations. If that occurs, we may incur significant costs, the attention of our key personnel could be diverted, or other significant customer relations problems may arise. We may also be subject to warranty and liability claims for damages related to errors or defects in our products or technologies. In addition, if we do not meet industry or quality standards, if applicable, our products may be subject to recall. A material liability claim, recall or other occurrence that harms our reputation or decreases market acceptance of our products or technologies could harm our business and operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our customers develop or use our products or assays for diagnostic purposes, someone could file a product liability claim alleging that one of our products contained a design or manufacturing defect that resulted in the failure to adequately perform, leading to death or injury. In addition, the marketing, sale and use of our current or future products and assays could lead to the filing of product liability claims against us if someone alleges that our products failed to perform as designed. We may also be subject to liability for errors in the results we provide or for a misunderstanding of, or inappropriate reliance upon, the information we provide.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product liability claim could result in substantial damages and be costly and time consuming to defend, either of which could materially harm our business or financial condition. We cannot assure investors that our product liability insurance would adequately protect our assets from the financial impact of defending a product liability claim. Any product liability claim brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability lawsuit could damage our reputation, or cause current partners to terminate existing agreements and potential partners to seek other partners, any of which could impact our results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also initiate a correction to our existing products or assays, which could lead to increased costs and increased scrutiny by regulatory authorities and our customers regarding the quality and safety of our products or services, as well as negative publicity. The occurrence of any of these events could have an adverse effect on our business and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance on distributors for sales of our products outside of the United States could limit or prevent us from selling our products and could impact our revenue.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to grow our business internationally, and to do so we must attract additional distributors and retain existing distributors to maximize the commercial opportunity for our products. There is no guarantee that we will be successful in attracting or retaining desirable sales and distribution partners or that we will be able to enter into such arrangements on favorable terms. Distributors may not commit the necessary resources to market and sell our products to the level of our expectations or may choose to favor marketing the products of our competitors. If current or future distributors do not perform adequately, or we are unable to enter into effective arrangements with distributors in particular geographic areas, we may not realize long-term international revenue growth. In addition, if our distributors fail to comply with applicable laws and ethical standards, including anti-bribery laws, this could damage our reputation and could have a significant adverse effect on our business and our revenues. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to generate a substantial portion of our revenue internationally in the future and can become further subject to various risks relating to our international activities, which could adversely affect our business, operating results and financial condition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, approximately 59% and 55%, respectively, of our revenue was generated from customers located outside of the United States. We believe that a substantial percentage of our future revenue </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will come from international sources as we expand our overseas operations and develop opportunities in additional areas. We have limited experience operating internationally and engaging in international business involves a number of difficulties and risks, including: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">required compliance with existing and changing foreign regulatory requirements and laws;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties and costs of staffing and managing foreign operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties protecting or procuring intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">required compliance with anti-bribery laws, such as the U.S. Foreign Corrupt Practices Act, data privacy and security requirements, labor laws and anti-competition regulations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">export or import restrictions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laws and business practices favoring local companies; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">longer payment cycles and difficulties in enforcing agreements and collecting receivables through certain foreign legal systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">political and economic instability; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially adverse tax consequences, tariffs, customs charges, bureaucratic requirements and other trade barriers. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, most of our revenue has been denominated in U.S. dollars. For sales made to customers outside of the United States, we may sell our products and services in local currency outside of the United States. As our operations in countries outside of the United States grow, our results of operations and cash flows may be subject to fluctuations due to changes in foreign currency exchange rates, which could harm our business in the future. For example, if the value of the U.S. dollar increases relative to foreign currencies, in the absence of a corresponding change in local currency prices, our revenue could be adversely affected as we convert revenue from local currencies to U.S. dollars. If we dedicate significant resources to our international operations and are unable to manage these risks effectively, our business, operating results and financial condition will suffer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the U.S. Foreign Corrupt Practices Act, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, the United Kingdom Bribery Act 2010, and other state and national anti-bribery and anti-money laundering laws in countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees and third-party intermediaries from authorizing, promising, offering, providing, soliciting, or accepting, directly or indirectly, improper payments or benefits to or from any person whether in the public or private sector for the purpose of obtaining or retaining business or securing any other improper advantage. We rely on third-party representatives, distributors, and other business partners to support sales of our products and services and our efforts to ensure regulatory compliance. In addition, as we increase our international sales and business, we may engage with additional business partners. We can be held liable for the corrupt or other illegal activities of our employees, representatives, contractors, business partners, and agents, even if we do not explicitly authorize or have actual knowledge of such activities. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any violations of anti-corruption and anti-money laundering laws, or allegations of such violations, could disrupt our operations, involve significant management distraction, involve significant costs and expenses, including legal fees, and could result in a material adverse effect on our business, prospects, financial condition, or results of operations. We could also incur severe penalties, including criminal and civil penalties, disgorgement, and other remedial measures. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to governmental export and import controls that could impair our ability to compete in international markets due to licensing requirements and subject us to liability if we are not in compliance with applicable laws. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls. Exports of our products must be made in compliance with these laws and regulations. If we fail to comply with these laws and regulations, we and certain of our employees could be subject to substantial civil or criminal penalties, including the possible loss of export or import privileges; fines, which may be imposed on us and responsible employees or managers; and, in extreme cases, the incarceration of responsible employees or managers. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, changes in our products or changes in applicable export or import laws and regulations may create delays in the introduction and sale of our products in international markets, prevent our customers from deploying our products or, in some cases, prevent the export or import of our products to certain countries, governments or persons altogether. Any change in export or import laws and regulations, shift in the enforcement or scope of existing laws and regulations, or change in the countries, governments, persons or technologies targeted by such laws and regulations, could also result in decreased use of our </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products, or in our decreased ability to export or sell our products to existing or potential customers. Any decreased use of our products or limitation on our ability to export or sell our products would likely adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to recruit, train, retain, motivate and integrate key personnel, we may not achieve our goals.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success depends on our ability to recruit, train, retain, motivate and integrate key personnel, including our recently expanded senior management team, as well as our research and development, manufacturing and sales and marketing personnel. Competition for qualified personnel is intense. This competition has become exacerbated by the increase in employee resignations throughout the United States, which is commonly referred to as the &#8220;great resignation.&#8221; We may also experience employee turnover as a result of the ongoing &#8220;great resignation.&#8221; Our growth depends, in particular, on attracting and retaining highly-trained sales personnel with the necessary scientific background and ability to understand our systems at a technical level to effectively identify and sell to potential new customers. Additionally, our growth depends on attracting and retaining highly-skilled personnel with the necessary technical and scientific background needed to develop new products and technologies. Because of the complex and technical nature of our products and technologies and the dynamic market in which we compete, any failure to attract, train, retain, motivate and integrate qualified personnel could materially harm our operating results and growth prospects. In response to competition, rising inflation rates and labor shortages, we may need to adjust employee cash compensation, which would affect our operating costs and our margins, or equity compensation, which would affect our outstanding share count, causing dilution to existing shareholders and possibly souring investor sentiment, which could in turn make it difficult to achieve our goals.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot provide quality technical and applications support, we could lose customers and our business and prospects will suffer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The placement of our products at new customer sites, the introduction of our technology into our customers&#8217; existing laboratory workflows and ongoing customer support can be complex. Accordingly, we need highly trained technical support personnel. Hiring technical support personnel is very competitive in our industry due to the limited number of people available with the necessary scientific and technical backgrounds and ability to understand our technology at a technical level. To effectively support potential new customers and the expanding needs of current customers, we will need to substantially expand our technical support staff. If we are unable to attract, train or retain the number of highly qualified technical services personnel that our business needs, our business and prospects will suffer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our information technology systems or data or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of our business, we and the third parties upon which we rely collect, store, use, protect, secure, generate, transfer, dispose of, transmit, disclose, and otherwise process sensitive, proprietary, and confidential information, including intellectual property, trade secrets, financial information, and personal data (including protected health information) (collectively, &#8220;Sensitive Data&#8221;). As a result, we and the third parties upon which we rely face a variety of evolving threats including but not limited to ransomware attacks, which could cause security incidents.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyberattacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our Sensitive Data and information technology systems, and those of the third parties upon which we rely. Such threats are prevalent and continue to rise, are becoming increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, personnel (such as through theft or misuse), &#8220;hacktivists,&#8221; sophisticated nation-states, and nation-state-supported actors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, including as a result of the ongoing military conflict between Russia and Ukraine and the related sanctions imposed against Russia, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services. We and the third parties upon which we rely are subject to a variety of evolving threats, including but not limited to social-engineering attacks (such as through phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks (such as credential stuffing), credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods, and other similar threats. In particular, severe ransomware attacks, including those perpetrated by organized criminal threat actors, nation-states, and nation-state supported actors, are becoming increasingly prevalent and can lead to significant interruptions in our operations, loss of Sensitive Data and income, reputational </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our reliance on third-party service providers and technologies to operate critical business systems to process Sensitive Data could introduce new cybersecurity risks and vulnerabilities and other threats to our business operations. We rely on third-party service providers in a variety of contexts, including, without limitation, third-party providers of cloud-based infrastructure, encryption and authentication technology, employee email, content delivery to customers, and other functions and, as a result, we and the third parties upon which we rely face a variety of evolving threats, including but not limited to ransomware attacks, which could cause security incidents. Our ability to monitor these third parties&#8217; cybersecurity practices is limited, and these third parties may not have adequate information security measures in place. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may share or receive sensitive data with or from third parties. Similarly, supply chain attacks have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to our information technology systems (including our software) or the third-party information technology systems that support us and our services. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers and devices outside our premises or network, including working at home, while in transit, and in public locations. Additionally, past or future business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems and Sensitive Data could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the previously identified or similar threats could cause a security incident or other interruption. that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our Sensitive Data or our information technology systems, or those of the third parties upon whom we rely. A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to provide our products, software and services. We may expend significant resources or modify our business activities in an effort to protect against security incidents. Certain data privacy and security obligations may require us to implement and maintain specific security measures, or industry-standard or reasonable security measures to protect our information technology systems and Sensitive Data.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We may be unable in the future to take steps to detect and remediate vulnerabilities in our information technology systems (including our software) because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Despite our efforts to identify and remediate vulnerabilities, if any, in our information technology systems (including our software), our efforts may not be successful. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosures or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause customers to stop using our software or services, deter new customers from using our software or services, and negatively impact our ability to grow and operate our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage, if any, will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruption of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we collect, store, protect, secure, generate, transfer, dispose of, use, transmit, disclose and otherwise process personal data (including protected health information) and other sensitive information, including proprietary and confidential business data, trade secrets, and intellectual property. Our data processing activities may subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations that govern the processing of personal data by us and on our behalf. In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). For example, the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective implementing regulations, impose specific requirements relating to the privacy, security, and transmission of individually identifiable health information. For more information regarding risks associated with HIPAA, please refer to the section above that discusses risks associated with federal and state healthcare laws.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As another example, the California Consumer Privacy Act of 2018, or the CCPA, imposes obligations on businesses to which it applies. These obligations include, but are not limited to, providing specific disclosures in privacy notices and affording California residents certain rights related to their personal data. The CCPA allows for statutory fines for noncompliance (up to $7,500 per violation and allows private litigants affected by certain data breaches to recover significant statutory damages). In addition, the California Privacy Rights Act of 2020, or the CPRA, operative January 1, 2023, expands the CCPA&#8217;s requirements, including by adding a new right for individuals to correct their personal information and establishing a new regulatory agency to implement and enforce relevant laws, which could increase the risk of an enforcement action, and the CPRA applies to personal information of business representatives and employees in addition to consumers. Other states have also recently enacted data privacy laws, as well as at the federal and local levels. For example, Virginia passed the Consumer Data Protection Act, and Colorado passed the Colorado Privacy Act, both of which differ from the CPRA and take effect in 2023. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example, the European Union&#8217;s General Data Protection Regulation, or EU GDPR, and the United Kingdom&#8217;s GDPR, or UK GDPR, impose strict requirements for processing the personal data of individuals. For example, under the EU GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million euros or 4% of annual global revenue, whichever is greater; or private litigation related to the processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area (EEA) and the United Kingdom (UK) have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA and UK&#8217;s standard contractual clauses, these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activities groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, privacy advocates and industry groups have proposed, and may propose in the future, standards with which we may be legally or contractually bound to comply. For example, we may also be subject to the Payment Card Industry Data Security Standard, or PCI DSS. The PCI DSS requires companies to adopt certain measures to ensure the security of cardholder information, including using and maintaining firewalls, adopting proper password protections for certain devices and software, and restricting data access. Noncompliance with PCI-DSS can result in penalties ranging from $5,000 to $100,000 per month </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by credit card companies, litigation, damage to our reputation, and revenue losses. We may also rely on vendors to process payment card data, and those vendors may be subject to PCI DSS, and our business may be negatively affected if our vendors are fined or suffer other consequences as a result of PCI DSS noncompliance.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to contractual obligations and policies related to data privacy and security and our efforts to comply with such obligations may not be successful. Publication of our privacy policies and other statements regarding data privacy and security may subject us to investigation or enforcement actions by regulators if those policies or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our data privacy and security obligations are quickly changing in an increasingly stringent fashion, creating some uncertainty as to the effective future legal framework. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or in conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources (including, without limitation, financial and time-related resources) and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties on which we rely. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited to, government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class action claims); additional reporting requirements and/or oversight; bans on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to, loss of customers; interruptions or stoppages in our business operations; inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The life sciences research and diagnostic markets are highly competitive. If we fail to effectively compete, our business, financial condition and operating results will suffer.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face significant competition in the life sciences research and diagnostic markets. We currently compete with both established and early stage companies that design, manufacture and market systems and consumable supplies. We believe our principal competitors in the life sciences research and genome mapping markets include PacBio, Oxford Nanopore Technologies, Genomic Vision, Qiagen, and Dovetail Genomics (now part of Cantata Bio). In addition, there are a number of new market entrants in the process of developing novel technologies for the life sciences research, diagnostic and screening markets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our current competitors are either publicly-traded, or are divisions of publicly-traded companies, and may enjoy a number of competitive advantages over us, including: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">greater name and brand recognition;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantially greater financial and human resources;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">broader product lines;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">larger sales forces and more established distributor networks;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial intellectual property portfolios;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">larger and more established customer bases and relationships; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">better established, larger scale, and lower cost manufacturing capabilities. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the principal competitive factors in all of our target markets include: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost of instruments and consumables;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">accuracy, including sensitivity and specificity, and reproducibility of results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reputation among customers and key opinion leaders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">innovation in product offerings;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">flexibility, scalability and ease of use; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compatibility with existing laboratory processes, tools and methods. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure investors that our products or technologies will compete favorably or that we will be successful in the face of increasing competition from new products and technologies introduced by our existing competitors or new companies entering our markets. In addition, we cannot assure investors that our competitors do not have or will not develop products or technologies that currently or in the future will enable them to produce competitive products or technologies with greater </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capabilities or at lower costs than ours. Any failure to compete effectively could materially and adversely affect our business, financial condition and operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, and any the third parties with access to our facilities, are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Each of our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. We could be held liable for any resulting damages in the event of contamination or injury resulting from the use of hazardous materials by us or the third parties with whom we contract, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. We do not have any insurance for liabilities arising from medical or hazardous materials. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Compliance with applicable environmental laws and regulations is expensive, and these current or future laws and regulations may impair our research, development and commercialization efforts, which could harm our business, prospects, financial condition or results of operations. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_124"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to government regulation and diagnostic product reimbursement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the FDA determines that our RUO products are medical devices or if we seek to market our RUO products for clinical diagnostic or health screening use, we will be required to obtain regulatory clearance(s) or approval(s), and may be required to cease or limit sales of our then marketed products, which could materially and adversely affect our business, financial condition and results of operations. Any such regulatory process would be expensive, time-consuming and uncertain both in timing and in outcome.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our RUO products are focused on the life sciences research market. This includes laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology and contract research companies. Accordingly, our products are labeled as RUO, and are not intended for diagnostic use. While we have focused initially on the life sciences research market and RUO products only, our strategy is to expand our product line to encompass products that are intended to be used for the diagnosis of disease, either alone or in collaboration with third parties. Such IVD products will be subject to regulation by the FDA as medical devices, or comparable international agencies, including requirements for regulatory clearance or approval of such products before they can be marketed. If the FDA were to determine that our products are intended for clinical use or if we decided to market our products for such use, we would be required to obtain FDA 510(k) clearance or premarket approval in order to sell our products in a manner consistent with FDA laws and regulations. Such regulatory approval processes or clearances are expensive, time-consuming and uncertain; our efforts may never result in any approved premarket approval application, or PMA, or 510(k) clearance for our products; and failure by us or a collaborator to obtain or comply with such approvals and clearances could have an adverse effect on our business, financial condition or operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IVD products may be regulated as medical devices by the FDA and comparable international agencies and may require either clearance from the FDA following the 510(k) pre-market notification process or PMA from the FDA, in each case prior to marketing. If we or our collaborators are required to obtain a PMA or 510(k) clearance for products based on our technology, we or they would be subject to a substantial number of additional requirements for medical devices, including establishment registration, device listing, Quality Systems Regulations which cover the design, testing, production, control, quality assurance, labeling, packaging, servicing, sterilization (if required), and storage and shipping of medical devices (among other activities), product labeling, advertising, recordkeeping, post-market surveillance, post-approval studies, adverse event reporting, and correction and removal (recall) regulations. One or more of the products we or a collaborator may develop using our technology may also require clinical trials in order to generate the data required for PMA approval. Complying with these requirements may be time-consuming and expensive. We or our collaborators may be required to expend significant resources to ensure ongoing compliance with the FDA regulations and/or take satisfactory corrective action in response to enforcement action, which may have a material adverse effect on the ability to design, develop, and commercialize products using our technology as planned. Failure to comply with these requirements may subject us or a collaborator to a range of enforcement actions, such as warning letters, injunctions, civil monetary penalties, criminal prosecution, recall and/or seizure of products, and revocation of marketing authorization, as well as significant adverse publicity. If we or our collaborators fail to obtain, or experience </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant delays in obtaining, regulatory approvals for IVD products, such products may not be able to be launched or successfully commercialized in a timely manner, or at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory developed tests, or LDTs, are a subset of IVD tests that are designed, manufactured and used within a single laboratory. Our Bionano Laboratories diagnostic services are provided as LDTs. The FDA maintains that LDTs are medical devices and has for the most part exercised enforcement discretion for most LDTs. A significant change in the way that the FDA regulates any LDTs that we, our collaborators or our customers market or develop using our technology could affect our business. If the FDA requires laboratories to undergo premarket review and comply with other applicable FDA requirements in the future, the cost and time required to commercialize an LDT will increase substantially, and may reduce the financial incentive for us to continue to offer our Bionano Laboratories genetic diagnostic services or for our customer laboratories to develop LDTs, which could reduce demand for our RUO instruments and our other products. In addition, if the FDA were to change the way that it regulates LDTs to require that we undergo pre-market review or comply with other applicable FDA requirements before we can sell our RUO instruments or our other products to clinical cytogenetics laboratories, our ability to sell our RUO instruments and other products to this addressable market would be delayed, thereby impeding our ability to penetrate this market and generate revenue from sales of our instruments and our other products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable FDA requirements could subject us to misbranding or adulteration allegations under the Federal Food, Drug, and Cosmetic Act. We could be subject to a range of enforcement actions, including warning letters, injunctions, civil monetary penalties, criminal prosecution, and recall and/or seizure of products, as well as significant adverse publicity. In addition, changes to the current regulatory framework, including the imposition of additional or new regulations, could arise at any time during the development or marketing of our products, which may negatively affect our ability to obtain or maintain FDA or comparable regulatory approval of our products, if required.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign jurisdictions have laws and regulations similar to those described above, which may adversely affect our ability to market our products as planned in such countries. The number and scope of these requirements are increasing. As in the United States, the cost and time required to comply with regulatory requirements may be substantial, and there is no guarantee that we will obtain the necessary authorization(s) required to make our products commercially viable. As a result, the imposition of foreign requirements may also have a material adverse effect on the commercial viability of our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to rely on third parties in conducting any required future studies of diagnostic products that may be required by the FDA or other regulatory authorities, and those third parties may not perform satisfactorily. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to independently conduct clinical trials or other studies that may be required to obtain FDA and other regulatory clearance or approval for future diagnostic products. Accordingly, we expect that we would rely on third parties, such as clinical investigators, consultants, and collaborators to conduct such studies if needed. Our reliance on these third parties for clinical and other development activities would reduce our control over these activities. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if the third parties need to be replaced or if the quality or accuracy of the data they obtain is compromised, we may not be able to obtain regulatory clearance or approval.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Billing for our Bionano Laboratories diagnostic testing procedures is complex and requires substantial time and resources to collect payment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Billing for clinical laboratory testing services in connection with our Bionano Laboratories diagnostic services is complex, time-consuming and expensive. Depending on the billing arrangement and applicable law, we bill various payors, including Medicare, Medicaid, private insurance companies, private healthcare institutions, and patients, all of which have different billing requirements. We generally bill third-party payors for our diagnostic testing services and pursue reimbursement on a case-by-case basis where pricing contracts are not in place. To the extent laws or contracts require us to bill patient co-payments or co-insurance, we must also comply with these requirements. We may also face increased risk in our collection efforts, including potential write-offs of accounts receivable and long collection cycles, which could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several factors make the billing process complex, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differences between the billing rates and reimbursement rates for our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with complex federal and state regulations related to billing government healthcare programs, including Medicare, Medicaid and TRICARE;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risk of government audits related to billing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes among payors as to which party is responsible for payment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differences in coverage and information and billing requirements among payors, including the need for prior authorization and/or advanced notification;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of patient co-payments or co-insurance and our ability to collect such payments from patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to billing codes used for our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to requirements related to our current or future clinical studies, including our registry studies, which can affect eligibility for payment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ongoing monitoring provisions of LCDs for our products, which can affect the circumstances under which a claim would be considered medically necessary;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incorrect or missing billing information; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the resources required to manage the billing and claims appeals process.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use standard industry billing codes, known as CPT codes, to bill for our diagnostic testing services. If these codes were to change, there is a risk of an error being made in the claim adjudication process. Such errors can occur with claims submission, third-party transmission or in the processing of the claim by the payor. Claim adjudication errors may result in a delay in payment processing or a reduction in the amount of the payment we receive.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we introduce new products, we may need to add new codes to our billing process as well as our financial reporting systems. Failure or delays in effecting these changes in external billing and internal systems and processes could negatively affect our collection rates, revenue and cost of collecting.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our billing activities require us to implement compliance procedures and oversight, train and monitor our employees, and undertake internal audits to evaluate compliance with applicable laws and regulations as well as internal compliance policies and procedures. When payors deny our claims, we may challenge the reason, low payment amount or payment denials. Payors also conduct external audits to evaluate payments, which add further complexity to the billing process. If the payor makes an overpayment determination, there is a risk that we may be required to return all or some portion of prior payments we have received.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, collectively the ACA, requires providers and suppliers to report and return any overpayments received from government payors under the Medicare and Medicaid programs within 60 days of identification. Failure to identify and return such overpayments exposes the provider or supplier to liability under federal false claims laws. These billing complexities, and the related uncertainty in obtaining payment for our products, could negatively affect our revenue and cash flow, our ability to achieve sustained profitability, and the consistency and comparability of our results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our Bionano Laboratories diagnostic testing procedures are subject to unfavorable pricing regulations or third-party payor coverage and reimbursement policies, our business could be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Bionano Laboratories-related revenue depends on achieving and maintaining broad coverage and adequate reimbursement for our Bionano Laboratories products and diagnostic assays from third-party payors, including both government and commercial third-party payors. If third-party payors do not provide coverage of, or do not provide adequate reimbursement for, a substantial portion of the list price of our Bionano Laboratories products and diagnostic assays, we may need to seek additional payment from the patient beyond any co-payments and deductibles, which may adversely affect demand for our Bionano Laboratories products and diagnostic assays. Coverage determinations by a third-party payor may depend on a number of factors, including, but not limited to, a third-party payor&#8217;s determination of whether our products or services are appropriate, medically necessary or cost-effective. If we are unable to provide third-party payors with sufficient evidence of the clinical utility and validity of our Bionano Laboratories products and diagnostic assays, they may not provide coverage, or may provide limited coverage, which will adversely affect our revenues and our ability to succeed. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since each third-party payor makes its own decision as to whether to establish a policy to cover our Bionano Laboratories products and diagnostic assays, enter into a contract with us and set the amount it will reimburse for a product, these negotiations are a time-consuming and costly process, and they do not guarantee that the third-party payor will provide coverage or adequate reimbursement for our Bionano Laboratories products and diagnostic assays. In addition, the determinations by a third-party payor whether to cover our Bionano Laboratories products and diagnostic assays and the amount it will reimburse for them are often made on an indication-by-indication basis.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In cases where there is no coverage policy or we do not have a contracted rate for reimbursement as a participating provider, the patient is typically responsible for a greater share of the cost of the product, which may result in further delay of our revenue, increase our collection costs or decrease the likelihood of collection.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our claims for reimbursement from third-party payors may be denied upon submission, and we may need to take additional steps to receive payment, such as appealing the denials. Such appeals and other processes are time-consuming and expensive, and may not result in payment. Third-party payors may perform audits of historically paid claims and attempt to recoup funds years after the funds were initially distributed if the third-party payors believe the funds were paid in error or determine that our </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bionano Laboratories products and diagnostic assays were medically unnecessary. If a third-party payor audits our claims and issues a negative audit finding, and we are not able to overturn the audit findings through appeal, the recoupment may result in a material adverse effect on our revenue. Additionally, in some cases commercial third-party payors for whom we are not a participating provider may elect at any time to review claims previously paid and determine the amount they paid was too much. In these situations, the third-party payor will typically notify us of their decision and then offset whatever amount they determine they overpaid against amounts they owe us on current claims. We cannot predict when, or how often, a third-party payor might engage in these reviews and we may not be able to dispute these retroactive adjustments. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, coverage policies and third-party payor reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future that may adversely affect the coverage and reimbursement of our Bionano Laboratories products and diagnostic assays.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If diagnostic procedures that are enabled by our Saphyr technology are subject to unfavorable pricing regulations or third-party payor coverage and reimbursement policies, our business could be harmed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, our Saphyr system is for RUO, but clinical laboratories may acquire our instrumentation through a capital purchase or capital lease and use the Saphyr and direct label stain chemistry to create their own potentially reimbursable products, such as laboratory developed tests for in vitro diagnostics. Our customers may generate revenue for these testing services by seeking the necessary approval of their product from the FDA or the Centers for Medicare &amp; Medicaid Services, or CMS, along with coverage and reimbursement from third-party payors, including government health programs and private health plans. The ability of our customers to commercialize diagnostic tests based on our technology will depend in part on the extent to which coverage and reimbursement for these tests will be available from such third-party payors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, molecular testing laboratories have multiple options for reimbursement coding, but we expect that the primary codes used will be the genomic sequencing procedure codes, or GSPs. The American Medical Association, or AMA, added GSPs to its clinical laboratory fee schedule in 2015. In addition, CMS issued a coverage determination providing for the reimbursement of next-generation sequencing for certain cancer diagnostics using an FDA-approved in vitro diagnostic test. Private health plans often follow CMS coverage and reimbursement guidelines to a substantial degree, and it is difficult to predict what CMS will decide with respect to the coverage and reimbursement of any products our customers try to commercialize.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, coverage for molecular diagnostic testing is varied. Countries with statutory health insurance (e.g., Germany, France, The Netherlands) tend to be more progressive in technology adoption with favorable reimbursement for molecular diagnostic testing. In countries such as the United Kingdom with tax-based insurance, adoption and reimbursement for molecular diagnostic testing is not uniform and is influenced by local budgets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ultimately, coverage and reimbursement of new products is uncertain, and whether laboratories that use our instruments to develop their own products will attain coverage and adequate reimbursement is unknown. In the United States, there is no uniform policy for determining coverage and reimbursement. Coverage can differ from payor to payor, and the process for determining whether a payor will provide coverage may be separate from the process for setting the reimbursement rate. In addition, the U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls and restrictions on reimbursement. We cannot be sure that coverage will be available for any diagnostic tests based on our technology, and, if coverage is available, the level of payments. Reimbursement may impact the demand for those tests. If coverage and reimbursement is not available or is available only to limited levels, our customers may not be able to successfully commercialize any tests for which they receive marketing authorization.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare legislative or regulatory reform measures may have a negative impact on our business and results of operations.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, the ACA became law. The ACA is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. For example, the ACA contained a 2.3% excise tax on certain entities that manufacture or import medical devices offered for sale in the United States, with limited exceptions, which has been permanently eliminated as part of the 2020 spending package.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been executive, judicial and Congressional challenges to certain aspects of the ACA. For example, while Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, starting January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry health insurance. On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA was unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 16, 2022, President Biden signed the Inflation Reduction Act, or the IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the coverage gap under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. In addition, on April 1, 2014, the Protecting Access to Medicare Act of 2014, or PAMA, was signed into law, which, among other things, significantly altered the payment methodology under the Medicare Clinical Laboratory Fee Schedule, or CLFS. PAMA requires certain laboratories performing clinical diagnostic laboratory tests to report to CMS the amounts paid by private payors for laboratory tests. Such reporting has been subject to numerous delays. Beginning on January 1, 2018, CMS has begun using reported private payor pricing to periodically revise payment rates under the CLFS. Based on current law, between January 1, 2023 and March 31, 2023, applicable laboratories will be required to report on data collected during January 1, 2019 and June 30, 2019. This data will be utilized to determine 2024 to 2026 CLFS rates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and additional downward pressure on the price that we or our collaborators will receive for any cleared or approved product. Any reduction in payments from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent our customers from successfully commercializing any tests for which they receive approval, which could prevent us from being able to generate revenue and attain profitability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Complying with numerous regulations pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the Clinical Laboratory Improvement Amendment of 1988, or CLIA, which is a federal law regulating clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. Our clinical laboratory is located in Utah and must be certified under CLIA in order for us to perform testing on human specimens. CLIA is intended to ensure the quality and reliability of clinical laboratories in the United States by mandating specific standards in the areas of personnel qualifications, administration, and participation in proficiency testing, patient test management, quality control, quality assurance and inspections. We have a current certificate of compliance under CLIA to perform cytogenetics. To renew this certificate, we are subject to survey and inspection every two years. Moreover, CLIA inspectors may make periodic inspections of our clinical laboratory outside of the renewal process. The failure to comply with CLIA requirements can result in enforcement actions, including the revocation, suspension, or limitation of our CLIA certificate of compliance, as well as a directed plan of correction, state on-site monitoring, civil money penalties, civil injunctive suit and/or criminal penalties. We must maintain CLIA compliance and certification to be eligible to bill for assays provided to Medicare beneficiaries. If we were to be found out of compliance with CLIA program requirements and subjected to sanctions, our business and reputation could be harmed. Even if it were possible for us to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hold laboratory licenses from the states of California, Pennsylvania, and Maryland, to test specimens from patients in those states or received from ordering physicians in those states. Other states may have similar requirements or may adopt similar requirements in the future. Finally, we may be subject to regulation in foreign jurisdictions if we seek to expand international distribution of our assays outside the United States. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to lose our CLIA certification or state laboratory licenses, whether as a result of a revocation, suspension or limitation, we would no longer be able to offer our assays, which would limit our revenues and harm our business. If we were to lose, or fail to obtain, a license in any other state where we are required to hold a license, we would not be able to test specimens from those states. Additionally, if we were to lose our CAP accreditation, our reputation for quality, as well as our business, financial condition and results of operations, could be significantly and adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to federal and state healthcare fraud and abuse laws and other federal and state laws applicable to our business activities, including our marketing practices. If we are unable to comply, or have not complied, with such laws, we could face substantial penalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to various federal and state fraud and abuse laws, including, without limitation, the federal and state anti-kickback statutes and false claims laws. These laws may impact, among other things, our sales and marketing and education programs, and our financial and business relationships with health care professionals. The laws that may affect our ability to operate include, but are not limited to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, or the AKS, which prohibits, among other things, any person or entity from knowingly and willfully soliciting, receiving, offering or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of an item or service reimbursable, in whole or in part, under a federal healthcare program, such as </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Medicare and Medicaid programs. The term &#8216;&#8216;remuneration&#8217;&#8217; has been broadly interpreted to include anything of value. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, however these are drawn narrowly. Additionally, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the federal False Claims Act, or the FCA;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Stark Law, which prohibits a physician from making a referral for certain designated health services covered by the Medicare or Medicaid program, including laboratory and pathology services, if the physician or an immediate family member of the physician has a financial relationship with the entity providing the designated health services and prohibits that entity from billing, presenting or causing to be presented a claim for the designated health services furnished pursuant to the prohibited referral, unless an exception applies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws and civil monetary penalty laws, such as the FCA, which can be enforced by private citizens through civil qui tam actions, prohibits individuals or entities from, among other things, knowingly presenting, or causing to be presented false, fictitious or fraudulent claims for payment or approval by the federal government, including federal health care programs, such as Medicare and Medicaid, and knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim, or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Eliminating Kickbacks in Recovery Act of 2018, or EKRA, prohibits payments for referrals to recovery homes, clinical treatment facilities, and laboratories. EKRA&#8217;s reach extends beyond federal health care programs to include private insurance (i.e., it is an &#8220;all payor&#8221; statute). For purposes of EKRA, the term &#8220;laboratory&#8221; is defined broadly and without reference to any connection to substance use disorder treatment. The law includes a limited number of exceptions, some of which closely align with corresponding federal Anti-Kickback Statute exceptions and safe harbors, and others that materially differ;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which, among other things, imposes criminal liability for executing or attempting to execute a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, in connection with the delivery of or payment for healthcare benefits, items or services. Like the AKS, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, which imposes privacy, security and breach reporting obligations with respect to individually identifiable health information upon entities subject to the law, such as health plans, healthcare clearinghouses and certain healthcare providers, known as covered entities, and their respective business associates, individuals or entities that perform services for them that involve individually identifiable health information as well as their covered subcontractors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state laws that prohibit other specified practices, such as billing physicians for tests that they order or providing tests at no or discounted cost to induce physician or patient adoption; insurance fraud laws; waiving coinsurance, co-payments, deductibles, and other amounts owed by patients; billing a state Medicaid program at a price that is higher than what is charged to one or more other third-party payors employing, exercising control over or splitting professional fees with licensed professionals in violation of state laws prohibiting fee splitting or the corporate practice of medicine and other professions; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prohibition on reassignment of Medicare claims, which, subject to certain exceptions, precludes the reassignment of Medicare claims to any other party;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by any non-governmental third-party payors, including private insurers; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal, state, local and foreign laws that govern the data privacy and security of health information or personally identifiable information in certain circumstances, including state health information privacy and data breach notification laws which govern the collection, use, disclosure, and protection of health-related and other personal data, </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a clinical laboratory, our business practices may face additional scrutiny from government regulatory agencies such as the Department of Justice, the U.S. Department of Health and Human Services Office of Inspector General, or OIG, and CMS. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain arrangements between clinical laboratories and referring physicians have been identified in fraud alerts issued by the OIG as implicating the AKS. The OIG has stated that it is particularly concerned about these types of arrangements because the choice of laboratory, as well as the decision to order laboratory tests, typically are made or strongly influenced by the physician, with little or no input from patients. Moreover, the provision of payments or other items of value by a clinical laboratory to a referral source could be prohibited under the Stark Law unless the arrangement meets all criteria of an applicable exception. The government has been active in enforcement of these laws as they apply to clinical laboratories.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into consulting and scientific advisory board arrangements, speaking arrangements and clinical research agreements with physicians and other healthcare providers, including some who could influence the use of our products. Although we believe that these have been structured in compliance with applicable laws, because of the complex and far-reaching nature of these laws, regulatory agencies may view these transactions as prohibited arrangements that must be restructured, or discontinued, or for which we could be subject to other significant penalties. We could be adversely affected if regulatory agencies interpret our financial relationships with providers who may influence the ordering of and use of our products to be in violation of applicable laws.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations is costly. If our operations are found to be in violation of any of these laws, we may be subject to significant penalties, including, without limitation, civil, criminal, and administrative penalties, damages, fines, disgorgement, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs, additional integrity oversight and reporting obligations, imprisonment, contractual damages, and reputational harm, any of which could adversely affect our ability to operate our business and our results of operations. If any of the physicians or other healthcare providers or entities with whom we do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, sales of our products outside of the United States will subject us to similar foreign regulatory requirements, all of which are far-reaching and complex, and our failure to comply with such regulatory requirements could result in substantial penalties and have a material adverse effect on our business.</span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_127"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to intellectual property</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect our intellectual property, it may reduce our ability to maintain any technological or competitive advantage over our competitors and potential competitors, and our business may be harmed. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on patent protection as well as trademark, copyright, trade secret and other intellectual property rights protection and contractual restrictions to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We have developed a global patent portfolio that includes more than 160 issued patents or allowed applications across approximately 35 patent families that are either owned or exclusively licensed. The owned and licensed patent families contain issued patents and pending applications that relate to devices, systems, and methods for macromolecular analysis, isolation and purification of molecules, genetic testing, computer software systems and reflect our active and ongoing research programs. We also were the assignee of approximately 97 pending patent applications and granted patents in particular jurisdictions outside the United States. If we fail to protect and/or maintain our intellectual property, third parties may be able to compete more effectively against us, we may lose our technological or competitive advantage, and/or we may incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure investors that any of our currently pending or future patent applications will result in granted patents, and we cannot predict how long it will take for such patents to issue, if at all. It is possible that, for any of our patents that have issued or that may issue in the future, our competitors may design their products, technologies or services around our patented technologies. Further, we cannot assure investors that other parties will not challenge any patents granted to us, or that courts or regulatory agencies will hold our patents to be valid, enforceable, and/or infringed. We cannot guarantee investors that we will be successful in defending challenges made against our patents and patent applications. Any successful third-party challenge or challenges to our patents could result in the unenforceability or invalidity of such patents, or such patents being interpreted narrowly and/or in a manner adverse to our interests. Our ability to establish or maintain a technological or competitive advantage over our competitors and/or market entrants may be diminished because of these uncertainties. For these and other reasons, our intellectual property may not provide us with any competitive advantage. For example: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors might not have been the first to make the inventions claimed or disclosed by our pending patent applications or issued patents;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we may have to participate in interference proceedings or derivation proceedings declared by the U.S. Patent and Trademark Office, or the USPTO, which could result in substantial cost to us, and could possibly result in a loss or narrowing of patent rights. No assurance can be given that our or our licensors&#8217; patent applications or granted patents will have priority over any other patent or patent application involved in such a proceeding, or will be held valid as an outcome of the proceeding;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other parties may independently develop similar or alternative products and technologies or duplicate any of our products and technologies, which can potentially impact our market share, revenue, and goodwill, regardless of whether intellectual property rights are successfully enforced against these other parties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our owned or licensed pending patent applications will not result in granted patents, and even if such pending patent applications issue as patents, they may not provide intellectual property protection of commercially viable products or product features, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties, patent offices, and/or the courts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unaware of or unfamiliar with prior art and/or interpretations of prior art that could potentially impact the validity or scope of our patents or pending patent applications, or patent applications that we intend to file; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we take efforts to enter into agreements with employees, consultants, collaborators, and, as applicable, advisors to confirm ownership and chain of title in intellectual property rights. However, an inventorship or ownership dispute could arise that may permit one or more third parties to practice or enforce our intellectual property rights, including possible efforts to enforce rights against us; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may elect not to maintain or pursue intellectual property rights that, at some point in time, may be considered relevant to or enforceable against a competitor; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary products and technologies that are patentable, or we may develop additional proprietary products and technologies that are not patentable;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents or other intellectual property rights of others may have an adverse effect on our business; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we apply for patents relating to our products and technologies and uses thereof, as we deem appropriate. However, we or our representatives or their agents may fail to apply for patents on important products and technologies in a timely fashion or at all, or we or our representatives or their agents may fail to apply for patents in potentially relevant jurisdictions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent our intellectual property offers inadequate protection, or is found to be invalid or unenforceable, we would be exposed to a greater risk of direct or indirect competition. If our intellectual property does not provide adequate coverage of our competitors&#8217; products, technologies or services, our competitive position could be adversely affected, as could our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, to the extent that computation methods implemented by software included in our products or technologies are not protected by our patents, our dependence on copyright and trade secret protection may not provide adequate protection. In addition, the Supreme Court&#8217;s ruling in Alice Corporation Pty. Ltd. v. CLS Bank International has narrowed the scope of patent protection available for computational methods in certain circumstances. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The measures that we use to protect the security of our intellectual property and other proprietary rights may not be adequate, which could result in the loss of legal protection for, and thereby diminish the value of, such intellectual property and other rights.* </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to pursuing patents on our technologies, we also rely upon trademarks, trade secrets, copyrights and unfair competition laws, as well as license agreements and other contractual provisions, to protect our intellectual property and other proprietary rights. Despite these measures, any of our intellectual property rights could be challenged, invalidated, circumvented or misappropriated. In addition, we take steps to protect our intellectual property and proprietary technologies by entering into confidentiality agreements and intellectual property assignment agreements with our employees, consultants, corporate partners and, when needed, our advisors. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets and/or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure. Moreover, if a party having an agreement with us has an overlapping or conflicting obligation to a third party, our rights in and to certain intellectual property could be undermined. Monitoring unauthorized and inadvertent disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time consuming, the outcome would be unpredictable, and any remedy may be inadequate. In addition, courts outside the United States may be less willing to protect trade secrets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, competitors could purchase our products or technologies and attempt to replicate and/or improve some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design their </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products or technologies around our protected technologies or develop their own competitive technologies that fall outside of our intellectual property rights. If our intellectual property does not adequately protect our market share against competitors&#8217; products or technologies, services and methods, our competitive position could be adversely affected, as could our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have rights in some intellectual property that has been discovered through government funded programs and thus is subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements, and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights, subject us to expenditure of resources with respect to reporting requirements, and limit our ability to contract with non-U.S. manufacturers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the intellectual property rights assigned to us and/or in-licensed to us have been generated through the use of U.S. government funding and are therefore subject to certain federal regulations. For example, all of the intellectual property rights licensed to us under our license agreement with Princeton University have been generated using U.S. government funds. As a result, the U.S. government has certain rights to intellectual property embodied in our current or future products pursuant to the Bayh-Dole Act of 1980. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third-party if the government determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if we fail, or the applicable licensor fails, to disclose the invention to the government, elect title, and file an application to register the intellectual property within specified time limits. In addition, the U.S. government may acquire title to these inventions in any country in which a patent application is not filed within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us, or the applicable licensor, to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that, under the circumstances, domestic manufacture is not commercially feasible. This preference for U.S. manufacturing may limit our ability to license the applicable patent rights on an exclusive basis under certain circumstances. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we enter into future arrangements involving government funding, and we make or license inventions that result from such funding, intellectual property rights to such discoveries may be subject to the applicable provisions of the Bayh-Dole Act. To the extent any of our current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. Any exercise by the government of certain of its rights could harm our competitive position, business, financial condition, results of operations and prospects. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on technology that is licensed to us by Princeton University. Any loss of our rights to this technology could prevent us from selling our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some technology that relates to analysis of nucleic acids is licensed exclusively to us from Princeton University, or Princeton. We do not own the patents that underlie this license. Our rights to use this technology and employ the inventions claimed in the licensed patents are subject to the continuation of and compliance with the terms of the license. Our principal obligations under our license agreement with Princeton are as follows: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">royalty payments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">annual maintenance fees;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">using commercially reasonable efforts to develop and sell a product using the licensed technology and developing a market for such product;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">paying and/or reimbursing fees related to prosecution, maintenance and enforcement of patent rights; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">providing certain reports. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we breach any of these obligations, Princeton may have the right to terminate or modify the license, which could result in our being unable to develop, manufacture and sell our products or a competitor gaining access to the relevant technology. Termination or certain modifications of our license agreement with Princeton would have a material adverse effect on our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are a party to a number of other agreements that include licenses to intellectual property, including non-exclusive licenses. We may need to enter into additional license agreements in the future. Our business could suffer, for example, if any current or future licenses terminate, if the licensors fail to abide by the terms of the license, if the licensed </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we have done previously, we may need or may choose to obtain licenses and/or acquire intellectual property rights from third parties to advance our research or begin commercialization of our current or future products or services, and we cannot provide any assurances that third-party patents do not exist that might be enforced against our current or future products or services in the absence of such a license. We may fail to obtain any of these licenses or intellectual property rights on commercially reasonable terms. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected products or services, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing of intellectual property is important to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether and the extent to which our technologies and processes infringe any intellectual property of the licensor that is not subject to the licensing agreement; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether to take action to enforce any intellectual property rights against an allegedly infringing product or process of a third-party; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our right to sublicense patent and other rights to third parties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations with respect to the use of licensed technology in relation to our development and commercialization of our products and services, and what activities satisfy those diligence obligations; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ownership of inventions and know-how, such as intellectual property resulting from the joint creation or use of intellectual property by our licensors and us and our partners. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product or service, or the dispute may have an adverse effect on our results of operation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to agreements pursuant to which we in-license intellectual property, we may in the future grant licenses under our intellectual property, or sell certain intellectual property. Like in-licenses, out-licenses can be complex and disputes may arise between us and our licensees, such as the types of disputes described above. Moreover, licensees may breach their obligations, or we may be exposed to liability due to our failure or alleged failure to satisfy our obligations. Any such occurrence could have an adverse effect on our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or any of our partners is sued for infringing intellectual property rights of third parties, it would be costly and time consuming, and an unfavorable outcome in that litigation could have a material adverse effect on our business.* </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success also depends on our ability to develop, manufacture, market and sell our products and technologies and perform our services without infringing the proprietary rights of third parties. Numerous U.S. and foreign-issued patents and pending patent applications owned by third parties exist in the fields in which we are developing manufacturing, marketing and selling products and technologies and performing services. As part of a business strategy to impede our successful commercialization and entry into new markets, competitors may allege that our products, technologies and/or services infringe their intellectual property rights. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could incur substantial costs and divert the attention of our management and technical personnel in defending ourselves against claims of infringement made by third parties. Any adverse ruling by a court or administrative body, or perception of an adverse ruling, may have a material adverse impact on our ability to conduct our business and our finances. Moreover, third parties making claims against us may be able to obtain injunctive relief against us, which could block our ability to offer one or more products, technologies or services and could result in a substantial award of damages against us. In addition, since we sometimes indemnify customers, collaborators or licensees, we may have additional liability in connection with any infringement or alleged infringement of third-party intellectual property. Intellectual property litigation can be very expensive, and we may not have the financial means to defend ourselves or our customers, collaborators and licensees. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications can take many years to issue, there may be pending applications, some of which are unknown to us, that may result in issued patents upon which our products, services or proprietary technologies may infringe. Moreover, we may fail to identify issued patents of relevance or incorrectly conclude that an issued patent is invalid or not infringed any of our products, services or proprietary technologies. There is a substantial amount of litigation involving patents and other intellectual </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">property rights in our industry. If a third party claims that we or any of our licensors, customers or collaboration partners infringe upon a third-party&#8217;s intellectual property rights, we may have to: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to obtain licenses that may not be available on commercially reasonable terms, if at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">abandon any product or service alleged or held to infringe, or redesign our products or technologies or processes to avoid potential assertion of infringement; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pay substantial damages including, in exceptional cases, treble damages and attorneys&#8217; fees, which we may have to pay if a court decides that the product or proprietary technology at issue infringes upon or violates the third-party&#8217;s rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pay substantial royalties or fees for, or grant cross-licenses to, our technology; or </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">defend litigation or administrative proceedings that may be costly whether we win or lose, and which could result in a substantial diversion of our financial and management resources. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents or the patents we license in. In the event of infringement or unauthorized use, we may file one or more infringement lawsuits, which can be expensive and time-consuming. An adverse result in any such litigation proceedings could put one or more of our patents at risk of being invalidated, being found to be unenforceable, and/or being interpreted narrowly and could put our patent applications at risk of not issuing and/or could impact the validity or enforceability positions of our other patents or those we license. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our competitors are larger than we are and have substantially greater resources. They are, therefore, likely to be able to sustain the costs of complex patent litigation longer than we could. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations, continue our internal research programs, in-license needed technology, pursue, obtain or maintain intellectual property rights, or enter into development partnerships that would help us bring our products, technologies or services to market. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patent litigation can be very costly and time-consuming. An adverse outcome in such litigation or proceedings may expose us or any of our future development partners to loss of our proprietary position, expose us to significant liabilities, or require us to seek licenses that may not be available on commercially acceptable terms, if at all. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our issued patents could be found invalid or unenforceable if challenged in court or at the Patent Office or other administrative agency, which could have a material adverse impact on our business.* </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any of our partners were to initiate legal proceedings against a third-party to enforce a patent related to one of our products, technologies or services, the defendant in such litigation could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, as are validity challenges by the defendant against the subject patent or other patents before the USPTO. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement, failure to meet the written description requirement, indefiniteness, and/or failure to disclose the best mode or to claim patent eligible subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent intentionally withheld material information from the USPTO, or made a misleading statement, during prosecution. Additional grounds for an unenforceability assertion include an allegation of misuse or anticompetitive use of patent rights, and an allegation of incorrect inventorship with deceptive intent. Third parties may also raise similar claims before the USPTO even outside the context of litigation. The outcome is unpredictable following legal assertions of invalidity and unenforceability. With respect to the validity question, for example, we cannot be certain that no invalidating prior art existed of which we and the patent examiner were unaware during prosecution. These assertions may also be based on information known to us or the USPTO. If a defendant or third party were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the claims of the challenged patent. Such a loss of patent protection would or could have a material adverse impact on our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed alleged trade secrets of their other clients or former employers to us, and/or that their other clients or former employers allegedly have rights in our intellectual property, which could subject us to costly litigation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the life sciences industry, we engage the services of consultants and independent contractors to assist us in the development of our products, technologies and services. Many of these consultants and independent contractors were previously employed at, or may have previously or may be currently providing consulting or other services to, universities or other technology, biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">become subject to claims that our company, a consultant or an independent contractor inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. We may similarly be subject to claims stemming from similar actions of an employee, such as one who was previously employed by another company, including a competitor or potential competitor. We may become subject to claims that one or more current or former employees, consultants, advisors, or independent contractors of ours owns rights in our intellectual property and/or has assigned or is under an obligation to assign rights in our intellectual property to another party. This may include a competitor of ours. If a competitor has rights in our patents, the competitor or a licensee or related entity of the competitor may be able to make, use, sell, import, and/or export the patented technology without liability to us under our patents or the patents we license. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team. If we were not successful, we could lose valuable intellectual property rights. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally enter into confidentiality and intellectual property assignment agreements with our employees, consultants, contractors, and, as applicable, advisors. These agreements generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, those agreements may not be honored and may not effectively assign or may be alleged to ineffectively assign intellectual property rights to us. For example, even if we have a consulting agreement in place with an academic advisor pursuant to which such academic advisor is required to assign any inventions developed in connection with providing services to us, such academic advisor may not have the right to assign such inventions to us, as it may conflict with his or her obligations to assign all such intellectual property to his or her employing institution. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we sometimes enter into agreements where we provide services to third parties, such as customers. Under such circumstances, our agreements may provide that certain intellectual property that we conceive in the course of providing those services is assigned to the customer. In those cases, we may not be able to use that particular intellectual property in, for example, our work for other customers without a license. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world, which could materially and negatively affect our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, maintaining, and defending patents on current and future products, technologies and services in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, regardless of whether we are able to prevent third parties from practicing our inventions in the United States, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not pursued and obtained patent protection to develop their own products, technologies or services, and further, may export otherwise infringing products or technologies to territories where we have patent protection, but enforcement is not as strong as it is in the United States. These products, technologies or services may compete with our products, technologies or services and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Even if we pursue and obtain issued patents in particular jurisdictions, our patent claims or other intellectual property rights may not be effective or sufficient to prevent third parties from so competing. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patents or marketing of competing products, technologies or services in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license and may adversely impact our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we and our partners also face the risk that our products or components thereof are imported, reimported, or exported into markets with relatively higher prices from markets with relatively lower prices, which would result in a decrease </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of sales and any payments we receive from the affected market. Recent developments in U.S. patent law have made it more difficult to stop these and related practices based on theories of patent infringement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our products or technologies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other life science industry companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents involve both technological complexity and legal complexity. Therefore, obtaining and enforcing patents is costly, time-consuming and inherently uncertain. In addition, the America Invents Act, or the AIA, became effective on March 16, 2013. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An important change introduced by the AIA is that the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third-party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent claiming or disclosing an invention of ours even if we had made the invention before it was made by the third-party. This will require us to be cognizant going forward of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions. Additionally, there can be a trade-off between obtaining an earlier filing date, and waiting to obtain additional data and/or further refine a patent application. In some circumstances, the effects of a decision to pursue an earlier filing or a later filing will not be known until prior art or third-party activities are subsequently discovered, such as by the USPTO or by a third-party seeking to challenge patent rights. These circumstances may apply, for example, to patent applications prepared and filed around the time of the implementation of the AIA, or with a priority application that preceded the implementation of the AIA. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among some of the other changes introduced by the AIA are changes that limit where a patent holder may file a patent infringement suit and providing additional opportunities for third parties to challenge an issued patent in the USPTO. This applies to all of our owned and in-licensed U.S. patents, even those issued before March 16, 2013. Because of a lower standard for evidence in USPTO proceedings compared to the standard for evidence in U.S. federal courts necessary to invalidate a patent claim, a third-party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a court action. Accordingly, a third-party may try to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third-party in court. The AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. In addition, the contours of the laws under the AIA are subject to further judicial interpretation and/or legislative changes. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years, such as Impression Products, Inc. v. Lexmark International, Inc., Association for Molecular Pathology v. Myriad Genetics, Inc., Mayo Collaborative Services v. Prometheus Laboratories, Inc. and Alice Corporation Pty. Ltd. v. CLS Bank International, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with our ability to obtain patents in the future, this combination of events has created uncertainty as to the value of patents, once obtained, including patents in the molecular biology analysis and diagnostic space in particular. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. In some cases, our licensors may be responsible for these payments, thereby decreasing our control over compliance with these requirements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">registered trademarks. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of third-party open source software components in our products or our future products or technologies, and failure to comply with the terms of the underlying open source software licenses could restrict our ability to sell such products or technologies. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Use and distribution of open source software may entail greater risks than use of third-party commercial software, as open source licensors generally do not provide warranties or other contractual protections regarding infringement claims or the quality of the code. Some open source licenses may contain requirements that we make available source code for modifications or derivative works we create based upon the type of open source software we use. If we combine our proprietary software with open source software in a certain manner, we could, under certain open source licenses, be required to release the source code of our proprietary software to the public. This would allow our competitors to create similar products with less development effort and time, and ultimately could result in a loss of product sales. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we intend to monitor any use of open source software to avoid subjecting our products to conditions, we do not intend, the terms of many open source licenses have not been interpreted by U.S. courts, and there is a risk that any such licenses could be construed in a way that could impose unanticipated conditions or restrictions on our ability to commercialize our products. Moreover, we cannot assure investors that our processes for controlling our use of open source software in our products will be effective. If we are held to have breached the terms of an open source software license, we could be required to seek licenses from third parties to continue offering our products on terms that are not economically feasible, to re-engineer our products, to discontinue the sale of our products if re-engineering could not be accomplished on a timely basis, or to make generally available, in source code form, our proprietary code, any of which could adversely affect our business, operating results, and financial condition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use third-party software that may be difficult to replace or cause errors or failures of our products that could lead to lost customers or harm to our reputation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use software licensed from third parties in our products. In the future, this software may not be available to us on commercially reasonable terms, or at all. Any loss of the right to use any of this software could result in delays in the production of our products until equivalent technology is either developed by us, or, if available, is identified, obtained and integrated, which could harm our business. In addition, any errors or defects in third-party software or other third-party software failures could result in errors or defects or cause our products to fail, which could harm our business and be costly to correct. Many of these providers attempt to impose limitations on their liability for such errors, defects or failures, and, if enforceable, we may have additional liability to our customers or third-party providers that could harm our reputation and increase our operating costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to maintain our relationships with third-party software providers and to seek software from such providers that does not contain any errors or defects. Any failure to do so could adversely impact our ability to deliver reliable products to our customers and could harm our results of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Numerous factors may limit any potential competitive advantage provided by our intellectual property rights.* </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. Moreover, if a third party has intellectual property rights that cover or impact our use of our technologies, we may not be able to fully use or extract value from our intellectual property rights. For example: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to develop and/or use technologies that are similar to our technologies or aspects of our technologies but that does not cover the claims of any our patents or patents that may issue from our patent applications or those we license;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or the licensor of our licensed-in patents might not have been the first to make the inventions disclosed and/or claimed in a pending patent application that we own or license;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or the licensor of our licensed-in patents might not have been the first to file patent applications disclosing and/or claiming an invention;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies without infringing our or our licensors&#8217; intellectual property rights; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pending patent applications that we own or license may not lead to issued patents or may not result in the claims that we want (for example, as to the scope of issued claims, if any);</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patents, if issued, that we own or license may not provide us with any competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by our competitors or other third parties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties may compete with us in jurisdictions where we do not pursue and obtain patent protection; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to obtain and/or maintain necessary or useful licenses on reasonable terms or at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights over that intellectual property; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to maintain the confidentiality of our trade secrets or other proprietary information;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop or in-license additional proprietary technologies that are patentable; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents or other intellectual property of others may have an adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could significantly harm our business and results of operations. </span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_130"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to ownership of our securities </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our securities has been and may in the future be volatile or may decline regardless of our operating performance, and you could lose all or part of your investment.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been and may continue to be volatile. The daily closing market price for our common stock has varied significantly in the last 12 months, ranging between a high price of $3.60 on August&#160;15, 2022 and August&#160;12, 2022 and a low price of $0.62 on May&#160;2, 2023. During this time, the price per share of common stock has ranged from an intra-day low of $0.60 per share to an intra-day high of $4.35 per share. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our securities is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the risk factors discussed in this section and elsewhere in our Quarterly Report on Form 10-Q, these factors include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercial progress in marketing and selling our genome analysis systems, including sales and revenue trends;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in laws or regulations applicable to our systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse developments related to our laboratory facilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased competition in the diagnostics services industry;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure or funding of research at academic and governmental research institutions, as well as pharmaceutical, biotechnology and contract research companies, including changes that would affect their ability to purchase our products, consumables and technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure to obtain and/or maintain coverage and adequate reimbursement for our Bionano Laboratories products and diagnostic assays and patients&#8217; willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure of our customers to obtain and/or maintain coverage and adequate reimbursement for their services using our Saphyr systems, Ionic Purification systems or our NxClinical software;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse developments concerning our manufacturers and suppliers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to establish future collaborations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key scientific or management personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of new testing services offered by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of significant acquisitions, dispositions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively manage our growth;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and growth, if any, of our targeted markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure or discontinuation of any of our product development and research programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated variations in quarterly operating results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our cash position;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to meet the estimates and projections of the investment community and securities analysts or that we may otherwise provide to the public;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publication of research reports about us or our industries or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the market valuations of similar companies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overall performance of the equity markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issuances of debt or equity securities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our securities by us or our stockholders in the future;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our securities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting practices;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ineffectiveness of our internal controls;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">data breaches of our company, providers, vendors or customers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments relating to proprietary rights, including our ability to adequately protect our proprietary rights in our technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">natural disasters, infectious diseases, conflict, including the ongoing military conflict between Russia and Ukraine and the related sanctions, civil unrest, epidemics or pandemics including COVID-19, outbreaks, resurgences or major catastrophic events; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general political and economic conditions, including recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our cost savings initiative announced in May 2023</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the announcement of the reverse stock split proposal to be voted on at our 2023 annual meeting of stockholders; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other events or factors, many of which are beyond our control.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and the market for life science technology companies in particular (including companies in the diagnostic, genomic and biotechnology related sectors), have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our securities, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. Because of the volatility of our stock price, we may become the target of securities litigation in the future. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we implement a reverse stock split, we may not achieve the intended results and the market price of our common stock may be materially and negatively impacted.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have submitted a proposal to our stockholders for consideration at our 2023 Annual Meeting of Stockholders to approve a series of alternate amendments to our Amended and Restated Certificate of Incorporation, as amended, to effect, at the option of our board of directors, a reverse stock split of our common stock at a ratio between 1-for-5 and 1-for-10, inclusive, as determined by our board of directors in its sole discretion. Subject to approval by our stockholders, we may file a certificate of amendment to effect the reverse split ratio chosen by our board of directors. We cannot assure you that the reverse stock split proposal will be approved by our stockholders. Further, we cannot assure you that the market price per share of our common stock after the reverse stock split is implemented, if at all, will increase in proportion to the reverse split ratio chosen by our board of directors or that we will achieve any of the other intended results of the reverse stock split, including improved marketability and liquidity of our common stock, maintaining compliance with Nasdaq listing standards and encouraging trading in our common stock by long-term investors. Accordingly, the market price and the value of your investment could be materially and negatively impacted.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The effective increase in the number of shares of our common stock available for issuance as a result of the reverse stock split, if approved and implemented, could result in further dilution to our existing stockholders and have antitakeover implications.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of authorized shares of our common stock will remain the same as before the reverse stock split discussed in the above risk factor, if approved and implemented. The reverse stock split as proposed will effectively increase the number of shares of our common stock (or securities convertible or exchangeable for our common stock) available for issuance by </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreasing the number of shares of our common stock issued and outstanding. The additional available shares would be available for issuance from time to time at the discretion of our board of directors when opportunities arise, without further stockholder action, except as may be required for a particular transaction by law, the rules of any exchange on which our securities may then be listed, or other agreements or restrictions. Any issuance of additional shares of our common stock would increase the number of outstanding shares of our common stock and (unless such issuance was pro-rata among all existing stockholders) the percentage ownership of existing stockholders would be diluted accordingly. In addition, any such issuance of additional shares of our common stock could have the effect of diluting the earnings per share and book value per share of outstanding shares of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, such effective increase in the number of shares of our common stock available for issuance could, under certain circumstances, have anti-takeover implications. For example, without further stockholder approval, our board of directors could adopt a &#8220;poison pill&#8221; which would, under certain circumstances related to an acquisition of our securities that is not approved by the board of directors, give certain holders the right to acquire additional shares of our common stock at a low price. Our board of directors also could strategically sell shares of common stock in a private transaction to purchasers who would oppose a takeover or favor the current board of directors. Although the proposed reverse stock split has been prompted by business and financial considerations, you should be aware the proposed reverse stock split proposal could facilitate future efforts by us to deter or prevent changes in control, including transactions in which you might otherwise receive a premium for your shares over then current market prices.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to comply with the applicable continued listing requirements or standards of The Nasdaq Capital Market, Nasdaq could delist our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to publicly or privately sell equity securities and the liquidity of our common stock could be adversely affected if we are delisted from The Nasdaq Capital Market or if we are unable to transfer our listing to another stock market. In order to maintain this listing, we must satisfy minimum financial and other continued listing requirements and standards, including a requirement to maintain a minimum bid price of the Company&#8217;s common stock of $1.00 per share.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, we have failed to comply with the per share minimum required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the &#8220;Minimum Bid Price Requirement&#8221;). As of April 24, 2023, the closing price of our common stock was $0.78. If the price of our common stock closes below $1.00 for 30 consecutive business days, we would receive notice from Nasdaq that we are not in compliance with the Minimum Bid Price Requirement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have regained compliance with Nasdaq continued listing requirements, if we fail to satisfy the Minimum Bid Price Requirement or another Nasdaq requirement for continued listing, Nasdaq staff could provide notice that our common stock may become subject to delisting. We cannot assure you that such an event will not happen and, if it does, that we will be able to regain compliance. Accordingly, there can be no guarantee that we will be able to maintain our Nasdaq listing. If our common stock is delisted by Nasdaq, it could lead to a number of negative implications, including an adverse effect on the price of our common stock, increased volatility in our common stock, reduced liquidity in our common stock, the loss of federal preemption of state securities laws and greater difficulty in obtaining financing. In addition, delisting of our common stock could deter broker-dealers from making a market in or otherwise seeking or generating interest in our common stock, could result in a loss of current or future coverage by certain sell-side analysts and might deter certain institutions and persons from investing in our securities at all. Delisting could also cause a loss of confidence of our customers, collaborators, vendors, suppliers and employees, which could harm our business and future prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers, directors and 5% stockholders and their affiliates currently beneficially own a significant percentage of our outstanding voting stock. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our securities that you may feel are in your best interest as one of our stockholders.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain effective internal control over financial reporting, we may not be able to accurately report our financial results or file our periodic reports in a timely manner, which may cause adverse effects on our business and may cause investors to lose confidence in our reported financial information and may lead to a decline in our stock price.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal controls over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with accounting principles generally accepted in the United States. Effective internal control over financial reporting is necessary for us to provide reliable financial reports in a timely manner. The rules governing the standards that must be met for </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that we will not experience future material weaknesses or that we will be able to successfully remediate any such material weakness in a timely manner or at all. If our independent registered public accounting firm is subsequently unable to conclude that our internal control over financial reporting is effective, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our securities could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities and we could be subject to shareholder litigation. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in connection with our Annual Report on Form 10-K for the period ended December 31, 2021, our independent registered public accounting firm was required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act. As of December 31, 2022, we qualified as a &#8220;non-accelerated filer&#8221; based on the market value of our common stock held by non-affiliates as of June 30, 2022 and revenue for the fiscal year ended December 31, 2021. For as long as we are a non-accelerated filer, we will not be required to obtain an independent assessment of the effectiveness of our internal controls. An independent assessment of the effectiveness of our internal controls could detect problems that our management&#8217;s assessment might not. Consequently, if we choose not to obtain an independent assessment, there is a risk that we may not detect problems with our internal controls that otherwise might have been detected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a smaller reporting company, and the reduced reporting requirements applicable to smaller reporting companies could make our securities less attractive to investors.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, the market value of our common stock held by non-affiliates exceeded $700.0 million, causing us to no longer qualify as a &#8220;smaller reporting company&#8221; beginning with our first Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022. However, as of June 30, 2022, the market value of our common stock held by non-affiliates did not exceed $560.0 million and our revenue for the fiscal year ended December 31, 2021 did not exceed $100.0 million. As a result, we once again qualified as a smaller reporting company effective as of our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2022, although we continued to be a large accelerated filer until the filing of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022. Consequently, we qualify as a smaller reporting company and a non-accelerated filer for our 2023 reporting period, which allows us to take advantage of many exemptions from various reporting requirements that are applicable to other public companies that are not smaller reporting companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, but we still expect to incur substantial legal and financial compliance costs. As we have chosen to avail ourselves of certain scaled disclosure requirements applicable to smaller reporting companies, the content of our disclosures may differ from period to period. We may no longer qualify as a smaller reporting company in the future should the market value of our common stock held by non-affiliates as of the end of the second quarter of any given year once again exceed $700.0 million or our revenue as of the end of any fiscal year exceed $100.0 million. There may be further variance in the content of our disclosures as we avail ourselves of certain scaled disclosure requirements if we subsequently no longer qualify as a smaller reporting company because we would be required to provide the full disclosures required of non-smaller reporting companies. We cannot predict if investors will find our securities less attractive because we rely on these exemptions, which could result in a less active trading market for our securities and increased volatility in the price of our securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A significant portion of our total outstanding shares are restricted from immediate resale but may be sold into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could occur at any time, subject to the restrictions and limitations described below. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly. All of our outstanding shares of common stock are available for sale in the public market, subject only to the restrictions of Rule 144 under the Securities Act in the case of our affiliates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of the date of this Quarterly Report on Form 10-Q, we have filed registration statements on Form S-8 under the Securities Act registering the issuance of an aggregate of 52,867,200 shares of common stock subject to options or other equity awards issued or reserved for future issuance under our equity incentive plans. We also intend to file future registration </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements on Form S-8 under the Securities Act registering the issuance of additional shares of common stock as the number of shares that may be issued under certain employee equity benefit plans automatically increase due to &#8220;evergreen&#8221; provisions. Shares registered under these registration statements on Form S-8 are available for sale in the public market subject to vesting arrangements and exercise of options, the lock-up agreements described above and the restrictions of Rule 144 in the case of our affiliates. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our securities and may prevent or frustrate attempts by our security holders to replace or remove our current management.* </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws, contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement that special meetings of stockholders be called only by the chairman of the board of directors, the chief executive officer, the president or by a majority of the total number of authorized directors; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance notice requirements for stockholder proposals and nominations for election to our board of directors; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our securities to decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our recurring losses, negative cash flows and significant accumulated deficit have raised substantial doubt regarding our ability to continue as a going concern.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have experienced recurring operating losses and negative cash flows from operating activities, and have significant accumulated deficit. We expect to continue to generate operating losses and consume significant cash resources for the foreseeable future. Without additional financing, these conditions raise substantial doubt about our ability to continue as a going concern, meaning that we may be unable to continue operations for the foreseeable future or realize assets and discharge liabilities in the ordinary course of operations. As a result, our financial statements include an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern. If we are unable to obtain sufficient funding, our business, prospects, financial condition and results of operations will be materially and adversely affected and we may be unable to continue as a going concern. If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our consolidated financial statements, and it is likely that investors will lose all or a part of their investment. Future reports from our independent registered public accounting firm may also contain statements expressing doubt about our ability to continue as a going concern. If we seek additional financing to fund our business activities in the future and there remains doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding on commercially reasonable terms or at all.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any derivative action or proceeding brought on our behalf;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a breach of fiduciary duty;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim against us arising under the Delaware General Corporation Law, our amended and restated certificate of incorporation, or our amended and restated bylaws; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim against us that is governed by the internal-affairs doctrine.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section-22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could adversely affect our results of operations and financial condition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for our common stock may not be sustained.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our shares of common stock began trading on The Nasdaq Capital Market on September 21, 2018. Given the limited trading history of our common stock, there is a risk that an active trading market for our shares will not be sustained, which could put downward pressure on the market price of our common stock and thereby affect the ability of our stockholders to sell their shares.</span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_133"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the price of our securities and trading volume could decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our securities will depend in part on the research and reports that securities or industry analysts publish about us or our business. As a newer public company, we have only limited research coverage on our company by equity research analysts. If securities or industry analysts elect not to initiate or continue to provide coverage of our company, the trading price for our securities would likely be negatively impacted. If one or more of the analysts who covers us downgrades our securities or publishes inaccurate or unfavorable research about our business, the price of our securities may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our securities could decrease, which might cause the price of our securities and trading volume to decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales of substantial amounts of our common stock, or the possibility that such sales could occur, could adversely affect the market price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future sales in the public market of shares of our common stock, including shares issued upon exercise of our outstanding stock options, or the perception by the market that these sales could occur, could lower the market price of our common stock or make it difficult for us to raise additional capital.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be negatively affected as a result of actions of activist stockholders, and such activism could impact the trading value of our securities.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders may, from time to time, engage in proxy solicitations or advance stockholder proposals, or otherwise attempt to effect changes and assert influence on our board of directors and management. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results and financial condition. A proxy contest would require us to incur significant legal and advisory fees, proxy solicitation expenses and administrative and associated costs and require significant time and attention by our board of directors and management, diverting their attention from the pursuit of our business strategy. Any perceived uncertainties as to our future direction and control, our ability to execute on our strategy, or changes to the composition of our board of directors or senior management team arising from a proxy contest could lead to the perception of a change in the direction of our business or instability which may result in the loss of potential business opportunities, make it more difficult to pursue our strategic initiatives, or limit our ability to attract and retain qualified personnel and business partners, any of which could adversely affect our business and operating results. If individuals are ultimately elected to our board of directors with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create additional value for our stockholders. We may choose to initiate, or may become subject to, litigation as a result of the proxy contest or matters arising from the proxy contest, which would serve as a further distraction to our board of directors and management and would require us to incur significant additional costs. In addition, actions such as those described above could cause significant fluctuations in our stock price based upon temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities class action litigation could divert our management&#8217;s attention and harm our business and could subject us to significant liabilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock markets have from time to time experienced significant price and volume fluctuations that have affected the market prices for the equity securities of life sciences and biotechnology companies. These broad market fluctuations may cause the market price of our ordinary shares to decline. In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and biopharma companies have experienced significant stock price volatility in recent years. Even if we are successful in defending claims that may be brought in the future, such litigation could result in substantial costs and may be a distraction to our management and may lead to an unfavorable outcome that could adversely impact our financial condition and prospects.</span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_136"></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_139"></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_142"></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i561259e69fbb4552820b7ec56e5dea3a_145"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5. OTHER INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i561259e69fbb4552820b7ec56e5dea3a_148"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;6. EXHIBITS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit21bngo-firstamendme.htm">First Amendment to Agreement and Plan of Merger, dated March 4, 2023, by and between the Company and Soheil Shams, as the Securityholders&#8217; Representative.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1411690/000141169021000004/ex31-arcertificateofincorp.htm">Amended and Restated Certificate of Incorporation, as amended.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1411690/000114036123018454/brhc20051350_ex3-1.htm">Certificate  of Designation of Preferences, Rights and Limitations of Series A Preferred Stock</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518257763/d607608dex32.htm">Amended and Restated Bylaws.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (7)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1411690/000114036123018454/brhc20051350_ex3-2.htm">Amendment to Amended and Restated Bylaws</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518219135/d782664dex41.htm">Form of Common Stock Certificate</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518217313/d782664dex48.htm">Form of Warrant to Purchase Series D-1 Preferred Stock issued to Midcap Financial Trust.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001411690/000119312518249108/d572381dex11.htm">Form of Warrant to Purchase Common Stock Issued to Underwriters (attached to the Underwriting Agreement).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001411690/000119312518249108/d572381dex411.htm">Form of Warrant Certificate (included in Exhibit 4.5).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001411690/000119312518249108/d572381dex411.htm">Form of Warrant Agent Agreement by and between the Registrant and American Stock Transfer &amp; Trust Company LLC, as warrant agent.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518332353/d635375dex41.htm">Form of Warrant to Purchase Common Stock for Service Providers.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000114036119016923/nt10004193x3_ex4-13.htm">Form of Warrant to Purchase Common Stock issued to Investors in October 2019 Public Offering.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1411690/000114036120006739/nt10007734x2_ex4-16.htm">Form of Warrant to Purchase Common Stock issued to Investors in April 2020 Public Offering</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit101amendmentno1tosa.htm">Amendment No. 1 to Sales Agreement, dated March 9, 2023, by and between the Company and Cowen and Company, LLC.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="bngo-20230331xexx311.htm">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="bngo-20230331xexx312.htm">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="bngo-20230331xexx321.htm">Certification of Principal </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="bngo-20230331xexx321.htm">Executive</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="bngo-20230331xexx321.htm"> Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document&#8212;the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.431%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="15" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 23, 2021.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on August 24, 2018.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-225970), as amended.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on November 21, 2018.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;Incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-233828), as amended.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)&#160;&#160;&#160;&#160;Incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-237074), as amended.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)&#160;&#160;&#160;&#160;Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on April 14, 2023.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+             Pursuant to Item 601(b)(10) of Regulation S-K, certain portions of this exhibit have been omitted (indicated by &#8220;[***]&#8221;) because the Company has determined that the information is both not material and is the type that the Company treats as private or confidential.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="i561259e69fbb4552820b7ec56e5dea3a_151"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i561259e69fbb4552820b7ec56e5dea3a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:21pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:50.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.141%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BIONANO GENOMICS, INC.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated:  May&#160;9, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By: /s/ R. Erik Holmlin, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Erik Holmlin, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated:  May&#160;9, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By: /s/ Christopher Stewart</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher Stewart</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101amendmentno1tosa.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i901a91d3d9b7404998659357f229945e_1"></div><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-top:9pt;text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">AMENDMENT NO. 1 TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">SALES AGREEMENT </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 9, 2023 </font></div><div style="margin-top:9pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Amendment No.&#160;1 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amendment No.&#160;1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) amends that certain Sales Agreement, dated as of March 23, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), by and between Bionano Genomics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and Cowen and Company, LLC, as sales agent (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Defined terms used herein and not otherwise defined shall have the meaning assigned to such terms in the Agreement. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WITNESSETH THAT&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, Section&#160;15 of the Agreement permits the Company and the Agent to amend the Agreement&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Company will not be a &#8220;well-known seasoned issuer&#8221; as such term is defined in Rule 405 under the Securities Act of 1933, as amended, upon the filing of the Annual Report on Form 10-K for the year ended December 31, 2022&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Company and the Agent now desire to amend the Agreement as provided herein. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the foregoing premises and other good and valuable consideration,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the receipt and sufficiency of which are hereby acknowledged, the Company and the Agent agree as follows&#58; </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Agreement is amended by replacing the first sentence of the first paragraph with&#58; &#8220;The Company agrees that, from time to time during the term of this Agreement, on the terms and subject to the conditions set forth herein and any Terms Agreement (defined below), it may issue and sell to or through Cowen, acting as agent and&#47;or principal, shares (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that in no event shall the Company issue or sell through Cowen such number or dollar amount of Shares that would (a) exceed the number of authorized but unissued shares of Common Stock (less shares of Common Stock issuable upon exercise, conversion or exchange of any outstanding securities of the Company or otherwise reserved from the Company&#8217;s authorized capital stock), (b) exceed the number or dollar amount of shares of Common Stock permitted to be sold under Form S-3 (including General Instruction I.B.6 thereof, if applicable) or (c) exceed the number or dollar amount of shares of Common Stock for which the Company has filed a Prospectus Supplement (defined below) (the lesser of (a), (b) and (c), the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Maximum Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Agreement is further amended by replacing the first sentence of the second paragraph with&#58; &#8220;The Company has filed or will file, in accordance with the provisions of the Securities Act of 1933, as amended, and the rules and regulations thereunder (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), with the Commission a shelf registration statement on Form S-3, including a base prospectus, relating to certain securities, including the Common Stock, to be issued from time to time by the Company, and which incorporates by reference documents that the Company has filed or will file in accordance with the provisions of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Agreement is further amended by adding the following to paragraph two immediately after the third sentence&#58; &#8220;The Company may file one or more additional registration statements from time to time that will contain a base prospectus and related prospectus or prospectus supplement, if applicable (which shall be a Prospectus Supplement), with respect to the Shares.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Agreement is amended by (i) deleting the first sentence thereof in its entirety and replacing it with &#8220;The Registration Statement has been filed, or any successor Registration Statement will </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">be filed, with the Commission and has been declared effective by the Commission under the Securities Act or, in the case of a successor Registration Statement, will be declared effective by the Commission under the Securities Act prior to the issuance of any Placement Notice by the Company.&#8221; and (ii) deleting the fourth sentence of such section in its entirety.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Agreement is amended and restated in its entirety as set forth below&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Reserved.&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6. A new </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 20</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> is added to the Agreement as set forth below&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Recognition of the U.S. Special Resolution Regimes</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#160; In the event that Cowen is a Covered Entity and becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from Cowen of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event that Cowen is a Covered Entity and Cowen or a BHC Act Affiliate of Cowen becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against Cowen are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For purposes of this Agreement, (A) &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">BHC Act Affiliate</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning assigned to the term &#8220;affiliate&#8221; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k)&#59; (B) &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Covered Entity</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any of the following&#58; (i) a &#8220;covered entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b)&#59; (ii) a &#8220;covered bank&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b)&#59; or (iii) a &#8220;covered FSI&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b)&#59; (C) &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Default Right</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable&#59; and (D) &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">U.S. Special Resolution Regime</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7. References to the date of the Agreement in the form of Placement Notice included as Schedule 1 to the Agreement are hereby revised to read, &#8220;March 23, 2021, as amended by Amendment No.&#160;1 thereto, dated March 9, 2023.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8. This Amendment No.&#160;1 shall be deemed effective on the date first set forth above. </font></div><div style="margin-bottom:12pt;padding-left:0.75pt;padding-right:0.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9. Except as amended hereby, the Agreement as now in effect is ratified and confirmed hereby in all respects. For the avoidance of doubt, this Amendment No.&#160;1 and all of its provisions shall be deemed to be a part of the Agreement, as amended hereby. The Agreement as amended by this Amendment No.&#160;1 constitutes the entire agreement of the parties hereto and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof and thereof. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10. This Amendment No.&#160;1 shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or based upon this Amendment No.&#160;1 or the transactions contemplated hereby may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in the Borough of Manhattan in the City of New York (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Specified Courts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court, as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party&#8217;s address set forth in the Agreement shall be effective service of process for any suit, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum. </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature page follows.&#93; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div><div id="i901a91d3d9b7404998659357f229945e_4"></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-right:0.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If the foregoing is in accordance with your understanding of our agreement, kindly sign and return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Very truly yours,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BIONANO GENOMICS, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58; _</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; R. Erik Holmlin, Ph.D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_______________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;       Name&#58; R. Erik Holmlin, Ph.D.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;       Title&#58; President and Chief Executive Officer&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The foregoing Amendment is hereby confirmed and accepted by the Agent in New York, New York as of the date first above written. </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">COWEN AND COMPANY, LLC</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; _</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Michael Murphy&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Name&#58; Michael Murphy</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Title&#58; Managing Director</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Signature Page to Amendment No. 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>3
<FILENAME>exhibit21bngo-firstamendme.htm
<DESCRIPTION>EX-21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1dc957c7b6444dbfa17adcfc68f427c0_1"></div><div style="min-height:124.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 2.1</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Execution Version</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FIRST AMENDMENT TO <br>AGREEMENT AND PLAN OF MERGER</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This First Amendment to Agreement and Plan of Merger (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is made as of March 4, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by and among Bionano Genomics, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and Soheil Shams, as the Securityholders&#8217; Representative (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Securityholders&#8217; Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Recitals</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt">Parent, Starship Merger Sub I, Inc., a California corporation and a wholly owned subsidiary of Parent, Starship Merger Sub II, LLC, a California limited liability company and a wholly owned subsidiary of Parent, BioDiscovery, Inc., a California corporation, and Securityholders&#8217; Representative entered into that certain Agreement and Plan of Merger, dated October 8, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25pt">Parent and Securityholders&#8217; Representative desire to amend the Agreement on the terms and subject to the conditions set forth herein&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25pt">Pursuant to Section 10.1 of the Agreement, the Agreement may only be amended by an instrument in writing signed on behalf of Parent and the Securityholders&#8217; Representative after the Closing.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agreement</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Now, Therefore</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in consideration of the mutual covenants and agreements of the parties hereto, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Capitalized Terms.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  All capitalized terms used but not defined in this Amendment have the meanings set forth in the Agreement.  From and after the date hereof, all references to the &#8220;Agreement&#8221; in the Agreement shall mean the Agreement as amended by this Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Amendment to the Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  As of the Effective Date, the defined term &#8220;Milestone&#8221; in Exhibit A of the Agreement is hereby amended and restated in its entirety as follows&#58; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Conflict&#59; Ratification.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In the event of any conflict between the terms of this Amendment and the terms of the Agreement, the terms of this Amendment shall control.  Except as expressly provided in this Amendment, all of the terms and provisions of the Agreement are and will remain in full force and effect and are hereby ratified and confirmed by the parties hereto. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Limited Effect.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The amendments contained herein will not be construed as an amendment to or waiver of any legal rights, other provisions of the Agreement, of any other agreement among the parties hereto, or as a waiver of or consent to any further or future action on the part of any party hereto that would require the waiver or consent of the other parties hereto.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:124.56pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Binding Effect&#59; Governing Law&#59; Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Amendment shall be binding upon and shall inure to the benefit of the successors and permitted assigns of the parties hereto.  The choice of law provisions in the Agreement remain in force and effect and govern this Amendment.  This Amendment constitutes the sole and entire agreement between the parties with respect to the subject matter contained herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Counterparts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This Amendment may be executed in counterparts, each of which is deemed an original, but all of which constitute one and the same agreement.  Delivery of an executed counterpart of this Amendment electronically or by facsimile shall be as effective as delivery of an original executed counterpart of this Amendment.    </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature Page Follows&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2&#160;&#160;&#160;&#160;</font></div></div></div><div id="i1dc957c7b6444dbfa17adcfc68f427c0_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">In Witness Whereof</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the parties have executed this Amendment in all applicable capacities effective as of the Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.747%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">PARENT&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Bionano Genomics, Inc.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; R. Erik Holmlin, Ph.D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">___________<br>Name&#58;&#160;&#160;&#160;&#160;R. Erik Holmlin, Ph.D.<br>Title&#58;&#160;&#160;&#160;&#160;President and Chief Executive Officer</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(Signature Page to First Amendment to Agreement and Plan of Merger)</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">In Witness Whereof</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the parties have executed this Amendment in all applicable capacities effective as of the Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.747%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">SECURITYHOLDERS&#8217; REPRESENTATIVE&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>By&#58;&#160;&#160;&#160;&#160;_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Soheil Shams</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">__________________ <br>Name&#58;&#160;&#160;&#160;&#160;Soheil Shams</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(Signature Page to First Amendment to Agreement and Plan of Merger)</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>bngo-20230331xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia8e21f60b22c4573ab3a82b0d1ccc5b6_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, R. Erik Holmlin, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Bionano Genomics, Inc., a Delaware corporation (the &#8220;registrant&#8221;)&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;   May&#160;9, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; R. Erik Holmlin, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Erik Holmlin, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)<br></font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>bngo-20230331xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic8b3fd81b0334949a37034c745faeaec_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher Stewart, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Bionano Genomics, Inc., a Delaware corporation (the &#8220;registrant&#8221;)&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;   May&#160;9, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Christopher Stewart</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christopher Stewart</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Financial and Accounting Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:1pt;padding-left:72pt;text-indent:-18pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>bngo-20230331xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="icb4322277f64492a908cc61335927e84_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, R. Erik Holmlin, Chief Executive Officer of Bionano Genomics, Inc., a Delaware corporation (the &#8220;Company&#8221;) and Christopher Stewart, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Company&#8217;s Quarterly Report on Form 10-Q for the period ended March&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Periodic Report&#8221;), and to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:38.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.837%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;    May&#160;9, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;    May&#160;9, 2023</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; R. Erik Holmlin, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher Stewart</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Erik Holmlin, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher Stewart</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)<br></font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Principal Financial and Accounting Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</font></div></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This certification accompanies and is being </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">furnished</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">with the Periodic Report, shall not be deemed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">filed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> by the Company for purposes of Section 18 of the Exchange Act, or otherwise subject to liability under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of the Periodic Report, irrespective of any general incorporation language contained in such filing.</font></div><div style="margin-top:10pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>bngo-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:89c9e3f0-6ddf-4644-8fed-0d858e04a501,g:e99df848-92d3-4a5f-ae11-c380aa17bbd2-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bngo="http://bionanogenomics.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://bionanogenomics.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bngo-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bngo-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bngo-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bngo-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://bionanogenomics.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsUnaudited" roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLossUnaudited" roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit) (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://bionanogenomics.com/role/OrganizationandBasisofPresentation">
        <link:definition>0000008 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://bionanogenomics.com/role/NetLossPerShare">
        <link:definition>0000009 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://bionanogenomics.com/role/RevenueRecognition">
        <link:definition>0000010 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetails" roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetails">
        <link:definition>0000011 - Disclosure - Balance Sheet Account Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandStockBasedCompensation" roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensation">
        <link:definition>0000012 - Disclosure - Stockholders&#8217; Equity and Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://bionanogenomics.com/role/CommitmentsandContingencies">
        <link:definition>0000013 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://bionanogenomics.com/role/Acquisitions">
        <link:definition>0000014 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsandFairValueMeasurements" roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurements">
        <link:definition>0000015 - Disclosure - Investments and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationPolicies" roleURI="http://bionanogenomics.com/role/OrganizationandBasisofPresentationPolicies">
        <link:definition>0000016 - Disclosure - Organization and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://bionanogenomics.com/role/NetLossPerShareTables">
        <link:definition>0000017 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTables" roleURI="http://bionanogenomics.com/role/RevenueRecognitionTables">
        <link:definition>0000018 - Disclosure - Revenue Recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsTables" roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsTables">
        <link:definition>0000019 - Disclosure - Balance Sheet Account Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandStockBasedCompensationTables" roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables">
        <link:definition>0000020 - Disclosure - Stockholders&#8217; Equity and Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesTables" roleURI="http://bionanogenomics.com/role/CommitmentandContingenciesTables">
        <link:definition>0000021 - Disclosure - Commitment and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://bionanogenomics.com/role/AcquisitionsTables">
        <link:definition>0000022 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsandFairValueMeasurementsTables" roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsTables">
        <link:definition>0000023 - Disclosure - Investments and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationDetails" roleURI="http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails">
        <link:definition>0000024 - Disclosure - Organization and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareDetails" roleURI="http://bionanogenomics.com/role/NetLossPerShareDetails">
        <link:definition>0000025 - Disclosure - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionRevenuebySourceandGeographicLocationDetails" roleURI="http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails">
        <link:definition>0000026 - Disclosure - Revenue Recognition - Revenue by Source and Geographic Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionNarrativeDetails" roleURI="http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails">
        <link:definition>0000027 - Disclosure - Revenue Recognition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionRemainingPerformanceObligationsDetails" roleURI="http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails">
        <link:definition>0000028 - Disclosure - Revenue Recognition - Remaining Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionRemainingPerformanceObligationsDetails_1" roleURI="http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails_1">
        <link:definition>0000028 - Disclosure - Revenue Recognition - Remaining Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails" roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails">
        <link:definition>0000029 - Disclosure - Balance Sheet Account Details - Schedule of Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsScheduleofAllowanceforCreditLossesDetails" roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAllowanceforCreditLossesDetails">
        <link:definition>0000030 - Disclosure - Balance Sheet Account Details - Schedule of Allowance for Credit Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails" roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails">
        <link:definition>0000031 - Disclosure - Balance Sheet Account Details - Schedule of Components of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails" roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails">
        <link:definition>0000032 - Disclosure - Balance Sheet Account Details - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsNarrativeDetails" roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails">
        <link:definition>0000033 - Disclosure - Balance Sheet Account Details - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails" roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails">
        <link:definition>0000034 - Disclosure - Balance Sheet Account Details - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandStockBasedCompensationNarrativeDetails" roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails">
        <link:definition>0000035 - Disclosure - Stockholders&#8217; Equity and Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandStockBasedCompensationWarrantActivityDetails" roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails">
        <link:definition>0000036 - Disclosure - Stockholders&#8217; Equity and Stock-Based Compensation - Warrant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails" roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails">
        <link:definition>0000037 - Disclosure - Stockholders&#8217; Equity and Stock-Based Compensation - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails">
        <link:definition>0000038 - Disclosure - Stockholders&#8217; Equity and Stock-Based Compensation - Recognized Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandStockBasedCompensationAssumptionsDetails" roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAssumptionsDetails">
        <link:definition>0000039 - Disclosure - Stockholders&#8217; Equity and Stock-Based Compensation - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails" roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails">
        <link:definition>0000040 - Disclosure - Stockholders&#8217; Equity and Stock-Based Compensation - Restricted Stock and Performance Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails" roleURI="http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails">
        <link:definition>0000041 - Disclosure - Commitments and Contingencies - Summary of Undiscounted Future Non-Cancellable Lease Payments Under Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1" roleURI="http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1">
        <link:definition>0000041 - Disclosure - Commitments and Contingencies - Summary of Undiscounted Future Non-Cancellable Lease Payments Under Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://bionanogenomics.com/role/AcquisitionsNarrativeDetails">
        <link:definition>0000042 - Disclosure - Acquisitions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAcquisitionPurchasePriceDetails" roleURI="http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails">
        <link:definition>0000043 - Disclosure - Acquisitions - Acquisition Purchase Price (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>0000044 - Disclosure - Acquisitions - Fair Value of Tangible and Identifiable Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsIdentifiableIntangibleAssetsDetails" roleURI="http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails">
        <link:definition>0000045 - Disclosure - Acquisitions - Identifiable Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsProFormaInformationDetails" roleURI="http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails">
        <link:definition>0000046 - Disclosure - Acquisitions - Pro Forma Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails" roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails">
        <link:definition>0000047 - Disclosure - Investments and Fair Value Measurements - Financial Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsandFairValueMeasurementsNarrativeDetails" roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails">
        <link:definition>0000048 - Disclosure - Investments and Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails" roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails">
        <link:definition>0000049 - Disclosure - Investments and Fair Value Measurements - Contingent Consideration Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails" roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails">
        <link:definition>0000050 - Disclosure - Investments and Fair Value Measurements - Amortized Cost and Unrealized Gains (Losses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails" roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails">
        <link:definition>0000051 - Disclosure - Investments and Fair Value Measurements - Unrealized Losses Positions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bngo_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightOutstandingRollForward" abstract="true" name="ClassOfWarrantOrRightOutstandingRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bngo_PurigenMember" abstract="true" name="PurigenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward" abstract="true" name="ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bngo_PerformanceShareUnitsPSUsMember" abstract="true" name="PerformanceShareUnitsPSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_AccruedClinicalStudyFeesCurrent" abstract="false" name="AccruedClinicalStudyFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive" abstract="false" name="DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_BusinessAcquisitionCashHeldInEscrowFund" abstract="false" name="BusinessAcquisitionCashHeldInEscrowFund" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne" abstract="false" name="DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bngo_CommonWarrantsMember" abstract="true" name="CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory" abstract="false" name="TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_BusinessCombinationContingentConsiderationMilestonePayment" abstract="false" name="BusinessCombinationContingentConsiderationMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract" abstract="true" name="DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward" abstract="true" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward" abstract="true" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" abstract="false" name="ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bngo_MeasurementInputProbabilityFactorMember" abstract="true" name="MeasurementInputProbabilityFactorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_FinanceLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="FinanceLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_ContingentConsiderationLiabilityMember" abstract="true" name="ContingentConsiderationLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_DebtSecuritiesAvailableForSaleUnrealizedGains" abstract="false" name="DebtSecuritiesAvailableForSaleUnrealizedGains" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_LiquidityAndGoingConcernPolicyTextBlock" abstract="false" name="LiquidityAndGoingConcernPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" abstract="false" name="TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_PreferredStockNumberOfVotes" abstract="false" name="PreferredStockNumberOfVotes" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bngo_CorporateNotesAndBondsMember" abstract="true" name="CorporateNotesAndBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_NonCashLeaseExpense" abstract="false" name="NonCashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_UnvestedRestrictedStockMember" abstract="true" name="UnvestedRestrictedStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" abstract="false" name="ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bngo_CowenMember" abstract="true" name="CowenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_ProfessionalFeesAndRoyaltiesCurrent" abstract="false" name="ProfessionalFeesAndRoyaltiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive" abstract="false" name="DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" abstract="false" name="ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bngo_WorkingCapital" abstract="false" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_CostOfProductRevenueMember" abstract="true" name="CostOfProductRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_ConsumableRevenueMember" abstract="true" name="ConsumableRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract" abstract="true" name="ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bngo_ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow" abstract="false" name="ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss" abstract="false" name="DebtSecuritiesAvailableForSaleUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent" abstract="false" name="StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bngo_BioDiscoveryMember" abstract="true" name="BioDiscoveryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_SoftwareMember" abstract="true" name="SoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_CostOfServiceAndOtherRevenueMember" abstract="true" name="CostOfServiceAndOtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_CostOfLeasedEquipmentSoldToCustomer" abstract="false" name="CostOfLeasedEquipmentSoldToCustomer" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_PaymentsForPropertyAndEquipment" abstract="false" name="PaymentsForPropertyAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_InstrumentRevenueMember" abstract="true" name="InstrumentRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow" abstract="false" name="BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_SaleOfStockValueSharesIssuedInTransaction" abstract="false" name="SaleOfStockValueSharesIssuedInTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_CommissionFeeMaximumPercentageOfGrossProceeds" abstract="false" name="CommissionFeeMaximumPercentageOfGrossProceeds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne" abstract="false" name="DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>bngo-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:89c9e3f0-6ddf-4644-8fed-0d858e04a501,g:e99df848-92d3-4a5f-ae11-c380aa17bbd2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="bngo-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_151ee810-d9dc-43af-bb82-a3f3022093a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_fc6a8018-5076-40c9-9453-6b8c186d0b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_151ee810-d9dc-43af-bb82-a3f3022093a3" xlink:to="loc_us-gaap_PreferredStockValue_fc6a8018-5076-40c9-9453-6b8c186d0b9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f2f73593-f052-45da-8e61-356fe4d4fe70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_151ee810-d9dc-43af-bb82-a3f3022093a3" xlink:to="loc_us-gaap_CommonStockValue_f2f73593-f052-45da-8e61-356fe4d4fe70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_aa7fde91-6ef4-4a85-9146-473cde23c805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_151ee810-d9dc-43af-bb82-a3f3022093a3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_aa7fde91-6ef4-4a85-9146-473cde23c805" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6be3c47f-7a11-45bf-b3d5-5339949c274b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_151ee810-d9dc-43af-bb82-a3f3022093a3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6be3c47f-7a11-45bf-b3d5-5339949c274b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5bcb863c-19cf-4326-b73b-167f0877e2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_151ee810-d9dc-43af-bb82-a3f3022093a3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5bcb863c-19cf-4326-b73b-167f0877e2f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0211fd42-ed63-4784-a2aa-a4df3a98e164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3f186ff1-c247-474d-9727-6437074983f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0211fd42-ed63-4784-a2aa-a4df3a98e164" xlink:to="loc_us-gaap_AssetsCurrent_3f186ff1-c247-474d-9727-6437074983f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_02405a66-0f6d-4618-a49f-7ff08d5bd664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0211fd42-ed63-4784-a2aa-a4df3a98e164" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_02405a66-0f6d-4618-a49f-7ff08d5bd664" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6255d9d4-6940-42c9-bba7-999fea6ccef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0211fd42-ed63-4784-a2aa-a4df3a98e164" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6255d9d4-6940-42c9-bba7-999fea6ccef1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_89c10678-016a-4884-82ad-40795ae740e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0211fd42-ed63-4784-a2aa-a4df3a98e164" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_89c10678-016a-4884-82ad-40795ae740e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4faac111-7d0c-4b20-8dce-5aa945d393a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0211fd42-ed63-4784-a2aa-a4df3a98e164" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4faac111-7d0c-4b20-8dce-5aa945d393a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_c14dbd87-de0d-4b49-903d-52802ecd7a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0211fd42-ed63-4784-a2aa-a4df3a98e164" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_c14dbd87-de0d-4b49-903d-52802ecd7a25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d68188b9-e3ee-4987-a74f-aa9911e0e342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0211fd42-ed63-4784-a2aa-a4df3a98e164" xlink:to="loc_us-gaap_Goodwill_d68188b9-e3ee-4987-a74f-aa9911e0e342" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9c244a14-28b6-4396-939f-47736a9c733e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0211fd42-ed63-4784-a2aa-a4df3a98e164" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9c244a14-28b6-4396-939f-47736a9c733e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0ea824c7-ffda-4490-ac3d-13d0d226203f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_e85c9bb6-863c-4734-9850-bbc08bb293d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ea824c7-ffda-4490-ac3d-13d0d226203f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_e85c9bb6-863c-4734-9850-bbc08bb293d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8105e5c0-2b8e-49cb-a043-8e428124b4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ea824c7-ffda-4490-ac3d-13d0d226203f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8105e5c0-2b8e-49cb-a043-8e428124b4e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_6469b2e2-d42f-43c5-97c7-7890f00fdf41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ea824c7-ffda-4490-ac3d-13d0d226203f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_6469b2e2-d42f-43c5-97c7-7890f00fdf41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e965ba60-a7c2-4406-b6c9-35ba5924c28a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ea824c7-ffda-4490-ac3d-13d0d226203f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e965ba60-a7c2-4406-b6c9-35ba5924c28a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_50064c4d-083d-4404-9cf2-89518f733f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ea824c7-ffda-4490-ac3d-13d0d226203f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_50064c4d-083d-4404-9cf2-89518f733f14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4c224dbf-e610-40ee-8c67-56850ebe8a11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ea824c7-ffda-4490-ac3d-13d0d226203f" xlink:to="loc_us-gaap_AccountsPayableCurrent_4c224dbf-e610-40ee-8c67-56850ebe8a11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4c547711-8357-4271-9887-53f0a6569f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3484a476-c213-4416-90c3-e707013ccba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4c547711-8357-4271-9887-53f0a6569f2b" xlink:to="loc_us-gaap_LiabilitiesCurrent_3484a476-c213-4416-90c3-e707013ccba1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ffad2f93-944c-4a8c-8028-aff6831625e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4c547711-8357-4271-9887-53f0a6569f2b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ffad2f93-944c-4a8c-8028-aff6831625e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_d5b5fc69-2416-44db-8ab6-f96c383a3e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4c547711-8357-4271-9887-53f0a6569f2b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_d5b5fc69-2416-44db-8ab6-f96c383a3e5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c93dcf16-a865-4107-af94-eff7326d4215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4c547711-8357-4271-9887-53f0a6569f2b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c93dcf16-a865-4107-af94-eff7326d4215" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_265af835-06d5-49eb-98d5-902bbaf9fe35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4c547711-8357-4271-9887-53f0a6569f2b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_265af835-06d5-49eb-98d5-902bbaf9fe35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8c019bb9-89d2-48a3-9f87-f40f19e8bca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_aa911841-9e4b-4424-8a09-413fdea416a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8c019bb9-89d2-48a3-9f87-f40f19e8bca2" xlink:to="loc_us-gaap_Liabilities_aa911841-9e4b-4424-8a09-413fdea416a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_57bec90b-836c-41bc-95ae-f80d04f33ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8c019bb9-89d2-48a3-9f87-f40f19e8bca2" xlink:to="loc_us-gaap_StockholdersEquity_57bec90b-836c-41bc-95ae-f80d04f33ccd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e0dcd781-b459-4539-b581-cc6b7eaed385" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8c019bb9-89d2-48a3-9f87-f40f19e8bca2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e0dcd781-b459-4539-b581-cc6b7eaed385" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_436c7b66-7ed3-4460-b106-d2be0b695add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9ed30e75-a594-4222-b338-d06abe79b6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_436c7b66-7ed3-4460-b106-d2be0b695add" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9ed30e75-a594-4222-b338-d06abe79b6cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fdc3fc4f-918a-47f0-b23d-a095338d932a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_436c7b66-7ed3-4460-b106-d2be0b695add" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fdc3fc4f-918a-47f0-b23d-a095338d932a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_548cda09-f77d-4729-aed1-0598db0ed341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_436c7b66-7ed3-4460-b106-d2be0b695add" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_548cda09-f77d-4729-aed1-0598db0ed341" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7ee0ebd0-0edb-4143-9e19-830763825064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_436c7b66-7ed3-4460-b106-d2be0b695add" xlink:to="loc_us-gaap_InventoryNet_7ee0ebd0-0edb-4143-9e19-830763825064" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8a68770b-d1c2-41fc-a065-4f6ebea40da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_436c7b66-7ed3-4460-b106-d2be0b695add" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8a68770b-d1c2-41fc-a065-4f6ebea40da1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="bngo-20230331.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b3b858d0-e8fc-4348-a8f0-18a3e8b0419e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8afc465d-0662-4178-b621-047c27709add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b3b858d0-e8fc-4348-a8f0-18a3e8b0419e" xlink:to="loc_us-gaap_OperatingIncomeLoss_8afc465d-0662-4178-b621-047c27709add" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_048c4035-87c5-4edb-8f41-722b7342ec95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b3b858d0-e8fc-4348-a8f0-18a3e8b0419e" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_048c4035-87c5-4edb-8f41-722b7342ec95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b2cdaf37-0edc-44ad-9c41-27a8a7ff3769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_d32af977-bd33-4aca-a75e-7d1412b57f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b2cdaf37-0edc-44ad-9c41-27a8a7ff3769" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_d32af977-bd33-4aca-a75e-7d1412b57f40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_33c46bcd-4c39-4d50-8eed-0bb3ac07e03c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b2cdaf37-0edc-44ad-9c41-27a8a7ff3769" xlink:to="loc_us-gaap_InterestExpense_33c46bcd-4c39-4d50-8eed-0bb3ac07e03c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_390dd43a-6cb5-4ef6-b117-f35e32518777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b2cdaf37-0edc-44ad-9c41-27a8a7ff3769" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_390dd43a-6cb5-4ef6-b117-f35e32518777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c9432233-ad39-4161-831e-6a9a024a6370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1dc869eb-8435-4e5a-8e97-313f6814acdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c9432233-ad39-4161-831e-6a9a024a6370" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1dc869eb-8435-4e5a-8e97-313f6814acdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f85a81a3-2f70-49f0-a32c-1685852cd559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c9432233-ad39-4161-831e-6a9a024a6370" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f85a81a3-2f70-49f0-a32c-1685852cd559" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_8e14812d-8272-4e40-b9c7-ad79cf1a2243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c9432233-ad39-4161-831e-6a9a024a6370" xlink:to="loc_us-gaap_CostsAndExpenses_8e14812d-8272-4e40-b9c7-ad79cf1a2243" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0f4d3496-5ed4-422c-b17b-106bac92d11a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_fad657ff-3bf0-441b-a9ce-6bd1ca7de973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0f4d3496-5ed4-422c-b17b-106bac92d11a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_fad657ff-3bf0-441b-a9ce-6bd1ca7de973" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3ce7c36b-f9df-4552-b8dc-2e1c2cd0c4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0f4d3496-5ed4-422c-b17b-106bac92d11a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3ce7c36b-f9df-4552-b8dc-2e1c2cd0c4d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_98b51545-c1e5-4e88-83ef-f8e1c8ef13c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_90ad940f-b2c2-46c1-93a7-fad53db4a1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_98b51545-c1e5-4e88-83ef-f8e1c8ef13c8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_90ad940f-b2c2-46c1-93a7-fad53db4a1e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b7a999bf-f149-44fb-a50b-443b4c7190bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_98b51545-c1e5-4e88-83ef-f8e1c8ef13c8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b7a999bf-f149-44fb-a50b-443b4c7190bb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="bngo-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_af34a7de-8548-4404-8bf6-4cf33983cb39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f8ee6809-4f89-4db2-919b-4d28f8322e38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_af34a7de-8548-4404-8bf6-4cf33983cb39" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f8ee6809-4f89-4db2-919b-4d28f8322e38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e9150c2f-a356-474e-b678-bcb0a3f08408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_af34a7de-8548-4404-8bf6-4cf33983cb39" xlink:to="loc_us-gaap_NetIncomeLoss_e9150c2f-a356-474e-b678-bcb0a3f08408" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6149d880-9d09-46dd-b54d-abf715a58061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_588d1e86-f7c0-482c-bbbf-e2dcf4fc1064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6149d880-9d09-46dd-b54d-abf715a58061" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_588d1e86-f7c0-482c-bbbf-e2dcf4fc1064" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_5f5212d6-35bd-4327-8c04-c4eece995d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6149d880-9d09-46dd-b54d-abf715a58061" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_5f5212d6-35bd-4327-8c04-c4eece995d5e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="bngo-20230331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_af601bb0-23a6-4987-9a8c-e991017b1c55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5b45c66e-1bff-4ca9-8bf5-9e2132764906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_af601bb0-23a6-4987-9a8c-e991017b1c55" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5b45c66e-1bff-4ca9-8bf5-9e2132764906" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_ba02301b-635b-4a03-9893-12791ca5e42b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_af601bb0-23a6-4987-9a8c-e991017b1c55" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_ba02301b-635b-4a03-9893-12791ca5e42b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0774dde-a837-4247-9d86-b9c128411a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1e867d6a-a705-434c-992a-88f437244924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0774dde-a837-4247-9d86-b9c128411a6e" xlink:to="loc_us-gaap_NetIncomeLoss_1e867d6a-a705-434c-992a-88f437244924" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_341f03af-0081-490b-ade6-aa5cab805575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0774dde-a837-4247-9d86-b9c128411a6e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_341f03af-0081-490b-ade6-aa5cab805575" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_9deafde5-7c62-45f8-90ab-2155744d24a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0774dde-a837-4247-9d86-b9c128411a6e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_9deafde5-7c62-45f8-90ab-2155744d24a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CostOfLeasedEquipmentSoldToCustomer_b859437c-0bd6-4425-bab7-a71036d5ead3" xlink:href="bngo-20230331.xsd#bngo_CostOfLeasedEquipmentSoldToCustomer"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0774dde-a837-4247-9d86-b9c128411a6e" xlink:to="loc_bngo_CostOfLeasedEquipmentSoldToCustomer_b859437c-0bd6-4425-bab7-a71036d5ead3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_dc68a190-2b1a-4a14-b217-e00714993c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0774dde-a837-4247-9d86-b9c128411a6e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_dc68a190-2b1a-4a14-b217-e00714993c8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1d7b6d11-e8b3-4f11-b1d2-cd96168d04c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0774dde-a837-4247-9d86-b9c128411a6e" xlink:to="loc_us-gaap_ShareBasedCompensation_1d7b6d11-e8b3-4f11-b1d2-cd96168d04c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_2ab5c12a-4f99-4c1a-a094-91f151c1c651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0774dde-a837-4247-9d86-b9c128411a6e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_2ab5c12a-4f99-4c1a-a094-91f151c1c651" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_fe09da75-19d1-4475-9572-653fbe603f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0774dde-a837-4247-9d86-b9c128411a6e" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_fe09da75-19d1-4475-9572-653fbe603f32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_69a6446d-6e78-4282-8188-0e17d42c69fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0774dde-a837-4247-9d86-b9c128411a6e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_69a6446d-6e78-4282-8188-0e17d42c69fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_df1bad8a-216c-475f-8dbf-a200de1e3ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0774dde-a837-4247-9d86-b9c128411a6e" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_df1bad8a-216c-475f-8dbf-a200de1e3ca7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_NonCashLeaseExpense_8397be24-26b7-4d49-be87-6b2ad4773509" xlink:href="bngo-20230331.xsd#bngo_NonCashLeaseExpense"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0774dde-a837-4247-9d86-b9c128411a6e" xlink:to="loc_bngo_NonCashLeaseExpense_8397be24-26b7-4d49-be87-6b2ad4773509" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_359f3f96-f9c3-44b5-881c-a329306c5e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0774dde-a837-4247-9d86-b9c128411a6e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_359f3f96-f9c3-44b5-881c-a329306c5e96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d468febd-4da4-4086-840f-488f3b040257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0774dde-a837-4247-9d86-b9c128411a6e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d468febd-4da4-4086-840f-488f3b040257" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9277a630-1f58-4617-b860-1185b2befff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0774dde-a837-4247-9d86-b9c128411a6e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9277a630-1f58-4617-b860-1185b2befff0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6d5c9144-8b61-4193-b20e-1a6547c0090a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0774dde-a837-4247-9d86-b9c128411a6e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6d5c9144-8b61-4193-b20e-1a6547c0090a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5c8d3c0b-668f-4b9c-b2bd-f15bc27dd3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_3945a546-80e8-4834-bcf8-bc9eac09a79c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5c8d3c0b-668f-4b9c-b2bd-f15bc27dd3bc" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_3945a546-80e8-4834-bcf8-bc9eac09a79c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_7b0f1ad8-e3d6-4943-aabc-280ac4d7b7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5c8d3c0b-668f-4b9c-b2bd-f15bc27dd3bc" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_7b0f1ad8-e3d6-4943-aabc-280ac4d7b7dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_74b51fd9-36ae-4ab4-b615-eb57cd403f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5c8d3c0b-668f-4b9c-b2bd-f15bc27dd3bc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_74b51fd9-36ae-4ab4-b615-eb57cd403f6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_b4f95c22-c2d8-484b-a224-30fa7771b75b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5c8d3c0b-668f-4b9c-b2bd-f15bc27dd3bc" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_b4f95c22-c2d8-484b-a224-30fa7771b75b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4672b062-877b-40fa-bada-967180610794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PaymentsForPropertyAndEquipment_d6c1cc7f-c5aa-4865-8787-3bd3e1b0148e" xlink:href="bngo-20230331.xsd#bngo_PaymentsForPropertyAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4672b062-877b-40fa-bada-967180610794" xlink:to="loc_bngo_PaymentsForPropertyAndEquipment_d6c1cc7f-c5aa-4865-8787-3bd3e1b0148e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_aa284459-5046-405d-84b2-0c866a9c926e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4672b062-877b-40fa-bada-967180610794" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_aa284459-5046-405d-84b2-0c866a9c926e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForConstructionInProcess_1e43025f-85ca-4843-ab14-bc4e50e4d145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForConstructionInProcess"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4672b062-877b-40fa-bada-967180610794" xlink:to="loc_us-gaap_PaymentsForConstructionInProcess_1e43025f-85ca-4843-ab14-bc4e50e4d145" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_23ff3d4d-3e36-44cf-83cb-7296b7f911c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4672b062-877b-40fa-bada-967180610794" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_23ff3d4d-3e36-44cf-83cb-7296b7f911c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_162a03da-a101-42d9-92a7-3d55def16c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4672b062-877b-40fa-bada-967180610794" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_162a03da-a101-42d9-92a7-3d55def16c52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow_4c753e9a-0cc0-44bc-9dc5-6bae21808729" xlink:href="bngo-20230331.xsd#bngo_ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4672b062-877b-40fa-bada-967180610794" xlink:to="loc_bngo_ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow_4c753e9a-0cc0-44bc-9dc5-6bae21808729" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ca83ef90-c8b5-4987-a464-e53d157902ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0e70e1ab-a0df-452e-b854-ad278efad7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ca83ef90-c8b5-4987-a464-e53d157902ad" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0e70e1ab-a0df-452e-b854-ad278efad7d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c577b2a6-cf2d-4038-9383-1b371b168b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ca83ef90-c8b5-4987-a464-e53d157902ad" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c577b2a6-cf2d-4038-9383-1b371b168b5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_03f1f753-192f-4a0e-ad0c-12f8e0bf7a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ca83ef90-c8b5-4987-a464-e53d157902ad" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_03f1f753-192f-4a0e-ad0c-12f8e0bf7a4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_61883a5c-1c8f-4962-adc4-a9b8c90faa26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ca83ef90-c8b5-4987-a464-e53d157902ad" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_61883a5c-1c8f-4962-adc4-a9b8c90faa26" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e9afba2b-a991-4f16-a4a9-b87e27262ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_9d92b8d4-7e29-4d67-9b9c-77f9edc7e310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_e9afba2b-a991-4f16-a4a9-b87e27262ecc" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_9d92b8d4-7e29-4d67-9b9c-77f9edc7e310" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_9f2cb6dd-5a9d-480c-a6c9-275fd724b669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_e9afba2b-a991-4f16-a4a9-b87e27262ecc" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_9f2cb6dd-5a9d-480c-a6c9-275fd724b669" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e07fd23e-bdd7-4793-ad12-37686edc450b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_ecd0ec24-b352-4780-852f-435b307fd156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e07fd23e-bdd7-4793-ad12-37686edc450b" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_ecd0ec24-b352-4780-852f-435b307fd156" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ac8e50da-3d74-4299-bc3d-544d2bb9bb85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e07fd23e-bdd7-4793-ad12-37686edc450b" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ac8e50da-3d74-4299-bc3d-544d2bb9bb85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_0a7f23bd-0345-4231-907c-9068a9f43cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e07fd23e-bdd7-4793-ad12-37686edc450b" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_0a7f23bd-0345-4231-907c-9068a9f43cd5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_92a4d6e1-dd81-4eb6-9fd9-ec851e47dc25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_dc069451-fbfc-4ab6-9d2b-0d875004f821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_92a4d6e1-dd81-4eb6-9fd9-ec851e47dc25" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_dc069451-fbfc-4ab6-9d2b-0d875004f821" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4d7ed6fe-e430-4344-8ddd-388b88043232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_92a4d6e1-dd81-4eb6-9fd9-ec851e47dc25" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4d7ed6fe-e430-4344-8ddd-388b88043232" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_10a0aefa-7b08-47a9-8434-429c26a54a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_00bd9793-4985-4cc1-8524-673c255657f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_10a0aefa-7b08-47a9-8434-429c26a54a17" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_00bd9793-4985-4cc1-8524-673c255657f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositLiabilityCurrent_0ccbbe12-2b57-4145-af77-f119063234f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_10a0aefa-7b08-47a9-8434-429c26a54a17" xlink:to="loc_us-gaap_DepositLiabilityCurrent_0ccbbe12-2b57-4145-af77-f119063234f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_69129e31-1be2-4a6b-9b68-17d52e442c12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_10a0aefa-7b08-47a9-8434-429c26a54a17" xlink:to="loc_us-gaap_TaxesPayableCurrent_69129e31-1be2-4a6b-9b68-17d52e442c12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ProfessionalFeesAndRoyaltiesCurrent_c79344bc-f732-4543-8cb8-57edc62214d1" xlink:href="bngo-20230331.xsd#bngo_ProfessionalFeesAndRoyaltiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_10a0aefa-7b08-47a9-8434-429c26a54a17" xlink:to="loc_bngo_ProfessionalFeesAndRoyaltiesCurrent_c79344bc-f732-4543-8cb8-57edc62214d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_AccruedClinicalStudyFeesCurrent_af624e07-1a92-45bd-bb16-738dbaa2404b" xlink:href="bngo-20230331.xsd#bngo_AccruedClinicalStudyFeesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_10a0aefa-7b08-47a9-8434-429c26a54a17" xlink:to="loc_bngo_AccruedClinicalStudyFeesCurrent_af624e07-1a92-45bd-bb16-738dbaa2404b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2fa9b719-1a44-46e4-bceb-eb8954b54f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_10a0aefa-7b08-47a9-8434-429c26a54a17" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2fa9b719-1a44-46e4-bceb-eb8954b54f34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_5581327b-3fae-4de0-848a-55c4476a7d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_10a0aefa-7b08-47a9-8434-429c26a54a17" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_5581327b-3fae-4de0-848a-55c4476a7d2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_cd815b41-b19a-4477-9b66-4c1b5e612a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_10a0aefa-7b08-47a9-8434-429c26a54a17" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_cd815b41-b19a-4477-9b66-4c1b5e612a6c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_e9a1bf4d-4354-4b36-9e0e-b2ac4d0c8b05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_abda8d9e-5fbd-4c18-946f-d20215ade2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_e9a1bf4d-4354-4b36-9e0e-b2ac4d0c8b05" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_abda8d9e-5fbd-4c18-946f-d20215ade2bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_8e1942e8-7bb5-445d-9ca8-711570415948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_e9a1bf4d-4354-4b36-9e0e-b2ac4d0c8b05" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_8e1942e8-7bb5-445d-9ca8-711570415948" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_6d31528d-c4dd-46c5-bb7a-f082dd24c332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_e9a1bf4d-4354-4b36-9e0e-b2ac4d0c8b05" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_6d31528d-c4dd-46c5-bb7a-f082dd24c332" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_FinanceLeaseLiabilityToBePaidAfterYearFour_91a96bcc-94d5-49ad-b55e-f61cfc0b00b2" xlink:href="bngo-20230331.xsd#bngo_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_e9a1bf4d-4354-4b36-9e0e-b2ac4d0c8b05" xlink:to="loc_bngo_FinanceLeaseLiabilityToBePaidAfterYearFour_91a96bcc-94d5-49ad-b55e-f61cfc0b00b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_3aa365a0-2b13-4a83-94b1-3baab59561be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_e9a1bf4d-4354-4b36-9e0e-b2ac4d0c8b05" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_3aa365a0-2b13-4a83-94b1-3baab59561be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_075827d9-a9f9-45e2-8729-e25dcb6af6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_e9a1bf4d-4354-4b36-9e0e-b2ac4d0c8b05" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_075827d9-a9f9-45e2-8729-e25dcb6af6dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7050080e-8ce9-424c-930d-955ab8854be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_12e2edb3-fa43-441c-b16d-cae098deed6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7050080e-8ce9-424c-930d-955ab8854be0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_12e2edb3-fa43-441c-b16d-cae098deed6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f655ee63-0bb6-4921-adff-fe17f44d6a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7050080e-8ce9-424c-930d-955ab8854be0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f655ee63-0bb6-4921-adff-fe17f44d6a19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_375caea1-64be-4b04-a8c9-2aa8d441e9be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7050080e-8ce9-424c-930d-955ab8854be0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_375caea1-64be-4b04-a8c9-2aa8d441e9be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ddb00a2a-c601-4a45-aaa7-d9fa3c9cb0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7050080e-8ce9-424c-930d-955ab8854be0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ddb00a2a-c601-4a45-aaa7-d9fa3c9cb0a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_1c479584-2e56-42b0-a449-0a1fabcc7a92" xlink:href="bngo-20230331.xsd#bngo_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7050080e-8ce9-424c-930d-955ab8854be0" xlink:to="loc_bngo_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_1c479584-2e56-42b0-a449-0a1fabcc7a92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6bd16393-61b1-4957-a25c-dccd9f778394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7050080e-8ce9-424c-930d-955ab8854be0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6bd16393-61b1-4957-a25c-dccd9f778394" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1" xlink:type="simple" xlink:href="bngo-20230331.xsd#CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e930c57e-1245-4f32-9a81-cac8ca65f6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e4392df4-c202-4668-a17a-d2b562d1e59e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e930c57e-1245-4f32-9a81-cac8ca65f6a6" xlink:to="loc_us-gaap_OperatingLeaseLiability_e4392df4-c202-4668-a17a-d2b562d1e59e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_74cb534c-558c-4181-acbc-f2c95d14c565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e930c57e-1245-4f32-9a81-cac8ca65f6a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_74cb534c-558c-4181-acbc-f2c95d14c565" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1012db2e-0537-4ad9-a106-e12fa936da2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_52baee1b-0e29-45b4-bf5e-c6a897529b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1012db2e-0537-4ad9-a106-e12fa936da2b" xlink:to="loc_us-gaap_FinanceLeaseLiability_52baee1b-0e29-45b4-bf5e-c6a897529b6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3f788036-e60a-43d7-8b3e-9eff66cf1367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1012db2e-0537-4ad9-a106-e12fa936da2b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3f788036-e60a-43d7-8b3e-9eff66cf1367" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e3804b63-36d2-4581-8f67-8bba00bb1d26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent_0c0ac822-4966-4b5d-9600-17bfbc604193" xlink:href="bngo-20230331.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e3804b63-36d2-4581-8f67-8bba00bb1d26" xlink:to="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent_0c0ac822-4966-4b5d-9600-17bfbc604193" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities_2c2c50e6-0219-4ba1-b506-65284451c30d" xlink:href="bngo-20230331.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e3804b63-36d2-4581-8f67-8bba00bb1d26" xlink:to="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities_2c2c50e6-0219-4ba1-b506-65284451c30d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_9bf8e6ef-840b-4943-8bc9-b128ab065030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e3804b63-36d2-4581-8f67-8bba00bb1d26" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_9bf8e6ef-840b-4943-8bc9-b128ab065030" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_697d05ae-e70d-4c07-83b0-6e75de4cc028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e3804b63-36d2-4581-8f67-8bba00bb1d26" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_697d05ae-e70d-4c07-83b0-6e75de4cc028" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_703d92ca-37c7-43fa-9fa9-60621755e09f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e3804b63-36d2-4581-8f67-8bba00bb1d26" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_703d92ca-37c7-43fa-9fa9-60621755e09f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_656971a0-24eb-4771-9c63-c98fbe0cbee1" xlink:href="bngo-20230331.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e3804b63-36d2-4581-8f67-8bba00bb1d26" xlink:to="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_656971a0-24eb-4771-9c63-c98fbe0cbee1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_79b8d062-a1aa-48ea-8d9e-a003260dc0f3" xlink:href="bngo-20230331.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e3804b63-36d2-4581-8f67-8bba00bb1d26" xlink:to="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_79b8d062-a1aa-48ea-8d9e-a003260dc0f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_d49b0c54-577b-40ec-8a85-6246a1873a42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e3804b63-36d2-4581-8f67-8bba00bb1d26" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_d49b0c54-577b-40ec-8a85-6246a1873a42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_9847fda1-28aa-4dbb-95c0-9e3cf55bbf29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e3804b63-36d2-4581-8f67-8bba00bb1d26" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_9847fda1-28aa-4dbb-95c0-9e3cf55bbf29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9e4ae4ee-e087-499a-b878-1147bc5de440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e3804b63-36d2-4581-8f67-8bba00bb1d26" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9e4ae4ee-e087-499a-b878-1147bc5de440" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_e5726602-a40f-41e9-92db-f7940006de13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e3804b63-36d2-4581-8f67-8bba00bb1d26" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_e5726602-a40f-41e9-92db-f7940006de13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a8971d55-d871-4e7c-9f99-b335c69b78cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e3804b63-36d2-4581-8f67-8bba00bb1d26" xlink:to="loc_us-gaap_Goodwill_a8971d55-d871-4e7c-9f99-b335c69b78cd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_e1df4ac7-ce45-4951-850e-2781986bc327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_ecf28d9c-f2ec-4675-9ce9-343267ada014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_e1df4ac7-ce45-4951-850e-2781986bc327" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_ecf28d9c-f2ec-4675-9ce9-343267ada014" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6a02e0c6-d943-43ef-8035-f1fbd31b0921" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_e1df4ac7-ce45-4951-850e-2781986bc327" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6a02e0c6-d943-43ef-8035-f1fbd31b0921" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGains_5d528a98-544f-4e53-bb98-9db42fc746f0" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedGains"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive_a0d4e7c1-4d96-41c6-8330-cadea9bc56b3" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGains_5d528a98-544f-4e53-bb98-9db42fc746f0" xlink:to="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive_a0d4e7c1-4d96-41c6-8330-cadea9bc56b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne_1ebb3d99-b5e3-4db5-9751-741695048083" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGains_5d528a98-544f-4e53-bb98-9db42fc746f0" xlink:to="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne_1ebb3d99-b5e3-4db5-9751-741695048083" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0ee29bc9-9bd7-4c0f-816d-c8f18dbb25d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0d82c2e0-8025-4525-8316-6ca818730315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0ee29bc9-9bd7-4c0f-816d-c8f18dbb25d0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0d82c2e0-8025-4525-8316-6ca818730315" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive_140fea2b-2d5f-4f87-b671-816271d6a8ec" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0ee29bc9-9bd7-4c0f-816d-c8f18dbb25d0" xlink:to="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive_140fea2b-2d5f-4f87-b671-816271d6a8ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive_66075c7d-d9b3-4e92-b90c-29c4aa8a2dcc" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0ee29bc9-9bd7-4c0f-816d-c8f18dbb25d0" xlink:to="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive_66075c7d-d9b3-4e92-b90c-29c4aa8a2dcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1ad2db48-0a43-40d4-a177-2dc17b28339f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne_4c341cd7-b4d3-403a-82a2-4de80c17a468" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1ad2db48-0a43-40d4-a177-2dc17b28339f" xlink:to="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne_4c341cd7-b4d3-403a-82a2-4de80c17a468" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6e6550cd-b78e-4942-97e8-a9c03505a040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1ad2db48-0a43-40d4-a177-2dc17b28339f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6e6550cd-b78e-4942-97e8-a9c03505a040" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne_6a71bcb8-67e9-4d9e-91e9-c8dd886edfd7" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1ad2db48-0a43-40d4-a177-2dc17b28339f" xlink:to="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne_6a71bcb8-67e9-4d9e-91e9-c8dd886edfd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e53e8d00-c7ad-4dc8-92ad-5c7c4cb55126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_30e01bc9-77b1-491a-b3d3-0d93c341402e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e53e8d00-c7ad-4dc8-92ad-5c7c4cb55126" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_30e01bc9-77b1-491a-b3d3-0d93c341402e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_eadeed59-5672-431b-a756-064ffc80dda5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e53e8d00-c7ad-4dc8-92ad-5c7c4cb55126" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_eadeed59-5672-431b-a756-064ffc80dda5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss_15e26bfd-d940-4ead-8c12-cdba16859952" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne_801a830f-7598-4efe-a544-d8244327d20a" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss_15e26bfd-d940-4ead-8c12-cdba16859952" xlink:to="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne_801a830f-7598-4efe-a544-d8244327d20a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive_c30a1a1c-97d6-4697-8d8d-389702560942" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss_15e26bfd-d940-4ead-8c12-cdba16859952" xlink:to="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive_c30a1a1c-97d6-4697-8d8d-389702560942" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_50051199-e5b9-485d-985f-64bf538f21de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_9102f998-c4d0-4ce8-99cb-9ae0819ad3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_50051199-e5b9-485d-985f-64bf538f21de" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_9102f998-c4d0-4ce8-99cb-9ae0819ad3ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_5110ed3e-9369-4b08-b2a5-adf3e6e867d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_50051199-e5b9-485d-985f-64bf538f21de" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_5110ed3e-9369-4b08-b2a5-adf3e6e867d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bfbae32d-5643-440c-8559-4e0b9417b927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_640409bc-ed74-4171-a3f9-a1912f4ea659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bfbae32d-5643-440c-8559-4e0b9417b927" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_640409bc-ed74-4171-a3f9-a1912f4ea659" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_bbb6f20e-b5a4-4a2f-8fbd-0c1748d617f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bfbae32d-5643-440c-8559-4e0b9417b927" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_bbb6f20e-b5a4-4a2f-8fbd-0c1748d617f9" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>bngo-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:89c9e3f0-6ddf-4644-8fed-0d858e04a501,g:e99df848-92d3-4a5f-ae11-c380aa17bbd2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/Cover" xlink:type="simple" xlink:href="bngo-20230331.xsd#Cover"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/Cover" xlink:type="extended" id="iecbc51835a964ddba19eda47dc8aef11_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d3f33b32-f844-45c1-b133-a75910501243" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_DocumentType_d3f33b32-f844-45c1-b133-a75910501243" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_ed26e9c1-388c-4d37-a570-a3556eda128e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_DocumentQuarterlyReport_ed26e9c1-388c-4d37-a570-a3556eda128e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4a0845e3-643a-4c59-9561-958f9fc2d86c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_DocumentPeriodEndDate_4a0845e3-643a-4c59-9561-958f9fc2d86c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f1096aae-c7f1-4a4e-a4cf-30691b7159a7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_DocumentTransitionReport_f1096aae-c7f1-4a4e-a4cf-30691b7159a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_97f8e85b-ca91-4064-8c32-c6ea1124f306" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityFileNumber_97f8e85b-ca91-4064-8c32-c6ea1124f306" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_491bcfce-b9ca-45d6-9611-43b599c86c80" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityRegistrantName_491bcfce-b9ca-45d6-9611-43b599c86c80" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7a4db9a8-c2cb-4ee6-8d05-f071557bea79" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7a4db9a8-c2cb-4ee6-8d05-f071557bea79" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c28a0ecc-7d8e-44b9-a956-5d3f6cc97ca5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityTaxIdentificationNumber_c28a0ecc-7d8e-44b9-a956-5d3f6cc97ca5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_06ba2be5-d153-4c46-8bdc-2a2c2854906c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityAddressAddressLine1_06ba2be5-d153-4c46-8bdc-2a2c2854906c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_340c1dda-a8c2-4283-aafa-d66af098046a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityAddressCityOrTown_340c1dda-a8c2-4283-aafa-d66af098046a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f5188a75-7efe-486b-b98a-2476b6cc9667" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityAddressStateOrProvince_f5188a75-7efe-486b-b98a-2476b6cc9667" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ea32652d-2eba-42fd-977b-1c231fb664c5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityAddressPostalZipCode_ea32652d-2eba-42fd-977b-1c231fb664c5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_543419c1-1af2-4fd0-9575-8cda98b4dd7c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_CityAreaCode_543419c1-1af2-4fd0-9575-8cda98b4dd7c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_51b9d4c6-3c36-45b2-bb5c-36baf6536786" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_LocalPhoneNumber_51b9d4c6-3c36-45b2-bb5c-36baf6536786" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_528d6d83-ca7d-4ce0-a722-ecd43ac616af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_Security12bTitle_528d6d83-ca7d-4ce0-a722-ecd43ac616af" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ec80eba6-5a8f-4848-8443-b248e05ab89d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_TradingSymbol_ec80eba6-5a8f-4848-8443-b248e05ab89d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2072cb55-64f1-4ba5-b5ec-d030add296e9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_SecurityExchangeName_2072cb55-64f1-4ba5-b5ec-d030add296e9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_a576b367-002e-4f6e-bb6a-e347c261f326" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityCurrentReportingStatus_a576b367-002e-4f6e-bb6a-e347c261f326" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_c48e4d64-bab0-4b87-98c4-95d7cffa804f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityInteractiveDataCurrent_c48e4d64-bab0-4b87-98c4-95d7cffa804f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_b77fe79b-c7c5-44df-aee9-66d73bbb8896" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityFilerCategory_b77fe79b-c7c5-44df-aee9-66d73bbb8896" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_291dc313-59d8-4bb0-9308-c53bca555ef2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntitySmallBusiness_291dc313-59d8-4bb0-9308-c53bca555ef2" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_eb07037e-8abe-4776-9ec9-5bd863353ba2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityEmergingGrowthCompany_eb07037e-8abe-4776-9ec9-5bd863353ba2" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_36c64989-4958-4a48-89e3-da0e9c3bae35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityShellCompany_36c64989-4958-4a48-89e3-da0e9c3bae35" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f66655b4-d99c-4496-871f-7028f1dc64c6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f66655b4-d99c-4496-871f-7028f1dc64c6" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_00a15632-6e00-4ab2-a722-f41c515ab193" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_AmendmentFlag_00a15632-6e00-4ab2-a722-f41c515ab193" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_3987186c-dda7-41b8-8f85-f48707c108b0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_DocumentFiscalYearFocus_3987186c-dda7-41b8-8f85-f48707c108b0" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_c36885ab-c9f7-4e60-b18b-de0b7c8454f1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_c36885ab-c9f7-4e60-b18b-de0b7c8454f1" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_99941c91-8ae2-49b6-983a-e757e0526091" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityCentralIndexKey_99941c91-8ae2-49b6-983a-e757e0526091" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c32cb2dd-c03c-42f1-9787-2199a462bd08" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_CurrentFiscalYearEndDate_c32cb2dd-c03c-42f1-9787-2199a462bd08" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_c6e9e14c-b739-478c-b4df-fa4c14c91536" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_DocumentInformationTable_c6e9e14c-b739-478c-b4df-fa4c14c91536" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6b9c94df-2fba-4663-ae0d-60d42460a2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_c6e9e14c-b739-478c-b4df-fa4c14c91536" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6b9c94df-2fba-4663-ae0d-60d42460a2dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6b9c94df-2fba-4663-ae0d-60d42460a2dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6b9c94df-2fba-4663-ae0d-60d42460a2dd" xlink:to="loc_us-gaap_ClassOfStockDomain_6b9c94df-2fba-4663-ae0d-60d42460a2dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4d36da1f-f75a-41f8-bc8b-c544f3eee308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6b9c94df-2fba-4663-ae0d-60d42460a2dd" xlink:to="loc_us-gaap_ClassOfStockDomain_4d36da1f-f75a-41f8-bc8b-c544f3eee308" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1d70b76a-7c04-4655-b095-32d0d136476a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4d36da1f-f75a-41f8-bc8b-c544f3eee308" xlink:to="loc_us-gaap_CommonStockMember_1d70b76a-7c04-4655-b095-32d0d136476a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_f70e6e0c-b9f3-4c97-b968-6ffc67c9cc99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4d36da1f-f75a-41f8-bc8b-c544f3eee308" xlink:to="loc_us-gaap_WarrantMember_f70e6e0c-b9f3-4c97-b968-6ffc67c9cc99" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="bngo-20230331.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended" id="i7589bda746984ef1ac337150457fc097_CondensedConsolidatedStatementsofOperationsUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_22c25896-6006-45fa-9637-3381fd04aa84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:to="loc_us-gaap_RevenuesAbstract_22c25896-6006-45fa-9637-3381fd04aa84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e4320eaa-53d1-42da-8f17-d2fd0bfd08ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_22c25896-6006-45fa-9637-3381fd04aa84" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e4320eaa-53d1-42da-8f17-d2fd0bfd08ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_2c47a252-1c8d-4651-8ac1-c6ed47dd118c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_2c47a252-1c8d-4651-8ac1-c6ed47dd118c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_11a8251e-0919-4e2d-b3dc-7931e0a20e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2c47a252-1c8d-4651-8ac1-c6ed47dd118c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_11a8251e-0919-4e2d-b3dc-7931e0a20e8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6555a054-46f0-4f17-855c-a6c5c4818e33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6555a054-46f0-4f17-855c-a6c5c4818e33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e01191d7-376d-4521-8e73-fa3e196c813b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6555a054-46f0-4f17-855c-a6c5c4818e33" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e01191d7-376d-4521-8e73-fa3e196c813b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9e1d1f49-5c37-4fbe-9a29-d10ed3333889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6555a054-46f0-4f17-855c-a6c5c4818e33" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9e1d1f49-5c37-4fbe-9a29-d10ed3333889" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_2d796968-b5c8-437c-b132-5edfb96533b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6555a054-46f0-4f17-855c-a6c5c4818e33" xlink:to="loc_us-gaap_CostsAndExpenses_2d796968-b5c8-437c-b132-5edfb96533b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2d17ac5c-5448-4711-9b90-9ced3d96a406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:to="loc_us-gaap_OperatingIncomeLoss_2d17ac5c-5448-4711-9b90-9ced3d96a406" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b829af58-7640-404a-bcf5-ad9ad94770ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b829af58-7640-404a-bcf5-ad9ad94770ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_7719b8dd-0399-4b4b-9289-b64fcd5b2ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b829af58-7640-404a-bcf5-ad9ad94770ab" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_7719b8dd-0399-4b4b-9289-b64fcd5b2ca6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_dc88e3b7-e2df-42bb-b6da-5db4b54f8ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b829af58-7640-404a-bcf5-ad9ad94770ab" xlink:to="loc_us-gaap_InterestExpense_dc88e3b7-e2df-42bb-b6da-5db4b54f8ba7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_cc7417d9-026a-4baa-9b2f-ab39af99918a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b829af58-7640-404a-bcf5-ad9ad94770ab" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_cc7417d9-026a-4baa-9b2f-ab39af99918a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_75e54fb0-2b17-410b-bb91-364295910c20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b829af58-7640-404a-bcf5-ad9ad94770ab" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_75e54fb0-2b17-410b-bb91-364295910c20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d778bfd4-1e7d-4e6d-b9cf-ea14a0306e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d778bfd4-1e7d-4e6d-b9cf-ea14a0306e64" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_36f6ecad-399c-4598-afb7-0b3b50879131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_36f6ecad-399c-4598-afb7-0b3b50879131" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7256dc9c-72ee-4061-986a-d7f940e9f66a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:to="loc_us-gaap_NetIncomeLoss_7256dc9c-72ee-4061-986a-d7f940e9f66a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_06bee885-06ec-48b7-8648-09ccf29dbb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:to="loc_us-gaap_EarningsPerShareBasic_06bee885-06ec-48b7-8648-09ccf29dbb9c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f26443a8-ac27-477c-9e72-a1dd3257d8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f26443a8-ac27-477c-9e72-a1dd3257d8b8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_49708a4b-d713-42c2-8ea3-49563a40b376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_49708a4b-d713-42c2-8ea3-49563a40b376" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1f85b324-7f1d-4dca-9800-400bb68dd465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1f85b324-7f1d-4dca-9800-400bb68dd465" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_149546b2-bbfc-4edf-baf2-b0f0f9734d99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:to="loc_us-gaap_StatementTable_149546b2-bbfc-4edf-baf2-b0f0f9734d99" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8fcb657b-d05c-4450-a4e3-c9a2e54d9740" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_149546b2-bbfc-4edf-baf2-b0f0f9734d99" xlink:to="loc_srt_ProductOrServiceAxis_8fcb657b-d05c-4450-a4e3-c9a2e54d9740" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8fcb657b-d05c-4450-a4e3-c9a2e54d9740_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8fcb657b-d05c-4450-a4e3-c9a2e54d9740" xlink:to="loc_srt_ProductsAndServicesDomain_8fcb657b-d05c-4450-a4e3-c9a2e54d9740_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_11c0af6b-684b-40de-99ec-cdac8fc4c339" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8fcb657b-d05c-4450-a4e3-c9a2e54d9740" xlink:to="loc_srt_ProductsAndServicesDomain_11c0af6b-684b-40de-99ec-cdac8fc4c339" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_f232528a-ce66-4224-b52e-6f2165f91a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_11c0af6b-684b-40de-99ec-cdac8fc4c339" xlink:to="loc_us-gaap_ProductMember_f232528a-ce66-4224-b52e-6f2165f91a13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_493603dd-2dcc-4c77-8f3d-91b4d8b79f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_11c0af6b-684b-40de-99ec-cdac8fc4c339" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_493603dd-2dcc-4c77-8f3d-91b4d8b79f6d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="simple" xlink:href="bngo-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="extended" id="i3877b7ba09ce46049fe7e8a6340da875_CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e0eff4f8-1eed-45b6-bc46-36bfd30bafc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e0eff4f8-1eed-45b6-bc46-36bfd30bafc3" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_39c397c7-68cb-4a31-b9ce-88cf9a948222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_39c397c7-68cb-4a31-b9ce-88cf9a948222" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_44185c31-43e5-4905-9b89-626e56d21976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:to="loc_us-gaap_StockholdersEquity_44185c31-43e5-4905-9b89-626e56d21976" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e4d5e84c-77bd-45da-aeb2-6a5546dd8da9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e4d5e84c-77bd-45da-aeb2-6a5546dd8da9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5bc4ed08-0067-462f-8e24-6915d7255fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5bc4ed08-0067-462f-8e24-6915d7255fd5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_499904bd-2bc3-4121-b34c-15b51ba3f1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_499904bd-2bc3-4121-b34c-15b51ba3f1ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_62774287-85bc-4f3e-ac45-36775ef02754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_62774287-85bc-4f3e-ac45-36775ef02754" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7bfe91c2-408d-44e8-a1d8-94942bb8f05e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7bfe91c2-408d-44e8-a1d8-94942bb8f05e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_c2aa0f9b-91c7-4eaf-b44a-9014d79018bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:to="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_c2aa0f9b-91c7-4eaf-b44a-9014d79018bf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_11a4c394-311d-4533-9ff5-a530fd94b9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:to="loc_us-gaap_NetIncomeLoss_11a4c394-311d-4533-9ff5-a530fd94b9c1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8eab7fee-c43d-4a8a-9f52-adb8ce936cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8eab7fee-c43d-4a8a-9f52-adb8ce936cda" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_faca118e-5b04-4d64-908e-a40c923ce0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f1074f03-eaf7-4643-a98b-909111513056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_997837e2-acef-4542-9a7d-499ec80560dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e0eff4f8-1eed-45b6-bc46-36bfd30bafc3" xlink:to="loc_us-gaap_StatementTable_997837e2-acef-4542-9a7d-499ec80560dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f9711dfb-07fc-4db2-896d-2074bada8342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_997837e2-acef-4542-9a7d-499ec80560dd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f9711dfb-07fc-4db2-896d-2074bada8342" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f9711dfb-07fc-4db2-896d-2074bada8342_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f9711dfb-07fc-4db2-896d-2074bada8342" xlink:to="loc_us-gaap_EquityComponentDomain_f9711dfb-07fc-4db2-896d-2074bada8342_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_53e27528-e32f-4ce9-a3e9-4c0338572ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f9711dfb-07fc-4db2-896d-2074bada8342" xlink:to="loc_us-gaap_EquityComponentDomain_53e27528-e32f-4ce9-a3e9-4c0338572ad2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_01a8f87a-efc7-4e81-8e32-bfd36115a438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_53e27528-e32f-4ce9-a3e9-4c0338572ad2" xlink:to="loc_us-gaap_CommonStockMember_01a8f87a-efc7-4e81-8e32-bfd36115a438" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_08f4d2ee-1ee0-4310-8c79-567478732c31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_53e27528-e32f-4ce9-a3e9-4c0338572ad2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_08f4d2ee-1ee0-4310-8c79-567478732c31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_bc21f537-42ee-4402-9bc2-ae71ac178181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_53e27528-e32f-4ce9-a3e9-4c0338572ad2" xlink:to="loc_us-gaap_RetainedEarningsMember_bc21f537-42ee-4402-9bc2-ae71ac178181" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_974d15b9-694b-4689-b980-d95657dea58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_53e27528-e32f-4ce9-a3e9-4c0338572ad2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_974d15b9-694b-4689-b980-d95657dea58f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/NetLossPerShareDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#NetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/NetLossPerShareDetails" xlink:type="extended" id="i33774acab6474cd9aa999930421b6216_NetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1d158ade-2293-4259-8243-b7089638456e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f45b4344-9903-4230-bc46-166feee4fd8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1d158ade-2293-4259-8243-b7089638456e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f45b4344-9903-4230-bc46-166feee4fd8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b901a0db-6de9-401e-9105-e97b9175f30f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1d158ade-2293-4259-8243-b7089638456e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b901a0db-6de9-401e-9105-e97b9175f30f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_178fcf28-6283-47ae-8d0f-1453c32a8f84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b901a0db-6de9-401e-9105-e97b9175f30f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_178fcf28-6283-47ae-8d0f-1453c32a8f84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_178fcf28-6283-47ae-8d0f-1453c32a8f84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_178fcf28-6283-47ae-8d0f-1453c32a8f84" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_178fcf28-6283-47ae-8d0f-1453c32a8f84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6daebcfa-c28b-47c8-9863-d09dc66fd107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_178fcf28-6283-47ae-8d0f-1453c32a8f84" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6daebcfa-c28b-47c8-9863-d09dc66fd107" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_468f6a8f-e29a-482b-b68f-b3f058d71365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6daebcfa-c28b-47c8-9863-d09dc66fd107" xlink:to="loc_us-gaap_StockOptionMember_468f6a8f-e29a-482b-b68f-b3f058d71365" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_UnvestedRestrictedStockMember_80635fec-299c-4a0b-a47a-0c89af827d68" xlink:href="bngo-20230331.xsd#bngo_UnvestedRestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6daebcfa-c28b-47c8-9863-d09dc66fd107" xlink:to="loc_bngo_UnvestedRestrictedStockMember_80635fec-299c-4a0b-a47a-0c89af827d68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommonWarrantsMember_324d589a-36b3-46ee-a7a1-5cdfc9639a51" xlink:href="bngo-20230331.xsd#bngo_CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6daebcfa-c28b-47c8-9863-d09dc66fd107" xlink:to="loc_bngo_CommonWarrantsMember_324d589a-36b3-46ee-a7a1-5cdfc9639a51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fd589dee-02d5-4477-8e82-b8478de6e35c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6daebcfa-c28b-47c8-9863-d09dc66fd107" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fd589dee-02d5-4477-8e82-b8478de6e35c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PerformanceShareUnitsPSUsMember_3a430f48-1cd0-49bb-978b-4b6fb5c4a3f4" xlink:href="bngo-20230331.xsd#bngo_PerformanceShareUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6daebcfa-c28b-47c8-9863-d09dc66fd107" xlink:to="loc_bngo_PerformanceShareUnitsPSUsMember_3a430f48-1cd0-49bb-978b-4b6fb5c4a3f4" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#RevenueRecognitionRevenuebySourceandGeographicLocationDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails" xlink:type="extended" id="ibb94ce2cbe564946b0dd3729d3ef39f9_RevenueRecognitionRevenuebySourceandGeographicLocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a628c045-e6f8-40bc-b6fc-7a8f0c5a4f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73f68b18-5444-4de0-82fd-218507ddc5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a628c045-e6f8-40bc-b6fc-7a8f0c5a4f07" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73f68b18-5444-4de0-82fd-218507ddc5cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_be6e1ef3-898d-4c4b-95d6-00857fb9b999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a628c045-e6f8-40bc-b6fc-7a8f0c5a4f07" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_be6e1ef3-898d-4c4b-95d6-00857fb9b999" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_cf773597-049e-44cb-9c15-f5efabeb4de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a628c045-e6f8-40bc-b6fc-7a8f0c5a4f07" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_cf773597-049e-44cb-9c15-f5efabeb4de1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d5146738-ceb0-484a-bc66-fc87b929629b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cf773597-049e-44cb-9c15-f5efabeb4de1" xlink:to="loc_srt_ProductOrServiceAxis_d5146738-ceb0-484a-bc66-fc87b929629b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d5146738-ceb0-484a-bc66-fc87b929629b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d5146738-ceb0-484a-bc66-fc87b929629b" xlink:to="loc_srt_ProductsAndServicesDomain_d5146738-ceb0-484a-bc66-fc87b929629b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8f91608f-c868-439f-97ac-a2934b4b45b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d5146738-ceb0-484a-bc66-fc87b929629b" xlink:to="loc_srt_ProductsAndServicesDomain_8f91608f-c868-439f-97ac-a2934b4b45b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_1cd5eb6f-5bab-4fc8-afcd-ce8224232bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8f91608f-c868-439f-97ac-a2934b4b45b1" xlink:to="loc_us-gaap_ProductMember_1cd5eb6f-5bab-4fc8-afcd-ce8224232bcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InstrumentRevenueMember_b907bc9d-8c06-45dc-a45e-7ef201973345" xlink:href="bngo-20230331.xsd#bngo_InstrumentRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_1cd5eb6f-5bab-4fc8-afcd-ce8224232bcf" xlink:to="loc_bngo_InstrumentRevenueMember_b907bc9d-8c06-45dc-a45e-7ef201973345" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ConsumableRevenueMember_66f3af85-db78-4f2e-a5cd-9bc8d3e815c0" xlink:href="bngo-20230331.xsd#bngo_ConsumableRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_1cd5eb6f-5bab-4fc8-afcd-ce8224232bcf" xlink:to="loc_bngo_ConsumableRevenueMember_66f3af85-db78-4f2e-a5cd-9bc8d3e815c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SoftwareMember_c1022078-7d6d-41cb-9327-cce145803a6b" xlink:href="bngo-20230331.xsd#bngo_SoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_1cd5eb6f-5bab-4fc8-afcd-ce8224232bcf" xlink:to="loc_bngo_SoftwareMember_c1022078-7d6d-41cb-9327-cce145803a6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_b4bf064e-9562-4f9d-95dd-bd7f0be5ae90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8f91608f-c868-439f-97ac-a2934b4b45b1" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_b4bf064e-9562-4f9d-95dd-bd7f0be5ae90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ae95aa28-67da-480d-ac95-73468f7b0b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cf773597-049e-44cb-9c15-f5efabeb4de1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ae95aa28-67da-480d-ac95-73468f7b0b68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ae95aa28-67da-480d-ac95-73468f7b0b68_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ae95aa28-67da-480d-ac95-73468f7b0b68" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ae95aa28-67da-480d-ac95-73468f7b0b68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5628e58b-91af-4c4e-b6cc-a51becf4611c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ae95aa28-67da-480d-ac95-73468f7b0b68" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5628e58b-91af-4c4e-b6cc-a51becf4611c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_7d21e88c-60c2-4be6-8e4c-1f70de59f64a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5628e58b-91af-4c4e-b6cc-a51becf4611c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_7d21e88c-60c2-4be6-8e4c-1f70de59f64a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_70a1b031-30c9-42d4-a8fa-900ebd4dc207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5628e58b-91af-4c4e-b6cc-a51becf4611c" xlink:to="loc_us-gaap_SalesRevenueNetMember_70a1b031-30c9-42d4-a8fa-900ebd4dc207" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_3d2af62b-29f1-406a-8014-c23a228ff3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cf773597-049e-44cb-9c15-f5efabeb4de1" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_3d2af62b-29f1-406a-8014-c23a228ff3b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3d2af62b-29f1-406a-8014-c23a228ff3b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3d2af62b-29f1-406a-8014-c23a228ff3b9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3d2af62b-29f1-406a-8014-c23a228ff3b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e30276e0-6e28-4031-8be8-904291288faf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3d2af62b-29f1-406a-8014-c23a228ff3b9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e30276e0-6e28-4031-8be8-904291288faf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_c6554f26-6fd9-4153-b6ae-353c3866d071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e30276e0-6e28-4031-8be8-904291288faf" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_c6554f26-6fd9-4153-b6ae-353c3866d071" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f56cc131-a961-4010-ac0e-6c5529629bd5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cf773597-049e-44cb-9c15-f5efabeb4de1" xlink:to="loc_srt_StatementGeographicalAxis_f56cc131-a961-4010-ac0e-6c5529629bd5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f56cc131-a961-4010-ac0e-6c5529629bd5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_f56cc131-a961-4010-ac0e-6c5529629bd5" xlink:to="loc_srt_SegmentGeographicalDomain_f56cc131-a961-4010-ac0e-6c5529629bd5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_33769771-7146-4f71-80fd-73f3d36e819e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_f56cc131-a961-4010-ac0e-6c5529629bd5" xlink:to="loc_srt_SegmentGeographicalDomain_33769771-7146-4f71-80fd-73f3d36e819e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AmericasMember_6c61d86d-91cb-43dd-9092-1164acd9ed11" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AmericasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_33769771-7146-4f71-80fd-73f3d36e819e" xlink:to="loc_srt_AmericasMember_6c61d86d-91cb-43dd-9092-1164acd9ed11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_5203ba39-80b6-4a73-b84e-0f230b144ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_33769771-7146-4f71-80fd-73f3d36e819e" xlink:to="loc_us-gaap_EMEAMember_5203ba39-80b6-4a73-b84e-0f230b144ed8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_74a85cd2-9467-4a4e-81a0-c59a90c9a54f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_33769771-7146-4f71-80fd-73f3d36e819e" xlink:to="loc_srt_AsiaPacificMember_74a85cd2-9467-4a4e-81a0-c59a90c9a54f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#RevenueRecognitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended" id="i516113978c0447a1b79cbcaed4057f03_RevenueRecognitionNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9fa5cffd-85a0-472f-8128-9161b7e114c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_450e55e1-9bc0-431a-b458-f306e24148e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9fa5cffd-85a0-472f-8128-9161b7e114c2" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_450e55e1-9bc0-431a-b458-f306e24148e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0b87af8f-3bf5-4622-9286-2e319b595cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9fa5cffd-85a0-472f-8128-9161b7e114c2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0b87af8f-3bf5-4622-9286-2e319b595cf3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_7622d935-af6d-425d-8944-04bb1a516bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0b87af8f-3bf5-4622-9286-2e319b595cf3" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_7622d935-af6d-425d-8944-04bb1a516bcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_7622d935-af6d-425d-8944-04bb1a516bcf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_7622d935-af6d-425d-8944-04bb1a516bcf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_7622d935-af6d-425d-8944-04bb1a516bcf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6d07f101-7ffa-48d4-98d5-c833e317aff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_7622d935-af6d-425d-8944-04bb1a516bcf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6d07f101-7ffa-48d4-98d5-c833e317aff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_43f40a78-82ba-4461-9611-4af28a88df0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_6d07f101-7ffa-48d4-98d5-c833e317aff0" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_43f40a78-82ba-4461-9611-4af28a88df0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e3f0a366-ec81-4ec9-b9d4-35fdda65fe2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0b87af8f-3bf5-4622-9286-2e319b595cf3" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e3f0a366-ec81-4ec9-b9d4-35fdda65fe2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e3f0a366-ec81-4ec9-b9d4-35fdda65fe2f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e3f0a366-ec81-4ec9-b9d4-35fdda65fe2f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e3f0a366-ec81-4ec9-b9d4-35fdda65fe2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_02a541bf-0e7a-409f-bd56-e269eb1cae31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e3f0a366-ec81-4ec9-b9d4-35fdda65fe2f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_02a541bf-0e7a-409f-bd56-e269eb1cae31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_41bd1a79-341b-4ede-932d-10e40eabd176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_02a541bf-0e7a-409f-bd56-e269eb1cae31" xlink:to="loc_us-gaap_SalesRevenueNetMember_41bd1a79-341b-4ede-932d-10e40eabd176" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f0e2af7f-2442-4c32-8411-67d8b6d54add" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0b87af8f-3bf5-4622-9286-2e319b595cf3" xlink:to="loc_srt_StatementGeographicalAxis_f0e2af7f-2442-4c32-8411-67d8b6d54add" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f0e2af7f-2442-4c32-8411-67d8b6d54add_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_f0e2af7f-2442-4c32-8411-67d8b6d54add" xlink:to="loc_srt_SegmentGeographicalDomain_f0e2af7f-2442-4c32-8411-67d8b6d54add_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_dab7758e-67ce-4471-9d91-9ca319349348" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_f0e2af7f-2442-4c32-8411-67d8b6d54add" xlink:to="loc_srt_SegmentGeographicalDomain_dab7758e-67ce-4471-9d91-9ca319349348" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_66b216f1-fa5b-41f1-992f-24b601095722" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_dab7758e-67ce-4471-9d91-9ca319349348" xlink:to="loc_country_US_66b216f1-fa5b-41f1-992f-24b601095722" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#RevenueRecognitionRemainingPerformanceObligationsDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails" xlink:type="extended" id="i73418515150249939922543f0a456683_RevenueRecognitionRemainingPerformanceObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1a840967-e365-436b-9db1-68eb885c105f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_c34cf1ce-1ae1-4a60-b06e-8b7591167c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1a840967-e365-436b-9db1-68eb885c105f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_c34cf1ce-1ae1-4a60-b06e-8b7591167c45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_c8d2c0a1-1982-47ce-a71e-2661d778c42e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1a840967-e365-436b-9db1-68eb885c105f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_c8d2c0a1-1982-47ce-a71e-2661d778c42e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_c3100bdb-98e3-4507-ae84-312a9a4413a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1a840967-e365-436b-9db1-68eb885c105f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_c3100bdb-98e3-4507-ae84-312a9a4413a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_87cadf8c-0a0e-49aa-abbf-1d11f5b615f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1a840967-e365-436b-9db1-68eb885c105f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_87cadf8c-0a0e-49aa-abbf-1d11f5b615f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_c677e4e2-eb61-4d9d-86ce-7e2277159cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1a840967-e365-436b-9db1-68eb885c105f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_c677e4e2-eb61-4d9d-86ce-7e2277159cdd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_962d2871-0dec-4049-9017-8415ab6bd512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_c677e4e2-eb61-4d9d-86ce-7e2277159cdd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_962d2871-0dec-4049-9017-8415ab6bd512" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="bngo-20230331.xsd#RevenueRecognitionRemainingPerformanceObligationsDetails_1"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails_1" xlink:type="extended" id="i37e6f343f3d0442c8e90e6be9c80b0ee_RevenueRecognitionRemainingPerformanceObligationsDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1a840967-e365-436b-9db1-68eb885c105f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_c34cf1ce-1ae1-4a60-b06e-8b7591167c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1a840967-e365-436b-9db1-68eb885c105f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_c34cf1ce-1ae1-4a60-b06e-8b7591167c45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_c8d2c0a1-1982-47ce-a71e-2661d778c42e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1a840967-e365-436b-9db1-68eb885c105f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_c8d2c0a1-1982-47ce-a71e-2661d778c42e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_c3100bdb-98e3-4507-ae84-312a9a4413a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1a840967-e365-436b-9db1-68eb885c105f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_c3100bdb-98e3-4507-ae84-312a9a4413a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_87cadf8c-0a0e-49aa-abbf-1d11f5b615f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1a840967-e365-436b-9db1-68eb885c105f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_87cadf8c-0a0e-49aa-abbf-1d11f5b615f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_c677e4e2-eb61-4d9d-86ce-7e2277159cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1a840967-e365-436b-9db1-68eb885c105f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_c677e4e2-eb61-4d9d-86ce-7e2277159cdd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i68f7a0e9ff7447048908286555e6a227_BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_71d049e6-b6f1-4710-b276-67c4380792de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a21767c3-e45b-4f7a-bb63-54e7d1d96a53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_71d049e6-b6f1-4710-b276-67c4380792de" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a21767c3-e45b-4f7a-bb63-54e7d1d96a53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_33d8426b-b42e-416c-9550-70a84b00b436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_71d049e6-b6f1-4710-b276-67c4380792de" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_33d8426b-b42e-416c-9550-70a84b00b436" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ba565886-6971-41ac-bbc0-682aca238a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_71d049e6-b6f1-4710-b276-67c4380792de" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ba565886-6971-41ac-bbc0-682aca238a2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f2c32641-eaa0-4dae-9263-8820c753de35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_71d049e6-b6f1-4710-b276-67c4380792de" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f2c32641-eaa0-4dae-9263-8820c753de35" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3866c66-f993-450b-b912-c8e03289842f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f2c32641-eaa0-4dae-9263-8820c753de35" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3866c66-f993-450b-b912-c8e03289842f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c3866c66-f993-450b-b912-c8e03289842f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3866c66-f993-450b-b912-c8e03289842f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c3866c66-f993-450b-b912-c8e03289842f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6622b35b-fb1a-451c-91af-e8ebdad7576b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3866c66-f993-450b-b912-c8e03289842f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6622b35b-fb1a-451c-91af-e8ebdad7576b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_a55a30bf-b311-4b05-b7b3-2cf61f2e920b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6622b35b-fb1a-451c-91af-e8ebdad7576b" xlink:to="loc_us-gaap_TradeNamesMember_a55a30bf-b311-4b05-b7b3-2cf61f2e920b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_d74071c1-a0f8-43d1-9579-c9ba7240f2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6622b35b-fb1a-451c-91af-e8ebdad7576b" xlink:to="loc_us-gaap_CustomerRelationshipsMember_d74071c1-a0f8-43d1-9579-c9ba7240f2ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_763b336b-57c8-4eef-b4eb-80147d62d342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6622b35b-fb1a-451c-91af-e8ebdad7576b" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_763b336b-57c8-4eef-b4eb-80147d62d342" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#BalanceSheetAccountDetailsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="extended" id="iac36f7ac4bfd4253b2c0a39df0fb9e56_BalanceSheetAccountDetailsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6f20f3b6-361f-442f-91da-700f2905ca8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3c4d9b11-f3f6-4a44-ace6-be768f8941ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6f20f3b6-361f-442f-91da-700f2905ca8a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3c4d9b11-f3f6-4a44-ace6-be768f8941ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a04fac64-3937-46a4-be86-c988f999491d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6f20f3b6-361f-442f-91da-700f2905ca8a" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a04fac64-3937-46a4-be86-c988f999491d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_96fb87fa-edc3-435d-9781-2c04b4f02184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a04fac64-3937-46a4-be86-c988f999491d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_96fb87fa-edc3-435d-9781-2c04b4f02184" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_96fb87fa-edc3-435d-9781-2c04b4f02184_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_96fb87fa-edc3-435d-9781-2c04b4f02184" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_96fb87fa-edc3-435d-9781-2c04b4f02184_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e40b0eb9-15a4-4153-87b5-c09acf9cb32d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_96fb87fa-edc3-435d-9781-2c04b4f02184" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e40b0eb9-15a4-4153-87b5-c09acf9cb32d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternetDomainNamesMember_006aeb48-d5fa-432e-938d-adb590d74492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternetDomainNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e40b0eb9-15a4-4153-87b5-c09acf9cb32d" xlink:to="loc_us-gaap_InternetDomainNamesMember_006aeb48-d5fa-432e-938d-adb590d74492" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#StockholdersEquityandStockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails" xlink:type="extended" id="i33fc080d31f34d65ace5c8d3822fccd0_StockholdersEquityandStockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SaleOfStockValueSharesIssuedInTransaction_b9c276d8-8451-4cb6-af98-22bfd5981f28" xlink:href="bngo-20230331.xsd#bngo_SaleOfStockValueSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_bngo_SaleOfStockValueSharesIssuedInTransaction_b9c276d8-8451-4cb6-af98-22bfd5981f28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommissionFeeMaximumPercentageOfGrossProceeds_0d185f47-b707-4fbc-8c46-ca2355e50a3d" xlink:href="bngo-20230331.xsd#bngo_CommissionFeeMaximumPercentageOfGrossProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_bngo_CommissionFeeMaximumPercentageOfGrossProceeds_0d185f47-b707-4fbc-8c46-ca2355e50a3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_41257aa3-5b57-4cc7-a35b-0715c200fd54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_41257aa3-5b57-4cc7-a35b-0715c200fd54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_c7fd3d37-f732-4362-b200-d5fdd49dfea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_c7fd3d37-f732-4362-b200-d5fdd49dfea5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_3b6c17d5-7b2e-417b-9d5f-300b9061749d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_3b6c17d5-7b2e-417b-9d5f-300b9061749d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_ec3c2326-46fd-428a-8ad6-cde63a764672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_ec3c2326-46fd-428a-8ad6-cde63a764672" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_13fc7d7e-86a5-4ebc-84e3-2df9012649dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_13fc7d7e-86a5-4ebc-84e3-2df9012649dd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_af72077d-b20e-41cb-8848-030a6cbc73d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_af72077d-b20e-41cb-8848-030a6cbc73d5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1356e1da-d773-41e7-be0b-0e3309f1323a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1356e1da-d773-41e7-be0b-0e3309f1323a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_089b2df3-f412-4519-b8bb-8b6e80de7bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_089b2df3-f412-4519-b8bb-8b6e80de7bb5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0d365bba-408d-47e5-a87e-3b729e49880b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0d365bba-408d-47e5-a87e-3b729e49880b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_84e33e39-3acf-4211-ad4e-0291e4419304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_84e33e39-3acf-4211-ad4e-0291e4419304" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_fd8c3726-49ec-4040-8b27-bc3b93524516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_fd8c3726-49ec-4040-8b27-bc3b93524516" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_32aeca2c-3f09-45f6-9c04-d6172776a930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_32aeca2c-3f09-45f6-9c04-d6172776a930" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cd4680e2-315a-4efe-aa11-2d9a4bc7dc98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cd4680e2-315a-4efe-aa11-2d9a4bc7dc98" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7da45d36-38f4-42e7-b001-f027728e6151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7da45d36-38f4-42e7-b001-f027728e6151" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_af284867-e5f8-439c-b9a9-ff2a4af9a9be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_af284867-e5f8-439c-b9a9-ff2a4af9a9be" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments_37224bfb-85ef-4088-9d96-13ab7d39a823" xlink:href="bngo-20230331.xsd#bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments_37224bfb-85ef-4088-9d96-13ab7d39a823" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_85694884-0a2a-49b0-b381-74e3d022837c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_85694884-0a2a-49b0-b381-74e3d022837c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_625ff4a0-54bb-41a0-8e0d-e909ffe9b7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_625ff4a0-54bb-41a0-8e0d-e909ffe9b7a5" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PreferredStockNumberOfVotes_53cb1ff3-e896-4f80-82b1-d3b9866623fa" xlink:href="bngo-20230331.xsd#bngo_PreferredStockNumberOfVotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_bngo_PreferredStockNumberOfVotes_53cb1ff3-e896-4f80-82b1-d3b9866623fa" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent_13481bba-2662-4c98-9413-5bd620ede6c1" xlink:href="bngo-20230331.xsd#bngo_StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_bngo_StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent_13481bba-2662-4c98-9413-5bd620ede6c1" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare_7c3944ad-15af-42c5-9283-7ed43d1670e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockRedemptionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_PreferredStockRedemptionPricePerShare_7c3944ad-15af-42c5-9283-7ed43d1670e2" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3898ba4c-f09d-47dc-b8e2-213752991978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3898ba4c-f09d-47dc-b8e2-213752991978" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_485e08cd-f179-4d5f-bc66-98894d9b69f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3898ba4c-f09d-47dc-b8e2-213752991978" xlink:to="loc_srt_CounterpartyNameAxis_485e08cd-f179-4d5f-bc66-98894d9b69f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_485e08cd-f179-4d5f-bc66-98894d9b69f7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_485e08cd-f179-4d5f-bc66-98894d9b69f7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_485e08cd-f179-4d5f-bc66-98894d9b69f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d009d453-1ef9-4fe0-9598-f6884951de87" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_485e08cd-f179-4d5f-bc66-98894d9b69f7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d009d453-1ef9-4fe0-9598-f6884951de87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CowenMember_5e8fa98d-5949-403a-aafa-34611b6cc4b5" xlink:href="bngo-20230331.xsd#bngo_CowenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d009d453-1ef9-4fe0-9598-f6884951de87" xlink:to="loc_bngo_CowenMember_5e8fa98d-5949-403a-aafa-34611b6cc4b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3ec9930d-999c-4d9a-9cfe-e7be7c383f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3898ba4c-f09d-47dc-b8e2-213752991978" xlink:to="loc_us-gaap_AwardTypeAxis_3ec9930d-999c-4d9a-9cfe-e7be7c383f25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ec9930d-999c-4d9a-9cfe-e7be7c383f25_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3ec9930d-999c-4d9a-9cfe-e7be7c383f25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ec9930d-999c-4d9a-9cfe-e7be7c383f25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0504a091-78fd-4a88-bb09-9c3a80d8ba46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3ec9930d-999c-4d9a-9cfe-e7be7c383f25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0504a091-78fd-4a88-bb09-9c3a80d8ba46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_088ff7d4-8980-43e3-8b46-e9bd560ff2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0504a091-78fd-4a88-bb09-9c3a80d8ba46" xlink:to="loc_us-gaap_RestrictedStockMember_088ff7d4-8980-43e3-8b46-e9bd560ff2ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b3f4d24a-0924-4138-9152-74a75e7d3882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0504a091-78fd-4a88-bb09-9c3a80d8ba46" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b3f4d24a-0924-4138-9152-74a75e7d3882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PerformanceShareUnitsPSUsMember_1d7759a7-5849-4b67-893f-35221fb0366b" xlink:href="bngo-20230331.xsd#bngo_PerformanceShareUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0504a091-78fd-4a88-bb09-9c3a80d8ba46" xlink:to="loc_bngo_PerformanceShareUnitsPSUsMember_1d7759a7-5849-4b67-893f-35221fb0366b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_91aa1068-3002-474b-86a4-092f0fc158dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0504a091-78fd-4a88-bb09-9c3a80d8ba46" xlink:to="loc_us-gaap_EmployeeStockOptionMember_91aa1068-3002-474b-86a4-092f0fc158dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4f371ee9-8e18-439d-8634-782127b5c7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3898ba4c-f09d-47dc-b8e2-213752991978" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4f371ee9-8e18-439d-8634-782127b5c7a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f371ee9-8e18-439d-8634-782127b5c7a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4f371ee9-8e18-439d-8634-782127b5c7a1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f371ee9-8e18-439d-8634-782127b5c7a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a53eb952-e6ba-4666-b99f-afc045950732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4f371ee9-8e18-439d-8634-782127b5c7a1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a53eb952-e6ba-4666-b99f-afc045950732" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember_94c2a399-a9e8-4bce-be67-dd7a9b984bfe" xlink:href="bngo-20230331.xsd#bngo_BioDiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a53eb952-e6ba-4666-b99f-afc045950732" xlink:to="loc_bngo_BioDiscoveryMember_94c2a399-a9e8-4bce-be67-dd7a9b984bfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_ebf6cd8c-d4c9-41a5-a067-0ab6a7f27654" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3898ba4c-f09d-47dc-b8e2-213752991978" xlink:to="loc_srt_TitleOfIndividualAxis_ebf6cd8c-d4c9-41a5-a067-0ab6a7f27654" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ebf6cd8c-d4c9-41a5-a067-0ab6a7f27654_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_ebf6cd8c-d4c9-41a5-a067-0ab6a7f27654" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ebf6cd8c-d4c9-41a5-a067-0ab6a7f27654_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b7b99843-e6d7-4d1a-87f4-a70153b5bbdd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_ebf6cd8c-d4c9-41a5-a067-0ab6a7f27654" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b7b99843-e6d7-4d1a-87f4-a70153b5bbdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_5dbc566e-417b-47a5-b000-d51c639c930a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b7b99843-e6d7-4d1a-87f4-a70153b5bbdd" xlink:to="loc_srt_ExecutiveOfficerMember_5dbc566e-417b-47a5-b000-d51c639c930a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_a19f42b4-194c-4615-a253-2b1411fb75f1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b7b99843-e6d7-4d1a-87f4-a70153b5bbdd" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_a19f42b4-194c-4615-a253-2b1411fb75f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_d9a04a5a-cf2c-4a0e-b838-0bfda0258275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3898ba4c-f09d-47dc-b8e2-213752991978" xlink:to="loc_us-gaap_VestingAxis_d9a04a5a-cf2c-4a0e-b838-0bfda0258275" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_d9a04a5a-cf2c-4a0e-b838-0bfda0258275_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_d9a04a5a-cf2c-4a0e-b838-0bfda0258275" xlink:to="loc_us-gaap_VestingDomain_d9a04a5a-cf2c-4a0e-b838-0bfda0258275_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a2fb7ffb-e5c3-42bc-a136-d71c7a64d87a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_d9a04a5a-cf2c-4a0e-b838-0bfda0258275" xlink:to="loc_us-gaap_VestingDomain_a2fb7ffb-e5c3-42bc-a136-d71c7a64d87a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_39ac35d8-f7fb-4248-a627-ab2d52ff8a06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a2fb7ffb-e5c3-42bc-a136-d71c7a64d87a" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_39ac35d8-f7fb-4248-a627-ab2d52ff8a06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_aa160dd6-f828-4343-8d94-de59c3fb63a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a2fb7ffb-e5c3-42bc-a136-d71c7a64d87a" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_aa160dd6-f828-4343-8d94-de59c3fb63a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_24fe5536-334b-4183-8da5-d825fa4c27e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3898ba4c-f09d-47dc-b8e2-213752991978" xlink:to="loc_us-gaap_StatementClassOfStockAxis_24fe5536-334b-4183-8da5-d825fa4c27e7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_24fe5536-334b-4183-8da5-d825fa4c27e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_24fe5536-334b-4183-8da5-d825fa4c27e7" xlink:to="loc_us-gaap_ClassOfStockDomain_24fe5536-334b-4183-8da5-d825fa4c27e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_97354c6b-b720-4ea3-b03a-2d46e2c61799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_24fe5536-334b-4183-8da5-d825fa4c27e7" xlink:to="loc_us-gaap_ClassOfStockDomain_97354c6b-b720-4ea3-b03a-2d46e2c61799" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_f31a33cd-dc52-4468-ae3c-563bef064d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_97354c6b-b720-4ea3-b03a-2d46e2c61799" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_f31a33cd-dc52-4468-ae3c-563bef064d8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8ee73e17-8e46-4a72-b1df-eb567fdf0d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3898ba4c-f09d-47dc-b8e2-213752991978" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8ee73e17-8e46-4a72-b1df-eb567fdf0d4c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8ee73e17-8e46-4a72-b1df-eb567fdf0d4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8ee73e17-8e46-4a72-b1df-eb567fdf0d4c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8ee73e17-8e46-4a72-b1df-eb567fdf0d4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_242421e4-1142-4651-9821-423cce835709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8ee73e17-8e46-4a72-b1df-eb567fdf0d4c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_242421e4-1142-4651-9821-423cce835709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b42fe33f-b7ea-490e-98eb-179f308e1467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_242421e4-1142-4651-9821-423cce835709" xlink:to="loc_us-gaap_SubsequentEventMember_b42fe33f-b7ea-490e-98eb-179f308e1467" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" xlink:type="extended" id="i11047178b63c40a99bfb29768216e026_StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_869ac748-9256-4bc1-81c4-810f9399ba0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8a78b1e0-f99b-4abc-b740-9ec76e257e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_869ac748-9256-4bc1-81c4-810f9399ba0f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8a78b1e0-f99b-4abc-b740-9ec76e257e9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d968504-c195-4812-9245-9e199956de50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_869ac748-9256-4bc1-81c4-810f9399ba0f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d968504-c195-4812-9245-9e199956de50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_53a49a7a-dad9-4de9-bbbb-213f8190de9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d968504-c195-4812-9245-9e199956de50" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_53a49a7a-dad9-4de9-bbbb-213f8190de9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_53a49a7a-dad9-4de9-bbbb-213f8190de9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_53a49a7a-dad9-4de9-bbbb-213f8190de9a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_53a49a7a-dad9-4de9-bbbb-213f8190de9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8973fc52-e5e1-4a39-a340-1f9e8df5ca59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_53a49a7a-dad9-4de9-bbbb-213f8190de9a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8973fc52-e5e1-4a39-a340-1f9e8df5ca59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CostOfProductRevenueMember_9b812f2e-98a3-43d3-bebf-220578a0ab45" xlink:href="bngo-20230331.xsd#bngo_CostOfProductRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8973fc52-e5e1-4a39-a340-1f9e8df5ca59" xlink:to="loc_bngo_CostOfProductRevenueMember_9b812f2e-98a3-43d3-bebf-220578a0ab45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CostOfServiceAndOtherRevenueMember_003e189c-df38-4b6a-914f-15e728a50635" xlink:href="bngo-20230331.xsd#bngo_CostOfServiceAndOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8973fc52-e5e1-4a39-a340-1f9e8df5ca59" xlink:to="loc_bngo_CostOfServiceAndOtherRevenueMember_003e189c-df38-4b6a-914f-15e728a50635" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_78df54bd-9eff-4630-a8e5-a3a77568404a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8973fc52-e5e1-4a39-a340-1f9e8df5ca59" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_78df54bd-9eff-4630-a8e5-a3a77568404a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2faa4aca-b493-4fe6-8306-fd173d7d58ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8973fc52-e5e1-4a39-a340-1f9e8df5ca59" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2faa4aca-b493-4fe6-8306-fd173d7d58ef" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails" xlink:type="extended" id="i89f681082fa54df5ab03fd7b96032dec_StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3828f5fd-473c-46fe-984f-58e4b38b94eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09e70fba-605a-4bc5-830e-561b7402a35d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3828f5fd-473c-46fe-984f-58e4b38b94eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09e70fba-605a-4bc5-830e-561b7402a35d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b58bb0fb-110d-4342-919e-d5c31985638f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09e70fba-605a-4bc5-830e-561b7402a35d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b58bb0fb-110d-4342-919e-d5c31985638f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_83215771-35cd-41a1-82b5-69f75632c792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09e70fba-605a-4bc5-830e-561b7402a35d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_83215771-35cd-41a1-82b5-69f75632c792" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f9ef4be6-f168-40dc-b4e4-98de79de85d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09e70fba-605a-4bc5-830e-561b7402a35d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f9ef4be6-f168-40dc-b4e4-98de79de85d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2d362394-0f6a-4302-b6ab-a1e95c7e075c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09e70fba-605a-4bc5-830e-561b7402a35d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2d362394-0f6a-4302-b6ab-a1e95c7e075c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f400757f-17dc-492c-b2b6-96f567a9d93c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f8ffb710-46ab-4a7d-988d-a3f182307115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3828f5fd-473c-46fe-984f-58e4b38b94eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f8ffb710-46ab-4a7d-988d-a3f182307115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b5d2c40a-0b30-4cf7-aeed-52b01e313be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f8ffb710-46ab-4a7d-988d-a3f182307115" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b5d2c40a-0b30-4cf7-aeed-52b01e313be0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_45dbda8e-3830-4692-ad90-c33f4d714b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f8ffb710-46ab-4a7d-988d-a3f182307115" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_45dbda8e-3830-4692-ad90-c33f4d714b87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30685770-ae5f-4b05-809e-cd952e8e07bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f8ffb710-46ab-4a7d-988d-a3f182307115" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30685770-ae5f-4b05-809e-cd952e8e07bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_420f8ec2-99a3-4f8b-9c33-28379a1b1690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f8ffb710-46ab-4a7d-988d-a3f182307115" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_420f8ec2-99a3-4f8b-9c33-28379a1b1690" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5a8e9674-e75e-449c-a28d-36f1a826f7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a46b0a2-9ca5-4809-8ff5-7ceda0159902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3828f5fd-473c-46fe-984f-58e4b38b94eb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a46b0a2-9ca5-4809-8ff5-7ceda0159902" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_845cff19-fea6-4a74-ac34-b4b9977fa2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a46b0a2-9ca5-4809-8ff5-7ceda0159902" xlink:to="loc_us-gaap_AwardTypeAxis_845cff19-fea6-4a74-ac34-b4b9977fa2c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_845cff19-fea6-4a74-ac34-b4b9977fa2c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_845cff19-fea6-4a74-ac34-b4b9977fa2c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_845cff19-fea6-4a74-ac34-b4b9977fa2c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65ccb4d0-72c5-4541-acc6-eade44670595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_845cff19-fea6-4a74-ac34-b4b9977fa2c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65ccb4d0-72c5-4541-acc6-eade44670595" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c196e980-9495-4fe8-a0c7-e14fa15d4fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65ccb4d0-72c5-4541-acc6-eade44670595" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c196e980-9495-4fe8-a0c7-e14fa15d4fe2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PerformanceShareUnitsPSUsMember_ba9c300c-8451-40df-ba91-75028fc54722" xlink:href="bngo-20230331.xsd#bngo_PerformanceShareUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65ccb4d0-72c5-4541-acc6-eade44670595" xlink:to="loc_bngo_PerformanceShareUnitsPSUsMember_ba9c300c-8451-40df-ba91-75028fc54722" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#AcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/AcquisitionsNarrativeDetails" xlink:type="extended" id="iea306016782a478c90c7b9fb5f4dd01c_AcquisitionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_651b1f78-9ae5-4c37-a24f-a5f01468eff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6aa9f9b5-dbec-49cb-b830-07f5bb58d8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_651b1f78-9ae5-4c37-a24f-a5f01468eff5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6aa9f9b5-dbec-49cb-b830-07f5bb58d8f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_bf5c257c-0675-430c-9b71-ee498068c2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_651b1f78-9ae5-4c37-a24f-a5f01468eff5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_bf5c257c-0675-430c-9b71-ee498068c2ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessAcquisitionCashHeldInEscrowFund_54364c22-a922-41b3-bb92-734dcc352c2b" xlink:href="bngo-20230331.xsd#bngo_BusinessAcquisitionCashHeldInEscrowFund"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_651b1f78-9ae5-4c37-a24f-a5f01468eff5" xlink:to="loc_bngo_BusinessAcquisitionCashHeldInEscrowFund_54364c22-a922-41b3-bb92-734dcc352c2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_3498e64d-4110-4510-8fca-05269e9dbf99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_651b1f78-9ae5-4c37-a24f-a5f01468eff5" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_3498e64d-4110-4510-8fca-05269e9dbf99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_25eeef18-3e0f-4295-8495-f21422dfc57b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_651b1f78-9ae5-4c37-a24f-a5f01468eff5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_25eeef18-3e0f-4295-8495-f21422dfc57b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_37f0edd9-e5dc-4344-a4dd-bf25ff0552eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_25eeef18-3e0f-4295-8495-f21422dfc57b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_37f0edd9-e5dc-4344-a4dd-bf25ff0552eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_37f0edd9-e5dc-4344-a4dd-bf25ff0552eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_37f0edd9-e5dc-4344-a4dd-bf25ff0552eb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_37f0edd9-e5dc-4344-a4dd-bf25ff0552eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_397895e7-fda9-4985-9746-72468940d0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_37f0edd9-e5dc-4344-a4dd-bf25ff0552eb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_397895e7-fda9-4985-9746-72468940d0d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PurigenMember_71d06054-d8b8-46ae-af00-eb5ed090a724" xlink:href="bngo-20230331.xsd#bngo_PurigenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_397895e7-fda9-4985-9746-72468940d0d6" xlink:to="loc_bngo_PurigenMember_71d06054-d8b8-46ae-af00-eb5ed090a724" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fc5abc04-2f05-4fbe-ba70-a6690cc033b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_25eeef18-3e0f-4295-8495-f21422dfc57b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fc5abc04-2f05-4fbe-ba70-a6690cc033b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc5abc04-2f05-4fbe-ba70-a6690cc033b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fc5abc04-2f05-4fbe-ba70-a6690cc033b0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc5abc04-2f05-4fbe-ba70-a6690cc033b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f95d3dfa-1307-42c5-a648-8427c56bf552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fc5abc04-2f05-4fbe-ba70-a6690cc033b0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f95d3dfa-1307-42c5-a648-8427c56bf552" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_9101c536-bf40-4289-9a53-5c6ba7f6aae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f95d3dfa-1307-42c5-a648-8427c56bf552" xlink:to="loc_us-gaap_CustomerRelationshipsMember_9101c536-bf40-4289-9a53-5c6ba7f6aae4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_5e7da62c-0b16-4d7f-95c5-572f4d4a4c99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f95d3dfa-1307-42c5-a648-8427c56bf552" xlink:to="loc_us-gaap_TradeNamesMember_5e7da62c-0b16-4d7f-95c5-572f4d4a4c99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_87caba04-cb89-45f4-a573-68e6e226d6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f95d3dfa-1307-42c5-a648-8427c56bf552" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_87caba04-cb89-45f4-a573-68e6e226d6c1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#AcquisitionsAcquisitionPurchasePriceDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails" xlink:type="extended" id="ibe25108a730b47459f557f5edf2c9d60_AcquisitionsAcquisitionPurchasePriceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8b3393ac-32f2-4049-945a-c829ea11ae4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_ae2c41f0-6196-4406-8b9b-6dd7dbb7047a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b3393ac-32f2-4049-945a-c829ea11ae4a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_ae2c41f0-6196-4406-8b9b-6dd7dbb7047a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c588a8de-873b-4f96-a9d4-97e134591329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b3393ac-32f2-4049-945a-c829ea11ae4a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c588a8de-873b-4f96-a9d4-97e134591329" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow_bd0aebcc-a473-486c-b5cd-3de2f5ba5bbd" xlink:href="bngo-20230331.xsd#bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b3393ac-32f2-4049-945a-c829ea11ae4a" xlink:to="loc_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow_bd0aebcc-a473-486c-b5cd-3de2f5ba5bbd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_55352537-8375-4931-8c99-a7de52e5ee81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b3393ac-32f2-4049-945a-c829ea11ae4a" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_55352537-8375-4931-8c99-a7de52e5ee81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1f3af56-ac91-4701-a083-e2e65b5bca4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b3393ac-32f2-4049-945a-c829ea11ae4a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1f3af56-ac91-4701-a083-e2e65b5bca4f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5b2035ce-21b8-447a-bc1a-bd9edc32de67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1f3af56-ac91-4701-a083-e2e65b5bca4f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5b2035ce-21b8-447a-bc1a-bd9edc32de67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5b2035ce-21b8-447a-bc1a-bd9edc32de67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5b2035ce-21b8-447a-bc1a-bd9edc32de67" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5b2035ce-21b8-447a-bc1a-bd9edc32de67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e848901c-646b-4a3a-986d-38cd36463cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5b2035ce-21b8-447a-bc1a-bd9edc32de67" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e848901c-646b-4a3a-986d-38cd36463cd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PurigenMember_65020419-3d54-4fe8-ad83-a0aa1ec10ead" xlink:href="bngo-20230331.xsd#bngo_PurigenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e848901c-646b-4a3a-986d-38cd36463cd3" xlink:to="loc_bngo_PurigenMember_65020419-3d54-4fe8-ad83-a0aa1ec10ead" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="i2ecc2aac633142299ce8138853a118e5_AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_cb27ed60-fe3d-474f-a883-a4c489cbaa56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_cb27ed60-fe3d-474f-a883-a4c489cbaa56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_20c14f55-21a6-4ca1-89f4-e9c790c74078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_20c14f55-21a6-4ca1-89f4-e9c790c74078" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_ccd9c1c1-b00e-4f2f-9707-e98e907ed190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_ccd9c1c1-b00e-4f2f-9707-e98e907ed190" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_74264870-ac74-4d4f-b20f-55aaa599bd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_74264870-ac74-4d4f-b20f-55aaa599bd5f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_1a5c66c8-38af-4bdf-92dd-bb95728a300f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_1a5c66c8-38af-4bdf-92dd-bb95728a300f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_1d5e58f7-b89c-4ffa-999c-b3e0d737deb5" xlink:href="bngo-20230331.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_1d5e58f7-b89c-4ffa-999c-b3e0d737deb5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_ab70e3de-9bf0-4c04-8cc0-d5e63a42d73c" xlink:href="bngo-20230331.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_ab70e3de-9bf0-4c04-8cc0-d5e63a42d73c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_24be3bd7-d81b-4989-9ed8-3d9e6a7bea66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_24be3bd7-d81b-4989-9ed8-3d9e6a7bea66" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_9e6eca3c-e72e-4a7b-b1c7-c676ae6731c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_9e6eca3c-e72e-4a7b-b1c7-c676ae6731c3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0f9e8cde-1c35-433e-a06a-e551c80a4fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_us-gaap_Goodwill_0f9e8cde-1c35-433e-a06a-e551c80a4fb2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities_c7bfa510-4d8c-4e09-a5ec-ffc6793e6dc9" xlink:href="bngo-20230331.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities_c7bfa510-4d8c-4e09-a5ec-ffc6793e6dc9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent_a21e9e72-589d-4b1c-b290-17c69942a276" xlink:href="bngo-20230331.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent_a21e9e72-589d-4b1c-b290-17c69942a276" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_16b2488d-dd2d-4298-95af-6c9e1ab26c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_16b2488d-dd2d-4298-95af-6c9e1ab26c83" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f3fe2cca-e26b-4172-a7da-118a4ab12277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f3fe2cca-e26b-4172-a7da-118a4ab12277" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_684fd53e-e75e-4e65-89c8-d2809ca6ce6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f3fe2cca-e26b-4172-a7da-118a4ab12277" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_684fd53e-e75e-4e65-89c8-d2809ca6ce6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_684fd53e-e75e-4e65-89c8-d2809ca6ce6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_684fd53e-e75e-4e65-89c8-d2809ca6ce6d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_684fd53e-e75e-4e65-89c8-d2809ca6ce6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7fe21ddb-ebe0-4fe8-b995-6acb7bcde73d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_684fd53e-e75e-4e65-89c8-d2809ca6ce6d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7fe21ddb-ebe0-4fe8-b995-6acb7bcde73d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PurigenMember_15d13f41-e4ed-48d2-b7e2-8a03472695d4" xlink:href="bngo-20230331.xsd#bngo_PurigenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7fe21ddb-ebe0-4fe8-b995-6acb7bcde73d" xlink:to="loc_bngo_PurigenMember_15d13f41-e4ed-48d2-b7e2-8a03472695d4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#AcquisitionsIdentifiableIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails" xlink:type="extended" id="i10176f2a75dc4095a953698ac8ce51ad_AcquisitionsIdentifiableIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d9b58a9c-795b-4abd-b1b0-20381b76fb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_04e6f0b2-bf81-4bab-975b-3cad78b32715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9b58a9c-795b-4abd-b1b0-20381b76fb8f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_04e6f0b2-bf81-4bab-975b-3cad78b32715" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5d5d40e-178e-4c4d-8e22-4f61d15f0634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9b58a9c-795b-4abd-b1b0-20381b76fb8f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5d5d40e-178e-4c4d-8e22-4f61d15f0634" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5bb34919-065f-47db-804d-1281642c5044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5d5d40e-178e-4c4d-8e22-4f61d15f0634" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5bb34919-065f-47db-804d-1281642c5044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5bb34919-065f-47db-804d-1281642c5044_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5bb34919-065f-47db-804d-1281642c5044" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5bb34919-065f-47db-804d-1281642c5044_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e01b3e0-ae5b-42fb-8f0a-5fa80fa698db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5bb34919-065f-47db-804d-1281642c5044" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e01b3e0-ae5b-42fb-8f0a-5fa80fa698db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PurigenMember_a40201f9-94a3-4e9d-b7f6-9a903fa4cf50" xlink:href="bngo-20230331.xsd#bngo_PurigenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e01b3e0-ae5b-42fb-8f0a-5fa80fa698db" xlink:to="loc_bngo_PurigenMember_a40201f9-94a3-4e9d-b7f6-9a903fa4cf50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_65ba0533-ab2e-4ef9-9a21-468f2952bb98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5d5d40e-178e-4c4d-8e22-4f61d15f0634" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_65ba0533-ab2e-4ef9-9a21-468f2952bb98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65ba0533-ab2e-4ef9-9a21-468f2952bb98_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_65ba0533-ab2e-4ef9-9a21-468f2952bb98" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65ba0533-ab2e-4ef9-9a21-468f2952bb98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_126fd2e4-555a-4c63-a85e-71108b200781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_65ba0533-ab2e-4ef9-9a21-468f2952bb98" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_126fd2e4-555a-4c63-a85e-71108b200781" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_fc6bcf1c-c5f5-4859-940c-66b62c27f69d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_126fd2e4-555a-4c63-a85e-71108b200781" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_fc6bcf1c-c5f5-4859-940c-66b62c27f69d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_cc623a79-dea9-470d-a595-2bacdceea9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_126fd2e4-555a-4c63-a85e-71108b200781" xlink:to="loc_us-gaap_CustomerRelationshipsMember_cc623a79-dea9-470d-a595-2bacdceea9b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_4efc8e3a-ed72-45d9-9e15-43b8050414e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_126fd2e4-555a-4c63-a85e-71108b200781" xlink:to="loc_us-gaap_TradeNamesMember_4efc8e3a-ed72-45d9-9e15-43b8050414e7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#AcquisitionsProFormaInformationDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails" xlink:type="extended" id="ic4d23a22bdf74a3482f259885ddd0f30_AcquisitionsProFormaInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_bb8b2b69-34cc-449d-b393-bb55c9f63d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_8993de80-33ea-414f-9852-6b847f3e0a71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb8b2b69-34cc-449d-b393-bb55c9f63d4d" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_8993de80-33ea-414f-9852-6b847f3e0a71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_65b7cd6f-dfb8-4d7d-a75d-a9e0555b9069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb8b2b69-34cc-449d-b393-bb55c9f63d4d" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_65b7cd6f-dfb8-4d7d-a75d-a9e0555b9069" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_6865960c-8717-4e3c-b8c6-e0a7d84006ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb8b2b69-34cc-449d-b393-bb55c9f63d4d" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_6865960c-8717-4e3c-b8c6-e0a7d84006ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_5e52b071-a3a0-4eca-9640-0ab448b8a8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb8b2b69-34cc-449d-b393-bb55c9f63d4d" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_5e52b071-a3a0-4eca-9640-0ab448b8a8c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2184b5a8-c4d6-41fc-9a66-5dc7548a2890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb8b2b69-34cc-449d-b393-bb55c9f63d4d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2184b5a8-c4d6-41fc-9a66-5dc7548a2890" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_10536a81-af81-4b50-8b9b-80cb13635c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2184b5a8-c4d6-41fc-9a66-5dc7548a2890" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_10536a81-af81-4b50-8b9b-80cb13635c40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10536a81-af81-4b50-8b9b-80cb13635c40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_10536a81-af81-4b50-8b9b-80cb13635c40" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10536a81-af81-4b50-8b9b-80cb13635c40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2a627bac-b89d-48c5-9501-95271102620f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_10536a81-af81-4b50-8b9b-80cb13635c40" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2a627bac-b89d-48c5-9501-95271102620f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PurigenMember_d01f8cc3-e4d7-4868-980d-7853ac5acfd9" xlink:href="bngo-20230331.xsd#bngo_PurigenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2a627bac-b89d-48c5-9501-95271102620f" xlink:to="loc_bngo_PurigenMember_d01f8cc3-e4d7-4868-980d-7853ac5acfd9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails" xlink:type="extended" id="ieed2ee055d1549c8808d1b2b7406d652_InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bb1a830e-08a7-4af6-80ad-eaf98cf359d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_d60dc66f-e893-46bb-a054-d6de4d7ae856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bb1a830e-08a7-4af6-80ad-eaf98cf359d9" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_d60dc66f-e893-46bb-a054-d6de4d7ae856" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_26a60ea7-9ac6-46dd-84cc-deca77bfa31e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bb1a830e-08a7-4af6-80ad-eaf98cf359d9" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_26a60ea7-9ac6-46dd-84cc-deca77bfa31e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_68076644-4d82-4a8f-83e0-f3121c605374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bb1a830e-08a7-4af6-80ad-eaf98cf359d9" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_68076644-4d82-4a8f-83e0-f3121c605374" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b0adc2e3-0a50-411a-b6e2-a40cc30de26b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_68076644-4d82-4a8f-83e0-f3121c605374" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b0adc2e3-0a50-411a-b6e2-a40cc30de26b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b0adc2e3-0a50-411a-b6e2-a40cc30de26b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b0adc2e3-0a50-411a-b6e2-a40cc30de26b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b0adc2e3-0a50-411a-b6e2-a40cc30de26b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2bef79bf-69bd-4cce-ac0e-25b01218abb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b0adc2e3-0a50-411a-b6e2-a40cc30de26b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2bef79bf-69bd-4cce-ac0e-25b01218abb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_86f03d49-8339-45d5-973c-20acc4977533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2bef79bf-69bd-4cce-ac0e-25b01218abb6" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_86f03d49-8339-45d5-973c-20acc4977533" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9f7b252f-aa11-419d-8475-c99169b54c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_68076644-4d82-4a8f-83e0-f3121c605374" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9f7b252f-aa11-419d-8475-c99169b54c96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f7b252f-aa11-419d-8475-c99169b54c96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9f7b252f-aa11-419d-8475-c99169b54c96" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f7b252f-aa11-419d-8475-c99169b54c96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a399fc09-544e-469c-97f1-14c4032d8c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9f7b252f-aa11-419d-8475-c99169b54c96" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a399fc09-544e-469c-97f1-14c4032d8c01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2d3cde65-e290-4d1e-a984-97ca4c0bc3af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a399fc09-544e-469c-97f1-14c4032d8c01" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2d3cde65-e290-4d1e-a984-97ca4c0bc3af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f72accda-2f7e-4f16-af8f-c6afa345ff10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a399fc09-544e-469c-97f1-14c4032d8c01" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f72accda-2f7e-4f16-af8f-c6afa345ff10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5f4fd640-616a-49df-8876-bf86a2c0c25c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a399fc09-544e-469c-97f1-14c4032d8c01" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5f4fd640-616a-49df-8876-bf86a2c0c25c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_123ccc99-6508-4340-97ca-92a2fbd17e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_68076644-4d82-4a8f-83e0-f3121c605374" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_123ccc99-6508-4340-97ca-92a2fbd17e58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_123ccc99-6508-4340-97ca-92a2fbd17e58_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_123ccc99-6508-4340-97ca-92a2fbd17e58" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_123ccc99-6508-4340-97ca-92a2fbd17e58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1995db25-cb52-4b8b-9b8c-fd04d3e90f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_123ccc99-6508-4340-97ca-92a2fbd17e58" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1995db25-cb52-4b8b-9b8c-fd04d3e90f1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_34a3cb76-edbb-4ffa-adcf-ede90326c53e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1995db25-cb52-4b8b-9b8c-fd04d3e90f1d" xlink:to="loc_us-gaap_InvestmentsMember_34a3cb76-edbb-4ffa-adcf-ede90326c53e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7bfe72bc-0dff-4cfe-a89b-1f18808e2ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1995db25-cb52-4b8b-9b8c-fd04d3e90f1d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7bfe72bc-0dff-4cfe-a89b-1f18808e2ac3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_c95ef387-f9f6-4160-9dc4-2d5b0e70c4ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_68076644-4d82-4a8f-83e0-f3121c605374" xlink:to="loc_us-gaap_InvestmentTypeAxis_c95ef387-f9f6-4160-9dc4-2d5b0e70c4ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_c95ef387-f9f6-4160-9dc4-2d5b0e70c4ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_c95ef387-f9f6-4160-9dc4-2d5b0e70c4ef" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_c95ef387-f9f6-4160-9dc4-2d5b0e70c4ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_3de55755-07bf-4e2b-b461-ddf46e46c3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_c95ef387-f9f6-4160-9dc4-2d5b0e70c4ef" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_3de55755-07bf-4e2b-b461-ddf46e46c3aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_5f7ef3f1-330e-4db7-b7f6-2a3278b39473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_3de55755-07bf-4e2b-b461-ddf46e46c3aa" xlink:to="loc_us-gaap_CommercialPaperMember_5f7ef3f1-330e-4db7-b7f6-2a3278b39473" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CorporateNotesAndBondsMember_41648a1a-ba26-4819-84af-f7f2ba329d12" xlink:href="bngo-20230331.xsd#bngo_CorporateNotesAndBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_3de55755-07bf-4e2b-b461-ddf46e46c3aa" xlink:to="loc_bngo_CorporateNotesAndBondsMember_41648a1a-ba26-4819-84af-f7f2ba329d12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_cf1ca20c-5241-417d-a9bc-5e3e8a442db2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_3de55755-07bf-4e2b-b461-ddf46e46c3aa" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_cf1ca20c-5241-417d-a9bc-5e3e8a442db2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ed922c41-3bee-4320-bf0b-0ab6db8394cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_68076644-4d82-4a8f-83e0-f3121c605374" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ed922c41-3bee-4320-bf0b-0ab6db8394cb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ed922c41-3bee-4320-bf0b-0ab6db8394cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ed922c41-3bee-4320-bf0b-0ab6db8394cb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ed922c41-3bee-4320-bf0b-0ab6db8394cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd97aae8-38cd-4315-8ecf-13ea545e9506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ed922c41-3bee-4320-bf0b-0ab6db8394cb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd97aae8-38cd-4315-8ecf-13ea545e9506" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationLiabilityMember_58986413-1b6f-4f88-9f17-ef3822145aa4" xlink:href="bngo-20230331.xsd#bngo_ContingentConsiderationLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd97aae8-38cd-4315-8ecf-13ea545e9506" xlink:to="loc_bngo_ContingentConsiderationLiabilityMember_58986413-1b6f-4f88-9f17-ef3822145aa4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#InvestmentsandFairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="extended" id="id600685bafab457ba12c1dc19daf199f_InvestmentsandFairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8017b051-d0ad-463b-baf3-71eb974ab040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_bc6ae69e-ca18-4297-abe6-d399b364fa85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8017b051-d0ad-463b-baf3-71eb974ab040" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_bc6ae69e-ca18-4297-abe6-d399b364fa85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationContingentConsiderationMilestonePayment_a8778a63-2635-43a5-a9c8-d299d9cb359b" xlink:href="bngo-20230331.xsd#bngo_BusinessCombinationContingentConsiderationMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8017b051-d0ad-463b-baf3-71eb974ab040" xlink:to="loc_bngo_BusinessCombinationContingentConsiderationMilestonePayment_a8778a63-2635-43a5-a9c8-d299d9cb359b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_d3f6bc8a-8c29-4cec-956c-bce3d3697ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8017b051-d0ad-463b-baf3-71eb974ab040" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_d3f6bc8a-8c29-4cec-956c-bce3d3697ca3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_347dfd94-ad46-4d8e-82f6-ecec520cb1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8017b051-d0ad-463b-baf3-71eb974ab040" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_347dfd94-ad46-4d8e-82f6-ecec520cb1e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_4f45c659-c121-4d7e-b348-ddbe697388a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8017b051-d0ad-463b-baf3-71eb974ab040" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_4f45c659-c121-4d7e-b348-ddbe697388a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_578eeda8-8691-4227-b944-be7230e624bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8017b051-d0ad-463b-baf3-71eb974ab040" xlink:to="loc_us-gaap_InterestReceivable_578eeda8-8691-4227-b944-be7230e624bf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3245f40-1eec-4cfe-b6bc-02f3a730fe74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8017b051-d0ad-463b-baf3-71eb974ab040" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3245f40-1eec-4cfe-b6bc-02f3a730fe74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1987ee7f-b29f-41d6-a563-c07de0246cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3245f40-1eec-4cfe-b6bc-02f3a730fe74" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1987ee7f-b29f-41d6-a563-c07de0246cf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1987ee7f-b29f-41d6-a563-c07de0246cf3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1987ee7f-b29f-41d6-a563-c07de0246cf3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1987ee7f-b29f-41d6-a563-c07de0246cf3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9dfdf863-4ef8-4f54-991a-e3751b034b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1987ee7f-b29f-41d6-a563-c07de0246cf3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9dfdf863-4ef8-4f54-991a-e3751b034b52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationLiabilityMember_e3b38936-4c9a-4413-adec-c0460e3f028d" xlink:href="bngo-20230331.xsd#bngo_ContingentConsiderationLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9dfdf863-4ef8-4f54-991a-e3751b034b52" xlink:to="loc_bngo_ContingentConsiderationLiabilityMember_e3b38936-4c9a-4413-adec-c0460e3f028d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_32c1c5c8-318e-4a60-9fa7-431514c11bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3245f40-1eec-4cfe-b6bc-02f3a730fe74" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_32c1c5c8-318e-4a60-9fa7-431514c11bef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_32c1c5c8-318e-4a60-9fa7-431514c11bef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_32c1c5c8-318e-4a60-9fa7-431514c11bef" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_32c1c5c8-318e-4a60-9fa7-431514c11bef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0ac990ed-a16e-44e8-8cc0-2cb06f7cb0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_32c1c5c8-318e-4a60-9fa7-431514c11bef" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0ac990ed-a16e-44e8-8cc0-2cb06f7cb0ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_c8998724-6e03-4662-91a5-d154b47485bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0ac990ed-a16e-44e8-8cc0-2cb06f7cb0ea" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_c8998724-6e03-4662-91a5-d154b47485bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_MeasurementInputProbabilityFactorMember_7886e568-d466-4480-a141-f93d28713e83" xlink:href="bngo-20230331.xsd#bngo_MeasurementInputProbabilityFactorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0ac990ed-a16e-44e8-8cc0-2cb06f7cb0ea" xlink:to="loc_bngo_MeasurementInputProbabilityFactorMember_7886e568-d466-4480-a141-f93d28713e83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e6a0f206-ca3f-46e8-b97f-528d48091dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3245f40-1eec-4cfe-b6bc-02f3a730fe74" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e6a0f206-ca3f-46e8-b97f-528d48091dbb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e6a0f206-ca3f-46e8-b97f-528d48091dbb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e6a0f206-ca3f-46e8-b97f-528d48091dbb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e6a0f206-ca3f-46e8-b97f-528d48091dbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c19046a-83df-44c6-95f6-6f0f1839ec34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e6a0f206-ca3f-46e8-b97f-528d48091dbb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c19046a-83df-44c6-95f6-6f0f1839ec34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember_545f81f7-589b-48ef-8a4d-77fcacbb12e4" xlink:href="bngo-20230331.xsd#bngo_BioDiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c19046a-83df-44c6-95f6-6f0f1839ec34" xlink:to="loc_bngo_BioDiscoveryMember_545f81f7-589b-48ef-8a4d-77fcacbb12e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PurigenMember_af8971e7-4784-4468-b3f9-ab289274624b" xlink:href="bngo-20230331.xsd#bngo_PurigenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c19046a-83df-44c6-95f6-6f0f1839ec34" xlink:to="loc_bngo_PurigenMember_af8971e7-4784-4468-b3f9-ab289274624b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_18955c7f-e462-4d0c-8807-771161045b02" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3245f40-1eec-4cfe-b6bc-02f3a730fe74" xlink:to="loc_srt_RangeAxis_18955c7f-e462-4d0c-8807-771161045b02" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_18955c7f-e462-4d0c-8807-771161045b02_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_18955c7f-e462-4d0c-8807-771161045b02" xlink:to="loc_srt_RangeMember_18955c7f-e462-4d0c-8807-771161045b02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_406b39b8-98e6-4e5f-bf2f-a691d7f011b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_18955c7f-e462-4d0c-8807-771161045b02" xlink:to="loc_srt_RangeMember_406b39b8-98e6-4e5f-bf2f-a691d7f011b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d2944f3f-32ec-47d6-a8c4-ad2c356d6942" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_406b39b8-98e6-4e5f-bf2f-a691d7f011b9" xlink:to="loc_srt_MinimumMember_d2944f3f-32ec-47d6-a8c4-ad2c356d6942" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a8152b8f-0e61-4997-84d5-0f22e8820587" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_406b39b8-98e6-4e5f-bf2f-a691d7f011b9" xlink:to="loc_srt_MaximumMember_a8152b8f-0e61-4997-84d5-0f22e8820587" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails" xlink:type="extended" id="i1c52c67fd8f548bfba4535cad8376ff1_InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_750a5e5b-260c-4f59-863a-751d08437669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8c69ff96-1f0f-464c-9aa3-0791f82762c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_750a5e5b-260c-4f59-863a-751d08437669" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8c69ff96-1f0f-464c-9aa3-0791f82762c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4b541feb-0d66-4fa3-88d1-54b50b896238" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8c69ff96-1f0f-464c-9aa3-0791f82762c7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4b541feb-0d66-4fa3-88d1-54b50b896238" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_971fcf72-2c0a-410f-9301-f0e824492eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8c69ff96-1f0f-464c-9aa3-0791f82762c7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_971fcf72-2c0a-410f-9301-f0e824492eb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_d7a48049-e538-4f95-862e-6be8f1742092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8c69ff96-1f0f-464c-9aa3-0791f82762c7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_d7a48049-e538-4f95-862e-6be8f1742092" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_43c8c453-bb42-477b-8ff6-cd690df65b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8c69ff96-1f0f-464c-9aa3-0791f82762c7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_43c8c453-bb42-477b-8ff6-cd690df65b9d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1d0cc1e5-161c-4221-8844-0907c26fd2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_393076aa-7beb-4ff4-84f3-4ce565336cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_750a5e5b-260c-4f59-863a-751d08437669" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_393076aa-7beb-4ff4-84f3-4ce565336cf6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9d29b663-16e0-42d6-a5dc-395b0c19dc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_393076aa-7beb-4ff4-84f3-4ce565336cf6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9d29b663-16e0-42d6-a5dc-395b0c19dc0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9d29b663-16e0-42d6-a5dc-395b0c19dc0f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9d29b663-16e0-42d6-a5dc-395b0c19dc0f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9d29b663-16e0-42d6-a5dc-395b0c19dc0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8325e76a-f4bd-4ffd-87d9-513c8fc36c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9d29b663-16e0-42d6-a5dc-395b0c19dc0f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8325e76a-f4bd-4ffd-87d9-513c8fc36c0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationLiabilityMember_147fe3d5-5963-4626-a305-ed2f39b91996" xlink:href="bngo-20230331.xsd#bngo_ContingentConsiderationLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8325e76a-f4bd-4ffd-87d9-513c8fc36c0c" xlink:to="loc_bngo_ContingentConsiderationLiabilityMember_147fe3d5-5963-4626-a305-ed2f39b91996" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails" xlink:type="extended" id="ia37e75c0d5e24b5aa08e02877520234f_InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0ad82ac5-f533-41fe-ae01-3f504decb1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_a6a98f25-6db2-4931-96d1-68013cf5b9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0ad82ac5-f533-41fe-ae01-3f504decb1e1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_a6a98f25-6db2-4931-96d1-68013cf5b9f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_9c38ba33-a99f-4e5d-9213-4a2a08f409bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_a6a98f25-6db2-4931-96d1-68013cf5b9f8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_9c38ba33-a99f-4e5d-9213-4a2a08f409bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0bd79e9c-5053-463a-926f-ec7052a4290b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_a6a98f25-6db2-4931-96d1-68013cf5b9f8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0bd79e9c-5053-463a-926f-ec7052a4290b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b8369ecc-7cbe-468c-a516-504cc31c8d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_a6a98f25-6db2-4931-96d1-68013cf5b9f8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b8369ecc-7cbe-468c-a516-504cc31c8d7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract_504a30d8-2040-44cb-b17b-70d7b93a910e" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0ad82ac5-f533-41fe-ae01-3f504decb1e1" xlink:to="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract_504a30d8-2040-44cb-b17b-70d7b93a910e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne_b265c9f8-1a7e-48ee-9e7e-e78a10ec608f" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract_504a30d8-2040-44cb-b17b-70d7b93a910e" xlink:to="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne_b265c9f8-1a7e-48ee-9e7e-e78a10ec608f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive_70029996-3fc3-4513-a174-bbc59a79f5a5" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract_504a30d8-2040-44cb-b17b-70d7b93a910e" xlink:to="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive_70029996-3fc3-4513-a174-bbc59a79f5a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGains_fee8c6ca-83c3-4ca8-ae29-e898d595ed9f" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedGains"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract_504a30d8-2040-44cb-b17b-70d7b93a910e" xlink:to="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGains_fee8c6ca-83c3-4ca8-ae29-e898d595ed9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_082e7e7f-6ff7-4c65-94b7-8edfa2b1a2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0ad82ac5-f533-41fe-ae01-3f504decb1e1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_082e7e7f-6ff7-4c65-94b7-8edfa2b1a2ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne_da2969e7-6037-495d-8d4b-3d7b19152661" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_082e7e7f-6ff7-4c65-94b7-8edfa2b1a2ce" xlink:to="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne_da2969e7-6037-495d-8d4b-3d7b19152661" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive_c87e5bf4-e83b-4e82-9bff-edf097fcd792" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_082e7e7f-6ff7-4c65-94b7-8edfa2b1a2ce" xlink:to="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive_c87e5bf4-e83b-4e82-9bff-edf097fcd792" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss_aa838f11-3042-4373-88a6-c04c8455f407" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_082e7e7f-6ff7-4c65-94b7-8edfa2b1a2ce" xlink:to="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss_aa838f11-3042-4373-88a6-c04c8455f407" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_8057c540-a617-480c-a59c-b4dfaf9c5454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0ad82ac5-f533-41fe-ae01-3f504decb1e1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_8057c540-a617-480c-a59c-b4dfaf9c5454" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_232ed0f0-4147-4e3e-bb39-d3372b3a5561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_8057c540-a617-480c-a59c-b4dfaf9c5454" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_232ed0f0-4147-4e3e-bb39-d3372b3a5561" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_ed03873a-6566-4d98-9040-f0f90fcbcd77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_8057c540-a617-480c-a59c-b4dfaf9c5454" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_ed03873a-6566-4d98-9040-f0f90fcbcd77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_8e2225e3-da68-4ab0-ba3c-547e70fbddb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_8057c540-a617-480c-a59c-b4dfaf9c5454" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_8e2225e3-da68-4ab0-ba3c-547e70fbddb2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_03c0efa0-c343-421c-9259-8807f2582959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0ad82ac5-f533-41fe-ae01-3f504decb1e1" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_03c0efa0-c343-421c-9259-8807f2582959" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_55c15e7d-2d68-4aa8-869a-e45787815363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_03c0efa0-c343-421c-9259-8807f2582959" xlink:to="loc_us-gaap_FinancialInstrumentAxis_55c15e7d-2d68-4aa8-869a-e45787815363" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_55c15e7d-2d68-4aa8-869a-e45787815363_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_55c15e7d-2d68-4aa8-869a-e45787815363" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_55c15e7d-2d68-4aa8-869a-e45787815363_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f795786f-b465-490e-9d02-df74c0b7abd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_55c15e7d-2d68-4aa8-869a-e45787815363" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f795786f-b465-490e-9d02-df74c0b7abd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_bde52c17-e893-4d67-92c6-cc10a9e2554b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f795786f-b465-490e-9d02-df74c0b7abd0" xlink:to="loc_us-gaap_CommercialPaperMember_bde52c17-e893-4d67-92c6-cc10a9e2554b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CorporateNotesAndBondsMember_0a0f1f55-2200-42f7-9264-02cb9715325b" xlink:href="bngo-20230331.xsd#bngo_CorporateNotesAndBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f795786f-b465-490e-9d02-df74c0b7abd0" xlink:to="loc_bngo_CorporateNotesAndBondsMember_0a0f1f55-2200-42f7-9264-02cb9715325b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_37438a91-c489-4f17-af95-1d62bee579ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f795786f-b465-490e-9d02-df74c0b7abd0" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_37438a91-c489-4f17-af95-1d62bee579ce" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails" xlink:type="extended" id="i98b4be8a80c34fc7b072edc4daa3542b_InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e7099915-6851-47f9-b227-1dc68d934ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_f0830c97-fa27-4643-9973-987f7728d7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e7099915-6851-47f9-b227-1dc68d934ef8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_f0830c97-fa27-4643-9973-987f7728d7a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_925ab685-0a6e-4b0f-b3ae-c713794018c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_f0830c97-fa27-4643-9973-987f7728d7a2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_925ab685-0a6e-4b0f-b3ae-c713794018c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_759bb143-9d05-48fd-a9fb-147cfe547e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_f0830c97-fa27-4643-9973-987f7728d7a2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_759bb143-9d05-48fd-a9fb-147cfe547e6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1cbeb7c6-8e82-45e4-889f-a5f59d02dacf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_f0830c97-fa27-4643-9973-987f7728d7a2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1cbeb7c6-8e82-45e4-889f-a5f59d02dacf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_0534d11a-ad17-418d-a848-792d085712ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e7099915-6851-47f9-b227-1dc68d934ef8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_0534d11a-ad17-418d-a848-792d085712ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_da8fac29-50d7-4cef-bf14-e704de487cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_0534d11a-ad17-418d-a848-792d085712ec" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_da8fac29-50d7-4cef-bf14-e704de487cea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_24ae58e8-0a10-42c8-aa00-672c13b07333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_0534d11a-ad17-418d-a848-792d085712ec" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_24ae58e8-0a10-42c8-aa00-672c13b07333" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_262644c7-2c1f-4a85-84f7-ea9a24f10142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_0534d11a-ad17-418d-a848-792d085712ec" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_262644c7-2c1f-4a85-84f7-ea9a24f10142" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_17bb2f86-e8a6-4f9b-976f-9e5442fb6e07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e7099915-6851-47f9-b227-1dc68d934ef8" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_17bb2f86-e8a6-4f9b-976f-9e5442fb6e07" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0405fc82-322f-4f45-9c49-cc12633a1992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_17bb2f86-e8a6-4f9b-976f-9e5442fb6e07" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0405fc82-322f-4f45-9c49-cc12633a1992" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0405fc82-322f-4f45-9c49-cc12633a1992_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0405fc82-322f-4f45-9c49-cc12633a1992" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0405fc82-322f-4f45-9c49-cc12633a1992_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d47948cf-a108-47b3-895c-9e4a873a9bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0405fc82-322f-4f45-9c49-cc12633a1992" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d47948cf-a108-47b3-895c-9e4a873a9bc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_ac3e70c5-fbeb-41d4-bd31-d6703898ab21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d47948cf-a108-47b3-895c-9e4a873a9bc6" xlink:to="loc_us-gaap_CommercialPaperMember_ac3e70c5-fbeb-41d4-bd31-d6703898ab21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CorporateNotesAndBondsMember_28010595-37f9-41c7-a5ff-99c33fc306ed" xlink:href="bngo-20230331.xsd#bngo_CorporateNotesAndBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d47948cf-a108-47b3-895c-9e4a873a9bc6" xlink:to="loc_bngo_CorporateNotesAndBondsMember_28010595-37f9-41c7-a5ff-99c33fc306ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0fbfafa1-302b-4dfe-a403-bf03aa033b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d47948cf-a108-47b3-895c-9e4a873a9bc6" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0fbfafa1-302b-4dfe-a403-bf03aa033b0b" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>bngo-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:89c9e3f0-6ddf-4644-8fed-0d858e04a501,g:e99df848-92d3-4a5f-ae11-c380aa17bbd2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_4a876003-b9cf-47a5-9d4d-f2ec93224c10_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_325a39bd-cc1f-4889-af50-4255d788ecb7_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0ec8e639-896d-4c12-8f1e-961f73ded1d3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 1 year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_3a52b308-2760-4f6f-a4df-de4ceaf3b6dc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4398147f-2511-43f3-966c-48257c832023_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1a2a6ef8-5430-4938-a513-51b116561415_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_784cd867-827c-4193-b24c-0058672dc121_verboseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for expected credit loss</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract_62ae9cb4-a682-481c-a69e-4c1cb92c91ed_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights [Abstract]</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract" xlink:href="bngo-20230331.xsd#bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract" xlink:to="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_80c50e33-d2aa-4071-9357-eb39074f5e7f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_13e26696-58f9-4ffb-a62a-bafe1c605a02_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_17e01af5-958a-4809-8fb2-64c0dde4b2d9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration milestone payment, maximum</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_49e413f3-04b3-4900-b48d-4c58f55ddc6d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_02953da7-6e7e-4121-8412-fd3091f16086_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_a9cda276-32c1-43ce-90f5-c024fc5cb7b2_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_e8289672-38ad-4cb4-98aa-a8d0eca774cb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_3e137803-6d45-400f-8e5e-448cae957ddd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9344481a-dca0-47a7-8823-2faa2f72d319_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_FinanceLeaseLiabilityToBePaidAfterYearFour_2a884b00-27a8-4d28-9e1d-f725f427d1a6_terseLabel_en-US" xlink:label="lab_bngo_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_bngo_FinanceLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_bngo_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Four</link:label>
    <link:label id="lab_bngo_FinanceLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_bngo_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:href="bngo-20230331.xsd#bngo_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_bngo_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_d434bdbc-e1ad-4a66-bafd-4d715d327640_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_93160aaf-a81f-4106-b51b-3931533d572e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e6e11e65-4ceb-4a94-b505-7611b37a94f0_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_55590f50-2f27-4719-8d6c-8e9bf97eccb3_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8abcd519-6413-4239-b3f4-bdb1bd548082_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGains_d0ee6b8a-ca24-4237-9818-239d66305f63_totalLabel_en-US" xlink:label="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGains_label_en-US" xlink:label="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Unrealized Gains</link:label>
    <link:label id="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGains_documentation_en-US" xlink:label="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Unrealized Gains</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGains" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGains" xlink:to="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGains" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod_62529333-0470-408b-83cd-d5248430d7cd_negatedTerseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Canceled In Period</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Canceled In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" xlink:href="bngo-20230331.xsd#bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" xlink:to="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49edb910-7974-4f62-929f-530f0e01da25_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_3029b9ba-a091-408f-a3b2-aec47d3d289b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_ed931f48-605e-4be5-8b66-2df01c1ecd70_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_45af313c-b032-4e62-84cd-b816ee52be62_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_30afbb9d-619b-4ba3-8fb1-a7237fc2c03c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_2e7e9078-2546-401c-833b-2e2906a4e737_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b8dc609e-168d-42c4-8678-9f6aee41b7b6_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_1cb2482c-b5a2-48dc-bcc6-3d5c720dccca_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_62cce8f2-6790-4e63-932b-200943fb6a4b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b0561223-75d7-47fb-8998-08a55ab6e2c1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_14b1933c-5143-4dc9-b655-ec8ef43fe975_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_045e72cc-6723-445c-9bdf-38c7d3df754c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share amount (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_57baffc8-27ef-405f-b309-e2d7409c8328_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_a206c948-ba22-44d3-8302-c99fc1ae5f98_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_537cd49d-81f8-43cb-a804-4a1d5abd06a8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d2971657-721c-4ab0-a2b6-cd31e6ae1219_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_af59a7e7-b4eb-4435-91c8-34982430f543_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_ce7481ba-9de0-4891-a2fb-798d28a7e101_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, trade</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_UnvestedRestrictedStockMember_ef8cdcb6-4535-4ce8-bac7-36771d566019_terseLabel_en-US" xlink:label="lab_bngo_UnvestedRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock</link:label>
    <link:label id="lab_bngo_UnvestedRestrictedStockMember_label_en-US" xlink:label="lab_bngo_UnvestedRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested Restricted Stock [Member]</link:label>
    <link:label id="lab_bngo_UnvestedRestrictedStockMember_documentation_en-US" xlink:label="lab_bngo_UnvestedRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested Restricted Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_UnvestedRestrictedStockMember" xlink:href="bngo-20230331.xsd#bngo_UnvestedRestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_UnvestedRestrictedStockMember" xlink:to="lab_bngo_UnvestedRestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_d09e625e-4e1e-42f9-bf8d-28639cbbcd13_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_5e0d9dac-f958-4b02-950a-5496ff0b46ae_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_bc4ebac8-6d1e-477d-8f5d-eef423779d42_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod_98e8823d-1c2e-41d0-87ed-95933c5931b4_negatedTerseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Exercised In Period</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Exercised In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" xlink:href="bngo-20230331.xsd#bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" xlink:to="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5f670e3e-52d6-4160-885d-fab422614bd6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_7e84bc55-272b-4b32-8182-f9e4769c3a8d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of financing lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_c5aeb0ea-f397-4f06-90b3-ee0b297e480e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in stock-based compensation cost from modification</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Plan Modification, Incremental Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne_04410c70-5b9b-4bb5-9ad9-db01b01cbe82_negatedLabel_en-US" xlink:label="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 1 year</link:label>
    <link:label id="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne_label_en-US" xlink:label="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:label id="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne_documentation_en-US" xlink:label="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne" xlink:to="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_02f06cc2-773b-48cf-8c29-52d3c0a11bd1_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5b4da41d-120f-487d-99b1-cdf77d40953f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ExecutiveOfficerMember_7f46b220-8d55-4385-8538-421860cfedda_terseLabel_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer</link:label>
    <link:label id="lab_srt_ExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ExecutiveOfficerMember" xlink:to="lab_srt_ExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive_b82dd8ed-1d72-4e7c-8df3-b18e0fc6c08c_negatedLabel_en-US" xlink:label="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive_label_en-US" xlink:label="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss, Maturity, Allocated and Single Maturity Date, After Year One Through Five</link:label>
    <link:label id="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive_documentation_en-US" xlink:label="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss, Maturity, Allocated and Single Maturity Date, After Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive" xlink:to="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d430b894-26f6-418f-a50a-1ccf183f74b7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_39c1c9e6-d23a-4a19-8afc-fca6981f2d61_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d2d9acee-7f0a-48c3-850c-7a9080a8e1ca_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_148aa07b-eb0e-4bd9-a039-08054e580129_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f016e840-f22e-423a-bc7b-0bef8f2bd5c4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_fc184f2f-85b6-404e-b68f-c7335bef663f_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_CowenMember_b90b9eda-5eab-40ca-a80e-c0e9dec10a6e_terseLabel_en-US" xlink:label="lab_bngo_CowenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cowen</link:label>
    <link:label id="lab_bngo_CowenMember_label_en-US" xlink:label="lab_bngo_CowenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cowen [Member]</link:label>
    <link:label id="lab_bngo_CowenMember_documentation_en-US" xlink:label="lab_bngo_CowenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cowen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CowenMember" xlink:href="bngo-20230331.xsd#bngo_CowenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_CowenMember" xlink:to="lab_bngo_CowenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_4f8f5f50-6a73-4d90-a55c-fede858d962d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_96b7fb61-9949-4524-8ae7-bd756d328d12_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3dd03226-7066-40db-be63-49d9091de2fc_negatedLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_277038cc-d0ea-4703-b29e-e9e70e887857_terseLabel_en-US" xlink:label="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_label_en-US" xlink:label="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Assets</link:label>
    <link:label id="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_documentation_en-US" xlink:label="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:href="bngo-20230331.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:to="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b2c4f79a-7306-49a4-baa5-86abb6bd7202_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_ec7fcc17-3663-4f04-b3f3-68905e854d48_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_10d4e854-3c78-4f91-8fbb-1b762eb7fb30_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_f7181c4f-d512-489b-bee7-4c3f8705aa20_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_04d8426c-4d6f-4fe0-9b28-1095f8a731d4_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_db383623-4091-44ff-8fa7-8ca34c7c6e00_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_bf7ae865-9430-40c2-9923-6ab3d8e9c52e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_d5de6b14-8e75-4bdd-9745-af0b5b102fd2_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19c1ee56-1892-4835-a5b8-6ca5bb3b9ccb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_c40cefc6-b34f-42a5-bd0e-00203ef529c3_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_88c979b5-fc41-42f2-8df0-3708ebe9c368_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination</link:label>
    <link:label id="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_853f514c-6d6c-4168-adfa-38a1953634ac_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c4c35cc8-6c99-49b5-ad3e-f6fc79d78785_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash &amp; cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_57a743ed-9671-48a4-a84f-043b1d15d215_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_41a8b901-cb48-4cac-970a-cc9d9ffa45bb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and contract liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_27f25e9e-2f64-4d5f-9616-73290702ad6c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_cbbb8459-5eed-4689-9b44-97d45f6c01f4_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_43b32992-5fce-4a38-91ce-6613507f08a5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_79aa8c1b-b93e-45ed-ac3d-048f60c15cd4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_b51fe169-7ce8-42fb-ae3e-52365050a410_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b823fd45-3d3f-4ffa-ac58-2269859a64f7_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dde130ba-8bd7-43da-bd21-d1142bfa0b1f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0ad1c5c8-3b8b-40b9-a63c-515c4c27c432_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_83039706-0a66-4052-bc66-29660c503748_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dd27c034-af49-461f-ad6b-89edc03f02cf_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1314bca9-c9fd-41e0-8c79-26075e0ec498_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_87f2e3c1-55fa-443f-a6ce-868c93f9ea03_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6f7137ff-071a-432b-bc9f-411fd9777689_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_CommissionFeeMaximumPercentageOfGrossProceeds_67e3327f-23df-471f-a327-39db03d477ab_terseLabel_en-US" xlink:label="lab_bngo_CommissionFeeMaximumPercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission fee</link:label>
    <link:label id="lab_bngo_CommissionFeeMaximumPercentageOfGrossProceeds_label_en-US" xlink:label="lab_bngo_CommissionFeeMaximumPercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission Fee, Maximum Percentage Of Gross Proceeds</link:label>
    <link:label id="lab_bngo_CommissionFeeMaximumPercentageOfGrossProceeds_documentation_en-US" xlink:label="lab_bngo_CommissionFeeMaximumPercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission Fee, Maximum Percentage Of Gross Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommissionFeeMaximumPercentageOfGrossProceeds" xlink:href="bngo-20230331.xsd#bngo_CommissionFeeMaximumPercentageOfGrossProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_CommissionFeeMaximumPercentageOfGrossProceeds" xlink:to="lab_bngo_CommissionFeeMaximumPercentageOfGrossProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_ecbfd4e3-3c72-49a7-bef0-60c0a3c0fc86_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_d9fa73d2-69ff-4d39-98a6-8b29cfed966a_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_f54e0cb4-1e06-4fe0-9b09-4398b8c7ce96_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive_0fdae9d6-ae44-4b0a-a3ea-35061ce7188e_terseLabel_en-US" xlink:label="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive_label_en-US" xlink:label="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Gain, Maturity, Allocated and Single Maturity Date, After Year One Through Five</link:label>
    <link:label id="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive_documentation_en-US" xlink:label="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Gain, Maturity, Allocated and Single Maturity Date, After Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive" xlink:to="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f6d4732e-1812-44ee-8977-62030be618a0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_CommonWarrantsMember_25ce4d3f-4c53-4575-b657-d168a2a0567c_terseLabel_en-US" xlink:label="lab_bngo_CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_bngo_CommonWarrantsMember_label_en-US" xlink:label="lab_bngo_CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Warrants [Member]</link:label>
    <link:label id="lab_bngo_CommonWarrantsMember_documentation_en-US" xlink:label="lab_bngo_CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommonWarrantsMember" xlink:href="bngo-20230331.xsd#bngo_CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_CommonWarrantsMember" xlink:to="lab_bngo_CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_3462fa0e-3cc3-4a8b-aff7-069f5958b8cf_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_ac915fde-877d-4eed-8722-8a020ac6d3f9_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_9ba0699e-94a6-47d1-9485-97befef96e4a_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_2b03fda5-9be7-4dd8-9c11-ca778a1a1d3b_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from warrant and option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_3e9de55d-a500-4a8b-b0c8-32e98097cec4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_89cafa47-f076-408c-8dca-904d24f15e00_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_10d32679-cb99-4191-9693-5d13d4674700_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_fe90f052-c94b-4cd7-a050-77361cd7c799_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting on October 18, 2022</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_152c7f3a-f787-4d87-bcdc-cb6ce41ccec0_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty liabilities</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:to="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_341acb0d-628b-4270-89e8-1a76ff7fbf9e_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_f37c529c-6a4c-4f46-8eb3-feb2de028ae0_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-offs and payments</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_1d94d3f4-23f4-488f-bf76-42957216576f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_f0461424-d1b3-4038-8109-e36c6be4733e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_18f70cfb-f813-4630-938e-b17cf71ae6f6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ProfessionalFeesAndRoyaltiesCurrent_9d29297b-f434-4b61-aeb5-ee3d26957874_terseLabel_en-US" xlink:label="lab_bngo_ProfessionalFeesAndRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees and royalties</link:label>
    <link:label id="lab_bngo_ProfessionalFeesAndRoyaltiesCurrent_label_en-US" xlink:label="lab_bngo_ProfessionalFeesAndRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Fees and Royalties, Current</link:label>
    <link:label id="lab_bngo_ProfessionalFeesAndRoyaltiesCurrent_documentation_en-US" xlink:label="lab_bngo_ProfessionalFeesAndRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Fees and Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ProfessionalFeesAndRoyaltiesCurrent" xlink:href="bngo-20230331.xsd#bngo_ProfessionalFeesAndRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ProfessionalFeesAndRoyaltiesCurrent" xlink:to="lab_bngo_ProfessionalFeesAndRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e7adaf55-2977-4015-869b-c936626ad445_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_40ec06ce-7294-4189-a9d5-f8f995363ab6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b5370dd3-c69b-4de7-98f7-001a0cd679af_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_15288017-ec99-4dec-8ca2-9769f6846958_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_325d19d7-52e0-41d0-be87-f1e3ade62020_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_61d8eb62-7440-4e2b-b1d2-e1a00641138f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_746d99ea-f571-4ab5-a433-96f143dc1495_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_76f7edad-a984-4e78-9662-0007a7390bd7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ff012ebe-24b5-4f80-8f26-5bfe1b1c4c1d_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_BioDiscoveryMember_3c1aecbe-cd0c-4951-8ba2-538bb975c832_terseLabel_en-US" xlink:label="lab_bngo_BioDiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioDiscovery</link:label>
    <link:label id="lab_bngo_BioDiscoveryMember_label_en-US" xlink:label="lab_bngo_BioDiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioDiscovery [Member]</link:label>
    <link:label id="lab_bngo_BioDiscoveryMember_documentation_en-US" xlink:label="lab_bngo_BioDiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioDiscovery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember" xlink:href="bngo-20230331.xsd#bngo_BioDiscoveryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_BioDiscoveryMember" xlink:to="lab_bngo_BioDiscoveryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_b6bcb332-c975-4c17-8739-dc2c52ffb606_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_b81c60b9-8847-4889-b7b3-77f90ddbedb8_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_AccruedClinicalStudyFeesCurrent_4799cbf3-e285-4007-94e2-482f4d54e429_terseLabel_en-US" xlink:label="lab_bngo_AccruedClinicalStudyFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical study fees</link:label>
    <link:label id="lab_bngo_AccruedClinicalStudyFeesCurrent_label_en-US" xlink:label="lab_bngo_AccruedClinicalStudyFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Study Fees, Current</link:label>
    <link:label id="lab_bngo_AccruedClinicalStudyFeesCurrent_documentation_en-US" xlink:label="lab_bngo_AccruedClinicalStudyFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Study Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_AccruedClinicalStudyFeesCurrent" xlink:href="bngo-20230331.xsd#bngo_AccruedClinicalStudyFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_AccruedClinicalStudyFeesCurrent" xlink:to="lab_bngo_AccruedClinicalStudyFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_dbfbe6c8-6162-4485-a992-01e3eb3b623c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-Average Assumptions in Black -Scholes Option Pricing Model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_524c01d1-8a79-4d81-9324-bbdbbd61baec_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_86b28863-05d6-475d-8000-b5bac1cafbcf_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Account Details</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d21e9e1-18b7-4162-b841-d1924f3e31a3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_InstrumentRevenueMember_c4e96923-0456-43a4-97b7-c5ee0dd38642_terseLabel_en-US" xlink:label="lab_bngo_InstrumentRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instruments</link:label>
    <link:label id="lab_bngo_InstrumentRevenueMember_label_en-US" xlink:label="lab_bngo_InstrumentRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instrument Revenue [Member]</link:label>
    <link:label id="lab_bngo_InstrumentRevenueMember_documentation_en-US" xlink:label="lab_bngo_InstrumentRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instrument Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InstrumentRevenueMember" xlink:href="bngo-20230331.xsd#bngo_InstrumentRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_InstrumentRevenueMember" xlink:to="lab_bngo_InstrumentRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_01a1277f-a95a-4fbe-8b57-903b9d2be70b_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities of government sponsored entities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_d32e4973-b08c-4a0a-9d8a-33bd58420c57_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_7bc85195-7f21-4e27-9e12-b2cdd9ae834b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration transferred in acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_3e3acb42-25ec-4ab0-b6f7-aced06c14647_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_69089185-a064-4d95-abc0-da37dbcc08db_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c243df1b-f0b9-4191-be88-901f7e6a6dbe_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9e700c2c-c299-413e-a0b4-80d2bbc07446_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_f05e88cd-405c-44db-b6e4-34df061bab28_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent_1ef635a4-d5d0-4e1b-a772-fd3a882bc445_negatedTerseLabel_en-US" xlink:label="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability (short-term and long-term)</link:label>
    <link:label id="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liability Current</link:label>
    <link:label id="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent_documentation_en-US" xlink:label="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liability Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent" xlink:href="bngo-20230331.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent" xlink:to="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_23001b12-a342-4a96-a5c7-54bc75ddf1b7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ade10dd7-a351-4589-81f5-ddbe1157e352_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_9685eac5-1f2a-4cbd-ab94-e962fc6bc82b_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a5e41301-ab37-405c-ab51-3a0798190c12_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EMEAMember_46503368-aa6d-4b86-a27f-46b1c37daa31_terseLabel_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMEA</link:label>
    <link:label id="lab_us-gaap_EMEAMember_label_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMEA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EMEAMember" xlink:to="lab_us-gaap_EMEAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_b1213b5f-4a38-4aa9-965a-c05ded45b74a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities_3267df9d-08ab-4ab4-9759-20bc861d4174_negatedTerseLabel_en-US" xlink:label="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities_label_en-US" xlink:label="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable and Other Accrued Liabilities</link:label>
    <link:label id="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities_documentation_en-US" xlink:label="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable and Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities" xlink:href="bngo-20230331.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities" xlink:to="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_99f2aa75-5d9b-40d8-a4b3-753c5cf15e84_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_eee0d3a4-e9cb-4db5-87df-831718836dfd_terseLabel_en-US" xlink:label="lab_bngo_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_bngo_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_bngo_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:label id="lab_bngo_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_bngo_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="bngo-20230331.xsd#bngo_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_bngo_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_02791f08-e693-4e1d-ba82-e4d7763eb24a_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3e117684-2ef2-4224-81fe-071f6169e6f4_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 1 year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_fdef3760-12e9-4792-955d-3fb063d8eaf0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_735381bd-fc64-4fd5-8b60-b80d9e186528_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1586851a-259c-460f-be6b-b629bbb089ce_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_96580e77-9170-4217-8c7e-606272725309_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b0cfa775-217f-4823-bbec-f731be959a1e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_368f708d-972b-4b33-b90a-840b0d194200_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_0269d411-9954-49c0-b981-3a948032edfe_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_f39a17bb-aabf-4c59-8749-fe9f6068e69c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ef4e4539-d546-4d16-8a0b-05384d6a6e19_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3d5f1b52-80fa-4f9b-ab47-d43a22d05a16_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow_d5c9fd24-eb8f-47e5-a8e0-ee9711ae60af_terseLabel_en-US" xlink:label="lab_bngo_ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioDiscovery acquisition, return of purchase consideration from escrow</link:label>
    <link:label id="lab_bngo_ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow_label_en-US" xlink:label="lab_bngo_ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Business Combination Return Of Purchase Consideration From Escrow</link:label>
    <link:label id="lab_bngo_ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow_documentation_en-US" xlink:label="lab_bngo_ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Business Combination Return Of Purchase Consideration From Escrow</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow" xlink:href="bngo-20230331.xsd#bngo_ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow" xlink:to="lab_bngo_ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_c6796893-94e3-483b-bac9-bec8049b780d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_b331cec4-438f-413b-b62d-b98d26711ddd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_33428f56-bbe9-4635-ab88-9d0a1bc24ec4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_f0fc25cf-a1f1-44f8-9e3b-510a45658f5b_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e1e3bf44-cf0b-44d2-8546-d6af5b6f617d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_f67d3b40-d3f8-4dba-9088-666f150a3a3d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_7f658fd1-d319-4792-86ba-655233d3d65f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_d6928983-8b43-4467-b503-b1d6aa32cd09_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights [Roll Forward]</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward" xlink:href="bngo-20230331.xsd#bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward" xlink:to="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_c8be370f-e96e-4669-9933-6a2a0ec17442_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_8da01c9b-fa4f-4f02-af79-9c65a1be998a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance</link:label>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Insurance, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedInsuranceCurrent" xlink:to="lab_us-gaap_AccruedInsuranceCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_3ea1a8f4-2c4b-47f8-878c-8db05e8159c0_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_9e427f97-d8a3-48a4-b51c-fe8709bfdc25_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_08cf3208-8f78-4b14-aacf-d7bf2055a129_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b43a6731-7a21-431a-ba6a-a600d8a88d96_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_92bf2f4f-267b-42e4-bfb9-7757f8e9f612_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_a3856cdd-1bec-4905-acbb-9a590cb6d53d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_7f983872-6e4b-498f-9f63-121043dc8e82_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities in an unrealized loss position, greater than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_bea4436e-e217-4c0b-9a88-93e549151014_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_56763e9d-d362-4408-b6cd-712e85c4e498_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_8ba6139b-736d-4611-9d3b-c3d984efbc6c_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 Months or Greater, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_f1ec4596-5f02-48d7-9fe9-4a43e7c1bedc_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f0f801e5-d7d9-4a58-ab81-92798287b6d6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4f428b8e-504e-4cbd-95e1-f8cc63d791e3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_f5b3cad4-0e00-4c36-9eaa-693a867cec29_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_bfab6898-1412-49a0-88e9-d44931747800_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_967d4317-48f8-42fe-8d48-dfc39250db55_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_SoftwareMember_e37c4316-6da2-4005-9e90-6a978598293f_terseLabel_en-US" xlink:label="lab_bngo_SoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_bngo_SoftwareMember_label_en-US" xlink:label="lab_bngo_SoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software [Member]</link:label>
    <link:label id="lab_bngo_SoftwareMember_documentation_en-US" xlink:label="lab_bngo_SoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SoftwareMember" xlink:href="bngo-20230331.xsd#bngo_SoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_SoftwareMember" xlink:to="lab_bngo_SoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_b3566ed7-8b79-45cb-b9d0-b3004feb078b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_494fb5e8-9b21-48c7-911d-d4bc15fdf9b5_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_fcddcfa8-c876-4466-8ad1-68a13873babc_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a58af3b4-4625-44b8-bc1a-869ac3df51f8_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2a551fcb-ff9d-4dcc-94e4-c3fabf92cad4_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_5c7b74b9-e37e-4e35-928f-3f5d1ea2cb65_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_59112153-dfbd-40d0-8cf7-390fe0378670_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_54967bdf-13dc-426f-b472-defc04cdec04_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_f911e55d-365a-409e-8189-ae1e6d0d10a9_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsMember_0fabc0a6-e6e6-4338-acaa-f4c7feadcedf_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsMember_label_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsMember" xlink:to="lab_us-gaap_InvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_1c033673-1f41-44af-bc5b-0a3f7a168106_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_BusinessAcquisitionCashHeldInEscrowFund_76c8caa1-08d6-4609-9099-c3148eaa02e8_terseLabel_en-US" xlink:label="lab_bngo_BusinessAcquisitionCashHeldInEscrowFund" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash held in escrow fund</link:label>
    <link:label id="lab_bngo_BusinessAcquisitionCashHeldInEscrowFund_label_en-US" xlink:label="lab_bngo_BusinessAcquisitionCashHeldInEscrowFund" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Cash Held in Escrow Fund</link:label>
    <link:label id="lab_bngo_BusinessAcquisitionCashHeldInEscrowFund_documentation_en-US" xlink:label="lab_bngo_BusinessAcquisitionCashHeldInEscrowFund" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Cash Held in Escrow Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessAcquisitionCashHeldInEscrowFund" xlink:href="bngo-20230331.xsd#bngo_BusinessAcquisitionCashHeldInEscrowFund"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_BusinessAcquisitionCashHeldInEscrowFund" xlink:to="lab_bngo_BusinessAcquisitionCashHeldInEscrowFund" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2ff4f241-9413-41fc-8f2a-e6763e7e13b9_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_5efcebf6-3902-4aa2-bad5-a90ce7243d6e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9f118819-4ac0-417a-acf2-d6f3a3f2d10a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_PaymentsForPropertyAndEquipment_1487a4ad-a4a5-4e68-bdc2-5f3991f3e427_negatedTerseLabel_en-US" xlink:label="lab_bngo_PaymentsForPropertyAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_bngo_PaymentsForPropertyAndEquipment_label_en-US" xlink:label="lab_bngo_PaymentsForPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Property and Equipment</link:label>
    <link:label id="lab_bngo_PaymentsForPropertyAndEquipment_documentation_en-US" xlink:label="lab_bngo_PaymentsForPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Property and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PaymentsForPropertyAndEquipment" xlink:href="bngo-20230331.xsd#bngo_PaymentsForPropertyAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_PaymentsForPropertyAndEquipment" xlink:to="lab_bngo_PaymentsForPropertyAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_31f53645-736c-4fb8-972d-489bc4ca32c3_verboseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities of government sponsored entities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_8f46dc26-1140-4ab2-afee-b3f066764bc0_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities of government sponsored entities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b74fc80f-caf0-4b2e-86ff-677ef5f40233_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_478a0598-575f-4be4-8be0-a3ed169d4338_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_27335000-82c1-444e-b3c3-b7ea0b0e8129_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_f2749a7d-8da3-47ee-8507-892c159758d9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_cf93c7bd-d22d-409b-ae03-d24160b4739c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0b09e809-1d75-4b4b-a0a4-82e8a338630e_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_90f3417b-8668-4ff2-b0c1-3fe36817901e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights_cb5cbd45-b61a-4b39-a92e-9f9e9f31d120_periodStartLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights_c4e02ae6-fced-40e8-91fa-c689fb8407eb_periodEndLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" xlink:href="bngo-20230331.xsd#bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" xlink:to="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_79a784d2-6401-4cb7-9d71-2d000d491c16_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of milestone consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_484c8b48-3495-4904-9584-64a5bade62b6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f6ccffc4-c849-4ee7-bace-deb7ff79bd3b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne_a66d56a5-1b6d-4091-8071-06a9fadde2a4_terseLabel_en-US" xlink:label="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 1 year</link:label>
    <link:label id="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne_label_en-US" xlink:label="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Gain, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:label id="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne_documentation_en-US" xlink:label="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Gain, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne" xlink:to="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5b6430a2-bc42-4f42-ab7a-207bd0add2b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Released (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_bf4698e2-af73-4ed7-b405-974423a16030_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_a7544eca-b6e5-4bf9-8846-5a087eb448d3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9f332d81-def7-4c53-b2ee-9b5190658f81_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_a5d6ca4c-df94-4cee-904d-498f601e7d22_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_MeasurementInputProbabilityFactorMember_485cf45e-2697-4794-bfb5-34637235027a_terseLabel_en-US" xlink:label="lab_bngo_MeasurementInputProbabilityFactorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability Factor</link:label>
    <link:label id="lab_bngo_MeasurementInputProbabilityFactorMember_label_en-US" xlink:label="lab_bngo_MeasurementInputProbabilityFactorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability Factor [Member]</link:label>
    <link:label id="lab_bngo_MeasurementInputProbabilityFactorMember_documentation_en-US" xlink:label="lab_bngo_MeasurementInputProbabilityFactorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability Factor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_MeasurementInputProbabilityFactorMember" xlink:href="bngo-20230331.xsd#bngo_MeasurementInputProbabilityFactorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_MeasurementInputProbabilityFactorMember" xlink:to="lab_bngo_MeasurementInputProbabilityFactorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1fdfa3db-fa8e-4bc3-a4c8-c51d1f077dc7_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets not subject to amortization</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c6b4a0c6-4389-4d5e-91a4-b0270bb22262_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in estimated fair value, recorded in selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0359bcc6-3100-440b-97d0-a7d45eb8f8b7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_a3a43feb-38ef-4d20-bc70-6d3ced77f66d_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_ef1b3092-029d-4e71-a358-f05003837a44_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_e2f0fd5a-e4a2-4910-82e7-be6a493d210e_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a44e4a23-006d-4d87-a329-5b24f44b0185_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_f086ce72-3deb-4087-8620-a4614a7e8e96_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_9d162805-ca06-4ddd-894d-7c16f09d88e6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_eeb328c4-cda2-4c55-b67c-73f371a8dfaf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisition, Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_f43ac362-6599-4852-b01e-2b5c91b0e387_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Than 12 Months, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_3b229cd5-d744-454e-8aaa-5cf0544f1fe3_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6d63a72f-6c08-4076-ab21-5e584eb5d6b6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_72304e74-2462-4ef2-9224-05e7f11623ef_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_1c08892c-54b9-4cb0-8dfc-2337258d46a7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_4bd4e4f0-debb-444a-b720-6aa19249712e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on financing lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_51d49b7a-e035-4c4f-a005-6e298ad8af2a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_04f5771d-faa8-4666-81ad-7c3f77ea5471_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_442f686f-ba4a-4055-9a4c-5cabf25440b6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_295f0e1d-2788-4a95-bcd5-174e7c050496_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_b832c5d7-c492-476d-b46d-e26c33c63f60_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_82cca884-c937-4a1d-83e1-d78dd1d51952_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_a024c92d-cd43-43df-ae06-a655f5efe7f7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_0b7fb60e-c2e2-4d22-8fa7-12f28c8b3922_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_676408bf-aeaa-4a06-8353-79e753b5f62b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_332c3570-8c8e-4cc0-a5a9-2ba8dd4aab8c_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_599dd63d-6418-4fe7-83e4-c7180e1a7c7f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7caeb4fd-c2ee-4b97-b717-a5e7efd47f5f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_978ee2f2-0e48-43e4-80b5-0de4111d90d9_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_5714df1f-0741-44a2-afd2-618994480c47_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8b9fdcdf-0e88-4387-9bce-b3da2fd2f1aa_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_755c6a61-1d0a-4892-b699-753b4313ac94_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a2e16b33-2046-4edf-a3e3-eef0498bd5a0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_0c42414b-fcd6-4d94-ad02-783cfa4e0f2c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2fddf3d8-3808-48e9-ba20-d89660aa128b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_08637a35-b62e-400e-9030-6e832eb49306_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_abd1c15e-cb5a-488a-a83d-5574f7bd8bd5_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_be20ca66-a17a-4003-9458-38c8a97e01c2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_664c3b34-09cc-4e21-ac01-33db01025343_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b9883b49-a26b-449e-87eb-6052d6bd03f8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_67a2d6a4-66ec-44a5-9794-39743af59777_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0faeb312-70b0-4751-b6b3-862ff10c5474_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_f21a5540-e395-49c2-9aeb-8b54908690d6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit (provision) for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_4fbd45bf-4065-44c0-ae31-1f2bdf1d41e0_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_b6d49fb7-4db5-496a-8d9c-06c8d4df7de2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0a032618-9aca-4c76-a1f0-29d1445b860b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_2c770ab3-5064-47b7-b59f-993a8bed8f65_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_895506fb-f089-4d3a-b23f-722b7f61935c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4810111d-c5f8-42fe-8118-0b007ef590b2_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_550b9f54-606b-4d33-ba06-9d3f3a3e889a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_6f3ee266-f82e-4a6e-bc56-e109f0d438bc_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a08d70cc-d0da-4885-8a64-9dccc4ee9bbf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_c2a727b1-7201-429b-979f-0a5ba6739fdd_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_13bc36c2-ba70-4008-bbe9-d7bc4df42236_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8986f2bb-72c4-465f-bbe5-a430c3c678ef_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_4823d4fe-c06d-4978-8bf8-b598887162ff_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_e76e0981-28f4-4cf7-bfcb-7351f5434327_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value, 400,000,000 shares authorized at March&#160;31, 2023 and December&#160;31, 2022; 306,790,000 and 297,183,000 shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_c9df46c9-5bfb-4b48-a521-39c185307f0d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_LiquidityAndGoingConcernPolicyTextBlock_996613b9-7afb-4893-9d90-631de8e6289d_terseLabel_en-US" xlink:label="lab_bngo_LiquidityAndGoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity and Going Concern</link:label>
    <link:label id="lab_bngo_LiquidityAndGoingConcernPolicyTextBlock_label_en-US" xlink:label="lab_bngo_LiquidityAndGoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity and Going Concern [Policy Text Block]</link:label>
    <link:label id="lab_bngo_LiquidityAndGoingConcernPolicyTextBlock_documentation_en-US" xlink:label="lab_bngo_LiquidityAndGoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity and Going Concern</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LiquidityAndGoingConcernPolicyTextBlock" xlink:href="bngo-20230331.xsd#bngo_LiquidityAndGoingConcernPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="lab_bngo_LiquidityAndGoingConcernPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_fa8bc646-716b-441d-b309-2bfa82ceed23_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock due to the vesting of restricted stock units, net of shares withheld to cover taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_label_en-US" xlink:label="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock, Shares Issued Net of Shares for Tax Withholdings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12995262-7fb0-44fb-82ae-fcd10cc945ad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AsiaPacificMember_052e3a90-fa33-455f-9b0f-c157a15b1dd2_terseLabel_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific</link:label>
    <link:label id="lab_srt_AsiaPacificMember_label_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AsiaPacificMember" xlink:to="lab_srt_AsiaPacificMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_67614336-2cc2-4904-9b74-ca46a57e28d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_29efd31f-6045-41a7-b453-4a6123bc1174_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net realized loss (gain) on investments</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d2727acc-df88-47c9-a0e3-746d90ec0570_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_1197e418-620a-43be-a83b-ddc3009f2927_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8c0cc6e4-f845-4ad2-9449-16405353ae71_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_df782340-8e7d-47cc-8625-492c947348c6_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_df353495-d539-4103-bb47-a022d4fa4474_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_a42c4de1-134f-4b2f-8861-9640cf9a3ccc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_b073ed0b-0cc6-4174-a020-87fe33cd7003_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_150d185e-5cce-4409-83d1-e60cf7de3c52_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability recorded as a result of current period acquisition</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_PurigenMember_ea88ca34-ea38-4aa6-bdf2-a5647bef3eb9_terseLabel_en-US" xlink:label="lab_bngo_PurigenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purigen</link:label>
    <link:label id="lab_bngo_PurigenMember_label_en-US" xlink:label="lab_bngo_PurigenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purigen [Member]</link:label>
    <link:label id="lab_bngo_PurigenMember_documentation_en-US" xlink:label="lab_bngo_PurigenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purigen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PurigenMember" xlink:href="bngo-20230331.xsd#bngo_PurigenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_PurigenMember" xlink:to="lab_bngo_PurigenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_40c9e270-913e-4604-aea4-04d4e4db8d9e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_cddc9429-b0c5-4564-a85f-4c5474039707_terseLabel_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">David Barker</link:label>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_label_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember" xlink:to="lab_srt_BoardOfDirectorsChairmanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e0751c26-35c6-4392-9061-31134d12a36c_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment included in accounts payable</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_38d5c869-c1fb-44f5-9858-d8578f713b17_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_5c246706-8590-4076-b851-7bb3831e98c3_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_07ae666f-92ed-4ec3-a901-9575df80177a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_dba5fb13-de9d-4563-8681-39a8d39bfe0f_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_fa87c642-523b-4019-8f35-423059d83e0d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_00793146-6694-4761-917d-04c91851ef04_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_CostOfServiceAndOtherRevenueMember_7b73955a-747b-4029-b93a-30ea4d5a4e81_terseLabel_en-US" xlink:label="lab_bngo_CostOfServiceAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of service and other revenue</link:label>
    <link:label id="lab_bngo_CostOfServiceAndOtherRevenueMember_label_en-US" xlink:label="lab_bngo_CostOfServiceAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Service And Other Revenue [Member]</link:label>
    <link:label id="lab_bngo_CostOfServiceAndOtherRevenueMember_documentation_en-US" xlink:label="lab_bngo_CostOfServiceAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Service And Other Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CostOfServiceAndOtherRevenueMember" xlink:href="bngo-20230331.xsd#bngo_CostOfServiceAndOtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_CostOfServiceAndOtherRevenueMember" xlink:to="lab_bngo_CostOfServiceAndOtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_99d8413b-86fa-4465-90e4-c772b25c97a3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_PerformanceShareUnitsPSUsMember_171c4b43-a75c-4c2d-83ea-002e973bf9b0_terseLabel_en-US" xlink:label="lab_bngo_PerformanceShareUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_bngo_PerformanceShareUnitsPSUsMember_label_en-US" xlink:label="lab_bngo_PerformanceShareUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units (PSUs) [Member]</link:label>
    <link:label id="lab_bngo_PerformanceShareUnitsPSUsMember_documentation_en-US" xlink:label="lab_bngo_PerformanceShareUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units (PSUs)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PerformanceShareUnitsPSUsMember" xlink:href="bngo-20230331.xsd#bngo_PerformanceShareUnitsPSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_PerformanceShareUnitsPSUsMember" xlink:to="lab_bngo_PerformanceShareUnitsPSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_548d9ecb-39ce-424a-b645-992f6aad2523_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_35bbde1d-c928-4070-b810-f12cda17a804_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_566da3de-1555-48e5-b2c6-37a6eaa89b6c_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_240c4f40-733e-4b33-a768-058d8fd694ae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_60bfb5a6-f4aa-41cf-bc19-bb21f704b58e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_36a2223d-5d16-49f9-b4fb-54cb468e9f34_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights_90101de7-833a-43ff-a9ec-3486536ee259_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted- Average Remaining Contractual Term Of Warrants Or Rights</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted- Average Remaining Contractual Term Of Warrants Or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" xlink:href="bngo-20230331.xsd#bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" xlink:to="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_6acd76ef-556d-4712-b1a5-8ea2236ede71_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_CorporateNotesAndBondsMember_7ec2f092-9082-4f58-a046-62b7ed7bed56_terseLabel_en-US" xlink:label="lab_bngo_CorporateNotesAndBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate notes/bonds</link:label>
    <link:label id="lab_bngo_CorporateNotesAndBondsMember_label_en-US" xlink:label="lab_bngo_CorporateNotesAndBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Notes And Bonds [Member]</link:label>
    <link:label id="lab_bngo_CorporateNotesAndBondsMember_documentation_en-US" xlink:label="lab_bngo_CorporateNotesAndBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Notes And Bonds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CorporateNotesAndBondsMember" xlink:href="bngo-20230331.xsd#bngo_CorporateNotesAndBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_CorporateNotesAndBondsMember" xlink:to="lab_bngo_CorporateNotesAndBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_557d67e6-9e94-4369-a5aa-a73749215b9e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_cbae4784-a217-4833-9c9c-dee6476e1119_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_2c6d35a1-13bc-4a42-ae0a-8ac625076bc3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward_48fde477-84c4-4f38-826e-c9d5e7678b86_terseLabel_en-US" xlink:label="lab_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term</link:label>
    <link:label id="lab_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward_label_en-US" xlink:label="lab_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term [Roll Forward]</link:label>
    <link:label id="lab_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward_documentation_en-US" xlink:label="lab_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward" xlink:href="bngo-20230331.xsd#bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward" xlink:to="lab_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d35ab253-e3c2-4cf2-9d3a-da8ea5280a64_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_410eb52e-4969-4535-bb80-e690a7f4f5ad_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_92a37940-cd0e-443c-b3dc-6e4c20df3cc5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_93cb8e74-32e1-4b5d-b124-c003fc2a8769_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_90f97227-6435-40b1-bd07-e9c6cccc3d51_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities in an unrealized loss position, less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b8c18404-41d2-4168-bc3f-4f42e36c1f1e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_db4ff3f4-78c5-4771-9b6f-ebdbc93ecbce_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_51c7690e-57e7-4596-bf53-05ec9be2180c_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_30f74238-8b0f-4014-93ab-08256abee9de_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ca530fdf-dd39-477c-8c0e-42dd5b18d04e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss_1dcdbefd-75c4-4af3-9029-6b28c54505d1_negatedTotalLabel_en-US" xlink:label="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss_label_en-US" xlink:label="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss</link:label>
    <link:label id="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss_documentation_en-US" xlink:label="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss" xlink:to="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_BusinessCombinationContingentConsiderationMilestonePayment_0928894b-8214-4135-ae3a-705406a25f34_terseLabel_en-US" xlink:label="lab_bngo_BusinessCombinationContingentConsiderationMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration milestone payment</link:label>
    <link:label id="lab_bngo_BusinessCombinationContingentConsiderationMilestonePayment_label_en-US" xlink:label="lab_bngo_BusinessCombinationContingentConsiderationMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Milestone Payment</link:label>
    <link:label id="lab_bngo_BusinessCombinationContingentConsiderationMilestonePayment_documentation_en-US" xlink:label="lab_bngo_BusinessCombinationContingentConsiderationMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationContingentConsiderationMilestonePayment" xlink:href="bngo-20230331.xsd#bngo_BusinessCombinationContingentConsiderationMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_BusinessCombinationContingentConsiderationMilestonePayment" xlink:to="lab_bngo_BusinessCombinationContingentConsiderationMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_fdf9e81e-8479-46e6-aa01-e5576eb8d349_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract_c2096501-54e3-4dd8-8e8f-868de135359e_terseLabel_en-US" xlink:label="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract_label_en-US" xlink:label="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available for Sale, Unrealized Gains [Abstract]</link:label>
    <link:label id="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract_documentation_en-US" xlink:label="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available for Sale, Unrealized Gains</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract" xlink:to="lab_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_e7a74131-bc04-4b18-a6a6-90e8d156ad2d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_e5f1b627-8acb-4a66-bbb8-e842f699fc31_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration milestone payment, maximum</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_40b90ab8-42a7-4c3a-bcde-5966b8f2614a_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f15aae5c-bfbf-488b-9bf8-f7e2c2481b6c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_dcb275ef-2708-4378-b808-d68ce21a283f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_b67b24de-760d-4010-878c-7897714554c6_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_a438bc5c-6ed3-4324-9822-5af3342a75d9_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2bd7fdb6-0112-4ee5-a4e2-a3e3040cd99c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option exercises</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b10e546b-0f36-4d83-8136-7f8caf58fc27_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_7eea5033-4017-4e83-ae58-099377fcb3fb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_cd49d058-49ae-4138-9509-424dfad0e4f4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investment securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_1c4e0a3e-e142-4242-b145-806fb7b87bf0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_804071c1-db64-417e-9607-4ff0da5c0f6f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, net of current portion</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow_5f2c6c7f-0114-4656-ac0d-0365e280b765_negatedLabel_en-US" xlink:label="lab_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated return of cash to buyer from escrow</link:label>
    <link:label id="lab_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow_label_en-US" xlink:label="lab_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Estimated Return of Cash to Buyer from Escrow</link:label>
    <link:label id="lab_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow_documentation_en-US" xlink:label="lab_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Estimated Return of Cash to Buyer from Escrow</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow" xlink:href="bngo-20230331.xsd#bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow" xlink:to="lab_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForConstructionInProcess_602fd362-d73d-4c52-9102-092ecc2c464a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForConstructionInProcess" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_PaymentsForConstructionInProcess_label_en-US" xlink:label="lab_us-gaap_PaymentsForConstructionInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Construction in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForConstructionInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForConstructionInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForConstructionInProcess" xlink:to="lab_us-gaap_PaymentsForConstructionInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_83383661-51b1-4398-a635-e3a043b3c3e5_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_28d5aecd-b682-4ec6-abdf-d01ca68754e9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0fa32e51-2c5b-454d-a4e5-3f0502901fd9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ea08d3ef-7b9f-47f6-8e5d-68606cd78198_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_1d885a4b-c250-463b-9c59-c945c7933afc_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_f4c30734-a944-4df5-9548-6a2a1d778076_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_445d8ed2-2853-47c0-9fe7-b434ace21d79_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_5d5a2e08-2f79-4062-ad9c-f432be561771_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_4f71b671-e81d-4965-865c-af92437c74f2_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_f6828d3a-505a-4edd-aa77-03ecd1e71180_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Warrant Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_c0b0996c-eb7a-4faf-ab9f-00c618d0819a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_355bd0be-82d1-47d5-8456-8f7836e988ce_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity and Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_eb1a1e9f-bf1f-41c4-8c36-22edc1bac026_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_58ab153d-5b66-483e-8b74-9ae63429f69e_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_a91a3d49-b4b8-4a2f-83a6-8e51588ec551_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of satisfaction of remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9e7d72d1-5730-41f7-b7f8-c6e385ef883c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of available for sale securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_157bf59c-77bc-42e0-9588-1b28ed18454d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of Stock under Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d7773580-b32f-4918-969a-2242ce617e85_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2f98233b-0c0e-4038-85c4-db4c338aef67_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_3d0d6e6a-8388-4c06-9e81-804c204ec699_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_cfd96e77-eead-4780-a31a-fd5835e9a321_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_cc9f6793-0a11-462b-b19e-ef47177708fa_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_afd8891b-e9f5-4df0-9380-1390125a9e0a_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_c2d0b6f8-6f93-4918-9933-2c21afecc5ce_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service and other revenue</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_ce51bdcf-1899-4b35-bb45-376b4ad45c91_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service and other</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_CostOfProductRevenueMember_79cc8f7d-3b23-4f00-a465-6603995c7534_terseLabel_en-US" xlink:label="lab_bngo_CostOfProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of product revenue</link:label>
    <link:label id="lab_bngo_CostOfProductRevenueMember_label_en-US" xlink:label="lab_bngo_CostOfProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Product Revenue [Member]</link:label>
    <link:label id="lab_bngo_CostOfProductRevenueMember_documentation_en-US" xlink:label="lab_bngo_CostOfProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Product Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CostOfProductRevenueMember" xlink:href="bngo-20230331.xsd#bngo_CostOfProductRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_CostOfProductRevenueMember" xlink:to="lab_bngo_CostOfProductRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_13eece51-e361-4044-9549-5e6546432926_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 12 months, Gross Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_615ebb68-03d7-482e-a5fd-72ce9a9c054e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_206fb810-d645-4375-ac3c-44e5948c2a37_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_da9f93ad-2b76-4d60-bcfe-345c190bc776_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization (accretion) of interest on securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_4bb663b9-27c1-4a1b-8494-77d038304ee9_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_1126c3da-b5a4-4af2-979c-87459f4e5ac4_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 Months or Greater, Gross Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent_5f2228df-6d1a-45fd-83e2-eaaf1849c8b3_terseLabel_en-US" xlink:label="lab_bngo_StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split, percentage of outstanding common stock are present</link:label>
    <link:label id="lab_bngo_StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent_label_en-US" xlink:label="lab_bngo_StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split, Percentage of Outstanding Common Stock Are Present</link:label>
    <link:label id="lab_bngo_StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent_documentation_en-US" xlink:label="lab_bngo_StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split, Percentage of Outstanding Common Stock Are Present</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent" xlink:href="bngo-20230331.xsd#bngo_StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent" xlink:to="lab_bngo_StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ccc52220-a30d-4de2-a341-37a734a7b16f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_c6d1c289-a029-4993-93a2-5e5d8a49e3e1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9ef8f997-4a94-46ab-9024-121f2b003838_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b11585ff-c206-4829-b75d-d05b6b88d1ce_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_PreferredStockNumberOfVotes_d5308768-276b-43ef-ba1c-73c3bc44a7b9_terseLabel_en-US" xlink:label="lab_bngo_PreferredStockNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, number of votes</link:label>
    <link:label id="lab_bngo_PreferredStockNumberOfVotes_label_en-US" xlink:label="lab_bngo_PreferredStockNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Votes</link:label>
    <link:label id="lab_bngo_PreferredStockNumberOfVotes_documentation_en-US" xlink:label="lab_bngo_PreferredStockNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Votes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PreferredStockNumberOfVotes" xlink:href="bngo-20230331.xsd#bngo_PreferredStockNumberOfVotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_PreferredStockNumberOfVotes" xlink:to="lab_bngo_PreferredStockNumberOfVotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_fac00468-9c11-4c63-b2e0-2aa221702553_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_d8cd4251-f7e7-4a9e-b210-f8bbf294899e_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_85d1ad25-653e-47eb-8843-f0ab60168a97_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_c4143cfd-04bb-4e87-ae17-cc9eb260df24_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_fd81ed6c-4630-4ace-91b6-b3afca12b46a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_89eabd67-68a0-416a-bdec-de7e1565f2b0_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_a6458002-e3ba-46f2-a0ed-221ebeaf4ce3_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_bd3b0488-907e-4174-bd40-749dae7ab2e2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_236e488d-f319-4953-9617-2362bf4a5bc2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_5f144982-e04e-45f4-93a1-631ced9ef688_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_53a4aea0-a987-4428-afea-4ae0ad59d0ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_55653988-dd60-4904-bfe2-136d4cf3e173_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments_77d95d07-7e92-4df8-bb07-03228b489727_terseLabel_en-US" xlink:label="lab_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of successive annual installments</link:label>
    <link:label id="lab_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments_label_en-US" xlink:label="lab_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Successive Annual Installments</link:label>
    <link:label id="lab_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments_documentation_en-US" xlink:label="lab_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Successive Annual Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments" xlink:href="bngo-20230331.xsd#bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments" xlink:to="lab_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ae85f4a4-6f91-4ca5-8271-d23cb665027c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_9a899892-fd02-45b5-b322-d464f9c6e2a3_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_de8e3ba1-dcd7-4289-b928-c059bdbc71ec_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_28fc514c-50a8-4ff0-abda-cb816bea2254_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4652e296-3294-4599-af6d-e21c37267c29_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_9397131c-f67a-42a4-bc96-8d9fbc79e890_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ffcbb678-a849-4234-b452-652feea58952_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_1535db0f-9879-4995-955b-3ce17ba4b157_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of March&#160;31, 2023 and December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_a7731581-4750-40ea-abe0-37dc04f7d117_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_f9dad639-6f02-4b8a-9caa-a34d89d5e22d_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8a98b627-3ed5-44b7-b159-0b1c1c4ab68f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4dee9573-42fd-48e7-ae50-ee915d616690_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_f83e1470-4daf-49cd-a6d4-7ff8635d8632_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_caea37cc-2a62-4e40-ab9e-3e874bc95956_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_00a3b0ab-44b2-41cc-9885-6696c9a6de34_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_c071ce8d-4c9f-406d-8446-45cb1dd8b693_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockRedemptionPricePerShare_9d59f6b0-5dbb-4f74-8762-ff12fd27cfc2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockRedemptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, redemption price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockRedemptionPricePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockRedemptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Redemption Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockRedemptionPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockRedemptionPricePerShare" xlink:to="lab_us-gaap_PreferredStockRedemptionPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_753202c2-2333-491b-b570-29da62a44be0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4a26c048-388d-4032-b12d-3eeceb843c1e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory_f3b058a3-4e5d-41df-804b-a319e3a2254b_terseLabel_en-US" xlink:label="lab_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of instruments and servers from inventory to property and equipment, net</link:label>
    <link:label id="lab_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory_label_en-US" xlink:label="lab_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer Of Instruments And Servers To Property And Equipment From Inventory</link:label>
    <link:label id="lab_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory_documentation_en-US" xlink:label="lab_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of instruments and servers to property and equipment from inventory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" xlink:href="bngo-20230331.xsd#bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" xlink:to="lab_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f37ec111-084a-4d6d-b09b-740ee4b23306_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ConsumableRevenueMember_e1ac3215-0070-4f51-a7b6-79d65875745c_terseLabel_en-US" xlink:label="lab_bngo_ConsumableRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumables</link:label>
    <link:label id="lab_bngo_ConsumableRevenueMember_label_en-US" xlink:label="lab_bngo_ConsumableRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumable Revenue [Member]</link:label>
    <link:label id="lab_bngo_ConsumableRevenueMember_documentation_en-US" xlink:label="lab_bngo_ConsumableRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumable Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ConsumableRevenueMember" xlink:href="bngo-20230331.xsd#bngo_ConsumableRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ConsumableRevenueMember" xlink:to="lab_bngo_ConsumableRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_62b48b95-1813-4c1e-8b48-3dc0bf158a4e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_e977dcc3-0a39-47e9-a966-57445f3e19ae_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternetDomainNamesMember_77b1efba-c71c-4ac5-9552-112b9d35c7df_terseLabel_en-US" xlink:label="lab_us-gaap_InternetDomainNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internet Domain Names</link:label>
    <link:label id="lab_us-gaap_InternetDomainNamesMember_label_en-US" xlink:label="lab_us-gaap_InternetDomainNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internet Domain Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternetDomainNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternetDomainNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternetDomainNamesMember" xlink:to="lab_us-gaap_InternetDomainNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_99e02be9-d4c6-40df-962d-be25c4f1ef5f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward_4d6f67c5-6b1b-471d-a87f-63f110537ab4_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted-Average Remaining Contractual Term Of Warrants Or Rights [Roll Forward]</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted-Average Remaining Contractual Term Of Warrants Or Rights [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward" xlink:href="bngo-20230331.xsd#bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward" xlink:to="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_e56326c4-8697-4028-9c10-480ad3160971_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e7bebe65-f31d-418f-8b12-9dafc8133cbb_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_73be8d59-1432-4492-8584-ca0d37690aa4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_7d5ef8c7-13f4-483a-ba68-55751e466bc4_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_fc264730-f3f7-4fa4-b9af-b57ecb17fef0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_30020bc3-6a81-49ca-a9ee-7fee1555a5c1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5457a6d6-d11f-4a8d-bb71-a3dc815a3ec3_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_d9bb8ba5-479e-4afa-8288-1ba9330c72cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting every three months following October 18, 2022</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_7b0dbfdf-8046-4af2-bdd1-39695e35fd33_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5740fbc3-c51f-4abe-bba9-99c2e5dbe33f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_2876494d-27f0-4bf1-8414-e3b163d2a69f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering expenses on sale of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fcdf9117-c15c-416b-bc4f-dcd9e648e379_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_c06b6a81-9356-428c-890c-d6a65df0629e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_5aab7ac4-d31f-4671-93b6-3c4ce2dbf67d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1a51ed8c-3b07-4167-8b3a-7a8189456dce_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_8ba530b9-c5f6-48aa-94bd-892b96453d9f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_cd17cb8f-1467-45db-ad09-74b657a2a50c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Units and Performance Stock Units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_4e08e0f4-6ee8-4830-a56a-c21f81b0785b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_WorkingCapital_6dc9b7d5-f186-4a1d-b1e0-cd188e70045a_terseLabel_en-US" xlink:label="lab_bngo_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_bngo_WorkingCapital_label_en-US" xlink:label="lab_bngo_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital</link:label>
    <link:label id="lab_bngo_WorkingCapital_documentation_en-US" xlink:label="lab_bngo_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_WorkingCapital" xlink:href="bngo-20230331.xsd#bngo_WorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_WorkingCapital" xlink:to="lab_bngo_WorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_92d18f64-f9e8-4a1d-8b01-d06213de6263_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_6ea3b8a7-57b5-45d3-a2a6-49564b8f0dc3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allowance for Credit Losses</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_eabb8df5-73c0-4600-a4a6-7ed08100787a_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AmericasMember_da822538-0a82-4be4-88ed-8fd5abedad40_terseLabel_en-US" xlink:label="lab_srt_AmericasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Americas</link:label>
    <link:label id="lab_srt_AmericasMember_label_en-US" xlink:label="lab_srt_AmericasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Americas [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AmericasMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AmericasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AmericasMember" xlink:to="lab_srt_AmericasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_021b6886-64d7-4ab4-a722-ddd5ae0895fc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1ed6b2dd-3d37-49c6-8bd1-b490d8c0837f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_80c243ac-d8b8-444a-8d77-ffb1a5341050_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod_3921d2a9-163a-4516-913b-f8292e3824dd_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Granted In Period</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Granted In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" xlink:href="bngo-20230331.xsd#bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" xlink:to="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_56a3bd08-26b6-41c5-9c8b-cf4a98c9689c_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_50338113-615c-4315-93d6-cd4fdb5356aa_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_1e6a4c17-8040-42e4-926e-2df78e7f3042_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_519afbdc-c207-4428-ab23-fcc1e9e5aaf6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_8d961658-3a93-41a9-bdc8-425b29819793_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_b046a9f1-5d37-4c5b-a287-2abdbacc259f_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tradename</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightOutstandingRollForward_5b41cbc5-4a45-4a20-a929-c694d140238d_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of Stock under Warrants</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightOutstandingRollForward_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightOutstandingRollForward_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward" xlink:href="bngo-20230331.xsd#bngo_ClassOfWarrantOrRightOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward" xlink:to="lab_bngo_ClassOfWarrantOrRightOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_b23e6333-fede-4444-a580-152c2fd72ede_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale and maturity of available for sale securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_50500411-138e-4bf5-8123-6bd4083cc38c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory_5776e276-5d84-44d5-bf6c-cea08b874a6d_terseLabel_en-US" xlink:label="lab_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of instruments and servers from property and equipment into inventory</link:label>
    <link:label id="lab_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory_label_en-US" xlink:label="lab_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer Of Instruments And Servers From Property And Equipment Into Inventory</link:label>
    <link:label id="lab_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory_documentation_en-US" xlink:label="lab_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer Of Instruments And Servers From Property And Equipment Into Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory" xlink:href="bngo-20230331.xsd#bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory" xlink:to="lab_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_b646327c-5040-4e6a-9723-b0e575ce2545_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash reported within the unaudited condensed consolidated balance sheets to the total amounts reported on the unaudited condensed consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_0380fe83-ff3a-4716-901e-e49c9ffb3d30_terseLabel_en-US" xlink:label="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_label_en-US" xlink:label="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash</link:label>
    <link:label id="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_documentation_en-US" xlink:label="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:href="bngo-20230331.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:to="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_66c9bc2b-5ad4-49b1-b3fb-7c020b11323b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_97ff017d-ba36-46bd-bed1-6fdd9669b8a2_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_607f5a91-1efe-48a0-b305-c0a064706d26_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_83896ca4-536a-4b0b-8e5c-77379c68b60b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_85ee5f31-c403-4dce-815b-cfdf2905fc37_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_be13466f-6878-4e75-b97d-2bf144ce7653_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0fd3eff2-ffc0-494f-8a3e-089460ffe0fd_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_NonCashLeaseExpense_e78b254d-22b1-49eb-b147-53fddc4c6397_terseLabel_en-US" xlink:label="lab_bngo_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_bngo_NonCashLeaseExpense_label_en-US" xlink:label="lab_bngo_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash Lease Expense</link:label>
    <link:label id="lab_bngo_NonCashLeaseExpense_documentation_en-US" xlink:label="lab_bngo_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_NonCashLeaseExpense" xlink:href="bngo-20230331.xsd#bngo_NonCashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_NonCashLeaseExpense" xlink:to="lab_bngo_NonCashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_80c488c2-535c-400c-848f-c6d3686976a5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_14485219-8f96-4d7a-b613-e98db9da5fe8_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_CostOfLeasedEquipmentSoldToCustomer_93a32fe3-8be7-4c9c-88a2-87801f27e626_terseLabel_en-US" xlink:label="lab_bngo_CostOfLeasedEquipmentSoldToCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of leased equipment sold to customer</link:label>
    <link:label id="lab_bngo_CostOfLeasedEquipmentSoldToCustomer_label_en-US" xlink:label="lab_bngo_CostOfLeasedEquipmentSoldToCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Leased Equipment Sold to Customer</link:label>
    <link:label id="lab_bngo_CostOfLeasedEquipmentSoldToCustomer_documentation_en-US" xlink:label="lab_bngo_CostOfLeasedEquipmentSoldToCustomer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Leased Equipment Sold to Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CostOfLeasedEquipmentSoldToCustomer" xlink:href="bngo-20230331.xsd#bngo_CostOfLeasedEquipmentSoldToCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_CostOfLeasedEquipmentSoldToCustomer" xlink:to="lab_bngo_CostOfLeasedEquipmentSoldToCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d7b97f84-3cac-41c4-8ea8-4b68349413a3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_SaleOfStockValueSharesIssuedInTransaction_976b647b-0be7-441d-b495-ad6fcae8a7b8_terseLabel_en-US" xlink:label="lab_bngo_SaleOfStockValueSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering price</link:label>
    <link:label id="lab_bngo_SaleOfStockValueSharesIssuedInTransaction_label_en-US" xlink:label="lab_bngo_SaleOfStockValueSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Value, Shares Issued in Transaction</link:label>
    <link:label id="lab_bngo_SaleOfStockValueSharesIssuedInTransaction_documentation_en-US" xlink:label="lab_bngo_SaleOfStockValueSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Value, Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SaleOfStockValueSharesIssuedInTransaction" xlink:href="bngo-20230331.xsd#bngo_SaleOfStockValueSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_SaleOfStockValueSharesIssuedInTransaction" xlink:to="lab_bngo_SaleOfStockValueSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_c0a7d2b5-8686-499b-ab8c-bd2f2aa1c5ce_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_b0373263-bc84-4e2f-9a1d-68d56b83d54c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9869faaf-e547-4a6d-83be-c31561239c04_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_da88ec04-d6b2-48d3-8b4c-3af54a28f1a2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9c00ea8f-4139-4c9b-9c4c-c844b72707a8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_99e7c671-44ef-420e-8a33-66199c7a874b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_ca4ffe6e-72b6-4c33-9baa-686e10eac25d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_42aee98b-96e6-436b-98ba-109501b749c4_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b311443f-21d8-4215-adec-0b037bbc62c7_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_e81c1172-4555-46cf-94cd-f66176767376_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_7b60ff19-90e5-47d9-81d5-1b000c51bee2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_00f1c840-98f1-470e-942f-935c800c4ee5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation, percentage</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositLiabilityCurrent_628a759c-7f28-4e12-ada2-c47497dd3461_terseLabel_en-US" xlink:label="lab_us-gaap_DepositLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer deposits</link:label>
    <link:label id="lab_us-gaap_DepositLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_DepositLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposit Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositLiabilityCurrent" xlink:to="lab_us-gaap_DepositLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ContingentConsiderationLiabilityMember_5424cf3e-5c5d-4ae1-b6df-567dd4a5a550_terseLabel_en-US" xlink:label="lab_bngo_ContingentConsiderationLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_bngo_ContingentConsiderationLiabilityMember_label_en-US" xlink:label="lab_bngo_ContingentConsiderationLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Liability [Member]</link:label>
    <link:label id="lab_bngo_ContingentConsiderationLiabilityMember_documentation_en-US" xlink:label="lab_bngo_ContingentConsiderationLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationLiabilityMember" xlink:href="bngo-20230331.xsd#bngo_ContingentConsiderationLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ContingentConsiderationLiabilityMember" xlink:to="lab_bngo_ContingentConsiderationLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abe9ed54-38f7-4b0b-a5ce-c8e9bb55fc55_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_33f31ab2-3f42-467c-a385-91a3bbda18bf_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_28d66a61-bfae-4a6a-b845-c02312dc69d4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_bb0ced84-78ed-4ac5-96be-6e792b34091a_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_260cdc99-4d36-4372-a5bc-8924e9a50b17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_36737162-3cfb-41e3-ad20-16d0af40f7ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Noncurrent [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bd667ff6-4278-4054-9433-a4f7b85d8415_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_6be607ba-b610-4f57-b58b-31bd4c88f6ac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_d67ecc0e-f731-4cf8-8d95-1d8696fa0183_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_8687a4b9-ea27-4045-8240-bb845b794cae_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_369f7ccc-5bb3-45d3-a818-a14af26af50e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_933717aa-05e9-4fb2-bf75-0d28a0c6c690_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_fbc0f602-eaf3-4cee-b06a-1bd22b33eded_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e1abe043-d3f1-4632-b3d5-fd1ecb8321a1_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities resulting from obtaining right-of-use assets</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>bngo-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:89c9e3f0-6ddf-4644-8fed-0d858e04a501,g:e99df848-92d3-4a5f-ae11-c380aa17bbd2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://bionanogenomics.com/role/Cover" xlink:type="simple" xlink:href="bngo-20230331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f35283b9-4b99-495c-9a77-346871d38952" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_c6e9e14c-b739-478c-b4df-fa4c14c91536" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f35283b9-4b99-495c-9a77-346871d38952" xlink:to="loc_dei_DocumentInformationTable_c6e9e14c-b739-478c-b4df-fa4c14c91536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6b9c94df-2fba-4663-ae0d-60d42460a2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_c6e9e14c-b739-478c-b4df-fa4c14c91536" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6b9c94df-2fba-4663-ae0d-60d42460a2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4d36da1f-f75a-41f8-bc8b-c544f3eee308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6b9c94df-2fba-4663-ae0d-60d42460a2dd" xlink:to="loc_us-gaap_ClassOfStockDomain_4d36da1f-f75a-41f8-bc8b-c544f3eee308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1d70b76a-7c04-4655-b095-32d0d136476a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4d36da1f-f75a-41f8-bc8b-c544f3eee308" xlink:to="loc_us-gaap_CommonStockMember_1d70b76a-7c04-4655-b095-32d0d136476a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_f70e6e0c-b9f3-4c97-b968-6ffc67c9cc99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4d36da1f-f75a-41f8-bc8b-c544f3eee308" xlink:to="loc_us-gaap_WarrantMember_f70e6e0c-b9f3-4c97-b968-6ffc67c9cc99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_c6e9e14c-b739-478c-b4df-fa4c14c91536" xlink:to="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d3f33b32-f844-45c1-b133-a75910501243" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_DocumentType_d3f33b32-f844-45c1-b133-a75910501243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_ed26e9c1-388c-4d37-a570-a3556eda128e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_DocumentQuarterlyReport_ed26e9c1-388c-4d37-a570-a3556eda128e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4a0845e3-643a-4c59-9561-958f9fc2d86c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_DocumentPeriodEndDate_4a0845e3-643a-4c59-9561-958f9fc2d86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f1096aae-c7f1-4a4e-a4cf-30691b7159a7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_DocumentTransitionReport_f1096aae-c7f1-4a4e-a4cf-30691b7159a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_97f8e85b-ca91-4064-8c32-c6ea1124f306" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityFileNumber_97f8e85b-ca91-4064-8c32-c6ea1124f306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_491bcfce-b9ca-45d6-9611-43b599c86c80" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityRegistrantName_491bcfce-b9ca-45d6-9611-43b599c86c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7a4db9a8-c2cb-4ee6-8d05-f071557bea79" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7a4db9a8-c2cb-4ee6-8d05-f071557bea79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c28a0ecc-7d8e-44b9-a956-5d3f6cc97ca5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityTaxIdentificationNumber_c28a0ecc-7d8e-44b9-a956-5d3f6cc97ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_06ba2be5-d153-4c46-8bdc-2a2c2854906c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityAddressAddressLine1_06ba2be5-d153-4c46-8bdc-2a2c2854906c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_340c1dda-a8c2-4283-aafa-d66af098046a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityAddressCityOrTown_340c1dda-a8c2-4283-aafa-d66af098046a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f5188a75-7efe-486b-b98a-2476b6cc9667" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityAddressStateOrProvince_f5188a75-7efe-486b-b98a-2476b6cc9667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ea32652d-2eba-42fd-977b-1c231fb664c5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityAddressPostalZipCode_ea32652d-2eba-42fd-977b-1c231fb664c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_543419c1-1af2-4fd0-9575-8cda98b4dd7c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_CityAreaCode_543419c1-1af2-4fd0-9575-8cda98b4dd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_51b9d4c6-3c36-45b2-bb5c-36baf6536786" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_LocalPhoneNumber_51b9d4c6-3c36-45b2-bb5c-36baf6536786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_528d6d83-ca7d-4ce0-a722-ecd43ac616af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_Security12bTitle_528d6d83-ca7d-4ce0-a722-ecd43ac616af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ec80eba6-5a8f-4848-8443-b248e05ab89d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_TradingSymbol_ec80eba6-5a8f-4848-8443-b248e05ab89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2072cb55-64f1-4ba5-b5ec-d030add296e9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_SecurityExchangeName_2072cb55-64f1-4ba5-b5ec-d030add296e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_a576b367-002e-4f6e-bb6a-e347c261f326" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityCurrentReportingStatus_a576b367-002e-4f6e-bb6a-e347c261f326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_c48e4d64-bab0-4b87-98c4-95d7cffa804f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityInteractiveDataCurrent_c48e4d64-bab0-4b87-98c4-95d7cffa804f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_b77fe79b-c7c5-44df-aee9-66d73bbb8896" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityFilerCategory_b77fe79b-c7c5-44df-aee9-66d73bbb8896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_291dc313-59d8-4bb0-9308-c53bca555ef2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntitySmallBusiness_291dc313-59d8-4bb0-9308-c53bca555ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_eb07037e-8abe-4776-9ec9-5bd863353ba2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityEmergingGrowthCompany_eb07037e-8abe-4776-9ec9-5bd863353ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_36c64989-4958-4a48-89e3-da0e9c3bae35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityShellCompany_36c64989-4958-4a48-89e3-da0e9c3bae35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f66655b4-d99c-4496-871f-7028f1dc64c6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f66655b4-d99c-4496-871f-7028f1dc64c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_00a15632-6e00-4ab2-a722-f41c515ab193" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_AmendmentFlag_00a15632-6e00-4ab2-a722-f41c515ab193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_3987186c-dda7-41b8-8f85-f48707c108b0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_DocumentFiscalYearFocus_3987186c-dda7-41b8-8f85-f48707c108b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_c36885ab-c9f7-4e60-b18b-de0b7c8454f1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_c36885ab-c9f7-4e60-b18b-de0b7c8454f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_99941c91-8ae2-49b6-983a-e757e0526091" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_EntityCentralIndexKey_99941c91-8ae2-49b6-983a-e757e0526091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c32cb2dd-c03c-42f1-9787-2199a462bd08" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_171ce50e-ea1e-46bd-8628-00aa911f814f" xlink:to="loc_dei_CurrentFiscalYearEndDate_c32cb2dd-c03c-42f1-9787-2199a462bd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="bngo-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b1b05c61-8430-49af-b061-287755b0879f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_1ab61ec3-118f-488c-8629-371e51e610a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b1b05c61-8430-49af-b061-287755b0879f" xlink:to="loc_us-gaap_AssetsAbstract_1ab61ec3-118f-488c-8629-371e51e610a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2b7d7de2-d292-4bb8-bb38-6e210a23c948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1ab61ec3-118f-488c-8629-371e51e610a5" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2b7d7de2-d292-4bb8-bb38-6e210a23c948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e5f001d3-cef2-455d-8067-0e3a4fbb2769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2b7d7de2-d292-4bb8-bb38-6e210a23c948" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e5f001d3-cef2-455d-8067-0e3a4fbb2769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3383784c-8b44-4640-a2ff-3e0b868b831a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2b7d7de2-d292-4bb8-bb38-6e210a23c948" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3383784c-8b44-4640-a2ff-3e0b868b831a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6c16f5c3-0abc-4c24-81d4-bc62a40e39a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2b7d7de2-d292-4bb8-bb38-6e210a23c948" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6c16f5c3-0abc-4c24-81d4-bc62a40e39a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_915f7a92-4742-47c8-bf9c-cb86f5393686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2b7d7de2-d292-4bb8-bb38-6e210a23c948" xlink:to="loc_us-gaap_InventoryNet_915f7a92-4742-47c8-bf9c-cb86f5393686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_69e99a1b-25aa-4c52-be88-57c29e1662de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2b7d7de2-d292-4bb8-bb38-6e210a23c948" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_69e99a1b-25aa-4c52-be88-57c29e1662de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_13d6794d-54ae-4529-8e94-d28d7a512f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2b7d7de2-d292-4bb8-bb38-6e210a23c948" xlink:to="loc_us-gaap_AssetsCurrent_13d6794d-54ae-4529-8e94-d28d7a512f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_3ede9a2d-d539-4866-86af-9b27c73e99b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1ab61ec3-118f-488c-8629-371e51e610a5" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_3ede9a2d-d539-4866-86af-9b27c73e99b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_18c4755a-89ea-4415-a6f5-c660503eab48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1ab61ec3-118f-488c-8629-371e51e610a5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_18c4755a-89ea-4415-a6f5-c660503eab48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_62ad28c8-020a-4a5f-8b90-9eb37326db31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1ab61ec3-118f-488c-8629-371e51e610a5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_62ad28c8-020a-4a5f-8b90-9eb37326db31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_03571c03-468d-44bb-84ca-4d5cdc977715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1ab61ec3-118f-488c-8629-371e51e610a5" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_03571c03-468d-44bb-84ca-4d5cdc977715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4ae8ded1-b85a-49b3-86af-e4d13f821ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1ab61ec3-118f-488c-8629-371e51e610a5" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4ae8ded1-b85a-49b3-86af-e4d13f821ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7a2765bf-eb2c-4a07-b469-64ac953b5a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1ab61ec3-118f-488c-8629-371e51e610a5" xlink:to="loc_us-gaap_Goodwill_7a2765bf-eb2c-4a07-b469-64ac953b5a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c8f332e9-801a-4295-a3b1-27f24aeb4c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1ab61ec3-118f-488c-8629-371e51e610a5" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c8f332e9-801a-4295-a3b1-27f24aeb4c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_fc8eba3d-24e6-4b00-bfdd-ff4da39ec67e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1ab61ec3-118f-488c-8629-371e51e610a5" xlink:to="loc_us-gaap_Assets_fc8eba3d-24e6-4b00-bfdd-ff4da39ec67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4febe7b7-7f97-4154-98a9-ee120126d653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b1b05c61-8430-49af-b061-287755b0879f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4febe7b7-7f97-4154-98a9-ee120126d653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_262bd03e-6eb4-4cc0-b6da-c160da89f978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4febe7b7-7f97-4154-98a9-ee120126d653" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_262bd03e-6eb4-4cc0-b6da-c160da89f978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4ec84da5-126a-4bbe-b359-ec78eca06c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_262bd03e-6eb4-4cc0-b6da-c160da89f978" xlink:to="loc_us-gaap_AccountsPayableCurrent_4ec84da5-126a-4bbe-b359-ec78eca06c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f60f32f3-8748-41f5-b35a-20d111981036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_262bd03e-6eb4-4cc0-b6da-c160da89f978" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f60f32f3-8748-41f5-b35a-20d111981036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_236eff36-2ec5-4c7b-9ee5-c8be2e0e67cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_262bd03e-6eb4-4cc0-b6da-c160da89f978" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_236eff36-2ec5-4c7b-9ee5-c8be2e0e67cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f87f69c9-4350-49c4-82e3-7422e7481705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_262bd03e-6eb4-4cc0-b6da-c160da89f978" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f87f69c9-4350-49c4-82e3-7422e7481705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_00a51574-f48b-47c1-84bc-34aa0c41e27b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_262bd03e-6eb4-4cc0-b6da-c160da89f978" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_00a51574-f48b-47c1-84bc-34aa0c41e27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_acc058b6-67c2-44a8-a0e8-cbcfe0457bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_262bd03e-6eb4-4cc0-b6da-c160da89f978" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_acc058b6-67c2-44a8-a0e8-cbcfe0457bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e5de2713-9e9a-49a0-9cf1-5011f00b0c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_262bd03e-6eb4-4cc0-b6da-c160da89f978" xlink:to="loc_us-gaap_LiabilitiesCurrent_e5de2713-9e9a-49a0-9cf1-5011f00b0c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_89558bab-a724-4ac2-b79b-9b45d0e55040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4febe7b7-7f97-4154-98a9-ee120126d653" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_89558bab-a724-4ac2-b79b-9b45d0e55040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_beb9c3c9-0e23-4d84-bfe1-552252f95a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4febe7b7-7f97-4154-98a9-ee120126d653" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_beb9c3c9-0e23-4d84-bfe1-552252f95a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_de79cccf-27f0-4f66-8899-9bf67ddfaf96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4febe7b7-7f97-4154-98a9-ee120126d653" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_de79cccf-27f0-4f66-8899-9bf67ddfaf96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_501fc12f-d8e5-491c-b7ac-c0b38efc83c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4febe7b7-7f97-4154-98a9-ee120126d653" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_501fc12f-d8e5-491c-b7ac-c0b38efc83c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_09f49da7-59a2-42b0-9f1a-8ad2fa560469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4febe7b7-7f97-4154-98a9-ee120126d653" xlink:to="loc_us-gaap_Liabilities_09f49da7-59a2-42b0-9f1a-8ad2fa560469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b69226d6-652c-4fcf-bd63-7d8ea141cbca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4febe7b7-7f97-4154-98a9-ee120126d653" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b69226d6-652c-4fcf-bd63-7d8ea141cbca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_5bac2147-27a7-46ca-a885-9d83a4168233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4febe7b7-7f97-4154-98a9-ee120126d653" xlink:to="loc_us-gaap_StockholdersEquityAbstract_5bac2147-27a7-46ca-a885-9d83a4168233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_9aa2e4b0-c7b9-465e-8fdd-c3ff4ee4094a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5bac2147-27a7-46ca-a885-9d83a4168233" xlink:to="loc_us-gaap_PreferredStockValue_9aa2e4b0-c7b9-465e-8fdd-c3ff4ee4094a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e094bd67-4b43-46f5-909b-0377275f0302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5bac2147-27a7-46ca-a885-9d83a4168233" xlink:to="loc_us-gaap_CommonStockValue_e094bd67-4b43-46f5-909b-0377275f0302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3e3caa31-74c6-4c68-bf8b-2cceb31e5680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5bac2147-27a7-46ca-a885-9d83a4168233" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3e3caa31-74c6-4c68-bf8b-2cceb31e5680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3860e0d3-1317-4142-aea5-6140d90c1e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5bac2147-27a7-46ca-a885-9d83a4168233" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3860e0d3-1317-4142-aea5-6140d90c1e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_20ac271a-97f9-468e-977f-37a622f3b839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5bac2147-27a7-46ca-a885-9d83a4168233" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_20ac271a-97f9-468e-977f-37a622f3b839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_49781b57-f851-4ef9-8792-c091e377f0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5bac2147-27a7-46ca-a885-9d83a4168233" xlink:to="loc_us-gaap_StockholdersEquity_49781b57-f851-4ef9-8792-c091e377f0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_10869712-6a16-4d69-8ce5-25c31f1c6252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4febe7b7-7f97-4154-98a9-ee120126d653" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_10869712-6a16-4d69-8ce5-25c31f1c6252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="bngo-20230331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_73f7fbf8-a6ad-4dc0-9255-875224ab4ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_abd7d175-94ac-47d4-aae1-e2fe7bd5070d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_73f7fbf8-a6ad-4dc0-9255-875224ab4ae2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_abd7d175-94ac-47d4-aae1-e2fe7bd5070d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_b07a2f49-0909-4454-834e-81e7e24c6a02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_73f7fbf8-a6ad-4dc0-9255-875224ab4ae2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_b07a2f49-0909-4454-834e-81e7e24c6a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_d00f4782-3875-4326-89cc-4614f7b30549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_73f7fbf8-a6ad-4dc0-9255-875224ab4ae2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_d00f4782-3875-4326-89cc-4614f7b30549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_a7e1e0ee-f40e-4630-9bbf-2458f8b6b5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_73f7fbf8-a6ad-4dc0-9255-875224ab4ae2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_a7e1e0ee-f40e-4630-9bbf-2458f8b6b5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_02601d86-c370-4276-a10b-f07a35a1cb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_73f7fbf8-a6ad-4dc0-9255-875224ab4ae2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_02601d86-c370-4276-a10b-f07a35a1cb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_06b52970-27fb-47f9-a45f-84d95b0386e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_73f7fbf8-a6ad-4dc0-9255-875224ab4ae2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_06b52970-27fb-47f9-a45f-84d95b0386e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ed708a2c-9cef-48b8-aa6e-537b8595c34d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_73f7fbf8-a6ad-4dc0-9255-875224ab4ae2" xlink:to="loc_us-gaap_CommonStockSharesIssued_ed708a2c-9cef-48b8-aa6e-537b8595c34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4c617357-5bef-40c1-bf1a-3d6a6b46d932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_73f7fbf8-a6ad-4dc0-9255-875224ab4ae2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4c617357-5bef-40c1-bf1a-3d6a6b46d932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="bngo-20230331.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_08e5a7b8-65d1-41d2-bf3f-0bfbf11789e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_149546b2-bbfc-4edf-baf2-b0f0f9734d99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_08e5a7b8-65d1-41d2-bf3f-0bfbf11789e8" xlink:to="loc_us-gaap_StatementTable_149546b2-bbfc-4edf-baf2-b0f0f9734d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8fcb657b-d05c-4450-a4e3-c9a2e54d9740" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_149546b2-bbfc-4edf-baf2-b0f0f9734d99" xlink:to="loc_srt_ProductOrServiceAxis_8fcb657b-d05c-4450-a4e3-c9a2e54d9740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_11c0af6b-684b-40de-99ec-cdac8fc4c339" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8fcb657b-d05c-4450-a4e3-c9a2e54d9740" xlink:to="loc_srt_ProductsAndServicesDomain_11c0af6b-684b-40de-99ec-cdac8fc4c339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_f232528a-ce66-4224-b52e-6f2165f91a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_11c0af6b-684b-40de-99ec-cdac8fc4c339" xlink:to="loc_us-gaap_ProductMember_f232528a-ce66-4224-b52e-6f2165f91a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_493603dd-2dcc-4c77-8f3d-91b4d8b79f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_11c0af6b-684b-40de-99ec-cdac8fc4c339" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_493603dd-2dcc-4c77-8f3d-91b4d8b79f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_149546b2-bbfc-4edf-baf2-b0f0f9734d99" xlink:to="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_22c25896-6006-45fa-9637-3381fd04aa84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:to="loc_us-gaap_RevenuesAbstract_22c25896-6006-45fa-9637-3381fd04aa84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e4320eaa-53d1-42da-8f17-d2fd0bfd08ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_22c25896-6006-45fa-9637-3381fd04aa84" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e4320eaa-53d1-42da-8f17-d2fd0bfd08ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_2c47a252-1c8d-4651-8ac1-c6ed47dd118c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_2c47a252-1c8d-4651-8ac1-c6ed47dd118c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_11a8251e-0919-4e2d-b3dc-7931e0a20e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2c47a252-1c8d-4651-8ac1-c6ed47dd118c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_11a8251e-0919-4e2d-b3dc-7931e0a20e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6555a054-46f0-4f17-855c-a6c5c4818e33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6555a054-46f0-4f17-855c-a6c5c4818e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e01191d7-376d-4521-8e73-fa3e196c813b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6555a054-46f0-4f17-855c-a6c5c4818e33" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e01191d7-376d-4521-8e73-fa3e196c813b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9e1d1f49-5c37-4fbe-9a29-d10ed3333889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6555a054-46f0-4f17-855c-a6c5c4818e33" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9e1d1f49-5c37-4fbe-9a29-d10ed3333889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_2d796968-b5c8-437c-b132-5edfb96533b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6555a054-46f0-4f17-855c-a6c5c4818e33" xlink:to="loc_us-gaap_CostsAndExpenses_2d796968-b5c8-437c-b132-5edfb96533b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2d17ac5c-5448-4711-9b90-9ced3d96a406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:to="loc_us-gaap_OperatingIncomeLoss_2d17ac5c-5448-4711-9b90-9ced3d96a406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b829af58-7640-404a-bcf5-ad9ad94770ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b829af58-7640-404a-bcf5-ad9ad94770ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_7719b8dd-0399-4b4b-9289-b64fcd5b2ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b829af58-7640-404a-bcf5-ad9ad94770ab" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_7719b8dd-0399-4b4b-9289-b64fcd5b2ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_dc88e3b7-e2df-42bb-b6da-5db4b54f8ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b829af58-7640-404a-bcf5-ad9ad94770ab" xlink:to="loc_us-gaap_InterestExpense_dc88e3b7-e2df-42bb-b6da-5db4b54f8ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_cc7417d9-026a-4baa-9b2f-ab39af99918a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b829af58-7640-404a-bcf5-ad9ad94770ab" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_cc7417d9-026a-4baa-9b2f-ab39af99918a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_75e54fb0-2b17-410b-bb91-364295910c20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b829af58-7640-404a-bcf5-ad9ad94770ab" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_75e54fb0-2b17-410b-bb91-364295910c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d778bfd4-1e7d-4e6d-b9cf-ea14a0306e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d778bfd4-1e7d-4e6d-b9cf-ea14a0306e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_36f6ecad-399c-4598-afb7-0b3b50879131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_36f6ecad-399c-4598-afb7-0b3b50879131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7256dc9c-72ee-4061-986a-d7f940e9f66a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:to="loc_us-gaap_NetIncomeLoss_7256dc9c-72ee-4061-986a-d7f940e9f66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_06bee885-06ec-48b7-8648-09ccf29dbb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:to="loc_us-gaap_EarningsPerShareBasic_06bee885-06ec-48b7-8648-09ccf29dbb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f26443a8-ac27-477c-9e72-a1dd3257d8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f26443a8-ac27-477c-9e72-a1dd3257d8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_49708a4b-d713-42c2-8ea3-49563a40b376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_49708a4b-d713-42c2-8ea3-49563a40b376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1f85b324-7f1d-4dca-9800-400bb68dd465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48ce595f-04cb-402b-a7b5-26ebefb52d10" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1f85b324-7f1d-4dca-9800-400bb68dd465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="bngo-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_948bc087-df08-43d9-9619-cb8e7a4759f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_22bed884-80b8-4267-bd70-4a7b1ca2c5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_948bc087-df08-43d9-9619-cb8e7a4759f8" xlink:to="loc_us-gaap_NetIncomeLoss_22bed884-80b8-4267-bd70-4a7b1ca2c5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_6e3bb1b7-ae1a-4ccc-afcd-4767bd3c1650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_948bc087-df08-43d9-9619-cb8e7a4759f8" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_6e3bb1b7-ae1a-4ccc-afcd-4767bd3c1650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4a0eb9ee-ab5c-41af-871d-8257b650aa4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_6e3bb1b7-ae1a-4ccc-afcd-4767bd3c1650" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4a0eb9ee-ab5c-41af-871d-8257b650aa4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_542445c3-1f3e-4616-bb4d-d508fd9bd8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_6e3bb1b7-ae1a-4ccc-afcd-4767bd3c1650" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_542445c3-1f3e-4616-bb4d-d508fd9bd8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1cd5dd2b-f344-4e5d-9d8f-6639ec916aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_6e3bb1b7-ae1a-4ccc-afcd-4767bd3c1650" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1cd5dd2b-f344-4e5d-9d8f-6639ec916aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_88125079-7e24-4ce4-8158-95c03d8cd00d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_948bc087-df08-43d9-9619-cb8e7a4759f8" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_88125079-7e24-4ce4-8158-95c03d8cd00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="simple" xlink:href="bngo-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_4c318e23-53cd-400e-9aa2-dc8b9548e40b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_997837e2-acef-4542-9a7d-499ec80560dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_4c318e23-53cd-400e-9aa2-dc8b9548e40b" xlink:to="loc_us-gaap_StatementTable_997837e2-acef-4542-9a7d-499ec80560dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f9711dfb-07fc-4db2-896d-2074bada8342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_997837e2-acef-4542-9a7d-499ec80560dd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f9711dfb-07fc-4db2-896d-2074bada8342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_53e27528-e32f-4ce9-a3e9-4c0338572ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f9711dfb-07fc-4db2-896d-2074bada8342" xlink:to="loc_us-gaap_EquityComponentDomain_53e27528-e32f-4ce9-a3e9-4c0338572ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_01a8f87a-efc7-4e81-8e32-bfd36115a438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_53e27528-e32f-4ce9-a3e9-4c0338572ad2" xlink:to="loc_us-gaap_CommonStockMember_01a8f87a-efc7-4e81-8e32-bfd36115a438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_08f4d2ee-1ee0-4310-8c79-567478732c31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_53e27528-e32f-4ce9-a3e9-4c0338572ad2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_08f4d2ee-1ee0-4310-8c79-567478732c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_bc21f537-42ee-4402-9bc2-ae71ac178181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_53e27528-e32f-4ce9-a3e9-4c0338572ad2" xlink:to="loc_us-gaap_RetainedEarningsMember_bc21f537-42ee-4402-9bc2-ae71ac178181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_974d15b9-694b-4689-b980-d95657dea58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_53e27528-e32f-4ce9-a3e9-4c0338572ad2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_974d15b9-694b-4689-b980-d95657dea58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e0eff4f8-1eed-45b6-bc46-36bfd30bafc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_997837e2-acef-4542-9a7d-499ec80560dd" xlink:to="loc_us-gaap_StatementLineItems_e0eff4f8-1eed-45b6-bc46-36bfd30bafc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e0eff4f8-1eed-45b6-bc46-36bfd30bafc3" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_39c397c7-68cb-4a31-b9ce-88cf9a948222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_39c397c7-68cb-4a31-b9ce-88cf9a948222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_44185c31-43e5-4905-9b89-626e56d21976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:to="loc_us-gaap_StockholdersEquity_44185c31-43e5-4905-9b89-626e56d21976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e4d5e84c-77bd-45da-aeb2-6a5546dd8da9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e4d5e84c-77bd-45da-aeb2-6a5546dd8da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5bc4ed08-0067-462f-8e24-6915d7255fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5bc4ed08-0067-462f-8e24-6915d7255fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_499904bd-2bc3-4121-b34c-15b51ba3f1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_499904bd-2bc3-4121-b34c-15b51ba3f1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_62774287-85bc-4f3e-ac45-36775ef02754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_62774287-85bc-4f3e-ac45-36775ef02754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7bfe91c2-408d-44e8-a1d8-94942bb8f05e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7bfe91c2-408d-44e8-a1d8-94942bb8f05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_c2aa0f9b-91c7-4eaf-b44a-9014d79018bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:to="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_c2aa0f9b-91c7-4eaf-b44a-9014d79018bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_11a4c394-311d-4533-9ff5-a530fd94b9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:to="loc_us-gaap_NetIncomeLoss_11a4c394-311d-4533-9ff5-a530fd94b9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8eab7fee-c43d-4a8a-9f52-adb8ce936cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8eab7fee-c43d-4a8a-9f52-adb8ce936cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_faca118e-5b04-4d64-908e-a40c923ce0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_faca118e-5b04-4d64-908e-a40c923ce0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f1074f03-eaf7-4643-a98b-909111513056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c7dd05a-50d9-455c-bc85-8096645eb8ee" xlink:to="loc_us-gaap_StockholdersEquity_f1074f03-eaf7-4643-a98b-909111513056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="bngo-20230331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_9aa8161e-392e-49fd-97b2-476d03e7f019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cb7e549d-e4c4-48ae-abee-39a819ba327b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9aa8161e-392e-49fd-97b2-476d03e7f019" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cb7e549d-e4c4-48ae-abee-39a819ba327b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_89d4fa29-333f-4107-8620-26367f8a6a93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cb7e549d-e4c4-48ae-abee-39a819ba327b" xlink:to="loc_us-gaap_NetIncomeLoss_89d4fa29-333f-4107-8620-26367f8a6a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_481e098c-53dd-4b91-882e-eb47b4941ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cb7e549d-e4c4-48ae-abee-39a819ba327b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_481e098c-53dd-4b91-882e-eb47b4941ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3c85ff89-91ff-4242-85a3-7eb33367743e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_481e098c-53dd-4b91-882e-eb47b4941ab1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3c85ff89-91ff-4242-85a3-7eb33367743e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_a73c4ab0-e889-4649-afae-449e719c12c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_481e098c-53dd-4b91-882e-eb47b4941ab1" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_a73c4ab0-e889-4649-afae-449e719c12c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ed82bebc-67dc-431d-a85c-1e97ead9316b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_481e098c-53dd-4b91-882e-eb47b4941ab1" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ed82bebc-67dc-431d-a85c-1e97ead9316b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_NonCashLeaseExpense_d064a804-0da1-4fe7-bb71-c2ebab1047be" xlink:href="bngo-20230331.xsd#bngo_NonCashLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_481e098c-53dd-4b91-882e-eb47b4941ab1" xlink:to="loc_bngo_NonCashLeaseExpense_d064a804-0da1-4fe7-bb71-c2ebab1047be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_fafd479b-086b-4f51-b905-b1cb38c1a7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_481e098c-53dd-4b91-882e-eb47b4941ab1" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_fafd479b-086b-4f51-b905-b1cb38c1a7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_de287f5a-f458-44f7-84bd-045208b9991f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_481e098c-53dd-4b91-882e-eb47b4941ab1" xlink:to="loc_us-gaap_ShareBasedCompensation_de287f5a-f458-44f7-84bd-045208b9991f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_152a4e01-b90b-4e8f-a8dd-a59db77f43ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_481e098c-53dd-4b91-882e-eb47b4941ab1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_152a4e01-b90b-4e8f-a8dd-a59db77f43ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CostOfLeasedEquipmentSoldToCustomer_f83adec1-ea95-495f-b6c8-cb2c64880a80" xlink:href="bngo-20230331.xsd#bngo_CostOfLeasedEquipmentSoldToCustomer"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_481e098c-53dd-4b91-882e-eb47b4941ab1" xlink:to="loc_bngo_CostOfLeasedEquipmentSoldToCustomer_f83adec1-ea95-495f-b6c8-cb2c64880a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f593cd42-0bd7-450b-87b3-edbcfecaeb12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_481e098c-53dd-4b91-882e-eb47b4941ab1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f593cd42-0bd7-450b-87b3-edbcfecaeb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cd1822de-5b7b-4aef-a421-0b901bc08ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f593cd42-0bd7-450b-87b3-edbcfecaeb12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cd1822de-5b7b-4aef-a421-0b901bc08ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_ca6699ef-ff90-4fc6-9a25-804adb9bc8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f593cd42-0bd7-450b-87b3-edbcfecaeb12" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_ca6699ef-ff90-4fc6-9a25-804adb9bc8e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfd88fe6-7046-4d3c-b899-c2c2611cb0a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f593cd42-0bd7-450b-87b3-edbcfecaeb12" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfd88fe6-7046-4d3c-b899-c2c2611cb0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7f540013-16c5-4b76-8e97-90d67f0cee5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f593cd42-0bd7-450b-87b3-edbcfecaeb12" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7f540013-16c5-4b76-8e97-90d67f0cee5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_25b8c2f0-5d35-4972-8bc9-ac0e42ce4262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f593cd42-0bd7-450b-87b3-edbcfecaeb12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_25b8c2f0-5d35-4972-8bc9-ac0e42ce4262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_301d8cec-215c-4e2a-8b18-f953132dd19f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f593cd42-0bd7-450b-87b3-edbcfecaeb12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_301d8cec-215c-4e2a-8b18-f953132dd19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_098273dd-86c1-473e-bd0d-338a778ea274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cb7e549d-e4c4-48ae-abee-39a819ba327b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_098273dd-86c1-473e-bd0d-338a778ea274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b35b6f2e-9c46-4ed2-9638-8173848b0b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9aa8161e-392e-49fd-97b2-476d03e7f019" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b35b6f2e-9c46-4ed2-9638-8173848b0b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow_fc268492-f9b7-4ea1-9483-a98e0572b315" xlink:href="bngo-20230331.xsd#bngo_ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b35b6f2e-9c46-4ed2-9638-8173848b0b81" xlink:to="loc_bngo_ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow_fc268492-f9b7-4ea1-9483-a98e0572b315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PaymentsForPropertyAndEquipment_ee6051fe-ebb8-498a-8139-b932651bdf82" xlink:href="bngo-20230331.xsd#bngo_PaymentsForPropertyAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b35b6f2e-9c46-4ed2-9638-8173848b0b81" xlink:to="loc_bngo_PaymentsForPropertyAndEquipment_ee6051fe-ebb8-498a-8139-b932651bdf82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_790de866-4451-43ae-bb1c-17042fe90bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b35b6f2e-9c46-4ed2-9638-8173848b0b81" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_790de866-4451-43ae-bb1c-17042fe90bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_31711dc9-7f84-45df-82b8-3727efbd6677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b35b6f2e-9c46-4ed2-9638-8173848b0b81" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_31711dc9-7f84-45df-82b8-3727efbd6677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForConstructionInProcess_e2d53ca3-9881-410c-8334-c28ea4e1d653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForConstructionInProcess"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b35b6f2e-9c46-4ed2-9638-8173848b0b81" xlink:to="loc_us-gaap_PaymentsForConstructionInProcess_e2d53ca3-9881-410c-8334-c28ea4e1d653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_7de06689-6867-46d0-afe1-af67fc14f96d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b35b6f2e-9c46-4ed2-9638-8173848b0b81" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_7de06689-6867-46d0-afe1-af67fc14f96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18abd9c9-6795-42af-9ca5-af65f498cd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b35b6f2e-9c46-4ed2-9638-8173848b0b81" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18abd9c9-6795-42af-9ca5-af65f498cd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f944fbe5-db6e-4fd6-8b2e-d249ea30460a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9aa8161e-392e-49fd-97b2-476d03e7f019" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f944fbe5-db6e-4fd6-8b2e-d249ea30460a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_ccc289aa-5794-49c3-bb4c-06dbc2765f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f944fbe5-db6e-4fd6-8b2e-d249ea30460a" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_ccc289aa-5794-49c3-bb4c-06dbc2765f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_786b9adc-454c-47c6-945c-9c8d2951228a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f944fbe5-db6e-4fd6-8b2e-d249ea30460a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_786b9adc-454c-47c6-945c-9c8d2951228a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_ab081838-c180-4743-a70b-2ab3e519b49e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f944fbe5-db6e-4fd6-8b2e-d249ea30460a" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_ab081838-c180-4743-a70b-2ab3e519b49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_56fb7a9a-a08c-4d16-9893-8e1c6cbe0e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f944fbe5-db6e-4fd6-8b2e-d249ea30460a" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_56fb7a9a-a08c-4d16-9893-8e1c6cbe0e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b6b91812-1275-4e18-91b1-ebbba3569a86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f944fbe5-db6e-4fd6-8b2e-d249ea30460a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b6b91812-1275-4e18-91b1-ebbba3569a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_227a6b52-3ec8-47fc-b269-a1a302668aec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9aa8161e-392e-49fd-97b2-476d03e7f019" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_227a6b52-3ec8-47fc-b269-a1a302668aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b352ec0e-cefc-450d-ae93-68eea163dc99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9aa8161e-392e-49fd-97b2-476d03e7f019" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b352ec0e-cefc-450d-ae93-68eea163dc99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_9151ab88-f0ba-4e85-a674-3ef402cc6dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9aa8161e-392e-49fd-97b2-476d03e7f019" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_9151ab88-f0ba-4e85-a674-3ef402cc6dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_9bbfad6b-5e87-49c1-85a4-1b0e1d69f33f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9aa8161e-392e-49fd-97b2-476d03e7f019" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_9bbfad6b-5e87-49c1-85a4-1b0e1d69f33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_04b03eb8-7aa2-4e89-a4e0-05f1a9fef21e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9aa8161e-392e-49fd-97b2-476d03e7f019" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_04b03eb8-7aa2-4e89-a4e0-05f1a9fef21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_72428c6e-0535-4ec3-bff7-88be8b13f98b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_04b03eb8-7aa2-4e89-a4e0-05f1a9fef21e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_72428c6e-0535-4ec3-bff7-88be8b13f98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_4972e69b-3514-4b38-983a-20e317fe46c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_04b03eb8-7aa2-4e89-a4e0-05f1a9fef21e" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_4972e69b-3514-4b38-983a-20e317fe46c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ecefabde-e900-4432-8b80-6f51ffb42669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_04b03eb8-7aa2-4e89-a4e0-05f1a9fef21e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ecefabde-e900-4432-8b80-6f51ffb42669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_e3195c63-e688-4893-9b81-0a5654fdffc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9aa8161e-392e-49fd-97b2-476d03e7f019" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_e3195c63-e688-4893-9b81-0a5654fdffc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_a1e78ad7-afb4-4980-aa92-ca6d22eafd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e3195c63-e688-4893-9b81-0a5654fdffc0" xlink:to="loc_us-gaap_InterestPaidNet_a1e78ad7-afb4-4980-aa92-ca6d22eafd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_d3107f48-22f5-4c29-be75-6ace4f28444a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e3195c63-e688-4893-9b81-0a5654fdffc0" xlink:to="loc_us-gaap_OperatingLeasePayments_d3107f48-22f5-4c29-be75-6ace4f28444a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_003fe53e-10ca-4647-b440-9ae9c90296fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9aa8161e-392e-49fd-97b2-476d03e7f019" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_003fe53e-10ca-4647-b440-9ae9c90296fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory_57f5b7f7-8bd7-4226-8d11-e68a87b7957f" xlink:href="bngo-20230331.xsd#bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_003fe53e-10ca-4647-b440-9ae9c90296fd" xlink:to="loc_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory_57f5b7f7-8bd7-4226-8d11-e68a87b7957f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory_282c8abd-20e5-421c-bd55-9830cb0fc8ea" xlink:href="bngo-20230331.xsd#bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_003fe53e-10ca-4647-b440-9ae9c90296fd" xlink:to="loc_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory_282c8abd-20e5-421c-bd55-9830cb0fc8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_309b806d-61ee-4e14-a5e7-4a8dd8343757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_003fe53e-10ca-4647-b440-9ae9c90296fd" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_309b806d-61ee-4e14-a5e7-4a8dd8343757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_965380be-102f-4397-ba6b-423379a794b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_003fe53e-10ca-4647-b440-9ae9c90296fd" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_965380be-102f-4397-ba6b-423379a794b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="bngo-20230331.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_31f9242c-3703-4700-be19-52f3a6d4986c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a28b384b-196f-4394-ae06-3a91723833b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_31f9242c-3703-4700-be19-52f3a6d4986c" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a28b384b-196f-4394-ae06-3a91723833b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/NetLossPerShare" xlink:type="simple" xlink:href="bngo-20230331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_db835f6e-ab37-400c-b899-af6e0397f7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_e2ecb649-90ad-4110-8338-609ef4cc2836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_db835f6e-ab37-400c-b899-af6e0397f7ea" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_e2ecb649-90ad-4110-8338-609ef4cc2836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognition" xlink:type="simple" xlink:href="bngo-20230331.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d16b2fe9-1cd1-4964-a12d-5626a6e6c0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_abfec63f-95b1-4659-8f7a-891efd1f25e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d16b2fe9-1cd1-4964-a12d-5626a6e6c0d9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_abfec63f-95b1-4659-8f7a-891efd1f25e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#BalanceSheetAccountDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12f113de-09b7-4d31-8ecd-ff17a4ddbd14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_5de41cd5-a598-4e9c-a6ae-303425336a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12f113de-09b7-4d31-8ecd-ff17a4ddbd14" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_5de41cd5-a598-4e9c-a6ae-303425336a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensation" xlink:type="simple" xlink:href="bngo-20230331.xsd#StockholdersEquityandStockBasedCompensation"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e573abcc-613c-4dae-a5fa-47f5e65caf38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_00dfeffd-1bea-4df9-9983-0b9eae5c572e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e573abcc-613c-4dae-a5fa-47f5e65caf38" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_00dfeffd-1bea-4df9-9983-0b9eae5c572e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="bngo-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1685179d-2fc3-4990-867d-266a22a96404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fd6150b3-a340-45ca-828e-5dbf7974922b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1685179d-2fc3-4990-867d-266a22a96404" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fd6150b3-a340-45ca-828e-5dbf7974922b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/Acquisitions" xlink:type="simple" xlink:href="bngo-20230331.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_28f7bd3c-e283-4b33-906e-93ce27eb33c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_144ec1b8-5625-4629-a71d-ad8ef46a872a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_28f7bd3c-e283-4b33-906e-93ce27eb33c2" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_144ec1b8-5625-4629-a71d-ad8ef46a872a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurements" xlink:type="simple" xlink:href="bngo-20230331.xsd#InvestmentsandFairValueMeasurements"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_398adbb1-7936-4342-abc7-067e020a18b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_7336efc0-0d7f-4e1f-9167-12ab2e5489a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_398adbb1-7936-4342-abc7-067e020a18b7" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_7336efc0-0d7f-4e1f-9167-12ab2e5489a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="bngo-20230331.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_90632e75-3920-42f0-85b4-f357ec4cbca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7459650c-8753-4266-82a2-9d9e141e9e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_90632e75-3920-42f0-85b4-f357ec4cbca6" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7459650c-8753-4266-82a2-9d9e141e9e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_2b24df5f-77a3-465d-a840-e840e0304507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_90632e75-3920-42f0-85b4-f357ec4cbca6" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_2b24df5f-77a3-465d-a840-e840e0304507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LiquidityAndGoingConcernPolicyTextBlock_797c31ba-b33a-489f-aee3-e814446dbc2f" xlink:href="bngo-20230331.xsd#bngo_LiquidityAndGoingConcernPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_90632e75-3920-42f0-85b4-f357ec4cbca6" xlink:to="loc_bngo_LiquidityAndGoingConcernPolicyTextBlock_797c31ba-b33a-489f-aee3-e814446dbc2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d67bfdc2-84c0-4f4f-8f72-99a97130bc09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_90632e75-3920-42f0-85b4-f357ec4cbca6" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d67bfdc2-84c0-4f4f-8f72-99a97130bc09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="bngo-20230331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c71c342b-bcca-44b1-95f9-2bcad199ff89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ae73bcef-2695-4126-b8f6-236b3bd4d8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c71c342b-bcca-44b1-95f9-2bcad199ff89" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ae73bcef-2695-4126-b8f6-236b3bd4d8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="bngo-20230331.xsd#RevenueRecognitionTables"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/RevenueRecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_355718f5-7a0d-4718-80b8-e5d92cf696fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_da19a12b-ba13-4796-a885-dceb51d0cd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_355718f5-7a0d-4718-80b8-e5d92cf696fb" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_da19a12b-ba13-4796-a885-dceb51d0cd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsTables" xlink:type="simple" xlink:href="bngo-20230331.xsd#BalanceSheetAccountDetailsTables"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetailsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_235421dc-b554-4c13-8f3e-7d99ee3c4b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_047dbaf8-abbe-400a-bdf1-8349befde617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_235421dc-b554-4c13-8f3e-7d99ee3c4b35" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_047dbaf8-abbe-400a-bdf1-8349befde617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_04c70579-31b2-4319-a072-02754be694cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_235421dc-b554-4c13-8f3e-7d99ee3c4b35" xlink:to="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_04c70579-31b2-4319-a072-02754be694cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_8e0dc27b-4e64-49bc-bfdc-684d2df00136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_235421dc-b554-4c13-8f3e-7d99ee3c4b35" xlink:to="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_8e0dc27b-4e64-49bc-bfdc-684d2df00136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_14273308-2e83-4123-bda5-b5d9114131ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_235421dc-b554-4c13-8f3e-7d99ee3c4b35" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_14273308-2e83-4123-bda5-b5d9114131ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_de7cf0e7-d506-492b-83fa-9cfbd2ebb2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_235421dc-b554-4c13-8f3e-7d99ee3c4b35" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_de7cf0e7-d506-492b-83fa-9cfbd2ebb2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables" xlink:type="simple" xlink:href="bngo-20230331.xsd#StockholdersEquityandStockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eba9c227-76d9-451a-b67f-4ba3d8a6b2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_e008c35e-1c63-4cc3-95d8-756b28809a60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eba9c227-76d9-451a-b67f-4ba3d8a6b2b1" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_e008c35e-1c63-4cc3-95d8-756b28809a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_c3e9906a-721a-4800-831e-e7e034917d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eba9c227-76d9-451a-b67f-4ba3d8a6b2b1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_c3e9906a-721a-4800-831e-e7e034917d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_450ef015-8381-499a-9abc-70e75a4ffde7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eba9c227-76d9-451a-b67f-4ba3d8a6b2b1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_450ef015-8381-499a-9abc-70e75a4ffde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ff968c6e-6d66-464f-b08c-49d31d743730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eba9c227-76d9-451a-b67f-4ba3d8a6b2b1" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ff968c6e-6d66-464f-b08c-49d31d743730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_e1b5459f-4db4-4291-a62f-0cf4489a0ded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eba9c227-76d9-451a-b67f-4ba3d8a6b2b1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_e1b5459f-4db4-4291-a62f-0cf4489a0ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CommitmentandContingenciesTables" xlink:type="simple" xlink:href="bngo-20230331.xsd#CommitmentandContingenciesTables"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/CommitmentandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3ab46c91-5f57-4a29-97d0-d30bd800f46e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4419b8be-0cf9-415e-a20b-865351f8b7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3ab46c91-5f57-4a29-97d0-d30bd800f46e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4419b8be-0cf9-415e-a20b-865351f8b7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="bngo-20230331.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_58a6c01e-23ee-407c-ad2a-1f671552715d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_3960bd25-4b01-4aff-8814-fd6469ba411a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_58a6c01e-23ee-407c-ad2a-1f671552715d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_3960bd25-4b01-4aff-8814-fd6469ba411a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_bd78ef95-e089-4b37-925b-dd3c081192c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_58a6c01e-23ee-407c-ad2a-1f671552715d" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_bd78ef95-e089-4b37-925b-dd3c081192c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_103efc69-a6b4-4ec2-86af-2c40bf7bfd37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_58a6c01e-23ee-407c-ad2a-1f671552715d" xlink:to="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_103efc69-a6b4-4ec2-86af-2c40bf7bfd37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_db469525-bdb2-4883-92a9-af7bd6a002ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_58a6c01e-23ee-407c-ad2a-1f671552715d" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_db469525-bdb2-4883-92a9-af7bd6a002ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsTables" xlink:type="simple" xlink:href="bngo-20230331.xsd#InvestmentsandFairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_18de8e11-456d-45a6-8edd-0ce0fda47090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ccedfe24-458c-40a4-b46d-3d999a3feed4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_18de8e11-456d-45a6-8edd-0ce0fda47090" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ccedfe24-458c-40a4-b46d-3d999a3feed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_eba9163b-eadc-4d79-83cf-68badee9788d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_18de8e11-456d-45a6-8edd-0ce0fda47090" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_eba9163b-eadc-4d79-83cf-68badee9788d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_108a138b-1be5-43a7-a81d-8e9e5ce6bf1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_18de8e11-456d-45a6-8edd-0ce0fda47090" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_108a138b-1be5-43a7-a81d-8e9e5ce6bf1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_30d862d1-ea1b-4b4b-ab0e-7c54d1572be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cd80bd3a-ed15-4f53-9c64-ec125bee25f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_30d862d1-ea1b-4b4b-ab0e-7c54d1572be6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cd80bd3a-ed15-4f53-9c64-ec125bee25f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_531f0053-9b44-47b2-a2a3-d63cf68d7c48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_30d862d1-ea1b-4b4b-ab0e-7c54d1572be6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_531f0053-9b44-47b2-a2a3-d63cf68d7c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_WorkingCapital_8226fb80-141c-4c91-9958-18735630698d" xlink:href="bngo-20230331.xsd#bngo_WorkingCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_30d862d1-ea1b-4b4b-ab0e-7c54d1572be6" xlink:to="loc_bngo_WorkingCapital_8226fb80-141c-4c91-9958-18735630698d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f0f61a4c-ba75-4c39-aac0-fabe0a54e9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_30d862d1-ea1b-4b4b-ab0e-7c54d1572be6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f0f61a4c-ba75-4c39-aac0-fabe0a54e9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_95dcfc5e-af41-410b-83e3-ee7aa6f71375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_30d862d1-ea1b-4b4b-ab0e-7c54d1572be6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_95dcfc5e-af41-410b-83e3-ee7aa6f71375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/NetLossPerShareDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#NetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/NetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_50d84bd9-5168-4726-8033-0239dd9015ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b901a0db-6de9-401e-9105-e97b9175f30f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_50d84bd9-5168-4726-8033-0239dd9015ac" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b901a0db-6de9-401e-9105-e97b9175f30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_178fcf28-6283-47ae-8d0f-1453c32a8f84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b901a0db-6de9-401e-9105-e97b9175f30f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_178fcf28-6283-47ae-8d0f-1453c32a8f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6daebcfa-c28b-47c8-9863-d09dc66fd107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_178fcf28-6283-47ae-8d0f-1453c32a8f84" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6daebcfa-c28b-47c8-9863-d09dc66fd107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_468f6a8f-e29a-482b-b68f-b3f058d71365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6daebcfa-c28b-47c8-9863-d09dc66fd107" xlink:to="loc_us-gaap_StockOptionMember_468f6a8f-e29a-482b-b68f-b3f058d71365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_UnvestedRestrictedStockMember_80635fec-299c-4a0b-a47a-0c89af827d68" xlink:href="bngo-20230331.xsd#bngo_UnvestedRestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6daebcfa-c28b-47c8-9863-d09dc66fd107" xlink:to="loc_bngo_UnvestedRestrictedStockMember_80635fec-299c-4a0b-a47a-0c89af827d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommonWarrantsMember_324d589a-36b3-46ee-a7a1-5cdfc9639a51" xlink:href="bngo-20230331.xsd#bngo_CommonWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6daebcfa-c28b-47c8-9863-d09dc66fd107" xlink:to="loc_bngo_CommonWarrantsMember_324d589a-36b3-46ee-a7a1-5cdfc9639a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fd589dee-02d5-4477-8e82-b8478de6e35c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6daebcfa-c28b-47c8-9863-d09dc66fd107" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fd589dee-02d5-4477-8e82-b8478de6e35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PerformanceShareUnitsPSUsMember_3a430f48-1cd0-49bb-978b-4b6fb5c4a3f4" xlink:href="bngo-20230331.xsd#bngo_PerformanceShareUnitsPSUsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6daebcfa-c28b-47c8-9863-d09dc66fd107" xlink:to="loc_bngo_PerformanceShareUnitsPSUsMember_3a430f48-1cd0-49bb-978b-4b6fb5c4a3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1d158ade-2293-4259-8243-b7089638456e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b901a0db-6de9-401e-9105-e97b9175f30f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1d158ade-2293-4259-8243-b7089638456e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f45b4344-9903-4230-bc46-166feee4fd8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1d158ade-2293-4259-8243-b7089638456e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f45b4344-9903-4230-bc46-166feee4fd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#RevenueRecognitionRevenuebySourceandGeographicLocationDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_38bb5317-a6a9-4d4a-809e-99901178fd75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_cf773597-049e-44cb-9c15-f5efabeb4de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_38bb5317-a6a9-4d4a-809e-99901178fd75" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_cf773597-049e-44cb-9c15-f5efabeb4de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d5146738-ceb0-484a-bc66-fc87b929629b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cf773597-049e-44cb-9c15-f5efabeb4de1" xlink:to="loc_srt_ProductOrServiceAxis_d5146738-ceb0-484a-bc66-fc87b929629b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8f91608f-c868-439f-97ac-a2934b4b45b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d5146738-ceb0-484a-bc66-fc87b929629b" xlink:to="loc_srt_ProductsAndServicesDomain_8f91608f-c868-439f-97ac-a2934b4b45b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_1cd5eb6f-5bab-4fc8-afcd-ce8224232bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8f91608f-c868-439f-97ac-a2934b4b45b1" xlink:to="loc_us-gaap_ProductMember_1cd5eb6f-5bab-4fc8-afcd-ce8224232bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InstrumentRevenueMember_b907bc9d-8c06-45dc-a45e-7ef201973345" xlink:href="bngo-20230331.xsd#bngo_InstrumentRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_1cd5eb6f-5bab-4fc8-afcd-ce8224232bcf" xlink:to="loc_bngo_InstrumentRevenueMember_b907bc9d-8c06-45dc-a45e-7ef201973345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ConsumableRevenueMember_66f3af85-db78-4f2e-a5cd-9bc8d3e815c0" xlink:href="bngo-20230331.xsd#bngo_ConsumableRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_1cd5eb6f-5bab-4fc8-afcd-ce8224232bcf" xlink:to="loc_bngo_ConsumableRevenueMember_66f3af85-db78-4f2e-a5cd-9bc8d3e815c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SoftwareMember_c1022078-7d6d-41cb-9327-cce145803a6b" xlink:href="bngo-20230331.xsd#bngo_SoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_1cd5eb6f-5bab-4fc8-afcd-ce8224232bcf" xlink:to="loc_bngo_SoftwareMember_c1022078-7d6d-41cb-9327-cce145803a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_b4bf064e-9562-4f9d-95dd-bd7f0be5ae90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8f91608f-c868-439f-97ac-a2934b4b45b1" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_b4bf064e-9562-4f9d-95dd-bd7f0be5ae90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ae95aa28-67da-480d-ac95-73468f7b0b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cf773597-049e-44cb-9c15-f5efabeb4de1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ae95aa28-67da-480d-ac95-73468f7b0b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5628e58b-91af-4c4e-b6cc-a51becf4611c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ae95aa28-67da-480d-ac95-73468f7b0b68" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5628e58b-91af-4c4e-b6cc-a51becf4611c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_7d21e88c-60c2-4be6-8e4c-1f70de59f64a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5628e58b-91af-4c4e-b6cc-a51becf4611c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_7d21e88c-60c2-4be6-8e4c-1f70de59f64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_70a1b031-30c9-42d4-a8fa-900ebd4dc207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5628e58b-91af-4c4e-b6cc-a51becf4611c" xlink:to="loc_us-gaap_SalesRevenueNetMember_70a1b031-30c9-42d4-a8fa-900ebd4dc207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_3d2af62b-29f1-406a-8014-c23a228ff3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cf773597-049e-44cb-9c15-f5efabeb4de1" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_3d2af62b-29f1-406a-8014-c23a228ff3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e30276e0-6e28-4031-8be8-904291288faf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3d2af62b-29f1-406a-8014-c23a228ff3b9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e30276e0-6e28-4031-8be8-904291288faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_c6554f26-6fd9-4153-b6ae-353c3866d071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e30276e0-6e28-4031-8be8-904291288faf" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_c6554f26-6fd9-4153-b6ae-353c3866d071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f56cc131-a961-4010-ac0e-6c5529629bd5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cf773597-049e-44cb-9c15-f5efabeb4de1" xlink:to="loc_srt_StatementGeographicalAxis_f56cc131-a961-4010-ac0e-6c5529629bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_33769771-7146-4f71-80fd-73f3d36e819e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_f56cc131-a961-4010-ac0e-6c5529629bd5" xlink:to="loc_srt_SegmentGeographicalDomain_33769771-7146-4f71-80fd-73f3d36e819e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AmericasMember_6c61d86d-91cb-43dd-9092-1164acd9ed11" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AmericasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_33769771-7146-4f71-80fd-73f3d36e819e" xlink:to="loc_srt_AmericasMember_6c61d86d-91cb-43dd-9092-1164acd9ed11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_5203ba39-80b6-4a73-b84e-0f230b144ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_33769771-7146-4f71-80fd-73f3d36e819e" xlink:to="loc_us-gaap_EMEAMember_5203ba39-80b6-4a73-b84e-0f230b144ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_74a85cd2-9467-4a4e-81a0-c59a90c9a54f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_33769771-7146-4f71-80fd-73f3d36e819e" xlink:to="loc_srt_AsiaPacificMember_74a85cd2-9467-4a4e-81a0-c59a90c9a54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a628c045-e6f8-40bc-b6fc-7a8f0c5a4f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cf773597-049e-44cb-9c15-f5efabeb4de1" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_a628c045-e6f8-40bc-b6fc-7a8f0c5a4f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73f68b18-5444-4de0-82fd-218507ddc5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a628c045-e6f8-40bc-b6fc-7a8f0c5a4f07" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73f68b18-5444-4de0-82fd-218507ddc5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_be6e1ef3-898d-4c4b-95d6-00857fb9b999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a628c045-e6f8-40bc-b6fc-7a8f0c5a4f07" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_be6e1ef3-898d-4c4b-95d6-00857fb9b999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#RevenueRecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4268a0ac-a251-4fc0-8a10-9f1ba51bd2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0b87af8f-3bf5-4622-9286-2e319b595cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4268a0ac-a251-4fc0-8a10-9f1ba51bd2fe" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0b87af8f-3bf5-4622-9286-2e319b595cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_7622d935-af6d-425d-8944-04bb1a516bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0b87af8f-3bf5-4622-9286-2e319b595cf3" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_7622d935-af6d-425d-8944-04bb1a516bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6d07f101-7ffa-48d4-98d5-c833e317aff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_7622d935-af6d-425d-8944-04bb1a516bcf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6d07f101-7ffa-48d4-98d5-c833e317aff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_43f40a78-82ba-4461-9611-4af28a88df0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_6d07f101-7ffa-48d4-98d5-c833e317aff0" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_43f40a78-82ba-4461-9611-4af28a88df0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e3f0a366-ec81-4ec9-b9d4-35fdda65fe2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0b87af8f-3bf5-4622-9286-2e319b595cf3" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e3f0a366-ec81-4ec9-b9d4-35fdda65fe2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_02a541bf-0e7a-409f-bd56-e269eb1cae31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e3f0a366-ec81-4ec9-b9d4-35fdda65fe2f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_02a541bf-0e7a-409f-bd56-e269eb1cae31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_41bd1a79-341b-4ede-932d-10e40eabd176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_02a541bf-0e7a-409f-bd56-e269eb1cae31" xlink:to="loc_us-gaap_SalesRevenueNetMember_41bd1a79-341b-4ede-932d-10e40eabd176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f0e2af7f-2442-4c32-8411-67d8b6d54add" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0b87af8f-3bf5-4622-9286-2e319b595cf3" xlink:to="loc_srt_StatementGeographicalAxis_f0e2af7f-2442-4c32-8411-67d8b6d54add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_dab7758e-67ce-4471-9d91-9ca319349348" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_f0e2af7f-2442-4c32-8411-67d8b6d54add" xlink:to="loc_srt_SegmentGeographicalDomain_dab7758e-67ce-4471-9d91-9ca319349348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_66b216f1-fa5b-41f1-992f-24b601095722" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_dab7758e-67ce-4471-9d91-9ca319349348" xlink:to="loc_country_US_66b216f1-fa5b-41f1-992f-24b601095722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9fa5cffd-85a0-472f-8128-9161b7e114c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0b87af8f-3bf5-4622-9286-2e319b595cf3" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_9fa5cffd-85a0-472f-8128-9161b7e114c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_450e55e1-9bc0-431a-b458-f306e24148e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9fa5cffd-85a0-472f-8128-9161b7e114c2" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_450e55e1-9bc0-431a-b458-f306e24148e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#RevenueRecognitionRemainingPerformanceObligationsDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ba3684fa-14db-4369-8e0a-6513adaf11e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_c677e4e2-eb61-4d9d-86ce-7e2277159cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ba3684fa-14db-4369-8e0a-6513adaf11e1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_c677e4e2-eb61-4d9d-86ce-7e2277159cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_962d2871-0dec-4049-9017-8415ab6bd512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_c677e4e2-eb61-4d9d-86ce-7e2277159cdd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_962d2871-0dec-4049-9017-8415ab6bd512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1a840967-e365-436b-9db1-68eb885c105f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_c677e4e2-eb61-4d9d-86ce-7e2277159cdd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1a840967-e365-436b-9db1-68eb885c105f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_c34cf1ce-1ae1-4a60-b06e-8b7591167c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1a840967-e365-436b-9db1-68eb885c105f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_c34cf1ce-1ae1-4a60-b06e-8b7591167c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_c8d2c0a1-1982-47ce-a71e-2661d778c42e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1a840967-e365-436b-9db1-68eb885c105f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_c8d2c0a1-1982-47ce-a71e-2661d778c42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_c3100bdb-98e3-4507-ae84-312a9a4413a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1a840967-e365-436b-9db1-68eb885c105f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_c3100bdb-98e3-4507-ae84-312a9a4413a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_87cadf8c-0a0e-49aa-abbf-1d11f5b615f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1a840967-e365-436b-9db1-68eb885c105f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_87cadf8c-0a0e-49aa-abbf-1d11f5b615f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="bngo-20230331.xsd#RevenueRecognitionRemainingPerformanceObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bc9b891e-420f-44ec-a479-decb052cf2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_0f4d7d72-153f-4608-9803-268c802efbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bc9b891e-420f-44ec-a479-decb052cf2dd" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_0f4d7d72-153f-4608-9803-268c802efbdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_6cdf8fab-1178-4c96-8d1c-05fa2a8fca16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bc9b891e-420f-44ec-a479-decb052cf2dd" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_6cdf8fab-1178-4c96-8d1c-05fa2a8fca16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_925b2116-f6b7-469c-9915-b9ebc318d3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bc9b891e-420f-44ec-a479-decb052cf2dd" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_925b2116-f6b7-469c-9915-b9ebc318d3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAllowanceforCreditLossesDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#BalanceSheetAccountDetailsScheduleofAllowanceforCreditLossesDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAllowanceforCreditLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_abb12af8-5150-419c-9ff7-661c3af70fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_055ca411-378e-4df1-8c78-b95a469b1705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_abb12af8-5150-419c-9ff7-661c3af70fc0" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_055ca411-378e-4df1-8c78-b95a469b1705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_ecdb6daa-909f-4c51-a2aa-4c374192e237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_055ca411-378e-4df1-8c78-b95a469b1705" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_ecdb6daa-909f-4c51-a2aa-4c374192e237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_d16c04c2-65cf-4a06-b980-a752142632cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_055ca411-378e-4df1-8c78-b95a469b1705" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_d16c04c2-65cf-4a06-b980-a752142632cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_edfc5632-89e6-496c-9190-8d2c6d44f4be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_055ca411-378e-4df1-8c78-b95a469b1705" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_edfc5632-89e6-496c-9190-8d2c6d44f4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_b60ab39a-9ea4-4b6f-a5fd-fb4f1e2bd9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_055ca411-378e-4df1-8c78-b95a469b1705" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_b60ab39a-9ea4-4b6f-a5fd-fb4f1e2bd9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a4863d9d-7a40-482f-9a8a-14562b223309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_77a95c03-1410-4f04-b2c0-944a7f72380a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a4863d9d-7a40-482f-9a8a-14562b223309" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_77a95c03-1410-4f04-b2c0-944a7f72380a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_7ccc9d67-48d7-489d-96e9-e3060cc3250d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a4863d9d-7a40-482f-9a8a-14562b223309" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_7ccc9d67-48d7-489d-96e9-e3060cc3250d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_dd3941d8-2e01-478c-9fc3-441ecbc8e585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a4863d9d-7a40-482f-9a8a-14562b223309" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_dd3941d8-2e01-478c-9fc3-441ecbc8e585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_16b00391-6a9f-4456-97ec-dc1694c08e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a4863d9d-7a40-482f-9a8a-14562b223309" xlink:to="loc_us-gaap_InventoryNet_16b00391-6a9f-4456-97ec-dc1694c08e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f78db038-3d3a-4f5e-9a99-02d293c56ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f2c32641-eaa0-4dae-9263-8820c753de35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f78db038-3d3a-4f5e-9a99-02d293c56ab5" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f2c32641-eaa0-4dae-9263-8820c753de35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3866c66-f993-450b-b912-c8e03289842f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f2c32641-eaa0-4dae-9263-8820c753de35" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3866c66-f993-450b-b912-c8e03289842f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6622b35b-fb1a-451c-91af-e8ebdad7576b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3866c66-f993-450b-b912-c8e03289842f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6622b35b-fb1a-451c-91af-e8ebdad7576b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_a55a30bf-b311-4b05-b7b3-2cf61f2e920b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6622b35b-fb1a-451c-91af-e8ebdad7576b" xlink:to="loc_us-gaap_TradeNamesMember_a55a30bf-b311-4b05-b7b3-2cf61f2e920b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_d74071c1-a0f8-43d1-9579-c9ba7240f2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6622b35b-fb1a-451c-91af-e8ebdad7576b" xlink:to="loc_us-gaap_CustomerRelationshipsMember_d74071c1-a0f8-43d1-9579-c9ba7240f2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_763b336b-57c8-4eef-b4eb-80147d62d342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6622b35b-fb1a-451c-91af-e8ebdad7576b" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_763b336b-57c8-4eef-b4eb-80147d62d342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_71d049e6-b6f1-4710-b276-67c4380792de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f2c32641-eaa0-4dae-9263-8820c753de35" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_71d049e6-b6f1-4710-b276-67c4380792de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a21767c3-e45b-4f7a-bb63-54e7d1d96a53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_71d049e6-b6f1-4710-b276-67c4380792de" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a21767c3-e45b-4f7a-bb63-54e7d1d96a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_33d8426b-b42e-416c-9550-70a84b00b436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_71d049e6-b6f1-4710-b276-67c4380792de" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_33d8426b-b42e-416c-9550-70a84b00b436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ba565886-6971-41ac-bbc0-682aca238a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_71d049e6-b6f1-4710-b276-67c4380792de" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ba565886-6971-41ac-bbc0-682aca238a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#BalanceSheetAccountDetailsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_77fb22ed-56a9-4e95-b849-03b6c0939991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a04fac64-3937-46a4-be86-c988f999491d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_77fb22ed-56a9-4e95-b849-03b6c0939991" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a04fac64-3937-46a4-be86-c988f999491d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_96fb87fa-edc3-435d-9781-2c04b4f02184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a04fac64-3937-46a4-be86-c988f999491d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_96fb87fa-edc3-435d-9781-2c04b4f02184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e40b0eb9-15a4-4153-87b5-c09acf9cb32d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_96fb87fa-edc3-435d-9781-2c04b4f02184" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e40b0eb9-15a4-4153-87b5-c09acf9cb32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternetDomainNamesMember_006aeb48-d5fa-432e-938d-adb590d74492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternetDomainNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e40b0eb9-15a4-4153-87b5-c09acf9cb32d" xlink:to="loc_us-gaap_InternetDomainNamesMember_006aeb48-d5fa-432e-938d-adb590d74492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6f20f3b6-361f-442f-91da-700f2905ca8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a04fac64-3937-46a4-be86-c988f999491d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6f20f3b6-361f-442f-91da-700f2905ca8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3c4d9b11-f3f6-4a44-ace6-be768f8941ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6f20f3b6-361f-442f-91da-700f2905ca8a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3c4d9b11-f3f6-4a44-ace6-be768f8941ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35d10d13-510f-4da4-81e5-ec8a0491dfc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_917a55c2-56a0-45a3-b69f-65b29b82fe89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35d10d13-510f-4da4-81e5-ec8a0491dfc8" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_917a55c2-56a0-45a3-b69f-65b29b82fe89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositLiabilityCurrent_d5085fb9-90c8-4730-8adc-345b50f8eb25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35d10d13-510f-4da4-81e5-ec8a0491dfc8" xlink:to="loc_us-gaap_DepositLiabilityCurrent_d5085fb9-90c8-4730-8adc-345b50f8eb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_88853f82-c7fa-4e73-b9b8-ab14285ae1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35d10d13-510f-4da4-81e5-ec8a0491dfc8" xlink:to="loc_us-gaap_TaxesPayableCurrent_88853f82-c7fa-4e73-b9b8-ab14285ae1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_e4932574-6f73-4844-9c75-43eb36b17f17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35d10d13-510f-4da4-81e5-ec8a0491dfc8" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_e4932574-6f73-4844-9c75-43eb36b17f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ProfessionalFeesAndRoyaltiesCurrent_54a8181b-b012-4360-bd3f-2b4f9c321043" xlink:href="bngo-20230331.xsd#bngo_ProfessionalFeesAndRoyaltiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35d10d13-510f-4da4-81e5-ec8a0491dfc8" xlink:to="loc_bngo_ProfessionalFeesAndRoyaltiesCurrent_54a8181b-b012-4360-bd3f-2b4f9c321043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_e6447fc8-4a6f-44fc-9c31-22fd9d0ed1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35d10d13-510f-4da4-81e5-ec8a0491dfc8" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_e6447fc8-4a6f-44fc-9c31-22fd9d0ed1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_AccruedClinicalStudyFeesCurrent_3469a23e-f637-45f1-a5fd-5cea9695cc5d" xlink:href="bngo-20230331.xsd#bngo_AccruedClinicalStudyFeesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35d10d13-510f-4da4-81e5-ec8a0491dfc8" xlink:to="loc_bngo_AccruedClinicalStudyFeesCurrent_3469a23e-f637-45f1-a5fd-5cea9695cc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a79f979a-bc00-4c21-8f27-e425ec03306a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35d10d13-510f-4da4-81e5-ec8a0491dfc8" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a79f979a-bc00-4c21-8f27-e425ec03306a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_56396347-1c74-41f3-8fa6-04fbbf2d3279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35d10d13-510f-4da4-81e5-ec8a0491dfc8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_56396347-1c74-41f3-8fa6-04fbbf2d3279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#StockholdersEquityandStockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1cf3bc37-dda4-44c5-83cb-49f07f45dc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3898ba4c-f09d-47dc-b8e2-213752991978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1cf3bc37-dda4-44c5-83cb-49f07f45dc0a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3898ba4c-f09d-47dc-b8e2-213752991978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_485e08cd-f179-4d5f-bc66-98894d9b69f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3898ba4c-f09d-47dc-b8e2-213752991978" xlink:to="loc_srt_CounterpartyNameAxis_485e08cd-f179-4d5f-bc66-98894d9b69f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d009d453-1ef9-4fe0-9598-f6884951de87" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_485e08cd-f179-4d5f-bc66-98894d9b69f7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d009d453-1ef9-4fe0-9598-f6884951de87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CowenMember_5e8fa98d-5949-403a-aafa-34611b6cc4b5" xlink:href="bngo-20230331.xsd#bngo_CowenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d009d453-1ef9-4fe0-9598-f6884951de87" xlink:to="loc_bngo_CowenMember_5e8fa98d-5949-403a-aafa-34611b6cc4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3ec9930d-999c-4d9a-9cfe-e7be7c383f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3898ba4c-f09d-47dc-b8e2-213752991978" xlink:to="loc_us-gaap_AwardTypeAxis_3ec9930d-999c-4d9a-9cfe-e7be7c383f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0504a091-78fd-4a88-bb09-9c3a80d8ba46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3ec9930d-999c-4d9a-9cfe-e7be7c383f25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0504a091-78fd-4a88-bb09-9c3a80d8ba46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_088ff7d4-8980-43e3-8b46-e9bd560ff2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0504a091-78fd-4a88-bb09-9c3a80d8ba46" xlink:to="loc_us-gaap_RestrictedStockMember_088ff7d4-8980-43e3-8b46-e9bd560ff2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b3f4d24a-0924-4138-9152-74a75e7d3882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0504a091-78fd-4a88-bb09-9c3a80d8ba46" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b3f4d24a-0924-4138-9152-74a75e7d3882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PerformanceShareUnitsPSUsMember_1d7759a7-5849-4b67-893f-35221fb0366b" xlink:href="bngo-20230331.xsd#bngo_PerformanceShareUnitsPSUsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0504a091-78fd-4a88-bb09-9c3a80d8ba46" xlink:to="loc_bngo_PerformanceShareUnitsPSUsMember_1d7759a7-5849-4b67-893f-35221fb0366b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_91aa1068-3002-474b-86a4-092f0fc158dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0504a091-78fd-4a88-bb09-9c3a80d8ba46" xlink:to="loc_us-gaap_EmployeeStockOptionMember_91aa1068-3002-474b-86a4-092f0fc158dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4f371ee9-8e18-439d-8634-782127b5c7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3898ba4c-f09d-47dc-b8e2-213752991978" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4f371ee9-8e18-439d-8634-782127b5c7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a53eb952-e6ba-4666-b99f-afc045950732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4f371ee9-8e18-439d-8634-782127b5c7a1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a53eb952-e6ba-4666-b99f-afc045950732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember_94c2a399-a9e8-4bce-be67-dd7a9b984bfe" xlink:href="bngo-20230331.xsd#bngo_BioDiscoveryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a53eb952-e6ba-4666-b99f-afc045950732" xlink:to="loc_bngo_BioDiscoveryMember_94c2a399-a9e8-4bce-be67-dd7a9b984bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_ebf6cd8c-d4c9-41a5-a067-0ab6a7f27654" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3898ba4c-f09d-47dc-b8e2-213752991978" xlink:to="loc_srt_TitleOfIndividualAxis_ebf6cd8c-d4c9-41a5-a067-0ab6a7f27654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b7b99843-e6d7-4d1a-87f4-a70153b5bbdd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_ebf6cd8c-d4c9-41a5-a067-0ab6a7f27654" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b7b99843-e6d7-4d1a-87f4-a70153b5bbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_5dbc566e-417b-47a5-b000-d51c639c930a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b7b99843-e6d7-4d1a-87f4-a70153b5bbdd" xlink:to="loc_srt_ExecutiveOfficerMember_5dbc566e-417b-47a5-b000-d51c639c930a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_a19f42b4-194c-4615-a253-2b1411fb75f1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b7b99843-e6d7-4d1a-87f4-a70153b5bbdd" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_a19f42b4-194c-4615-a253-2b1411fb75f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_d9a04a5a-cf2c-4a0e-b838-0bfda0258275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3898ba4c-f09d-47dc-b8e2-213752991978" xlink:to="loc_us-gaap_VestingAxis_d9a04a5a-cf2c-4a0e-b838-0bfda0258275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a2fb7ffb-e5c3-42bc-a136-d71c7a64d87a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_d9a04a5a-cf2c-4a0e-b838-0bfda0258275" xlink:to="loc_us-gaap_VestingDomain_a2fb7ffb-e5c3-42bc-a136-d71c7a64d87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_39ac35d8-f7fb-4248-a627-ab2d52ff8a06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a2fb7ffb-e5c3-42bc-a136-d71c7a64d87a" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_39ac35d8-f7fb-4248-a627-ab2d52ff8a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_aa160dd6-f828-4343-8d94-de59c3fb63a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a2fb7ffb-e5c3-42bc-a136-d71c7a64d87a" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_aa160dd6-f828-4343-8d94-de59c3fb63a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_24fe5536-334b-4183-8da5-d825fa4c27e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3898ba4c-f09d-47dc-b8e2-213752991978" xlink:to="loc_us-gaap_StatementClassOfStockAxis_24fe5536-334b-4183-8da5-d825fa4c27e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_97354c6b-b720-4ea3-b03a-2d46e2c61799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_24fe5536-334b-4183-8da5-d825fa4c27e7" xlink:to="loc_us-gaap_ClassOfStockDomain_97354c6b-b720-4ea3-b03a-2d46e2c61799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_f31a33cd-dc52-4468-ae3c-563bef064d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_97354c6b-b720-4ea3-b03a-2d46e2c61799" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_f31a33cd-dc52-4468-ae3c-563bef064d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8ee73e17-8e46-4a72-b1df-eb567fdf0d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3898ba4c-f09d-47dc-b8e2-213752991978" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8ee73e17-8e46-4a72-b1df-eb567fdf0d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_242421e4-1142-4651-9821-423cce835709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8ee73e17-8e46-4a72-b1df-eb567fdf0d4c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_242421e4-1142-4651-9821-423cce835709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b42fe33f-b7ea-490e-98eb-179f308e1467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_242421e4-1142-4651-9821-423cce835709" xlink:to="loc_us-gaap_SubsequentEventMember_b42fe33f-b7ea-490e-98eb-179f308e1467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3898ba4c-f09d-47dc-b8e2-213752991978" xlink:to="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SaleOfStockValueSharesIssuedInTransaction_b9c276d8-8451-4cb6-af98-22bfd5981f28" xlink:href="bngo-20230331.xsd#bngo_SaleOfStockValueSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_bngo_SaleOfStockValueSharesIssuedInTransaction_b9c276d8-8451-4cb6-af98-22bfd5981f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommissionFeeMaximumPercentageOfGrossProceeds_0d185f47-b707-4fbc-8c46-ca2355e50a3d" xlink:href="bngo-20230331.xsd#bngo_CommissionFeeMaximumPercentageOfGrossProceeds"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_bngo_CommissionFeeMaximumPercentageOfGrossProceeds_0d185f47-b707-4fbc-8c46-ca2355e50a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_41257aa3-5b57-4cc7-a35b-0715c200fd54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_41257aa3-5b57-4cc7-a35b-0715c200fd54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_c7fd3d37-f732-4362-b200-d5fdd49dfea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_c7fd3d37-f732-4362-b200-d5fdd49dfea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_3b6c17d5-7b2e-417b-9d5f-300b9061749d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_3b6c17d5-7b2e-417b-9d5f-300b9061749d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_ec3c2326-46fd-428a-8ad6-cde63a764672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_ec3c2326-46fd-428a-8ad6-cde63a764672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_13fc7d7e-86a5-4ebc-84e3-2df9012649dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_13fc7d7e-86a5-4ebc-84e3-2df9012649dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_af72077d-b20e-41cb-8848-030a6cbc73d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_af72077d-b20e-41cb-8848-030a6cbc73d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1356e1da-d773-41e7-be0b-0e3309f1323a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1356e1da-d773-41e7-be0b-0e3309f1323a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_089b2df3-f412-4519-b8bb-8b6e80de7bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_089b2df3-f412-4519-b8bb-8b6e80de7bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0d365bba-408d-47e5-a87e-3b729e49880b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0d365bba-408d-47e5-a87e-3b729e49880b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_84e33e39-3acf-4211-ad4e-0291e4419304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_84e33e39-3acf-4211-ad4e-0291e4419304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_fd8c3726-49ec-4040-8b27-bc3b93524516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_fd8c3726-49ec-4040-8b27-bc3b93524516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_32aeca2c-3f09-45f6-9c04-d6172776a930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_32aeca2c-3f09-45f6-9c04-d6172776a930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cd4680e2-315a-4efe-aa11-2d9a4bc7dc98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cd4680e2-315a-4efe-aa11-2d9a4bc7dc98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7da45d36-38f4-42e7-b001-f027728e6151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7da45d36-38f4-42e7-b001-f027728e6151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_af284867-e5f8-439c-b9a9-ff2a4af9a9be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_af284867-e5f8-439c-b9a9-ff2a4af9a9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments_37224bfb-85ef-4088-9d96-13ab7d39a823" xlink:href="bngo-20230331.xsd#bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments_37224bfb-85ef-4088-9d96-13ab7d39a823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_85694884-0a2a-49b0-b381-74e3d022837c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_85694884-0a2a-49b0-b381-74e3d022837c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_625ff4a0-54bb-41a0-8e0d-e909ffe9b7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_625ff4a0-54bb-41a0-8e0d-e909ffe9b7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PreferredStockNumberOfVotes_53cb1ff3-e896-4f80-82b1-d3b9866623fa" xlink:href="bngo-20230331.xsd#bngo_PreferredStockNumberOfVotes"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_bngo_PreferredStockNumberOfVotes_53cb1ff3-e896-4f80-82b1-d3b9866623fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent_13481bba-2662-4c98-9413-5bd620ede6c1" xlink:href="bngo-20230331.xsd#bngo_StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_bngo_StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent_13481bba-2662-4c98-9413-5bd620ede6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare_7c3944ad-15af-42c5-9283-7ed43d1670e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockRedemptionPricePerShare"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_227062ef-2643-4cd8-86c5-06432742a3d3" xlink:to="loc_us-gaap_PreferredStockRedemptionPricePerShare_7c3944ad-15af-42c5-9283-7ed43d1670e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#StockholdersEquityandStockBasedCompensationWarrantActivityDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_405bdea7-31d1-40ee-9169-55b47e4758e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward_0a7a3324-3cef-40ec-a456-da238d2f6877" xlink:href="bngo-20230331.xsd#bngo_ClassOfWarrantOrRightOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_405bdea7-31d1-40ee-9169-55b47e4758e5" xlink:to="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward_0a7a3324-3cef-40ec-a456-da238d2f6877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9de1d5e7-0ca5-43b7-97d2-436122d24c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward_0a7a3324-3cef-40ec-a456-da238d2f6877" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9de1d5e7-0ca5-43b7-97d2-436122d24c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod_45598fe8-d814-4283-92dc-f19a06adc94c" xlink:href="bngo-20230331.xsd#bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward_0a7a3324-3cef-40ec-a456-da238d2f6877" xlink:to="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod_45598fe8-d814-4283-92dc-f19a06adc94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod_648140d9-ec67-4b0c-a285-c0b5ea45167b" xlink:href="bngo-20230331.xsd#bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward_0a7a3324-3cef-40ec-a456-da238d2f6877" xlink:to="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod_648140d9-ec67-4b0c-a285-c0b5ea45167b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod_7d709f74-a963-4957-8674-8bd95c9f7403" xlink:href="bngo-20230331.xsd#bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward_0a7a3324-3cef-40ec-a456-da238d2f6877" xlink:to="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod_7d709f74-a963-4957-8674-8bd95c9f7403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_03c99f65-bdbb-41ea-8dfa-54076798306f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward_0a7a3324-3cef-40ec-a456-da238d2f6877" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_03c99f65-bdbb-41ea-8dfa-54076798306f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_d243b05c-c0cb-4021-8ff3-2a15f0291f8a" xlink:href="bngo-20230331.xsd#bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_405bdea7-31d1-40ee-9169-55b47e4758e5" xlink:to="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_d243b05c-c0cb-4021-8ff3-2a15f0291f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_995b342c-65c1-4b3e-b178-1c82202ff3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_d243b05c-c0cb-4021-8ff3-2a15f0291f8a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_995b342c-65c1-4b3e-b178-1c82202ff3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_020b68b7-3fe5-4c47-9474-2d3d66ab6b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_d243b05c-c0cb-4021-8ff3-2a15f0291f8a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_020b68b7-3fe5-4c47-9474-2d3d66ab6b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward_62add84b-54fa-436c-b5f2-68bba816a511" xlink:href="bngo-20230331.xsd#bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_405bdea7-31d1-40ee-9169-55b47e4758e5" xlink:to="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward_62add84b-54fa-436c-b5f2-68bba816a511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights_70eae171-8714-4564-8d18-a197ef730ac9" xlink:href="bngo-20230331.xsd#bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward_62add84b-54fa-436c-b5f2-68bba816a511" xlink:to="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights_70eae171-8714-4564-8d18-a197ef730ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract_8b851163-a431-4f5d-b46b-ac6c00aa10c7" xlink:href="bngo-20230331.xsd#bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_405bdea7-31d1-40ee-9169-55b47e4758e5" xlink:to="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract_8b851163-a431-4f5d-b46b-ac6c00aa10c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights_044e7bc5-b489-4836-aab3-9ddd3fc58a81" xlink:href="bngo-20230331.xsd#bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract_8b851163-a431-4f5d-b46b-ac6c00aa10c7" xlink:to="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights_044e7bc5-b489-4836-aab3-9ddd3fc58a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights_9bfb1d67-1f13-43b1-88a8-62130ef0450d" xlink:href="bngo-20230331.xsd#bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract_8b851163-a431-4f5d-b46b-ac6c00aa10c7" xlink:to="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights_9bfb1d67-1f13-43b1-88a8-62130ef0450d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13479b01-2535-4ce9-aede-d070004b2eae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_748838a6-b8a8-4c83-837c-0061c7af9fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13479b01-2535-4ce9-aede-d070004b2eae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_748838a6-b8a8-4c83-837c-0061c7af9fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c9e167bf-0891-45c1-8007-a0025d49da4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_748838a6-b8a8-4c83-837c-0061c7af9fe0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c9e167bf-0891-45c1-8007-a0025d49da4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8d459415-c55c-4c28-bdcd-7a40d7577fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_748838a6-b8a8-4c83-837c-0061c7af9fe0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8d459415-c55c-4c28-bdcd-7a40d7577fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8ce1b64d-54b9-4a77-9406-f6cedb0b0e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_748838a6-b8a8-4c83-837c-0061c7af9fe0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8ce1b64d-54b9-4a77-9406-f6cedb0b0e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c4176a01-1f30-4379-a3ed-626f1a2e1d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_748838a6-b8a8-4c83-837c-0061c7af9fe0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c4176a01-1f30-4379-a3ed-626f1a2e1d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_15b457ee-7f54-4f7e-9e6c-a137203c7043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_748838a6-b8a8-4c83-837c-0061c7af9fe0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_15b457ee-7f54-4f7e-9e6c-a137203c7043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_23332f67-9a1f-44d1-8a3b-8ceb05971f65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13479b01-2535-4ce9-aede-d070004b2eae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_23332f67-9a1f-44d1-8a3b-8ceb05971f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3ed72b23-e56c-49bb-a588-01efefe6433e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13479b01-2535-4ce9-aede-d070004b2eae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3ed72b23-e56c-49bb-a588-01efefe6433e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b51b3571-7dd2-4225-b44e-3059302b20ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3ed72b23-e56c-49bb-a588-01efefe6433e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b51b3571-7dd2-4225-b44e-3059302b20ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bd56178c-c1b2-4b57-a2ba-44d6bc53d18f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3ed72b23-e56c-49bb-a588-01efefe6433e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bd56178c-c1b2-4b57-a2ba-44d6bc53d18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6ad2c859-554a-4966-b097-cbd1632e1f92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3ed72b23-e56c-49bb-a588-01efefe6433e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6ad2c859-554a-4966-b097-cbd1632e1f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_72ef4967-e4b0-416d-997b-b64879ff1fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3ed72b23-e56c-49bb-a588-01efefe6433e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_72ef4967-e4b0-416d-997b-b64879ff1fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ed7c9558-082e-4036-b022-2beaa72387bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3ed72b23-e56c-49bb-a588-01efefe6433e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ed7c9558-082e-4036-b022-2beaa72387bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_867c284a-04e3-41b8-b1be-65dbff45e5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13479b01-2535-4ce9-aede-d070004b2eae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_867c284a-04e3-41b8-b1be-65dbff45e5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward_c8e739b8-1604-49d7-85a9-5a46f60fd8ae" xlink:href="bngo-20230331.xsd#bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13479b01-2535-4ce9-aede-d070004b2eae" xlink:to="loc_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward_c8e739b8-1604-49d7-85a9-5a46f60fd8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_02dcb19d-3dcf-4216-90f4-2623e82ea95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward_c8e739b8-1604-49d7-85a9-5a46f60fd8ae" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_02dcb19d-3dcf-4216-90f4-2623e82ea95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_fb7c6abc-66f4-4fdc-a51c-9e12af06bab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward_c8e739b8-1604-49d7-85a9-5a46f60fd8ae" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_fb7c6abc-66f4-4fdc-a51c-9e12af06bab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4dde45cc-e6a9-4568-a1c8-ad3850361a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13479b01-2535-4ce9-aede-d070004b2eae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4dde45cc-e6a9-4568-a1c8-ad3850361a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f62621cb-6552-4ba3-8b56-a7b1e5d20050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4dde45cc-e6a9-4568-a1c8-ad3850361a26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f62621cb-6552-4ba3-8b56-a7b1e5d20050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e4f579e5-abab-4734-8cdf-f1c632877fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4dde45cc-e6a9-4568-a1c8-ad3850361a26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e4f579e5-abab-4734-8cdf-f1c632877fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2b382a0c-e470-4cf4-9f7e-563b9e35890b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4dde45cc-e6a9-4568-a1c8-ad3850361a26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2b382a0c-e470-4cf4-9f7e-563b9e35890b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_c166549e-ca21-4e9a-af6c-c0cef9c2d615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13479b01-2535-4ce9-aede-d070004b2eae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_c166549e-ca21-4e9a-af6c-c0cef9c2d615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab087127-2efb-4056-b086-4ed2c664d25a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d968504-c195-4812-9245-9e199956de50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab087127-2efb-4056-b086-4ed2c664d25a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d968504-c195-4812-9245-9e199956de50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_53a49a7a-dad9-4de9-bbbb-213f8190de9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d968504-c195-4812-9245-9e199956de50" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_53a49a7a-dad9-4de9-bbbb-213f8190de9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8973fc52-e5e1-4a39-a340-1f9e8df5ca59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_53a49a7a-dad9-4de9-bbbb-213f8190de9a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8973fc52-e5e1-4a39-a340-1f9e8df5ca59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CostOfProductRevenueMember_9b812f2e-98a3-43d3-bebf-220578a0ab45" xlink:href="bngo-20230331.xsd#bngo_CostOfProductRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8973fc52-e5e1-4a39-a340-1f9e8df5ca59" xlink:to="loc_bngo_CostOfProductRevenueMember_9b812f2e-98a3-43d3-bebf-220578a0ab45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CostOfServiceAndOtherRevenueMember_003e189c-df38-4b6a-914f-15e728a50635" xlink:href="bngo-20230331.xsd#bngo_CostOfServiceAndOtherRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8973fc52-e5e1-4a39-a340-1f9e8df5ca59" xlink:to="loc_bngo_CostOfServiceAndOtherRevenueMember_003e189c-df38-4b6a-914f-15e728a50635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_78df54bd-9eff-4630-a8e5-a3a77568404a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8973fc52-e5e1-4a39-a340-1f9e8df5ca59" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_78df54bd-9eff-4630-a8e5-a3a77568404a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2faa4aca-b493-4fe6-8306-fd173d7d58ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8973fc52-e5e1-4a39-a340-1f9e8df5ca59" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2faa4aca-b493-4fe6-8306-fd173d7d58ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_869ac748-9256-4bc1-81c4-810f9399ba0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d968504-c195-4812-9245-9e199956de50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_869ac748-9256-4bc1-81c4-810f9399ba0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8a78b1e0-f99b-4abc-b740-9ec76e257e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_869ac748-9256-4bc1-81c4-810f9399ba0f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8a78b1e0-f99b-4abc-b740-9ec76e257e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAssumptionsDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#StockholdersEquityandStockBasedCompensationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4017fe27-dc87-43db-8ace-d15c639f819c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6eae437c-b283-4469-b3f1-1899ba1c8c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4017fe27-dc87-43db-8ace-d15c639f819c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6eae437c-b283-4469-b3f1-1899ba1c8c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_51ff5643-c4b8-4354-b471-57fe952c4a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4017fe27-dc87-43db-8ace-d15c639f819c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_51ff5643-c4b8-4354-b471-57fe952c4a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3e7a45a4-3217-49b7-8851-f3bd49b686bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4017fe27-dc87-43db-8ace-d15c639f819c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3e7a45a4-3217-49b7-8851-f3bd49b686bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_525086a9-c9f1-42db-ae96-f264e0cdebac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4017fe27-dc87-43db-8ace-d15c639f819c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_525086a9-c9f1-42db-ae96-f264e0cdebac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4d091176-4d49-44f5-893f-56abda98212f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a46b0a2-9ca5-4809-8ff5-7ceda0159902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4d091176-4d49-44f5-893f-56abda98212f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a46b0a2-9ca5-4809-8ff5-7ceda0159902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_845cff19-fea6-4a74-ac34-b4b9977fa2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a46b0a2-9ca5-4809-8ff5-7ceda0159902" xlink:to="loc_us-gaap_AwardTypeAxis_845cff19-fea6-4a74-ac34-b4b9977fa2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65ccb4d0-72c5-4541-acc6-eade44670595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_845cff19-fea6-4a74-ac34-b4b9977fa2c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65ccb4d0-72c5-4541-acc6-eade44670595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c196e980-9495-4fe8-a0c7-e14fa15d4fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65ccb4d0-72c5-4541-acc6-eade44670595" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c196e980-9495-4fe8-a0c7-e14fa15d4fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PerformanceShareUnitsPSUsMember_ba9c300c-8451-40df-ba91-75028fc54722" xlink:href="bngo-20230331.xsd#bngo_PerformanceShareUnitsPSUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65ccb4d0-72c5-4541-acc6-eade44670595" xlink:to="loc_bngo_PerformanceShareUnitsPSUsMember_ba9c300c-8451-40df-ba91-75028fc54722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3828f5fd-473c-46fe-984f-58e4b38b94eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a46b0a2-9ca5-4809-8ff5-7ceda0159902" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3828f5fd-473c-46fe-984f-58e4b38b94eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09e70fba-605a-4bc5-830e-561b7402a35d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3828f5fd-473c-46fe-984f-58e4b38b94eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09e70fba-605a-4bc5-830e-561b7402a35d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b58bb0fb-110d-4342-919e-d5c31985638f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09e70fba-605a-4bc5-830e-561b7402a35d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b58bb0fb-110d-4342-919e-d5c31985638f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_83215771-35cd-41a1-82b5-69f75632c792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09e70fba-605a-4bc5-830e-561b7402a35d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_83215771-35cd-41a1-82b5-69f75632c792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f9ef4be6-f168-40dc-b4e4-98de79de85d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09e70fba-605a-4bc5-830e-561b7402a35d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f9ef4be6-f168-40dc-b4e4-98de79de85d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2d362394-0f6a-4302-b6ab-a1e95c7e075c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09e70fba-605a-4bc5-830e-561b7402a35d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2d362394-0f6a-4302-b6ab-a1e95c7e075c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f400757f-17dc-492c-b2b6-96f567a9d93c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09e70fba-605a-4bc5-830e-561b7402a35d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f400757f-17dc-492c-b2b6-96f567a9d93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f8ffb710-46ab-4a7d-988d-a3f182307115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3828f5fd-473c-46fe-984f-58e4b38b94eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f8ffb710-46ab-4a7d-988d-a3f182307115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b5d2c40a-0b30-4cf7-aeed-52b01e313be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f8ffb710-46ab-4a7d-988d-a3f182307115" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b5d2c40a-0b30-4cf7-aeed-52b01e313be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_45dbda8e-3830-4692-ad90-c33f4d714b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f8ffb710-46ab-4a7d-988d-a3f182307115" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_45dbda8e-3830-4692-ad90-c33f4d714b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30685770-ae5f-4b05-809e-cd952e8e07bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f8ffb710-46ab-4a7d-988d-a3f182307115" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30685770-ae5f-4b05-809e-cd952e8e07bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_420f8ec2-99a3-4f8b-9c33-28379a1b1690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f8ffb710-46ab-4a7d-988d-a3f182307115" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_420f8ec2-99a3-4f8b-9c33-28379a1b1690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5a8e9674-e75e-449c-a28d-36f1a826f7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f8ffb710-46ab-4a7d-988d-a3f182307115" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5a8e9674-e75e-449c-a28d-36f1a826f7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2f1d4f13-a091-4a9e-8bf8-39b7e0d65231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_367bbaac-c622-43de-93ae-b6c120a5a348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2f1d4f13-a091-4a9e-8bf8-39b7e0d65231" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_367bbaac-c622-43de-93ae-b6c120a5a348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e9f7e498-8612-4227-8ab8-96941d6180f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_367bbaac-c622-43de-93ae-b6c120a5a348" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e9f7e498-8612-4227-8ab8-96941d6180f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8bb7ad6e-11ba-4462-b097-d30a2e803802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_367bbaac-c622-43de-93ae-b6c120a5a348" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8bb7ad6e-11ba-4462-b097-d30a2e803802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c9e6c590-1a50-46d1-b2a8-fa46e81cb20a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_367bbaac-c622-43de-93ae-b6c120a5a348" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c9e6c590-1a50-46d1-b2a8-fa46e81cb20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f95d1e7f-c00c-4669-a987-ddaf836c4a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_367bbaac-c622-43de-93ae-b6c120a5a348" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f95d1e7f-c00c-4669-a987-ddaf836c4a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1a4274da-deb3-463e-bd41-bce3debcb7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_367bbaac-c622-43de-93ae-b6c120a5a348" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1a4274da-deb3-463e-bd41-bce3debcb7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_b5cc47fd-8832-4a2b-8ca2-5c49a8186f89" xlink:href="bngo-20230331.xsd#bngo_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_367bbaac-c622-43de-93ae-b6c120a5a348" xlink:to="loc_bngo_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_b5cc47fd-8832-4a2b-8ca2-5c49a8186f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c4f06caf-24fe-4d59-8cb8-94f215946c73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_367bbaac-c622-43de-93ae-b6c120a5a348" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c4f06caf-24fe-4d59-8cb8-94f215946c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_81b9a9d0-6cb3-4246-81b7-aa2f77079cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_367bbaac-c622-43de-93ae-b6c120a5a348" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_81b9a9d0-6cb3-4246-81b7-aa2f77079cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_273503e9-79a5-48a4-98d2-cb342ae7c281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_367bbaac-c622-43de-93ae-b6c120a5a348" xlink:to="loc_us-gaap_OperatingLeaseLiability_273503e9-79a5-48a4-98d2-cb342ae7c281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_48e1caf1-da61-4363-9168-b213a7173f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2f1d4f13-a091-4a9e-8bf8-39b7e0d65231" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_48e1caf1-da61-4363-9168-b213a7173f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_8125720e-ad35-43f2-8e6f-77e157853da8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_48e1caf1-da61-4363-9168-b213a7173f10" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_8125720e-ad35-43f2-8e6f-77e157853da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_6ffac37e-b07f-4758-b40c-b5b4541fd072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_48e1caf1-da61-4363-9168-b213a7173f10" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_6ffac37e-b07f-4758-b40c-b5b4541fd072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_4a72843a-3ccf-4e58-9f67-a96d15b9d638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_48e1caf1-da61-4363-9168-b213a7173f10" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_4a72843a-3ccf-4e58-9f67-a96d15b9d638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_c5ddd737-97cb-4c9d-a9e9-e7e538adeea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_48e1caf1-da61-4363-9168-b213a7173f10" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_c5ddd737-97cb-4c9d-a9e9-e7e538adeea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_b260daf7-d282-4c8b-acd6-35cea6a3729b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_48e1caf1-da61-4363-9168-b213a7173f10" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_b260daf7-d282-4c8b-acd6-35cea6a3729b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_FinanceLeaseLiabilityToBePaidAfterYearFour_2297e4f2-71f1-48ef-94d1-c72334758f03" xlink:href="bngo-20230331.xsd#bngo_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_48e1caf1-da61-4363-9168-b213a7173f10" xlink:to="loc_bngo_FinanceLeaseLiabilityToBePaidAfterYearFour_2297e4f2-71f1-48ef-94d1-c72334758f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_36d460f9-2574-4602-8372-587886bcafc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_48e1caf1-da61-4363-9168-b213a7173f10" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_36d460f9-2574-4602-8372-587886bcafc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_392d4a14-49bd-4954-89c8-a04d35d3048d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_48e1caf1-da61-4363-9168-b213a7173f10" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_392d4a14-49bd-4954-89c8-a04d35d3048d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_98ee561c-0057-4ecd-ad3c-61852127be18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_48e1caf1-da61-4363-9168-b213a7173f10" xlink:to="loc_us-gaap_FinanceLeaseLiability_98ee561c-0057-4ecd-ad3c-61852127be18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1" xlink:type="simple" xlink:href="bngo-20230331.xsd#CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#AcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9ad32745-f3cb-40fe-9513-04dabda44328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_25eeef18-3e0f-4295-8495-f21422dfc57b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9ad32745-f3cb-40fe-9513-04dabda44328" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_25eeef18-3e0f-4295-8495-f21422dfc57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_37f0edd9-e5dc-4344-a4dd-bf25ff0552eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_25eeef18-3e0f-4295-8495-f21422dfc57b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_37f0edd9-e5dc-4344-a4dd-bf25ff0552eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_397895e7-fda9-4985-9746-72468940d0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_37f0edd9-e5dc-4344-a4dd-bf25ff0552eb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_397895e7-fda9-4985-9746-72468940d0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PurigenMember_71d06054-d8b8-46ae-af00-eb5ed090a724" xlink:href="bngo-20230331.xsd#bngo_PurigenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_397895e7-fda9-4985-9746-72468940d0d6" xlink:to="loc_bngo_PurigenMember_71d06054-d8b8-46ae-af00-eb5ed090a724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fc5abc04-2f05-4fbe-ba70-a6690cc033b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_25eeef18-3e0f-4295-8495-f21422dfc57b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fc5abc04-2f05-4fbe-ba70-a6690cc033b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f95d3dfa-1307-42c5-a648-8427c56bf552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fc5abc04-2f05-4fbe-ba70-a6690cc033b0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f95d3dfa-1307-42c5-a648-8427c56bf552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_9101c536-bf40-4289-9a53-5c6ba7f6aae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f95d3dfa-1307-42c5-a648-8427c56bf552" xlink:to="loc_us-gaap_CustomerRelationshipsMember_9101c536-bf40-4289-9a53-5c6ba7f6aae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_5e7da62c-0b16-4d7f-95c5-572f4d4a4c99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f95d3dfa-1307-42c5-a648-8427c56bf552" xlink:to="loc_us-gaap_TradeNamesMember_5e7da62c-0b16-4d7f-95c5-572f4d4a4c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_87caba04-cb89-45f4-a573-68e6e226d6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f95d3dfa-1307-42c5-a648-8427c56bf552" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_87caba04-cb89-45f4-a573-68e6e226d6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_651b1f78-9ae5-4c37-a24f-a5f01468eff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_25eeef18-3e0f-4295-8495-f21422dfc57b" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_651b1f78-9ae5-4c37-a24f-a5f01468eff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6aa9f9b5-dbec-49cb-b830-07f5bb58d8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_651b1f78-9ae5-4c37-a24f-a5f01468eff5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6aa9f9b5-dbec-49cb-b830-07f5bb58d8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_bf5c257c-0675-430c-9b71-ee498068c2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_651b1f78-9ae5-4c37-a24f-a5f01468eff5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_bf5c257c-0675-430c-9b71-ee498068c2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessAcquisitionCashHeldInEscrowFund_54364c22-a922-41b3-bb92-734dcc352c2b" xlink:href="bngo-20230331.xsd#bngo_BusinessAcquisitionCashHeldInEscrowFund"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_651b1f78-9ae5-4c37-a24f-a5f01468eff5" xlink:to="loc_bngo_BusinessAcquisitionCashHeldInEscrowFund_54364c22-a922-41b3-bb92-734dcc352c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_3498e64d-4110-4510-8fca-05269e9dbf99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_651b1f78-9ae5-4c37-a24f-a5f01468eff5" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_3498e64d-4110-4510-8fca-05269e9dbf99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#AcquisitionsAcquisitionPurchasePriceDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a99ac177-eb4f-4fcf-a3f9-b436acc916eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1f3af56-ac91-4701-a083-e2e65b5bca4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a99ac177-eb4f-4fcf-a3f9-b436acc916eb" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1f3af56-ac91-4701-a083-e2e65b5bca4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5b2035ce-21b8-447a-bc1a-bd9edc32de67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1f3af56-ac91-4701-a083-e2e65b5bca4f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5b2035ce-21b8-447a-bc1a-bd9edc32de67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e848901c-646b-4a3a-986d-38cd36463cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5b2035ce-21b8-447a-bc1a-bd9edc32de67" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e848901c-646b-4a3a-986d-38cd36463cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PurigenMember_65020419-3d54-4fe8-ad83-a0aa1ec10ead" xlink:href="bngo-20230331.xsd#bngo_PurigenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e848901c-646b-4a3a-986d-38cd36463cd3" xlink:to="loc_bngo_PurigenMember_65020419-3d54-4fe8-ad83-a0aa1ec10ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8b3393ac-32f2-4049-945a-c829ea11ae4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1f3af56-ac91-4701-a083-e2e65b5bca4f" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_8b3393ac-32f2-4049-945a-c829ea11ae4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_ae2c41f0-6196-4406-8b9b-6dd7dbb7047a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b3393ac-32f2-4049-945a-c829ea11ae4a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_ae2c41f0-6196-4406-8b9b-6dd7dbb7047a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c588a8de-873b-4f96-a9d4-97e134591329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b3393ac-32f2-4049-945a-c829ea11ae4a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c588a8de-873b-4f96-a9d4-97e134591329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow_bd0aebcc-a473-486c-b5cd-3de2f5ba5bbd" xlink:href="bngo-20230331.xsd#bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b3393ac-32f2-4049-945a-c829ea11ae4a" xlink:to="loc_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow_bd0aebcc-a473-486c-b5cd-3de2f5ba5bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_55352537-8375-4931-8c99-a7de52e5ee81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b3393ac-32f2-4049-945a-c829ea11ae4a" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_55352537-8375-4931-8c99-a7de52e5ee81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_efa75f28-a43e-4e53-9400-d63b4d8dc9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f3fe2cca-e26b-4172-a7da-118a4ab12277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_efa75f28-a43e-4e53-9400-d63b4d8dc9d9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f3fe2cca-e26b-4172-a7da-118a4ab12277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_684fd53e-e75e-4e65-89c8-d2809ca6ce6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f3fe2cca-e26b-4172-a7da-118a4ab12277" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_684fd53e-e75e-4e65-89c8-d2809ca6ce6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7fe21ddb-ebe0-4fe8-b995-6acb7bcde73d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_684fd53e-e75e-4e65-89c8-d2809ca6ce6d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7fe21ddb-ebe0-4fe8-b995-6acb7bcde73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PurigenMember_15d13f41-e4ed-48d2-b7e2-8a03472695d4" xlink:href="bngo-20230331.xsd#bngo_PurigenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7fe21ddb-ebe0-4fe8-b995-6acb7bcde73d" xlink:to="loc_bngo_PurigenMember_15d13f41-e4ed-48d2-b7e2-8a03472695d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f3fe2cca-e26b-4172-a7da-118a4ab12277" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_cb27ed60-fe3d-474f-a883-a4c489cbaa56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_cb27ed60-fe3d-474f-a883-a4c489cbaa56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_20c14f55-21a6-4ca1-89f4-e9c790c74078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_20c14f55-21a6-4ca1-89f4-e9c790c74078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_ccd9c1c1-b00e-4f2f-9707-e98e907ed190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_ccd9c1c1-b00e-4f2f-9707-e98e907ed190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_74264870-ac74-4d4f-b20f-55aaa599bd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_74264870-ac74-4d4f-b20f-55aaa599bd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_1a5c66c8-38af-4bdf-92dd-bb95728a300f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_1a5c66c8-38af-4bdf-92dd-bb95728a300f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_1d5e58f7-b89c-4ffa-999c-b3e0d737deb5" xlink:href="bngo-20230331.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_1d5e58f7-b89c-4ffa-999c-b3e0d737deb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_ab70e3de-9bf0-4c04-8cc0-d5e63a42d73c" xlink:href="bngo-20230331.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_ab70e3de-9bf0-4c04-8cc0-d5e63a42d73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_24be3bd7-d81b-4989-9ed8-3d9e6a7bea66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_24be3bd7-d81b-4989-9ed8-3d9e6a7bea66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_9e6eca3c-e72e-4a7b-b1c7-c676ae6731c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_9e6eca3c-e72e-4a7b-b1c7-c676ae6731c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0f9e8cde-1c35-433e-a06a-e551c80a4fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_us-gaap_Goodwill_0f9e8cde-1c35-433e-a06a-e551c80a4fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities_c7bfa510-4d8c-4e09-a5ec-ffc6793e6dc9" xlink:href="bngo-20230331.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities_c7bfa510-4d8c-4e09-a5ec-ffc6793e6dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent_a21e9e72-589d-4b1c-b290-17c69942a276" xlink:href="bngo-20230331.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent_a21e9e72-589d-4b1c-b290-17c69942a276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_16b2488d-dd2d-4298-95af-6c9e1ab26c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a93d6a2-20b9-4591-a23b-c603349f0a00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_16b2488d-dd2d-4298-95af-6c9e1ab26c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#AcquisitionsIdentifiableIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_488a8984-6f5a-496b-985c-9b76fd143d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5d5d40e-178e-4c4d-8e22-4f61d15f0634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_488a8984-6f5a-496b-985c-9b76fd143d6a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5d5d40e-178e-4c4d-8e22-4f61d15f0634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5bb34919-065f-47db-804d-1281642c5044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5d5d40e-178e-4c4d-8e22-4f61d15f0634" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5bb34919-065f-47db-804d-1281642c5044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e01b3e0-ae5b-42fb-8f0a-5fa80fa698db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5bb34919-065f-47db-804d-1281642c5044" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e01b3e0-ae5b-42fb-8f0a-5fa80fa698db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PurigenMember_a40201f9-94a3-4e9d-b7f6-9a903fa4cf50" xlink:href="bngo-20230331.xsd#bngo_PurigenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e01b3e0-ae5b-42fb-8f0a-5fa80fa698db" xlink:to="loc_bngo_PurigenMember_a40201f9-94a3-4e9d-b7f6-9a903fa4cf50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_65ba0533-ab2e-4ef9-9a21-468f2952bb98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5d5d40e-178e-4c4d-8e22-4f61d15f0634" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_65ba0533-ab2e-4ef9-9a21-468f2952bb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_126fd2e4-555a-4c63-a85e-71108b200781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_65ba0533-ab2e-4ef9-9a21-468f2952bb98" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_126fd2e4-555a-4c63-a85e-71108b200781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_fc6bcf1c-c5f5-4859-940c-66b62c27f69d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_126fd2e4-555a-4c63-a85e-71108b200781" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_fc6bcf1c-c5f5-4859-940c-66b62c27f69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_cc623a79-dea9-470d-a595-2bacdceea9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_126fd2e4-555a-4c63-a85e-71108b200781" xlink:to="loc_us-gaap_CustomerRelationshipsMember_cc623a79-dea9-470d-a595-2bacdceea9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_4efc8e3a-ed72-45d9-9e15-43b8050414e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_126fd2e4-555a-4c63-a85e-71108b200781" xlink:to="loc_us-gaap_TradeNamesMember_4efc8e3a-ed72-45d9-9e15-43b8050414e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d9b58a9c-795b-4abd-b1b0-20381b76fb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5d5d40e-178e-4c4d-8e22-4f61d15f0634" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_d9b58a9c-795b-4abd-b1b0-20381b76fb8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_04e6f0b2-bf81-4bab-975b-3cad78b32715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9b58a9c-795b-4abd-b1b0-20381b76fb8f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_04e6f0b2-bf81-4bab-975b-3cad78b32715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#AcquisitionsProFormaInformationDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_cd14962b-29d1-40f6-8304-7820ba61386e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2184b5a8-c4d6-41fc-9a66-5dc7548a2890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_cd14962b-29d1-40f6-8304-7820ba61386e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2184b5a8-c4d6-41fc-9a66-5dc7548a2890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_10536a81-af81-4b50-8b9b-80cb13635c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2184b5a8-c4d6-41fc-9a66-5dc7548a2890" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_10536a81-af81-4b50-8b9b-80cb13635c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2a627bac-b89d-48c5-9501-95271102620f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_10536a81-af81-4b50-8b9b-80cb13635c40" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2a627bac-b89d-48c5-9501-95271102620f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PurigenMember_d01f8cc3-e4d7-4868-980d-7853ac5acfd9" xlink:href="bngo-20230331.xsd#bngo_PurigenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2a627bac-b89d-48c5-9501-95271102620f" xlink:to="loc_bngo_PurigenMember_d01f8cc3-e4d7-4868-980d-7853ac5acfd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_bb8b2b69-34cc-449d-b393-bb55c9f63d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2184b5a8-c4d6-41fc-9a66-5dc7548a2890" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_bb8b2b69-34cc-449d-b393-bb55c9f63d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_8993de80-33ea-414f-9852-6b847f3e0a71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb8b2b69-34cc-449d-b393-bb55c9f63d4d" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_8993de80-33ea-414f-9852-6b847f3e0a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_65b7cd6f-dfb8-4d7d-a75d-a9e0555b9069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb8b2b69-34cc-449d-b393-bb55c9f63d4d" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_65b7cd6f-dfb8-4d7d-a75d-a9e0555b9069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_6865960c-8717-4e3c-b8c6-e0a7d84006ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb8b2b69-34cc-449d-b393-bb55c9f63d4d" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_6865960c-8717-4e3c-b8c6-e0a7d84006ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_5e52b071-a3a0-4eca-9640-0ab448b8a8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb8b2b69-34cc-449d-b393-bb55c9f63d4d" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_5e52b071-a3a0-4eca-9640-0ab448b8a8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ce60bbcb-7ce3-489a-8ba2-e108941a9a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_68076644-4d82-4a8f-83e0-f3121c605374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ce60bbcb-7ce3-489a-8ba2-e108941a9a13" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_68076644-4d82-4a8f-83e0-f3121c605374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b0adc2e3-0a50-411a-b6e2-a40cc30de26b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_68076644-4d82-4a8f-83e0-f3121c605374" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b0adc2e3-0a50-411a-b6e2-a40cc30de26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2bef79bf-69bd-4cce-ac0e-25b01218abb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b0adc2e3-0a50-411a-b6e2-a40cc30de26b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2bef79bf-69bd-4cce-ac0e-25b01218abb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_86f03d49-8339-45d5-973c-20acc4977533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2bef79bf-69bd-4cce-ac0e-25b01218abb6" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_86f03d49-8339-45d5-973c-20acc4977533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9f7b252f-aa11-419d-8475-c99169b54c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_68076644-4d82-4a8f-83e0-f3121c605374" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9f7b252f-aa11-419d-8475-c99169b54c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a399fc09-544e-469c-97f1-14c4032d8c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9f7b252f-aa11-419d-8475-c99169b54c96" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a399fc09-544e-469c-97f1-14c4032d8c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2d3cde65-e290-4d1e-a984-97ca4c0bc3af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a399fc09-544e-469c-97f1-14c4032d8c01" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2d3cde65-e290-4d1e-a984-97ca4c0bc3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f72accda-2f7e-4f16-af8f-c6afa345ff10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a399fc09-544e-469c-97f1-14c4032d8c01" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f72accda-2f7e-4f16-af8f-c6afa345ff10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5f4fd640-616a-49df-8876-bf86a2c0c25c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a399fc09-544e-469c-97f1-14c4032d8c01" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5f4fd640-616a-49df-8876-bf86a2c0c25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_123ccc99-6508-4340-97ca-92a2fbd17e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_68076644-4d82-4a8f-83e0-f3121c605374" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_123ccc99-6508-4340-97ca-92a2fbd17e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1995db25-cb52-4b8b-9b8c-fd04d3e90f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_123ccc99-6508-4340-97ca-92a2fbd17e58" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1995db25-cb52-4b8b-9b8c-fd04d3e90f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_34a3cb76-edbb-4ffa-adcf-ede90326c53e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1995db25-cb52-4b8b-9b8c-fd04d3e90f1d" xlink:to="loc_us-gaap_InvestmentsMember_34a3cb76-edbb-4ffa-adcf-ede90326c53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7bfe72bc-0dff-4cfe-a89b-1f18808e2ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1995db25-cb52-4b8b-9b8c-fd04d3e90f1d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7bfe72bc-0dff-4cfe-a89b-1f18808e2ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_c95ef387-f9f6-4160-9dc4-2d5b0e70c4ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_68076644-4d82-4a8f-83e0-f3121c605374" xlink:to="loc_us-gaap_InvestmentTypeAxis_c95ef387-f9f6-4160-9dc4-2d5b0e70c4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_3de55755-07bf-4e2b-b461-ddf46e46c3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_c95ef387-f9f6-4160-9dc4-2d5b0e70c4ef" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_3de55755-07bf-4e2b-b461-ddf46e46c3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_5f7ef3f1-330e-4db7-b7f6-2a3278b39473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_3de55755-07bf-4e2b-b461-ddf46e46c3aa" xlink:to="loc_us-gaap_CommercialPaperMember_5f7ef3f1-330e-4db7-b7f6-2a3278b39473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CorporateNotesAndBondsMember_41648a1a-ba26-4819-84af-f7f2ba329d12" xlink:href="bngo-20230331.xsd#bngo_CorporateNotesAndBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_3de55755-07bf-4e2b-b461-ddf46e46c3aa" xlink:to="loc_bngo_CorporateNotesAndBondsMember_41648a1a-ba26-4819-84af-f7f2ba329d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_cf1ca20c-5241-417d-a9bc-5e3e8a442db2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_3de55755-07bf-4e2b-b461-ddf46e46c3aa" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_cf1ca20c-5241-417d-a9bc-5e3e8a442db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ed922c41-3bee-4320-bf0b-0ab6db8394cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_68076644-4d82-4a8f-83e0-f3121c605374" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ed922c41-3bee-4320-bf0b-0ab6db8394cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd97aae8-38cd-4315-8ecf-13ea545e9506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ed922c41-3bee-4320-bf0b-0ab6db8394cb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd97aae8-38cd-4315-8ecf-13ea545e9506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationLiabilityMember_58986413-1b6f-4f88-9f17-ef3822145aa4" xlink:href="bngo-20230331.xsd#bngo_ContingentConsiderationLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd97aae8-38cd-4315-8ecf-13ea545e9506" xlink:to="loc_bngo_ContingentConsiderationLiabilityMember_58986413-1b6f-4f88-9f17-ef3822145aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bb1a830e-08a7-4af6-80ad-eaf98cf359d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_68076644-4d82-4a8f-83e0-f3121c605374" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bb1a830e-08a7-4af6-80ad-eaf98cf359d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_d60dc66f-e893-46bb-a054-d6de4d7ae856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bb1a830e-08a7-4af6-80ad-eaf98cf359d9" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_d60dc66f-e893-46bb-a054-d6de4d7ae856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_26a60ea7-9ac6-46dd-84cc-deca77bfa31e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bb1a830e-08a7-4af6-80ad-eaf98cf359d9" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_26a60ea7-9ac6-46dd-84cc-deca77bfa31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#InvestmentsandFairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ffb590af-db98-421a-b45f-0992277404a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3245f40-1eec-4cfe-b6bc-02f3a730fe74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ffb590af-db98-421a-b45f-0992277404a0" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3245f40-1eec-4cfe-b6bc-02f3a730fe74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1987ee7f-b29f-41d6-a563-c07de0246cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3245f40-1eec-4cfe-b6bc-02f3a730fe74" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1987ee7f-b29f-41d6-a563-c07de0246cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9dfdf863-4ef8-4f54-991a-e3751b034b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1987ee7f-b29f-41d6-a563-c07de0246cf3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9dfdf863-4ef8-4f54-991a-e3751b034b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationLiabilityMember_e3b38936-4c9a-4413-adec-c0460e3f028d" xlink:href="bngo-20230331.xsd#bngo_ContingentConsiderationLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9dfdf863-4ef8-4f54-991a-e3751b034b52" xlink:to="loc_bngo_ContingentConsiderationLiabilityMember_e3b38936-4c9a-4413-adec-c0460e3f028d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_32c1c5c8-318e-4a60-9fa7-431514c11bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3245f40-1eec-4cfe-b6bc-02f3a730fe74" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_32c1c5c8-318e-4a60-9fa7-431514c11bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0ac990ed-a16e-44e8-8cc0-2cb06f7cb0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_32c1c5c8-318e-4a60-9fa7-431514c11bef" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0ac990ed-a16e-44e8-8cc0-2cb06f7cb0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_c8998724-6e03-4662-91a5-d154b47485bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0ac990ed-a16e-44e8-8cc0-2cb06f7cb0ea" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_c8998724-6e03-4662-91a5-d154b47485bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_MeasurementInputProbabilityFactorMember_7886e568-d466-4480-a141-f93d28713e83" xlink:href="bngo-20230331.xsd#bngo_MeasurementInputProbabilityFactorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0ac990ed-a16e-44e8-8cc0-2cb06f7cb0ea" xlink:to="loc_bngo_MeasurementInputProbabilityFactorMember_7886e568-d466-4480-a141-f93d28713e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e6a0f206-ca3f-46e8-b97f-528d48091dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3245f40-1eec-4cfe-b6bc-02f3a730fe74" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e6a0f206-ca3f-46e8-b97f-528d48091dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c19046a-83df-44c6-95f6-6f0f1839ec34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e6a0f206-ca3f-46e8-b97f-528d48091dbb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c19046a-83df-44c6-95f6-6f0f1839ec34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember_545f81f7-589b-48ef-8a4d-77fcacbb12e4" xlink:href="bngo-20230331.xsd#bngo_BioDiscoveryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c19046a-83df-44c6-95f6-6f0f1839ec34" xlink:to="loc_bngo_BioDiscoveryMember_545f81f7-589b-48ef-8a4d-77fcacbb12e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PurigenMember_af8971e7-4784-4468-b3f9-ab289274624b" xlink:href="bngo-20230331.xsd#bngo_PurigenMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c19046a-83df-44c6-95f6-6f0f1839ec34" xlink:to="loc_bngo_PurigenMember_af8971e7-4784-4468-b3f9-ab289274624b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_18955c7f-e462-4d0c-8807-771161045b02" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3245f40-1eec-4cfe-b6bc-02f3a730fe74" xlink:to="loc_srt_RangeAxis_18955c7f-e462-4d0c-8807-771161045b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_406b39b8-98e6-4e5f-bf2f-a691d7f011b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_18955c7f-e462-4d0c-8807-771161045b02" xlink:to="loc_srt_RangeMember_406b39b8-98e6-4e5f-bf2f-a691d7f011b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d2944f3f-32ec-47d6-a8c4-ad2c356d6942" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_406b39b8-98e6-4e5f-bf2f-a691d7f011b9" xlink:to="loc_srt_MinimumMember_d2944f3f-32ec-47d6-a8c4-ad2c356d6942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a8152b8f-0e61-4997-84d5-0f22e8820587" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_406b39b8-98e6-4e5f-bf2f-a691d7f011b9" xlink:to="loc_srt_MaximumMember_a8152b8f-0e61-4997-84d5-0f22e8820587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8017b051-d0ad-463b-baf3-71eb974ab040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3245f40-1eec-4cfe-b6bc-02f3a730fe74" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8017b051-d0ad-463b-baf3-71eb974ab040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_bc6ae69e-ca18-4297-abe6-d399b364fa85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8017b051-d0ad-463b-baf3-71eb974ab040" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_bc6ae69e-ca18-4297-abe6-d399b364fa85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationContingentConsiderationMilestonePayment_a8778a63-2635-43a5-a9c8-d299d9cb359b" xlink:href="bngo-20230331.xsd#bngo_BusinessCombinationContingentConsiderationMilestonePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8017b051-d0ad-463b-baf3-71eb974ab040" xlink:to="loc_bngo_BusinessCombinationContingentConsiderationMilestonePayment_a8778a63-2635-43a5-a9c8-d299d9cb359b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_d3f6bc8a-8c29-4cec-956c-bce3d3697ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8017b051-d0ad-463b-baf3-71eb974ab040" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_d3f6bc8a-8c29-4cec-956c-bce3d3697ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_347dfd94-ad46-4d8e-82f6-ecec520cb1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8017b051-d0ad-463b-baf3-71eb974ab040" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_347dfd94-ad46-4d8e-82f6-ecec520cb1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_4f45c659-c121-4d7e-b348-ddbe697388a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8017b051-d0ad-463b-baf3-71eb974ab040" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_4f45c659-c121-4d7e-b348-ddbe697388a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_578eeda8-8691-4227-b944-be7230e624bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8017b051-d0ad-463b-baf3-71eb974ab040" xlink:to="loc_us-gaap_InterestReceivable_578eeda8-8691-4227-b944-be7230e624bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8253c739-c622-4969-98c6-ee6fa4121295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_393076aa-7beb-4ff4-84f3-4ce565336cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8253c739-c622-4969-98c6-ee6fa4121295" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_393076aa-7beb-4ff4-84f3-4ce565336cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9d29b663-16e0-42d6-a5dc-395b0c19dc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_393076aa-7beb-4ff4-84f3-4ce565336cf6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9d29b663-16e0-42d6-a5dc-395b0c19dc0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8325e76a-f4bd-4ffd-87d9-513c8fc36c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9d29b663-16e0-42d6-a5dc-395b0c19dc0f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8325e76a-f4bd-4ffd-87d9-513c8fc36c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationLiabilityMember_147fe3d5-5963-4626-a305-ed2f39b91996" xlink:href="bngo-20230331.xsd#bngo_ContingentConsiderationLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8325e76a-f4bd-4ffd-87d9-513c8fc36c0c" xlink:to="loc_bngo_ContingentConsiderationLiabilityMember_147fe3d5-5963-4626-a305-ed2f39b91996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_750a5e5b-260c-4f59-863a-751d08437669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_393076aa-7beb-4ff4-84f3-4ce565336cf6" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_750a5e5b-260c-4f59-863a-751d08437669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8c69ff96-1f0f-464c-9aa3-0791f82762c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_750a5e5b-260c-4f59-863a-751d08437669" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8c69ff96-1f0f-464c-9aa3-0791f82762c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4b541feb-0d66-4fa3-88d1-54b50b896238" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8c69ff96-1f0f-464c-9aa3-0791f82762c7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4b541feb-0d66-4fa3-88d1-54b50b896238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_971fcf72-2c0a-410f-9301-f0e824492eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8c69ff96-1f0f-464c-9aa3-0791f82762c7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_971fcf72-2c0a-410f-9301-f0e824492eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_d7a48049-e538-4f95-862e-6be8f1742092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8c69ff96-1f0f-464c-9aa3-0791f82762c7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_d7a48049-e538-4f95-862e-6be8f1742092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_43c8c453-bb42-477b-8ff6-cd690df65b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8c69ff96-1f0f-464c-9aa3-0791f82762c7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_43c8c453-bb42-477b-8ff6-cd690df65b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1d0cc1e5-161c-4221-8844-0907c26fd2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8c69ff96-1f0f-464c-9aa3-0791f82762c7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1d0cc1e5-161c-4221-8844-0907c26fd2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_15db11ba-587b-4bc8-b203-70b2e99c5438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_03c0efa0-c343-421c-9259-8807f2582959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_15db11ba-587b-4bc8-b203-70b2e99c5438" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_03c0efa0-c343-421c-9259-8807f2582959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_55c15e7d-2d68-4aa8-869a-e45787815363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_03c0efa0-c343-421c-9259-8807f2582959" xlink:to="loc_us-gaap_FinancialInstrumentAxis_55c15e7d-2d68-4aa8-869a-e45787815363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f795786f-b465-490e-9d02-df74c0b7abd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_55c15e7d-2d68-4aa8-869a-e45787815363" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f795786f-b465-490e-9d02-df74c0b7abd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_bde52c17-e893-4d67-92c6-cc10a9e2554b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f795786f-b465-490e-9d02-df74c0b7abd0" xlink:to="loc_us-gaap_CommercialPaperMember_bde52c17-e893-4d67-92c6-cc10a9e2554b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CorporateNotesAndBondsMember_0a0f1f55-2200-42f7-9264-02cb9715325b" xlink:href="bngo-20230331.xsd#bngo_CorporateNotesAndBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f795786f-b465-490e-9d02-df74c0b7abd0" xlink:to="loc_bngo_CorporateNotesAndBondsMember_0a0f1f55-2200-42f7-9264-02cb9715325b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_37438a91-c489-4f17-af95-1d62bee579ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f795786f-b465-490e-9d02-df74c0b7abd0" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_37438a91-c489-4f17-af95-1d62bee579ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0ad82ac5-f533-41fe-ae01-3f504decb1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_03c0efa0-c343-421c-9259-8807f2582959" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0ad82ac5-f533-41fe-ae01-3f504decb1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_a6a98f25-6db2-4931-96d1-68013cf5b9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0ad82ac5-f533-41fe-ae01-3f504decb1e1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_a6a98f25-6db2-4931-96d1-68013cf5b9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_9c38ba33-a99f-4e5d-9213-4a2a08f409bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_a6a98f25-6db2-4931-96d1-68013cf5b9f8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_9c38ba33-a99f-4e5d-9213-4a2a08f409bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0bd79e9c-5053-463a-926f-ec7052a4290b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_a6a98f25-6db2-4931-96d1-68013cf5b9f8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0bd79e9c-5053-463a-926f-ec7052a4290b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b8369ecc-7cbe-468c-a516-504cc31c8d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_a6a98f25-6db2-4931-96d1-68013cf5b9f8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b8369ecc-7cbe-468c-a516-504cc31c8d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract_504a30d8-2040-44cb-b17b-70d7b93a910e" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0ad82ac5-f533-41fe-ae01-3f504decb1e1" xlink:to="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract_504a30d8-2040-44cb-b17b-70d7b93a910e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne_b265c9f8-1a7e-48ee-9e7e-e78a10ec608f" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract_504a30d8-2040-44cb-b17b-70d7b93a910e" xlink:to="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne_b265c9f8-1a7e-48ee-9e7e-e78a10ec608f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive_70029996-3fc3-4513-a174-bbc59a79f5a5" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract_504a30d8-2040-44cb-b17b-70d7b93a910e" xlink:to="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive_70029996-3fc3-4513-a174-bbc59a79f5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGains_fee8c6ca-83c3-4ca8-ae29-e898d595ed9f" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedGains"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract_504a30d8-2040-44cb-b17b-70d7b93a910e" xlink:to="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedGains_fee8c6ca-83c3-4ca8-ae29-e898d595ed9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_082e7e7f-6ff7-4c65-94b7-8edfa2b1a2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0ad82ac5-f533-41fe-ae01-3f504decb1e1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_082e7e7f-6ff7-4c65-94b7-8edfa2b1a2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne_da2969e7-6037-495d-8d4b-3d7b19152661" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_082e7e7f-6ff7-4c65-94b7-8edfa2b1a2ce" xlink:to="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne_da2969e7-6037-495d-8d4b-3d7b19152661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive_c87e5bf4-e83b-4e82-9bff-edf097fcd792" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_082e7e7f-6ff7-4c65-94b7-8edfa2b1a2ce" xlink:to="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive_c87e5bf4-e83b-4e82-9bff-edf097fcd792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss_aa838f11-3042-4373-88a6-c04c8455f407" xlink:href="bngo-20230331.xsd#bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_082e7e7f-6ff7-4c65-94b7-8edfa2b1a2ce" xlink:to="loc_bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss_aa838f11-3042-4373-88a6-c04c8455f407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_8057c540-a617-480c-a59c-b4dfaf9c5454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0ad82ac5-f533-41fe-ae01-3f504decb1e1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_8057c540-a617-480c-a59c-b4dfaf9c5454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_232ed0f0-4147-4e3e-bb39-d3372b3a5561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_8057c540-a617-480c-a59c-b4dfaf9c5454" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_232ed0f0-4147-4e3e-bb39-d3372b3a5561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_ed03873a-6566-4d98-9040-f0f90fcbcd77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_8057c540-a617-480c-a59c-b4dfaf9c5454" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_ed03873a-6566-4d98-9040-f0f90fcbcd77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_8e2225e3-da68-4ab0-ba3c-547e70fbddb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_8057c540-a617-480c-a59c-b4dfaf9c5454" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_8e2225e3-da68-4ab0-ba3c-547e70fbddb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails" xlink:type="simple" xlink:href="bngo-20230331.xsd#InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_38e0ca46-77ba-4e2d-bd94-9cdc88a0e377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_17bb2f86-e8a6-4f9b-976f-9e5442fb6e07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_38e0ca46-77ba-4e2d-bd94-9cdc88a0e377" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_17bb2f86-e8a6-4f9b-976f-9e5442fb6e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0405fc82-322f-4f45-9c49-cc12633a1992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_17bb2f86-e8a6-4f9b-976f-9e5442fb6e07" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0405fc82-322f-4f45-9c49-cc12633a1992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d47948cf-a108-47b3-895c-9e4a873a9bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0405fc82-322f-4f45-9c49-cc12633a1992" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d47948cf-a108-47b3-895c-9e4a873a9bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_ac3e70c5-fbeb-41d4-bd31-d6703898ab21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d47948cf-a108-47b3-895c-9e4a873a9bc6" xlink:to="loc_us-gaap_CommercialPaperMember_ac3e70c5-fbeb-41d4-bd31-d6703898ab21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CorporateNotesAndBondsMember_28010595-37f9-41c7-a5ff-99c33fc306ed" xlink:href="bngo-20230331.xsd#bngo_CorporateNotesAndBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d47948cf-a108-47b3-895c-9e4a873a9bc6" xlink:to="loc_bngo_CorporateNotesAndBondsMember_28010595-37f9-41c7-a5ff-99c33fc306ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0fbfafa1-302b-4dfe-a403-bf03aa033b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d47948cf-a108-47b3-895c-9e4a873a9bc6" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0fbfafa1-302b-4dfe-a403-bf03aa033b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e7099915-6851-47f9-b227-1dc68d934ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_17bb2f86-e8a6-4f9b-976f-9e5442fb6e07" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e7099915-6851-47f9-b227-1dc68d934ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_f0830c97-fa27-4643-9973-987f7728d7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e7099915-6851-47f9-b227-1dc68d934ef8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_f0830c97-fa27-4643-9973-987f7728d7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_925ab685-0a6e-4b0f-b3ae-c713794018c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_f0830c97-fa27-4643-9973-987f7728d7a2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_925ab685-0a6e-4b0f-b3ae-c713794018c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_759bb143-9d05-48fd-a9fb-147cfe547e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_f0830c97-fa27-4643-9973-987f7728d7a2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_759bb143-9d05-48fd-a9fb-147cfe547e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1cbeb7c6-8e82-45e4-889f-a5f59d02dacf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_f0830c97-fa27-4643-9973-987f7728d7a2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1cbeb7c6-8e82-45e4-889f-a5f59d02dacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_0534d11a-ad17-418d-a848-792d085712ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e7099915-6851-47f9-b227-1dc68d934ef8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_0534d11a-ad17-418d-a848-792d085712ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_da8fac29-50d7-4cef-bf14-e704de487cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_0534d11a-ad17-418d-a848-792d085712ec" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_da8fac29-50d7-4cef-bf14-e704de487cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_24ae58e8-0a10-42c8-aa00-672c13b07333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_0534d11a-ad17-418d-a848-792d085712ec" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_24ae58e8-0a10-42c8-aa00-672c13b07333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_262644c7-2c1f-4a85-84f7-ea9a24f10142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_0534d11a-ad17-418d-a848-792d085712ec" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_262644c7-2c1f-4a85-84f7-ea9a24f10142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@  #+(   "6" (   #_S]?8   GQTE$051X7NW=
M:905Y;D_[&YFF:$%91)0$ 6<T.C?F.A949<2-4Z)&LT18]2<1&,<$A6#<8I#
M/,'$!&,4G%")<<1XHLMY0(Y'Q %Q5D1(4)EE; '!MV";>JOO[J;W;GIRK^OZ
MU+V?WWT_57M7?;M75<D7            %)&2^ $           !?9<;"
M        BHJQ,           @*)B+ P          *"H& L#           H
M*L;"            BHJQ,           @*)B+ P          *"H& L#
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M+*@C];=O U_/J;0P+E#QKC_CC#/B\D;=?OOMV?)$MV[=EB]?'G,
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M+\Y]F&Z1JEA4!^IUWX:_GE-I25P@\^4\^NBC<2T/+[[X8MHA9^C0H3$$
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MK^<T'!?J3N:(:K;''GO$^G\[Z*"#8KJ26-.H;KWUUG!XYYY[;@P!
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MNV[=NKC<4)*MERQ9\J]__6O*E"ECQXY-OK2RLK+L>24WX%%''57HT!L
M    0 .K>N0E.P;1K5NWFV^^>>-/#WKWW7<//?30;%5BN^VVR_.%=!T[=@RU
M*U>NC*'\K%BQ(K3JW+ES#-6%D2-'9G<9.G3HZM6K8Z@0SSWWW%%''55Y0*=*
M2>Q[W_O>I$F38I?Z,7SX\'3K$2-&Q.5").6Y/OWZ]4M^K+B<D>Z8BHE"-.2^
MC7X]9_,-</\F3COMM%!>Z)M&O_:UK^4*K[[ZZKC6(%YYY96*9Q#U[-GSU%-/
M?>NMMV(E         $#34_7(2SH)L==>>^4_&C)JU*C,$,5ZN^VVVV>??19S
ME;1NW3H4UGK$:M6J5:'59IMM%D.;[/777\_.;[5JU6KJU*DQ5+AUZ]:]^NJK
M)YQP0M(P<P85)/O^YW_^Y\LOO]Q@3U1Z[[WWLH\HVY0S?>*))](^#S_\<%RN
M*$VF8B)O#;QOHU_/:;AA[M_$&V^\$6H3#SSP0,Q5XZ677LJ5M&G39N'"A7&Y
M06Q\+&R__?:[XXX[9LR8$<L          )JDJD=><I,0W_SF-PM]RM&99YY9
M<9JBY(PSSHBA2IHU:Q:J:CWSM';MVM"J>?/F,;1I5JQ8,73HT.P6?_SC'V.H
M0.^]]][(D2,KOWQP(Y+P>>>=]^Z[[\9>=>WG/_]YNNF>>^X9E_-67EX^<.#
M7)_O?__[<;F2=--43.2GX?=M].LYEVRP^S<GV2[4'GC@@3%4C9-..BE7<OSQ
MQ\>UAK+QL;#4+KOL,GKTZ,6+%\=Z         ("FI."1EXTK+R\?-&A0=HJB
M>?/FTZ=/C[F*ZG",)BD,K?(9HRG(#W[P@VS_HX\^.B8*L7CQXI___.<M6K3(
M]APZ=.B%%U[XS#//S)HU:^7*E2M6K$C^2/Y-/APR9$@VF10FY?4WI+)\^?).
MG3JEV]UQQQTQD;?SSS\_UZ1KUZ[Y/,(JW305$_EI^'V_6M=S5NWNWYP)$R9D
M"Q/)]_#!!Q_$7"5+EBQIUZY=KN3YYY^/RXTAN>/FS)GS^NNOWWGGG6>>>>;V
MVV]?\<Q*RLK*QHP94]!;,@$         &E+!(R\UNO/..\,(Q;'''AM#%37Z
M2_?R=_'%%V>;[['''N7EY3&4MW?>>6>;;;;)-MQRRRWONNNNC4P1)4M)8(LM
MMLA6)4WJZ;%A?_[SG]-=DF.K]>\R??KT]+6;-]YX8URN2KIO*B;RT"C[?H6N
MY\IJ<?_F)(?:K5NW4'ONN>?&7"5CQHS)A7?:::>XUF0\^>23^^RS3\636_\X
MM"5+EL0H         $ 34/#(2XTJ3X>T;-ERT:)%,9?1L6/';#Y1Z,OO4BM6
MK BM.G?N'$.U=<,--V0[;[WUUI]\\DD,Y>W--]\L*RO+-APZ=.CLV;-CKBI)
M++S(,FGUUEMOQ=PF&SQX<+K%A1=>&)?SLW;MVCWWW#/79)]]]MG(T%M6NF\J
M)FK26/M^5:[G*M7B_DV=<\XYV<)$TBII&',5I5?R7_[RE[C6E"27TU57714>
M!;?##CM\^NFG,0H         T-@*'GG)QX]^]*/LY$3BMMMNBZ&,/GWZA/S\
M^?-C*#]SY\X-K?KV[1M#M3)^_/CFS9NG;7OUZI7/"_*JLVS9LO!FNBY=NLR<
M.3/FJI>$DY)LA\&#!R]?OCSF-L'CCS^>-F_9LN5''WT4$_FY]MIK<TU:MV[]
M]MMOQ^5JI%NG8J(FC;7O5^)ZWHA"[]_4C!DS2DM+0^V$"1-B+F/2I$FY6(<.
M'9*;(BXW/==<<TW%\RLYY)!#\IPX!         !H, 6/O.3CNNNN"Y,3/_[Q
MCV,H8Y===@GY6D]<S9@Q([3:====8ZAP-]YX8_8I0=VZ==O$1W.=>^ZYF6-<
M[^:;;XZAFMQTTTVAR7GGG1=#F^#00P]-.Q]SS#%Q.3]SYLQ)GYYUR267Q.7J
MI5NG8F*C&FO?+[X*U_/&%7K_9AUPP &A=N^]]XZAC....RX7^Z__^J^XUE0=
M>^RQ%4^Q9-RX<3$$         -"H"AYYR<>4*5/"V,2>>^X90QD''GA@R$^=
M.C6&\E-YZ^'#A\=0@<:-&Y=]!E+W[MU??_WU&"K$HD6+.G3HD#G&DMZ]>Z]>
MO3KF:I*4)(79/DG;/-_W5Z,//_PP^W2TR9,GQT1^#C_\\%R'P8,'U_@^P:QT
MZU1,;%1C[?M%D[^>:U1YTXW?OUD3)TX,M8DWWG@CYC:8/W]^Z]:M<YE77WTU
M+C=5,V;,:-&B1?8$^_?OOV;-FI@#         &@\!8^\Y./##S_,SDPD>O;L
M&4,9/_G)3T+^H8<>BJ'\_,___$]H]=.?_C2&"G';;;=EGQ.VY99;OOGFFS%4
MH+%CQV8.<+VSSSX[AO)SUEEGA59U]>"B<\XY)^TY;-BPN)R?=$BHM+3TN>>>
MB\L;E>Z>BHGJ-=:^.4WY>LY'H?=OUN>??QY&%1,_^]G/8FZ#JZZZ*A?(?^RL
MB<@^2"_GP0<?C"$         @,93\,A+/C[]]-,P,]&V;=L8ROC=[WX7\F/'
MCHVA_-QPPPVAU>C1HV,H;W?==5?VB5F]>O5ZYYUW8JAP1Q]]=.8 U[O__OMC
M*#_WW7=?:/7][W\_A@JW<N7*KEV[ICUK\8++G'1"*/^W$*;2W5,Q4;W&VC>G
MR5[/>2KT_@TNNNBB4-ZI4Z<5*U:$V+IUZ[;99IM<8/SX\6&UB?O3G_Y4\11+
M3C_]]!@"         &@\!8^\Y&/-FC5A9J)9LV8QE/'HHX^&_,B1(V,H/^>>
M>VYH]=ACC\50?B9.G)A]5=Q66VWU_OOOQU"M#!HT*'. Z]6Z\WOOO1=:;;?=
M=C%4N''CQJ4-R\K*RLO+8R(_F>.J7TUDWYRF>3WGK]#[-Y@S9TYXQV))50^Q
M>^211W)+7;MVK?4%UEA>>NFEBN=7LMMNN\40         $#CJ7JN91,M6K0H
MS$QL_&E#E?-''GED#.7GB".."*V2YC&4AX<>>JA5JU9ID_[]^W_XX8<Q5%O9
M!W'EU.X@$PL7+@RMRLK*8JAP.^^\<]KPO//.B\MYRQQ7_6HB^^8TP>NY()6/
M?^/W;V6''WYXZ+#KKKM6ESGKK+/"4M/WKW_]J^+YE?3NW3N&           :
M3]5S+9MHYLR986:B9\^>,531X,&#L_F! P?&1'ZVWGKK;)^D;4SDX?'''V_3
MIDW:9,"  ;-GSXZA39!],67.FC5K8B@_E1_LE#2/H0)-FC0IVVW6K%DQD;?,
M<=6O)K)OJDE=SX6JQ?T;5'Y>6F+*E"EI('VB6&EI:9V\F+6!E9>7A[-KW;IU
M# $         -)YJYUHVQ?///Q]F)O;<<\\8JNC,,\_,YDM+2Q<N7!A#-9D_
M?WY2F.V3M(VAFCS[[+-MV[9-.PP:-&C.G#DQM&DVVVRSS#&N5^M'0%5^6EB[
M=NUBJ$!''754VNWPPP^/RPTE<TY?BHGZ$7>MU;Y-YWJNA5K<O\&Z=>L&#!@0
MFIQXXHEIX**++LI]N.^^^V;JOC*6+EU:X=R,A0$         34P<>4FG'&HQ
MQ9(:,V9,9EYBO9-//CF&*GKZZ:=#R<2)$V.H)O?>>V]H\M133\701CW__/,=
M.G1(RX<,&?+))Y_$4/72PKA0T59;;94F<]Y___T8RL][[[T76O7KUR^&"I$^
MQBGGR2>?C(F&DCFG+\5$_8B[UFK?QKJ>TV0#W[^577755:%)V[9M%R]>G"Q]
M_OGGO7OWSGUXSSWWQ,KZE![,@@4+XEHA9LR8D;;*V6*++6((         *#Q
MQ)&7=,KAA1=>"$OY&S%B1&9>8KU;;KDEABI:MVY=W[Y]LR4GG712#-4D[+O5
M5ELE;6.H>E.G3NW4J5-:ON...\Z;-R^&-BJMC0L5[;OOOFDRY_[[[X^A_-QW
MWWVAU7[[[1=#A1@U:E3::LB0(7&Y 67.Z4LQ43_BKK7:M[&NYS3<P/=O90L6
M+&C=NG7H<\TUUR1+R=6>^[='CQZU?GUJ[:1',GGRY+A6B'_\XQ]IJYQ"'Z@&
M         %"OXLA+.N7PAS_\(2SEJ;R\O$N7+IEYB9+FS9O/GS\_YBKYS6]^
MDZTJ*RO[[+//8JAZE?>]]-)+8ZAZTZ9-Z]JU:UH[;-BP6CQO*2V/"Q7]ZE>_
M2I,Y9YUU5@SE)[RL,#%JU*@8RMNJ5:NVV&*+M-5?_O*7F&A F7/Z4DS4C[AK
M;?=ME.LY#3?\_5O9<<<=E^V3V'[[[9//#SC@@-R_FW*MUDYZ)%=>>65<*\3I
MIY^>MLHYXXPS8@@         H/'$D9=TRF&OO?8*2WFZ]=9;,\,2ZQUQQ!$Q
M5)7%BQ=G7^"82%K%4/5NO/'&;&W[]NT7+5H40]5X\\TWNW7KEM;NOOONN;?=
M%2KM$!<J>O[YY]-D3N_>O5>O7AUS-4E*>O7J%5IMRF.B;KOMMK1/ITZ=EB]?
M'A,-*'-.7XJ)^A%WK>V^C7(]I_F&OW\K>^ZYYT*KQ$TWW51:6EJR8=ILUJQ9
ML::>I8>QXXX[QK6\K5BQHD>/'O__*6WPZ*./QAP         0..)(R_908>G
MGWXZK-9HV;)E_?OWSS8I+2V=,F5*S%7CLLLNR]8.'#@PSW?,K5JU:NNMM\[6
MYO-HI9QWWWTW.^3Q]:]_?<F2)3&4G[1)7*ADAQUV2,,Y-]UT4PS5)"D)39*V
M,52(W7??/6UUYIEGQN6&E3FM+\5$_8B[;L*^#7\]9TL:_OZMK/)UGKY9\I!#
M#HGI0DR?/OV@@PYJW[Y]APX=#CWTT+???CLFJI(]DGONN2<NY^?RRR_/]DDD
M/];:M6MC#@        "@\<21E^RLP]"A0Y<N71H"&W?**:=D.R1^^,,?QE#U
M5JU:-6C0H&SYQ1=?'$-5N>"""[)5 P<.S/.%?1]\\$&?/GW2PF]^\YO+EBV+
MH;RE?>)")??>>V\:SNG2I<N''WX8<]6;.7-F>-E?XK[[[HNYO+WPP@MIG]+2
MTO???S\F&E;FM+X4$_4C[KH)^S;\]9RM:OC[M[(Q8\:$AJF''GHHIO/VQAMO
MA">Q=>[<.9_)L&Q)KUZ]YLR9$Q,U>>:99UJU:I7MD[C]]MMC#@        "@
M4<61ES#NL.^^^^8_67+VV6>'\D&#!A4Z9?7**Z^DSQ,JV?"FN;___>\Q5-'$
MB1.36%J2E$^=.C6&JC)[]NQ^_?JEA74H[E25(X\\,E3ML,,.R2'%7%62V-"A
M0T-YTC#F"O&#'_P@;77000?%Y0:7.;,OQ43]B+MNVKX->3U_4>G@&_[^#98L
M6=*^??O0-I'<=YOR>*V##SXX=BPI.?300V.NDE"R[;;;SIPY,X:J]]ACCU6>
MQ<QG7P        " !A9'7L+$0Z)___Z///)(B 5OOOGF\.'#0V&?/GT*&KE(
M39@PH5FS9FF?5JU:_?G/?UZW;EW,??%%\N&UUU[;LF7+-%Q:6GK;;;?%7#4&
M#!B0%M:MN%-5EBU;-FS8L%"XY99;WGWWW56>;$ZRE 226"C<99==\A\ JFSN
MW+G9Z:6''WXX)AI<YN2^%!/U(^ZZR?LVV/7\154'W_#W;W#RR2>'SHG++[\\
MY@I1Y:A9APX=8JZ26%-2DK2Z^NJKER]?'J,5)3?(+W[QB^SOF+/[[KMOXN0<
M         $!]B",O8>@A-7CPX(LOOOB11QZ9-6O6TJ5+5Z]>_<DGGTR;-NVZ
MZZX[Y)!#L@\WRADV;-@___G/T#Q_-]]\<W8X)K';;KN-&S?NO??>*]\@^6/L
MV+&[[KIK-M.B18LD$WM5+UM;M^).U?CTTT^__>UOQ^(-K_^[Z**+GGGFF=FS
M9Z_<(/DC^3?Y<,B0(3%=4G+  0<L7KPX=B_$I9=>FG8;.'!@E4-+]2=S*@6+
MO0H1>Q4B]MJHAKF>OZC^C!KX_LUZ^>670_-6K5K-G3LWY@K1KEV[T+-DPX!7
MS%42:_ZM0X<.(T:,2'Z"Y&@__OCCY([+?46OO?9:\N%QQQW7IDV;6%-2\MWO
M?K?&>3(         @$81IUM>?OGE4T\]M?*+TO+7IDV;"RZX8-6J5:%SH9Y^
M^NFMMMHJ=J]>[]Z]GWSRR=AEHV*+NA-WVJAQX\9U[-@QMLA/4GC##3?$C@5:
MLV9-KUZ]TI[77'--3-2SS D5+/8J1.Q5B-BK)@UP/7_1E.[?K-UWWSV[Q=%'
M'QT3!:IRF/([W_E.S%6RZ=]/3K]^_1Y\\,'8'0        "@R:AZNN6SSSZ[
M^^Z[?_C#'V:GA6JTQ19;G'/..1]]]%%L5UO+ER^_X((+NG;M&G>JJ$N7+N>?
M?WXM7N46&]6=N%--%BY<.'KTZ.VVVRXVJMZVVV[[N]_];L&"!;%7X?[VM[^E
M;=NW;[]DR9*8J&>9TRI8[%6(V*L0L5<>ZOMZ3C61^S=U\\TW9S=ZZJFG8J)
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M/0        ! DU3S6!@           !?(<;"            BHJQ,
M    @*)B+ P          *"H& L#           H*L;"            BHJQ
M,           @*)B+ P          *"H& L#           H*L;"
M    BHJQ,           @*)B+ P          *"H& L#           H*L;"
M            BHJQ,           @*)B+ P          *"H& L#
M   H*L;"            BHJQ,           @*)B+ P          *"H& L#
M           H*L;"            BHJQ,           @*)B+ P
M *"H& L#           H*L;"            BHJQ,           @*)B+ P
M         *"H& L#           H*L;"            BHJQ,
M@*)B+ P          *"H& L#           H*L;"            BHJQ,
M        @*)B+ P          *"H& L#           H*L;"
MBHJQ,           @*)B+ P          *"H& L#           H*L;"
M        BHJQ,           @*)B+ P          *"H& L#           H
M*L;"            BHJQ,           @*)B+ P          *"H& L#
M       H*L;"            BHJQ,           @*)B+ P          *"H
M& L#           H*L;"            BHJQ,           @*)B+ P
M     *"H& L#           H*L;"            BHJQ,           @*)B
M+ P          *"H& L#           H*L;"            BHJQ,
M    @*)B+ P          *"H& L#           H*L;"            BHJQ
M,           @*)B+ P          *"H& L#           H*L;"
M    BHJQ,           @*)B+ P          *"H& L#           H*L;"
M            BHJQ,           @*)B+ P          *"H& L#
M   H*L;"            BHJQ,           @*)B+ P          *"H& L#
M           H*L;"            BHJQ,           @*)B+ P
M *"H& L#           H*L;"            BHJQ,           @*)B+ P
M         *"H& L#           H*L;"            BHJQ,
9@*+R_P'3\*+'U^UKUP    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514831124368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 04, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Bionano Genomics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1756290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9540 Towne Centre Drive, Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">888-7600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">306,790,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001411690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BNGO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrants to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants to purchase Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BNGOW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514831212128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,104<span></span>
</td>
<td class="nump">$ 5,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">91,704<span></span>
</td>
<td class="nump">108,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">6,780<span></span>
</td>
<td class="nump">7,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">33,113<span></span>
</td>
<td class="nump">29,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,856<span></span>
</td>
<td class="nump">7,329<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">142,557<span></span>
</td>
<td class="nump">157,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">19,050<span></span>
</td>
<td class="nump">18,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">7,062<span></span>
</td>
<td class="nump">7,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">3,657<span></span>
</td>
<td class="nump">3,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">39,351<span></span>
</td>
<td class="nump">41,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">77,289<span></span>
</td>
<td class="nump">77,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">2,785<span></span>
</td>
<td class="nump">2,414<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">292,151<span></span>
</td>
<td class="nump">307,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">15,780<span></span>
</td>
<td class="nump">12,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">9,250<span></span>
</td>
<td class="nump">10,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">1,127<span></span>
</td>
<td class="nump">871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">2,235<span></span>
</td>
<td class="nump">2,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liability</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration</a></td>
<td class="nump">9,461<span></span>
</td>
<td class="nump">9,382<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">38,135<span></span>
</td>
<td class="nump">35,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">5,043<span></span>
</td>
<td class="nump">5,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liability, net of current portion</a></td>
<td class="nump">3,612<span></span>
</td>
<td class="nump">3,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration, net of current portion</a></td>
<td class="nump">13,680<span></span>
</td>
<td class="nump">12,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term contract liabilities</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">60,664<span></span>
</td>
<td class="nump">58,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of March&#160;31, 2023 and December&#160;31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 400,000,000 shares authorized at March&#160;31, 2023 and December&#160;31, 2022; 306,790,000 and 297,183,000 shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">617,960<span></span>
</td>
<td class="nump">599,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(385,839)<span></span>
</td>
<td class="num">(348,715)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(665)<span></span>
</td>
<td class="num">(1,124)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">231,487<span></span>
</td>
<td class="nump">249,398<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 292,151<span></span>
</td>
<td class="nump">$ 307,502<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514828420416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">306,790,000<span></span>
</td>
<td class="nump">297,183,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">306,790,000<span></span>
</td>
<td class="nump">297,183,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514830763296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 7,415<span></span>
</td>
<td class="nump">$ 5,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total cost of revenue</a></td>
<td class="nump">5,345<span></span>
</td>
<td class="nump">4,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">13,937<span></span>
</td>
<td class="nump">10,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">25,976<span></span>
</td>
<td class="nump">20,277<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">39,913<span></span>
</td>
<td class="nump">30,804<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(37,843)<span></span>
</td>
<td class="num">(29,943)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">704<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(76)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">117<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">745<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(37,098)<span></span>
</td>
<td class="num">(29,943)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit (provision) for income taxes</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (37,124)<span></span>
</td>
<td class="num">$ (29,952)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">302,045<span></span>
</td>
<td class="nump">284,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">302,045<span></span>
</td>
<td class="nump">284,613<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 5,447<span></span>
</td>
<td class="nump">$ 4,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total cost of revenue</a></td>
<td class="nump">3,858<span></span>
</td>
<td class="nump">3,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Service and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,968<span></span>
</td>
<td class="nump">1,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total cost of revenue</a></td>
<td class="nump">$ 1,487<span></span>
</td>
<td class="nump">$ 1,259<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514831842384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss:</a></td>
<td class="num">$ (37,124)<span></span>
</td>
<td class="num">$ (29,952)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on investment securities</a></td>
<td class="nump">423<span></span>
</td>
<td class="num">(1,098)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">459<span></span>
</td>
<td class="num">(1,098)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (36,665)<span></span>
</td>
<td class="num">$ (31,050)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514833084528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit) (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,602,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 337,118<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 553,747<span></span>
</td>
<td class="num">$ (216,119)<span></span>
</td>
<td class="num">$ (539)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option exercises</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Issuance of common stock due to the vesting of restricted stock units, net of shares withheld to cover taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(29,952)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,952)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(1,098)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,098)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,688,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 311,185<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">558,864<span></span>
</td>
<td class="num">(246,071)<span></span>
</td>
<td class="num">(1,637)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">297,183,000<span></span>
</td>
<td class="nump">297,183,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 249,398<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">599,207<span></span>
</td>
<td class="num">(348,715)<span></span>
</td>
<td class="num">(1,124)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises (in shares)</a></td>
<td class="nump">42,000<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option exercises</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issue common stock, net of issuance costs</a></td>
<td class="nump">14,849<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">14,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Issuance of common stock due to the vesting of restricted stock units, net of shares withheld to cover taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(37,124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">$ 459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">306,790,000<span></span>
</td>
<td class="nump">306,790,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 231,487<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 617,960<span></span>
</td>
<td class="num">$ (385,839)<span></span>
</td>
<td class="num">$ (665)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514825800256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (37,124)<span></span>
</td>
<td class="num">$ (29,952)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">3,190<span></span>
</td>
<td class="nump">2,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of financing lease right-of-use asset</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization (accretion) of interest on securities</a></td>
<td class="num">(82)<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_NonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Net realized loss (gain) on investments</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,882<span></span>
</td>
<td class="nump">5,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">789<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_CostOfLeasedEquipmentSoldToCustomer', window );">Cost of leased equipment sold to customer</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">242<span></span>
</td>
<td class="num">(640)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(5,707)<span></span>
</td>
<td class="num">(5,938)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">471<span></span>
</td>
<td class="num">(323)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(372)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">3,017<span></span>
</td>
<td class="num">(3,168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and contract liabilities</a></td>
<td class="num">(978)<span></span>
</td>
<td class="num">(443)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(32,413)<span></span>
</td>
<td class="num">(32,494)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow', window );">BioDiscovery acquisition, return of purchase consideration from escrow</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_PaymentsForPropertyAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(360)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of available for sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(14,954)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sale and maturity of available for sale securities</a></td>
<td class="nump">16,888<span></span>
</td>
<td class="nump">47,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForConstructionInProcess', window );">Construction in progress</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(832)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Sale of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">16,528<span></span>
</td>
<td class="nump">31,964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments on financing lease liability</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="nump">15,229<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses on sale of common stock</a></td>
<td class="num">(380)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant and option exercises</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">14,862<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rates on cash, cash equivalents and restricted cash</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(987)<span></span>
</td>
<td class="num">(523)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">5,491<span></span>
</td>
<td class="nump">24,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">4,504<span></span>
</td>
<td class="nump">24,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash reported within the unaudited condensed consolidated balance sheets to the total amounts reported on the unaudited condensed consolidated statements of cash flows</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">4,104<span></span>
</td>
<td class="nump">24,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">4,504<span></span>
</td>
<td class="nump">24,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">644<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory', window );">Transfer of instruments and servers from property and equipment into inventory</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory', window );">Transfer of instruments and servers from inventory to property and equipment, net</a></td>
<td class="nump">2,356<span></span>
</td>
<td class="nump">2,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment included in accounts payable</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liabilities resulting from obtaining right-of-use assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 513<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_CostOfLeasedEquipmentSoldToCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of Leased Equipment Sold to Customer</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_CostOfLeasedEquipmentSoldToCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_PaymentsForPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for Property and Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_PaymentsForPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Business Combination Return Of Purchase Consideration From Escrow</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfer Of Instruments And Servers From Property And Equipment Into Inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfer of instruments and servers to property and equipment from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForConstructionInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from construction costs to date on capital projects that have not been completed and assets being constructed that are not ready to be placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForConstructionInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514836408640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">Organization and Basis of Presentation<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bionano Genomics, Inc. (collectively, with its consolidated subsidiaries, the &#8220;Company&#8221;) is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company offers optical genome mapping (&#8220;OGM&#8221;) solutions for applications across basic, translational and clinical research, and for other applications including bioprocessing. Through its Lineagen, Inc. (doing business as Bionano Laboratories, &#8220;Bionano Laboratories&#8221;) business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery, LLC (&#8220;BioDiscovery&#8221;) business, the Company also offers platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. Through our Purigen Biosystems Inc. (&#8220;Purigen&#8221;) business, we offer nucleic acid extraction and purification solutions using proprietary isotachophoresis (&#8220;ITP&#8221;) technology.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial information has been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for interim reporting purposes. The condensed consolidated financial statements are unaudited. The unaudited condensed consolidated financial statements reflect, in the opinion of the Company&#8217;s management, all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of financial position, results of operations, changes in equity, and comprehensive loss and cash flows for each period presented in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). All intercompany transactions and balances have been eliminated. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts reported in prior years have been reclassified to conform with the presentation in the current year. These reclassifications had no effect on the reported results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has experienced recurring net losses from operations, negative cash flows from operating activities, and accumulated deficit since its inception and expects to continue to incur net losses into the foreseeable future. As of March&#160;31, 2023, the Company had approximately $4.1 million in cash and cash equivalents, $91.7 million in short term investments, and working capital of $104.4 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an accumulated deficit of $385.8 million as of March&#160;31, 2023. During the three months ended March&#160;31, 2023, the Company used $32.4 million cash in operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management expects operating losses and negative cash flows to continue for at least the next year as the Company continues to incur costs related to research and commercialization efforts. Management has prepared cash flows forecasts which indicate that based on the Company&#8217;s expected operating losses and negative cash flows, there is substantial doubt about the Company&#8217;s ability to continue as a going concern within twelve months after the date that the unaudited condensed consolidated financial statements for the three months ended March&#160;31, 2023, are issued. Management&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional funding. Management&#8217;s plans to raise additional capital to fulfill its operating and </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital requirements for at least 12 months include public or private equity or debt financings. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company&#8217;s existing stockholders. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the outcome of this uncertainty.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, there were no changes to the Company&#8217;s significant accounting policies as described in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which amends the impairment model by requiring entities to use a forward looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. For trade receivables and other instruments, entities will be required to use a new forward-looking expected loss model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. The Company adopted ASU 2016-13 as of January 1, 2023. </span></div>The cumulative effect of applying the new credit loss standard was not material and, therefore, did not result in an adjustment to retained earnings. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements or related financial statement disclosures. In accordance with ASU 2016-13, the Company no longer evaluates whether its available-for-sale debt securities in an unrealized loss position are other than temporarily impaired. Instead, the Company assesses whether such unrealized loss positions are credit-related. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in other income through an allowance account. Unrealized gains and losses that are not credit-related are included in accumulated other comprehensive income.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514834563536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common share equivalents are only included when their effect is dilutive. The Company&#8217;s potentially dilutive securities which include outstanding warrants to purchase stock, restricted stock units (&#8220;RSUs&#8221;), performance stock units (&#8220;PSUs&#8221;), and outstanding stock options under the Company&#8217;s equity incentive plans have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. Restricted stock is treated as outstanding for accounting purposes. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding because all potentially dilutive securities were anti-dilutive.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:72.653%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.658%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,013,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,531,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,257,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,356,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,356,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,457,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,116,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,730,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514834673344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by Source</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Instruments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,896,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,596,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,235,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,520,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,316,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,090,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,447,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,206,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service and other</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,968,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,490,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,415,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,696,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has revised the classification of its revenue between the categories in the table above for the March 31, 2022 statement of operations. In the March 31, 2022 statement of operations, &#8220;software&#8221; was included in &#8220;service and other.&#8221;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by Geographic Location</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.284%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Americas</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,444,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,328,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,992,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">979,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">629,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,415,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,696,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table above provides revenue from contracts with customers by source and geographic region (based on the customer&#8217;s billing address) on a disaggregated basis. Americas consists of North America and South America. EMEA consists of Europe, the Middle East, and Africa. Asia Pacific includes China, Japan, South Korea, Singapore, India and Australia. During the three months ended September 30, 2022, the Company changed the presentation of its revenues from India to be included in the Asia Pacific geographic region. Prior to the three months ended September 30, 2022, the Company had presented revenues from India in the EMEA geographic region. The impact of this change on prior period disclosures is immaterial. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023 and 2022, the United States represented 41.2% and 45.0% of total revenue, respectively. No other countries represented greater than 10% of revenue during the three months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remaining Performance Obligations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was approximately $1.3 million. These remaining performance obligations primarily relate to extended warranty and support and maintenance obligations. The Company expects to recognize approximately&#160;74.9% of this amount as revenue during the remainder of 2023,&#160;20.5%&#160;in 2024, and 4.6%&#160;in 2025 and thereafter. Warranty revenue is included in service and other revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue of approximately&#160;$0.7 million&#160;and $0.3 million during the three months ended March&#160;31, 2023 and 2022, respectively, which was included in the contract liability balance at the end of the previous year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514833383664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Account Details</a></td>
<td class="text">Balance Sheet Account Details<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, trade</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,030,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,315,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allowance for credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(250,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(293,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,780,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,022,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the allowance for credit losses during the three months ended March&#160;31, 2023 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of January 1, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(293,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for expected credit loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-offs and payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(250,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's adoption of ASU No. 2016-13, Financial Instruments - Credit Losses, included an assessment of our aged trade receivables balances and their underlying credit risk characteristics. Our evaluation of past events, current conditions, and reasonable and supportable forecasts about the future resulted in an expectation of immaterial credit losses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventories are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,800,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,319,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Work in process</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,003,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,055,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,310,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,387,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,113,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,761,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that are subject to amortization consisted of the following for the periods presented:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,630,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(684,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,946,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,630,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(552,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,078,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,379,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,771,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,172,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,978,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,600,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,068,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,532,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,600,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,615,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,985,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,380,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,131,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,249,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,380,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,339,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,041,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets not subject to amortization totaled $0.1&#160;million at March&#160;31, 2023 and December&#160;31, 2022, and related to the Company&#8217;s domain name. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following: </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,349,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,002,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">848,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">825,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">613,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional fees and royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warranty liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">591,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">489,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical study fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">849,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,146,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,250,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,552,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514834669824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity and Stock-Based Compensation</a></td>
<td class="text">Stockholders&#8217; Equity and Stock-Based Compensation<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cowen At-the-Market Facility</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2021, the Company entered into a Sales Agreement with Cowen and Company, LLC (&#8220;Cowen&#8221;) which provides for the sale, in the Company&#8217;s sole discretion, of shares of common stock having an aggregate offering price of up to $350.0&#160;million through or to Cowen, acting as sales agent or principal, which was amended on March 9, 2023 to decrease the maximum aggregate offering price to $200.0&#160;million for sales made on and after the date of the amendment (the &#8220;Cowen ATM&#8221;). The Company agreed to pay Cowen a commission of up to 3.0% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. In August 2022, the Company sold approximately 6.6&#160;million shares of common stock under the Cowen ATM at an average share price of $3.46 per share, and received gross proceeds of approximately $23.1 million before deducting offering costs of $0.6 million. During the first quarter of 2023, the Company sold approximately 9.5&#160;million shares of common stock under the Cowen ATM at an average share price of $1.60 per share, and received gross proceeds of approximately $15.2 million before deducting offering costs of $0.4 million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Warrants</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s warrant activity during the three months ended March&#160;31, 2023 was as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares of Stock under Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,356,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,356,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.96&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.52</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity during the three months ended March&#160;31, 2023 was as follows: &#160;&#160;</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares of Stock under Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,022,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,068,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,121,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,088,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,013,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.84</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,149,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.56&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.89</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023, the weighted-average grant date fair value of stock options granted was $1.07 per share.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation expense for the periods presented as follows:&#160;</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,357,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,328,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,882,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,102,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants during the periods presented were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A restricted stock award in the amount of 5.0 million shares with a grant date fair value of $5.20 a share was granted as part of the acquisition of BioDiscovery. One-third of the Restricted Shares was scheduled to vest on October 18, 2022 and one-twelfth of the Restricted Shares was scheduled to vest every three months following October 18, 2022, subject to continuous service of the key employee. The fair value of the restricted stock award was based on the market value of common stock as of the date of grant and was amortized to stock-based compensation expense over the service period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 4, 2022, the restricted stock award was modified due to the change in employment status of the key employee from full time to emeritus. As a result of the modification, the restricted stock award vested in full on October 4, 2022. The award was revalued on the modification date, resulting in a modified grant date fair value of $2.04 a share ($15.8&#160;million less than the initial grant date fair value of the award). The fair value of the modified restricted stock award was based on the market value of common stock as of the modification date. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units and Performance Stock Units</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the three months ended March&#160;31, 2023:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,461,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.67</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of the RSUs that vested during the three months ended March&#160;31, 2023 was $0.3&#160;million, determined as of the date of vesting. The weighted average remaining contractual term for the RSUs is 3.5 years as of March&#160;31, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes PSU activity during the three months ended March&#160;31, 2023:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.74</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining contractual term for the PSUs is 2.1 years as of March&#160;31, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Option Grants and RSUs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2023, the compensation committee of the Company&#8217;s board of directors granted various executive officers stock options to purchase an aggregate of 3.3 million shares of common stock at an exercise price of $1.63 per share, and RSUs amounting to 0.7 million shares of common stock at a grant date fair value of $1.63 per share, in each case with an effective grant date and vesting commencement date of February 15, 2023 (the &#8220;Grant Date&#8221;). These stock option grants and RSUs were issued from the 2018 Plan. The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of the Grant Date, such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. The RSUs shall vest annually over four years beginning one year after the Grant Date, and the balance of the shares vest in a series of three successive equal annual installments measured from the first anniversary of the Grant Date, such that the RSU shall be fully vested on the four-year anniversary of the Grant Date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series A Preferred Stock</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 13, 2023, the Company entered into an agreement with David Barker, the Chair of the Company&#8217;s board of directors, pursuant to which the Company agreed to issue and sell one share of the Company&#8217;s Series A Preferred Stock, par value $0.0001 per share for a purchase price of $100.00. The closing of the sale and purchase of the share of Series A Preferred was completed on April 13, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The share of Series A Preferred will have 3.0 billion votes, but has the right to vote only on a proposal submitted to the stockholders of the Company to adopt an amendment, or a series of alternate amendments, to the Company&#8217;s Amended and Restated Certificate of Incorporation, as amended, to combine the outstanding shares of Common Stock into a smaller number of shares of Common Stock at a ratio specified in or determined in accordance with the terms of such amendment or series of alternate amendments (&#8220;Reverse Stock Split Proposal&#8221;), and will have no voting rights (i) except with respect to a Reverse Stock Split Proposal and the votes of the share of Series A Preferred are required to be cast for and against such Reverse Stock Split Proposal in the same proportion as shares of Common Stock are voted for and against such Reverse Stock Split Proposal (with any shares of Common Stock that are not voted, whether due to abstentions, broker non-votes or otherwise not counted as votes for or against a Reverse Stock Split Proposal) and (ii) unless the holders of one-third (1/3rd) of the outstanding shares of Common Stock are present and vote, in person or by proxy, at the meeting of stockholders at which a Reverse Stock Split Proposal is submitted for stockholder approval (or any adjournment thereof). The share of Series A Preferred will vote together with the Common Stock as a single class on a Reverse Stock Split Proposal. The Series A Preferred has no other voting rights, except as may be required by the General Corporation Law of the State of Delaware. The outstanding share of Series A Preferred will be redeemed in whole, but not in part, for a redemption price of $100.00, payable out of funds lawfully available therefor, (i) if such redemption is ordered by the Company&#8217;s Board of Directors in its sole discretion, automatically and effective on such time and date specified by the Board of Directors in its sole discretion, or (ii) automatically immediately following the approval by the stockholders of a Reverse Stock Split Proposal.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514836404400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various operating lease agreements and a finance lease agreement, primarily relating to our office, laboratory, and manufacturing space. See Note 11 &#8211; Commitments and Contingencies, subsection titled &#8220;Leases&#8221;, in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December 31, 2022 for information regarding the Company&#8217;s lease agreements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future minimum payments under non-cancellable operating and finance leases as of March&#160;31, 2023, are as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,942,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,684,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,788,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">729,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">347,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">356,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,594,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,398,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,207,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,120,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,313,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,278,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,894,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to potential liabilities under various claims and legal actions that are pending or may be asserted. These matters arise in the ordinary course and conduct of the business. The Company regularly assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in the unaudited condensed consolidated financial statements. An estimated loss contingency is accrued in the unaudited condensed consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on the Company&#8217;s assessment, it currently does not have any material loss exposure as it is not a defendant in any claims or legal actions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div>See Note 8 to our unaudited condensed consolidated financial statements for a discussion of the contingent consideration liability.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514918223984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text">Acquisitions<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purigen Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company completed the acquisition of Purigen Biosystems, Inc. for approximately $32.0&#160;million in cash and up to an aggregate of $32.0&#160;million in cash payable based on the achievement of certain milestones. Cash of $1.2&#160;million will be held in an escrow fund for purposes of satisfying any post-closing purchase price adjustments and indemnification claims under the Purigen Merger Agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The purchase price allocation for the acquisition of Purigen is preliminary and subject to revision as additional information about the fair value of assets and liabilities becomes available. As permitted under ASC 805, the Company is allowed a measurement period, which may not exceed one year, in which to complete its accounting for the acquisition. Per the terms of the Purigen Merger Agreement, the purchase price is still subject to adjustment for the final determination of cash, unpaid indebtedness, unpaid transaction expenses and working capital, as well for deferred and current tax assets and liabilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the estimated purchase price for the acquisition of Purigen:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,034,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Estimated fair value of milestone consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,970,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Estimated return of cash to buyer from escrow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(90,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total estimated purchase price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,914,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated purchase price was allocated to Purigen&#8217;s tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date, with the excess recorded as goodwill, as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash &amp; cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">944,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">805,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,636,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">533,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,651,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounts payable and other accrued liabilities </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,152,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Operating lease liability (short-term and long-term)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,636,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">44,914,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair values of identifiable intangible assets acquired are as following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">18,800,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Tradename</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Fair value of identifiable intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">20,000,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the income approach to derive the fair value of the identified intangible assets acquired. This approach calculates fair value by estimating future cash flows attributable to the assets and then discounting these cash flows to a present value using a risk-adjusted discount rate. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The customer relationships and trade name intangibles are being amortized on a straight-line basis over their estimated useful lives of 5 years. The developed technology intangible is being amortized on a straight-line basis over its estimated useful live of 15 years. Straight-line amortization was determined to be materially consistent with the pattern of expected use of the intangible assets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company began integrating Purigen&#8217;s operations with its existing operations during the fourth quarter of 2022, it is not practical or meaningful to distinguish Purigen&#8217;s expenses or net income or loss from that of the combined operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pro forma Financial Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma financial information in the table below summarizes the combined results of operations for the Company and Purigen as if the companies had been combined as of the beginning of the year prior to the acquisition. These amounts have been calculated after applying the Company&#8217;s accounting policies and adjusting the results of Purigen to reflect </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the additional amortization that would have been charged assuming the fair value adjustments to intangible assets had been applied at the beginning of the year prior to the acquisition. The following unaudited pro forma financial information is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved as if the acquisition had taken place as of January 1, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr style="height:29pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,220,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32,048,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Basic and diluted net loss per share</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514825757904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Investments and Fair Value Measurements</a></td>
<td class="text">Investments and Fair Value Measurements<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds investment securities that consist of highly liquid, investment grade debt securities. The Company determines the fair value of its investment securities based upon one or more valuations reported by its investment accounting and reporting service provider. The investment service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curves, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, and broker and dealer quotes, as well as other relevant economic measures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis as of March&#160;31, 2023 and December&#160;31, 2022: </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March&#160;31, 2023</span></div></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Fair Value and Carrying Value on Balance Sheet</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurement&#160;Category</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,216,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,216,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government sponsored entities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,988,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,988,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,704,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,704,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252,000&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252,000&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,141,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,141,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2022</span></div></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Fair Value and Carrying Value on Balance Sheet</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurement&#160;Category</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,020,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,020,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,094,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,094,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government sponsored entities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,981,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,981,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,095,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,095,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,868,000&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,868,000&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,352,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,352,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds are classified as cash equivalents on the unaudited condensed consolidated balance sheet. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration relates to the acquisitions of BioDiscovery and Purigen. The outcome of the milestone consideration for all contingent consideration liabilities is binary, meaning the milestones are either achieved or not achieved, and the only other variable factor is the timing of when the milestones are achieved. The fair value measurement of the contingent consideration liabilities is based on significant inputs not observed in the market (Level 3 inputs). These unobservable inputs represent a Level 3 measurement because they are supported by little or no market activity and reflect the Company&#8217;s assumptions in measuring fair value.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the BioDiscovery contingent consideration liability is reassessed on a quarterly basis using a probability weighted model. Assumptions used to estimate the acquisition date fair value of the contingent consideration related to the acquisition of BioDiscovery include the probability of achieving, or changes in timing, of certain milestones, and a discount rate. As of March&#160;31, 2023 a discount rate of 3% was used. The Company determined the fair value of the BioDiscovery milestone consideration using a scenario-based technique, as the trigger for payment is event driven. The Company determined it is highly likely that the milestone related to the BioDiscovery acquisition will be achieved and therefore used a 95% probability factor which is applied to the $10.0 million milestone consideration. The change in fair value of the contingent consideration during the three months ended March&#160;31, 2023 was due to the passage of time. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liabilities related to the Purigen milestones are related to the achievement of two independent milestones with aggregate possible milestone payments totaling $32.0 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Purigen milestones are reassessed on a quarterly basis using a probability weighted model and a Monte Carlo Simulation. Assumptions used to estimate the acquisition date fair value of the milestones using a probability weighted model include the probability of achieving, or changes in timing, of independent milestones, and a discount rate of 15%. The Company determined the fair value of this milestone consideration using a scenario-based technique, as the trigger for payment is event driven. The Company determined the likelihood of each independent milestone and used probability factors ranging from 20% to 80% which were applied to the individual payments. A Monte Carlo Simulation was performed to determine the likelihood that the milestone will be achieved and was applied to the milestone consideration payment. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in estimated fair value of contingent consideration liability in the three months ended March&#160;31, 2023 is as follows: </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Contingent</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Consideration</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Liability</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(Level 3</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Measurement)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of January 1, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,352,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liability recorded as a result of current period acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in estimated fair value, recorded in selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,141,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available for Sale Investments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in U.S. Treasury and agency securities, corporate debt securities, and commercial paper, which are classified as available-for-sale investments. These investments are carried at fair value and are included in the tables below. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. At each reporting date, the Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. The Company evaluates, among others, whether the Company has the intention to sell any of these investments and whether it is not more likely than not that the Company will be required to sell any of them before recovery of the amortized cost basis. Neither of these criteria were met in any period presented. The credit ratings of the securities held remain of the highest quality. Moreover, the Company continues to receive payments of interest and principal as they become due, and our expectation is that those payments will continue to be received timely. Based on this evaluation, as of March&#160;31, 2023 and December&#160;31, 2022, the Company determined that unrealized losses of the below securities were primarily attributable to changes in interest rates and non-credit related factors. As such, no allowances for credit losses were recorded during these periods. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, the Company held 17 and 16 securities, respectively, which have been in an unrealized loss position for a period of less than 12 months. As of March&#160;31, 2023 and December&#160;31, 2022, the Company held 19 and 24 securities, respectively, which have been in an unrealized loss position for a period of greater than 12 months.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses are calculated using the specific identification method and recorded in other income (expense) in the Company&#8217;s unaudited condensed consolidated statements of operations and comprehensive loss. The Company has the ability, if necessary, to liquidate any of its cash equivalents and marketable securities to meet its liquidity needs in the next 12 months.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable as of March&#160;31, 2023 and December&#160;31, 2022 was $0.6 million and $0.5 million, respectively, and is recorded as a component of prepaid expenses and other current assets on the unaudited condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the following table summarizes the amortized cost and the unrealized gains/losses of the available for sale securities:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Contractual Maturity (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,259,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,216,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,739,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(561,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,178,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,998,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,988,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total maturity less than 1 year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,996,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(614,000)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,382,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,372,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,322,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,368,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(664,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,704,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the following table summarizes the amortized cost and the unrealized gains/losses of the available for sale securities:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Contractual Maturity (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,093,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,020,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,823,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(911,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,913,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,998,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,982,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total maturity less than 1 year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,914,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,000,000)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,915,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,268,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,180,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,182,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,088,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,095,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the following table summarizes available-for-sale securities in an unrealized loss position with no credit losses reported:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Gross Unrealized Loss</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Gross Unrealized Loss</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Gross Unrealized Loss</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,216,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,216,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,687,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,813,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(571,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,500,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(611,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of Government Sponsored Entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,988,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,988,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,891,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,813,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(571,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,704,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(664,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the following table summarizes available-for-sale securities in an unrealized loss position with no credit losses reported:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Gross Unrealized Loss</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Gross Unrealized Loss</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Gross Unrealized Loss</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,020,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,020,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,661,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,452,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(972,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,113,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(999,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of Government Sponsored Entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,981,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,981,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,662,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,452,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(972,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,114,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,088,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514837312080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of PresentationThe accompanying financial information has been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for interim reporting purposes. The condensed consolidated financial statements are unaudited. The unaudited condensed consolidated financial statements reflect, in the opinion of the Company&#8217;s management, all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of financial position, results of operations, changes in equity, and comprehensive loss and cash flows for each period presented in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). All intercompany transactions and balances have been eliminated. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts reported in prior years have been reclassified to conform with the presentation in the current year. These reclassifications had no effect on the reported results of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_LiquidityAndGoingConcernPolicyTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has experienced recurring net losses from operations, negative cash flows from operating activities, and accumulated deficit since its inception and expects to continue to incur net losses into the foreseeable future. As of March&#160;31, 2023, the Company had approximately $4.1 million in cash and cash equivalents, $91.7 million in short term investments, and working capital of $104.4 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an accumulated deficit of $385.8 million as of March&#160;31, 2023. During the three months ended March&#160;31, 2023, the Company used $32.4 million cash in operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management expects operating losses and negative cash flows to continue for at least the next year as the Company continues to incur costs related to research and commercialization efforts. Management has prepared cash flows forecasts which indicate that based on the Company&#8217;s expected operating losses and negative cash flows, there is substantial doubt about the Company&#8217;s ability to continue as a going concern within twelve months after the date that the unaudited condensed consolidated financial statements for the three months ended March&#160;31, 2023, are issued. Management&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional funding. Management&#8217;s plans to raise additional capital to fulfill its operating and </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital requirements for at least 12 months include public or private equity or debt financings. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company&#8217;s existing stockholders. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the outcome of this uncertainty.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which amends the impairment model by requiring entities to use a forward looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. For trade receivables and other instruments, entities will be required to use a new forward-looking expected loss model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. The Company adopted ASU 2016-13 as of January 1, 2023. </span></div>The cumulative effect of applying the new credit loss standard was not material and, therefore, did not result in an adjustment to retained earnings. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements or related financial statement disclosures. In accordance with ASU 2016-13, the Company no longer evaluates whether its available-for-sale debt securities in an unrealized loss position are other than temporarily impaired. Instead, the Company assesses whether such unrealized loss positions are credit-related. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in other income through an allowance account. Unrealized gains and losses that are not credit-related are included in accumulated other comprehensive income.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_LiquidityAndGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity and Going Concern</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_LiquidityAndGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514833410192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:72.653%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.658%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,013,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,531,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,257,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,356,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,356,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,457,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,116,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,730,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514831837792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by Source</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Instruments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,896,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,596,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,235,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,520,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,316,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,090,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,447,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,206,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service and other</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,968,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,490,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,415,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,696,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has revised the classification of its revenue between the categories in the table above for the March 31, 2022 statement of operations. In the March 31, 2022 statement of operations, &#8220;software&#8221; was included in &#8220;service and other.&#8221;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by Geographic Location</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.284%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Americas</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,444,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,328,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,992,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">979,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">629,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,415,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,696,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514831842864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts Receivable</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, trade</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,030,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,315,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allowance for credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(250,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(293,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,780,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,022,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Schedule of Allowance for Credit Losses</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the allowance for credit losses during the three months ended March&#160;31, 2023 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of January 1, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(293,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for expected credit loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-offs and payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(250,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock', window );">Schedule of Components of Inventories</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventories are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,800,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,319,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Work in process</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,003,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,055,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,310,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,387,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,113,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,761,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that are subject to amortization consisted of the following for the periods presented:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,630,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(684,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,946,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,630,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(552,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,078,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,379,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,771,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,172,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,978,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,600,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,068,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,532,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,600,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,615,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,985,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,380,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,131,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,249,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,380,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,339,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,041,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following: </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,349,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,002,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">848,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">825,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">613,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional fees and royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warranty liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">591,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">489,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical study fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">849,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,146,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,250,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,552,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514837196608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s warrant activity during the three months ended March&#160;31, 2023 was as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares of Stock under Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,356,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,356,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.96&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.52</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity during the three months ended March&#160;31, 2023 was as follows: &#160;&#160;</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares of Stock under Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,022,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,068,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,121,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,088,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,013,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.84</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,149,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.56&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.89</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Recognized Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation expense for the periods presented as follows:&#160;</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,357,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,328,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,882,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,102,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Assumptions in Black -Scholes Option Pricing Model</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants during the periods presented were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Units and Performance Stock Units</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the three months ended March&#160;31, 2023:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,461,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.67</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes PSU activity during the three months ended March&#160;31, 2023:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.74</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514836273200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future minimum payments under non-cancellable operating and finance leases as of March&#160;31, 2023, are as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,942,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,684,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,788,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">729,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">347,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">356,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,594,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,398,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,207,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,120,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,313,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,278,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,894,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140515008727952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the estimated purchase price for the acquisition of Purigen:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,034,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Estimated fair value of milestone consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,970,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Estimated return of cash to buyer from escrow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(90,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total estimated purchase price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,914,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated purchase price was allocated to Purigen&#8217;s tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date, with the excess recorded as goodwill, as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash &amp; cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">944,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">805,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,636,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">533,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,651,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounts payable and other accrued liabilities </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,152,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Operating lease liability (short-term and long-term)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,636,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">44,914,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock', window );">Schedule of Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair values of identifiable intangible assets acquired are as following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">18,800,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Tradename</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Fair value of identifiable intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">20,000,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of Business Acquisition, Pro Forma Information</a></td>
<td class="text">The following unaudited pro forma financial information is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved as if the acquisition had taken place as of January 1, 2021.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr style="height:29pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,220,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32,048,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Basic and diluted net loss per share</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514831089712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis as of March&#160;31, 2023 and December&#160;31, 2022: </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March&#160;31, 2023</span></div></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Fair Value and Carrying Value on Balance Sheet</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurement&#160;Category</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,216,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,216,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government sponsored entities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,988,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,988,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,704,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,704,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252,000&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252,000&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,141,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,141,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2022</span></div></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Fair Value and Carrying Value on Balance Sheet</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurement&#160;Category</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,020,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,020,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,094,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,094,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government sponsored entities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,981,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,981,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,095,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,095,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,868,000&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,868,000&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,352,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,352,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text">Changes in estimated fair value of contingent consideration liability in the three months ended March&#160;31, 2023 is as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Contingent</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Consideration</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Liability</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(Level 3</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Measurement)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of January 1, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,352,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liability recorded as a result of current period acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in estimated fair value, recorded in selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,141,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the following table summarizes the amortized cost and the unrealized gains/losses of the available for sale securities:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Contractual Maturity (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,259,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,216,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,739,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(561,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,178,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,998,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,988,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total maturity less than 1 year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,996,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(614,000)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,382,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,372,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,322,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,368,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(664,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,704,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the following table summarizes the amortized cost and the unrealized gains/losses of the available for sale securities:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Contractual Maturity (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,093,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,020,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,823,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(911,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,913,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,998,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,982,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total maturity less than 1 year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,914,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,000,000)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,915,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,268,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,180,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,182,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,088,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,095,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the following table summarizes available-for-sale securities in an unrealized loss position with no credit losses reported:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Gross Unrealized Loss</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Gross Unrealized Loss</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Gross Unrealized Loss</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,216,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,216,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,687,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,813,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(571,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,500,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(611,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of Government Sponsored Entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,988,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,988,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,891,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,813,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(571,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,704,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(664,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the following table summarizes available-for-sale securities in an unrealized loss position with no credit losses reported:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Gross Unrealized Loss</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Gross Unrealized Loss</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Gross Unrealized Loss</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,020,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,020,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,661,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,452,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(972,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,113,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(999,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of Government Sponsored Entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,981,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,981,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,662,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,452,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(972,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,114,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,088,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514831829808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,104<span></span>
</td>
<td class="nump">$ 24,048<span></span>
</td>
<td class="nump">$ 5,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">91,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_WorkingCapital', window );">Working capital</a></td>
<td class="nump">104,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">385,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 348,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="nump">$ 32,413<span></span>
</td>
<td class="nump">$ 32,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514833067328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount (in shares)</a></td>
<td class="nump">39,116<span></span>
</td>
<td class="nump">30,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount (in shares)</a></td>
<td class="nump">32,013<span></span>
</td>
<td class="nump">21,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bngo_UnvestedRestrictedStockMember', window );">Unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bngo_CommonWarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount (in shares)</a></td>
<td class="nump">4,356<span></span>
</td>
<td class="nump">4,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount (in shares)</a></td>
<td class="nump">2,457<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bngo_PerformanceShareUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount (in shares)</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bngo_UnvestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bngo_UnvestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bngo_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bngo_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bngo_PerformanceShareUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bngo_PerformanceShareUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514826879200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Revenue by Source and Geographic Location (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 7,415<span></span>
</td>
<td class="nump">$ 5,696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AmericasMember', window );">Americas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">3,444<span></span>
</td>
<td class="nump">3,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember', window );">EMEA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">2,992<span></span>
</td>
<td class="nump">1,739<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia Pacific</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 979<span></span>
</td>
<td class="nump">$ 629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer | Geographic Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer | Geographic Concentration Risk | Americas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer | Geographic Concentration Risk | EMEA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer | Geographic Concentration Risk | Asia Pacific</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 5,447<span></span>
</td>
<td class="nump">$ 4,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bngo_InstrumentRevenueMember', window );">Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">1,896<span></span>
</td>
<td class="nump">1,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bngo_ConsumableRevenueMember', window );">Consumables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">2,235<span></span>
</td>
<td class="nump">1,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bngo_SoftwareMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">1,316<span></span>
</td>
<td class="nump">1,090<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Service and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 1,968<span></span>
</td>
<td class="nump">$ 1,490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AmericasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AmericasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EMEAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bngo_InstrumentRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bngo_InstrumentRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bngo_ConsumableRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bngo_ConsumableRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bngo_SoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bngo_SoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514837146976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic Concentration Risk | Revenue Benchmark | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">41.20%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514830747264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Remaining Performance Obligations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance obligation</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-04-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Performance obligation, percentage</a></td>
<td class="nump">74.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Timing of satisfaction of remaining performance obligation</a></td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Performance obligation, percentage</a></td>
<td class="nump">20.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Timing of satisfaction of remaining performance obligation</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Performance obligation, percentage</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Timing of satisfaction of remaining performance obligation</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-04-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-04-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514831162048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Schedule of Accounts Receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable, trade</a></td>
<td class="nump">$ 7,030<span></span>
</td>
<td class="nump">$ 7,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for credit losses</a></td>
<td class="num">(250)<span></span>
</td>
<td class="num">(293)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 6,780<span></span>
</td>
<td class="nump">$ 7,022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514830657136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details - Schedule of Allowance for Credit Losses (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Beginning balance</a></td>
<td class="num">$ (293)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for expected credit loss</a></td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-offs and payments</a></td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Ending balance</a></td>
<td class="num">$ (250)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514831069472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Schedule of Components of Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="nump">$ 5,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">10,003<span></span>
</td>
<td class="nump">7,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">17,310<span></span>
</td>
<td class="nump">17,387<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">$ 33,113<span></span>
</td>
<td class="nump">$ 29,761<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514833114992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 48,380<span></span>
</td>
<td class="nump">$ 48,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(9,131)<span></span>
</td>
<td class="num">(7,339)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">39,249<span></span>
</td>
<td class="nump">41,041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Tradename</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">2,630<span></span>
</td>
<td class="nump">2,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(684)<span></span>
</td>
<td class="num">(552)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">1,946<span></span>
</td>
<td class="nump">2,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">4,150<span></span>
</td>
<td class="nump">4,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,379)<span></span>
</td>
<td class="num">(1,172)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">2,771<span></span>
</td>
<td class="nump">2,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">41,600<span></span>
</td>
<td class="nump">41,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(7,068)<span></span>
</td>
<td class="num">(5,615)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 34,532<span></span>
</td>
<td class="nump">$ 35,985<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514831077408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember', window );">Internet Domain Names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Intangible assets not subject to amortization</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514830770368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation expenses</a></td>
<td class="nump">$ 6,349<span></span>
</td>
<td class="nump">$ 7,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositLiabilityCurrent', window );">Customer deposits</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">848<span></span>
</td>
<td class="nump">825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedInsuranceCurrent', window );">Insurance</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_ProfessionalFeesAndRoyaltiesCurrent', window );">Professional fees and royalties</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent', window );">Warranty liabilities</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_AccruedClinicalStudyFeesCurrent', window );">Accrued clinical study fees</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">849<span></span>
</td>
<td class="nump">1,146<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 9,250<span></span>
</td>
<td class="nump">$ 10,552<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_AccruedClinicalStudyFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Study Fees, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_AccruedClinicalStudyFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ProfessionalFeesAndRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Professional Fees and Royalties, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ProfessionalFeesAndRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInsuranceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInsuranceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current portion, due within one year or one operating cycle, if longer, of deposits held other than customer deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12524-110249<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126907644&amp;loc=d3e11281-110244<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514825125952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock-Based Compensation - Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 13, 2023 </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 09, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 15, 2023 </div>
<div>installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 04, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 23, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Average share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent', window );">Reverse stock split, percentage of outstanding common stock are present</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_PreferredStockNumberOfVotes', window );">Preferred stock, number of votes | vote</a></td>
<td class="nump">3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Preferred stock, redemption price (in dollars per share)</a></td>
<td class="nump">$ 100.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">David Barker | Series A Preferred Stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Average share price (in dollars per share)</a></td>
<td class="nump">$ 100.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Grant fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Reduction in stock-based compensation cost from modification | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Vesting on October 18, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Granted vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Vesting every three months following October 18, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Granted vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | BioDiscovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Units granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Units granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,461,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Grant fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.67<span></span>
</td>
<td class="nump">4.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Total intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments', window );">Number of successive annual installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bngo_PerformanceShareUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Units granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Grant fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Option | Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bngo_CowenMember', window );">Cowen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_SaleOfStockValueSharesIssuedInTransaction', window );">Aggregate offering price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_CommissionFeeMaximumPercentageOfGrossProceeds', window );">Commission fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_CommissionFeeMaximumPercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission Fee, Maximum Percentage Of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_CommissionFeeMaximumPercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_PreferredStockNumberOfVotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Number of Votes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_PreferredStockNumberOfVotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_SaleOfStockValueSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Value, Shares Issued in Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_SaleOfStockValueSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Successive Annual Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders' Equity, Reverse Stock Split, Percentage of Outstanding Common Stock Are Present</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bngo_PerformanceShareUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bngo_PerformanceShareUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bngo_CowenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bngo_CowenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514831098928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock-Based Compensation - Warrant Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightOutstandingRollForward', window );"><strong>Shares of Stock under Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Beginning balance (in shares)</a></td>
<td class="nump">4,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod', window );">Canceled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Ending balance (in shares)</a></td>
<td class="nump">4,356<span></span>
</td>
<td class="nump">4,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 5.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 5.96<span></span>
</td>
<td class="nump">$ 5.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward', window );"><strong>Weighted- Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights', window );">Balance</a></td>
<td class="text">6 months 7 days<span></span>
</td>
<td class="text">9 months 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights', window );">Beginning balance</a></td>
<td class="nump">$ 273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights', window );">Ending balance</a></td>
<td class="nump">$ 156<span></span>
</td>
<td class="nump">$ 273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Securities Canceled In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Securities Exercised In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Securities Granted In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Outstanding [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Weighted- Average Remaining Contractual Term Of Warrants Or Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Weighted-Average Remaining Contractual Term Of Warrants Or Rights [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514827247904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock-Based Compensation - Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares of Stock under Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">24,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">9,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares)</a></td>
<td class="num">(1,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">32,013<span></span>
</td>
<td class="nump">24,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and exercisable (in shares)</a></td>
<td class="nump">9,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 3.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in dollars per share)</a></td>
<td class="nump">3.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">2.80<span></span>
</td>
<td class="nump">$ 3.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and exercisable (in dollars per share)</a></td>
<td class="nump">$ 3.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward', window );"><strong>Weighted- Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (in years)</a></td>
<td class="text">8 years 10 months 2 days<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable (in years)</a></td>
<td class="text">7 years 10 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Beginning balance</a></td>
<td class="nump">$ 2,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Ending balance</a></td>
<td class="nump">1,147<span></span>
</td>
<td class="nump">$ 2,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested and exercisable</a></td>
<td class="nump">$ 892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514830970496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock-Based Compensation - Recognized Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,882<span></span>
</td>
<td class="nump">$ 5,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=bngo_CostOfProductRevenueMember', window );">Cost of product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=bngo_CostOfServiceAndOtherRevenueMember', window );">Cost of service and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,357<span></span>
</td>
<td class="nump">3,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,379<span></span>
</td>
<td class="nump">$ 1,774<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=bngo_CostOfProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=bngo_CostOfProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=bngo_CostOfServiceAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=bngo_CostOfServiceAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514837075120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock-Based Compensation - Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">72.70%<span></span>
</td>
<td class="nump">70.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514830629424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock-Based Compensation - Restricted Stock and Performance Stock Activity (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Units granted (in shares) | shares</a></td>
<td class="nump">2,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released (in shares) | shares</a></td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">2,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">1.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released (in dollars per share) | $ / shares</a></td>
<td class="nump">4.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">1.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bngo_PerformanceShareUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Units granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bngo_PerformanceShareUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bngo_PerformanceShareUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514830971792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Undiscounted Future Non-Cancellable Lease Payments Under Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">$ 1,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">2,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">2,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future lease payments</a></td>
<td class="nump">8,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(1,120)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">7,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_FinanceLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">5,594<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future lease payments</a></td>
<td class="nump">7,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(3,313)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 3,894<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_FinanceLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Liability, to be Paid, after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_FinanceLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514831102640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Narrative (Details) - Purigen<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration transferred in acquisition</a></td>
<td class="nump">$ 32,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Consideration milestone payment, maximum</a></td>
<td class="nump">32,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_BusinessAcquisitionCashHeldInEscrowFund', window );">Cash held in escrow fund</a></td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_PurigenMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_PurigenMember', window );">Tradename</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_PurigenMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_BusinessAcquisitionCashHeldInEscrowFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Cash Held in Escrow Fund</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_BusinessAcquisitionCashHeldInEscrowFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_PurigenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_PurigenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514833103168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Acquisition Purchase Price (Details) - Purigen<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="nump">$ 32,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Estimated fair value of milestone consideration</a></td>
<td class="nump">12,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow', window );">Estimated return of cash to buyer from escrow</a></td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total estimated purchase price</a></td>
<td class="nump">$ 44,914<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Estimated Return of Cash to Buyer from Escrow</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_PurigenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_PurigenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514830583728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Fair Value of Tangible and Identifiable Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 77,289<span></span>
</td>
<td class="nump">$ 77,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_PurigenMember', window );">Purigen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash &amp; cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities', window );">Accounts payable and other accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,152)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent', window );">Operating lease liability (short-term and long-term)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,636)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,914<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable and Other Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liability Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_PurigenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_PurigenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514826341536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Identifiable Intangible Assets (Details) - Purigen<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_PurigenMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="nump">18,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_PurigenMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_PurigenMember', window );">Tradename</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_PurigenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_PurigenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514833565824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Pro Forma Information (Details) - Purigen<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Revenue | $</a></td>
<td class="nump">$ 6,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss | $</a></td>
<td class="num">$ (32,048)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Basic net loss per share (in dollars per share) | $ / shares</a></td>
<td class="num">$ (0.11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted', window );">Diluted net loss per share (in dollars per share) | $ / shares</a></td>
<td class="num">$ (0.11)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_PurigenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_PurigenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514826596944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments and Fair Value Measurements - Financial Assets and Liabilities (Details) - Fair Value, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="nump">$ 23,141<span></span>
</td>
<td class="nump">$ 22,352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Total investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">91,704<span></span>
</td>
<td class="nump">108,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Total investments | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">15,216<span></span>
</td>
<td class="nump">20,020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Total investments | Corporate notes/bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">74,500<span></span>
</td>
<td class="nump">86,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Total investments | Securities of government sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">1,988<span></span>
</td>
<td class="nump">1,981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">1,868<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Total investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Total investments | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Total investments | Corporate notes/bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Total investments | Securities of government sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">1,868<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Total investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">91,704<span></span>
</td>
<td class="nump">108,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Total investments | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">15,216<span></span>
</td>
<td class="nump">20,020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Total investments | Corporate notes/bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">74,500<span></span>
</td>
<td class="nump">86,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Total investments | Securities of government sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">1,988<span></span>
</td>
<td class="nump">1,981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="nump">23,141<span></span>
</td>
<td class="nump">22,352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Total investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Total investments | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Total investments | Corporate notes/bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Total investments | Securities of government sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=bngo_ContingentConsiderationLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=bngo_ContingentConsiderationLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=bngo_CorporateNotesAndBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=bngo_CorporateNotesAndBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514826355008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments and Fair Value Measurements - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>security</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of securities in an unrealized loss position, less than 12 months | security</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of securities in an unrealized loss position, greater than 12 months | security</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=bngo_ContingentConsiderationLiabilityMember', window );">Contingent consideration | Purigen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh', window );">Consideration milestone payment, maximum</a></td>
<td class="nump">$ 32.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=bngo_ContingentConsiderationLiabilityMember', window );">Contingent consideration | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=bngo_ContingentConsiderationLiabilityMember', window );">Contingent consideration | Measurement Input, Discount Rate | Purigen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=bngo_ContingentConsiderationLiabilityMember', window );">Contingent consideration | Measurement Input, Probability Factor | BioDiscovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_BusinessCombinationContingentConsiderationMilestonePayment', window );">Consideration milestone payment</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=bngo_ContingentConsiderationLiabilityMember', window );">Contingent consideration | Measurement Input, Probability Factor | Purigen | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=bngo_ContingentConsiderationLiabilityMember', window );">Contingent consideration | Measurement Input, Probability Factor | Purigen | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_BusinessCombinationContingentConsiderationMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_BusinessCombinationContingentConsiderationMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=bngo_ContingentConsiderationLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=bngo_ContingentConsiderationLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_PurigenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_PurigenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=bngo_MeasurementInputProbabilityFactorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=bngo_MeasurementInputProbabilityFactorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514827266384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments and Fair Value Measurements - Contingent Consideration Liability (Details) - Contingent consideration<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 22,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Liability recorded as a result of current period acquisition</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in estimated fair value, recorded in selling, general and administrative expenses</a></td>
<td class="nump">789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Cash payments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 23,141<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=bngo_ContingentConsiderationLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=bngo_ContingentConsiderationLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514824994496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments and Fair Value Measurements - Amortized Cost and Unrealized Gains (Losses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Less than 1 year</a></td>
<td class="nump">$ 85,996<span></span>
</td>
<td class="nump">$ 94,914<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total</a></td>
<td class="nump">92,368<span></span>
</td>
<td class="nump">109,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract', window );"><strong>Unrealized Gains</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne', window );">Less than 1 year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_DebtSecuritiesAvailableForSaleUnrealizedGains', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne', window );">Less than 1 year</a></td>
<td class="num">(614)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss', window );">Total</a></td>
<td class="num">(664)<span></span>
</td>
<td class="num">(1,088)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Aggregate Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Less than 1 year</a></td>
<td class="nump">85,382<span></span>
</td>
<td class="nump">93,915<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total</a></td>
<td class="nump">91,704<span></span>
</td>
<td class="nump">108,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Less than 1 year</a></td>
<td class="nump">15,259<span></span>
</td>
<td class="nump">20,093<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract', window );"><strong>Unrealized Gains</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne', window );">Less than 1 year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne', window );">Less than 1 year</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Aggregate Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Less than 1 year</a></td>
<td class="nump">15,216<span></span>
</td>
<td class="nump">20,020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=bngo_CorporateNotesAndBondsMember', window );">Corporate notes/bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Less than 1 year</a></td>
<td class="nump">68,739<span></span>
</td>
<td class="nump">72,823<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">6,372<span></span>
</td>
<td class="nump">14,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract', window );"><strong>Unrealized Gains</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne', window );">Less than 1 year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive', window );">Due after one year through five years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne', window );">Less than 1 year</a></td>
<td class="num">(561)<span></span>
</td>
<td class="num">(911)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive', window );">Due after one year through five years</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Aggregate Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Less than 1 year</a></td>
<td class="nump">68,178<span></span>
</td>
<td class="nump">71,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">6,322<span></span>
</td>
<td class="nump">14,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Less than 1 year</a></td>
<td class="nump">1,998<span></span>
</td>
<td class="nump">1,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract', window );"><strong>Unrealized Gains</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne', window );">Less than 1 year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne', window );">Less than 1 year</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Aggregate Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Less than 1 year</a></td>
<td class="nump">$ 1,988<span></span>
</td>
<td class="nump">$ 1,982<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Unrealized Gain, Maturity, Allocated and Single Maturity Date, After Year One Through Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Unrealized Gain, Maturity, Allocated and Single Maturity Date, Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtSecuritiesAvailableForSaleUnrealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available For Sale, Unrealized Gains</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtSecuritiesAvailableForSaleUnrealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available for Sale, Unrealized Gains</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Unrealized Loss, Maturity, Allocated and Single Maturity Date, After Year One Through Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Unrealized Loss, Maturity, Allocated and Single Maturity Date, Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=bngo_CorporateNotesAndBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=bngo_CorporateNotesAndBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140514826621776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments and Fair Value Measurements - Unrealized Losses Positions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months, Fair Value</a></td>
<td class="nump">$ 28,891<span></span>
</td>
<td class="nump">$ 31,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater, Fair Value</a></td>
<td class="nump">62,813<span></span>
</td>
<td class="nump">74,452<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">91,704<span></span>
</td>
<td class="nump">106,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Gross Unrealized Loss</a></td>
<td class="num">(93)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater, Gross Unrealized Loss</a></td>
<td class="num">(571)<span></span>
</td>
<td class="num">(972)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Securities of government sponsored entities</a></td>
<td class="num">(664)<span></span>
</td>
<td class="num">(1,088)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months, Fair Value</a></td>
<td class="nump">15,216<span></span>
</td>
<td class="nump">20,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">15,216<span></span>
</td>
<td class="nump">20,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Gross Unrealized Loss</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater, Gross Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Securities of government sponsored entities</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=bngo_CorporateNotesAndBondsMember', window );">Corporate notes/bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months, Fair Value</a></td>
<td class="nump">11,687<span></span>
</td>
<td class="nump">9,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater, Fair Value</a></td>
<td class="nump">62,813<span></span>
</td>
<td class="nump">74,452<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">74,500<span></span>
</td>
<td class="nump">84,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Gross Unrealized Loss</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater, Gross Unrealized Loss</a></td>
<td class="num">(571)<span></span>
</td>
<td class="num">(972)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Securities of government sponsored entities</a></td>
<td class="num">(611)<span></span>
</td>
<td class="num">(999)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months, Fair Value</a></td>
<td class="nump">1,988<span></span>
</td>
<td class="nump">1,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">1,988<span></span>
</td>
<td class="nump">1,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Gross Unrealized Loss</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater, Gross Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Securities of government sponsored entities</a></td>
<td class="num">$ (10)<span></span>
</td>
<td class="num">$ (16)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=bngo_CorporateNotesAndBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=bngo_CorporateNotesAndBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>bngo-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bngo="http://bionanogenomics.com/20230331"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bngo-20230331.xsd" xlink:type="simple"/>
    <context id="i60895e78119b46fe84d724fc783d3619_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib13a94b835db433b868b1047f2e0d08c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iad7fb23a31ff4cebb8ed73e94c311b74_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5dffd8e896cf4da18e2a7981e161bfa7_I20230504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2023-05-04</instant>
        </period>
    </context>
    <context id="i62aa37a9d1f149238d68dcecec48dda4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2491644bc39e40a3a0147bbb28e81a57_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i16a495a5dc5b4d72a5d69105c54ed1d5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7ae84972110b4c82abdd96887a8dc98b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i22c603917ec343e5b40cf1377f2dd0fa_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i103e1f66718e42e092ef57cf65cbad93_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id1fe061275f84c0db4bc966cec7ea694_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifebd115420624a60b9827cd166e72988_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifc1dfa094b4c4c1fa40f179234ec50e6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa3c9898447244ed80a321d3bb3f00b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1cca8398bdff4ba383ffbba2ea3b7387_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d8e7646f2804373ac2db3a030f1359c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0cfe18ad0d8e4978ada52e1560b4b9dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i58b67d95244b409ab6ee9c70973a72be_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i081d4286b8024fc38cd6cc1cfb880bac_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib545fe18002040049f1dd40e745063cf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i26505e829d91462f95377df48fcf6c59_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i35bd51c6773a4f30bc0cda985ac95b56_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6ba62f46aa8044098043951d2b4e437f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i20e6f07f9ffb41f3b64c9ac35f75d302_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i17b0d4ea6adf427eb9d4b02037d2964a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i955cc10e676a434da3908ec8ee79b5a0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7e39a84040944ede8fdaa4d1b105ad7a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i49cef66a2bf8465c9be9162628f1973b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i39f18943e70e4009b385fa4e3abd198f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5409b1552b72472894786a349c3cf6ab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i368dfe51ced845ce9ce881dbe02ac125_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6b2f680c76ee497394f0b63f4a9b399a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id4838c75f09847d6962eaee26a7817f1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i85aa7ee73fd04055b335ec2d997a0f0c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6b9c8029a5394f4bafac617b2deb2c22_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2c6f1ced20ec4e9aa8a3fb4827f7be65_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib90ef8426ec84d859ee8b194da09c4eb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic370404fbb3041c6a839fd87ac238005_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i235c6220aed04a31be7cf68dde5f7075_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3ee348f6918a4dccb9a11bb16deb4771_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i80cbed6d5ffd48e39df9647e8b69fd38_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i990b58e8540b402f9deabf1b1e8d0d7a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia5f34adecdf04ebca8394a17d3e26a73_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9ea78ca938894da3a2c044b50e0ecd12_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6fa1ec9e299d43dea83ee07700d9f2e8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4db80e7428124ae89fef6d38056d80eb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4e41522832874c03827a502c55e81ea1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i93dc12a23ca743058cc875c7385cba95_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id2e2589f149c48c98dbde0d23aeb1c9c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:InstrumentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i09f8c8fdda344e15915c6c62c7945dcc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:InstrumentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id6b13878be8b45768ae8ee86b23ec8b8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:ConsumableRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7d3a177eaaa94180a39abb73b6e894d5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:ConsumableRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie5c588f3ec9a49a9926f153fcb7f5e22_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if1dda61a7dbc48e3acfd918b47fcb93b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6669836447414cf385db5ed716981bad_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1b1a8735b85a466297034ff9a73884a0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6f04d40d0a8a454f84a321e4acea14d8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idc3e1023716e476aab35caddbed89579_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if6f8e39f135240fd97ecb419976b9597_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie92600da576c4047864e9f7117cc5fdf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i72bd82e51a92475595d3e02336fdfb2d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibf59dab4a829447b87dd7cfb6e935afc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i917de2a823d54fc7a1e5c49a7ec6d043_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3e339b6ff4f0444a9fc421813ed7f9fc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if817cc0631b9461ca84a6ce880217661_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i16ed69d918584dbcb3ba99cd2e78d70d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iec1a90f2c7e6457d9c6916e2e00a8d96_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if4e04fca88824c018823bdc8633103aa_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4b3236b899344cfc8b2fdf441232a276_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ida637f06483b4c35bd6bc6a61abb2280_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i303c93e0678640749a33b09eedfdd18e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i91fc38e2fd89410d85c4aaa28c03aa5a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i678356c830584df394c07359661df8fe_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i29d038c26e154c959a4f83462f9a3b3d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic21009a40b5d4f3a9d49db39e85d0352_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6b57f1747a864d48806216f6ebcb9b52_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id18ec7102f5243eead2eb22c65c27ed0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1d06ccbd81864c1aa7ab64abb42f4f5c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i30a742016d854b90bc517ceec127c4da_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib5a9db6b0ffb4fe28ef89805f31f26bc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iafccbaea24c04903bdeb891f986857c7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i25be08a217074beba4e4c3f2222e4263_D20210323-20210323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bngo:CowenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-23</startDate>
            <endDate>2021-03-23</endDate>
        </period>
    </context>
    <context id="i97754e6d8ba6487d87fcb2566157286b_D20230309-20230309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bngo:CowenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <context id="i93b42a0d7db1482cba91fd543f66a9ba_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i99f3f173943c45748c287bda013eed0c_I20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="i4be8520461cc4836b2bf1279c0c49b2a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic493e64bbaa14b51affea368a758865b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bngo:CostOfProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i80b89abf30d44e039ce4fc8aeb1da4ae_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bngo:CostOfProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i29ed40c40dab442291465632e6882e02_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bngo:CostOfServiceAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i144c849f01554b1a993c3b250ed79d33_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bngo:CostOfServiceAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7f330defb5aa4fb081aecf68faa28812_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i94ccbf7f373d449baf5526bf6037b3f3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if7a2e48e810643a8b0e555a9c8954d9f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6f37993d3f264fb1b3d0691e711f9da5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i45ddfb39b1e74f6dad0c0bf181cf9a21_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="i649fe5ed0003466fbb184c5508561d25_I20221004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-04</instant>
        </period>
    </context>
    <context id="i9253ac3721c14085873be006d0cf4172_D20221004-20221004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-04</startDate>
            <endDate>2022-10-04</endDate>
        </period>
    </context>
    <context id="ib9d74a66fe4c4a139d49dde0ca471851_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0d6b4ade60694ff6bfb130ce265977e6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i80c9f5e585bc49d69df5c0b0bc90a1dc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0787e57ce57b4647b096721e6444f9b9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bngo:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i230745a88815483fa50ae23b1a6526e9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bngo:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia333c3d4c489480f91a0918cb06c6e33_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bngo:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iecac66c4d00049b992c7f860853fdc4b_D20230215-20230215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-15</startDate>
            <endDate>2023-02-15</endDate>
        </period>
    </context>
    <context id="ibb4acb3d6c734dba8bac4bebe9c2b85d_D20230215-20230215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-15</startDate>
            <endDate>2023-02-15</endDate>
        </period>
    </context>
    <context id="i759bd048bf3e4098b83b5604fbce9f26_D20230215-20230215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-15</startDate>
            <endDate>2023-02-15</endDate>
        </period>
    </context>
    <context id="i22680561557b45ba98cf2f10a2456635_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i38b1d6628a394f1fbbbfd993ec043869_I20230215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-15</instant>
        </period>
    </context>
    <context id="ib50b0f103ebb406f8f4f5c1eef93d1bd_D20230413-20230413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-13</startDate>
            <endDate>2023-04-13</endDate>
        </period>
    </context>
    <context id="ib6be39fe53974c5089ff9986b857d774_I20230413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-13</instant>
        </period>
    </context>
    <context id="iffc1f718b13b4c9abe1418bc8c792699_I20230413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-13</instant>
        </period>
    </context>
    <context id="i6dc9970304de496b885ae5a58e7fedba_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="i210ababbb09845abadbcacdcd33eb108_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="if1b97395b892463d82ebcc58b1fd3f08_I20230413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-13</instant>
        </period>
    </context>
    <context id="i7d2c0cf7229242a88304bb4f867c0c9d_D20221101-20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="i91fff28e789d4fdc80fbfa9100a620b7_I20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="ic97685b2136f4353b8df0de2a7e10ad3_I20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="i295a9a13609e47d0bbdd3fe79bcb04e1_I20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="i925ef02d711544878675a77e949a4453_I20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="i6e35fc0471424eaeb1aa538040aea91e_D20221101-20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="if1dc3f6d0e094c2196112c84227fe802_D20221101-20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="if3a2c1a4485a471c820ca4842e5c1c64_D20221101-20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="i6925d4a44b4d4f8ab1473a6ec01745a1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i15907a4c560a493d87c23e62f68ec83c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id7a4d7a1847949aca50c56b25a88bd21_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i310d4215052d4ca0a49959195011a0ca_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i93d2a3e0250e47bcb4b130e733307695_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i647cc339b7ba4424aa0eb336ee4b0a30_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0f5ab08df5bf405bb9bf921da040bd2d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ice1331001dd149aab4965f0b8b08572c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i75520dd1a92c4e7f98c4a30068aa125f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if7617b2529de45d9b88866d405c216e8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i52aa8a7998954d46afe56844fc671bed_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4c44b89669c84b58ac68a7d82a6f060f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie7b8d23c3c2d432086d989ce0d5b3510_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i773ffb9b71e74f0fbb5045402bab92e2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icfdbb8c8377342dba83719c152d876ca_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i91aa339ce2224ab2b4c95c616a46b05a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7c30654b099944fe816f08038b543686_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i21767da9f078468aaa8154704501d4ef_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if31d69e265f548ce81614232c6d0622e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5dfdfcb6eabc4fdf95b79cf9538f70c7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i62d84f69387345d4810fabcf98a5a295_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i541c9938b3c74107adcc551aaa42ea63_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i98f19aa7ddf044ea8bec0a50eb8c00be_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5b14269404374b769581777b4169a1f0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic18218c1e1fa4ecba456ceeee9c63aff_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6627384d34dc4218abc8ef93db117f35_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i999a70848ee64e86a9903a8300ea18ae_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1ab3ed3cf5644f68a916db4cc62581fe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic17b4d26f18349fbb811e5538089dabe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id843769ea0ce4178b71b8b98c986b0ee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7c33d6de7efe40e2a08f973235f91b19_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8d60828b8d294052882c3b89d2fd9265_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia6001106820441dbaa8649a391b20f27_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id9394339fa2c426f9dac1c7946f4249c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9019ad460da54067a92ced4519dbc280_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7cff04acd40b44bb97ada25f13cf507d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i971953b96b7546e2b31d70534f703931_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ica6f16598c254520b8de2a1aba7fd14f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i04186447695d45da87b4e76c39d70450_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i229abcae1df149319098554f196c3b4a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3d182bb719e0486b93ba7f98d8b1537b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0903ef6ff3f94b54a15562d6f61e5049_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9e330387d6c34591aca484734572ae7d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i042557760bda403e9553e36b701f1ab8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8c398cac425e49a5a91b7758fa11343b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iadf82eab802a4fc0a2d085cc0c3baeae_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieabf435d9321492eb0f1862ccf31dc71_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9d5aec6d9ea84d38855de750ab9fd43e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i01b4a9caaa104277aa2c4a4bb45c1c91_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia6c6c5c8311f41aa99327db95ebffefc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i764a624557c84d788711b6db863a88fa_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bngo:MeasurementInputProbabilityFactorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idf80aacd0d8b4d49bda88deb4fe34f82_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bngo:MeasurementInputProbabilityFactorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id0516c6ac8dd4d63874b612f0c8e9150_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i775844669d9443f18408dc91c0ed82e0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i92407742ad83484e8413c0f98a6ddb72_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bngo:MeasurementInputProbabilityFactorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i026227378deb46939c6b0b7015b7862c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:PurigenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bngo:MeasurementInputProbabilityFactorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0b30d459d41d4643a4ff9a4e0f57f5f7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie44567efb5fb4e42820714c15bc00b89_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i110925712b904ad2ad4771d5056f1576_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1becd5a6f0af415fae96defb606a1b8b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iae48309cf5ff43dda82b169b4c36444e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4118894962b9424d92128e02a9adf2bc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i206731c08e11447b8873b07b61772810_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic2908d99b8fe4704bcd189727c191080_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="installment">
        <measure>bngo:installment</measure>
    </unit>
    <unit id="vote">
        <measure>bngo:vote</measure>
    </unit>
    <unit id="security">
        <measure>bngo:security</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80L2ZyYWc6NjRmM2QxZDE4NWRiNDA0ZDk0NTdiNDk4MDA4ODU2MDIvdGFibGU6ZTQzOWI4ZDNhNmEzNGUxOGJjOGIyMjlkMjY1Mzc4MzIvdGFibGVyYW5nZTplNDM5YjhkM2E2YTM0ZTE4YmM4YjIyOWQyNjUzNzgzMl8xLTEtMS0xLTEwNDExOQ_61000f64-2cb4-4c9b-bbcb-9d97cf4daa12">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80L2ZyYWc6NjRmM2QxZDE4NWRiNDA0ZDk0NTdiNDk4MDA4ODU2MDIvdGFibGU6ZTQzOWI4ZDNhNmEzNGUxOGJjOGIyMjlkMjY1Mzc4MzIvdGFibGVyYW5nZTplNDM5YjhkM2E2YTM0ZTE4YmM4YjIyOWQyNjUzNzgzMl8yLTEtMS0xLTEwNDExOQ_fa704205-dfcb-4d11-9cee-5b3543dd7a0f">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80L2ZyYWc6NjRmM2QxZDE4NWRiNDA0ZDk0NTdiNDk4MDA4ODU2MDIvdGFibGU6ZTQzOWI4ZDNhNmEzNGUxOGJjOGIyMjlkMjY1Mzc4MzIvdGFibGVyYW5nZTplNDM5YjhkM2E2YTM0ZTE4YmM4YjIyOWQyNjUzNzgzMl8zLTEtMS0xLTEwNDExOQ_491aa12e-bd5b-469f-b1f7-1208b8982437">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80L2ZyYWc6NjRmM2QxZDE4NWRiNDA0ZDk0NTdiNDk4MDA4ODU2MDIvdGFibGU6ZTQzOWI4ZDNhNmEzNGUxOGJjOGIyMjlkMjY1Mzc4MzIvdGFibGVyYW5nZTplNDM5YjhkM2E2YTM0ZTE4YmM4YjIyOWQyNjUzNzgzMl80LTEtMS0xLTEwNDExOQ_056fdb3b-b55b-4b44-a5e4-8a4fa731ea50">0001411690</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80L2ZyYWc6NjRmM2QxZDE4NWRiNDA0ZDk0NTdiNDk4MDA4ODU2MDIvdGFibGU6ZTQzOWI4ZDNhNmEzNGUxOGJjOGIyMjlkMjY1Mzc4MzIvdGFibGVyYW5nZTplNDM5YjhkM2E2YTM0ZTE4YmM4YjIyOWQyNjUzNzgzMl81LTEtMS0xLTEwNDExOQ_9ff4e03a-b6e9-4b5a-8e0d-01b094af59d9">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i303c93e0678640749a33b09eedfdd18e_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80My9mcmFnOjEzMThiNmNiNTI0ODQ4NzNhMmNhNjVmOWY5YmQ2NzgyL3RhYmxlOjE2MmZhYjljNjNhNDRlMjQ4YTM3ZWZjY2VkNjI4ZDYxL3RhYmxlcmFuZ2U6MTYyZmFiOWM2M2E0NGUyNDhhMzdlZmNjZWQ2MjhkNjFfMS0xLTEtMS0xMDQxMTk_fd29a88b-a70f-4e22-b59b-5448178ece6f">P9M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i91fc38e2fd89410d85c4aaa28c03aa5a_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80My9mcmFnOjEzMThiNmNiNTI0ODQ4NzNhMmNhNjVmOWY5YmQ2NzgyL3RhYmxlOjE2MmZhYjljNjNhNDRlMjQ4YTM3ZWZjY2VkNjI4ZDYxL3RhYmxlcmFuZ2U6MTYyZmFiOWM2M2E0NGUyNDhhMzdlZmNjZWQ2MjhkNjFfMi0xLTEtMS0xMDQxMTk_88f82a8a-4079-4b02-abee-ff6c0ae4b97d">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i678356c830584df394c07359661df8fe_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80My9mcmFnOjEzMThiNmNiNTI0ODQ4NzNhMmNhNjVmOWY5YmQ2NzgyL3RhYmxlOjE2MmZhYjljNjNhNDRlMjQ4YTM3ZWZjY2VkNjI4ZDYxL3RhYmxlcmFuZ2U6MTYyZmFiOWM2M2E0NGUyNDhhMzdlZmNjZWQ2MjhkNjFfMy0xLTEtMS0xMDgxNTU_b7b9adb6-1813-4d23-8ddb-4d1bb1f4cdf2">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i6dc9970304de496b885ae5a58e7fedba_D20211001-20211031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81NS9mcmFnOjk4ODM0MzdlOGU4NjRjMTBhOTA4YzdlMTg2ZWZkMDNhL3RhYmxlOjQxYmFmMDc2NzYwNDQ1NGRiOTA4NWE3ZGU4YzVhNmFmL3RhYmxlcmFuZ2U6NDFiYWYwNzY3NjA0NDU0ZGI5MDg1YTdkZThjNWE2YWZfMC0xLTEtMS0xMDQxMTk_20fb25ee-20e7-4924-b66c-7321167e7608"
      unitRef="number">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i210ababbb09845abadbcacdcd33eb108_D20211001-20211031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81NS9mcmFnOjk4ODM0MzdlOGU4NjRjMTBhOTA4YzdlMTg2ZWZkMDNhL3RhYmxlOjQxYmFmMDc2NzYwNDQ1NGRiOTA4NWE3ZGU4YzVhNmFmL3RhYmxlcmFuZ2U6NDFiYWYwNzY3NjA0NDU0ZGI5MDg1YTdkZThjNWE2YWZfMS0xLTEtMS0xMDQxMTk_f3e615dc-e222-41d2-a3a0-2552088587c9"
      unitRef="number">0.08</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <bngo:StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent
      contextRef="if1b97395b892463d82ebcc58b1fd3f08_I20230413"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81NS9mcmFnOjk4ODM0MzdlOGU4NjRjMTBhOTA4YzdlMTg2ZWZkMDNhL3RhYmxlOjQxYmFmMDc2NzYwNDQ1NGRiOTA4NWE3ZGU4YzVhNmFmL3RhYmxlcmFuZ2U6NDFiYWYwNzY3NjA0NDU0ZGI5MDg1YTdkZThjNWE2YWZfMi0xLTEtMS0xMTQ5NDY_bb5867f5-8ee8-498b-b493-3e0ce98e0979"
      unitRef="number">0.33</bngo:StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent>
    <dei:DocumentType
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGV4dHJlZ2lvbjo3ODkxNDRkZGE0Y2Q0NTM0YmY1OWM2NjU1NzBlNDk1Y18yMTgy_733965a0-88d5-44d9-9030-a46fd81f275c">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6MWE2OWM3NDg4OWQzNGJmYTk5OTFlMWFkY2YwOTIwMDkvdGFibGVyYW5nZToxYTY5Yzc0ODg5ZDM0YmZhOTk5MWUxYWRjZjA5MjAwOV8wLTAtMS0xLTEwNDExOQ_865e09a2-433b-417a-a7a6-9520f6da4308">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGV4dHJlZ2lvbjo3ODkxNDRkZGE0Y2Q0NTM0YmY1OWM2NjU1NzBlNDk1Y18yNDk_1d030a01-5af2-4d13-b0d8-106ad617ee7e">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6ZDI0NWE4NzFkYWI4NGQyN2I2NGY2MGRiNzhkMjEwNGMvdGFibGVyYW5nZTpkMjQ1YTg3MWRhYjg0ZDI3YjY0ZjYwZGI3OGQyMTA0Y18wLTAtMS0xLTEwNDExOQ_5e4da987-ab28-44f9-9e77-e5da3500af19">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGV4dHJlZ2lvbjo3ODkxNDRkZGE0Y2Q0NTM0YmY1OWM2NjU1NzBlNDk1Y18yMTg2_415b3a18-1225-4252-ab1f-545e53779bc7">001-38613</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGV4dHJlZ2lvbjo3ODkxNDRkZGE0Y2Q0NTM0YmY1OWM2NjU1NzBlNDk1Y18yMTc4_abadb48f-b319-44a8-9f65-6088873a0de8">Bionano Genomics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6NWM0MWE3M2NhYTU0NDY5ZDliYTM2ZDBiYTIzYjk2ZjUvdGFibGVyYW5nZTo1YzQxYTczY2FhNTQ0NjlkOWJhMzZkMGJhMjNiOTZmNV8wLTAtMS0xLTEwNDExOQ_449550e7-0aa7-41eb-92e1-ba5836cfd901">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6NWM0MWE3M2NhYTU0NDY5ZDliYTM2ZDBiYTIzYjk2ZjUvdGFibGVyYW5nZTo1YzQxYTczY2FhNTQ0NjlkOWJhMzZkMGJhMjNiOTZmNV8wLTItMS0xLTEwNDExOQ_f415659f-7689-4b3b-aa8e-cc0e5cdf077e">26-1756290</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6NWM0MWE3M2NhYTU0NDY5ZDliYTM2ZDBiYTIzYjk2ZjUvdGFibGVyYW5nZTo1YzQxYTczY2FhNTQ0NjlkOWJhMzZkMGJhMjNiOTZmNV8zLTAtMS0xLTEwNDExOS90ZXh0cmVnaW9uOmE4NTQ2MDJhMmYyZjRiNTE5NjA1ODI3MDk0ZmU5Mzg2XzQ_25470da6-3c68-4fca-9318-0526b99ef8d6">9540 Towne Centre Drive, Suite 100</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6NWM0MWE3M2NhYTU0NDY5ZDliYTM2ZDBiYTIzYjk2ZjUvdGFibGVyYW5nZTo1YzQxYTczY2FhNTQ0NjlkOWJhMzZkMGJhMjNiOTZmNV8zLTAtMS0xLTEwNDExOS90ZXh0cmVnaW9uOmE4NTQ2MDJhMmYyZjRiNTE5NjA1ODI3MDk0ZmU5Mzg2Xzg_34bd8179-8085-43af-bb02-27ee784128a8">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6NWM0MWE3M2NhYTU0NDY5ZDliYTM2ZDBiYTIzYjk2ZjUvdGFibGVyYW5nZTo1YzQxYTczY2FhNTQ0NjlkOWJhMzZkMGJhMjNiOTZmNV8zLTAtMS0xLTEwNDExOS90ZXh0cmVnaW9uOmE4NTQ2MDJhMmYyZjRiNTE5NjA1ODI3MDk0ZmU5Mzg2XzEy_8a7db2c9-6b9d-4f1e-8b7d-2c56c2af8bc9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6NWM0MWE3M2NhYTU0NDY5ZDliYTM2ZDBiYTIzYjk2ZjUvdGFibGVyYW5nZTo1YzQxYTczY2FhNTQ0NjlkOWJhMzZkMGJhMjNiOTZmNV8zLTItMS0xLTEwNDExOQ_4238961a-ff50-460b-9ef8-dd5c094fe364">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGV4dHJlZ2lvbjo3ODkxNDRkZGE0Y2Q0NTM0YmY1OWM2NjU1NzBlNDk1Y18yMTg3_dd46718a-0845-4909-8a93-53c5a9f28b38">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGV4dHJlZ2lvbjo3ODkxNDRkZGE0Y2Q0NTM0YmY1OWM2NjU1NzBlNDk1Y18yMTg0_1b365d1e-8080-4f48-99db-931288f0f498">888-7600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ib13a94b835db433b868b1047f2e0d08c_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6Y2E0NzU2ZTY4YzYwNDM2NDk3YWM0YTg0NmM1M2U1MjUvdGFibGVyYW5nZTpjYTQ3NTZlNjhjNjA0MzY0OTdhYzRhODQ2YzUzZTUyNV8xLTAtMS0xLTEwNDExOQ_0fed4ee9-9791-4bed-8a2b-904625543ebb">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib13a94b835db433b868b1047f2e0d08c_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6Y2E0NzU2ZTY4YzYwNDM2NDk3YWM0YTg0NmM1M2U1MjUvdGFibGVyYW5nZTpjYTQ3NTZlNjhjNjA0MzY0OTdhYzRhODQ2YzUzZTUyNV8xLTItMS0xLTEwNDExOQ_6d07523a-b55b-4fff-be97-a79f34d5a068">BNGO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib13a94b835db433b868b1047f2e0d08c_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6Y2E0NzU2ZTY4YzYwNDM2NDk3YWM0YTg0NmM1M2U1MjUvdGFibGVyYW5nZTpjYTQ3NTZlNjhjNjA0MzY0OTdhYzRhODQ2YzUzZTUyNV8xLTQtMS0xLTEwNDExOQ_2043db07-26e9-4c8c-a9e0-2f7397d3d965">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="iad7fb23a31ff4cebb8ed73e94c311b74_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6Y2E0NzU2ZTY4YzYwNDM2NDk3YWM0YTg0NmM1M2U1MjUvdGFibGVyYW5nZTpjYTQ3NTZlNjhjNjA0MzY0OTdhYzRhODQ2YzUzZTUyNV8yLTAtMS0xLTEwNDExOQ_2a3882b2-542e-4def-bd18-aa12dc730945">Warrants to purchase Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iad7fb23a31ff4cebb8ed73e94c311b74_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6Y2E0NzU2ZTY4YzYwNDM2NDk3YWM0YTg0NmM1M2U1MjUvdGFibGVyYW5nZTpjYTQ3NTZlNjhjNjA0MzY0OTdhYzRhODQ2YzUzZTUyNV8yLTItMS0xLTEwNDExOQ_4d6c5344-827d-4e17-a452-a742459cdd71">BNGOW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iad7fb23a31ff4cebb8ed73e94c311b74_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6Y2E0NzU2ZTY4YzYwNDM2NDk3YWM0YTg0NmM1M2U1MjUvdGFibGVyYW5nZTpjYTQ3NTZlNjhjNjA0MzY0OTdhYzRhODQ2YzUzZTUyNV8yLTQtMS0xLTEwNDExOQ_a74585d4-7f92-43bd-bbcc-54c427e4dcc6">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGV4dHJlZ2lvbjo3ODkxNDRkZGE0Y2Q0NTM0YmY1OWM2NjU1NzBlNDk1Y18yMTc5_89bf60a1-3407-46b2-ba51-42083e54fd62">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGV4dHJlZ2lvbjo3ODkxNDRkZGE0Y2Q0NTM0YmY1OWM2NjU1NzBlNDk1Y18yMTgw_c299ebbc-b43b-4f9c-a85f-9fb26355b072">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6YWM1OTZjZDBkYmRhNGU4OWI2OGJmOTZjMjVhMDBiMmIvdGFibGVyYW5nZTphYzU5NmNkMGRiZGE0ZTg5YjY4YmY5NmMyNWEwMGIyYl8xLTAtMS0xLTEwNzY0Nw_b650adc4-d62c-438a-aa7a-fb5af4ac114b">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6YWM1OTZjZDBkYmRhNGU4OWI2OGJmOTZjMjVhMDBiMmIvdGFibGVyYW5nZTphYzU5NmNkMGRiZGE0ZTg5YjY4YmY5NmMyNWEwMGIyYl8xLTQtMS0xLTEwNDExOQ_1a494c83-942e-44e4-8186-316008790dcd">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGFibGU6YWM1OTZjZDBkYmRhNGU4OWI2OGJmOTZjMjVhMDBiMmIvdGFibGVyYW5nZTphYzU5NmNkMGRiZGE0ZTg5YjY4YmY5NmMyNWEwMGIyYl8yLTQtMS0xLTEwNDExOQ_26e1ab56-8093-4f8f-b74e-36e8abe3f60c">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGV4dHJlZ2lvbjo3ODkxNDRkZGE0Y2Q0NTM0YmY1OWM2NjU1NzBlNDk1Y18yMTgx_e53e3efc-2a4c-4999-b837-ff944eadce17">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i5dffd8e896cf4da18e2a7981e161bfa7_I20230504"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xL2ZyYWc6Nzg5MTQ0ZGRhNGNkNDUzNGJmNTljNjY1NTcwZTQ5NWMvdGV4dHJlZ2lvbjo3ODkxNDRkZGE0Y2Q0NTM0YmY1OWM2NjU1NzBlNDk1Y18yMTE3_f6a46532-fac8-49df-b1ef-707723c5c156"
      unitRef="shares">306790214</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNC0xLTEtMS0xMDQxMTk_61d44e34-766a-4455-ab02-717d1d474515"
      unitRef="usd">4104000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNC0zLTEtMS0xMDQxMTk_82c734ae-7db9-46b9-a468-fdf102703dc3"
      unitRef="usd">5091000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNS0xLTEtMS0xMDQxMTk_9affae1a-d6a2-4f63-a031-3853d87b5ac1"
      unitRef="usd">91704000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNS0zLTEtMS0xMDQxMTk_a2f3bdfc-134d-4afe-947a-bd3b588d7073"
      unitRef="usd">108095000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNi0xLTEtMS0xMDQxMTk_3b4d9a67-6a56-423e-b0ed-d1deca65241f"
      unitRef="usd">6780000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNi0zLTEtMS0xMDQxMTk_53be7f54-5f84-4cbc-a9dc-62220bcd7f29"
      unitRef="usd">7022000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNy0xLTEtMS0xMDQxMTk_c8a12eb9-5da2-47ce-a036-2836e286706e"
      unitRef="usd">33113000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNy0zLTEtMS0xMDQxMTk_efcd008d-28a2-4879-be60-07c3ffbb43ec"
      unitRef="usd">29761000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfOC0xLTEtMS0xMDQxMTk_5efa63d8-f3b3-4769-ad3b-f3699858ec83"
      unitRef="usd">6856000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfOC0zLTEtMS0xMDQxMTk_e5e94b00-050c-49b6-9136-f519459c028e"
      unitRef="usd">7329000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfOS0xLTEtMS0xMDQxMTk_18e6b583-9add-4db8-9105-7c7c9733c946"
      unitRef="usd">142557000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfOS0zLTEtMS0xMDQxMTk_55302fe7-360e-45bb-b582-b7f2803b67be"
      unitRef="usd">157298000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTAtMS0xLTEtMTA0ODQ3_8c69dfb0-b631-48c4-abbd-1ff4f26245c6"
      unitRef="usd">400000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTAtMy0xLTEtMTA0ODQw_c6bd7785-5ce2-44b5-8ab4-3544138e6ca1"
      unitRef="usd">400000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTAtMS0xLTEtMTA0MTE5_163cd5f1-06b0-4e05-a541-b61fe7346ee4"
      unitRef="usd">19050000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTAtMy0xLTEtMTA0MTE5_6007f50c-2d3f-4d33-9757-b60f6396ca38"
      unitRef="usd">18029000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTEtMS0xLTEtMTA0MTE5_58bfc0cc-0259-4da1-9c38-6860b7ab4b06"
      unitRef="usd">7062000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTEtMy0xLTEtMTA0MTE5_ddd01b0b-fcfc-4525-9161-27260e13cb70"
      unitRef="usd">7222000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTItMS0xLTEtMTA0MTE5_d28e2169-5226-4d54-9e4a-b75a24304906"
      unitRef="usd">3657000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTItMy0xLTEtMTA0MTE5_d4357e95-fe03-4a3f-8950-329e6989e122"
      unitRef="usd">3707000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTMtMS0xLTEtMTA0MTE5_fc670850-b190-4e59-b100-a8e253d47679"
      unitRef="usd">39351000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTMtMy0xLTEtMTA0MTE5_f59ba500-c10a-49a8-88d0-2b5f1513c4d5"
      unitRef="usd">41143000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTQtMS0xLTEtMTA0MTE5_bd62dc01-6895-4c88-a677-091239f52b7c"
      unitRef="usd">77289000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTQtMy0xLTEtMTA0MTE5_afb3b4e8-5268-44e2-8893-c3558d005478"
      unitRef="usd">77289000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTUtMS0xLTEtMTA0MTE5_ab50a950-1060-40bb-a880-859904b885ba"
      unitRef="usd">2785000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTUtMy0xLTEtMTA0MTE5_0dcca78d-0af4-4413-b12c-59a4ce3f2f66"
      unitRef="usd">2414000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTYtMS0xLTEtMTA0MTE5_a90d6607-506e-42e5-90d7-4a660f4be109"
      unitRef="usd">292151000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMTYtMy0xLTEtMTA0MTE5_4e9a04d7-be91-402f-aad0-13e9916393cc"
      unitRef="usd">307502000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjAtMS0xLTEtMTA0MTE5_1d448941-9574-493a-9034-b62f494dbb89"
      unitRef="usd">15780000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjAtMy0xLTEtMTA0MTE5_a904dd0b-4055-4706-bd5e-069fa1567275"
      unitRef="usd">12534000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjEtMS0xLTEtMTA0MTE5_6950166d-5ac6-465b-b31b-9201437b9f8e"
      unitRef="usd">9250000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjEtMy0xLTEtMTA0MTE5_14ba3272-52e9-4151-9c7e-eedd45cde9bf"
      unitRef="usd">10552000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjItMS0xLTEtMTA0MTE5_d6cee479-8e17-4a87-8b6b-94a7c0bf56fd"
      unitRef="usd">1127000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjItMy0xLTEtMTA0MTE5_50bad892-61b3-4430-8dee-a88e549ca12e"
      unitRef="usd">871000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjQtMS0xLTEtMTA0MTE5_ade55ac2-2137-4f27-adff-176c0a3b3b98"
      unitRef="usd">2235000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjQtMy0xLTEtMTA0MTE5_1bc73140-9278-4258-aa31-367f2b23ae01"
      unitRef="usd">2260000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjUtMS0xLTEtMTA0MTE5_d5e316af-6e33-444b-8674-b8818103e485"
      unitRef="usd">282000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjUtMy0xLTEtMTA0MTE5_2e06372f-c8ab-4fb3-8974-46e98e752f7c"
      unitRef="usd">285000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjYtMS0xLTEtMTA0MTE5_aca63530-cd16-41c0-84fb-d26659edb32e"
      unitRef="usd">9461000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjYtMy0xLTEtMTA0MTE5_fa9adde1-4344-49af-859b-667b8b46450a"
      unitRef="usd">9382000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjctMS0xLTEtMTA0MTE5_aaf19441-8399-411b-962b-c3de2875b946"
      unitRef="usd">38135000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjctMy0xLTEtMTA0MTE5_46d9d5cd-9937-4f55-8401-193104fa2c5c"
      unitRef="usd">35884000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjgtMS0xLTEtMTA0MTE5_dd86d7e8-69b5-4575-967b-68772dab4b80"
      unitRef="usd">5043000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjgtMy0xLTEtMTA0MTE5_e1eaf2cc-0b76-4ab0-8f62-3dfe46f81ead"
      unitRef="usd">5504000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjktMS0xLTEtMTA0MTE5_5fdd6872-3ee1-4544-abd6-518b904a8810"
      unitRef="usd">3612000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMjktMy0xLTEtMTA0MTE5_69df39a2-4029-4391-b181-c3a12163d79a"
      unitRef="usd">3619000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMzAtMS0xLTEtMTA0MTE5_264613d8-8b91-42c0-9a26-0992937f924f"
      unitRef="usd">13680000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMzAtMy0xLTEtMTA0MTE5_c877c976-b3d6-40e3-bc0a-a86fb0be7c40"
      unitRef="usd">12970000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMzItMS0xLTEtMTA0MTE5_d51e85f9-3157-4b26-b60c-a07bb2fc33c5"
      unitRef="usd">194000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMzItMy0xLTEtMTA0MTE5_31c59a0b-4400-46d4-990a-a3fdc00215d8"
      unitRef="usd">127000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMzQtMS0xLTEtMTA0MTE5_9ff913c5-9e92-4542-b598-b696e037ae36"
      unitRef="usd">60664000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMzQtMy0xLTEtMTA0MTE5_aebeb20f-ad86-4d42-bb75-680a706d061b"
      unitRef="usd">58104000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMzUtMS0xLTEtMTA0MTE5_8692d9fe-30ce-482e-b4bd-7f16522d50a4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfMzUtMy0xLTEtMTA0MTE5_23859748-73ba-4894-9de1-dbbc33aef79f"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i16a495a5dc5b4d72a5d69105c54ed1d5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDMtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246NDYzMzU4YzhkOTczNGIzYTgzNDIwNjRhOTQwMTMwZjVfMjI_943b55b9-1de6-4d91-9607-ed93a316da90"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i7ae84972110b4c82abdd96887a8dc98b_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDMtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246NDYzMzU4YzhkOTczNGIzYTgzNDIwNjRhOTQwMTMwZjVfMjI_a8b560c7-cc2f-4d4f-8627-3154a377a804"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDMtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246NDYzMzU4YzhkOTczNGIzYTgzNDIwNjRhOTQwMTMwZjVfMzY_061c402a-6a33-434a-9ea8-c3806e070971"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDMtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246NDYzMzU4YzhkOTczNGIzYTgzNDIwNjRhOTQwMTMwZjVfMzY_38d49c24-e0d8-460d-bfea-acebebdd06df"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDMtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246NDYzMzU4YzhkOTczNGIzYTgzNDIwNjRhOTQwMTMwZjVfNjE_34f3aaa3-8ba9-4dc0-af84-4de6557c2200"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDMtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246NDYzMzU4YzhkOTczNGIzYTgzNDIwNjRhOTQwMTMwZjVfNjE_ace255fd-8565-448c-a188-a969cc7c7579"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDMtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246NDYzMzU4YzhkOTczNGIzYTgzNDIwNjRhOTQwMTMwZjVfNjE_b2255d4d-09dd-4ce0-aeea-86c7c94758d8"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDMtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246NDYzMzU4YzhkOTczNGIzYTgzNDIwNjRhOTQwMTMwZjVfNjE_c8548c4e-43f9-4fcb-b3a6-744baca7745c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDMtMS0xLTEtMTA0MTE5_44b861db-fd25-49e4-8bc3-ccf40a717bfe"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDMtMy0xLTEtMTA0MTE5_7dc6a2d6-9632-43c2-9e0b-908743dde704"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDQtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246ZjM4Y2NiMjc0NDI1NGQ0MzgyMTllN2ZjNjFjM2MxYTVfMTg_9d5bd003-1fe6-4638-8668-a8c1266b9c59"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDQtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246ZjM4Y2NiMjc0NDI1NGQ0MzgyMTllN2ZjNjFjM2MxYTVfMTg_ba71d0a1-6f99-45d0-9f06-e51a69b6de81"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDQtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246ZjM4Y2NiMjc0NDI1NGQ0MzgyMTllN2ZjNjFjM2MxYTVfMzI_01313144-fe76-4aae-8451-ea3b40c2c838"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDQtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246ZjM4Y2NiMjc0NDI1NGQ0MzgyMTllN2ZjNjFjM2MxYTVfMzI_ac174c58-c0c8-4bfe-8ced-1237104a5d05"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDQtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246ZjM4Y2NiMjc0NDI1NGQ0MzgyMTllN2ZjNjFjM2MxYTVfNjc_014f57fa-4d5e-48fc-a66c-117d5505c51e"
      unitRef="shares">306790000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDQtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246ZjM4Y2NiMjc0NDI1NGQ0MzgyMTllN2ZjNjFjM2MxYTVfNjc_f7249bdb-ef4c-461d-b77e-5fb6d939a3ec"
      unitRef="shares">306790000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDQtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246ZjM4Y2NiMjc0NDI1NGQ0MzgyMTllN2ZjNjFjM2MxYTVfNzQ_3d5e9f53-a648-461e-b6bb-7038e2f6452f"
      unitRef="shares">297183000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDQtMC0xLTEtMTA0MTE5L3RleHRyZWdpb246ZjM4Y2NiMjc0NDI1NGQ0MzgyMTllN2ZjNjFjM2MxYTVfNzQ_b250958d-e38d-4ad6-a13e-93f853486722"
      unitRef="shares">297183000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDQtMS0xLTEtMTA0MTE5_e7161c77-d7d3-439e-8cba-8352ab4b8a1b"
      unitRef="usd">31000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDQtMy0xLTEtMTA0MTE5_7ea3d474-e08b-4637-a980-0e37ada1e9b1"
      unitRef="usd">30000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDUtMS0xLTEtMTA0MTE5_950150d2-122f-4e4b-a63e-4c772a3db93d"
      unitRef="usd">617960000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDUtMy0xLTEtMTA0MTE5_f24f9fba-71a5-4f4d-9db8-82bdcad5f39d"
      unitRef="usd">599207000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDYtMS0xLTEtMTA0MTE5_4f759be9-8930-4018-bbf9-6cb15bd87139"
      unitRef="usd">-385839000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDYtMy0xLTEtMTA0MTE5_3b1e844c-9254-4528-99c4-85e27c7d37eb"
      unitRef="usd">-348715000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDctMS0xLTEtMTA0MTE5_7411d118-aba8-4f41-85b3-92b463365621"
      unitRef="usd">-665000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDctMy0xLTEtMTA0MTE5_6300c14b-2ea3-4a80-90ba-f73e62a187f3"
      unitRef="usd">-1124000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDgtMS0xLTEtMTA0MTE5_f8c10a38-0e26-4d83-addd-c1739814c42f"
      unitRef="usd">231487000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDgtMy0xLTEtMTA0MTE5_4a6d0f16-d5c3-424e-a34d-58bede4456eb"
      unitRef="usd">249398000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDktMS0xLTEtMTA0MTE5_d48570a5-7023-48ea-bc63-a61438f1d7af"
      unitRef="usd">292151000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xNi9mcmFnOjBiYjUzNTNjNmRkMDQ3M2JiNDZmOGZmZmRmYTZmZDkyL3RhYmxlOmU5OGUzMmVkNjU1YTRiNWNhMzM0OWZmZTQwNTI0NzJhL3RhYmxlcmFuZ2U6ZTk4ZTMyZWQ2NTVhNGI1Y2EzMzQ5ZmZlNDA1MjQ3MmFfNDktMy0xLTEtMTA0MTE5_65351b0e-c6f5-4dab-92e1-7943809654b7"
      unitRef="usd">307502000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22c603917ec343e5b40cf1377f2dd0fa_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMy05LTEtMS0xMDQxMTk_e98e4b0b-6cbb-4b7a-8a59-208a5030900e"
      unitRef="usd">5447000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i103e1f66718e42e092ef57cf65cbad93_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMy03LTEtMS0xMDU0MzU_b78ab7f8-9302-46b1-be43-59ffa4f46494"
      unitRef="usd">4206000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1fe061275f84c0db4bc966cec7ea694_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfNC05LTEtMS0xMDQxMTk_722cc110-2a97-48d4-b8c3-e314e8869b52"
      unitRef="usd">1968000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifebd115420624a60b9827cd166e72988_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfNC03LTEtMS0xMDU0MzU_576c871d-efbc-4795-abe2-2eaa20a9846d"
      unitRef="usd">1490000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfNS05LTEtMS0xMDQxMTk_fdc4d68c-546b-4eb8-8cfd-29324d48c6f7"
      unitRef="usd">7415000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfNS0xMS0xLTEtMTA0MTE5_0d4b30a9-be47-4790-9877-195b4d848214"
      unitRef="usd">5696000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i22c603917ec343e5b40cf1377f2dd0fa_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfNy05LTEtMS0xMDQxMTk_cbcad507-ab44-4d99-9f8a-8413941bb4cd"
      unitRef="usd">3858000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i103e1f66718e42e092ef57cf65cbad93_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfNy03LTEtMS0xMDU0Mzg_c85266b3-320f-4d1f-8466-e3706f6c7b80"
      unitRef="usd">3576000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id1fe061275f84c0db4bc966cec7ea694_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfOC05LTEtMS0xMDQxMTk_5829ca04-a251-48a6-a8c9-cbaee4b9b8b7"
      unitRef="usd">1487000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ifebd115420624a60b9827cd166e72988_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfOC03LTEtMS0xMDU0Mzg_c550ccbe-f3b5-4989-b760-002785a79e5b"
      unitRef="usd">1259000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfOS05LTEtMS0xMDQxMTk_4fb287c5-f062-4d25-b135-ce8a7f07c5c3"
      unitRef="usd">5345000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfOS0xMS0xLTEtMTA0MTE5_bd99d4bb-633f-4b8a-ad30-87c01732db82"
      unitRef="usd">4835000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTEtOS0xLTEtMTA0MTE5_bb320709-b94d-4575-ba57-55bf8b33a375"
      unitRef="usd">13937000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTEtNy0xLTEtMTA1NDQx_47fbcbe4-1d6c-4391-98ea-2d1425cef3b4"
      unitRef="usd">10527000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTItOS0xLTEtMTA0MTE5_3108cc48-2e86-46c4-8f84-6fef55ec805d"
      unitRef="usd">25976000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTItNy0xLTEtMTA1NDQx_28d35e5a-c95b-4bfc-aaa8-a196c5a00e59"
      unitRef="usd">20277000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTMtOS0xLTEtMTA0MTE5_0f24aa18-52b4-4b11-bb98-3a9ae055dff5"
      unitRef="usd">39913000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTMtMTEtMS0xLTEwNDExOQ_3bbeb88a-2ce8-4a15-abd4-225f121bf3af"
      unitRef="usd">30804000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTQtOS0xLTEtMTA0MTE5_524dc2b0-01d6-460b-b40b-f11a94eee336"
      unitRef="usd">-37843000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTQtMTEtMS0xLTEwNDExOQ_2f15408c-b894-4810-90a0-f28381eaa795"
      unitRef="usd">-29943000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTYtNS0xLTEtMTA1NDE5_43a4f058-2f5d-4f73-8b40-443eb140baca"
      unitRef="usd">704000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTYtNy0xLTEtMTA1NDQ0_dae011f0-1099-4930-a42d-4d7f81e0d4bf"
      unitRef="usd">110000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestExpense
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTctOS0xLTEtMTA0MTE5_745bf3fd-c6ab-47a3-8ff2-b2496395521d"
      unitRef="usd">76000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTctNy0xLTEtMTA1NDQ0_8dbe628e-a811-402c-bb18-148adeee5768"
      unitRef="usd">77000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjAtOS0xLTEtMTA0MTE5_0f0c621f-5785-4673-9ab1-8640a1718290"
      unitRef="usd">117000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMTgtNy0xLTEtMTA1NDQ0_64417253-27ad-448e-b704-c0ec400cf269"
      unitRef="usd">-33000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjEtOS0xLTEtMTA0MTE5_16c62ef8-caaf-4326-b0fe-ecb8fcd65094"
      unitRef="usd">745000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjEtMTEtMS0xLTEwNDExOQ_61e24136-1235-4855-b165-b12401d470c5"
      unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjItOS0xLTEtMTA0MTE5_22e4ed4d-253b-4c97-8ae5-2395c9173a35"
      unitRef="usd">-37098000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjItMTEtMS0xLTEwNDExOQ_c33c007b-3f4a-4496-9abe-20b54605aa1a"
      unitRef="usd">-29943000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjMtOS0xLTEtMTA0MTE5_e50846fb-1620-43c5-9c88-835e6f287970"
      unitRef="usd">26000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjEtNy0xLTEtMTA1NDQ3_7e7ab820-df13-4144-938d-b01d8c48305e"
      unitRef="usd">9000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjQtOS0xLTEtMTA0MTE5_a330b78a-ba32-40a7-a87b-d2356db353fe"
      unitRef="usd">-37124000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjQtMTEtMS0xLTEwNDExOQ_53cb1095-63e3-44a6-9db2-2ac9b019179e"
      unitRef="usd">-29952000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjUtOS0xLTEtMTA0MTE5_87f399f3-e168-4371-a004-1688787f7e58"
      unitRef="usdPerShare">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjUtOS0xLTEtMTA0MTE5_f5efeea1-77e5-4755-a087-64feabf1bd5d"
      unitRef="usdPerShare">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjUtMTEtMS0xLTEwNDExOQ_554ed464-9091-420c-8065-3a59e302eba7"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjUtMTEtMS0xLTEwNDExOQ_d7230d1c-c799-4bdb-ae6d-9b650a14e193"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjYtOS0xLTEtMTA0MTE5_498defcb-5622-4751-81c9-96514034b3cc"
      unitRef="shares">302045000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjYtOS0xLTEtMTA0MTE5_e4a29437-16ed-4ce3-af68-31c0283ee519"
      unitRef="shares">302045000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjQtNy0xLTEtMTA3Nzg0_1b694634-c1f7-476d-b3a7-80905ed44805"
      unitRef="shares">284613000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjQtNy0xLTEtMTA3Nzg0_278805e1-4ce5-4aa2-a006-835e35d11a7f"
      unitRef="shares">284613000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjQtNy0xLTEtMTA3Nzg0_2db6429b-0561-487f-a069-3416a4bea6a8"
      unitRef="shares">284613000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8xOS9mcmFnOmU3YzIxNjdkZjgyMjQ0OTZhZjJkMmRkMmJkMTQ4YzNhL3RhYmxlOjc0ZjljNmU2NDJjOTQ4OTBiNGEzZjMzZTJiYTZiOWJjL3RhYmxlcmFuZ2U6NzRmOWM2ZTY0MmM5NDg5MGI0YTNmMzNlMmJhNmI5YmNfMjQtNy0xLTEtMTA3Nzg0_59b23c08-d50f-40e9-97e4-e89d16d6909b"
      unitRef="shares">284613000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yMi9mcmFnOjRhNGUzMDY3MGM3MTQxNmE4MmU0ZGZhMjRhOWQ0MzZjL3RhYmxlOmMyNWQzYjhkMmI5MjQ2YWZiNGZhNGNlZGY2MzM1NWRjL3RhYmxlcmFuZ2U6YzI1ZDNiOGQyYjkyNDZhZmI0ZmE0Y2VkZjYzMzU1ZGNfMi0xLTEtMS0xMDQxMTk_3ee1c1bd-e4b6-4ef6-8a8d-fc884c1fd2d2"
      unitRef="usd">-37124000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yMi9mcmFnOjRhNGUzMDY3MGM3MTQxNmE4MmU0ZGZhMjRhOWQ0MzZjL3RhYmxlOmMyNWQzYjhkMmI5MjQ2YWZiNGZhNGNlZGY2MzM1NWRjL3RhYmxlcmFuZ2U6YzI1ZDNiOGQyYjkyNDZhZmI0ZmE0Y2VkZjYzMzU1ZGNfMi0zLTEtMS0xMDQxMTk_7bf758c0-da0a-49dd-bf25-280530b52f76"
      unitRef="usd">-29952000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yMi9mcmFnOjRhNGUzMDY3MGM3MTQxNmE4MmU0ZGZhMjRhOWQ0MzZjL3RhYmxlOmMyNWQzYjhkMmI5MjQ2YWZiNGZhNGNlZGY2MzM1NWRjL3RhYmxlcmFuZ2U6YzI1ZDNiOGQyYjkyNDZhZmI0ZmE0Y2VkZjYzMzU1ZGNfNC0xLTEtMS0xMDQxMTk_0fe88fc6-719e-4e5b-921f-26ef0e27bf82"
      unitRef="usd">423000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yMi9mcmFnOjRhNGUzMDY3MGM3MTQxNmE4MmU0ZGZhMjRhOWQ0MzZjL3RhYmxlOmMyNWQzYjhkMmI5MjQ2YWZiNGZhNGNlZGY2MzM1NWRjL3RhYmxlcmFuZ2U6YzI1ZDNiOGQyYjkyNDZhZmI0ZmE0Y2VkZjYzMzU1ZGNfNC0zLTEtMS0xMDQxMTk_34d037ef-a7bc-479d-b675-8fe3b0ec59e3"
      unitRef="usd">-1098000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yMi9mcmFnOjRhNGUzMDY3MGM3MTQxNmE4MmU0ZGZhMjRhOWQ0MzZjL3RhYmxlOmMyNWQzYjhkMmI5MjQ2YWZiNGZhNGNlZGY2MzM1NWRjL3RhYmxlcmFuZ2U6YzI1ZDNiOGQyYjkyNDZhZmI0ZmE0Y2VkZjYzMzU1ZGNfNS0xLTEtMS0xMDQxMTk_a47949da-e34a-415e-ad3e-eff9ab8b00b8"
      unitRef="usd">36000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yMi9mcmFnOjRhNGUzMDY3MGM3MTQxNmE4MmU0ZGZhMjRhOWQ0MzZjL3RhYmxlOmMyNWQzYjhkMmI5MjQ2YWZiNGZhNGNlZGY2MzM1NWRjL3RhYmxlcmFuZ2U6YzI1ZDNiOGQyYjkyNDZhZmI0ZmE0Y2VkZjYzMzU1ZGNfNS0zLTEtMS0xMDQxMTk_c3d60090-5573-4ee6-9c10-f81ed9c7a08a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yMi9mcmFnOjRhNGUzMDY3MGM3MTQxNmE4MmU0ZGZhMjRhOWQ0MzZjL3RhYmxlOmMyNWQzYjhkMmI5MjQ2YWZiNGZhNGNlZGY2MzM1NWRjL3RhYmxlcmFuZ2U6YzI1ZDNiOGQyYjkyNDZhZmI0ZmE0Y2VkZjYzMzU1ZGNfNi0xLTEtMS0xMDQxMTk_cb006580-5306-481d-a4e9-89c045724b4b"
      unitRef="usd">459000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yMi9mcmFnOjRhNGUzMDY3MGM3MTQxNmE4MmU0ZGZhMjRhOWQ0MzZjL3RhYmxlOmMyNWQzYjhkMmI5MjQ2YWZiNGZhNGNlZGY2MzM1NWRjL3RhYmxlcmFuZ2U6YzI1ZDNiOGQyYjkyNDZhZmI0ZmE0Y2VkZjYzMzU1ZGNfNi0zLTEtMS0xMDQxMTk_db9bd104-3307-445e-b6f6-fbc98662fc08"
      unitRef="usd">-1098000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yMi9mcmFnOjRhNGUzMDY3MGM3MTQxNmE4MmU0ZGZhMjRhOWQ0MzZjL3RhYmxlOmMyNWQzYjhkMmI5MjQ2YWZiNGZhNGNlZGY2MzM1NWRjL3RhYmxlcmFuZ2U6YzI1ZDNiOGQyYjkyNDZhZmI0ZmE0Y2VkZjYzMzU1ZGNfNy0xLTEtMS0xMDQxMTk_040db713-1ba4-45e7-88ce-fba3c7d4d99e"
      unitRef="usd">-36665000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yMi9mcmFnOjRhNGUzMDY3MGM3MTQxNmE4MmU0ZGZhMjRhOWQ0MzZjL3RhYmxlOmMyNWQzYjhkMmI5MjQ2YWZiNGZhNGNlZGY2MzM1NWRjL3RhYmxlcmFuZ2U6YzI1ZDNiOGQyYjkyNDZhZmI0ZmE0Y2VkZjYzMzU1ZGNfNy0zLTEtMS0xMDQxMTk_7bfdba58-7a6d-45f7-b614-33f4757706be"
      unitRef="usd">-31050000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifc1dfa094b4c4c1fa40f179234ec50e6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMi0yLTEtMS0xMDQxMTk_095fa2a9-44e6-4940-b1dc-a91a7e47396a"
      unitRef="shares">289602000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifc1dfa094b4c4c1fa40f179234ec50e6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMi00LTEtMS0xMDQxMTk_5c931121-4cb4-48d2-9031-3fd51c77cb21"
      unitRef="usd">29000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifa3c9898447244ed80a321d3bb3f00b1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMi02LTEtMS0xMDQxMTk_70f6879d-70ad-43f7-8324-94036d0e5a6c"
      unitRef="usd">553747000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1cca8398bdff4ba383ffbba2ea3b7387_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMi04LTEtMS0xMDQxMTk_81cf30d0-6b1e-4c79-81af-b7ebd1a7bbfa"
      unitRef="usd">-216119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8d8e7646f2804373ac2db3a030f1359c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMi0xMC0xLTEtMTA0MTE5_460e2281-f2fe-45df-bfad-9128ce286b8d"
      unitRef="usd">-539000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0cfe18ad0d8e4978ada52e1560b4b9dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMi0xMi0xLTEtMTA0MTE5_225c962b-8305-4851-96b8-7c4901c5e76a"
      unitRef="usd">337118000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i58b67d95244b409ab6ee9c70973a72be_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMy0yLTEtMS0xMDQxMTk_3b16e891-447f-4ea0-a386-220575fbc1ab"
      unitRef="shares">21000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i081d4286b8024fc38cd6cc1cfb880bac_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMy02LTEtMS0xMDQxMTk_22983a31-8107-4e27-8b2f-329c84fbbb28"
      unitRef="usd">15000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMy0xMi0xLTEtMTA0MTE5_f3794908-049f-4010-b41c-2ee35fa59634"
      unitRef="usd">15000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i081d4286b8024fc38cd6cc1cfb880bac_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfNC02LTEtMS0xMDQxMTk_240d995d-abe8-4e1f-83c6-6c6ae42088df"
      unitRef="usd">5102000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfNC0xMi0xLTEtMTA0MTE5_dceffe98-5dd4-48c3-b3c2-6d291ff6f86c"
      unitRef="usd">5102000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="i58b67d95244b409ab6ee9c70973a72be_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfNS0yLTEtMS0xMDU2MTk_e0f9d0ce-84b2-4922-adba-6ed10c834ff6"
      unitRef="shares">65000</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:NetIncomeLoss
      contextRef="ib545fe18002040049f1dd40e745063cf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfNy04LTEtMS0xMDQxMTk_ed3c0db4-d33a-4440-a5d1-ff9245aec039"
      unitRef="usd">-29952000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfNy0xMi0xLTEtMTA0MTE5_59efb701-46c9-49c5-a04d-7d091449d3c7"
      unitRef="usd">-29952000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i26505e829d91462f95377df48fcf6c59_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfNy0xMC0xLTEtMTA1NjI2_95200ae5-239c-43bb-a370-05a547953d69"
      unitRef="usd">-1098000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfNy0xMi0xLTEtMTA3Nzk0_8835d8b3-1222-430a-a1ba-3287ddcb92d2"
      unitRef="usd">-1098000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i35bd51c6773a4f30bc0cda985ac95b56_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfOC0yLTEtMS0xMDQxMTk_ddf6294b-2d0d-4003-8469-c48a3846d24a"
      unitRef="shares">289688000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i35bd51c6773a4f30bc0cda985ac95b56_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfOC00LTEtMS0xMDQxMTk_78a5c217-7947-4c9a-b2e5-dbf900d1ce69"
      unitRef="usd">29000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6ba62f46aa8044098043951d2b4e437f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfOC02LTEtMS0xMDQxMTk_f4163595-022f-4aa5-aaf5-2895eb784405"
      unitRef="usd">558864000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i20e6f07f9ffb41f3b64c9ac35f75d302_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfOC04LTEtMS0xMDQxMTk_6beeeeb6-09b4-43b1-ac20-4565f4f621e8"
      unitRef="usd">-246071000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i17b0d4ea6adf427eb9d4b02037d2964a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfOC0xMC0xLTEtMTA0MTE5_085a149a-100b-4d20-853c-d305393e7760"
      unitRef="usd">-1637000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i955cc10e676a434da3908ec8ee79b5a0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfOC0xMi0xLTEtMTA0MTE5_cb3e5f5f-9a9d-4e7a-9f5b-5a70c3951c38"
      unitRef="usd">311185000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7e39a84040944ede8fdaa4d1b105ad7a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzEtMi0xLTEtMTA0MTE5_5fd24835-092f-4503-89ad-3e47bb5f3429"
      unitRef="shares">297183000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7e39a84040944ede8fdaa4d1b105ad7a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzEtNC0xLTEtMTA0MTE5_7c35d271-20b9-4216-a4f0-c457cadd3155"
      unitRef="usd">30000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i49cef66a2bf8465c9be9162628f1973b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzEtNi0xLTEtMTA0MTE5_f9839aef-3fed-45b9-9353-28d3de1c6764"
      unitRef="usd">599207000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i39f18943e70e4009b385fa4e3abd198f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzEtOC0xLTEtMTA0MTE5_c2a59899-c84b-4b50-ae05-e6c91ecc2b4f"
      unitRef="usd">-348715000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5409b1552b72472894786a349c3cf6ab_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzEtMTAtMS0xLTEwNDExOQ_1ff0bd98-3d08-4d8a-96b3-4f88fc2f5339"
      unitRef="usd">-1124000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzEtMTItMS0xLTEwNDExOQ_3b1d39eb-3d6a-4117-8ca7-316714fac105"
      unitRef="usd">249398000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i368dfe51ced845ce9ce881dbe02ac125_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzItMi0xLTEtMTA0MTE5_07beca0b-13b1-454d-b5b5-c00c21fc33bb"
      unitRef="shares">42000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6b2f680c76ee497394f0b63f4a9b399a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzItNi0xLTEtMTA0MTE5_7db51d11-f63c-4d64-8ace-ba9a70025d6c"
      unitRef="usd">23000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzItMTItMS0xLTEwNDExOQ_a246ff21-b811-4590-91cd-88f70f88cc78"
      unitRef="usd">23000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6b2f680c76ee497394f0b63f4a9b399a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzMtNi0xLTEtMTA0MTE5_444c9ffa-f3f0-412e-b4a5-d66c65471d21"
      unitRef="usd">3882000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzMtMTItMS0xLTEwNDExOQ_c37a88a7-8822-413a-b965-83a3c0409706"
      unitRef="usd">3882000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i368dfe51ced845ce9ce881dbe02ac125_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMTMtMi0xLTEtMTA5MjU3_d52c2cb8-f95a-453f-801e-7c75bb18fd58"
      unitRef="shares">9500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i368dfe51ced845ce9ce881dbe02ac125_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMTMtNC0xLTEtMTA5MjU3_ca20d57a-6eb4-4aa7-b61e-e658ba4d1d40"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6b2f680c76ee497394f0b63f4a9b399a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMTMtNi0xLTEtMTA5MjU3_2e4934ba-839c-4344-842c-434349be668b"
      unitRef="usd">14848000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMTMtMTItMS0xLTEwOTI1Nw_c3011331-e1f0-44ad-ae2f-9ddf781699d7"
      unitRef="usd">14849000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="i368dfe51ced845ce9ce881dbe02ac125_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzQtMi0xLTEtMTA0MTE5_2b39efd9-4258-474e-9586-e27e0c82b800"
      unitRef="shares">65000</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:NetIncomeLoss
      contextRef="id4838c75f09847d6962eaee26a7817f1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzUtOC0xLTEtMTA0MTE5_8043a7cd-7674-4892-a8cb-3f2b8dd91d65"
      unitRef="usd">-37124000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzUtMTItMS0xLTEwNDExOQ_fcef1d21-ef6c-40e1-9e8b-3a011dd0842b"
      unitRef="usd">-37124000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i85aa7ee73fd04055b335ec2d997a0f0c_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzYtMTAtMS0xLTEwNDExOQ_94d1509f-4498-41d8-aaea-787cc5c6e59b"
      unitRef="usd">459000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzYtMTItMS0xLTEwNDExOQ_62a01a1c-9b64-4eed-93e9-80de7eb6d0d8"
      unitRef="usd">459000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6b9c8029a5394f4bafac617b2deb2c22_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzctMi0xLTEtMTA0MTE5_bdea912e-1baf-4424-bdf8-73ca60a5f16e"
      unitRef="shares">306790000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6b9c8029a5394f4bafac617b2deb2c22_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzctNC0xLTEtMTA0MTE5_c26afcae-e5bb-41f8-ac02-867475c12cb6"
      unitRef="usd">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2c6f1ced20ec4e9aa8a3fb4827f7be65_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzctNi0xLTEtMTA0MTE5_2d717647-1220-4041-9940-8628643d5b00"
      unitRef="usd">617960000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib90ef8426ec84d859ee8b194da09c4eb_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzctOC0xLTEtMTA0MTE5_c7b1da3d-6d7f-4238-933b-8616d3fc5c8a"
      unitRef="usd">-385839000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic370404fbb3041c6a839fd87ac238005_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzctMTAtMS0xLTEwNDExOQ_91def79a-2056-45a6-9444-9c7f5c6ffd27"
      unitRef="usd">-665000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yNS9mcmFnOjliMjc4ZTgyYzcxZjQ4MjI5MGEyMjUyZTA3YjExZjM4L3RhYmxlOjI2ZDU1M2Q2N2ZmNDRiYjVhMTE2ZTY5YmY5MmQ3ZWExL3RhYmxlcmFuZ2U6MjZkNTUzZDY3ZmY0NGJiNWExMTZlNjliZjkyZDdlYTFfMzctMTItMS0xLTEwNDExOQ_6a75d5e8-02b3-4420-a30e-a5ddf9773b9e"
      unitRef="usd">231487000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMy0xLTEtMS0xMDQxMTk_c6707c28-9b3a-4b53-9bed-99da55086e49"
      unitRef="usd">-37124000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMy0zLTEtMS0xMDQxMTk_67762b58-4f13-45e2-8388-3887beaa4ffa"
      unitRef="usd">-29952000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNS0xLTEtMS0xMDQxMTk_5a8252e7-5053-4e72-8616-4983d4133ecb"
      unitRef="usd">3190000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNS0zLTEtMS0xMDQxMTk_f9200311-272d-43c8-9ce5-739d160bd072"
      unitRef="usd">2210000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNi0xLTEtMS0xMDQxMTk_b713662c-77bb-4b72-9ab7-181eb5ea28bd"
      unitRef="usd">51000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNi0zLTEtMS0xMDQxMTk_a1f45e3b-25e6-40f8-a533-33cf5cd78ceb"
      unitRef="usd">29000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNy0xLTEtMS0xMDQxMTk_64391950-9a4b-44d1-87c6-13bf01b80111"
      unitRef="usd">82000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNy0zLTEtMS0xMDQxMTk_88e00a09-ef36-4838-a32e-c4b5feb46732"
      unitRef="usd">-299000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <bngo:NonCashLeaseExpense
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfOC0xLTEtMS0xMDQxMTk_2d2f0135-971c-48ca-8035-f5d8401b3427"
      unitRef="usd">113000</bngo:NonCashLeaseExpense>
    <bngo:NonCashLeaseExpense
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfOC0zLTEtMS0xMDQxMTk_c48d6dc9-0d47-49a2-8303-1e8b86d084b9"
      unitRef="usd">299000</bngo:NonCashLeaseExpense>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTAtMS0xLTEtMTA4NDQz_9aa3f213-dd8f-461a-b771-ec96b66c595f"
      unitRef="usd">-7000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTAtMy0xLTEtMTA4NDUw_9c6a415c-2408-469c-947e-c7c932e34fa6"
      unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:ShareBasedCompensation
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTAtMS0xLTEtMTA0MTE5_cb70c4db-57cd-4ca1-9e41-fd52485b3ede"
      unitRef="usd">3882000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTAtMy0xLTEtMTA0MTE5_77238790-8f8b-430e-b036-35e90100293f"
      unitRef="usd">5102000</us-gaap:ShareBasedCompensation>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTItMS0xLTEtMTA0MTE5_7f7dbd54-0807-44a3-b51d-de03134d17cf"
      unitRef="usd">789000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTItMy0xLTEtMTA0MTE5_b6e14f94-a261-4dc3-851c-720cf3121ea4"
      unitRef="usd">79000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <bngo:CostOfLeasedEquipmentSoldToCustomer
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTUtMS0xLTEtMTA0MTE5_62cd2b50-bb1f-4e89-b783-0741aa2a7ce6"
      unitRef="usd">88000</bngo:CostOfLeasedEquipmentSoldToCustomer>
    <bngo:CostOfLeasedEquipmentSoldToCustomer
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTUtMy0xLTEtMTA0MTE5_5a9961ea-b16e-4ae3-80f5-0d5dedb085fc"
      unitRef="usd">0</bngo:CostOfLeasedEquipmentSoldToCustomer>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTctMS0xLTEtMTA0MTE5_1cf7f2c6-98bd-4bed-b77c-abca17cc2fc2"
      unitRef="usd">-242000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTctMy0xLTEtMTA0MTE5_30a0de9a-6e24-4013-9a2c-7c64f71e3284"
      unitRef="usd">640000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTgtMS0xLTEtMTA0MTE5_e322074c-633d-4bd6-afb4-5bb8919af976"
      unitRef="usd">5707000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTgtMy0xLTEtMTA0MTE5_d16d8561-4d98-4b6e-bb6d-71c6db6b1b49"
      unitRef="usd">5938000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTktMS0xLTEtMTA0MTE5_3e31d5f9-8edd-4ea8-adc1-d6d88852af6e"
      unitRef="usd">-471000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTktMy0xLTEtMTA0MTE5_7c9fbf2d-fde6-451b-9455-1c8f83892a30"
      unitRef="usd">323000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTctMS0xLTEtMTE0ODE5_82751b40-5635-47f0-afe6-337c45f15937"
      unitRef="usd">372000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMTctMy0xLTEtMTE0ODQ5_d35c46f1-25b0-449c-8f3e-5e2859e955bd"
      unitRef="usd">48000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjAtMS0xLTEtMTA0MTE5_15fa362c-aefb-4582-9e1e-2723df030a75"
      unitRef="usd">3017000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjAtMy0xLTEtMTA0MTE5_51fbcf7e-64c9-443f-b294-b7df6dd9f582"
      unitRef="usd">-3168000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjEtMS0xLTEtMTA0MTE5_24b4c601-6e7a-4be7-a231-daede4e9f93a"
      unitRef="usd">-978000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjEtMy0xLTEtMTA0MTE5_6a155513-c296-4069-a3bf-43b5d31aca9f"
      unitRef="usd">-443000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjItMS0xLTEtMTA0MTE5_fd3bd244-f2e3-44fe-82d2-b43cb988a7c9"
      unitRef="usd">-32413000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjItMy0xLTEtMTA0MTE5_c46af176-9b63-4be3-a620-619f992282f2"
      unitRef="usd">-32494000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <bngo:ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjUtMS0xLTEtMTA0MTE5_cd8e1db4-112e-4894-ac0b-71902ed95b77"
      unitRef="usd">0</bngo:ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow>
    <bngo:ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjUtMy0xLTEtMTA0MTE5_d2e2b148-6367-4506-83af-467deaa09106"
      unitRef="usd">694000</bngo:ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow>
    <bngo:PaymentsForPropertyAndEquipment
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjYtMS0xLTEtMTA0MTE5_8c042868-d643-4e84-a7d6-1bebac999002"
      unitRef="usd">360000</bngo:PaymentsForPropertyAndEquipment>
    <bngo:PaymentsForPropertyAndEquipment
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjYtMy0xLTEtMTA0MTE5_5c0c6577-6d5c-4916-bc2c-bc779f9ec2b4"
      unitRef="usd">150000</bngo:PaymentsForPropertyAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjctMS0xLTEtMTA0MTE5_b551298d-ade1-4857-96d6-dd5e77361bdf"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjctMy0xLTEtMTA0MTE5_f7b5180d-125a-4df9-9fd6-b5361b75a6ba"
      unitRef="usd">14954000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjgtMS0xLTEtMTA0MTE5_3aa441b3-33c0-405f-8c56-16c75f6350db"
      unitRef="usd">16888000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjgtMy0xLTEtMTA0MTE5_c141c894-4a7a-4064-b52f-44556c304366"
      unitRef="usd">47179000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsForConstructionInProcess
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjktMS0xLTEtMTA0MTE5_c046d85f-f76f-415d-86d9-b598b0d79dad"
      unitRef="usd">0</us-gaap:PaymentsForConstructionInProcess>
    <us-gaap:PaymentsForConstructionInProcess
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMjktMy0xLTEtMTA0MTE5_2bd8bd5e-d5e9-4558-b82b-618828c191ec"
      unitRef="usd">832000</us-gaap:PaymentsForConstructionInProcess>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMzAtMS0xLTEtMTA0MTE5_866e0bd5-803b-4ff5-b827-78065e921a2d"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMzAtMy0xLTEtMTA0MTE5_e8b32369-ec3e-477d-ab37-f204445a439d"
      unitRef="usd">27000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMzEtMS0xLTEtMTA0MTE5_847f19c9-b69f-42ce-adc4-28bc5eaef60b"
      unitRef="usd">16528000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMzEtMy0xLTEtMTA0MTE5_69bd55e4-69d1-479c-9c9d-681a8c6ee973"
      unitRef="usd">31964000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMzgtMS0xLTEtMTA0MTE5_bc017366-06fa-4669-99ff-aeb5fa4e314b"
      unitRef="usd">10000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMzgtMy0xLTEtMTA0MTE5_304a208e-402f-4001-a2f5-ea0297f0c5ff"
      unitRef="usd">8000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMzktMS0xLTEtMTA0MTE5_96cc9422-a879-4509-8edd-55b5fe5b7d72"
      unitRef="usd">15229000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfMzktMy0xLTEtMTA0MTE5_31ae0cd9-1d95-4a99-b3e4-43f05d13f744"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDAtMS0xLTEtMTA0MTE5_1138ff5f-c1eb-44e8-a225-a1618fa0758e"
      unitRef="usd">380000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDAtMy0xLTEtMTA0MTE5_06b33002-5851-414f-b4ab-9655f735c8a4"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDItMS0xLTEtMTA0MTE5_ee3e3b2b-2b8f-4bf4-87d0-f61f9cc1c92b"
      unitRef="usd">23000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDItMy0xLTEtMTA0MTE5_66c4cccd-6e46-49ce-98ef-6ac89e0f0a80"
      unitRef="usd">15000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDMtMS0xLTEtMTA0MTE5_94473f28-b346-4942-9480-e46127898172"
      unitRef="usd">14862000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDMtMy0xLTEtMTA0MTE5_5866e220-b139-4295-903d-89c1f388975c"
      unitRef="usd">7000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDQtMS0xLTEtMTA0MTE5_4187d9a0-1ff6-4947-a443-696677d40989"
      unitRef="usd">36000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDQtMy0xLTEtMTA0MTE5_afa46534-4048-4115-a8eb-87e73d44c29d"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDUtMS0xLTEtMTA0MTE5_a2930984-c2a3-44f5-a8ff-9777839e3ffe"
      unitRef="usd">-987000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDUtMy0xLTEtMTA0MTE5_6a0575cb-629e-478f-b7ef-9e2d45afdd72"
      unitRef="usd">-523000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDYtMS0xLTEtMTA0MTE5_70bb7b33-0278-4f9b-95fa-bc7111bc35c4"
      unitRef="usd">5491000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i0cfe18ad0d8e4978ada52e1560b4b9dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDYtMy0xLTEtMTA0MTE5_6f5d7de0-ecca-4284-8372-1097d180cc80"
      unitRef="usd">24571000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDctMS0xLTEtMTA0MTE5_aedae8f0-c23b-4bad-8488-21ecda6f7d8f"
      unitRef="usd">4504000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
      contextRef="i955cc10e676a434da3908ec8ee79b5a0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDctMy0xLTEtMTA0MTE5_c19991f0-1a88-4348-bb76-e3e68d730559"
      unitRef="usd">24048000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDktMS0xLTEtMTA3ODA2_e7e0f993-f2c9-456a-8fb1-4ea24f80d64f"
      unitRef="usd">4104000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i955cc10e676a434da3908ec8ee79b5a0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNDktMy0xLTEtMTA2Nzgz_6601d822-1d3c-4e65-af54-eba5bc3741fe"
      unitRef="usd">24048000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTAtMS0xLTEtMTA3ODA4_f631175f-6121-45d2-a6eb-9f610eb0833a"
      unitRef="usd">400000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i955cc10e676a434da3908ec8ee79b5a0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTAtMy0xLTEtMTA2Nzgz_a024f340-4e2b-4ca5-bb33-213dc939f8e8"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTEtMS0xLTEtMTA3ODEx_52c38c04-bc7d-40f8-bd6e-378aee520633"
      unitRef="usd">4504000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i955cc10e676a434da3908ec8ee79b5a0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTEtMy0xLTEtMTA3ODE0_f12a5586-08cb-4799-a05d-4cc9874b0a81"
      unitRef="usd">24048000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTAtMS0xLTEtMTA0MTE5_26297521-df0a-47c7-9505-59213ec2cc8d"
      unitRef="usd">76000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTAtMy0xLTEtMTA0MTE5_8626004f-40e3-4540-acbd-6043b921e2a4"
      unitRef="usd">70000</us-gaap:InterestPaidNet>
    <us-gaap:OperatingLeasePayments
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTEtMS0xLTEtMTA0MTE5_2c979e17-7c11-4cdc-ba03-d832f7e467ae"
      unitRef="usd">644000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTEtMy0xLTEtMTA0MTE5_23a78e24-9c4a-431d-9e64-068d7315cec4"
      unitRef="usd">217000</us-gaap:OperatingLeasePayments>
    <bngo:TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTQtMS0xLTEtMTEyODY1_8c2848c1-a06d-4a25-a752-79f6db8b40cc"
      unitRef="usd">0</bngo:TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory>
    <bngo:TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTQtMy0xLTEtMTEyODY2_3a7914ae-f180-408f-96bc-cd548ad1e593"
      unitRef="usd">544000</bngo:TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory>
    <bngo:TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTctMS0xLTEtMTA0MTE5_4e10fb99-9c0d-42f9-9223-83ec1b0b23a3"
      unitRef="usd">2356000</bngo:TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory>
    <bngo:TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTctMy0xLTEtMTA0MTE5_55ddd3ff-8a33-4796-8b8d-2a17520215be"
      unitRef="usd">2056000</bngo:TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTgtMS0xLTEtMTA0MTE5_21aa558a-be67-4b35-ad7a-6cddf5254c6a"
      unitRef="usd">230000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNTgtMy0xLTEtMTA0MTE5_88f58045-dba2-494d-b1ed-d6636ef7b039"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNjAtMS0xLTEtMTEyNzg2_bd70da1f-9c0f-4838-83f8-9ad0bef5fdc4"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8yOC9mcmFnOmIzNjM2ZjJlZGFiYTQ5NTc4NDk2NzI1ZDIyNDM1OGJjL3RhYmxlOjRmMTBmNDc1NWZjODRiOGJiYjU4ZDkzNDdmMWVkYjFhL3RhYmxlcmFuZ2U6NGYxMGY0NzU1ZmM4NGI4YmJiNThkOTM0N2YxZWRiMWFfNjAtMy0xLTEtMTEyNzg2_3b769e18-797e-471f-8389-05b1b5524abe"
      unitRef="usd">513000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNC9mcmFnOmJlNGM2MDUwNGY2MDRlZmQ5Y2M2YjIwNmZmYjRkMjUzL3RleHRyZWdpb246YmU0YzYwNTA0ZjYwNGVmZDljYzZiMjA2ZmZiNGQyNTNfMTI2NjU_4d5e382b-50f6-4d96-9f53-19dd8347b970">Organization and Basis of Presentation&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bionano Genomics, Inc. (collectively, with its consolidated subsidiaries, the &#x201c;Company&#x201d;) is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company offers optical genome mapping (&#x201c;OGM&#x201d;) solutions for applications across basic, translational and clinical research, and for other applications including bioprocessing. Through its Lineagen, Inc. (doing business as Bionano Laboratories, &#x201c;Bionano Laboratories&#x201d;) business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery, LLC (&#x201c;BioDiscovery&#x201d;) business, the Company also offers platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. Through our Purigen Biosystems Inc. (&#x201c;Purigen&#x201d;) business, we offer nucleic acid extraction and purification solutions using proprietary isotachophoresis (&#x201c;ITP&#x201d;) technology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial information has been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) for interim reporting purposes. The condensed consolidated financial statements are unaudited. The unaudited condensed consolidated financial statements reflect, in the opinion of the Company&#x2019;s management, all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of financial position, results of operations, changes in equity, and comprehensive loss and cash flows for each period presented in accordance with United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;). All intercompany transactions and balances have been eliminated. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain amounts reported in prior years have been reclassified to conform with the presentation in the current year. These reclassifications had no effect on the reported results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has experienced recurring net losses from operations, negative cash flows from operating activities, and accumulated deficit since its inception and expects to continue to incur net losses into the foreseeable future. As of March&#160;31, 2023, the Company had approximately $4.1 million in cash and cash equivalents, $91.7 million in short term investments, and working capital of $104.4 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an accumulated deficit of $385.8 million as of March&#160;31, 2023. During the three months ended March&#160;31, 2023, the Company used $32.4 million cash in operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management expects operating losses and negative cash flows to continue for at least the next year as the Company continues to incur costs related to research and commercialization efforts. Management has prepared cash flows forecasts which indicate that based on the Company&#x2019;s expected operating losses and negative cash flows, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern within twelve months after the date that the unaudited condensed consolidated financial statements for the three months ended March&#160;31, 2023, are issued. Management&#x2019;s ability to continue as a going concern is dependent upon its ability to raise additional funding. Management&#x2019;s plans to raise additional capital to fulfill its operating and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;capital requirements for at least 12 months include public or private equity or debt financings. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company&#x2019;s existing stockholders. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the outcome of this uncertainty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023, there were no changes to the Company&#x2019;s significant accounting policies as described in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which amends the impairment model by requiring entities to use a forward looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. For trade receivables and other instruments, entities will be required to use a new forward-looking expected loss model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. The Company adopted ASU 2016-13 as of January 1, 2023. &lt;/span&gt;&lt;/div&gt;The cumulative effect of applying the new credit loss standard was not material and, therefore, did not result in an adjustment to retained earnings. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements or related financial statement disclosures. In accordance with ASU 2016-13, the Company no longer evaluates whether its available-for-sale debt securities in an unrealized loss position are other than temporarily impaired. Instead, the Company assesses whether such unrealized loss positions are credit-related. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in other income through an allowance account. Unrealized gains and losses that are not credit-related are included in accumulated other comprehensive income.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNC9mcmFnOmJlNGM2MDUwNGY2MDRlZmQ5Y2M2YjIwNmZmYjRkMjUzL3RleHRyZWdpb246YmU0YzYwNTA0ZjYwNGVmZDljYzZiMjA2ZmZiNGQyNTNfMTI2NzA_9287c70c-1226-443c-b341-aa76b32649fd">Basis of PresentationThe accompanying financial information has been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) for interim reporting purposes. The condensed consolidated financial statements are unaudited. The unaudited condensed consolidated financial statements reflect, in the opinion of the Company&#x2019;s management, all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of financial position, results of operations, changes in equity, and comprehensive loss and cash flows for each period presented in accordance with United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;). All intercompany transactions and balances have been eliminated. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNC9mcmFnOmJlNGM2MDUwNGY2MDRlZmQ5Y2M2YjIwNmZmYjRkMjUzL3RleHRyZWdpb246YmU0YzYwNTA0ZjYwNGVmZDljYzZiMjA2ZmZiNGQyNTNfMTI2NzE_cd45c5cc-fc59-4046-b36b-3f435a42294a">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain amounts reported in prior years have been reclassified to conform with the presentation in the current year. These reclassifications had no effect on the reported results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <bngo:LiquidityAndGoingConcernPolicyTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNC9mcmFnOmJlNGM2MDUwNGY2MDRlZmQ5Y2M2YjIwNmZmYjRkMjUzL3RleHRyZWdpb246YmU0YzYwNTA0ZjYwNGVmZDljYzZiMjA2ZmZiNGQyNTNfMzI5ODUzNDkxMTc3Mw_4e2f4468-36f7-49f9-ba64-a06d7ae6608d">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has experienced recurring net losses from operations, negative cash flows from operating activities, and accumulated deficit since its inception and expects to continue to incur net losses into the foreseeable future. As of March&#160;31, 2023, the Company had approximately $4.1 million in cash and cash equivalents, $91.7 million in short term investments, and working capital of $104.4 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an accumulated deficit of $385.8 million as of March&#160;31, 2023. During the three months ended March&#160;31, 2023, the Company used $32.4 million cash in operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management expects operating losses and negative cash flows to continue for at least the next year as the Company continues to incur costs related to research and commercialization efforts. Management has prepared cash flows forecasts which indicate that based on the Company&#x2019;s expected operating losses and negative cash flows, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern within twelve months after the date that the unaudited condensed consolidated financial statements for the three months ended March&#160;31, 2023, are issued. Management&#x2019;s ability to continue as a going concern is dependent upon its ability to raise additional funding. Management&#x2019;s plans to raise additional capital to fulfill its operating and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;capital requirements for at least 12 months include public or private equity or debt financings. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company&#x2019;s existing stockholders. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the outcome of this uncertainty.&lt;/span&gt;&lt;/div&gt;</bngo:LiquidityAndGoingConcernPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNC9mcmFnOmJlNGM2MDUwNGY2MDRlZmQ5Y2M2YjIwNmZmYjRkMjUzL3RleHRyZWdpb246YmU0YzYwNTA0ZjYwNGVmZDljYzZiMjA2ZmZiNGQyNTNfMTY0OTI2NzQ3MDExMw_f4fa35a2-8c8d-4edc-9417-1a1248606e78"
      unitRef="usd">4100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNC9mcmFnOmJlNGM2MDUwNGY2MDRlZmQ5Y2M2YjIwNmZmYjRkMjUzL3RleHRyZWdpb246YmU0YzYwNTA0ZjYwNGVmZDljYzZiMjA2ZmZiNGQyNTNfMTY0OTI2NzQ3MDEyMA_a3de5bce-7e75-428e-8101-5f4fba879bc4"
      unitRef="usd">91700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <bngo:WorkingCapital
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNC9mcmFnOmJlNGM2MDUwNGY2MDRlZmQ5Y2M2YjIwNmZmYjRkMjUzL3RleHRyZWdpb246YmU0YzYwNTA0ZjYwNGVmZDljYzZiMjA2ZmZiNGQyNTNfNTQ5NzU1ODQyMjk3_7793c21c-f5b0-4284-ba9c-c5de913221ee"
      unitRef="usd">104400000</bngo:WorkingCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNC9mcmFnOmJlNGM2MDUwNGY2MDRlZmQ5Y2M2YjIwNmZmYjRkMjUzL3RleHRyZWdpb246YmU0YzYwNTA0ZjYwNGVmZDljYzZiMjA2ZmZiNGQyNTNfMTY0OTI2NzQ3MDEyNw_bf5fe4cd-df92-4f1c-a562-86986849e352"
      unitRef="usd">-385800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNC9mcmFnOmJlNGM2MDUwNGY2MDRlZmQ5Y2M2YjIwNmZmYjRkMjUzL3RleHRyZWdpb246YmU0YzYwNTA0ZjYwNGVmZDljYzZiMjA2ZmZiNGQyNTNfMTA5OTUxMTY1NjIxOQ_a8dadc8e-a642-46b3-9027-93a7c2b49e7e"
      unitRef="usd">-32400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNC9mcmFnOmJlNGM2MDUwNGY2MDRlZmQ5Y2M2YjIwNmZmYjRkMjUzL3RleHRyZWdpb246YmU0YzYwNTA0ZjYwNGVmZDljYzZiMjA2ZmZiNGQyNTNfMTI2NzM_c125128e-8122-4d47-8bd1-1514082add07">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which amends the impairment model by requiring entities to use a forward looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. For trade receivables and other instruments, entities will be required to use a new forward-looking expected loss model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. The Company adopted ASU 2016-13 as of January 1, 2023. &lt;/span&gt;&lt;/div&gt;The cumulative effect of applying the new credit loss standard was not material and, therefore, did not result in an adjustment to retained earnings. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements or related financial statement disclosures. In accordance with ASU 2016-13, the Company no longer evaluates whether its available-for-sale debt securities in an unrealized loss position are other than temporarily impaired. Instead, the Company assesses whether such unrealized loss positions are credit-related. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in other income through an allowance account. Unrealized gains and losses that are not credit-related are included in accumulated other comprehensive income.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RleHRyZWdpb246Y2ZiMzNjYmU2MTcxNGVkMWJjM2M0MGU4NDE3YWI0MDJfMTMxMg_d2f43cb3-b7a0-49f3-9adf-165dc8b997c5">Net Loss Per Share&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common share equivalents are only included when their effect is dilutive. The Company&#x2019;s potentially dilutive securities which include outstanding warrants to purchase stock, restricted stock units (&#x201c;RSUs&#x201d;), performance stock units (&#x201c;PSUs&#x201d;), and outstanding stock options under the Company&#x2019;s equity incentive plans have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. Restricted stock is treated as outstanding for accounting purposes. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding because all potentially dilutive securities were anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.653%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.658%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,013,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,531,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,257,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,356,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,356,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,457,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;296,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,116,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,730,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RleHRyZWdpb246Y2ZiMzNjYmU2MTcxNGVkMWJjM2M0MGU4NDE3YWI0MDJfMTMxMw_5a092318-0fd4-4550-ba26-ee568d49f7e5">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.653%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.658%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,013,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,531,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,257,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,356,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,356,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,457,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;296,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,116,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,730,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i235c6220aed04a31be7cf68dde5f7075_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RhYmxlOmFkOTA1NWI4MTRmNTRhY2RhNTFlMzE0ZDNjOGRlOTA4L3RhYmxlcmFuZ2U6YWQ5MDU1YjgxNGY1NGFjZGE1MWUzMTRkM2M4ZGU5MDhfMS0xLTEtMS0xMDQxMTk_2c18f385-48ac-4f72-8c70-7befa8ff673c"
      unitRef="shares">32013000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3ee348f6918a4dccb9a11bb16deb4771_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RhYmxlOmFkOTA1NWI4MTRmNTRhY2RhNTFlMzE0ZDNjOGRlOTA4L3RhYmxlcmFuZ2U6YWQ5MDU1YjgxNGY1NGFjZGE1MWUzMTRkM2M4ZGU5MDhfMS0zLTEtMS0xMDQxMTk_93d41803-e1a3-43f7-ae87-e4853ec58e9c"
      unitRef="shares">21531000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i80cbed6d5ffd48e39df9647e8b69fd38_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RhYmxlOmFkOTA1NWI4MTRmNTRhY2RhNTFlMzE0ZDNjOGRlOTA4L3RhYmxlcmFuZ2U6YWQ5MDU1YjgxNGY1NGFjZGE1MWUzMTRkM2M4ZGU5MDhfMi0xLTEtMS0xMDQxMTk_5d92df09-7a3b-477d-b291-8ad21cd590e1"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i990b58e8540b402f9deabf1b1e8d0d7a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RhYmxlOmFkOTA1NWI4MTRmNTRhY2RhNTFlMzE0ZDNjOGRlOTA4L3RhYmxlcmFuZ2U6YWQ5MDU1YjgxNGY1NGFjZGE1MWUzMTRkM2M4ZGU5MDhfMi0zLTEtMS0xMDQxMTk_dff8dbe2-21f9-4554-b8da-91c5b259271b"
      unitRef="shares">4257000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia5f34adecdf04ebca8394a17d3e26a73_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RhYmxlOmFkOTA1NWI4MTRmNTRhY2RhNTFlMzE0ZDNjOGRlOTA4L3RhYmxlcmFuZ2U6YWQ5MDU1YjgxNGY1NGFjZGE1MWUzMTRkM2M4ZGU5MDhfMy0xLTEtMS0xMDQxMTk_8773e8d4-e196-40bc-a3c5-a54c1af456f8"
      unitRef="shares">4356000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9ea78ca938894da3a2c044b50e0ecd12_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RhYmxlOmFkOTA1NWI4MTRmNTRhY2RhNTFlMzE0ZDNjOGRlOTA4L3RhYmxlcmFuZ2U6YWQ5MDU1YjgxNGY1NGFjZGE1MWUzMTRkM2M4ZGU5MDhfMy0zLTEtMS0xMDQxMTk_db9883c0-5a92-4cf9-a2d5-7439ba0a85b5"
      unitRef="shares">4356000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6fa1ec9e299d43dea83ee07700d9f2e8_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RhYmxlOmFkOTA1NWI4MTRmNTRhY2RhNTFlMzE0ZDNjOGRlOTA4L3RhYmxlcmFuZ2U6YWQ5MDU1YjgxNGY1NGFjZGE1MWUzMTRkM2M4ZGU5MDhfNC0xLTEtMS0xMDQxMTk_05ac8f98-2997-4c13-a7ef-8d7fa44cfc0b"
      unitRef="shares">2457000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4db80e7428124ae89fef6d38056d80eb_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RhYmxlOmFkOTA1NWI4MTRmNTRhY2RhNTFlMzE0ZDNjOGRlOTA4L3RhYmxlcmFuZ2U6YWQ5MDU1YjgxNGY1NGFjZGE1MWUzMTRkM2M4ZGU5MDhfNC0zLTEtMS0xMDQxMTk_4de44ebd-1068-4374-b23f-8626bc6444f5"
      unitRef="shares">296000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4e41522832874c03827a502c55e81ea1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RhYmxlOmFkOTA1NWI4MTRmNTRhY2RhNTFlMzE0ZDNjOGRlOTA4L3RhYmxlcmFuZ2U6YWQ5MDU1YjgxNGY1NGFjZGE1MWUzMTRkM2M4ZGU5MDhfNS0xLTEtMS0xMDQxMTk_a0a6c159-d197-486b-b9f9-7999785c1003"
      unitRef="shares">290000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i93dc12a23ca743058cc875c7385cba95_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RhYmxlOmFkOTA1NWI4MTRmNTRhY2RhNTFlMzE0ZDNjOGRlOTA4L3RhYmxlcmFuZ2U6YWQ5MDU1YjgxNGY1NGFjZGE1MWUzMTRkM2M4ZGU5MDhfNS0zLTEtMS0xMDQxMTk_c0278200-3bd4-41b6-ba0b-7456afa399d9"
      unitRef="shares">290000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RhYmxlOmFkOTA1NWI4MTRmNTRhY2RhNTFlMzE0ZDNjOGRlOTA4L3RhYmxlcmFuZ2U6YWQ5MDU1YjgxNGY1NGFjZGE1MWUzMTRkM2M4ZGU5MDhfNi0xLTEtMS0xMDQxMTk_da088923-8e0e-47ab-95ff-e6089280ac7f"
      unitRef="shares">39116000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV8zNy9mcmFnOmNmYjMzY2JlNjE3MTRlZDFiYzNjNDBlODQxN2FiNDAyL3RhYmxlOmFkOTA1NWI4MTRmNTRhY2RhNTFlMzE0ZDNjOGRlOTA4L3RhYmxlcmFuZ2U6YWQ5MDU1YjgxNGY1NGFjZGE1MWUzMTRkM2M4ZGU5MDhfNi0zLTEtMS0xMDQxMTk_dbbe29e8-2d9f-456b-b27f-f57b8a219818"
      unitRef="shares">30730000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RleHRyZWdpb246OWQzYzk4ZGEwMmM5NGZlZDk3NGJmMTBmOTU0YmU3OWVfMjE0Mw_3ebbb2d7-194e-4d28-9bdc-336fee7e4ab1">Revenue Recognition&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue by Source&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Instruments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,896,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,596,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consumables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,235,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,520,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,316,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,090,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,447,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,206,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,968,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,490,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,415,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,696,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has revised the classification of its revenue between the categories in the table above for the March 31, 2022 statement of operations. In the March 31, 2022 statement of operations, &#x201c;software&#x201d; was included in &#x201c;service and other.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue by Geographic Location&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Americas&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,444,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,328,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;EMEA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,992,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,739,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asia Pacific&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;979,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;629,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,415,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,696,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table above provides revenue from contracts with customers by source and geographic region (based on the customer&#x2019;s billing address) on a disaggregated basis. Americas consists of North America and South America. EMEA consists of Europe, the Middle East, and Africa. Asia Pacific includes China, Japan, South Korea, Singapore, India and Australia. During the three months ended September 30, 2022, the Company changed the presentation of its revenues from India to be included in the Asia Pacific geographic region. Prior to the three months ended September 30, 2022, the Company had presented revenues from India in the EMEA geographic region. The impact of this change on prior period disclosures is immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2023 and 2022, the United States represented 41.2% and 45.0% of total revenue, respectively. No other countries represented greater than 10% of revenue during the three months ended March&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Remaining Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was approximately $1.3 million. These remaining performance obligations primarily relate to extended warranty and support and maintenance obligations. The Company expects to recognize approximately&#160;74.9% of this amount as revenue during the remainder of 2023,&#160;20.5%&#160;in 2024, and 4.6%&#160;in 2025 and thereafter. Warranty revenue is included in service and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized revenue of approximately&#160;$0.7 million&#160;and $0.3 million during the three months ended March&#160;31, 2023 and 2022, respectively, which was included in the contract liability balance at the end of the previous year.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RleHRyZWdpb246OWQzYzk4ZGEwMmM5NGZlZDk3NGJmMTBmOTU0YmU3OWVfMjE0Ng_b0a98ec6-e0aa-44a1-b250-9e7359aa94cf">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue by Source&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Instruments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,896,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,596,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consumables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,235,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,520,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,316,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,090,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,447,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,206,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,968,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,490,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,415,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,696,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has revised the classification of its revenue between the categories in the table above for the March 31, 2022 statement of operations. In the March 31, 2022 statement of operations, &#x201c;software&#x201d; was included in &#x201c;service and other.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue by Geographic Location&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Americas&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,444,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,328,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;EMEA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,992,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,739,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asia Pacific&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;979,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;629,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,415,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,696,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2e2589f149c48c98dbde0d23aeb1c9c_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOmEwYzY4ZTkyNjQ3YjRmOTFhMzc1MGExYWZkM2IyMjViL3RhYmxlcmFuZ2U6YTBjNjhlOTI2NDdiNGY5MWEzNzUwYTFhZmQzYjIyNWJfMi0xLTEtMS0xMDQxMTk_00e3440e-1e50-403b-bac4-5a0021a1116f"
      unitRef="usd">1896000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09f8c8fdda344e15915c6c62c7945dcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOmEwYzY4ZTkyNjQ3YjRmOTFhMzc1MGExYWZkM2IyMjViL3RhYmxlcmFuZ2U6YTBjNjhlOTI2NDdiNGY5MWEzNzUwYTFhZmQzYjIyNWJfMi0zLTEtMS0xMDQxMTk_9d71284a-fdab-49ec-b053-da035f7fe2d2"
      unitRef="usd">1596000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6b13878be8b45768ae8ee86b23ec8b8_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOmEwYzY4ZTkyNjQ3YjRmOTFhMzc1MGExYWZkM2IyMjViL3RhYmxlcmFuZ2U6YTBjNjhlOTI2NDdiNGY5MWEzNzUwYTFhZmQzYjIyNWJfMy0xLTEtMS0xMDQxMTk_1623f3ea-0ddb-4cb4-8d0f-80e3ad66b26a"
      unitRef="usd">2235000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d3a177eaaa94180a39abb73b6e894d5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOmEwYzY4ZTkyNjQ3YjRmOTFhMzc1MGExYWZkM2IyMjViL3RhYmxlcmFuZ2U6YTBjNjhlOTI2NDdiNGY5MWEzNzUwYTFhZmQzYjIyNWJfMy0zLTEtMS0xMDQxMTk_056395b2-c7ad-4537-b974-d238d968f630"
      unitRef="usd">1520000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5c588f3ec9a49a9926f153fcb7f5e22_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOmEwYzY4ZTkyNjQ3YjRmOTFhMzc1MGExYWZkM2IyMjViL3RhYmxlcmFuZ2U6YTBjNjhlOTI2NDdiNGY5MWEzNzUwYTFhZmQzYjIyNWJfNC0xLTEtMS0xMDQ2ODU_08e5a98b-c485-4060-99e1-18bdc1ec2fa3"
      unitRef="usd">1316000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1dda61a7dbc48e3acfd918b47fcb93b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOmEwYzY4ZTkyNjQ3YjRmOTFhMzc1MGExYWZkM2IyMjViL3RhYmxlcmFuZ2U6YTBjNjhlOTI2NDdiNGY5MWEzNzUwYTFhZmQzYjIyNWJfNC0zLTEtMS0xMDQ2OTI_8d374fa4-4860-4951-8aef-f21464db7b0b"
      unitRef="usd">1090000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22c603917ec343e5b40cf1377f2dd0fa_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOmEwYzY4ZTkyNjQ3YjRmOTFhMzc1MGExYWZkM2IyMjViL3RhYmxlcmFuZ2U6YTBjNjhlOTI2NDdiNGY5MWEzNzUwYTFhZmQzYjIyNWJfNC0xLTEtMS0xMDQxMTk_3790dd9a-8892-490f-90ea-5bdd5f7edb2b"
      unitRef="usd">5447000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i103e1f66718e42e092ef57cf65cbad93_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOmEwYzY4ZTkyNjQ3YjRmOTFhMzc1MGExYWZkM2IyMjViL3RhYmxlcmFuZ2U6YTBjNjhlOTI2NDdiNGY5MWEzNzUwYTFhZmQzYjIyNWJfNC0zLTEtMS0xMDQxMTk_db90560b-9136-4a05-ae0e-fd3b338c6dfa"
      unitRef="usd">4206000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1fe061275f84c0db4bc966cec7ea694_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOmEwYzY4ZTkyNjQ3YjRmOTFhMzc1MGExYWZkM2IyMjViL3RhYmxlcmFuZ2U6YTBjNjhlOTI2NDdiNGY5MWEzNzUwYTFhZmQzYjIyNWJfNS0xLTEtMS0xMDQxMTk_522ca6ca-5a41-498a-a93a-84b090bf5006"
      unitRef="usd">1968000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifebd115420624a60b9827cd166e72988_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOmEwYzY4ZTkyNjQ3YjRmOTFhMzc1MGExYWZkM2IyMjViL3RhYmxlcmFuZ2U6YTBjNjhlOTI2NDdiNGY5MWEzNzUwYTFhZmQzYjIyNWJfNS0zLTEtMS0xMDQxMTk_24483e33-7d36-441e-a186-215e29c1e1e4"
      unitRef="usd">1490000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOmEwYzY4ZTkyNjQ3YjRmOTFhMzc1MGExYWZkM2IyMjViL3RhYmxlcmFuZ2U6YTBjNjhlOTI2NDdiNGY5MWEzNzUwYTFhZmQzYjIyNWJfNi0xLTEtMS0xMDQxMTk_bdefea21-92ae-4e17-bcaa-13e18fc2f1b0"
      unitRef="usd">7415000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOmEwYzY4ZTkyNjQ3YjRmOTFhMzc1MGExYWZkM2IyMjViL3RhYmxlcmFuZ2U6YTBjNjhlOTI2NDdiNGY5MWEzNzUwYTFhZmQzYjIyNWJfNi0zLTEtMS0xMDQxMTk_9b94f88a-03bf-483d-8487-8e37d8071b6e"
      unitRef="usd">5696000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6669836447414cf385db5ed716981bad_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfMy0xLTEtMS0xMDQxMTk_971d5b43-0133-4f5f-b190-f5b20136a098"
      unitRef="usd">3444000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1b1a8735b85a466297034ff9a73884a0_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfMy0zLTEtMS0xMDQxMTk_2bf1dee7-6eeb-4b83-b939-f4daccb11675"
      unitRef="number">0.47</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f04d40d0a8a454f84a321e4acea14d8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfMy01LTEtMS0xMDQxMTk_a2e1b007-8f63-4af0-877f-ade93fcf444c"
      unitRef="usd">3328000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idc3e1023716e476aab35caddbed89579_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfMy03LTEtMS0xMDQxMTk_6a5fe116-fbcc-4ca5-af64-d772e08526c1"
      unitRef="number">0.58</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6f8e39f135240fd97ecb419976b9597_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfNC0xLTEtMS0xMDQxMTk_6cdb092c-fac5-4309-9f4c-9209df8a6645"
      unitRef="usd">2992000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie92600da576c4047864e9f7117cc5fdf_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfNC0zLTEtMS0xMDQxMTk_b5c3dd74-49bb-4b81-84eb-e5fe2e0dc26e"
      unitRef="number">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72bd82e51a92475595d3e02336fdfb2d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfNC01LTEtMS0xMDQxMTk_d78929cc-44b2-4497-8ab4-52aeb114e086"
      unitRef="usd">1739000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibf59dab4a829447b87dd7cfb6e935afc_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfNC03LTEtMS0xMDQxMTk_fec441ff-371f-4745-8f62-abf36a6eab3d"
      unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i917de2a823d54fc7a1e5c49a7ec6d043_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfNS0xLTEtMS0xMDQxMTk_9a4cb7d0-525b-49ff-9c60-c294e1e9790b"
      unitRef="usd">979000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3e339b6ff4f0444a9fc421813ed7f9fc_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfNS0zLTEtMS0xMDQxMTk_86c26ad4-0ea0-4716-be56-70dd56bfc6bd"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if817cc0631b9461ca84a6ce880217661_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfNS01LTEtMS0xMDQxMTk_faf7fc10-9bdf-4c3b-aece-77844529740b"
      unitRef="usd">629000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i16ed69d918584dbcb3ba99cd2e78d70d_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfNS03LTEtMS0xMDQxMTk_afb50801-19b8-4896-9375-159ee59a8af6"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfNi0xLTEtMS0xMDQxMTk_0b248c88-0c18-4562-8c54-f24e404a67e2"
      unitRef="usd">7415000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iec1a90f2c7e6457d9c6916e2e00a8d96_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfNi0zLTEtMS0xMDQxMTk_6fb56937-97bb-406e-a17f-bddb57e6e3df"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfNi01LTEtMS0xMDQxMTk_ddef8e1e-5239-488b-b161-a3e6d043cf19"
      unitRef="usd">5696000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if4e04fca88824c018823bdc8633103aa_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RhYmxlOjVhNGM2N2YwZDZiNTRjZGY5NTk5MTAxMTVmOGM5MzE1L3RhYmxlcmFuZ2U6NWE0YzY3ZjBkNmI1NGNkZjk1OTkxMDExNWY4YzkzMTVfNi03LTEtMS0xMDQxMTk_26cf8e6a-fba0-49ee-ace8-d7142cc93ce7"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4b3236b899344cfc8b2fdf441232a276_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RleHRyZWdpb246OWQzYzk4ZGEwMmM5NGZlZDk3NGJmMTBmOTU0YmU3OWVfODM3_f5e2c0cd-03a8-4acd-aacc-68452f9c3653"
      unitRef="number">0.412</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ida637f06483b4c35bd6bc6a61abb2280_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RleHRyZWdpb246OWQzYzk4ZGEwMmM5NGZlZDk3NGJmMTBmOTU0YmU3OWVfODQ0_86cb7db8-cccf-486f-90bd-65d144f09d49"
      unitRef="number">0.450</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RleHRyZWdpb246OWQzYzk4ZGEwMmM5NGZlZDk3NGJmMTBmOTU0YmU3OWVfMTUyNA_6b98a67b-421f-49c5-9008-01799b63ff7e"
      unitRef="usd">1300000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="i303c93e0678640749a33b09eedfdd18e_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RleHRyZWdpb246OWQzYzk4ZGEwMmM5NGZlZDk3NGJmMTBmOTU0YmU3OWVfMTY5NA_69def23d-0a6d-48b9-ad74-131544c9eb10"
      unitRef="number">0.749</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="i91fc38e2fd89410d85c4aaa28c03aa5a_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RleHRyZWdpb246OWQzYzk4ZGEwMmM5NGZlZDk3NGJmMTBmOTU0YmU3OWVfMTc1Mw_0837da0d-3b64-4024-b678-c8c65d5b76c0"
      unitRef="number">0.205</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="i678356c830584df394c07359661df8fe_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RleHRyZWdpb246OWQzYzk4ZGEwMmM5NGZlZDk3NGJmMTBmOTU0YmU3OWVfMTc2OQ_a05c0f16-6b8c-40ab-96a6-2793b69d1976"
      unitRef="number">0.046</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RleHRyZWdpb246OWQzYzk4ZGEwMmM5NGZlZDk3NGJmMTBmOTU0YmU3OWVfMTkwMw_0b06e993-f02e-4326-bbdb-39a322eaf54c"
      unitRef="usd">700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80MC9mcmFnOjlkM2M5OGRhMDJjOTRmZWQ5NzRiZjEwZjk1NGJlNzllL3RleHRyZWdpb246OWQzYzk4ZGEwMmM5NGZlZDk3NGJmMTBmOTU0YmU3OWVfMTkxMA_94d0f5fb-fd8d-4784-ad90-eef57a8cf5ab"
      unitRef="usd">300000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RleHRyZWdpb246MWNmOThmMDQyMzU2NDEzNTk2YzM2ZjE4NGE1MDJmZGZfNTY2_d6d7d9fe-5dba-408e-966f-d7eca7337189">Balance Sheet Account Details&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable and Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts receivable, trade&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,030,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,315,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Allowance for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(250,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(293,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,780,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,022,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes to the allowance for credit losses during the three months ended March&#160;31, 2023 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(293,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for expected credit loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Write-offs and payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(250,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's adoption of ASU No. 2016-13, Financial Instruments - Credit Losses, included an assessment of our aged trade receivables balances and their underlying credit risk characteristics. Our evaluation of past events, current conditions, and reasonable and supportable forecasts about the future resulted in an expectation of immaterial credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventories are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Inventory:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,319,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;Work in process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,003,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,055,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,310,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,387,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,113,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,761,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets that are subject to amortization consisted of the following for the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,630,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(684,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,946,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,630,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(552,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,078,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,379,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,771,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,172,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,978,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,600,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,068,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,532,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,600,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,615,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,985,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,380,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,131,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,249,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,380,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,339,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,041,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets not subject to amortization totaled $0.1&#160;million at March&#160;31, 2023 and December&#160;31, 2022, and related to the Company&#x2019;s domain name. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Compensation expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,349,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,002,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;848,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;825,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Insurance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;326,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;613,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Professional fees and royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warranty liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;591,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;489,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued clinical study fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;849,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,146,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,552,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RleHRyZWdpb246MWNmOThmMDQyMzU2NDEzNTk2YzM2ZjE4NGE1MDJmZGZfNTYx_ce11ec3d-15f0-4589-b386-b42d573cb563">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts receivable, trade&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,030,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,315,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Allowance for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(250,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(293,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,780,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,022,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjkzOTcxMjJmZmUyYTQ3MjE4NGJhMTM4YTdlMzRmN2RkL3RhYmxlcmFuZ2U6OTM5NzEyMmZmZTJhNDcyMTg0YmExMzhhN2UzNGY3ZGRfMi0xLTEtMS0xMDQxMTk_216931b5-4e73-4a54-8e17-f3caa4597ac5"
      unitRef="usd">7030000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjkzOTcxMjJmZmUyYTQ3MjE4NGJhMTM4YTdlMzRmN2RkL3RhYmxlcmFuZ2U6OTM5NzEyMmZmZTJhNDcyMTg0YmExMzhhN2UzNGY3ZGRfMi00LTEtMS0xMDQxMTk_70a441ae-b07c-47d5-a096-94d41edbbea5"
      unitRef="usd">7315000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjkzOTcxMjJmZmUyYTQ3MjE4NGJhMTM4YTdlMzRmN2RkL3RhYmxlcmFuZ2U6OTM5NzEyMmZmZTJhNDcyMTg0YmExMzhhN2UzNGY3ZGRfMy0xLTEtMS0xMDQxMTk_1b510d8b-8643-4062-8b8d-e55c36c53598"
      unitRef="usd">250000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjkzOTcxMjJmZmUyYTQ3MjE4NGJhMTM4YTdlMzRmN2RkL3RhYmxlcmFuZ2U6OTM5NzEyMmZmZTJhNDcyMTg0YmExMzhhN2UzNGY3ZGRfMy00LTEtMS0xMDQxMTk_c1a325b8-42aa-4ca3-924a-b2c066567253"
      unitRef="usd">293000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjkzOTcxMjJmZmUyYTQ3MjE4NGJhMTM4YTdlMzRmN2RkL3RhYmxlcmFuZ2U6OTM5NzEyMmZmZTJhNDcyMTg0YmExMzhhN2UzNGY3ZGRfNC0xLTEtMS0xMDQxMTk_01708d36-a2d9-4922-91ef-eaf13764f75b"
      unitRef="usd">6780000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjkzOTcxMjJmZmUyYTQ3MjE4NGJhMTM4YTdlMzRmN2RkL3RhYmxlcmFuZ2U6OTM5NzEyMmZmZTJhNDcyMTg0YmExMzhhN2UzNGY3ZGRfNC00LTEtMS0xMDQxMTk_f914c7a8-aec8-402d-92d5-1fbc7c6fda0a"
      unitRef="usd">7022000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RleHRyZWdpb246MWNmOThmMDQyMzU2NDEzNTk2YzM2ZjE4NGE1MDJmZGZfNDk0NzgwMjMyNzEzMQ_d69da13b-883a-4f78-b7e1-f760d06cb1b9">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes to the allowance for credit losses during the three months ended March&#160;31, 2023 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(293,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for expected credit loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Write-offs and payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(250,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjllYWIyZGQyOWM2YzQ1N2ZiZDI3NzkxNDA2MGY5NjI0L3RhYmxlcmFuZ2U6OWVhYjJkZDI5YzZjNDU3ZmJkMjc3OTE0MDYwZjk2MjRfMS0xLTEtMS0xMTMxODA_f3d8430c-98c0-4524-876a-f16e1f85153f"
      unitRef="usd">293000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjllYWIyZGQyOWM2YzQ1N2ZiZDI3NzkxNDA2MGY5NjI0L3RhYmxlcmFuZ2U6OWVhYjJkZDI5YzZjNDU3ZmJkMjc3OTE0MDYwZjk2MjRfMi0xLTEtMS0xMTMxODA_95fc3ca3-2c21-4db7-8547-13714d4dcd1c"
      unitRef="usd">-5000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjllYWIyZGQyOWM2YzQ1N2ZiZDI3NzkxNDA2MGY5NjI0L3RhYmxlcmFuZ2U6OWVhYjJkZDI5YzZjNDU3ZmJkMjc3OTE0MDYwZjk2MjRfMy0xLTEtMS0xMTMxODA_650adaf8-f1bc-45c0-bae8-ad78d90fcda9"
      unitRef="usd">48000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjllYWIyZGQyOWM2YzQ1N2ZiZDI3NzkxNDA2MGY5NjI0L3RhYmxlcmFuZ2U6OWVhYjJkZDI5YzZjNDU3ZmJkMjc3OTE0MDYwZjk2MjRfNC0xLTEtMS0xMTMxODA_1e65b130-ae3d-4dd9-bb43-72ea04dc29a1"
      unitRef="usd">250000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RleHRyZWdpb246MWNmOThmMDQyMzU2NDEzNTk2YzM2ZjE4NGE1MDJmZGZfNTY3_f86bbcf1-35e3-4230-b595-ddd366acb11c">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventories are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Inventory:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,319,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;Work in process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,003,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,055,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,310,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,387,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,113,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,761,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjFlZmMwZTQxNmVkZDQxYWViNTY3NGI4YzZjMDAxNGEyL3RhYmxlcmFuZ2U6MWVmYzBlNDE2ZWRkNDFhZWI1Njc0YjhjNmMwMDE0YTJfMi0xLTEtMS0xMDQxMTk_1327865b-af1f-482d-96c5-b4b1b9cd9915"
      unitRef="usd">5800000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjFlZmMwZTQxNmVkZDQxYWViNTY3NGI4YzZjMDAxNGEyL3RhYmxlcmFuZ2U6MWVmYzBlNDE2ZWRkNDFhZWI1Njc0YjhjNmMwMDE0YTJfMi0zLTEtMS0xMDQxMTk_c393b2e8-b694-4cb6-8ee8-dd24e7e57321"
      unitRef="usd">5319000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjFlZmMwZTQxNmVkZDQxYWViNTY3NGI4YzZjMDAxNGEyL3RhYmxlcmFuZ2U6MWVmYzBlNDE2ZWRkNDFhZWI1Njc0YjhjNmMwMDE0YTJfMy0xLTEtMS0xMDQxMTk_4898dc80-3108-4367-a661-d6be6158777e"
      unitRef="usd">10003000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjFlZmMwZTQxNmVkZDQxYWViNTY3NGI4YzZjMDAxNGEyL3RhYmxlcmFuZ2U6MWVmYzBlNDE2ZWRkNDFhZWI1Njc0YjhjNmMwMDE0YTJfMy0zLTEtMS0xMDQxMTk_14094897-2037-42c8-b63f-c20e2c2439e5"
      unitRef="usd">7055000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjFlZmMwZTQxNmVkZDQxYWViNTY3NGI4YzZjMDAxNGEyL3RhYmxlcmFuZ2U6MWVmYzBlNDE2ZWRkNDFhZWI1Njc0YjhjNmMwMDE0YTJfNC0xLTEtMS0xMDQxMTk_70612b59-d5db-4057-96b8-9dcb3f8f96ae"
      unitRef="usd">17310000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjFlZmMwZTQxNmVkZDQxYWViNTY3NGI4YzZjMDAxNGEyL3RhYmxlcmFuZ2U6MWVmYzBlNDE2ZWRkNDFhZWI1Njc0YjhjNmMwMDE0YTJfNC0zLTEtMS0xMDQxMTk_51a015c0-3fe9-4b2d-8973-aa6130ec67fc"
      unitRef="usd">17387000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjFlZmMwZTQxNmVkZDQxYWViNTY3NGI4YzZjMDAxNGEyL3RhYmxlcmFuZ2U6MWVmYzBlNDE2ZWRkNDFhZWI1Njc0YjhjNmMwMDE0YTJfNS0xLTEtMS0xMDQxMTk_956f09a2-bcad-4e55-9ce1-1c740dd97c1a"
      unitRef="usd">33113000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjFlZmMwZTQxNmVkZDQxYWViNTY3NGI4YzZjMDAxNGEyL3RhYmxlcmFuZ2U6MWVmYzBlNDE2ZWRkNDFhZWI1Njc0YjhjNmMwMDE0YTJfNS0zLTEtMS0xMDQxMTk_fa25d76b-30f0-47a0-a2c9-0a1e4ae19f5f"
      unitRef="usd">29761000</us-gaap:InventoryNet>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RleHRyZWdpb246MWNmOThmMDQyMzU2NDEzNTk2YzM2ZjE4NGE1MDJmZGZfNTY1_79bc9a8c-f3cf-4c0c-aeaa-5a16bc886731">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets that are subject to amortization consisted of the following for the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,630,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(684,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,946,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,630,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(552,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,078,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,379,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,771,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,172,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,978,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,600,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,068,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,532,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,600,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,615,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,985,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,380,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,131,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,249,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,380,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,339,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,041,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i29d038c26e154c959a4f83462f9a3b3d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfMi0yLTEtMS0xMDQxMTk_83f2609d-d35c-421f-b3a2-9ab8651269f5"
      unitRef="usd">2630000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i29d038c26e154c959a4f83462f9a3b3d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfMi00LTEtMS0xMDQxMTk_ee1f3191-c504-491f-ba17-8e24d4a0f69b"
      unitRef="usd">684000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i29d038c26e154c959a4f83462f9a3b3d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfMi02LTEtMS0xMDQxMTk_e3898b83-40a0-4a61-8f05-9924bf08b050"
      unitRef="usd">1946000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic21009a40b5d4f3a9d49db39e85d0352_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfMi04LTEtMS0xMDQxMTk_03464035-de84-4a8b-8831-1bfddab809c8"
      unitRef="usd">2630000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic21009a40b5d4f3a9d49db39e85d0352_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfMi0xMC0xLTEtMTA0MTE5_742522d2-4786-468b-bd7e-40e7e8619965"
      unitRef="usd">552000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic21009a40b5d4f3a9d49db39e85d0352_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfMi0xMi0xLTEtMTA0MTE5_46bed165-96d5-4f9d-b708-ecea6e805c9d"
      unitRef="usd">2078000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6b57f1747a864d48806216f6ebcb9b52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfMy0yLTEtMS0xMDQxMTk_c231dafe-cddb-42fe-aacc-0b0be8f15426"
      unitRef="usd">4150000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6b57f1747a864d48806216f6ebcb9b52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfMy00LTEtMS0xMDQxMTk_c2956e2f-fec2-43be-bddb-7ae9dc91813d"
      unitRef="usd">1379000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6b57f1747a864d48806216f6ebcb9b52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfMy02LTEtMS0xMDQxMTk_5b730831-2f19-425d-b08c-93f573f9a2b8"
      unitRef="usd">2771000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id18ec7102f5243eead2eb22c65c27ed0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfMy04LTEtMS0xMDQxMTk_b136d2f4-9614-4f22-927d-992622e51810"
      unitRef="usd">4150000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id18ec7102f5243eead2eb22c65c27ed0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfMy0xMC0xLTEtMTA0MTE5_493cd3b8-f3a7-4fe4-baf6-d63bc09baf83"
      unitRef="usd">1172000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id18ec7102f5243eead2eb22c65c27ed0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfMy0xMi0xLTEtMTA0MTE5_119b2ed1-ce9f-4bea-ba09-7efd9e7ed031"
      unitRef="usd">2978000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1d06ccbd81864c1aa7ab64abb42f4f5c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfNC0yLTEtMS0xMDQxMTk_a821e874-24d3-459c-adc1-83e6974dab99"
      unitRef="usd">41600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1d06ccbd81864c1aa7ab64abb42f4f5c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfNC00LTEtMS0xMDQxMTk_accc917d-9535-472c-b711-14aa40b931df"
      unitRef="usd">7068000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1d06ccbd81864c1aa7ab64abb42f4f5c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfNC02LTEtMS0xMDQxMTk_53a032a6-081b-4759-8837-ad8be41753fc"
      unitRef="usd">34532000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i30a742016d854b90bc517ceec127c4da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfNC04LTEtMS0xMDQxMTk_26d8d653-3c57-4dec-85ea-afbf176908dd"
      unitRef="usd">41600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i30a742016d854b90bc517ceec127c4da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfNC0xMC0xLTEtMTA0MTE5_b3eb3a60-eea5-4f3e-ac37-bba397614631"
      unitRef="usd">5615000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i30a742016d854b90bc517ceec127c4da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfNC0xMi0xLTEtMTA0MTE5_64548433-1d91-4306-b21d-6b92c425e667"
      unitRef="usd">35985000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfNS0yLTEtMS0xMDQxMTk_d882121f-f5f3-4c0a-8c2d-c6b02312ff56"
      unitRef="usd">48380000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfNS00LTEtMS0xMDQxMTk_7f866c55-5591-4c0c-ac12-77260bd472a3"
      unitRef="usd">9131000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfNS02LTEtMS0xMDQxMTk_fc7f4680-465c-481c-9ce9-4847221e1f20"
      unitRef="usd">39249000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfNS04LTEtMS0xMDQxMTk_27688311-31a3-46b2-958a-5164fa257962"
      unitRef="usd">48380000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfNS0xMC0xLTEtMTA0MTE5_fcab77dd-8e05-4d53-9410-1734d071d73f"
      unitRef="usd">7339000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOjliYjEzY2ZiNmY1ZDRkNmViYzk0ZjQ1MzgxODcyYTc5L3RhYmxlcmFuZ2U6OWJiMTNjZmI2ZjVkNGQ2ZWJjOTRmNDUzODE4NzJhNzlfNS0xMi0xLTEtMTA0MTE5_fe85f327-253e-4a59-bb14-d6562c00df91"
      unitRef="usd">41041000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib5a9db6b0ffb4fe28ef89805f31f26bc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RleHRyZWdpb246MWNmOThmMDQyMzU2NDEzNTk2YzM2ZjE4NGE1MDJmZGZfNTQ5NzU1ODE1MDEz_22d8fdc4-fbb5-4c35-96b5-c033f37cdadd"
      unitRef="usd">100000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iafccbaea24c04903bdeb891f986857c7_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RleHRyZWdpb246MWNmOThmMDQyMzU2NDEzNTk2YzM2ZjE4NGE1MDJmZGZfNTQ5NzU1ODE1MDEz_f99ae2e3-7bac-4224-be5e-aeeb1f39e25b"
      unitRef="usd">100000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RleHRyZWdpb246MWNmOThmMDQyMzU2NDEzNTk2YzM2ZjE4NGE1MDJmZGZfNTY0_b4788c8d-c726-4d86-9f78-fd56b45f3079">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Compensation expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,349,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,002,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;848,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;825,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Insurance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;326,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;613,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Professional fees and royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warranty liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;591,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;489,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued clinical study fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;849,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,146,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,552,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfMS0xLTEtMS0xMDQxMTk_f404352a-d5a1-4b0d-9629-108c4719038d"
      unitRef="usd">6349000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfMS0zLTEtMS0xMDQxMTk_d12c7c8c-144a-4705-bb45-d5bf47d814a3"
      unitRef="usd">7002000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:DepositLiabilityCurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfMy0xLTEtMS0xMDQxMTk_07030618-fba4-4c33-9988-16cd01f8cf56"
      unitRef="usd">17000</us-gaap:DepositLiabilityCurrent>
    <us-gaap:DepositLiabilityCurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfMy0zLTEtMS0xMDQxMTk_68a1ef1f-9e6e-4996-9f7a-31dac1e34665"
      unitRef="usd">17000</us-gaap:DepositLiabilityCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfNC0xLTEtMS0xMDQxMTk_a9b9f72b-eb64-4292-b8ae-d4997d2996e4"
      unitRef="usd">848000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfNC0zLTEtMS0xMDQxMTk_c4da87c6-a364-4960-b5ea-b7c177a654f2"
      unitRef="usd">825000</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfNS0xLTEtMS0xMDQxMTk_6405141f-0690-4681-b6dc-69600dc5515b"
      unitRef="usd">326000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfNS0zLTEtMS0xMDQxMTk_eb9c4335-058c-457e-a853-ad74f1b32eed"
      unitRef="usd">613000</us-gaap:AccruedInsuranceCurrent>
    <bngo:ProfessionalFeesAndRoyaltiesCurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfNi0xLTEtMS0xMDQxMTk_7de4d4a0-f343-45a1-8579-09cbe9366a58"
      unitRef="usd">96000</bngo:ProfessionalFeesAndRoyaltiesCurrent>
    <bngo:ProfessionalFeesAndRoyaltiesCurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfNi0zLTEtMS0xMDQxMTk_9a8f716b-fec8-495b-8131-f385e61808db"
      unitRef="usd">210000</bngo:ProfessionalFeesAndRoyaltiesCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfNy0xLTEtMS0xMDQxMTk_2a012f02-4a74-43b7-8e91-2947ec381e34"
      unitRef="usd">591000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfNy0zLTEtMS0xMDQxMTk_a0a567d7-cb7c-471f-aa7e-411aafa9a485"
      unitRef="usd">489000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <bngo:AccruedClinicalStudyFeesCurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfOC0xLTEtMS0xMDQxMTk_1ae5118b-d08c-46d7-b003-f8941eff7145"
      unitRef="usd">174000</bngo:AccruedClinicalStudyFeesCurrent>
    <bngo:AccruedClinicalStudyFeesCurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfOC0zLTEtMS0xMDQxMTk_0f154643-9cc2-4c16-8950-77b8a7a76db4"
      unitRef="usd">250000</bngo:AccruedClinicalStudyFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfOS0xLTEtMS0xMDQxMTk_a7cb503d-353e-4154-ab6b-1bf045ef0b20"
      unitRef="usd">849000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfOS0zLTEtMS0xMDQxMTk_0d4c9f32-594a-402f-bade-1f2aef604f15"
      unitRef="usd">1146000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfMTAtMS0xLTEtMTA0MTE5_3d450668-26da-4c81-b07c-a7e12e249acd"
      unitRef="usd">9250000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV80Ni9mcmFnOjFjZjk4ZjA0MjM1NjQxMzU5NmMzNmYxODRhNTAyZmRmL3RhYmxlOmU2ZTM0NDY2ZTUyODQzODFiYTI1ZTQ0NGE0YmYyMjIxL3RhYmxlcmFuZ2U6ZTZlMzQ0NjZlNTI4NDM4MWJhMjVlNDQ0YTRiZjIyMjFfMTAtMy0xLTEtMTA0MTE5_46ebd4a5-d388-4e2b-bdc6-2786ac0691e0"
      unitRef="usd">10552000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNjM0NQ_7526821b-5fff-4732-a68c-2b4b9261efee">Stockholders&#x2019; Equity and Stock-Based Compensation&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cowen At-the-Market Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 23, 2021, the Company entered into a Sales Agreement with Cowen and Company, LLC (&#x201c;Cowen&#x201d;) which provides for the sale, in the Company&#x2019;s sole discretion, of shares of common stock having an aggregate offering price of up to $350.0&#160;million through or to Cowen, acting as sales agent or principal, which was amended on March 9, 2023 to decrease the maximum aggregate offering price to $200.0&#160;million for sales made on and after the date of the amendment (the &#x201c;Cowen ATM&#x201d;). The Company agreed to pay Cowen a commission of up to 3.0% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. In August 2022, the Company sold approximately 6.6&#160;million shares of common stock under the Cowen ATM at an average share price of $3.46 per share, and received gross proceeds of approximately $23.1 million before deducting offering costs of $0.6 million. During the first quarter of 2023, the Company sold approximately 9.5&#160;million shares of common stock under the Cowen ATM at an average share price of $1.60 per share, and received gross proceeds of approximately $15.2 million before deducting offering costs of $0.4 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s warrant activity during the three months ended March&#160;31, 2023 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares of Stock under Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,356,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,356,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity during the three months ended March&#160;31, 2023 was as follows: &#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares of Stock under Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,022,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,068,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,121,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,088,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,013,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,147,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,149,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;892,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2023, the weighted-average grant date fair value of stock options granted was $1.07 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized stock-based compensation expense for the periods presented as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,357,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,328,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,774,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,102,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants during the periods presented were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A restricted stock award in the amount of 5.0 million shares with a grant date fair value of $5.20 a share was granted as part of the acquisition of BioDiscovery. One-third of the Restricted Shares was scheduled to vest on October 18, 2022 and one-twelfth of the Restricted Shares was scheduled to vest every three months following October 18, 2022, subject to continuous service of the key employee. The fair value of the restricted stock award was based on the market value of common stock as of the date of grant and was amortized to stock-based compensation expense over the service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 4, 2022, the restricted stock award was modified due to the change in employment status of the key employee from full time to emeritus. As a result of the modification, the restricted stock award vested in full on October 4, 2022. The award was revalued on the modification date, resulting in a modified grant date fair value of $2.04 a share ($15.8&#160;million less than the initial grant date fair value of the award). The fair value of the modified restricted stock award was based on the market value of common stock as of the modification date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units and Performance Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity during the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Grant Date Fair Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,461,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,457,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.67&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of the RSUs that vested during the three months ended March&#160;31, 2023 was $0.3&#160;million, determined as of the date of vesting. The weighted average remaining contractual term for the RSUs is 3.5 years as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes PSU activity during the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Grant Date Fair Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.74&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average remaining contractual term for the PSUs is 2.1 years as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Executive Option Grants and RSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 15, 2023, the compensation committee of the Company&#x2019;s board of directors granted various executive officers stock options to purchase an aggregate of 3.3 million shares of common stock at an exercise price of $1.63 per share, and RSUs amounting to 0.7 million shares of common stock at a grant date fair value of $1.63 per share, in each case with an effective grant date and vesting commencement date of February 15, 2023 (the &#x201c;Grant Date&#x201d;). These stock option grants and RSUs were issued from the 2018 Plan. The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of the Grant Date, such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. The RSUs shall vest annually over four years beginning one year after the Grant Date, and the balance of the shares vest in a series of three successive equal annual installments measured from the first anniversary of the Grant Date, such that the RSU shall be fully vested on the four-year anniversary of the Grant Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 13, 2023, the Company entered into an agreement with David Barker, the Chair of the Company&#x2019;s board of directors, pursuant to which the Company agreed to issue and sell one share of the Company&#x2019;s Series A Preferred Stock, par value $0.0001 per share for a purchase price of $100.00. The closing of the sale and purchase of the share of Series A Preferred was completed on April 13, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The share of Series A Preferred will have 3.0 billion votes, but has the right to vote only on a proposal submitted to the stockholders of the Company to adopt an amendment, or a series of alternate amendments, to the Company&#x2019;s Amended and Restated Certificate of Incorporation, as amended, to combine the outstanding shares of Common Stock into a smaller number of shares of Common Stock at a ratio specified in or determined in accordance with the terms of such amendment or series of alternate amendments (&#x201c;Reverse Stock Split Proposal&#x201d;), and will have no voting rights (i) except with respect to a Reverse Stock Split Proposal and the votes of the share of Series A Preferred are required to be cast for and against such Reverse Stock Split Proposal in the same proportion as shares of Common Stock are voted for and against such Reverse Stock Split Proposal (with any shares of Common Stock that are not voted, whether due to abstentions, broker non-votes or otherwise not counted as votes for or against a Reverse Stock Split Proposal) and (ii) unless the holders of one-third (1/3rd) of the outstanding shares of Common Stock are present and vote, in person or by proxy, at the meeting of stockholders at which a Reverse Stock Split Proposal is submitted for stockholder approval (or any adjournment thereof). The share of Series A Preferred will vote together with the Common Stock as a single class on a Reverse Stock Split Proposal. The Series A Preferred has no other voting rights, except as may be required by the General Corporation Law of the State of Delaware. The outstanding share of Series A Preferred will be redeemed in whole, but not in part, for a redemption price of $100.00, payable out of funds lawfully available therefor, (i) if such redemption is ordered by the Company&#x2019;s Board of Directors in its sole discretion, automatically and effective on such time and date specified by the Board of Directors in its sole discretion, or (ii) automatically immediately following the approval by the stockholders of a Reverse Stock Split Proposal.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <bngo:SaleOfStockValueSharesIssuedInTransaction
      contextRef="i25be08a217074beba4e4c3f2222e4263_D20210323-20210323"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMjU3OQ_d070c395-f0f4-4d18-ae3b-b4dec7e8f684"
      unitRef="usd">350000000</bngo:SaleOfStockValueSharesIssuedInTransaction>
    <bngo:SaleOfStockValueSharesIssuedInTransaction
      contextRef="i97754e6d8ba6487d87fcb2566157286b_D20230309-20230309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNDk0NzgwMjM0MTQ2Mw_ae8ca176-03c8-42c0-8c26-b69fcc20b17f"
      unitRef="usd">200000000</bngo:SaleOfStockValueSharesIssuedInTransaction>
    <bngo:CommissionFeeMaximumPercentageOfGrossProceeds
      contextRef="i25be08a217074beba4e4c3f2222e4263_D20210323-20210323"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMjcxMQ_e8351f54-c947-4f86-985c-6883da8e232a"
      unitRef="number">0.030</bngo:CommissionFeeMaximumPercentageOfGrossProceeds>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i93b42a0d7db1482cba91fd543f66a9ba_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMzE2OQ_525610c0-b77f-4174-8d0a-72b1dff6daa2"
      unitRef="shares">6600000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i99f3f173943c45748c287bda013eed0c_I20220831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMzI0NA_60a1820e-adc9-4fda-95dd-382452369e7e"
      unitRef="usdPerShare">3.46</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i93b42a0d7db1482cba91fd543f66a9ba_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMzMwMw_65a3fe6e-0fe6-4311-810c-242596b9e98c"
      unitRef="usd">23100000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i99f3f173943c45748c287bda013eed0c_I20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMzM0MQ_53af180b-db71-40ff-8942-b12b763ac7d7"
      unitRef="usd">600000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMTA5OTUxMTY0MTUyMw_25d9bfa8-a02f-49aa-88d3-a9db9ae2df9d"
      unitRef="shares">9500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMTA5OTUxMTY0MTUyNw_c7c011d2-329b-43cf-b28e-27e3cdb0e080"
      unitRef="usdPerShare">1.60</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMTA5OTUxMTY0MTUzMQ_bd00fc6e-0799-45db-a345-018cff6e2b47"
      unitRef="usd">15200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMTA5OTUxMTY0MTUzNQ_fe435273-1880-4d43-b4e7-013369174ce8"
      unitRef="usd">400000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNjM0Ng_80e022e1-9c29-41fe-8f3e-02744766b931">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s warrant activity during the three months ended March&#160;31, 2023 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares of Stock under Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,356,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,356,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjU4NTJlZmU0NWVhMjRkZjBhZDJjYjY4Y2IxNjAzOWVjL3RhYmxlcmFuZ2U6NTg1MmVmZTQ1ZWEyNGRmMGFkMmNiNjhjYjE2MDM5ZWNfMS0xLTEtMS0xMDQxMTk_a9201b96-393e-44f1-8eb1-d4ba1edf7a6c"
      unitRef="shares">4356000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjU4NTJlZmU0NWVhMjRkZjBhZDJjYjY4Y2IxNjAzOWVjL3RhYmxlcmFuZ2U6NTg1MmVmZTQ1ZWEyNGRmMGFkMmNiNjhjYjE2MDM5ZWNfMS0zLTEtMS0xMDQxMTk_d529c2d3-f2a6-4140-81dc-4b5fd79f5de4"
      unitRef="usdPerShare">5.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights
      contextRef="i4be8520461cc4836b2bf1279c0c49b2a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjU4NTJlZmU0NWVhMjRkZjBhZDJjYjY4Y2IxNjAzOWVjL3RhYmxlcmFuZ2U6NTg1MmVmZTQ1ZWEyNGRmMGFkMmNiNjhjYjE2MDM5ZWNfMS01LTEtMS0xMDQxMTk_d7ebd10a-bc9f-40dc-987f-3652a207a0c4">P0Y9M3D</bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights>
    <bngo:ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjU4NTJlZmU0NWVhMjRkZjBhZDJjYjY4Y2IxNjAzOWVjL3RhYmxlcmFuZ2U6NTg1MmVmZTQ1ZWEyNGRmMGFkMmNiNjhjYjE2MDM5ZWNfMS03LTEtMS0xMDQxMTk_ea386e91-7dbd-4521-b35f-b7e7c2ede0e2"
      unitRef="usd">273000</bngo:ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights>
    <bngo:ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjU4NTJlZmU0NWVhMjRkZjBhZDJjYjY4Y2IxNjAzOWVjL3RhYmxlcmFuZ2U6NTg1MmVmZTQ1ZWEyNGRmMGFkMmNiNjhjYjE2MDM5ZWNfMi0xLTEtMS0xMDQxMTk_e77b606b-e4e7-4a8f-82b1-2d46ef9e4970"
      unitRef="shares">0</bngo:ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod>
    <bngo:ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjU4NTJlZmU0NWVhMjRkZjBhZDJjYjY4Y2IxNjAzOWVjL3RhYmxlcmFuZ2U6NTg1MmVmZTQ1ZWEyNGRmMGFkMmNiNjhjYjE2MDM5ZWNfMy0xLTEtMS0xMDQxMTk_857f30ec-4f75-4109-904c-882f8baf8b1a"
      unitRef="shares">0</bngo:ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod>
    <bngo:ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjU4NTJlZmU0NWVhMjRkZjBhZDJjYjY4Y2IxNjAzOWVjL3RhYmxlcmFuZ2U6NTg1MmVmZTQ1ZWEyNGRmMGFkMmNiNjhjYjE2MDM5ZWNfNC0xLTEtMS0xMDQxMTk_e0d93e7c-05b0-44a5-a075-44b9b592400a"
      unitRef="shares">0</bngo:ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjU4NTJlZmU0NWVhMjRkZjBhZDJjYjY4Y2IxNjAzOWVjL3RhYmxlcmFuZ2U6NTg1MmVmZTQ1ZWEyNGRmMGFkMmNiNjhjYjE2MDM5ZWNfNS0xLTEtMS0xMDQxMTk_14607b8f-c494-4ed7-a6e9-0d35d93ac6e6"
      unitRef="shares">4356000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjU4NTJlZmU0NWVhMjRkZjBhZDJjYjY4Y2IxNjAzOWVjL3RhYmxlcmFuZ2U6NTg1MmVmZTQ1ZWEyNGRmMGFkMmNiNjhjYjE2MDM5ZWNfNS0zLTEtMS0xMDQxMTk_63877a03-a5a5-49f0-8a67-5c29b539aaa3"
      unitRef="usdPerShare">5.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjU4NTJlZmU0NWVhMjRkZjBhZDJjYjY4Y2IxNjAzOWVjL3RhYmxlcmFuZ2U6NTg1MmVmZTQ1ZWEyNGRmMGFkMmNiNjhjYjE2MDM5ZWNfNS01LTEtMS0xMDQxMTk_d46d5f32-b86b-4d23-959c-02ce70723f05">P0Y6M7D</bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights>
    <bngo:ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjU4NTJlZmU0NWVhMjRkZjBhZDJjYjY4Y2IxNjAzOWVjL3RhYmxlcmFuZ2U6NTg1MmVmZTQ1ZWEyNGRmMGFkMmNiNjhjYjE2MDM5ZWNfNS03LTEtMS0xMDQxMTk_c1fb5abb-99d7-40ed-836d-277cedaf45e3"
      unitRef="usd">156000</bngo:ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNjMzOQ_252dc0c3-3928-41af-b8c9-8b1047a503d6">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity during the three months ended March&#160;31, 2023 was as follows: &#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares of Stock under Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,022,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,068,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,121,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,088,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,013,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,147,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,149,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;892,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfMS0xLTEtMS0xMDQxMTk_42c98c8c-0412-425b-acb5-dfced1339dc1"
      unitRef="shares">24022000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfMS0zLTEtMS0xMDQxMTk_8039c53a-2dee-4a3f-bb20-4d6aafc8fb5f"
      unitRef="usdPerShare">3.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i4be8520461cc4836b2bf1279c0c49b2a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfMS01LTEtMS0xMDQxMTk_fec03270-f8b2-40e9-8c2d-a5f1e730c9c2">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfMS03LTEtMS0xMDQxMTk_305585d6-c138-4b02-bbc4-69922e904f3f"
      unitRef="usd">2068000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfMi0xLTEtMS0xMDQxMTk_7a5b769f-861e-4b63-bc25-27f58535f18c"
      unitRef="shares">9121000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfMi0zLTEtMS0xMDQxMTk_6dc72305-082c-4491-81af-c0a77d80bf4a"
      unitRef="usdPerShare">1.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfMy0xLTEtMS0xMDQxMTk_17fa4715-2b3d-4da7-ac70-ed9fbae65162"
      unitRef="shares">42000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfMy0zLTEtMS0xMDQxMTk_ed220795-1602-479e-8cda-23e64e52e01c"
      unitRef="usdPerShare">0.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfMy03LTEtMS0xMDQxMTk_015e1ba6-987e-458d-86df-9a70446ec6f5"
      unitRef="usd">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfNC0xLTEtMS0xMDQxMTk_629ed354-7a5f-4cfd-872b-c87a89c24867"
      unitRef="shares">1088000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfNC0zLTEtMS0xMDQxMTk_028c1730-3376-4bf5-8aa3-62e6c5bdbd3a"
      unitRef="usdPerShare">3.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfNS0xLTEtMS0xMDQxMTk_dbad613d-2444-42ce-b0b3-f2b194102ce8"
      unitRef="shares">32013000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfNS0zLTEtMS0xMDQxMTk_08247c9d-a326-431b-9680-751e73849033"
      unitRef="usdPerShare">2.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfNS01LTEtMS0xMDQxMTk_b4587f7c-e78c-4c12-b136-ba2f20666694">P8Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfNS03LTEtMS0xMDQxMTk_300e999c-6e17-4535-ad75-2127d05b4af6"
      unitRef="usd">1147000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfNi0xLTEtMS0xMDQxMTk_a7f9f00a-5431-44d1-9be1-20b8ff52fac5"
      unitRef="shares">9149000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfNi0zLTEtMS0xMDQxMTk_fd71fcca-6c17-4398-9bfa-71b04f42f4ae"
      unitRef="usdPerShare">3.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfNi01LTEtMS0xMDQxMTk_330152c9-1fcc-4806-bb9b-e25429b7cfaa">P7Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOmU4OTQ2YWE3MGE0NTQ1NjNhZTBiMmZmYmI2YjU2MmQ3L3RhYmxlcmFuZ2U6ZTg5NDZhYTcwYTQ1NDU2M2FlMGIyZmZiYjZiNTYyZDdfNi03LTEtMS0xMDQxMTk_3e5c8c92-1744-4823-a357-aac6bdca2e08"
      unitRef="usd">892000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTQ5NzU1ODI5NzM2_6979a6e6-0566-4557-a589-addcf00d7eeb"
      unitRef="usdPerShare">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNjM0MA_d472bfad-ec89-4404-b483-10d7d1cf4f6c">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized stock-based compensation expense for the periods presented as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,357,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,328,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,774,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,102,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic493e64bbaa14b51affea368a758865b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjcxOTcxYmNhNjNiYjQ4MWU4OTFiYWRkYTc4ODNjODU4L3RhYmxlcmFuZ2U6NzE5NzFiY2E2M2JiNDgxZTg5MWJhZGRhNzg4M2M4NThfMi0xLTEtMS0xMDUwMTk_23c26aaf-4696-4195-8ba4-66cdc0e5d545"
      unitRef="usd">102000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i80b89abf30d44e039ce4fc8aeb1da4ae_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjcxOTcxYmNhNjNiYjQ4MWU4OTFiYWRkYTc4ODNjODU4L3RhYmxlcmFuZ2U6NzE5NzFiY2E2M2JiNDgxZTg5MWJhZGRhNzg4M2M4NThfMi0zLTEtMS0xMDUwMjY_c2ba1186-6fbd-473f-9fac-61b946864fea"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i29ed40c40dab442291465632e6882e02_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjcxOTcxYmNhNjNiYjQ4MWU4OTFiYWRkYTc4ODNjODU4L3RhYmxlcmFuZ2U6NzE5NzFiY2E2M2JiNDgxZTg5MWJhZGRhNzg4M2M4NThfMy0xLTEtMS0xMDUwMTk_66b6f569-d2a1-4526-9764-9049642df87c"
      unitRef="usd">44000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i144c849f01554b1a993c3b250ed79d33_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjcxOTcxYmNhNjNiYjQ4MWU4OTFiYWRkYTc4ODNjODU4L3RhYmxlcmFuZ2U6NzE5NzFiY2E2M2JiNDgxZTg5MWJhZGRhNzg4M2M4NThfMy0zLTEtMS0xMDUwMjY_95d3e066-6e85-460a-8c1a-3c1214ecf0f2"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7f330defb5aa4fb081aecf68faa28812_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjcxOTcxYmNhNjNiYjQ4MWU4OTFiYWRkYTc4ODNjODU4L3RhYmxlcmFuZ2U6NzE5NzFiY2E2M2JiNDgxZTg5MWJhZGRhNzg4M2M4NThfMi0xLTEtMS0xMDQxMTk_da58b151-cf0c-4f7c-9eee-7bdfc32bdc26"
      unitRef="usd">1357000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i94ccbf7f373d449baf5526bf6037b3f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjcxOTcxYmNhNjNiYjQ4MWU4OTFiYWRkYTc4ODNjODU4L3RhYmxlcmFuZ2U6NzE5NzFiY2E2M2JiNDgxZTg5MWJhZGRhNzg4M2M4NThfMi0zLTEtMS0xMDQxMTk_4c901ee6-ed37-4f50-801b-a8185b790b44"
      unitRef="usd">3328000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if7a2e48e810643a8b0e555a9c8954d9f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjcxOTcxYmNhNjNiYjQ4MWU4OTFiYWRkYTc4ODNjODU4L3RhYmxlcmFuZ2U6NzE5NzFiY2E2M2JiNDgxZTg5MWJhZGRhNzg4M2M4NThfMy0xLTEtMS0xMDQxMTk_720386d2-206f-43dc-a6a1-5880e1756690"
      unitRef="usd">2379000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6f37993d3f264fb1b3d0691e711f9da5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjcxOTcxYmNhNjNiYjQ4MWU4OTFiYWRkYTc4ODNjODU4L3RhYmxlcmFuZ2U6NzE5NzFiY2E2M2JiNDgxZTg5MWJhZGRhNzg4M2M4NThfMy0zLTEtMS0xMDQxMTk_def491ea-57ab-4677-9aad-3c0f66119075"
      unitRef="usd">1774000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjcxOTcxYmNhNjNiYjQ4MWU4OTFiYWRkYTc4ODNjODU4L3RhYmxlcmFuZ2U6NzE5NzFiY2E2M2JiNDgxZTg5MWJhZGRhNzg4M2M4NThfNC0xLTEtMS0xMDQxMTk_80831bf9-f695-425a-892d-879d6830f5a0"
      unitRef="usd">3882000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjcxOTcxYmNhNjNiYjQ4MWU4OTFiYWRkYTc4ODNjODU4L3RhYmxlcmFuZ2U6NzE5NzFiY2E2M2JiNDgxZTg5MWJhZGRhNzg4M2M4NThfNC0zLTEtMS0xMDQxMTk_75a550a4-6205-449f-9f8f-df033e3306d4"
      unitRef="usd">5102000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNjM0NA_4690d503-bd0d-41db-9dd6-29d2351a474d">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants during the periods presented were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjEzNTNkODFhNTg1MTRjZGU5OTQ2MGZmOWI2ODk5NTk2L3RhYmxlcmFuZ2U6MTM1M2Q4MWE1ODUxNGNkZTk5NDYwZmY5YjY4OTk1OTZfMi0xLTEtMS0xMDQxMTk_3d89fa63-21f7-4adb-9cf9-2c68fd771f1a"
      unitRef="number">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjEzNTNkODFhNTg1MTRjZGU5OTQ2MGZmOWI2ODk5NTk2L3RhYmxlcmFuZ2U6MTM1M2Q4MWE1ODUxNGNkZTk5NDYwZmY5YjY4OTk1OTZfMi0zLTEtMS0xMDQxMTk_8c06bfba-7eaa-4a9a-b513-cfcc7ae12bcd"
      unitRef="number">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjEzNTNkODFhNTg1MTRjZGU5OTQ2MGZmOWI2ODk5NTk2L3RhYmxlcmFuZ2U6MTM1M2Q4MWE1ODUxNGNkZTk5NDYwZmY5YjY4OTk1OTZfMy0xLTEtMS0xMDQxMTk_45356908-7e32-42f2-85e3-9731cc71d25a"
      unitRef="number">0.727</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjEzNTNkODFhNTg1MTRjZGU5OTQ2MGZmOWI2ODk5NTk2L3RhYmxlcmFuZ2U6MTM1M2Q4MWE1ODUxNGNkZTk5NDYwZmY5YjY4OTk1OTZfMy0zLTEtMS0xMDQxMTk_5caeef45-95d8-4028-857a-7d5191c58417"
      unitRef="number">0.701</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjEzNTNkODFhNTg1MTRjZGU5OTQ2MGZmOWI2ODk5NTk2L3RhYmxlcmFuZ2U6MTM1M2Q4MWE1ODUxNGNkZTk5NDYwZmY5YjY4OTk1OTZfNC0xLTEtMS0xMDQxMTk_398cd627-644f-45e4-a690-240cb2561d98">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjEzNTNkODFhNTg1MTRjZGU5OTQ2MGZmOWI2ODk5NTk2L3RhYmxlcmFuZ2U6MTM1M2Q4MWE1ODUxNGNkZTk5NDYwZmY5YjY4OTk1OTZfNC0zLTEtMS0xMDQxMTk_c5b43850-11bd-4be4-b502-72f92fbcc01a">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjEzNTNkODFhNTg1MTRjZGU5OTQ2MGZmOWI2ODk5NTk2L3RhYmxlcmFuZ2U6MTM1M2Q4MWE1ODUxNGNkZTk5NDYwZmY5YjY4OTk1OTZfNS0xLTEtMS0xMDQxMTk_91157733-c362-4b64-95e9-d3ba887f538c"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8fbc203ef77e4b2eb4a3930ae31a8024_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjEzNTNkODFhNTg1MTRjZGU5OTQ2MGZmOWI2ODk5NTk2L3RhYmxlcmFuZ2U6MTM1M2Q4MWE1ODUxNGNkZTk5NDYwZmY5YjY4OTk1OTZfNS0zLTEtMS0xMDQxMTk_00dde8d1-1ffc-4e18-a05b-0fafbc32e6a4"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i45ddfb39b1e74f6dad0c0bf181cf9a21_D20211001-20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTQ5NzU1ODI3NjA5_8212d695-ba7b-4381-a2fb-c2d81771347f"
      unitRef="shares">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i45ddfb39b1e74f6dad0c0bf181cf9a21_D20211001-20211031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTQ5NzU1ODI3NjEz_778f5ae5-b265-49e1-9549-cafad5bb6910"
      unitRef="usdPerShare">5.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i649fe5ed0003466fbb184c5508561d25_I20221004"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTQ5NzU1ODI3NjE3_554b44c1-adaf-4864-9c87-c928540475a7"
      unitRef="usdPerShare">2.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="i9253ac3721c14085873be006d0cf4172_D20221004-20221004"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTQ5NzU1ODI3NjIx_5f539252-cf29-4b9e-8a23-d7936f04353f"
      unitRef="usd">15800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNjM0Mw_cdd34d8a-19b2-4cd3-9504-3213bec44330">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity during the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Grant Date Fair Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,461,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,457,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.67&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes PSU activity during the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Grant Date Fair Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.74&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib9d74a66fe4c4a139d49dde0ca471851_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjIxN2I4MWY0NzY4YTQxNjc5ZGZmZTY5NzRjYmE5ODU2L3RhYmxlcmFuZ2U6MjE3YjgxZjQ3NjhhNDE2NzlkZmZlNjk3NGNiYTk4NTZfMS0xLTEtMS0xMDQxMTk_c7de3e1a-9dc4-4cdd-aa9a-4acdd894e008"
      unitRef="shares">96000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ib9d74a66fe4c4a139d49dde0ca471851_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjIxN2I4MWY0NzY4YTQxNjc5ZGZmZTY5NzRjYmE5ODU2L3RhYmxlcmFuZ2U6MjE3YjgxZjQ3NjhhNDE2NzlkZmZlNjk3NGNiYTk4NTZfMS0zLTEtMS0xMDQxMTk_0b22a118-4803-4ee9-9e42-cc48249388b5"
      unitRef="usdPerShare">4.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i0d6b4ade60694ff6bfb130ce265977e6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjIxN2I4MWY0NzY4YTQxNjc5ZGZmZTY5NzRjYmE5ODU2L3RhYmxlcmFuZ2U6MjE3YjgxZjQ3NjhhNDE2NzlkZmZlNjk3NGNiYTk4NTZfMi0xLTEtMS0xMDQxMTk_f3c9bdc1-b54b-4956-8354-753af8a7dccd"
      unitRef="shares">2461000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0d6b4ade60694ff6bfb130ce265977e6_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjIxN2I4MWY0NzY4YTQxNjc5ZGZmZTY5NzRjYmE5ODU2L3RhYmxlcmFuZ2U6MjE3YjgxZjQ3NjhhNDE2NzlkZmZlNjk3NGNiYTk4NTZfMi0zLTEtMS0xMDQxMTk_e5c59c5a-9bc8-4a56-b0b5-5f4d320b453b"
      unitRef="usdPerShare">1.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i0d6b4ade60694ff6bfb130ce265977e6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjIxN2I4MWY0NzY4YTQxNjc5ZGZmZTY5NzRjYmE5ODU2L3RhYmxlcmFuZ2U6MjE3YjgxZjQ3NjhhNDE2NzlkZmZlNjk3NGNiYTk4NTZfMy0xLTEtMS0xMDQxMTk_39afa251-e128-4519-a24b-e2315a090992"
      unitRef="shares">65000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0d6b4ade60694ff6bfb130ce265977e6_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjIxN2I4MWY0NzY4YTQxNjc5ZGZmZTY5NzRjYmE5ODU2L3RhYmxlcmFuZ2U6MjE3YjgxZjQ3NjhhNDE2NzlkZmZlNjk3NGNiYTk4NTZfMy0zLTEtMS0xMDQxMTk_44376b2a-d462-41c7-adbb-8f9a5d725ada"
      unitRef="usdPerShare">4.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i0d6b4ade60694ff6bfb130ce265977e6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjIxN2I4MWY0NzY4YTQxNjc5ZGZmZTY5NzRjYmE5ODU2L3RhYmxlcmFuZ2U6MjE3YjgxZjQ3NjhhNDE2NzlkZmZlNjk3NGNiYTk4NTZfNC0xLTEtMS0xMDQxMTk_acfc6bc5-4357-4149-8224-74ce041166ba"
      unitRef="shares">35000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i0d6b4ade60694ff6bfb130ce265977e6_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjIxN2I4MWY0NzY4YTQxNjc5ZGZmZTY5NzRjYmE5ODU2L3RhYmxlcmFuZ2U6MjE3YjgxZjQ3NjhhNDE2NzlkZmZlNjk3NGNiYTk4NTZfNC0zLTEtMS0xMDQxMTk_e38ab0e5-3928-466b-a0a1-533176a73846"
      unitRef="usdPerShare">1.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i80c9f5e585bc49d69df5c0b0bc90a1dc_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjIxN2I4MWY0NzY4YTQxNjc5ZGZmZTY5NzRjYmE5ODU2L3RhYmxlcmFuZ2U6MjE3YjgxZjQ3NjhhNDE2NzlkZmZlNjk3NGNiYTk4NTZfNS0xLTEtMS0xMDQxMTk_6e58e887-8669-4f1b-8a97-e0ac2a4963bf"
      unitRef="shares">2457000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i80c9f5e585bc49d69df5c0b0bc90a1dc_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjIxN2I4MWY0NzY4YTQxNjc5ZGZmZTY5NzRjYmE5ODU2L3RhYmxlcmFuZ2U6MjE3YjgxZjQ3NjhhNDE2NzlkZmZlNjk3NGNiYTk4NTZfNS0zLTEtMS0xMDQxMTk_2e1a8f8d-3add-4fea-b710-bf4630ac321b"
      unitRef="usdPerShare">1.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i0d6b4ade60694ff6bfb130ce265977e6_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTM5MA_9ca8e3cb-cc14-481c-a78f-c95fe152b7c8"
      unitRef="usd">300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i0d6b4ade60694ff6bfb130ce265977e6_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTQ5Ng_30460989-5297-46f3-9462-76aa7828d3e6">P3Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i0787e57ce57b4647b096721e6444f9b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjA2ZTRjZDBhYTYyMDQxNDVhMDdlMzVjYmM4M2Q0ZWY4L3RhYmxlcmFuZ2U6MDZlNGNkMGFhNjIwNDE0NWEwN2UzNWNiYzgzZDRlZjhfMS0xLTEtMS0xMDQxMTk_d137f351-9052-4601-9368-bd5c731230b8"
      unitRef="shares">290000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i0787e57ce57b4647b096721e6444f9b9_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjA2ZTRjZDBhYTYyMDQxNDVhMDdlMzVjYmM4M2Q0ZWY4L3RhYmxlcmFuZ2U6MDZlNGNkMGFhNjIwNDE0NWEwN2UzNWNiYzgzZDRlZjhfMS0zLTEtMS0xMDQxMTk_e39eb22c-8cdc-4aa5-8051-c012e55045f1"
      unitRef="usdPerShare">4.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i230745a88815483fa50ae23b1a6526e9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjA2ZTRjZDBhYTYyMDQxNDVhMDdlMzVjYmM4M2Q0ZWY4L3RhYmxlcmFuZ2U6MDZlNGNkMGFhNjIwNDE0NWEwN2UzNWNiYzgzZDRlZjhfMi0xLTEtMS0xMDQxMTk_232ebd46-b39f-4e6a-9521-73d3cf9ddcfe"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i230745a88815483fa50ae23b1a6526e9_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjA2ZTRjZDBhYTYyMDQxNDVhMDdlMzVjYmM4M2Q0ZWY4L3RhYmxlcmFuZ2U6MDZlNGNkMGFhNjIwNDE0NWEwN2UzNWNiYzgzZDRlZjhfMi0zLTEtMS0xMDQxMTk_087d3fac-d22e-495b-a53c-ef099301f78a"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i230745a88815483fa50ae23b1a6526e9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjA2ZTRjZDBhYTYyMDQxNDVhMDdlMzVjYmM4M2Q0ZWY4L3RhYmxlcmFuZ2U6MDZlNGNkMGFhNjIwNDE0NWEwN2UzNWNiYzgzZDRlZjhfMy0xLTEtMS0xMDQxMTk_69d090f8-7751-46e8-ad92-571f29fa1367"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i230745a88815483fa50ae23b1a6526e9_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjA2ZTRjZDBhYTYyMDQxNDVhMDdlMzVjYmM4M2Q0ZWY4L3RhYmxlcmFuZ2U6MDZlNGNkMGFhNjIwNDE0NWEwN2UzNWNiYzgzZDRlZjhfMy0zLTEtMS0xMDQxMTk_e7feaeab-2fb0-45a6-9da7-a07b8f52db9c"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i230745a88815483fa50ae23b1a6526e9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjA2ZTRjZDBhYTYyMDQxNDVhMDdlMzVjYmM4M2Q0ZWY4L3RhYmxlcmFuZ2U6MDZlNGNkMGFhNjIwNDE0NWEwN2UzNWNiYzgzZDRlZjhfNC0xLTEtMS0xMDQxMTk_d572be84-bbe0-4087-9cdc-70734fe13eed"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i230745a88815483fa50ae23b1a6526e9_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjA2ZTRjZDBhYTYyMDQxNDVhMDdlMzVjYmM4M2Q0ZWY4L3RhYmxlcmFuZ2U6MDZlNGNkMGFhNjIwNDE0NWEwN2UzNWNiYzgzZDRlZjhfNC0zLTEtMS0xMDQxMTk_1f202998-9493-4a2a-bc07-6d8e42dffeb4"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia333c3d4c489480f91a0918cb06c6e33_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjA2ZTRjZDBhYTYyMDQxNDVhMDdlMzVjYmM4M2Q0ZWY4L3RhYmxlcmFuZ2U6MDZlNGNkMGFhNjIwNDE0NWEwN2UzNWNiYzgzZDRlZjhfNS0xLTEtMS0xMDQxMTk_2c0c31b2-b5b8-4ef8-af89-1867f5e0f822"
      unitRef="shares">290000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia333c3d4c489480f91a0918cb06c6e33_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RhYmxlOjA2ZTRjZDBhYTYyMDQxNDVhMDdlMzVjYmM4M2Q0ZWY4L3RhYmxlcmFuZ2U6MDZlNGNkMGFhNjIwNDE0NWEwN2UzNWNiYzgzZDRlZjhfNS0zLTEtMS0xMDQxMTk_7ba11770-0477-4527-8110-4eb40279e1fc"
      unitRef="usdPerShare">4.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i230745a88815483fa50ae23b1a6526e9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTY3Nw_9579ecb4-aa41-4c0f-b15a-3d9cf9d245c0">P2Y1M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iecac66c4d00049b992c7f860853fdc4b_D20230215-20230215"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTQ5NzU1ODI5NjA2_be516495-90df-45bb-b921-a1e28b2f2356"
      unitRef="shares">3300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iecac66c4d00049b992c7f860853fdc4b_D20230215-20230215"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTQ5NzU1ODI5NjAy_3d8a1f6e-181e-4823-b4bd-f9be61cee53c"
      unitRef="usdPerShare">1.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ibb4acb3d6c734dba8bac4bebe9c2b85d_D20230215-20230215"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTQ5NzU1ODI5NjEz_460062d4-d71e-47c9-b31b-09405f87103f"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iecac66c4d00049b992c7f860853fdc4b_D20230215-20230215"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTQ5NzU1ODI5NjIy_3d8a1f6e-181e-4823-b4bd-f9be61cee53c"
      unitRef="usdPerShare">1.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i759bd048bf3e4098b83b5604fbce9f26_D20230215-20230215"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNDk0NzgwMjM0MDgwOQ_66c982e3-380b-4c7f-a85c-7936c1d3e525">P48M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i22680561557b45ba98cf2f10a2456635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMTY0OTI2NzQ4MjY2Mw_70f3e7b4-6dfd-4997-9916-6bbeadf960d1">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <bngo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments
      contextRef="i38b1d6628a394f1fbbbfd993ec043869_I20230215"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNDk0NzgwMjM0MDgxNg_cb89c96f-0b90-4503-b426-44613c430539"
      unitRef="installment">3</bngo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib50b0f103ebb406f8f4f5c1eef93d1bd_D20230413-20230413"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMTY0OTI2NzQ1NzUyNA_d7995989-980a-4c14-b024-3b2d5d4dd544"
      unitRef="shares">1</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib6be39fe53974c5089ff9986b857d774_I20230413"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfMTY0OTI2NzQ1NzUzNg_9bf76a32-7574-47c3-b675-4a9051cb3b1d"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="ib6be39fe53974c5089ff9986b857d774_I20230413"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTQ5NzU1ODI5NjI2_c7df646b-faf4-42c3-9eae-fd0b7dcba6f4"
      unitRef="usdPerShare">100.00</us-gaap:SharesIssuedPricePerShare>
    <bngo:PreferredStockNumberOfVotes
      contextRef="iffc1f718b13b4c9abe1418bc8c792699_I20230413"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNTQ5NzU1ODMzMDIy_b7573845-a3f6-4131-aac7-a6c2c7e4548e"
      unitRef="vote">3000000000</bngo:PreferredStockNumberOfVotes>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="iffc1f718b13b4c9abe1418bc8c792699_I20230413"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81Mi9mcmFnOmVjYzY5YWMzMDZlMzRjZTVhY2Y4MjQwN2JjN2VlZTY0L3RleHRyZWdpb246ZWNjNjlhYzMwNmUzNGNlNWFjZjgyNDA3YmM3ZWVlNjRfNDk0NzgwMjM3NjkyNA_cf202ff7-a2b0-44c1-aae7-c269e31a4fbf"
      unitRef="usdPerShare">100.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RleHRyZWdpb246NWI2NmE1ZGQyYmJiNGJhYmFmYzc0MTY5Y2YzOThjN2ZfMTk0Nw_6d5766e9-15bd-4c57-a9c5-98a306940382">Commitments and Contingencies &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into various operating lease agreements and a finance lease agreement, primarily relating to our office, laboratory, and manufacturing space. See Note 11 &#x2013; Commitments and Contingencies, subsection titled &#x201c;Leases&#x201d;, in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December 31, 2022 for information regarding the Company&#x2019;s lease agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The future minimum payments under non-cancellable operating and finance leases as of March&#160;31, 2023, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Finance Lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,942,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;242,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,684,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,788,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;338,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;729,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;347,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;255,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;356,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,594,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,398,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,207,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,120,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,313,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,278,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,894,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be subject to potential liabilities under various claims and legal actions that are pending or may be asserted. These matters arise in the ordinary course and conduct of the business. The Company regularly assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in the unaudited condensed consolidated financial statements. An estimated loss contingency is accrued in the unaudited condensed consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on the Company&#x2019;s assessment, it currently does not have any material loss exposure as it is not a defendant in any claims or legal actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;See Note 8 to our unaudited condensed consolidated financial statements for a discussion of the contingent consideration liability.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RleHRyZWdpb246NWI2NmE1ZGQyYmJiNGJhYmFmYzc0MTY5Y2YzOThjN2ZfMTk0NQ_3b3287ae-5e55-4003-a46d-4794aa45ae55">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The future minimum payments under non-cancellable operating and finance leases as of March&#160;31, 2023, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Finance Lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,942,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;242,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,684,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,788,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;338,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;729,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;347,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;255,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;356,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,594,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,398,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,207,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,120,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,313,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,278,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,894,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfMS0xLTEtMS0xMDQxMTk_f1b00986-1c7f-4d14-bc5d-8d2623cc93c9"
      unitRef="usd">1942000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfMS0zLTEtMS0xMDQxMTk_a9b7c935-83a6-4c44-8e4a-730c069fe36b"
      unitRef="usd">242000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfMi0xLTEtMS0xMDQxMTk_0558f172-70a0-4edc-9d3e-c6a4db8bb12d"
      unitRef="usd">2684000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfMi0zLTEtMS0xMDQxMTk_5dea9ddc-bb2f-4460-9204-4684198ed9f0"
      unitRef="usd">330000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfMy0xLTEtMS0xMDQxMTk_4c9c989e-5b67-465f-9c6d-7e16e14f8702"
      unitRef="usd">2788000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfMy0zLTEtMS0xMDQxMTk_467ada5d-e367-46d7-948c-acee446aa73e"
      unitRef="usd">338000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfNC0xLTEtMS0xMDQxMTk_221a977e-0c07-47a8-afb3-117a3494a7fb"
      unitRef="usd">729000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfNC0zLTEtMS0xMDQxMTk_69cdea38-cc0a-4b2b-bcdf-df4b6c12ffbc"
      unitRef="usd">347000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfNS0xLTEtMS0xMDQxMTk_9c609186-c1fa-4ac9-9d93-fb21daa085bf"
      unitRef="usd">255000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfNS0zLTEtMS0xMDQxMTk_833b8d5e-8910-49b9-bbb0-aafc767a8946"
      unitRef="usd">356000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <bngo:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfNi0xLTEtMS0xMDQxMTk_cad6a552-8d23-4ffd-8d53-272c54b6093c"
      unitRef="usd">0</bngo:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <bngo:FinanceLeaseLiabilityToBePaidAfterYearFour
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfNi0zLTEtMS0xMDQxMTk_ec8afd41-e8ea-4c1e-afd4-a40083a21743"
      unitRef="usd">5594000</bngo:FinanceLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfNy0xLTEtMS0xMDQxMTk_2cbc94ac-c509-4ebd-bafe-02c9cc945592"
      unitRef="usd">8398000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfNy0zLTEtMS0xMDQxMTk_6d691eb4-db18-42d8-aefd-22b821b7e2f4"
      unitRef="usd">7207000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfOC0xLTEtMS0xMDQxMTk_eb031512-51ee-4821-850f-552d1e4b3c63"
      unitRef="usd">1120000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfOC0zLTEtMS0xMDQxMTk_a7d11123-36c1-43a0-b71f-c4de43ab19c7"
      unitRef="usd">3313000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfOS0xLTEtMS0xMDQxMTk_58b03fd7-f8cb-4e1c-aa80-5687a5108fd8"
      unitRef="usd">7278000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV81OC9mcmFnOjViNjZhNWRkMmJiYjRiYWJhZmM3NDE2OWNmMzk4YzdmL3RhYmxlOjBlMmJhNWM5MmExZjRlYjQ4MzE2ZDI3ZWRjMzE5ZThlL3RhYmxlcmFuZ2U6MGUyYmE1YzkyYTFmNGViNDgzMTZkMjdlZGMzMTllOGVfOS0zLTEtMS0xMDQxMTk_24a8f34e-b460-482f-9f50-21a71682710c"
      unitRef="usd">3894000</us-gaap:FinanceLeaseLiability>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RleHRyZWdpb246YjRmYTQ3OWVkNzVhNDg4ODg5N2RiYjFlZmQyMDkxZjNfMzQ5MA_4382f356-3ca9-4c39-af39-b89e71bcfd54">Acquisitions&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purigen Acquisition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, the Company completed the acquisition of Purigen Biosystems, Inc. for approximately $32.0&#160;million in cash and up to an aggregate of $32.0&#160;million in cash payable based on the achievement of certain milestones. Cash of $1.2&#160;million will be held in an escrow fund for purposes of satisfying any post-closing purchase price adjustments and indemnification claims under the Purigen Merger Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The purchase price allocation for the acquisition of Purigen is preliminary and subject to revision as additional information about the fair value of assets and liabilities becomes available. As permitted under ASC 805, the Company is allowed a measurement period, which may not exceed one year, in which to complete its accounting for the acquisition. Per the terms of the Purigen Merger Agreement, the purchase price is still subject to adjustment for the final determination of cash, unpaid indebtedness, unpaid transaction expenses and working capital, as well for deferred and current tax assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is the estimated purchase price for the acquisition of Purigen:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,034,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Estimated fair value of milestone consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,970,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Estimated return of cash to buyer from escrow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(90,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Total estimated purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,914,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total estimated purchase price was allocated to Purigen&#x2019;s tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date, with the excess recorded as goodwill, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cash &amp;amp; cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;259,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;944,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;805,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,636,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;533,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,651,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Accounts payable and other accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,152,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Operating lease liability (short-term and long-term)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,636,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;44,914,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition date fair values of identifiable intangible assets acquired are as following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;18,800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Tradename&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Fair value of identifiable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;20,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the income approach to derive the fair value of the identified intangible assets acquired. This approach calculates fair value by estimating future cash flows attributable to the assets and then discounting these cash flows to a present value using a risk-adjusted discount rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The customer relationships and trade name intangibles are being amortized on a straight-line basis over their estimated useful lives of 5 years. The developed technology intangible is being amortized on a straight-line basis over its estimated useful live of 15 years. Straight-line amortization was determined to be materially consistent with the pattern of expected use of the intangible assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Company began integrating Purigen&#x2019;s operations with its existing operations during the fourth quarter of 2022, it is not practical or meaningful to distinguish Purigen&#x2019;s expenses or net income or loss from that of the combined operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pro forma Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited pro forma financial information in the table below summarizes the combined results of operations for the Company and Purigen as if the companies had been combined as of the beginning of the year prior to the acquisition. These amounts have been calculated after applying the Company&#x2019;s accounting policies and adjusting the results of Purigen to reflect &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the additional amortization that would have been charged assuming the fair value adjustments to intangible assets had been applied at the beginning of the year prior to the acquisition. The following unaudited pro forma financial information is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved as if the acquisition had taken place as of January 1, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,220,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(32,048,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i7d2c0cf7229242a88304bb4f867c0c9d_D20221101-20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RleHRyZWdpb246YjRmYTQ3OWVkNzVhNDg4ODg5N2RiYjFlZmQyMDkxZjNfMTA5OTUxMTY0MDE3Ng_8a6457e2-eaa1-4609-8837-67c9b4242bdf"
      unitRef="usd">32000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RleHRyZWdpb246YjRmYTQ3OWVkNzVhNDg4ODg5N2RiYjFlZmQyMDkxZjNfMTA5OTUxMTY0MDE4MA_e773d7a1-fbc7-491f-905b-be802f981c4e"
      unitRef="usd">32000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <bngo:BusinessAcquisitionCashHeldInEscrowFund
      contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RleHRyZWdpb246YjRmYTQ3OWVkNzVhNDg4ODg5N2RiYjFlZmQyMDkxZjNfMTA5OTUxMTY0MDE4OQ_0cbb9718-7e79-472d-93ae-b621700a70d8"
      unitRef="usd">1200000</bngo:BusinessAcquisitionCashHeldInEscrowFund>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RleHRyZWdpb246YjRmYTQ3OWVkNzVhNDg4ODg5N2RiYjFlZmQyMDkxZjNfMzg0ODI5MDcwOTY0OA_c50210cc-7d9c-4471-9189-02607fde9aea">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is the estimated purchase price for the acquisition of Purigen:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,034,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Estimated fair value of milestone consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,970,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Estimated return of cash to buyer from escrow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(90,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Total estimated purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,914,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i7d2c0cf7229242a88304bb4f867c0c9d_D20221101-20221130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOjdmYWUxNTk4ZTQ4ZDRmY2ViNWM4ODU0MmU1NzFhMzhiL3RhYmxlcmFuZ2U6N2ZhZTE1OThlNDhkNGZjZWI1Yzg4NTQyZTU3MWEzOGJfMC0yLTEtMS0xMDQ1Njg_10d6d510-2b70-44de-845d-5ab772d23060"
      unitRef="usd">32034000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOjdmYWUxNTk4ZTQ4ZDRmY2ViNWM4ODU0MmU1NzFhMzhiL3RhYmxlcmFuZ2U6N2ZhZTE1OThlNDhkNGZjZWI1Yzg4NTQyZTU3MWEzOGJfMS0yLTEtMS0xMDQ1Njg_f4f35d48-f5a3-4d6f-931e-eae4efeb20f0"
      unitRef="usd">12970000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <bngo:BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow
      contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOjdmYWUxNTk4ZTQ4ZDRmY2ViNWM4ODU0MmU1NzFhMzhiL3RhYmxlcmFuZ2U6N2ZhZTE1OThlNDhkNGZjZWI1Yzg4NTQyZTU3MWEzOGJfMi0yLTEtMS0xMDQ1Njg_b48b0c3d-08aa-421b-bd97-ad2776f3d40c"
      unitRef="usd">90000</bngo:BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i7d2c0cf7229242a88304bb4f867c0c9d_D20221101-20221130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOjdmYWUxNTk4ZTQ4ZDRmY2ViNWM4ODU0MmU1NzFhMzhiL3RhYmxlcmFuZ2U6N2ZhZTE1OThlNDhkNGZjZWI1Yzg4NTQyZTU3MWEzOGJfMy0yLTEtMS0xMDYwODU_0ee1f3c6-1e75-4688-a15f-c2ea5bd7b7a4"
      unitRef="usd">44914000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RleHRyZWdpb246YjRmYTQ3OWVkNzVhNDg4ODg5N2RiYjFlZmQyMDkxZjNfMzg0ODI5MDcwOTY0OQ_f23d48aa-617b-4250-9fad-c5bda0427753">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total estimated purchase price was allocated to Purigen&#x2019;s tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date, with the excess recorded as goodwill, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cash &amp;amp; cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;259,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;944,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;805,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,636,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;533,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,651,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Accounts payable and other accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,152,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Operating lease liability (short-term and long-term)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,636,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;44,914,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfMC0yLTEtMS0xMDQ1Njg_e47bf23b-3d7e-445d-ac90-02e6a42f4034"
      unitRef="usd">290000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfMS0yLTEtMS0xMDQ1Njg_36e0d503-1f42-444b-96b5-497a12aeebda"
      unitRef="usd">259000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfMi0yLTEtMS0xMDQ1Njg_07757069-3269-4dd3-8b1d-24d982ec93fc"
      unitRef="usd">944000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfMy0yLTEtMS0xMDQ1Njg_c6ab3905-ee42-4273-9b87-3ebd9cc17787"
      unitRef="usd">184000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfNC0yLTEtMS0xMDQ1Njg_0ea10ec7-ee89-4f9b-a260-757f0be42b24"
      unitRef="usd">805000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <bngo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash
      contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfNS0yLTEtMS0xMDQ1Njg_782bb8b5-5aea-41c8-87ee-6ecff349ba02"
      unitRef="usd">400000</bngo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash>
    <bngo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets
      contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfNi0yLTEtMS0xMDQ1Njg_10e900a5-6aff-47f2-9aa4-2f69fe75025e"
      unitRef="usd">1636000</bngo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfNy0yLTEtMS0xMDQ1Njg_bafaaf3d-15dc-49ef-9ff2-253783bd6a79"
      unitRef="usd">533000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfOC0yLTEtMS0xMDQ1Njg_ecb53a97-40d6-4163-9fc1-896b27535bac"
      unitRef="usd">20000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfOS0yLTEtMS0xMDQ1Njg_1e4a83a9-e9e5-4b1c-8a8f-ec68025caf6a"
      unitRef="usd">22651000</us-gaap:Goodwill>
    <bngo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities
      contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfMTAtMi0xLTEtMTA0NTY4_71fbf7d1-40f5-4a2b-bc03-471f5464db35"
      unitRef="usd">1152000</bngo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities>
    <bngo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent
      contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfMTEtMi0xLTEtMTA0NTY4_4eeb58de-0432-4f87-be14-93129dbe1d37"
      unitRef="usd">1636000</bngo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOmZjMjQyNWVhMzZkNTRjMzI5OTEwODE3NTVhM2U1ZjQ0L3RhYmxlcmFuZ2U6ZmMyNDI1ZWEzNmQ1NGMzMjk5MTA4MTc1NWEzZTVmNDRfMTItMi0xLTEtMTA3ODU3_3175bfee-c9f6-4a4a-9d9d-a668403d1bd0"
      unitRef="usd">44914000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RleHRyZWdpb246YjRmYTQ3OWVkNzVhNDg4ODg5N2RiYjFlZmQyMDkxZjNfMzg0ODI5MDcwOTY1MA_fb726260-1819-4471-b0ba-f8ae7b6b9528">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition date fair values of identifiable intangible assets acquired are as following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;18,800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Tradename&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Fair value of identifiable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;20,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ic97685b2136f4353b8df0de2a7e10ad3_I20221130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOjE1ODEzMmQ2NGJjYjRmN2JiNzBhYTFhZjI5NTc4NzM1L3RhYmxlcmFuZ2U6MTU4MTMyZDY0YmNiNGY3YmI3MGFhMWFmMjk1Nzg3MzVfMC0yLTEtMS0xMDQ1Njg_6b3ef418-b615-4625-8280-f2eadc344221"
      unitRef="usd">18800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i295a9a13609e47d0bbdd3fe79bcb04e1_I20221130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOjE1ODEzMmQ2NGJjYjRmN2JiNzBhYTFhZjI5NTc4NzM1L3RhYmxlcmFuZ2U6MTU4MTMyZDY0YmNiNGY3YmI3MGFhMWFmMjk1Nzg3MzVfMS0yLTEtMS0xMDQ1Njg_dae891e9-d38a-4c97-919a-ef501f2300ad"
      unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i925ef02d711544878675a77e949a4453_I20221130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOjE1ODEzMmQ2NGJjYjRmN2JiNzBhYTFhZjI5NTc4NzM1L3RhYmxlcmFuZ2U6MTU4MTMyZDY0YmNiNGY3YmI3MGFhMWFmMjk1Nzg3MzVfMi0yLTEtMS0xMDQ1Njg_21c49587-2015-4cab-8024-d456054699d5"
      unitRef="usd">1000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i91fff28e789d4fdc80fbfa9100a620b7_I20221130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOjE1ODEzMmQ2NGJjYjRmN2JiNzBhYTFhZjI5NTc4NzM1L3RhYmxlcmFuZ2U6MTU4MTMyZDY0YmNiNGY3YmI3MGFhMWFmMjk1Nzg3MzVfMy0yLTEtMS0xMDYxMzA_5cfa20fa-ad98-4d4b-a77f-1a968e666858"
      unitRef="usd">20000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i6e35fc0471424eaeb1aa538040aea91e_D20221101-20221130"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RleHRyZWdpb246YjRmYTQ3OWVkNzVhNDg4ODg5N2RiYjFlZmQyMDkxZjNfMTA5OTUxMTY0MDE5Ng_31ee4d48-a3cd-4d23-8654-9d7e2d550588">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="if1dc3f6d0e094c2196112c84227fe802_D20221101-20221130"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RleHRyZWdpb246YjRmYTQ3OWVkNzVhNDg4ODg5N2RiYjFlZmQyMDkxZjNfMTA5OTUxMTY0MDE5Ng_f4f15e03-c2ba-46c6-aafa-a7bb3a7cd923">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="if3a2c1a4485a471c820ca4842e5c1c64_D20221101-20221130"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RleHRyZWdpb246YjRmYTQ3OWVkNzVhNDg4ODg5N2RiYjFlZmQyMDkxZjNfMTA5OTUxMTY0MDIwMw_6dfd7791-a3fa-4b0e-94f6-668390b5d8d5">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RleHRyZWdpb246YjRmYTQ3OWVkNzVhNDg4ODg5N2RiYjFlZmQyMDkxZjNfMzQ5NA_dce0ddfd-8cbc-4279-8516-c1db7dd005c1">The following unaudited pro forma financial information is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved as if the acquisition had taken place as of January 1, 2021.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,220,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(32,048,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i6925d4a44b4d4f8ab1473a6ec01745a1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOjRhMGFkOTA2ZGRkYjRlYjc4YWUyMTg2ZTZhYjhlZDU4L3RhYmxlcmFuZ2U6NGEwYWQ5MDZkZGRiNGViNzhhZTIxODZlNmFiOGVkNThfMi00LTEtMS0xMDQxMTk_7412b978-0122-404b-943d-4922cf85beb7"
      unitRef="usd">6220000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i6925d4a44b4d4f8ab1473a6ec01745a1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOjRhMGFkOTA2ZGRkYjRlYjc4YWUyMTg2ZTZhYjhlZDU4L3RhYmxlcmFuZ2U6NGEwYWQ5MDZkZGRiNGViNzhhZTIxODZlNmFiOGVkNThfMy00LTEtMS0xMDQxMTk_607b4603-d1e8-4d6c-a971-f566812f63ce"
      unitRef="usd">-32048000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="i6925d4a44b4d4f8ab1473a6ec01745a1_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOjRhMGFkOTA2ZGRkYjRlYjc4YWUyMTg2ZTZhYjhlZDU4L3RhYmxlcmFuZ2U6NGEwYWQ5MDZkZGRiNGViNzhhZTIxODZlNmFiOGVkNThfNC00LTEtMS0xMDQxMTk_f1249d0e-6bce-47be-b41e-dd3b38974f93"
      unitRef="usdPerShare">-0.11</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="i6925d4a44b4d4f8ab1473a6ec01745a1_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82MS9mcmFnOmI0ZmE0NzllZDc1YTQ4ODg4OTdkYmIxZWZkMjA5MWYzL3RhYmxlOjRhMGFkOTA2ZGRkYjRlYjc4YWUyMTg2ZTZhYjhlZDU4L3RhYmxlcmFuZ2U6NGEwYWQ5MDZkZGRiNGViNzhhZTIxODZlNmFiOGVkNThfNC00LTEtMS0xMDQxMTk_fa5333f4-5805-480a-9dfb-b1a08e387576"
      unitRef="usdPerShare">-0.11</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfNDE0OQ_76445f4d-0f7c-4e48-a68b-b006a9529bd1">Investments and Fair Value Measurements&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds investment securities that consist of highly liquid, investment grade debt securities. The Company determines the fair value of its investment securities based upon one or more valuations reported by its investment accounting and reporting service provider. The investment service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curves, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, and broker and dealer quotes, as well as other relevant economic measures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis as of March&#160;31, 2023 and December&#160;31, 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Fair Value and Carrying Value on Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurement&#160;Category&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,216,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,216,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,988,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,988,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total investments:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,704,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,704,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;252,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;252,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,141,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,141,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Fair Value and Carrying Value on Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurement&#160;Category&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,020,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,020,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86,094,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86,094,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,981,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,981,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total investments:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108,095,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108,095,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,868,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,868,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,352,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,352,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money Market Funds are classified as cash equivalents on the unaudited condensed consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration relates to the acquisitions of BioDiscovery and Purigen. The outcome of the milestone consideration for all contingent consideration liabilities is binary, meaning the milestones are either achieved or not achieved, and the only other variable factor is the timing of when the milestones are achieved. The fair value measurement of the contingent consideration liabilities is based on significant inputs not observed in the market (Level 3 inputs). These unobservable inputs represent a Level 3 measurement because they are supported by little or no market activity and reflect the Company&#x2019;s assumptions in measuring fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the BioDiscovery contingent consideration liability is reassessed on a quarterly basis using a probability weighted model. Assumptions used to estimate the acquisition date fair value of the contingent consideration related to the acquisition of BioDiscovery include the probability of achieving, or changes in timing, of certain milestones, and a discount rate. As of March&#160;31, 2023 a discount rate of 3% was used. The Company determined the fair value of the BioDiscovery milestone consideration using a scenario-based technique, as the trigger for payment is event driven. The Company determined it is highly likely that the milestone related to the BioDiscovery acquisition will be achieved and therefore used a 95% probability factor which is applied to the $10.0 million milestone consideration. The change in fair value of the contingent consideration during the three months ended March&#160;31, 2023 was due to the passage of time. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration liabilities related to the Purigen milestones are related to the achievement of two independent milestones with aggregate possible milestone payments totaling $32.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Purigen milestones are reassessed on a quarterly basis using a probability weighted model and a Monte Carlo Simulation. Assumptions used to estimate the acquisition date fair value of the milestones using a probability weighted model include the probability of achieving, or changes in timing, of independent milestones, and a discount rate of 15%. The Company determined the fair value of this milestone consideration using a scenario-based technique, as the trigger for payment is event driven. The Company determined the likelihood of each independent milestone and used probability factors ranging from 20% to 80% which were applied to the individual payments. A Monte Carlo Simulation was performed to determine the likelihood that the milestone will be achieved and was applied to the milestone consideration payment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in estimated fair value of contingent consideration liability in the three months ended March&#160;31, 2023 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Contingent&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;(Level 3&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Measurement)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,352,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liability recorded as a result of current period acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in estimated fair value, recorded in selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;789,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,141,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Available for Sale Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests its excess cash in U.S. Treasury and agency securities, corporate debt securities, and commercial paper, which are classified as available-for-sale investments. These investments are carried at fair value and are included in the tables below. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. At each reporting date, the Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. The Company evaluates, among others, whether the Company has the intention to sell any of these investments and whether it is not more likely than not that the Company will be required to sell any of them before recovery of the amortized cost basis. Neither of these criteria were met in any period presented. The credit ratings of the securities held remain of the highest quality. Moreover, the Company continues to receive payments of interest and principal as they become due, and our expectation is that those payments will continue to be received timely. Based on this evaluation, as of March&#160;31, 2023 and December&#160;31, 2022, the Company determined that unrealized losses of the below securities were primarily attributable to changes in interest rates and non-credit related factors. As such, no allowances for credit losses were recorded during these periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023 and December&#160;31, 2022, the Company held 17 and 16 securities, respectively, which have been in an unrealized loss position for a period of less than 12 months. As of March&#160;31, 2023 and December&#160;31, 2022, the Company held 19 and 24 securities, respectively, which have been in an unrealized loss position for a period of greater than 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses are calculated using the specific identification method and recorded in other income (expense) in the Company&#x2019;s unaudited condensed consolidated statements of operations and comprehensive loss. The Company has the ability, if necessary, to liquidate any of its cash equivalents and marketable securities to meet its liquidity needs in the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest receivable as of March&#160;31, 2023 and December&#160;31, 2022 was $0.6 million and $0.5 million, respectively, and is recorded as a component of prepaid expenses and other current assets on the unaudited condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the following table summarizes the amortized cost and the unrealized gains/losses of the available for sale securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining Contractual Maturity (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,259,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,216,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68,739,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(561,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68,178,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,998,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,988,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total maturity less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85,996,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(614,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85,382,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1 to 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,372,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,322,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92,368,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(664,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,704,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the following table summarizes the amortized cost and the unrealized gains/losses of the available for sale securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining Contractual Maturity (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,093,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(73,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,020,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,823,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(911,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,913,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,998,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,982,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total maturity less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94,914,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,000,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93,915,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1 to 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,268,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(88,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,180,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,088,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108,095,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the following table summarizes available-for-sale securities in an unrealized loss position with no credit losses reported:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,216,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,216,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate Notes/Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,687,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(40,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,813,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(571,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(611,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of Government Sponsored Entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,988,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,988,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,891,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(93,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,813,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(571,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,704,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(664,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the following table summarizes available-for-sale securities in an unrealized loss position with no credit losses reported:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,020,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(73,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,020,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(73,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate Notes/Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,661,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74,452,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(972,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84,113,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(999,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of Government Sponsored Entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,981,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,981,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,662,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(116,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74,452,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(972,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106,114,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,088,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfNDE1MA_f7905c39-a84d-42aa-b467-9cffe731c55b">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis as of March&#160;31, 2023 and December&#160;31, 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Fair Value and Carrying Value on Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurement&#160;Category&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,216,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,216,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,988,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,988,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total investments:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,704,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,704,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;252,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;252,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,141,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,141,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Fair Value and Carrying Value on Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurement&#160;Category&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,020,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,020,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86,094,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86,094,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,981,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,981,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total investments:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108,095,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108,095,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,868,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,868,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,352,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,352,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i15907a4c560a493d87c23e62f68ec83c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNC0xLTEtMS0xMDQxMTk_59ba22fa-2d2f-414b-9234-daf1ef4f8322"
      unitRef="usd">15216000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id7a4d7a1847949aca50c56b25a88bd21_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNC0zLTEtMS0xMDQxMTk_bd3af6e1-73e7-491c-854a-23a52f7c9acc"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i310d4215052d4ca0a49959195011a0ca_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNC01LTEtMS0xMDQxMTk_beee7614-036e-41dc-9a98-ba2e0903eadb"
      unitRef="usd">15216000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i93d2a3e0250e47bcb4b130e733307695_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNC03LTEtMS0xMDQxMTk_47797af1-40b3-411f-a677-b830d1e4f5c7"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i647cc339b7ba4424aa0eb336ee4b0a30_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNS0xLTEtMS0xMDQxMTk_a5d62169-9902-4dc5-aafc-0c71e2b28434"
      unitRef="usd">74500000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i0f5ab08df5bf405bb9bf921da040bd2d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNS0zLTEtMS0xMDQxMTk_b6b0ede2-87a4-45a0-9922-2a57a7ae973f"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ice1331001dd149aab4965f0b8b08572c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNS01LTEtMS0xMDQxMTk_ce0bbf3f-2598-4050-8996-c4a662350fd3"
      unitRef="usd">74500000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i75520dd1a92c4e7f98c4a30068aa125f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNS03LTEtMS0xMDQxMTk_4f2d5d2d-70a3-4885-902b-2cbb1fb155fd"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if7617b2529de45d9b88866d405c216e8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNi0xLTEtMS0xMDQxMTk_5e6b6cad-eb7e-4b5f-aadd-1837202e847c"
      unitRef="usd">1988000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i52aa8a7998954d46afe56844fc671bed_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNi0zLTEtMS0xMDQxMTk_c585bfe1-95ae-4123-95d7-714aeb883f45"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i4c44b89669c84b58ac68a7d82a6f060f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNi01LTEtMS0xMDQxMTk_bf924d96-ceb1-4da6-b43b-41cbafd3aed6"
      unitRef="usd">1988000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ie7b8d23c3c2d432086d989ce0d5b3510_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNi03LTEtMS0xMDQxMTk_91579c8e-154c-47fd-81de-5070e3ceddf2"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i773ffb9b71e74f0fbb5045402bab92e2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNy0xLTEtMS0xMDQxMTk_529180be-7ad5-4556-910b-f714a5862822"
      unitRef="usd">91704000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="icfdbb8c8377342dba83719c152d876ca_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNy0zLTEtMS0xMDQxMTk_46eb1eeb-0045-4a01-8ffb-346bfbbb256e"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i91aa339ce2224ab2b4c95c616a46b05a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNy01LTEtMS0xMDQxMTk_9e25d72d-715b-40d7-b9d3-6f7bdba2d9f7"
      unitRef="usd">91704000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7c30654b099944fe816f08038b543686_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfNy03LTEtMS0xMDQxMTk_e420ec7b-35d4-4dca-b4a8-992b61b2055d"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i21767da9f078468aaa8154704501d4ef_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfOC0xLTEtMS0xMDQxMTk_7987a1ac-9f16-47b3-9828-aef0a8236e02"
      unitRef="usd">252000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if31d69e265f548ce81614232c6d0622e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfOC0zLTEtMS0xMDQxMTk_2908d771-f6ae-497f-9e0e-1ee1f89837f4"
      unitRef="usd">252000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i5dfdfcb6eabc4fdf95b79cf9538f70c7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfOC01LTEtMS0xMDQxMTk_3485854b-e65e-4a54-9df4-aead9b34720b"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i62d84f69387345d4810fabcf98a5a295_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfOC03LTEtMS0xMDQxMTk_a2db50a2-caeb-4400-8df5-08a771c6ef52"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i541c9938b3c74107adcc551aaa42ea63_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfMTAtMS0xLTEtMTA0MTE5_fef46185-0b61-449a-972d-a8d104b7ebfb"
      unitRef="usd">23141000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i98f19aa7ddf044ea8bec0a50eb8c00be_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfMTAtMy0xLTEtMTA0MTE5_2ab52d51-fa37-4752-b8b6-e02f58909901"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i5b14269404374b769581777b4169a1f0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfMTAtNS0xLTEtMTA0MTE5_8031cd24-5fa8-4a02-8fc3-1bfd1f2df6c6"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ic18218c1e1fa4ecba456ceeee9c63aff_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjA3MzFkYzU5YTdiNjRkY2RiMGMzYWRlNTEzZGFlZGVmL3RhYmxlcmFuZ2U6MDczMWRjNTlhN2I2NGRjZGIwYzNhZGU1MTNkYWVkZWZfMTAtNy0xLTEtMTA0MTE5_50dcbc3b-e11e-46bc-a0f0-a625cd566ddc"
      unitRef="usd">23141000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i6627384d34dc4218abc8ef93db117f35_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNC0xLTEtMS0xMDQxMTk_9e1716a3-5654-4988-8211-dc2acec09a55"
      unitRef="usd">20020000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i999a70848ee64e86a9903a8300ea18ae_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNC0zLTEtMS0xMDQxMTk_d5f8ed3c-9e57-454e-bfe5-9f9d62310024"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i1ab3ed3cf5644f68a916db4cc62581fe_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNC01LTEtMS0xMDQxMTk_9128a832-d191-4f0c-9ab3-6dba52d821da"
      unitRef="usd">20020000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ic17b4d26f18349fbb811e5538089dabe_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNC03LTEtMS0xMDQxMTk_1264cb72-4bb2-40a2-8a13-8c11281258a9"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id843769ea0ce4178b71b8b98c986b0ee_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNS0xLTEtMS0xMDQxMTk_e9d9ac50-374e-44aa-aa8b-f777b659a52f"
      unitRef="usd">86094000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7c33d6de7efe40e2a08f973235f91b19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNS0zLTEtMS0xMDQxMTk_6a39a81d-f6cc-4d17-8a81-4605f3e2bb96"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i8d60828b8d294052882c3b89d2fd9265_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNS01LTEtMS0xMDQxMTk_c66dd54b-efd4-4394-9c1b-a801f164cbe7"
      unitRef="usd">86094000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia6001106820441dbaa8649a391b20f27_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNS03LTEtMS0xMDQxMTk_edbdb9fe-d549-4a57-9bd6-fc7ee301d309"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id9394339fa2c426f9dac1c7946f4249c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNi0xLTEtMS0xMTE4MzY_d5d7600b-4690-4a23-bd21-be8b057251e6"
      unitRef="usd">1981000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i9019ad460da54067a92ced4519dbc280_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNi0zLTEtMS0xMTI4ODE_88928cf4-0f22-4ced-a105-ea1465f4bcb9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7cff04acd40b44bb97ada25f13cf507d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNi01LTEtMS0xMTE4NDM_3e1d2b8f-a527-4024-bf9b-9a60af31da6b"
      unitRef="usd">1981000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i971953b96b7546e2b31d70534f703931_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNi03LTEtMS0xMTI4ODc_97eba81e-5223-45c6-9a80-355fc52c9803"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ica6f16598c254520b8de2a1aba7fd14f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNi0xLTEtMS0xMDQxMTk_621aff8b-d2fa-4d14-abcc-bef9d21e61b6"
      unitRef="usd">108095000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i04186447695d45da87b4e76c39d70450_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNi0zLTEtMS0xMDQxMTk_1b9cd9ce-2d59-43d4-8a47-8eac3edaa406"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i229abcae1df149319098554f196c3b4a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNi01LTEtMS0xMDQxMTk_21e8318b-94ca-4b52-a6a7-5258dd31d0f9"
      unitRef="usd">108095000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i3d182bb719e0486b93ba7f98d8b1537b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNi03LTEtMS0xMDQxMTk_2ea82527-237b-4ddb-9a73-87c940a8f44f"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i0903ef6ff3f94b54a15562d6f61e5049_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNy0xLTEtMS0xMDQxMTk_ebd86529-9e29-4e03-b717-39d06eb43b25"
      unitRef="usd">1868000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i9e330387d6c34591aca484734572ae7d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNy0zLTEtMS0xMDQxMTk_e9e9a0fe-e2c8-4e68-8f29-785716656682"
      unitRef="usd">1868000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i042557760bda403e9553e36b701f1ab8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNy01LTEtMS0xMDQxMTk_11ea3725-2b0e-49af-b625-565e38f8fe9c"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i8c398cac425e49a5a91b7758fa11343b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfNy03LTEtMS0xMDQxMTk_46705662-0afb-43aa-bf54-62cc0ca1ea14"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="iadf82eab802a4fc0a2d085cc0c3baeae_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfOS0xLTEtMS0xMDQxMTk_698fd813-eee0-4182-ae18-59aceee6b66b"
      unitRef="usd">22352000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ieabf435d9321492eb0f1862ccf31dc71_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfOS0zLTEtMS0xMDQxMTk_947597ce-b7de-49b1-bd78-2f1a2f560570"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i9d5aec6d9ea84d38855de750ab9fd43e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfOS01LTEtMS0xMDQxMTk_f1ef49bf-798b-4196-8eee-bb0dc69ab463"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i01b4a9caaa104277aa2c4a4bb45c1c91_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjE0ODAxYTNjNTk0NTQ2YThhNWNiYmI5YjBkM2VmYTljL3RhYmxlcmFuZ2U6MTQ4MDFhM2M1OTQ1NDZhOGE1Y2JiYjliMGQzZWZhOWNfOS03LTEtMS0xMDQxMTk_84ba9861-43e5-4e56-9ab6-b53db620dd91"
      unitRef="usd">22352000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ia6c6c5c8311f41aa99327db95ebffefc_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfMTA5OTUxMTY1NTczMQ_95dc91f6-395b-4dd4-9735-aa833f49fc4c"
      unitRef="number">0.03</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i764a624557c84d788711b6db863a88fa_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfMTA5OTUxMTY1NTczNQ_92e65263-01bb-4dbf-8dde-c40c6b47c75e"
      unitRef="number">0.95</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <bngo:BusinessCombinationContingentConsiderationMilestonePayment
      contextRef="idf80aacd0d8b4d49bda88deb4fe34f82_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfMTA5OTUxMTY1NTczOQ_e015453a-6084-49cc-8bcb-99e804d2cbc4"
      unitRef="usd">10000000</bngo:BusinessCombinationContingentConsiderationMilestonePayment>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh
      contextRef="id0516c6ac8dd4d63874b612f0c8e9150_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfNTQ5NzU1ODQxNzYx_76f2594f-e8fa-4ba4-a437-16836cc84399"
      unitRef="usd">32000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i775844669d9443f18408dc91c0ed82e0_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfNTQ5NzU1ODQxNzc1_ab6250bf-5635-4077-8ba7-7d1680669b64"
      unitRef="number">0.15</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i92407742ad83484e8413c0f98a6ddb72_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfNTQ5NzU1ODQxNzY1_2b9bd43f-a71c-4ca4-a190-876dd2fe4cae"
      unitRef="number">0.20</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i026227378deb46939c6b0b7015b7862c_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfNTQ5NzU1ODQxNzcx_7b6d6a53-4dc1-42f1-a7ac-b081c8df31c4"
      unitRef="number">0.80</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfNDE1MQ_fefc3929-9434-4062-bead-887cf8149517">Changes in estimated fair value of contingent consideration liability in the three months ended March&#160;31, 2023 is as follows: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Contingent&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;(Level 3&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Measurement)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,352,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liability recorded as a result of current period acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in estimated fair value, recorded in selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;789,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,141,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i0b30d459d41d4643a4ff9a4e0f57f5f7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjJlY2M3YmYwMjMyMDRiODViZmJkMjNkZTMwOTVjNWMyL3RhYmxlcmFuZ2U6MmVjYzdiZjAyMzIwNGI4NWJmYmQyM2RlMzA5NWM1YzJfMS0xLTEtMS0xMDQxMTk_aa83aec0-f4e8-441d-80fb-fa3e35039df8"
      unitRef="usd">22352000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="ie44567efb5fb4e42820714c15bc00b89_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjJlY2M3YmYwMjMyMDRiODViZmJkMjNkZTMwOTVjNWMyL3RhYmxlcmFuZ2U6MmVjYzdiZjAyMzIwNGI4NWJmYmQyM2RlMzA5NWM1YzJfMi0xLTEtMS0xMDQxMTk_7848df45-7013-4dca-b613-d114cdc1478a"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="ie44567efb5fb4e42820714c15bc00b89_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjJlY2M3YmYwMjMyMDRiODViZmJkMjNkZTMwOTVjNWMyL3RhYmxlcmFuZ2U6MmVjYzdiZjAyMzIwNGI4NWJmYmQyM2RlMzA5NWM1YzJfMy0xLTEtMS0xMDQxMTk_7cab4a81-2ae3-4f20-8db0-c3d1c9d7add3"
      unitRef="usd">789000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ie44567efb5fb4e42820714c15bc00b89_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjJlY2M3YmYwMjMyMDRiODViZmJkMjNkZTMwOTVjNWMyL3RhYmxlcmFuZ2U6MmVjYzdiZjAyMzIwNGI4NWJmYmQyM2RlMzA5NWM1YzJfNC0xLTEtMS0xMDQxMTk_f94fd0d9-ac0a-4483-ad4f-23c558b3c23c"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i110925712b904ad2ad4771d5056f1576_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjJlY2M3YmYwMjMyMDRiODViZmJkMjNkZTMwOTVjNWMyL3RhYmxlcmFuZ2U6MmVjYzdiZjAyMzIwNGI4NWJmYmQyM2RlMzA5NWM1YzJfNS0xLTEtMS0xMDQxMTk_8e364709-cbf7-4860-9463-7f8badfd3585"
      unitRef="usd">23141000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfMTA5OTUxMTY1NjUwMA_be48a18f-97a8-4e40-9576-10ab484e67ae"
      unitRef="security">17</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfMTA5OTUxMTY1NjQzNg_c07b5e79-5ff6-4dbe-b781-6b088f72d59a"
      unitRef="security">16</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfMTA5OTUxMTY1NjUyMw_41397ba2-6550-4faf-8b05-dd76d89a6b5a"
      unitRef="security">19</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfMTA5OTUxMTY1NjUyNw_a4218b56-7eae-446a-8cf8-ec45de643965"
      unitRef="security">24</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:InterestReceivable
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfNTQ5NzU1ODQxODM5_2deb62ca-24c4-46e4-a6c5-c0f95ea6bf0d"
      unitRef="usd">600000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfMTA5OTUxMTY1NTc0OQ_2c844d88-3ffa-420f-8a21-86f650248640"
      unitRef="usd">500000</us-gaap:InterestReceivable>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="i60895e78119b46fe84d724fc783d3619_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RleHRyZWdpb246NDc4OTUwNjJiZWE5NDQyNmI2MTczNzg4ODQ4MjJkMzZfNDE1Mg_5b0239c1-c2e5-4af4-a7ff-07935e1e4e29">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the following table summarizes the amortized cost and the unrealized gains/losses of the available for sale securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining Contractual Maturity (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,259,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,216,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68,739,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(561,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68,178,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,998,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,988,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total maturity less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85,996,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(614,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85,382,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1 to 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,372,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,322,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92,368,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(664,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,704,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the following table summarizes the amortized cost and the unrealized gains/losses of the available for sale securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining Contractual Maturity (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,093,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(73,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,020,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,823,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(911,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,913,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,998,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,982,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total maturity less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94,914,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,000,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93,915,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1 to 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,268,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(88,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,180,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,088,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108,095,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the following table summarizes available-for-sale securities in an unrealized loss position with no credit losses reported:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,216,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,216,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate Notes/Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,687,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(40,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,813,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(571,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(611,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of Government Sponsored Entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,988,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,988,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,891,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(93,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,813,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(571,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,704,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(664,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the following table summarizes available-for-sale securities in an unrealized loss position with no credit losses reported:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,020,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(73,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,020,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(73,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate Notes/Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,661,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74,452,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(972,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84,113,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(999,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of Government Sponsored Entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,981,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,981,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,662,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(116,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74,452,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(972,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106,114,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,088,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i1becd5a6f0af415fae96defb606a1b8b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfMi0zLTEtMS0xMDQxMTk_1691df40-71bd-4cde-ba21-394ded72b414"
      unitRef="usd">15259000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne
      contextRef="i1becd5a6f0af415fae96defb606a1b8b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfMi01LTEtMS0xMDQxMTk_a1f46ec8-a237-4cea-9141-51ed89c8efee"
      unitRef="usd">0</bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne>
    <bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne
      contextRef="i1becd5a6f0af415fae96defb606a1b8b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfMi03LTEtMS0xMDQxMTk_84e13e5b-97d1-4f03-827f-ec636122934a"
      unitRef="usd">43000</bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i1becd5a6f0af415fae96defb606a1b8b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfMi05LTEtMS0xMDQxMTk_ad6091c5-0443-4947-a1e1-f4729ef66180"
      unitRef="usd">15216000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfMy0zLTEtMS0xMDQxMTk_5fd82603-7d86-43d5-9b7e-64db9307e8f6"
      unitRef="usd">68739000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne
      contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfMy01LTEtMS0xMDQxMTk_d5aded91-824c-4136-a5a2-3ebc1ec45835"
      unitRef="usd">0</bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne>
    <bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne
      contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfMy03LTEtMS0xMDQxMTk_fa95a302-9fec-4d1a-8913-b8a1a6c7a493"
      unitRef="usd">561000</bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfMy05LTEtMS0xMDQxMTk_af750b7b-6b6b-4c99-a2ca-3d7cbdf2aa4c"
      unitRef="usd">68178000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="iae48309cf5ff43dda82b169b4c36444e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfNC0zLTEtMS0xMDQxMTk_b11b176c-62cd-4293-aa17-13da4a4221d4"
      unitRef="usd">1998000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne
      contextRef="iae48309cf5ff43dda82b169b4c36444e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfNC01LTEtMS0xMDQxMTk_c97fdfc3-261f-491f-9972-9ab63849aa96"
      unitRef="usd">0</bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne>
    <bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne
      contextRef="iae48309cf5ff43dda82b169b4c36444e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfNC03LTEtMS0xMDQxMTk_9d83c563-018d-49f4-949c-0a4236d72a4a"
      unitRef="usd">10000</bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="iae48309cf5ff43dda82b169b4c36444e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfNC05LTEtMS0xMDQxMTk_2d48e993-4f4e-4c91-8b7c-066a0952db69"
      unitRef="usd">1988000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfNC0zLTEtMS0xMDcxNjA_fb5eb4e0-5da3-4bcd-a53d-51085654de4f"
      unitRef="usd">85996000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfNC01LTEtMS0xMDcxNjE_dcdc1528-373d-40ed-a1ce-194473d38455"
      unitRef="usd">0</bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne>
    <bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfNC03LTEtMS0xMDc5NDQ_67388ee1-15d0-4e59-91cc-a2440e2f4c3c"
      unitRef="usd">614000</bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfNC05LTEtMS0xMDc5NDc_65c1224d-5b5b-40b3-be8b-6d1af4feabf0"
      unitRef="usd">85382000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfNS0zLTEtMS0xMDcxNTA_a0aaf9bb-46c9-4841-8300-df61e54d0123"
      unitRef="usd">6372000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive
      contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfNS01LTEtMS0xMDcxNTA_3d38bc24-dee1-4254-806b-d962a49dc133"
      unitRef="usd">0</bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive>
    <bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive
      contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfNS03LTEtMS0xMDcxNTA_fe1f38bf-8eb3-47be-a452-99bc57f14147"
      unitRef="usd">50000</bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfNS05LTEtMS0xMDcxNTA_b194f749-e187-40d6-b258-fae86fa05edf"
      unitRef="usd">6322000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfOC0zLTEtMS0xMDc5NjQ_0d3b932a-ed69-4044-9efa-9f1645c143b2"
      unitRef="usd">92368000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bngo:DebtSecuritiesAvailableForSaleUnrealizedGains
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfOC01LTEtMS0xMDc5NjY_8c0b5cfd-1c5c-4172-a563-2428611d029e"
      unitRef="usd">0</bngo:DebtSecuritiesAvailableForSaleUnrealizedGains>
    <bngo:DebtSecuritiesAvailableForSaleUnrealizedLoss
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfOC03LTEtMS0xMDc5Njk_746e5476-cb4c-434f-844b-39a605922e24"
      unitRef="usd">664000</bngo:DebtSecuritiesAvailableForSaleUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjFiZGRjNzkxMzJkMDQ0MzBhNWUzN2E0OTQ3OGY2NzZlL3RhYmxlcmFuZ2U6MWJkZGM3OTEzMmQwNDQzMGE1ZTM3YTQ5NDc4ZjY3NmVfOC05LTEtMS0xMDc5NzE_6897dc13-cc81-4c1e-aafc-ed3d2fe9f516"
      unitRef="usd">91704000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i4118894962b9424d92128e02a9adf2bc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfMS0zLTEtMS0xMDUyNzg_d2aa190b-e2ca-4ffa-9233-a5d1fb07b46c"
      unitRef="usd">20093000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne
      contextRef="i4118894962b9424d92128e02a9adf2bc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfMS01LTEtMS0xMDUyNzg_319675f7-2a0d-4256-aea5-64e27cb5416d"
      unitRef="usd">0</bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne>
    <bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne
      contextRef="i4118894962b9424d92128e02a9adf2bc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfMS03LTEtMS0xMDUyNzg_d391eac5-59e3-40ee-8ee9-7b97fabc5687"
      unitRef="usd">73000</bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i4118894962b9424d92128e02a9adf2bc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfMS05LTEtMS0xMDUyNzg_e7d2efdb-5ed8-40fb-a36e-e889dcdf6103"
      unitRef="usd">20020000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i206731c08e11447b8873b07b61772810_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfMi0zLTEtMS0xMDUyNzg_325b250c-537b-43e0-9742-2dd94f5e9fa3"
      unitRef="usd">72823000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne
      contextRef="i206731c08e11447b8873b07b61772810_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfMi01LTEtMS0xMDUyNzg_f7be9fb2-672a-4e65-86c3-1c003ad155ea"
      unitRef="usd">1000</bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne>
    <bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne
      contextRef="i206731c08e11447b8873b07b61772810_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfMi03LTEtMS0xMDUyNzg_278a9608-6b3d-4ef7-ba14-9c2f8dbbd92a"
      unitRef="usd">911000</bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i206731c08e11447b8873b07b61772810_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfMi05LTEtMS0xMDUyNzg_80ed5727-f157-45a8-9edd-206062652f1a"
      unitRef="usd">71913000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="ic2908d99b8fe4704bcd189727c191080_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfMy0zLTEtMS0xMDUyNzg_bb749a29-83de-4232-8e71-da96b428313c"
      unitRef="usd">1998000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne
      contextRef="ic2908d99b8fe4704bcd189727c191080_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfMy01LTEtMS0xMDUyNzg_fdcb6005-2eba-499f-ae29-83168c4e8eed"
      unitRef="usd">0</bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne>
    <bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne
      contextRef="ic2908d99b8fe4704bcd189727c191080_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfMy03LTEtMS0xMDUyNzg_1212dcde-dee6-4ec4-8b98-fb8e0d166835"
      unitRef="usd">16000</bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ic2908d99b8fe4704bcd189727c191080_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfMy05LTEtMS0xMDUyNzg_0f7b998e-d322-4c5e-98c5-2ff8d6bb5d11"
      unitRef="usd">1982000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfNC0zLTEtMS0xMDcyMDY_56a090e9-65ca-48c9-ae24-2647eb43b638"
      unitRef="usd">94914000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfNC01LTEtMS0xMDcyMDc_a0545224-94cb-4122-bde5-5f6714965e95"
      unitRef="usd">1000</bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne>
    <bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfNC03LTEtMS0xMDc5OTI_bd0d988f-6fd4-486d-9c80-5ff3c4f595ce"
      unitRef="usd">1000000</bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfNC05LTEtMS0xMDc5OTQ_30db0c64-4b22-4c87-89fe-c9228c28d255"
      unitRef="usd">93915000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i206731c08e11447b8873b07b61772810_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfNS0zLTEtMS0xMDcxOTY_e7fa9299-513f-4123-9676-9b661ad42256"
      unitRef="usd">14268000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive
      contextRef="i206731c08e11447b8873b07b61772810_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfNS01LTEtMS0xMDcxOTY_4d0bb85b-6232-441c-9de3-8b01709c3579"
      unitRef="usd">0</bngo:DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive>
    <bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive
      contextRef="i206731c08e11447b8873b07b61772810_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfNS03LTEtMS0xMDcxOTY_8e6fb93a-35b9-4163-b639-43bbcc8b68c2"
      unitRef="usd">88000</bngo:DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i206731c08e11447b8873b07b61772810_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfNS05LTEtMS0xMDcxOTY_617012ec-4bf9-48c9-8148-442b085d5f40"
      unitRef="usd">14180000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfOC0zLTEtMS0xMDgwNzE_e21ee451-0e9a-4cd5-a924-77fc819bdbbf"
      unitRef="usd">109182000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bngo:DebtSecuritiesAvailableForSaleUnrealizedGains
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfOC01LTEtMS0xMDgwNzM_b7f3f3c5-a28b-4ef4-b1b4-7ca7708c60e2"
      unitRef="usd">1000</bngo:DebtSecuritiesAvailableForSaleUnrealizedGains>
    <bngo:DebtSecuritiesAvailableForSaleUnrealizedLoss
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfOC03LTEtMS0xMDgwNzQ_73cd685f-56a7-4ff8-a699-1dd175d9fe33"
      unitRef="usd">1088000</bngo:DebtSecuritiesAvailableForSaleUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjcyNjFlMjlmOTc4ZjRjOThiNWI5YTY0NGU2NTU2YTU5L3RhYmxlcmFuZ2U6NzI2MWUyOWY5NzhmNGM5OGI1YjlhNjQ0ZTY1NTZhNTlfOC05LTEtMS0xMDgwNzc_d5e15d50-9716-4451-9b38-4898d5c1d4b3"
      unitRef="usd">108095000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i1becd5a6f0af415fae96defb606a1b8b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfMi0xLTEtMS0xMDUwOTU_ee337f0f-61f8-48a8-8ba1-ea621284602e"
      unitRef="usd">15216000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i1becd5a6f0af415fae96defb606a1b8b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfMi0zLTEtMS0xMDUwOTU_e53bcc52-2be1-4307-b073-bf5792be5152"
      unitRef="usd">43000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i1becd5a6f0af415fae96defb606a1b8b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfMi01LTEtMS0xMDUwOTU_64ffe2a4-d84b-4b40-b690-a51f7500a494"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i1becd5a6f0af415fae96defb606a1b8b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfMi03LTEtMS0xMDUwOTU_892d99d1-8992-4058-a0f7-3835f44324fe"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i1becd5a6f0af415fae96defb606a1b8b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfMi05LTEtMS0xMDUwOTU_dca8467f-45a3-49c4-9c74-49bcd2267d9e"
      unitRef="usd">15216000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i1becd5a6f0af415fae96defb606a1b8b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfMi0xMS0xLTEtMTA1MDk1_c3caa15e-50a2-4522-a6cb-67124ac6e369"
      unitRef="usd">43000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfMy0xLTEtMS0xMDUwOTU_16428f53-7b29-468f-8db9-f300478aec21"
      unitRef="usd">11687000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfMy0zLTEtMS0xMDUwOTU_6b3e0888-9c67-4bad-a9e1-170f5be0911f"
      unitRef="usd">40000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfMy01LTEtMS0xMDUwOTU_85ed65a3-29ae-40e2-a970-85d4691783b3"
      unitRef="usd">62813000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfMy03LTEtMS0xMDUwOTU_0c362921-bba2-4917-bc8d-0144c11f10fa"
      unitRef="usd">571000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfMy05LTEtMS0xMDUwOTU_9499cc3f-e7ce-4fd4-84a6-7b3d4c4d6cdd"
      unitRef="usd">74500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i938d49d7edeb4dbe8bd3fc4696c90ae6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfMy0xMS0xLTEtMTA1MDk1_5664e948-9bc4-45f8-b8ee-e2de34468b78"
      unitRef="usd">611000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="iae48309cf5ff43dda82b169b4c36444e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfNC0xLTEtMS0xMDUwOTU_fd88ca56-980c-456f-ab44-d2605556022a"
      unitRef="usd">1988000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="iae48309cf5ff43dda82b169b4c36444e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfNC0zLTEtMS0xMDUwOTU_ca487e36-3f96-44fe-b91d-7505e740192d"
      unitRef="usd">10000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="iae48309cf5ff43dda82b169b4c36444e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfNC01LTEtMS0xMDUwOTU_292e88b2-d308-4a44-aeba-9e40431c4498"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="iae48309cf5ff43dda82b169b4c36444e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfNC03LTEtMS0xMDUwOTU_a9bc5cbc-1555-4198-8bf9-01eac5d406c9"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="iae48309cf5ff43dda82b169b4c36444e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfNC05LTEtMS0xMDUwOTU_0b2eca12-269f-4dff-b667-963f0c6d6abb"
      unitRef="usd">1988000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="iae48309cf5ff43dda82b169b4c36444e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfNC0xMS0xLTEtMTA1MDk1_e272803f-863c-4205-a7cf-45fc4ae6320b"
      unitRef="usd">10000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfNS0xLTEtMS0xMDYzOTU_50120c30-602e-4c98-8daf-496f3459b66a"
      unitRef="usd">28891000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfNS0zLTEtMS0xMDYzOTU_7ff5cf59-a8bf-4ee5-8832-9a02a5d76177"
      unitRef="usd">93000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfNS01LTEtMS0xMDYzOTU_7aa4d86e-fc00-489e-8070-a4be786a07a2"
      unitRef="usd">62813000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfNS03LTEtMS0xMDYzOTU_119efebc-2d8b-4966-884b-e9afd15471d8"
      unitRef="usd">571000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfNS05LTEtMS0xMDYzOTU_ad83dfdc-6e21-4e35-bdb0-64de97e1e9d7"
      unitRef="usd">91704000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i62aa37a9d1f149238d68dcecec48dda4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOjdhMWZkOTU3YmU2OTQ0YjRhYmVlZTZhYTQxN2MzM2FmL3RhYmxlcmFuZ2U6N2ExZmQ5NTdiZTY5NDRiNGFiZWVlNmFhNDE3YzMzYWZfNS0xMS0xLTEtMTA2Mzk1_c429ef47-5b8a-44ef-a541-fb892bb1f1cd"
      unitRef="usd">664000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i4118894962b9424d92128e02a9adf2bc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfMi0xLTEtMS0xMDUwOTU_c039e03f-979a-44cd-9760-a8656403fd97"
      unitRef="usd">20020000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i4118894962b9424d92128e02a9adf2bc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfMi0zLTEtMS0xMDUwOTU_fc02cbf5-cda4-4125-a9d4-4af0f5c69485"
      unitRef="usd">73000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i4118894962b9424d92128e02a9adf2bc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfMi01LTEtMS0xMDUwOTU_1c7470c6-c94d-4977-8ce6-12161f012d64"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i4118894962b9424d92128e02a9adf2bc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfMi03LTEtMS0xMDUwOTU_ef238eb7-07ab-4409-83d6-a83e337bf748"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i4118894962b9424d92128e02a9adf2bc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfMi05LTEtMS0xMDUwOTU_c6ca3c63-706e-433a-9d7e-c48386d6606f"
      unitRef="usd">20020000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i4118894962b9424d92128e02a9adf2bc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfMi0xMS0xLTEtMTA1MDk1_573e3ba3-5642-4860-95b3-b5eb10d54dbb"
      unitRef="usd">73000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i206731c08e11447b8873b07b61772810_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfMy0xLTEtMS0xMDUwOTU_194a71ba-5175-45b8-bad4-e6066c2e4ca0"
      unitRef="usd">9661000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i206731c08e11447b8873b07b61772810_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfMy0zLTEtMS0xMDUwOTU_0bff36ca-e16a-485f-8a42-496e3d7a8f41"
      unitRef="usd">27000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i206731c08e11447b8873b07b61772810_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfMy01LTEtMS0xMDUwOTU_16524261-c9fa-4a57-9e7c-03b6fbc6eb5b"
      unitRef="usd">74452000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i206731c08e11447b8873b07b61772810_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfMy03LTEtMS0xMDUwOTU_e1cbba61-74d9-4035-8d1b-bb82dbd9286a"
      unitRef="usd">972000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i206731c08e11447b8873b07b61772810_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfMy05LTEtMS0xMDUwOTU_e7aa34c3-25ee-4a7c-be90-59c3804c17ce"
      unitRef="usd">84113000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i206731c08e11447b8873b07b61772810_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfMy0xMS0xLTEtMTA1MDk1_12d8af4c-dd29-4774-b1cd-9857637b6297"
      unitRef="usd">999000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ic2908d99b8fe4704bcd189727c191080_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfNC0xLTEtMS0xMDUwOTU_5fc0286e-fe4f-4af9-aabd-347213fae1c4"
      unitRef="usd">1981000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ic2908d99b8fe4704bcd189727c191080_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfNC0zLTEtMS0xMDUwOTU_87217d36-e54a-4dae-999e-0e17b4183b3c"
      unitRef="usd">16000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ic2908d99b8fe4704bcd189727c191080_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfNC01LTEtMS0xMDUwOTU_d6b9c991-e406-41ca-a3ff-d9f99b64c85b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ic2908d99b8fe4704bcd189727c191080_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfNC03LTEtMS0xMDUwOTU_08d29f64-ea3e-4ea3-b039-3b64f6e475c0"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ic2908d99b8fe4704bcd189727c191080_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfNC05LTEtMS0xMDUwOTU_9f1456c3-dd17-4eca-8884-24c6584b9237"
      unitRef="usd">1981000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ic2908d99b8fe4704bcd189727c191080_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfNC0xMS0xLTEtMTA1MDk1_31d5293d-877e-4e4f-9c0b-fb8f3d3199b3"
      unitRef="usd">16000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfNS0xLTEtMS0xMDgwMDY_4820772e-7cd9-42a4-827e-efcffe3e8c70"
      unitRef="usd">31662000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfNS0zLTEtMS0xMDgwMjY_aa963801-f4c6-4495-879c-22936ada6e3a"
      unitRef="usd">116000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfNS01LTEtMS0xMDgwMjg_82b53908-1aae-43d3-ad2a-8e62f0bdaa51"
      unitRef="usd">74452000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfNS03LTEtMS0xMDgwMzA_8b7faaa1-c983-49f7-997d-a6914c390d82"
      unitRef="usd">972000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfNS05LTEtMS0xMDgwMzI_1aa2b736-28c3-4c5e-979f-12b2fc0a850a"
      unitRef="usd">106114000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i2491644bc39e40a3a0147bbb28e81a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2MTI1OWU2OWZiYjQ1NTI4MjBiN2VjNTZlNWRlYTNhL3NlYzo1NjEyNTllNjlmYmI0NTUyODIwYjdlYzU2ZTVkZWEzYV82NC9mcmFnOjQ3ODk1MDYyYmVhOTQ0MjZiNjE3Mzc4ODg0ODIyZDM2L3RhYmxlOmM0OWQwYzAwYjVkNTQzMmM4ZjJmZDdhZjFjZTQ0OTdjL3RhYmxlcmFuZ2U6YzQ5ZDBjMDBiNWQ1NDMyYzhmMmZkN2FmMWNlNDQ5N2NfNS0xMS0xLTEtMTA4MDM0_7b9f7e40-36e2-4827-add3-ff05e2d55a83"
      unitRef="usd">1088000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>65
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M'@:QN1#=O"B^[.X4[[A2O.D>%Y1H\,9 ?Y]SK0^V+^::LK^6GOT/4$L#!!0
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M@T=TV<SP$@7*!N#[N93FI6//Z>9:%O\#4$L#!!0    (  B!J58R:R:<E@4
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M)4OSRRTE$>7:0+U?,R9/-_H#U;'=\C]02P,$%     @ "(&I5CX"@78M P
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M3Y8W@+*CQ:HX1.="XY%<-!.\-($T!OA](83>=LP/ZFM8^ =02P,$%     @
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M:1OZP+8T*-[2F-EA-H;U OMP!.DUV].8C*G>)Q/*/-N]H'CW,H1H=P&'*XE
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MMC67&X)+PK6 ^GW-F#S<Z!?TGZ=>_Q=02P,$%     @ "(&I5ID:X#13"P
M:!T  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6RU6=MRVS@2_164)C65
MJ;)E2W8NFXNK;.<RF4UV7/%D]V%K'R 2DC ! 0X 2E&^?D\W0)!*E&PR4_MB
MBR30Z,OIT]WDDZWS[\-:J2@^-,:&IY-UC.VCDY-0K54CP]2URN+)TOE&1ESZ
MU4EHO9(U;VK,R?ST]/Y)([6=7#SA>S?^XHGKHM%6W7@1NJ:1?G>EC-L^G<PF
M_8VW>K6.=./DXDDK5^I6Q7?MC<?529%2ZT;9H)T57BV?3BYGCZ[.:3TO^*=6
MVS#Z+<B2A7/OZ>)5_71R2@HIHZI($B3^;=2U,H8$08T_LLQ).9(VCG_WTE^P
M[;!E(8.Z=N9?NH[KIY.'$U&KI>Q,?.NV/ZMLSSV25SD3^*_8YK6G$U%U(;HF
M;X8&C;;IO_R0_? M&^9YPYSU3@>QEL]DE!=/O-L*3ZLAC7ZPJ;P;RFE+0;F-
M'D\U]L6+7_U*6OU1)A?96ES)H(-P2W'C55 V\I,G)Q%GT8Z3*LN]2G+G7Y![
M)MXX&]=!/+>UJO?WGT#'HNB\5_1J_E6!;Z2?BK/9D9B?SL^^(N^L&'[&\LZ^
MP? C<>UL<$;7@Q_&YI,[7F@K;:6E$;>XJ8#+&,2_+Q<A>B#K/X<\E!0X/ZP
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M;4B\E5!$Z" \/9B_8:.T>TGREON.XB\\CL,(+_ A%](_Q:X**=R%EI@PMO,
MQ;D&JT^]9/O82RUQO, 413+[<'OUV<;IPPW@YP5+B+XO+ZN'@ZQ-DS#NIV$<
MQY#TPR$JT/)1K3$YT*=7U>23.AG!($R&EU[W^ZX8!V$ZO/!'+RLJ-TC"0:N;
M7#?'<W]\';>'S?\W[9B$]#KL]QNM- XOTT9V[&L3[<T")3<K/_%0_\0L;<:"
M[K0;JFZ;6>)%O9G(,#HK@=&0?(FF<>]R&(!IIIQFXW3E)XN%=CBG^&6!@R$W
MI(#RI<8\:C=T03=J3O\#4$L#!!0    (  B!J598-8O2XP4  (L.   9
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M$1*5R"TA</R[%Y>BJ@@(-/[I, ?K+4EQ>]RCOW.VPY89-^)259]D8<O3P=&
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M?4&EW1'!Z9(+[F3R::#FQ/O=YJ: =PXO -?8IMQY]&0\]("!Q)\A61K\]9K
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M-2D:UQ+TI?)+7G'@[YM=PR%OJ3=\A#AL7&[+6).[)>.)'K)4'#Q(!OT8DZ:
MJ7/!(QFF)$M(G<8]!.[@0IS;2RXNA,<G5V+QHR9"-"3C<:W)**FU^O20DW5
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MN S'=69/S,P6',JQF1$\Y'<0HX 5?&@=4&ST('0'RW&UO,=P8A@MK.LZNCM
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M10\Q 1%VWVPP [8CV@9FF!UV''C9?=C8!W65JDN#2JJ15&Y[OWY/INK6T/0
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M+"H;0/Z=E.8XL0L,3_;J'U!+ P04    "  (@:E63$LT?6\%  !+#@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6RM5VUOVS80_BN$%PPIH-5ZL6S9
M2PPXSKIU:-<@R98/PS[0TMGB*I$J2<7Q?OV.I"3;J:-FP+[8)'7W\'AWSQUY
ML17RL\H!-'DJ"ZXN![G6U6PX5&D.)55O104<OZR%+*G&J=P,526!9E:I+(:A
M[X^')65\,+^P:S=R?B%J73 .-Y*HNBRIW%U!(;:7@V#0+MRR3:[-PG!^4=$-
MW('^O;J1.!MV*!DK@2LF.)&POAPL@ME58N2MP!\,MNI@3,Q)5D)\-I/WV>7
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M 8P$\/U22M,^$$#WZ\3L;U!+ P04    "  (@:E6-!N6@A@#  "S!@  &0
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MGA.%42'8?/X)7/A.< 1>+8$CI#VJ2'OT,Z1]A*0=\B$3<Z1:0ZQOLVVN448
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M*ENO!Z(M%S2MG&4$:9R5__'7JA -!XEC=H"5 SQT"%H<4.6 BD3+R(JT;K'
MTPFC.\!R:XF6'Q2U*;QE-G&63^-<,'DUEGYB^D1>2;8EX(E$=)7%16E_!OO1
MYV]@3K<L(@!G"_ ;H2N&-^LX I]IA O;C[=$X#CAGZ37E_DM^/CA$_@ X@S\
ML:9;+KWXI"]DG/G=^E$5TTT9$VR)"8$'FHDU!W?9@BQT_[[,KTX2[I.\@5;
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MBP+*)N#Y2DJSV]BAU7VCTC]02P,$%     @ "(&I5A/\IA>J @  <@8  !D
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M81JDWL3=]TMY*6K &+:,X45&M7QWU:Y$4OU4"I!+\A_2?Q8FS*-2U .XRF
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MCX]E7OTTK98KKS^6V>SS7;:<Z[SX^]\N//?\'T[X^R8MOSC)>NYL?_S#^ZH
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MWYZX)\ZGK"RSU?;+.YW,=5X_H?KY(LO*IV_J 1ZS_/-VM:__!U!+ P04
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MWE"X;SYH+8.:J*5S=J,8RX OBQI5H(CE5)9U6=U;U\'3HOJS=\/+(EI5$"H
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MW4"]GS,FWVYT!\6A^?0?4$L#!!0    (  B!J59\44%?PP,  *$1   9
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M]Z* $6_::T8:VT(DT25INP7Z\$M2LNA=2:RC-#>Q#ISAQ^',/PJG1\8?Q19
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M#TWL]HEW)XJOBYW3)ZX43XO#%= Y"'T#7E]PKO8G>C.VVJV?_@M02P,$%
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M,H "5Z1A^EYLW^.NGK'-EPNFW!.VN]@H@+Q16E0[L%%04>[?Y&77APX@28X
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M&DS-<4H_#;VA1>TFT)/09IZY96E^("AM@-E?":'WAB5H?TG9+U!+ P04
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MH_1/=C7P<_<NW1"-*0$J3(P\.!16=9LM-/,>6=!MLU-O,9P=GQGBV/UW>,Q
M0,VZ3!99YZX'#M>W9K;0S,6#6)N-/%J<6=5RMM#,;(&6FYTZ6BP<!<9PS.00
MT+3RY)+LL3'7?GP?Z"2'\D[[.*]F^AL4'Y[$<CA(U39_F,FM2E.UR5\^2'\M
MX\Q ?WZGM"PI#K+GHY3/PUG^#U!+ P04    "  (@:E6.FUX?;4$   ]&P
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M8A2ZS0R YPLA],.%25"=F(W_!U!+ P04    "  (@:E62,J=V!\#  "6!P
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M"F+@(=P(6<=1U.U'XW#=$+E?1^X?C/Q2DYK4TU0HP*C :6>H74$MP>GNBK-
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MC)*!"=$=0>2[(XB\=@2^U,STSQZ,C^\(3A*)<5M*>P_)K5;=9^3!V8LH]5M
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M_.3R0WZ@0JIUD0*0? W>D82#KR3=4W!'B=AS>CIW!;[DJDW2Y%^Z!A^9$%2
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MNS&KO_XYVMS32A?U,9^U?Z"GGU!+ 0(4 Q0    (  B!J58'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ "(&I5@"F!-WO    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ "(&I5IE<G",0!@  G"<  !,
M     ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  (@:E6
MA5>*8V@&  "A)0  &               @($."   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ "(&I5J.__&?D!@  HAX  !@
M     ("!K X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M  B!J58B_BYBY0(  *()   8              " @<85  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    "  (@:E6,FLFG)8%  #"&P  &
M            @('A&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ "(&I5CX"@78M P  D@D  !@              ("!K1X  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (  B!J58K$]W[@P8  + K
M   8              " @1 B  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    "  (@:E67C6C=3$)  "J*@  &               @(')*
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ "(&I5ID:X#13
M"P  :!T  !@              ("!,#(  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    (  B!J5:YNB,L. 0  '8*   8              "
M@;D]  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  (@:E6
M6#6+TN,%  "+#@  &0              @($G0@  >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    (  B!J5863M%K]@4   D.   9
M      " @4%(  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ "(&I5E3,G@!T#0  ."@  !D              ("!;DX  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  (@:E6ZZ<N_Q,%  !V"P
M&0              @($97   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    (  B!J59EJ+2T9P@   85   9              " @6-A  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ "(&I5KS 8^_Q
M#0  22X  !D              ("! 6H  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    "  (@:E6$W&8P"P)  "O&   &0
M@($I>   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (  B!
MJ59?WI:&#0,  ,L&   9              " @8R!  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ "(&I5LBU1Y)Q P  O@<  !D
M         ("!T(0  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    "  (@:E63$LT?6\%  !+#@  &0              @(%XB   >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (  B!J58N4/"+D 4  *D0
M   9              " @1Z.  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ "(&I5C0;EH(8 P  LP8  !D              ("!Y9,
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  (@:E6FRVM
M@E@%  !Y#0  &0              @($TEP  >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    (  B!J5;A$$=SUP8  +07   9
M  " @<.<  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
M"(&I5@'[Q:Q' P  O H  !D              ("!T:,  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    "  (@:E63QZK@<T#  !(%0  &0
M            @(%/IP  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    (  B!J58:&ZZ@>P4  (DE   9              " @5.K  !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ "(&I5BK%'A&+ @
MQP8  !D              ("!!;$  'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    "  (@:E6$=UMV;T#  #J$P  &0              @(''
MLP  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (  B!J5:$
MM>&HH (  *\&   9              " @;NW  !X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ "(&I5A/\IA>J @  <@8  !D
M     ("!DKH  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  B!J59EO@59X X  'K0   9              "
M@:S*  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ "(&I
M5OCO5<[< P  *1   !D              ("!P]D  'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    "  (@:E6Y19Y<L0$  ! %P  &0
M        @('6W0  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   (  B!J59\44%?PP,  *$1   9              " @='B  !X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ "(&I5B ]UBG3 @  W <
M !D              ("!R^8  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    "  (@:E6$4XP7Q8$   I$P  &0              @('5Z0
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (  B!J58J@K+!
M>@,  -@,   9              " @2+N  !X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ "(&I5F?N>L8Z P  N0L  !D
M ("!T_$  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  (
M@:E68HT 6<("  "/!@  &0              @(%$]0  >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (  B!J5;=AOMVI00  +D7   9
M          " @3WX  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#
M%     @ "(&I5GLLT(6Z @  JPD  !D              ("!&?T  'AL+W=O
M<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  (@:E6RW>6N*0"  ">
M!@  &0              @($*  $ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM
M;%!+ 0(4 Q0    (  B!J59052AAH <  !M'   9              " @>4"
M 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ "(&I5CIM
M>'VU!   /1L  !D              ("!O H! 'AL+W=O<FMS:&5E=',O<VAE
M970T."YX;6Q02P$"% ,4    "  (@:E62,J=V!\#  "6!P  &0
M    @(&H#P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (
M  B!J5;>,$MZN04  .HD   9              " @?X2 0!X;"]W;W)K<VAE
M971S+W-H965T-3 N>&UL4$L! A0#%     @ "(&I5F#X82XE!0  @QX  !D
M             ("![A@! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"
M% ,4    "  (@:E6Y/952#H#  #N$P  #0              @ %*'@$ >&PO
M<W1Y;&5S+GAM;%!+ 0(4 Q0    (  B!J5:7BKL<P    !,"   +
M      "  :\A 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    (  B!J5:C  $2  0
M &PB   /              "  9@B 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    "  (@:E6H9?JE,D!  "@'@  &@              @ '%)@$ >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  (@:E6*+1H$\,!  ")
M'@  $P              @ '&* $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    .P [ !00  "Z*@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>188</ContextCount>
  <ElementCount>315</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (Deficit) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity (Deficit) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Balance Sheet Account Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/BalanceSheetAccountDetails</Role>
      <ShortName>Balance Sheet Account Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Stockholders??? Equity and Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensation</Role>
      <ShortName>Stockholders??? Equity and Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Investments and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/InvestmentsandFairValueMeasurements</Role>
      <ShortName>Investments and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Organization and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/OrganizationandBasisofPresentationPolicies</Role>
      <ShortName>Organization and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/NetLossPerShare</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/RevenueRecognition</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Balance Sheet Account Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/BalanceSheetAccountDetailsTables</Role>
      <ShortName>Balance Sheet Account Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/BalanceSheetAccountDetails</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Stockholders??? Equity and Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables</Role>
      <ShortName>Stockholders??? Equity and Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Commitment and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/CommitmentandContingenciesTables</Role>
      <ShortName>Commitment and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/Acquisitions</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Investments and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsTables</Role>
      <ShortName>Investments and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/InvestmentsandFairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Organization and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails</Role>
      <ShortName>Organization and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/OrganizationandBasisofPresentationPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/NetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/NetLossPerShareTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Revenue Recognition - Revenue by Source and Geographic Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails</Role>
      <ShortName>Revenue Recognition - Revenue by Source and Geographic Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Revenue Recognition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails</Role>
      <ShortName>Revenue Recognition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Revenue Recognition - Remaining Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails</Role>
      <ShortName>Revenue Recognition - Remaining Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Balance Sheet Account Details - Schedule of Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails</Role>
      <ShortName>Balance Sheet Account Details - Schedule of Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Balance Sheet Account Details - Schedule of Allowance for Credit Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAllowanceforCreditLossesDetails</Role>
      <ShortName>Balance Sheet Account Details - Schedule of Allowance for Credit Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Balance Sheet Account Details - Schedule of Components of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails</Role>
      <ShortName>Balance Sheet Account Details - Schedule of Components of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Balance Sheet Account Details - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Balance Sheet Account Details - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Balance Sheet Account Details - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails</Role>
      <ShortName>Balance Sheet Account Details - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Balance Sheet Account Details - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails</Role>
      <ShortName>Balance Sheet Account Details - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Stockholders??? Equity and Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stockholders??? Equity and Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Stockholders??? Equity and Stock-Based Compensation - Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails</Role>
      <ShortName>Stockholders??? Equity and Stock-Based Compensation - Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Stockholders??? Equity and Stock-Based Compensation - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails</Role>
      <ShortName>Stockholders??? Equity and Stock-Based Compensation - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Stockholders??? Equity and Stock-Based Compensation - Recognized Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders??? Equity and Stock-Based Compensation - Recognized Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Stockholders??? Equity and Stock-Based Compensation - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAssumptionsDetails</Role>
      <ShortName>Stockholders??? Equity and Stock-Based Compensation - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Stockholders??? Equity and Stock-Based Compensation - Restricted Stock and Performance Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails</Role>
      <ShortName>Stockholders??? Equity and Stock-Based Compensation - Restricted Stock and Performance Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Commitments and Contingencies - Summary of Undiscounted Future Non-Cancellable Lease Payments Under Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Undiscounted Future Non-Cancellable Lease Payments Under Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Acquisitions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisitions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Acquisitions - Acquisition Purchase Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails</Role>
      <ShortName>Acquisitions - Acquisition Purchase Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Acquisitions - Fair Value of Tangible and Identifiable Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisitions - Fair Value of Tangible and Identifiable Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Acquisitions - Identifiable Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails</Role>
      <ShortName>Acquisitions - Identifiable Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Acquisitions - Pro Forma Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails</Role>
      <ShortName>Acquisitions - Pro Forma Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Investments and Fair Value Measurements - Financial Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails</Role>
      <ShortName>Investments and Fair Value Measurements - Financial Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Investments and Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Investments and Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Investments and Fair Value Measurements - Contingent Consideration Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails</Role>
      <ShortName>Investments and Fair Value Measurements - Contingent Consideration Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Investments and Fair Value Measurements - Amortized Cost and Unrealized Gains (Losses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails</Role>
      <ShortName>Investments and Fair Value Measurements - Amortized Cost and Unrealized Gains (Losses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="bngo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Investments and Fair Value Measurements - Unrealized Losses Positions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails</Role>
      <ShortName>Investments and Fair Value Measurements - Unrealized Losses Positions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 6 fact(s) appearing in ix:hidden were eligible for transformation: bngo:StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent, us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage -  bngo-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="bngo-20230331.htm">bngo-20230331.htm</File>
    <File>bngo-20230331.xsd</File>
    <File>bngo-20230331_cal.xml</File>
    <File>bngo-20230331_def.xml</File>
    <File>bngo-20230331_lab.xml</File>
    <File>bngo-20230331_pre.xml</File>
    <File>bngo-20230331xexx311.htm</File>
    <File>bngo-20230331xexx312.htm</File>
    <File>bngo-20230331xexx321.htm</File>
    <File>exhibit101amendmentno1tosa.htm</File>
    <File>exhibit21bngo-firstamendme.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="667">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="32">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>71
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bngo-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 667,
    "http://xbrl.sec.gov/dei/2022": 32
   },
   "contextCount": 188,
   "dts": {
    "calculationLink": {
     "local": [
      "bngo-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bngo-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "bngo-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bngo-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bngo-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bngo-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 488,
   "entityCount": 1,
   "hidden": {
    "http://bionanogenomics.com/20230331": 1,
    "http://fasb.org/us-gaap/2022": 5,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 11
   },
   "keyCustom": 35,
   "keyStandard": 280,
   "memberCustom": 14,
   "memberStandard": 42,
   "nsprefix": "bngo",
   "nsuri": "http://bionanogenomics.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://bionanogenomics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Revenue Recognition",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://bionanogenomics.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Balance Sheet Account Details",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://bionanogenomics.com/role/BalanceSheetAccountDetails",
     "shortName": "Balance Sheet Account Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Stockholders\u2019 Equity and Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensation",
     "shortName": "Stockholders\u2019 Equity and Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://bionanogenomics.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Acquisitions",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://bionanogenomics.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Investments and Fair Value Measurements",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurements",
     "shortName": "Investments and Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Organization and Basis of Presentation (Policies)",
     "menuCat": "Policies",
     "order": "16",
     "role": "http://bionanogenomics.com/role/OrganizationandBasisofPresentationPolicies",
     "shortName": "Organization and Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Net Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "17",
     "role": "http://bionanogenomics.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Revenue Recognition (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://bionanogenomics.com/role/RevenueRecognitionTables",
     "shortName": "Revenue Recognition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Balance Sheet Account Details (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://bionanogenomics.com/role/BalanceSheetAccountDetailsTables",
     "shortName": "Balance Sheet Account Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i62aa37a9d1f149238d68dcecec48dda4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i62aa37a9d1f149238d68dcecec48dda4_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Stockholders\u2019 Equity and Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables",
     "shortName": "Stockholders\u2019 Equity and Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Commitment and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://bionanogenomics.com/role/CommitmentandContingenciesTables",
     "shortName": "Commitment and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Acquisitions (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://bionanogenomics.com/role/AcquisitionsTables",
     "shortName": "Acquisitions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Investments and Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsTables",
     "shortName": "Investments and Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i62aa37a9d1f149238d68dcecec48dda4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Organization and Basis of Presentation (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails",
     "shortName": "Organization and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "bngo:LiquidityAndGoingConcernPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i62aa37a9d1f149238d68dcecec48dda4_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "bngo:WorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://bionanogenomics.com/role/NetLossPerShareDetails",
     "shortName": "Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Revenue Recognition - Revenue by Source and Geographic Location (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails",
     "shortName": "Revenue Recognition - Revenue by Source and Geographic Location (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i6669836447414cf385db5ed716981bad_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i4b3236b899344cfc8b2fdf441232a276_D20230101-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Revenue Recognition - Narrative (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails",
     "shortName": "Revenue Recognition - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i4b3236b899344cfc8b2fdf441232a276_D20230101-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i62aa37a9d1f149238d68dcecec48dda4_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Revenue Recognition - Remaining Performance Obligations (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails",
     "shortName": "Revenue Recognition - Remaining Performance Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i62aa37a9d1f149238d68dcecec48dda4_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i62aa37a9d1f149238d68dcecec48dda4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Balance Sheet Account Details - Schedule of Accounts Receivable (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails",
     "shortName": "Balance Sheet Account Details - Schedule of Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i62aa37a9d1f149238d68dcecec48dda4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i62aa37a9d1f149238d68dcecec48dda4_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i62aa37a9d1f149238d68dcecec48dda4_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i2491644bc39e40a3a0147bbb28e81a57_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Balance Sheet Account Details - Schedule of Allowance for Credit Losses (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAllowanceforCreditLossesDetails",
     "shortName": "Balance Sheet Account Details - Schedule of Allowance for Credit Losses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i62aa37a9d1f149238d68dcecec48dda4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Balance Sheet Account Details - Schedule of Components of Inventories (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails",
     "shortName": "Balance Sheet Account Details - Schedule of Components of Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i62aa37a9d1f149238d68dcecec48dda4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i62aa37a9d1f149238d68dcecec48dda4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Balance Sheet Account Details - Schedule of Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails",
     "shortName": "Balance Sheet Account Details - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i62aa37a9d1f149238d68dcecec48dda4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "iafccbaea24c04903bdeb891f986857c7_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Balance Sheet Account Details - Narrative (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails",
     "shortName": "Balance Sheet Account Details - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "iafccbaea24c04903bdeb891f986857c7_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i62aa37a9d1f149238d68dcecec48dda4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Balance Sheet Account Details - Schedule of Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails",
     "shortName": "Balance Sheet Account Details - Schedule of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i62aa37a9d1f149238d68dcecec48dda4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i93b42a0d7db1482cba91fd543f66a9ba_D20220801-20220831",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Stockholders\u2019 Equity and Stock-Based Compensation - Narrative (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails",
     "shortName": "Stockholders\u2019 Equity and Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i93b42a0d7db1482cba91fd543f66a9ba_D20220801-20220831",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i2491644bc39e40a3a0147bbb28e81a57_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Stockholders\u2019 Equity and Stock-Based Compensation - Warrant Activity (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails",
     "shortName": "Stockholders\u2019 Equity and Stock-Based Compensation - Warrant Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "bngo:ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i2491644bc39e40a3a0147bbb28e81a57_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Stockholders\u2019 Equity and Stock-Based Compensation - Schedule of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails",
     "shortName": "Stockholders\u2019 Equity and Stock-Based Compensation - Schedule of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Stockholders\u2019 Equity and Stock-Based Compensation - Recognized Stock-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails",
     "shortName": "Stockholders\u2019 Equity and Stock-Based Compensation - Recognized Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Stockholders\u2019 Equity and Stock-Based Compensation - Assumptions (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAssumptionsDetails",
     "shortName": "Stockholders\u2019 Equity and Stock-Based Compensation - Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "ib9d74a66fe4c4a139d49dde0ca471851_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Stockholders\u2019 Equity and Stock-Based Compensation - Restricted Stock and Performance Stock Activity (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails",
     "shortName": "Stockholders\u2019 Equity and Stock-Based Compensation - Restricted Stock and Performance Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "ib9d74a66fe4c4a139d49dde0ca471851_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i62aa37a9d1f149238d68dcecec48dda4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Commitments and Contingencies - Summary of Undiscounted Future Non-Cancellable Lease Payments Under Leases (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails",
     "shortName": "Commitments and Contingencies - Summary of Undiscounted Future Non-Cancellable Lease Payments Under Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i62aa37a9d1f149238d68dcecec48dda4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i7d2c0cf7229242a88304bb4f867c0c9d_D20221101-20221130",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Acquisitions - Narrative (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://bionanogenomics.com/role/AcquisitionsNarrativeDetails",
     "shortName": "Acquisitions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i91fff28e789d4fdc80fbfa9100a620b7_I20221130",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i7d2c0cf7229242a88304bb4f867c0c9d_D20221101-20221130",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Acquisitions - Acquisition Purchase Price (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails",
     "shortName": "Acquisitions - Acquisition Purchase Price (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i91fff28e789d4fdc80fbfa9100a620b7_I20221130",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i62aa37a9d1f149238d68dcecec48dda4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Acquisitions - Fair Value of Tangible and Identifiable Assets Acquired and Liabilities Assumed (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Acquisitions - Fair Value of Tangible and Identifiable Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i91fff28e789d4fdc80fbfa9100a620b7_I20221130",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i91fff28e789d4fdc80fbfa9100a620b7_I20221130",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Acquisitions - Identifiable Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails",
     "shortName": "Acquisitions - Identifiable Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "ic97685b2136f4353b8df0de2a7e10ad3_I20221130",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i6925d4a44b4d4f8ab1473a6ec01745a1_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Acquisitions - Pro Forma Information (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails",
     "shortName": "Acquisitions - Pro Forma Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i6925d4a44b4d4f8ab1473a6ec01745a1_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i541c9938b3c74107adcc551aaa42ea63_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Investments and Fair Value Measurements - Financial Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails",
     "shortName": "Investments and Fair Value Measurements - Financial Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i541c9938b3c74107adcc551aaa42ea63_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i62aa37a9d1f149238d68dcecec48dda4_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Investments and Fair Value Measurements - Narrative (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails",
     "shortName": "Investments and Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i62aa37a9d1f149238d68dcecec48dda4_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i0b30d459d41d4643a4ff9a4e0f57f5f7_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Investments and Fair Value Measurements - Contingent Consideration Liability (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails",
     "shortName": "Investments and Fair Value Measurements - Contingent Consideration Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i0b30d459d41d4643a4ff9a4e0f57f5f7_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i62aa37a9d1f149238d68dcecec48dda4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Investments and Fair Value Measurements - Amortized Cost and Unrealized Gains (Losses) (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails",
     "shortName": "Investments and Fair Value Measurements - Amortized Cost and Unrealized Gains (Losses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i62aa37a9d1f149238d68dcecec48dda4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i62aa37a9d1f149238d68dcecec48dda4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Investments and Fair Value Measurements - Unrealized Losses Positions (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails",
     "shortName": "Investments and Fair Value Measurements - Unrealized Losses Positions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i62aa37a9d1f149238d68dcecec48dda4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "ifc1dfa094b4c4c1fa40f179234ec50e6_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (Deficit) (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (Deficit) (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "ifc1dfa094b4c4c1fa40f179234ec50e6_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Organization and Basis of Presentation",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://bionanogenomics.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Net Loss Per Share",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://bionanogenomics.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20230331.htm",
      "contextRef": "i60895e78119b46fe84d724fc783d3619_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 62,
   "tag": {
    "bngo_AccruedClinicalStudyFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Study Fees, Current",
        "label": "Accrued Clinical Study Fees, Current",
        "terseLabel": "Accrued clinical study fees"
       }
      }
     },
     "localname": "AccruedClinicalStudyFeesCurrent",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_BioDiscoveryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BioDiscovery",
        "label": "BioDiscovery [Member]",
        "terseLabel": "BioDiscovery"
       }
      }
     },
     "localname": "BioDiscoveryMember",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_BusinessAcquisitionCashHeldInEscrowFund": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Cash Held in Escrow Fund",
        "label": "Business Acquisition, Cash Held in Escrow Fund",
        "terseLabel": "Cash held in escrow fund"
       }
      }
     },
     "localname": "BusinessAcquisitionCashHeldInEscrowFund",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_BusinessCombinationContingentConsiderationMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Milestone Payment",
        "label": "Business Combination, Contingent Consideration, Milestone Payment",
        "terseLabel": "Consideration milestone payment"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationMilestonePayment",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Estimated Return of Cash to Buyer from Escrow",
        "label": "Business Combination, Estimated Return of Cash to Buyer from Escrow",
        "negatedLabel": "Estimated return of cash to buyer from escrow"
       }
      }
     },
     "localname": "BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable and Other Accrued Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable and Other Accrued Liabilities",
        "negatedTerseLabel": "Accounts payable and other accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liability Current",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liability Current",
        "negatedTerseLabel": "Operating lease liability (short-term and long-term)"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Assets",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights",
        "label": "Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights [Abstract]",
        "label": "Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights [Roll Forward]",
        "label": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights [Roll Forward]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Number Of Securities Canceled In Period",
        "label": "Class Of Warrant Or Right, Number Of Securities Canceled In Period",
        "negatedTerseLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Number Of Securities Exercised In Period",
        "label": "Class Of Warrant Or Right, Number Of Securities Exercised In Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Number Of Securities Granted In Period",
        "label": "Class Of Warrant Or Right, Number Of Securities Granted In Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bngo_ClassOfWarrantOrRightOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Outstanding [Roll Forward]",
        "label": "Class Of Warrant Or Right, Outstanding [Roll Forward]",
        "terseLabel": "Shares of Stock under Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstandingRollForward",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Weighted- Average Remaining Contractual Term Of Warrants Or Rights",
        "label": "Class Of Warrant Or Right, Weighted- Average Remaining Contractual Term Of Warrants Or Rights",
        "terseLabel": "Balance"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Weighted-Average Remaining Contractual Term Of Warrants Or Rights [Roll Forward]",
        "label": "Class Of Warrant Or Right, Weighted-Average Remaining Contractual Term Of Warrants Or Rights [Roll Forward]",
        "terseLabel": "Weighted- Average Remaining Contractual Term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bngo_CommissionFeeMaximumPercentageOfGrossProceeds": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission Fee, Maximum Percentage Of Gross Proceeds",
        "label": "Commission Fee, Maximum Percentage Of Gross Proceeds",
        "terseLabel": "Commission fee"
       }
      }
     },
     "localname": "CommissionFeeMaximumPercentageOfGrossProceeds",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bngo_CommonWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common warrants.",
        "label": "Common Warrants [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "CommonWarrantsMember",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_ConsumableRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumable Revenue [Member]",
        "label": "Consumable Revenue [Member]",
        "terseLabel": "Consumables"
       }
      }
     },
     "localname": "ConsumableRevenueMember",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_ContingentConsiderationLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration Liability",
        "label": "Contingent Consideration Liability [Member]",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "ContingentConsiderationLiabilityMember",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_CorporateNotesAndBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Notes And Bonds",
        "label": "Corporate Notes And Bonds [Member]",
        "terseLabel": "Corporate notes/bonds"
       }
      }
     },
     "localname": "CorporateNotesAndBondsMember",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_CostOfLeasedEquipmentSoldToCustomer": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of Leased Equipment Sold to Customer",
        "label": "Cost of Leased Equipment Sold to Customer",
        "terseLabel": "Cost of leased equipment sold to customer"
       }
      }
     },
     "localname": "CostOfLeasedEquipmentSoldToCustomer",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_CostOfProductRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of Product Revenue",
        "label": "Cost of Product Revenue [Member]",
        "terseLabel": "Cost of product revenue"
       }
      }
     },
     "localname": "CostOfProductRevenueMember",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_CostOfServiceAndOtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Of Service And Other Revenue",
        "label": "Cost Of Service And Other Revenue [Member]",
        "terseLabel": "Cost of service and other revenue"
       }
      }
     },
     "localname": "CostOfServiceAndOtherRevenueMember",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_CowenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cowen",
        "label": "Cowen [Member]",
        "terseLabel": "Cowen"
       }
      }
     },
     "localname": "CowenMember",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Unrealized Gain, Maturity, Allocated and Single Maturity Date, After Year One Through Five",
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain, Maturity, Allocated and Single Maturity Date, After Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Unrealized Gain, Maturity, Allocated and Single Maturity Date, Year One",
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Less than 1 year"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainMaturityAllocatedAndSingleMaturityDateYearOne",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_DebtSecuritiesAvailableForSaleUnrealizedGains": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available For Sale, Unrealized Gains",
        "label": "Debt Securities, Available For Sale, Unrealized Gains",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGains",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available for Sale, Unrealized Gains",
        "label": "Debt Securities, Available for Sale, Unrealized Gains [Abstract]",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainsAbstract",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Unrealized Loss",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLoss",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails": {
       "order": 2.0,
       "parentTag": "bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Unrealized Loss, Maturity, Allocated and Single Maturity Date, After Year One Through Five",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss, Maturity, Allocated and Single Maturity Date, After Year One Through Five",
        "negatedLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails": {
       "order": 1.0,
       "parentTag": "bngo_DebtSecuritiesAvailableForSaleUnrealizedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Unrealized Loss, Maturity, Allocated and Single Maturity Date, Year One",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss, Maturity, Allocated and Single Maturity Date, Year One",
        "negatedLabel": "Less than 1 year"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossMaturityAllocatedAndSingleMaturityDateYearOne",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_FinanceLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Liability, to be Paid, after Year Four",
        "label": "Finance Lease, Liability, to be Paid, after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_InstrumentRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument Revenue [Member]",
        "label": "Instrument Revenue [Member]",
        "terseLabel": "Instruments"
       }
      }
     },
     "localname": "InstrumentRevenueMember",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_LiquidityAndGoingConcernPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity and Going Concern",
        "label": "Liquidity and Going Concern [Policy Text Block]",
        "terseLabel": "Liquidity and Going Concern"
       }
      }
     },
     "localname": "LiquidityAndGoingConcernPolicyTextBlock",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bngo_MeasurementInputProbabilityFactorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Probability Factor",
        "label": "Measurement Input, Probability Factor [Member]",
        "terseLabel": "Measurement Input, Probability Factor"
       }
      }
     },
     "localname": "MeasurementInputProbabilityFactorMember",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_NonCashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash Lease Expense",
        "label": "Non-cash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NonCashLeaseExpense",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_PaymentsForPropertyAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Property and Equipment",
        "label": "Payments for Property and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsForPropertyAndEquipment",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_PerformanceShareUnitsPSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Share Units (PSUs)",
        "label": "Performance Share Units (PSUs) [Member]",
        "terseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceShareUnitsPSUsMember",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/NetLossPerShareDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_PreferredStockNumberOfVotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Number of Votes",
        "label": "Preferred Stock, Number of Votes",
        "terseLabel": "Preferred stock, number of votes"
       }
      }
     },
     "localname": "PreferredStockNumberOfVotes",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bngo_ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Business Combination Return Of Purchase Consideration From Escrow",
        "label": "Proceeds From Business Combination Return Of Purchase Consideration From Escrow",
        "terseLabel": "BioDiscovery acquisition, return of purchase consideration from escrow"
       }
      }
     },
     "localname": "ProceedsFromBusinessCombinationReturnOfPurchaseConsiderationFromEscrow",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_ProfessionalFeesAndRoyaltiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Professional Fees and Royalties, Current",
        "label": "Professional Fees and Royalties, Current",
        "terseLabel": "Professional fees and royalties"
       }
      }
     },
     "localname": "ProfessionalFeesAndRoyaltiesCurrent",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_PurigenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purigen",
        "label": "Purigen [Member]",
        "terseLabel": "Purigen"
       }
      }
     },
     "localname": "PurigenMember",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails",
      "http://bionanogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_SaleOfStockValueSharesIssuedInTransaction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Value, Shares Issued in Transaction",
        "label": "Sale of Stock, Value, Shares Issued in Transaction",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "SaleOfStockValueSharesIssuedInTransaction",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Successive Annual Installments",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Successive Annual Installments",
        "terseLabel": "Number of successive annual installments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSuccessiveAnnualInstallments",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term [Roll Forward]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term [Roll Forward]",
        "terseLabel": "Weighted- Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bngo_SoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Software",
        "label": "Software [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareMember",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders' Equity, Reverse Stock Split, Percentage of Outstanding Common Stock Are Present",
        "label": "Stockholders' Equity, Reverse Stock Split, Percentage of Outstanding Common Stock Are Present",
        "terseLabel": "Reverse stock split, percentage of outstanding common stock are present"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplitPercentageOfOutstandingCommonStockArePresent",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bngo_TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer Of Instruments And Servers From Property And Equipment Into Inventory",
        "label": "Transfer Of Instruments And Servers From Property And Equipment Into Inventory",
        "terseLabel": "Transfer of instruments and servers from property and equipment into inventory"
       }
      }
     },
     "localname": "TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer of instruments and servers to property and equipment from inventory.",
        "label": "Transfer Of Instruments And Servers To Property And Equipment From Inventory",
        "terseLabel": "Transfer of instruments and servers from inventory to property and equipment, net"
       }
      }
     },
     "localname": "TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_UnvestedRestrictedStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested Restricted Stock",
        "label": "Unvested Restricted Stock [Member]",
        "terseLabel": "Unvested restricted stock"
       }
      }
     },
     "localname": "UnvestedRestrictedStockMember",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_WorkingCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working Capital",
        "label": "Working Capital",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://bionanogenomics.com/20230331",
     "presentation": [
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AmericasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Americas [Member]",
        "terseLabel": "Americas"
       }
      }
     },
     "localname": "AmericasMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AsiaPacificMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia Pacific [Member]",
        "terseLabel": "Asia Pacific"
       }
      }
     },
     "localname": "AsiaPacificMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]",
        "terseLabel": "David Barker"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r185",
      "r186",
      "r286",
      "r291",
      "r505",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Executive Officer"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r273",
      "r274",
      "r275",
      "r276",
      "r332",
      "r446",
      "r461",
      "r497",
      "r498",
      "r515",
      "r528",
      "r534",
      "r580",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r273",
      "r274",
      "r275",
      "r276",
      "r332",
      "r446",
      "r461",
      "r497",
      "r498",
      "r515",
      "r528",
      "r534",
      "r580",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r230",
      "r447",
      "r516",
      "r532",
      "r575",
      "r576",
      "r584",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r230",
      "r447",
      "r516",
      "r532",
      "r575",
      "r576",
      "r584",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r273",
      "r274",
      "r275",
      "r276",
      "r325",
      "r332",
      "r358",
      "r359",
      "r360",
      "r422",
      "r446",
      "r461",
      "r497",
      "r498",
      "r515",
      "r528",
      "r534",
      "r574",
      "r580",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r273",
      "r274",
      "r275",
      "r276",
      "r325",
      "r332",
      "r358",
      "r359",
      "r360",
      "r422",
      "r446",
      "r461",
      "r497",
      "r498",
      "r515",
      "r528",
      "r534",
      "r574",
      "r580",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r185",
      "r186",
      "r286",
      "r291",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r231",
      "r232",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r517",
      "r533",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r231",
      "r232",
      "r484",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r517",
      "r533",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r563",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r8",
      "r531"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Schedule of Allowance for Credit Losses"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r156",
      "r234",
      "r235",
      "r502"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, trade"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r234",
      "r235"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net",
        "totalLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails",
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization (accretion) of interest on securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedInsuranceCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Insurance, Current",
        "terseLabel": "Insurance"
       }
      }
     },
     "localname": "AccruedInsuranceCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails",
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r157",
      "r457",
      "r466",
      "r467"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r16",
      "r19",
      "r116",
      "r414",
      "r462",
      "r463",
      "r550",
      "r551",
      "r552",
      "r558",
      "r559",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Intangible assets useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r558",
      "r559",
      "r560",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r92",
      "r93",
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r158",
      "r236",
      "r247"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "negatedPeriodEndLabel": "Ending balance",
        "negatedPeriodStartLabel": "Beginning balance",
        "negatedTerseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccountsReceivableDetails",
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "terseLabel": "Write-offs and payments"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share amount (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r129",
      "r135",
      "r152",
      "r183",
      "r221",
      "r224",
      "r228",
      "r245",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r379",
      "r381",
      "r395",
      "r531",
      "r578",
      "r579",
      "r620"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r146",
      "r160",
      "r183",
      "r245",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r379",
      "r381",
      "r395",
      "r531",
      "r578",
      "r579",
      "r620"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r237",
      "r255"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]",
        "terseLabel": "Gross Unrealized Loss",
        "verboseLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "totalLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r52",
      "r239",
      "r455"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Aggregate Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r564",
      "r565",
      "r630"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "totalLabel": "Less than 1 year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r52",
      "r238",
      "r454"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Less than 1 year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r51",
      "r255"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets",
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r374",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails",
      "http://bionanogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r95",
      "r96",
      "r374",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails",
      "http://bionanogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails",
      "http://bionanogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": {
     "auth_ref": [
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": {
     "auth_ref": [
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisition, Pro Forma Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r105",
      "r106",
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total estimated purchase price"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r378",
      "r554"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High",
        "terseLabel": "Consideration milestone payment, maximum"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Consideration milestone payment, maximum"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r104",
      "r107",
      "r377"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Estimated fair value of milestone consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r104",
      "r108"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Measurement input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r104",
      "r108"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration, net of current portion"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r112",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash &amp; cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r97",
      "r98"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r97",
      "r98"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r97",
      "r98"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r41",
      "r42",
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment included in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r40",
      "r148",
      "r500"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets",
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r35",
      "r40",
      "r44"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "totalLabel": "Total cash, cash equivalents and restricted cash at end of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash reported within the unaudited condensed consolidated balance sheets to the total amounts reported on the unaudited condensed consolidated statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations": {
     "auth_ref": [
      "r35",
      "r40",
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r35",
      "r40",
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r35",
      "r126"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r183",
      "r202",
      "r203",
      "r205",
      "r207",
      "r214",
      "r215",
      "r245",
      "r277",
      "r279",
      "r280",
      "r281",
      "r284",
      "r285",
      "r289",
      "r290",
      "r293",
      "r297",
      "r304",
      "r395",
      "r499",
      "r541",
      "r556",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r13",
      "r131",
      "r139"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r65",
      "r271",
      "r272",
      "r487",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r558",
      "r559",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r2",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r2",
      "r531"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value, 400,000,000 shares authorized at March\u00a031, 2023 and December\u00a031, 2022; 306,790,000 and 297,183,000 shares issued and outstanding at March\u00a031, 2023 and December\u00a031, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r20",
      "r166",
      "r168",
      "r173",
      "r451",
      "r458"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r47",
      "r48",
      "r124",
      "r125",
      "r233",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r47",
      "r48",
      "r124",
      "r125",
      "r233",
      "r468",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r47",
      "r48",
      "r124",
      "r125",
      "r233",
      "r486",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r47",
      "r48",
      "r124",
      "r125",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r47",
      "r48",
      "r124",
      "r125",
      "r233",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r307",
      "r308",
      "r321"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r307",
      "r308",
      "r321"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r25",
      "r447"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Total cost of revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails",
      "http://bionanogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r244",
      "r259",
      "r511"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "verboseLabel": "12 Months or Greater, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r244",
      "r259"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "12 Months or Greater, Gross Unrealized Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "Number of securities in an unrealized loss position, greater than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r244",
      "r259",
      "r511"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "verboseLabel": "Less Than 12 Months, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r244",
      "r259"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Less than 12 months, Gross Unrealized Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions",
        "terseLabel": "Number of securities in an unrealized loss position, less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r242",
      "r256",
      "r511"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r243",
      "r257"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Securities of government sponsored entities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract]",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost [Abstract]",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforsaleAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r127",
      "r581"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Offering costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositLiabilityCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current portion, due within one year or one operating cycle, if longer, of deposits held other than customer deposits.",
        "label": "Deposit Liability, Current",
        "terseLabel": "Customer deposits"
       }
      }
     },
     "localname": "DepositLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r38",
      "r219"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails",
      "http://bionanogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r320",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Revenue Recognition"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EMEAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regions of Europe, Middle East and Africa.",
        "label": "EMEA [Member]",
        "terseLabel": "EMEA"
       }
      }
     },
     "localname": "EMEAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r174",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r200",
      "r202",
      "r205",
      "r206",
      "r207",
      "r211",
      "r386",
      "r387",
      "r452",
      "r459",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r174",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r202",
      "r205",
      "r206",
      "r207",
      "r211",
      "r386",
      "r387",
      "r452",
      "r459",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r396"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rates on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r73",
      "r144",
      "r169",
      "r170",
      "r171",
      "r187",
      "r188",
      "r189",
      "r191",
      "r197",
      "r199",
      "r213",
      "r246",
      "r306",
      "r364",
      "r365",
      "r366",
      "r368",
      "r369",
      "r385",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r414",
      "r462",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r119",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r118",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r118",
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r287",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r389",
      "r419",
      "r420",
      "r421",
      "r513",
      "r514",
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r388",
      "r389",
      "r391",
      "r392",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Investments and Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r287",
      "r326",
      "r331",
      "r389",
      "r419",
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r287",
      "r326",
      "r331",
      "r389",
      "r420",
      "r513",
      "r514",
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r287",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r389",
      "r421",
      "r513",
      "r514",
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "terseLabel": "Change in estimated fair value, recorded in selling, general and administrative expenses"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Liability recorded as a result of current period acquisition"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Cash payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r287",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r419",
      "r420",
      "r421",
      "r513",
      "r514",
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Finance Lease"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r406",
      "r413"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "verboseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease liability"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease liability, net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Total future lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r618"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r408",
      "r411"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Principal payments on financing lease liability"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r407",
      "r410",
      "r530"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of financing lease right-of-use asset"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r240",
      "r241",
      "r248",
      "r251",
      "r252",
      "r253",
      "r254",
      "r258",
      "r260",
      "r261",
      "r288",
      "r302",
      "r383",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r511",
      "r566",
      "r567",
      "r568",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.",
        "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r150",
      "r266"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r263",
      "r265",
      "r266",
      "r268",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails",
      "http://bionanogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r62",
      "r449"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r57",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails",
      "http://bionanogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r62",
      "r448"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r46",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r149",
      "r262",
      "r450",
      "r512",
      "r531",
      "r572",
      "r573"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r21",
      "r128",
      "r132",
      "r141",
      "r221",
      "r223",
      "r227",
      "r229",
      "r453",
      "r510"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r184",
      "r198",
      "r199",
      "r220",
      "r367",
      "r370",
      "r371",
      "r460"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Benefit (provision) for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r554"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and contract liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r264",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-Lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Intangible assets not subject to amortization"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r59",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r56",
      "r60"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r127",
      "r134",
      "r172",
      "r218",
      "r404"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r178",
      "r180",
      "r181"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r546"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternetDomainNamesMember": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "String of typographic characters used to describe the location of a specific individual, business, computer, or piece of information online. Formally known as the Uniform Resource Locator or URL, it is often considered to be the address of a certain World Wide Web site.",
        "label": "Internet Domain Names [Member]",
        "terseLabel": "Internet Domain Names"
       }
      }
     },
     "localname": "InternetDomainNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r55",
      "r503"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r159",
      "r501",
      "r531"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails",
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "auth_ref": [
      "r55",
      "r547"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r55",
      "r504"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets held for their financial return, rather than for the entity's operations.",
        "label": "Investments [Member]",
        "terseLabel": "Total investments"
       }
      }
     },
     "localname": "InvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r618"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r10",
      "r183",
      "r245",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r380",
      "r381",
      "r382",
      "r395",
      "r509",
      "r578",
      "r620",
      "r621"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r7",
      "r130",
      "r137",
      "r531",
      "r557",
      "r569",
      "r617"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r147",
      "r183",
      "r245",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r380",
      "r381",
      "r382",
      "r395",
      "r531",
      "r578",
      "r620",
      "r621"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r35",
      "r36",
      "r39"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r22",
      "r39",
      "r133",
      "r140",
      "r145",
      "r164",
      "r167",
      "r171",
      "r183",
      "r190",
      "r192",
      "r193",
      "r194",
      "r195",
      "r198",
      "r199",
      "r204",
      "r221",
      "r223",
      "r227",
      "r229",
      "r245",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r387",
      "r395",
      "r510",
      "r578"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss:"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r221",
      "r223",
      "r227",
      "r229",
      "r510"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r409",
      "r411"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r113",
      "r114",
      "r115"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r161",
      "r162",
      "r163"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized gain (loss) on investment securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r165",
      "r168"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss)",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForConstructionInProcess": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from construction costs to date on capital projects that have not been completed and assets being constructed that are not ready to be placed into service.",
        "label": "Payments for Construction in Process",
        "negatedTerseLabel": "Construction in progress"
       }
      }
     },
     "localname": "PaymentsForConstructionInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Offering expenses on sale of common stock"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r30",
      "r50",
      "r176"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedTerseLabel": "Purchase of available for sale securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r31",
      "r376"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash consideration transferred in acquisition",
        "verboseLabel": "Payments to Acquire Businesses, Gross"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r1",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockRedemptionPricePerShare": {
     "auth_ref": [
      "r72",
      "r74",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.",
        "label": "Preferred Stock, Redemption Price Per Share",
        "terseLabel": "Preferred stock, redemption price (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockRedemptionPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r1",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r1",
      "r531"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of March\u00a031, 2023 and December\u00a031, 2022"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from sale of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r50",
      "r176",
      "r177"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "terseLabel": "Sale and maturity of available for sale securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r553"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "verboseLabel": "Proceeds from warrant and option exercises"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Service and other revenue",
        "verboseLabel": "Service and other"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenue"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductWarrantyAccrualClassifiedCurrent": {
     "auth_ref": [
      "r11",
      "r66",
      "r67"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Product Warranty Accrual, Current",
        "terseLabel": "Warranty liabilities"
       }
      }
     },
     "localname": "ProductWarrantyAccrualClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r64",
      "r138",
      "r456",
      "r531"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r175",
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "verboseLabel": "Provision for expected credit loss"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment.",
        "label": "Realized Investment Gains (Losses)",
        "negatedTerseLabel": "Net realized loss (gain) on investments"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r94",
      "r143",
      "r628"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r485",
      "r543",
      "r555"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets",
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.",
        "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings",
        "terseLabel": "Issuance of common stock due to the vesting of restricted stock units, net of shares withheld to cover taxes (in shares)"
       }
      }
     },
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/NetLossPerShareDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r4",
      "r81",
      "r136",
      "r465",
      "r467",
      "r531"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets",
      "http://bionanogenomics.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r144",
      "r187",
      "r188",
      "r189",
      "r191",
      "r197",
      "r199",
      "r246",
      "r364",
      "r365",
      "r366",
      "r368",
      "r369",
      "r385",
      "r462",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r216",
      "r217",
      "r222",
      "r225",
      "r226",
      "r230",
      "r231",
      "r233",
      "r319",
      "r320",
      "r447"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r233",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r317",
      "r318",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Timing of satisfaction of remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "terseLabel": "Performance obligation, percentage"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r412",
      "r530"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease liabilities resulting from obtaining right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "verboseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r233",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/RevenueRecognitionNarrativeDetails",
      "http://bionanogenomics.com/role/RevenueRecognitionRevenuebySourceandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Accounts Receivable"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r95",
      "r96",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails",
      "http://bionanogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r95",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Recognized Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r57",
      "r61",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r57",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.",
        "label": "Schedule of Inventory, Noncurrent [Table Text Block]",
        "terseLabel": "Schedule of Components of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryNoncurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Units and Performance Stock Units"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Weighted-Average Assumptions in Black -Scholes Option Pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r69",
      "r70",
      "r71",
      "r74",
      "r75",
      "r77",
      "r78",
      "r79",
      "r80",
      "r81",
      "r153",
      "r154",
      "r155",
      "r214",
      "r289",
      "r290",
      "r291",
      "r293",
      "r297",
      "r302",
      "r304",
      "r515",
      "r541",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r82",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Warrant Activity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r544",
      "r545",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Units granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Stock Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "terseLabel": "Grant fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- Average Grant Date Fair Value per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted average remaining contractual term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Released (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r339",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares of Stock under Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r339",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Vested and exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Vested and exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "auth_ref": [
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.",
        "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost",
        "terseLabel": "Reduction in stock-based compensation cost from modification"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Vesting on October 18, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Vesting every three months following October 18, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Granted vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Total intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Average share price (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r183",
      "r202",
      "r203",
      "r205",
      "r207",
      "r214",
      "r215",
      "r245",
      "r277",
      "r279",
      "r280",
      "r281",
      "r284",
      "r285",
      "r289",
      "r290",
      "r293",
      "r297",
      "r304",
      "r395",
      "r499",
      "r541",
      "r556",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r14",
      "r73",
      "r144",
      "r169",
      "r170",
      "r171",
      "r187",
      "r188",
      "r189",
      "r191",
      "r197",
      "r199",
      "r213",
      "r246",
      "r306",
      "r364",
      "r365",
      "r366",
      "r368",
      "r369",
      "r385",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r414",
      "r462",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "verboseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r213",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r73",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issue common stock, net of issuance costs (in shares)",
        "verboseLabel": "Stock issued during period (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r1",
      "r2",
      "r73",
      "r81",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "verboseLabel": "Stock option exercises (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r73",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issue common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r73",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock option exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r2",
      "r5",
      "r6",
      "r49",
      "r531",
      "r557",
      "r569",
      "r617"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets",
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r83",
      "r182",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r306",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders\u2019 Equity and Stock-Based Compensation"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r403",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r403",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r403",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Account Details"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Tradename"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails",
      "http://bionanogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://bionanogenomics.com/role/BalanceSheetAccountDetailsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r240",
      "r241",
      "r288",
      "r302",
      "r383",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r566",
      "r567",
      "r568",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r586",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "Securities of government sponsored entities",
        "verboseLabel": "Securities of government sponsored entities"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsUnrealizedLossesPositionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase Common Stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r201",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r200",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r535": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r536": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r537": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r538": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r539": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907644&loc=d3e11281-110244",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12524-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21564-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>72
<FILENAME>0001411690-23-000024-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001411690-23-000024-xbrl.zip
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M&,!;#%XQ[@( H5+8VX"(<9CP$D2!+-/HM/@X$&%)% HY*4)::Z":160%C<P
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MBD)C99AWSFJ#4_(G 1R%28E+%"6P8NJPF'T(R-G@A><Q@O,9J/91"R9AU!4
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M1,1+C#EC2L)HS(V403-M&..KBB$/3H;X))5"!,JC0TQB1EA(N\Z-X50AADR
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M5".<N>.41;@&V/OE.(=?O@'T7%>L%^K'?8^?6DR-9E91[FW:F:B$LA@Q&4E
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ML]N7XU!L%DB3_%>V5?Z!_ZS!,%AL=_<UT^G P92/(ZT:_&><IS4#&"QMF)X
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M\H'3?\TFN(_1JZ"T<)%Y@U4@1FJ% Q;81B,_[A2FP!%; R-U>1?4^Y]KZ([
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M6EAEP*K-*DW%[.8O)>+\I!%G?]V3N=34Z,7'E&J//!>0?0*0G1%@YLE1K;Q
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MJ<,(DY ]6-@AQ^%'(L0:'F-D3 +RJE7-9Q.P?]W7MFT,]ZK1L_6"P: &\E7
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M#2"R:A[DOJC@X[A0_Z];:A<OVH)ZT8J4BI2*E(J4BI1>J)3N0[NI%%A$34T
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M9.8!GHFD1&"8W@YPI<W)<R#=5*ZB=!'^STF$36[(R1Q!UE.,N) B<3!@2=1
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M9KSX 6W[@ZH]RFO0XSC([X(QV<:,I74PR-O0__Q:1$#_=K/:YY)U&WD'J[3
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M?;A.]X[V.NVW[V%,[03/0MN'G[[P("+3U"&!DT0\&(E,$@P1$X)F7#FC\)B
M5SW?UC/595*30*Q@F@NN-':&1X<Q$TKF#M!JI16!^1YG_1N< /I?%545\_S3
M#CM5EZFK@CKG;Y,%<P-FX=ID$./;5,+Z]4"N#QS> N^+UANN>>3)PKH3SI)(
M,)!)'U>:HEO5'5]G7WC'WT';-F&^!YWC\_9C?YX,X2W#VRG;\Z/&;&;U)SR
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M>Y2\,(AC+L'>2X=8XDQ83JGA,_9[2:SQ'5GE52E8O1C(N]C+^\^S?=Q;F16
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M*MZ!<6X-BO^4L97?B@;PXF%O8EPO?5KBTMS;_!,>.W[4O\86'> "*%OYZBU
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M6G]\]]LGT=C\2G8/OP.]VR7-#^\/]SYLD<:WK^=PKR.@>GSOPU?XSD&:-$^
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MTWT;M;=$2819SK^G'B/MJ40.6*;W0#")2F_>4GRSE&:LK$2Q8T/,DI8QUR9
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M@X/ #+F  ^(D.&1"D(B:0)D@EBL>UC5%?*XVB)VL?6V8+<-FI\@'_[,%:(!
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MD6:"(R683=JJX'-))[K!)5F+AE?W3URX(S**33'&QK4%BJMIT0/1H@HM>BZ
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ML)F]Y?/X[=].7CZ7).\_LY+D#TL'/SQ@F$MLM$&" EOF,C%D\G&+DA8DENK
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M/AT CAE-(T-,8P=VK$K(:N&1,DQZ$E@4-'>_TW-F[*@PA8M@L!7>$I"50FS
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MXLQA1*X7[3$J(.BU;9W:L_ZKWR_[3)N=\<TYW52Y+LWLZU_YDBD]VDN6SEO
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M0#X)=OU8,HM!<]""5QK91O_.8^R/K*""G_X-5*7V\>-&[>,@MFMZ3)/*\ #
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M L\GH\05="X1.N>H+^56)\8C<CF9&VS:A$P2&%%B%9&:*H)S-/2&7LYAX@I
M9\&;?R_JGT[7@9\NBKU2=6D7%W3_-Y#APZ)^\MIUWGI?="[.'01R%R/X[^46
MG*/>'?VA^S[JJG/2+3K!9&M@8@>,JN^.2W'[EFVVRX+7K7B8>^T4\MF?M)HY
MB64+CVYO_ C;AS< 0[MH\P%6!H#,H&BRTLM=948=<[JY-'7N?@Q6>6XKD)\
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M+A=HZ\O;FL;B,G7*?MK<1RY[36OM:+-=5: /7-WL%MW6<Q?Q[ C/7LO<.;M
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ML:=BX:X".E1M'<O;.CY.;QUL9_LK.V!$"9=B1-XD"7R;6V2""<A*J3EF@;B
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M#'B:4X;][CM>/]\[""(HV#H<\'^# 7@H0RY0@ES4#@M%!8FCGL4K577D#G&
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MU2J\680WC=U/HG'^E<#??C;.]WX>*)FH,#RAJ',90V<YLIPI1*1FT@.W8,8
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M*16#O6?_),#YBU5[3T1(1'PO-CT[YB:U0\=DC/@F<3BCC-HVX1@V-PK#G0B
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MM*IYQ/?M@%B#&74/I4"Z:D9U;#>R72LV7<>/3.H(RPQ]:ILVYR%-7!$F#*2
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M^4213T-FAV;@<&%2V['-0/C$Y*#^1=0.'(+%<$  A'VK*CMP?+\X?@@.VP<
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MRPO@#>,\GXORQY_RC-^NOM3>UJ2] 8S9EN<[)+8"00BE?A0$OA-9?H39D>R
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M'C^NMU\>/:9HM4TQ4@=.),@BB^Q+EE^J?>X&-E7N(O3P1<+(Q(4\$*#K1?:
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MD4=Z21,W3GU0V37V6+3_;TO2C;2@1GJX:D>>- 0D99F^<8<B*UD? %R'I"R
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M2I9"N1"=DMA\R0^ 5J"VT4PPM@VC_;;-X,JT;G!6"'1#:RPI0VB:((D(@<T
MZA<3\$,[:A,,:"#]Q$?.()TI7N?.3KNI41!1BI1^G"I9CY.;2#AFE2UH,?*E
M[ )L\67!2]< AH=^VM#R$#](ZE&S/R*IP5##/W$6@\E)%]/3KR_,*XF<J,H9
M$BA@??+VR>R;:@&ARC?J-'#;DW@PN;&]Y<A<8R(%F&0'/1:"3"IP0]F@M+]R
M4PRD?5T'>,T:/6/#)RI8O3AMVC&VH$."#?+0P.:F9T\]455*7')DOW&WE9N6
MR!Z+?LAN/T2C=]=.2LU&O+!LQ->6C7C4$0WG,EDTNIQASE*=R<E5:L_ H(<+
M;@<J0OPM;,8%ZQNP[E$SMPYP'22RRAT]7VF?NW=);B+O,4F(;M)WZ ;S.4[,
M/3<5SI;#-Y).\CQ[9*PX;G6L^!QS2FRW.2 #GG$S*MZ'Y]3C!J94%+"::L,Q
MSSXT@+VFF 5$'K"5[$30IN>[3+P6/\4@ZS5^1&.AZ2^K:B,/;#Y/>L +.D_T
ML53MLPLX@O%X[?QQ45?'P>T$%;=",H0DN+1FT9-?TO<X1N)GD,+D1))/EH@\
M80HID/]N-IV.GV#OV:FEX^5'3K$6LQ>7O&)I+U8-Q31G=3'[>MNU8NU>4/"U
MJ&D!R6*-P6"R@N@L5]Z9>#[:0_I47%:+B[RO]S%&-L[8H,J.PU0QA=1\8OG!
M.\+=3"Y9P^C:H+%R:$U#SRP9?0#[ .+:SK--_/=1EOE $IB#!07$3#W'9#F&
M7;'A<TWL3[IQL&SZLGNVMM7EIRY+(RK8Z,F!RJU:-*53YB(^T&VMU]@TJ"B\
M>FKJ^.:7L1KG\!C''Q1F%%%&SE<CPZ0B]DB%W,ZFS$![979YY'33Y>62E46]
M8V,B&0<:-I63U#*\$EJ9M59K%Y%O^V;.<#8Y91K=O>ZRMQA/#4<I]KZK]DH7
M7@D#O!G.--S<Z1S?04RY-FHC=<-U[NFE26:Y%?W"*1/OQ7!5TZ[)QM#:6S+\
M*]LI_CI^/<U>;@*[EM3M,X37(*Q^^LF_6F@='F98U-D['!)ZW^SQ)OW"">1C
MH9*?8^3C/X./^LJJ80_Q70X^^;=5RP -16V,\%%H$>D+S7<;8(3^>DX#LW',
MW4_O.\8%X0)O&!);*M)5C <]X#Q![L3$S;U9K^6B"TY[B6*B]JJ@5MD;YF:
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MO1:.JG[97NL_SC/FOU!)SOC]K#<G)QU"HK_LM2%VP5<&ES92(5'5AHEH,K@
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MY]XMMY)P&;^"9;)37WTB<^8/,P,PH(!.10JA KA1O671>FKT08)E;Z#O"#C
M,H-(*F9O3&*4,.I=:B/DIK#Z9P%1-*4WS07&4*<^%K=]+HU\WB"W!-)1O%]@
M)ZM%UD8A@.Q220J$(:G)83*I)<[9%)"09.;Q>8N_<#_=MI%?H0=($#G]);TL
M(W "5";A_2\0)RMX6B'"C.Z(HS4P#!/X'FZ94^P'^Y#ZG^@&!.H$-"$:3FPZ
M4<X]C.<!9&@ YH&V,()G=5>E(U!1Q?8AGA^=DP9F2;$7=T<F$'AYUBH.OUKV
MU35W"0QQ,J;)Q4C\!&4%-K($HPKHU1@,-0UL6M .8+GE2*I@L"8T/SKT"0!^
MVM\"Z\30_5I<U?2-Z!_*.4)WN]C6BU*[\-A?5R9Z:\SDJ\:OZ)^9(?R.M_T5
M&*ZWF+X,:FK?E-]A=<UXH*19W[E:*IC)ZN=Y52W06KB+S"#2;\(TT1N$V?ZB
M;=[[^2 MWQW;!*98!1,KX*+Z'_1:VV+3/AK.F>[7R<"NDF\68SSVB*3'VN>$
M#_ 1(O.T*0=]S=K"$Q:JO;"D\R9[IVP#[H%C3VQO,PG6PLY7TIXG VNG0VS4
M@I'!MM^UW$EC;9,VA_#S BI?KV&SRD:!QGP@4>=<D@N+_W+6F-C^A=Z&+1OB
M;2=9?\O&<GK(R).$][A<4(A:]];8$^/1>>*?T&X(/4W1%6DY"JS(&WZ6,A$4
M\\8S.C:Q?Z/"'9M;#9IWG;D.AS1ZL2-VHCV;W/W%$&3[-XU?"+N*U$2KJ<0X
M%FB:C"W[S\-1=%V5[Y6=0P^F87N_#TCKK23DR%_P93N6<N,G#7=?T5VYK:?0
M/K/"!3T\<O,407W%!VZ;:8/PI&Z;>F/A0GA6NU"U6B_;7569"(14:/)KLGX(
M+S4X9?;] U;C]]=1\.=C1\'#>);?;4?!:VU.XZ-A8 9-\CD+(R8:R$.G(;UP
M1>=!IIY%]FQN)&^NUOP/^!.QH#+(8 U0EE&RZX#(LW1CI4;@_0(G$+$(RLO5
MHC#_&11IPEO1=NO64^<\'&KJ:[)F AX<E/&BH;[DP<MR[A*86Z5RHRW0Z@/D
M9Y8+F9&;GEPY2'O6(:A)AIFFHBD[.K(70EB(2CD]B':S6;87=$R%.M^:0\(?
M\"Q<R8=V0]T:?9.?]3+$<F3WUAG7KUN$VMJ+;:W"%&TNEQ4'G#0CKJ&EY-7H
M1SA76IB2PUA70AB2"*6.:\1G6F3*@I4;M6R,F0G12;FRTS^I7GG/?7)T[:*>
M.'E\KJ[&GK*.!"C1A\#AUCY1D7,\"-6T)A]0'H<VD&4L<DG1/"14VD_Y%:\@
M%D:+/S8""64=3P^;MEL6HQAP5T@Y=0%/]+7OLQ:X$0ND<E/,S;VJ@Q7C/*@9
MULS=:E/,<H_KGR$$#4)C=A*PM>PU*HV-PSJ/=H@,2$Z4D#>0'S"K A/7SRLC
M0W/;G(5(OU( -6?4O<4BR<@(/(A22JJ#C"M&I&7RO"HW,QZ)3*"&?CI7I4*V
MX(7+ = F9*+$Q@G51B.T[SD>7WM]Z*!STAG!TS"4(D3LY8J#5 EMF!:A'U,K
M920^.4<>"EP'KP<\W$(RHNF7A];G@7.(I_OPRJ$?D]/#_H/2$AZ@<E&6+>YT
MJ *09%H''%V&<W9")"7J%)AKLFIEWLTR1;.8"(YJ9J*;[9@N28B>7E;S"HPE
M2MKT*9:S)BXJH6XRL+7I B:+Z8,*0IF+5B M;$EDXLYHT5<L?>(-Z9.$GYR1
M+Q)'4Y(QY$ETT@RV15?E4LB@>;]ILWT0R;;W;&@KS#:T[Z^<U\IIBB,W3^"0
M%M*D\&XV.0.-!6:"$FU&;]D+/[JHFDHR(:6)-.\U'-ZBH+1 +1]ES-_$7MR9
M^^',&<[))U\C9.Q9449K';2I%:,)(])U7"E0AIQOD$<M^?Q-5FI9O^>CT?SD
MKN041+:+1MS"]+V_'HN.]]D!Y:RF:1TE:E?C! L$J5DP=&L/2O)<PA 9 X (
MG#N"!#[.Q-_("">>=<<%M,QHWG;B7>NS<77M6\;I12 \9HB:RP[<>MTQ5K*J
M5E(D9*/\TY.W;*Y:B2)>=MN+V6F6C$9,_LW+TT*97R;D!^$47JLU,]KF8,Q4
MI8O-I-Z5KG=<WO>XO-?;KF=G(1-,*QGM8 X-9AA$:N$K9^UBYWQ,6"T-Z*7?
MLH,#M8XH-ND;(5.=;+M<.%ZZ691-/ZA0TB.NVV/'[_VN"Z S,@^IG+-+I6T>
M9]MZN3AAOG:?V_ %82:,@0'R%%@*6K8XY(@7J) W6&B'.-./"^)>P7*!UGQ(
M[[[?%!SGZ#Y]%>561QBX+P8IU#L0.$MS(K'+ 3;*XQ3>)R&-]@8X3$AZKYAO
M%?!%/GN3]D1K_07'.;I7TJ!%1 <4&8QMD54(@D"9\0$=X<+WW < X8.\(ZM/
MG.\#WN54NO49GJ*5CEA7N:!< HZ0:26,J)F1(+J)G5GL\YHV_)S+-<50*\,
M(\(T66ZVRAW=K[A$V&GN3#O9<-$QC%U_AR<MZ3F;$VZ,6R)/QK(P2TG0"DG\
MX'-NE:-56HW_]" +,C>FQ8TK6C. D=#::PC<VK=U\1$PTSI/K2^$8S[NGIL
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MY.%:&#Q%[BE4 A&2BI*-_':J)&J:55EI-$>V30RX)_DU$4 W^XYFC58S P!
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MVKJ4["3G,+MH%[7A^?'MOP%<Q+1/6$I4LN#:^4SK[+H5YBF& M-&T4..$[\
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M\Y@SFJ?E-$7%-"2,"'1UE0"IX%0,DS.?+]OK0GOP[72V^FRU$=RY93_$LC&
MF(F%H^;1 "O4<^,_[[>;A':.37SW6OUM.Z9GXNA01!5WR5D6DFY9O8EW6O^-
M(U-/],DO'BLF]SB-9%7;>;DQ^OX]^>6 PC@$YZ&#_9+N5W4CK;WCG-[GG+H,
MI6%;UYR5,#98-<9M2H#<WFO/CY7CM-[GM.JX5W%WCBIHDO\*F+QX7AID,?M"
MQKR4::BR&UTOZI)%V05MB*04(K0SY#94+P $@*D%82P]Z%JOR+1!,#<^048
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MAN9PDC8>8WI95MH]6;;M>]&^I*<4VXUA1)+&98:RTI:D'+-V1*R.OU_62VO
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MPVV=/XI>6I"V*!9QD?!$ EE4M9'QU0TA+-#9DI*;D&>>56.Y.U*A!@+[4=K
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MJ<3!FSG3B0\JY@Y2]C*7/.?]L ",%[:3^NYF9V#,#GMG#]+TWT#T,0#[&61
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MDIBPP9/<\ @]U+SD=NMQ0I%\@5>FR;*5R/9+K%O%M)>2ZZ&$0[PO&]&P -J
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MNHJ&'SN]*65<$TUMEM54XDFZZU]'QIZ([!IM$S['6$A;B4/6D"_UV$)E1\*
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MZER7?*;-(A!S(<5 U2Q5PE$R'P;AL=CX?_H)-?QN:+RJ,+P(@G_]O]F0-!0
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M8XBVX0!0\Y:Y9U-"<U:-97*3GZB-J.<7 ^Y]P>(X-$O!=U-R<\-+,/.(T',
MHK9*\13,.^@2_VXQZ#K@**-RMY#$9 A$=BU %KHRZ K@$*&.OD2Q0VX9QO&\
MM1\_T1A!0=SAQ'/BI5N)!+IF8=UJ8$"@(,-PLFIH+(=NY?NZ?>4-P*7X3[8G
M#J@-?*8^P]G,/W9\:5N:-CLU<@1G( RAMCA9XM-TGSF =!Z-L0FYC$6(/22W
MP1"6DQ?5/(I8!K)TYV7PZ*>]YPJD[!1!FN_*#4/SUZR\)R%:>=W>5;YOSQW_
M*<0PBRPL(E!/:*X4[:\GGRU*<!-%+L"HWD0UJ@/S_L[+V$*?A].:%E;3-A<Q
M99T5"<DE(N GD$VBNYX7Y*.?4=*R50@YZV2!RE'"\\JY#*(4D$"/SS>-]8P:
M+HD\R'E$KF(>I_BOU9$P;5EWRW'+Z=UDR7C\=_)C_SAX/@DY(>*B+15X&SY5
MW>M$73DJ*54%'.)-VZ/77^K+>E[;"YKBL'.UY!UQ_^(,T8L0O=^=(7I/XUG.
M$#U;E%MX0EKK\>3$? )C2]<I;^]>94V9 UXA[<$)NZ L/1^$DIL;;L$&LD6C
MB9#[6GMHM0Z6ZSGR7U_UP,C,.ITG;:N6KH /@<86KTJY[*C (1 =QSCB8(?!
M&#3+*8OYE\3L;*P _TTCL:P<2W/Z=\EITGQ]@RY^U?58?$\\^UC:K[7)>_$'
MD'ALD/[\_O4?V/*_^N[M,^PQ?*74E5U'E&A<A%:>HCP+ 8,^J40]22E%-C4]
MMYEC08I.FW"K7D4=) <=1H\FK'9+7ZH67)*EOQ,8#&?Y2A(VR,\P,0'1RX/C
M@QC3P:UZ3>5@QH\.AQT7F2<O%]D>E[>M3*Y?GFGV,PJY42H(&;(I4U7AE.!H
MHRNJ)#C)+4I0*:]]@G4S6M9A8(Q_0RFUW3BDK;^><D!"1&;X]%S7D0I'/'#!
M]+)\<XYT &@6PPWV86,NJ]A'Z-!ID>#*H(F*4V-V"1OAQ;:J*&48!M!XC;C/
MP77265S*T^RE;A2X+"IR$_H"CG:L>4\$\2SRR*[8YV<ZE0(#GIC2QB$?L[$6
MKIY(.."P4G<G01H.B^N6&E7\<B\H,2R52[\+4+G0P:*B).C'2I(9X2]@5;K-
M'7W7?*'#^=V$C-C?ML8/(&L?"V5DIA<Z 523X')QM2$4Q\TM]3=&"=U2]W&T
M*UP4'GE(9AP*"64:A;2ZU4V7F@I3/TD W%W ZZ<G;DHF6/9KJ\B>,'1$07)2
M+ R14@L.#_S(<<,DH\VQM3#,('B6UR@LJ4[5LE$^B'Q3>[<;77I'4O[.W4@9
M+^PW\[Y?PN;FWLSZ R8]@)FV/YMUS#)2!LD<&PD!MOTJ-^<"OYNFM2<S^/PV
M[E>4GN!33'2=8T'/+PBI]=>=,.Q4?4+HXL;![3;#F7K^+"I5M/VP8979=M[/
MRK0C1\:;_5J_ZK.\#=F5=F^_*^"JA:$WA*3+D0R1R'B\VJK<AM7(;>_X=]W?
MM)TR"6$#C^2L;"*<0C>2++;T[:D0$YX/AZ2<I1,NHY/=XJXQ-KJCM$MN.'U!
M&PN:J<*[,J]6 [[3!<LL %>MG(Z(^^5E4]860N&5W;98)!$';^>9 .>15MH9
M*0QS#^3$#2!,;&O F_L<J5[<][X(C06K4KZK-J%O\VN/HI^'&&T<Z/,E&%<1
MHZ )\)0N)<>+$P\C6P+]+((@@?9JE9ORYV=WTK8H[OJ>FMP)P53*(@:Z2!UN
M)@/2!+#F]Q*EC<@ 4\#5L[4*D^,/5W@:?/*Z'O,\D57/A*_9^SR,R$_H14 ?
M=H^*M7&/S&>[7OW7K^[/>[SX]+>_>I)K),^6\4/=OY,V?NT!'"JD,T?F&2,J
MQL-37/KOK[T[X]F0O*RH967>&RAF9B_EON_4N!I]&+.""DP*WG/KZK&0O;X+
MBY)H7;GH/\8_$TX@X<3R?XF;PRRH6$$E\'J*4W-?&-/1>44Y]W(0GE@K9[LH
MNRM)AZE[1V?D[M#1)0K^E.H%Y)3&\",[>PO\II^6R_V)F^A7358$729$BNC:
MB9-;36V;JH@I,GQR-Y5S4BDU--7$F\@C<H6#:)'8S)+P#;I&JFHGT/7,8HJT
MB%%$MUS<;-IK&@49W.""K-M-W2KR2\J]*-\!W/+B\T\T <._P>.4)$])U]M)
M%@:NX[)K^YX;=WX2';O%9[_1>V&]&'8 >M9,C]#N&R88EI/WCGZGJ!:.]ODK
MZ%0PM,ODJD+T.WU8;!Y1G$F>%D_!IDT$\ 0 !:%EK5&"-9VA3UMZOZA06(;C
MXP!JT>"NB7^,FP7?,K)LK573D"XM!).1!)/F;1PH+FO7PQY4,GQWS9AMS&GC
MU ;6='/3,DQ20O#8]$WL1L2TS_12E&1!P;ZJ)%)R\_+[WRZB$ ]&,IW+<*-P
M4<"V="B%2H)3:!,*MA,D:FQ;E95+E[?P+YJ1/&%ETZ!'R;,=&U(UB 0FG]:\
M@%0>:HP1BK%M/<P:%_J0\G.A+70^!+70W"AW8L]#A-EB7+WOQK'HHUX./KS-
MOO/S--PBYE<R[S@#[UMM09&8@1FU1>#<5B E,, &F%V+PDNN3MQD68K@I=U>
ME6UOVSVXYT!>25<8B&(5>E?D,NJB)J>&+ 8ZD.DY-YNP9#E?K&R7] *%,:*K
MDZP7H+>#F17+ PR= B/HHRG!^_1\IR]R*[! 9Z,BNC]9$G1$V0DUJ#X(%-+C
MER\77X?(]Y9RO_M[9B;B=4PL )1BIIT$(AYY6QW\,&QC7]B[+DEZJ9^(ZUFB
M"-<$H5XR<(CQ[L+B716:L&7^&MEV=;.F,)W.@+BZ;L82CS![C7T4C(P<[: ,
MK=:RS)P$%_+M:B+\4TE_^G01,M>]N[#'GCB9J6ZB\^4O/8U&D-QL[,V%R9G>
M&X,BB >_6C'@R?)EJGC/U*'$%W$4$=<T#6%@):J1!U.AT)ZIKYWO:@HH"V^C
MRW_4C66+3_A"2@;0/)H]7]6(S*GC/<W!]E44M^5LY=>MT7V8BT?8-..WS?M[
MZFNI2S9*(N*$ ^64V/[S#&]]1.A0E*A@?P]F$JDSFL&8W8=9K3N&E8-#FSXA
MR]#PV0&\&AMEP=UP00W[\H3_0QLG<22/0QE_>8";WY\!-T_C69XBX.9LVOX%
MIFU-(J Y.[6VLS :/>@71/TE4?]I%4(Y_;J%1[@W^"*TZ '7%5Z"]LI#6Z"B
MMX*-A$J'L8+:7\)BW92.)PCPF3?R^.',_E&S-X*5,>*H/[]]\^/WJ3A./GNK
MK42C^/\BI,,>>ZHGM*&D!*$DX!A)W4?&DA,LEXL_M4Y>0OA5;NH[3(-4Y::3
MIK1I1TZ/:?#,/C"-<)P+\I(\8GZ0*M7\DMJ3M^)QH*2Y&W ,GSJ_MU48"#B0
MC..FT'PIS /#K9_!,SK_$;=]&F5Q.F%5D0O"H;#DZ#R&'C)^C10]M22#%M!)
M5+@:>:%427QZ[!>>1LAW\*C.N7%1+_K;LH-@-WC8>:/=M.V*EAK #F6W IX'
MZ<[J_EPKDR4[ 2WC,-)0C(U3,ECG9?J(R[2>9S[8^FF.-N9?3WC/ED2X)VM3
MB;X(A[0G+LAY%,B)R\^MYNM#NOSB2P'V4;-M0\ <.$6QX&G[9K&N /'IB_</
M'#E.E\#6\@&<OY;@OAST='2YS<+. )R*O65"&(I$*9;S9GA<5TTF<6S*/?.%
M@/JKX:I#V2FZJ29SW0TQYR+Y&/4'UNX[FC#;K'+FEZ8ZIG]"-+4,JWB:<VQ/
M!J]%WH>(>3(6%U._\MRX^\AK"HEHP>BSOMO !V<[0U-RBW@%%B_&<I:P?HEP
M)\P$TW48,J90A&?/19(FA!);6/$.C)CPF6]1> EN83ULS-4_=GA?+KYAJMV"
M^<LI?&CY8FWGKKRJ>ZII*0*IJ_LJYL.EC.G;X]/J#BI$VG+>J7]P(JO'#Y?T
M_>GAE0PQ7T?]$*L-G1?_SV!0*Y0UZ4CU, FF>>-ZR0D?DHLQ83T!-+QKPY>1
M3 _/7MB9&_8*P<[ D;JI[H0^-2XHG/JZ"DJ7ICZOAY]A/=!*T/C'(2<]Q.)X
M_&-H C[QV/C%HNT_?EVX?G;MLP/VV,P&T>=Y )J''"4F/K2,%K61G$3SH3'\
MO.\?=]]S_\VZC4XMETRBJ//QK2D= NCDZ:IV+?U78:]76X:YA/T=KNI<EIAU
M]8QZ=YP_X:H[E:L';2EDL,K\(2D5MR745,G0M"-/R,72,(S@^PM^$?>I,[Y
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MXE>3 D;"DW]DMO81@UPWTKKA]#^F2="I'DC,2-5PRF.F./FEKB9;"YSOG$M
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MF!M/16V</L9/GM3:Y9 T 3_SL_@]_: _*\5[S'JV(?1;,"=X^,]ZV N-J.(
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MTQ:Y&6-IVB*W3[F1.M%NF_;)4JR:4OJI#\W^YJS*R65&G2%M<8M.8!S>$%P
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M/I$ZR<>0J#'N?H4L@P)12TW>%B$<"+RB<FD14IOJQ$LP"+4R#P[HBML#?/V
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MD&I/1.XF+&XZ@:,FEP7)8J^T8E]2BD6K1=O"]/)C7H73.XR-N7W:03=Z4/E
MS*SGZ IB.Q U&"W2G/^GD.KQ6<VC'HEWRI'#0'7/Q_R3WWK$-H9<E%XD4/XY
MJ&69\Y60R^IWLYV"N^;7W>OLR0&FXKBAONEV.ET2NLI+)/56?OLNJHN_U PJ
M<P.1BLQ4$<5)O /"-(%(,AXQU5]23]3'4'RR@)9;G8\;AQ-,'^ M3>@*6TB]
M_U6H\VBO0^-QJ,ME 4?J5*2F:!X&:=TJ4FA)W7""U7Z9).D"K_(U6HYML>LK
M;1Y'1RK(P-L-_:LAU$&)Y)/<R,H/#+ P1UF.:6;L1543J7D41>35V[;!_](6
M2')Q@W$"U@)F8X49D-03GABQ6< &[X>;E$>I]^OB:]$+Z"P&#133C%CI1'?:
MT(Z<9=T<:(!AJ@#/*9I&N687$6./I^J)%?3[LQC>Z,.OLJ(1- GO<.Z'<WVC
M ').TG*O?H3GG&%RIVX-ER1@V2%Y*1W2&1HB+TQ3[BR;*@T7?($#L5LY:82-
MGD3%@;?8[2&E?4HF(G7P!;4;#)@V#+*DG,]I87XHF4!_(QWM\[L$GPF=*+,P
MF5'71A^,+7A IL$%=&(*1VK>&-8>LO.>?;?UNV:&;=P%-JTM>&\KO,! -C@M
M&-Y+@X(B9C2#V!Q&"F*CQ?"!(=4_1#=F4[7J86H9'XWF:'"F*)M:$U6S*LW
MS:JYGW$+E1R'98<1*[B5"46@U5N\D>GYV[ZHY,F"5?-;WV0FH1D@!*OW-[6<
M[0[@A4WP+ B[ ":9PE%Q@L9/33_9\[ECS6N76EMTY?7$&(S2NEKY.LJK^:>F
M05ITLOZI;;0A2W+<K0_(="#>1MO[/;F#*M-6E>W_MED:1D,^*,)L>7_;/[#F
MBKM#TL>X%@MW]NU50,]*FB'1K4BP0Q(K-TJ.5>T:6&>!0#L WS3OI8D-K H>
M4R)#H$.!-P$H#&_!2?+ Y9WP-$VLJH45?.[E\]HM.R+:$9TOFRU"T*AT['0N
M#=$'+*<:)T=2,@'@D62\;\ .0FHFT+G1*;7,<"D(%R@ -QC@^M4H0C3#J%4=
MC4A'O?(ASEP-<G6/UK2K9L@060^N+ =4!@RH-/E(0M'U<AYDM5,%>>*D_:V\
MA'+H]"'=Q/Y-,AOI/.-,@ZA49LLXI_%U;@7[E5TOT(=4RAN[=69\>%=3  ;#
M E(A0-MRN;LN14.<%=R84K#&S?9P5(.V#AA4%DYNN>Y?:EF4Q+KO^CA3U]*^
M"_OX, 7FKI0UAM(A$%<0+=ZYD%+ O["TC#SI2I5>OS,<T!JI]O_V(QH>4N*A
M_)D!\N!05(]DTZ&[(Z8=;ZE 49J.Z1(6 M'&"T^!^SDJI%KU?L)3"!<-2/\,
MDOA98:Y[%H+/B8\6"3H[.1&]!R^9.+.Z_+1T&M4$:+BNDXGS G:D"%;N'JFT
MZQ5GZB<0-D+L(LDRXW%8[:?A,O_,&G$*L5&* D!>6ZM,MW#**2\+&4[J-M00
M$!9B6+GR*S9=@N7*OX6"00L=:A.=Q@<ZZ2=N\0X#BO"K$DA 13-?@")*44%I
M)HBF$NQ6WT"I"^A9WC19@GV8'+DRA878)@<[S\&_HN6DU5\)*0D*A=)D9K\*
MF'K8]B!\3O4#E)HB'NY=.)ELH=]_+;PK@6.K5NMA9G$F/X&GE6:;3Z(YZD3(
M1K06"QY,0R[#MYAS\##,!FG4A],[5,/KO(53=@55G#IZ*(L*Y6+1;6A%F$JD
M,8 Z@Z80?VV_<S"%<.GJKUJ?5Z@LD*42%D>FH(EN4E775M/>AYZ:T^&).Z-Z
M<#+?23R95TZZNCMV1_A[>]Q<B3Z5T6/@3XDY"C+]=L;0;J3&6AT8TACP(>-)
M83?1O4<8J[D%>ULH[,X%(5:01GYSO7-4/[D2LY=B"J?=6HWTY@9\51K:?K=U
M='#8ZG8Z==)A;;!DIC-4G+:A-C#HGQQF CY ;?%A>LM=-^R Z5'0N!'-AGZN
MC!K ^ZF7GTV"F(PSIG3,ML):,[Z1,S=-)8C(X&&GJ039C+'\L)4@3ZJHJKK>
M7;.550,84,48N72LDMPF?VEI$/U#M>(Y:1_(HB=0,DIM\1HN@</C'$&$N!T
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MO3*@=N$XZC.<4%R!? :K3'FJ%,"G8^K7AX(3,@_26,$)E,FDXA[0]X])G9@
M@BSBC++Z:-9_O>OOP'U@H_PLQ.0-KQ'5DMCZ'4I0(*0]I. +5Z H:Q$!<8&[
MT=W>0+HN"D>+C98MZ3\!HT%> Q2C4+\?=Z[D]T.QZ@<U(K16$8(T[4 #-SC)
MF%&)%<]T6E(9CSK@<TP4KI264D$97A2A9F6?63G$"1MT4=T5+H2&QYPB^!SF
M.VB75^'&"ZXF(H502R9B<9A0)F$FS3G6!WQ,)L<FZ)K%C.M>[7YB<$$PMZ6&
M'D/%VTX^CAA4"^Q4/?"BW7E-Z&40&<P9[@>'P,=-+;.-F&Z&F":C[R(#"1W
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M7*]L0+2T=BQ5PW-2']\:6O&S1^L6,^>Z*LP,2K2BEE!8%QZMU'+;;T,[">0
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MH)' 8//=E#&A8%85=UU>!98:+%L<?@L;I5:OBQM55=O# _!/@"3 M@8"ZG+
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M4!\KW^TGP[GZUSB?3O[Q_P%02P,$%     @ "(&I5K!,H5-,#P  6JH  !$
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M^H#3\O/G#ZW2#.]TYVZ?G253H0O>L_E?9$M4D#7S6M2"9=518C]0E.[G9SO
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M%\-R_(J[VT.H_R&*'&3+RZA"![FJPLNI#A!UT""3]C))Q\+I??Q^WR('C[B
MQBCHN:_Z'R+0*W25E3=<D%'55B.$>.:(#%+50")5C^9 ]+PUT/NPATV/GY[[
MJK\;/4^&^+*>'_;+^7X%=)P,0:-EY+F=U$2V7[%DW@9B"CFR$8NJ=PKQ ,,8
MTS7T1T3XAR;4T"4(?\)9.SI\\YYHO4T]?$YK=N!7;_)[*L<S6M1O+Q1M/W(1
MY&[%"/=[8*>RA!U'W:E X;=/:TOMMMH6NZPUH6J]BZ)LMY<=$Q@C6Z.>E%=.
M4>Z=K7$3G@Y77"]]]]^6"W;HMZ.-):H4B@$>7*ME[CS$=CSN?8U4LB<M>^<F
MWXQH3)Y6-YY<<4>UEU+ZW86>S1:?VD1]L5@^7QRG=3V>?8OS#&)5.;7*LQ8C
MV\.!;0UT.8+RMA:O3'+=NYG?">"H2EH-QZ/!=#:&K; 5E5C,3TK7GBL5,/!^
M>,M3#[@IWF7\G7;&T\=\:2WB2?A:E"9(I7@P/K:FF%*!]BXX7H>,%?W;+7U]
M_O[W*K;?]1H__<:6Y'**LTUCUN,/'V8LQTT!Z];1<,G^U(1R$925@:2MXL$&
M <$V7TK;I)L@I.WM>-P)X)CVQ7NSY-M;%$.IJ./MG"W$%ZUY(4_-37_?B\ P
M![*B(.CB6YO$R*MWUKS.MIIK*<640O]"C[?"&E-0L#]C.JFC/T_^L5C^\RSC
MY"(P@;XJG0H(;=@W5EI"%#[S/RY@K$;G,AA/KH<UINA<?YYT4L<8[*%?YFN<
MOYNR17=RNVQ@0^BZQQW0 MIIQ)U,G[:@K.G7Z<<68[WXV$;&J) =,9)02BO\
M2LE!;%<%* <KR?B25>^Y>S.B#K?CKOOVC3,Z*5FX:*R$FFINMR%XQ+Q^@BC!
M6R%,#:IWS;3;,(W)".K(ERNNQ?533<^2GM>AXOE[?-1401<OY)OBJ;A*T/(N
M6[5N Z&P ZI#2"$(HU7W0FEW1SFJ4,'#L*J'_L:P0V[K)9_V+Q\^<G[5TPX;
M-K]UO/UBYI=*49^&E:1 @501?!*!S;36UH2IT@SOK!Q:@[)WE91KP>Q]I,G<
M6'PA9N9F,EPQ6B%2B<T4-3&PT9BS;$ZH ><USSWKK*^] Y^W@AK3MMB')]^<
M#';52\\J0HO5='U6S.@,3,XI$;LJ*EGV7"2[%UB]ARHE.Q>\:IKN)+D&RIB"
M ,-0HX<.NA'B+7ZFTVHRIT!<E"H2.Y<RD6)CS26(R060OEA%QJ@L>QM!5\ 8
MDY<_#!'VE7VW'/A*JU7;U6<O:-.PX?7B"\[.CS+S.K5)B*Y>MSX-1D/(*8!E
M:RL[I:0I\C8#9=>'C2D5I:_>!Q%W'Q)L!_J,?SEED;]9'Y<O#=TI(JQ.&1(>
M),:&*!5(23KP.I2$J(PP:2<"W/*@,=V6&4#Y/<7<MV_O]8-5%6/R,C(F]J:,
MHW;[D!)0"M&:9$W5@_25WM%D?MCK+<-L#!TUTO.F7CG.ZVT)FR\;=#A[-D->
MR^J4.;T%9VUHO2$3Z-I*DA02/.Z 8&TVQCOT10UP67T7:'=L8? (>3.$CKJV
M+CAND9S5\7)3C^1TLRM!VF1:RXV(K8Y]RQURKG542):<5-B]V- U4.[8?. 1
M$J2'#H9O>WUT-#WI<8#S<E:--[,(WC3A+;\LZN_SLNV.0.7%\?IX29O2U3RB
MV>9NZ4E]MNT%:/XP+3?O[!-?.P2L;FVU#RS!?@=:9\7USKSC4PS/CZEEGLE4
M36O,;IGP23N() B2:M721 Y)#'"D=2.FGB4?K_K^O[-LWWZBV4?ZC?7X?C7!
M5#"42&!KJQN<98!H7(7"T*7%0JI[ <R[8AQ3=*\KIVZJ!ME=>8-TMKL*Y?\E
M7+Y8'"\G@60TB@+O+.TFA+$%8D9^*:7UPD@;3>\+K;MB&U-4\$$I=2]E'91*
M;YD:-'%%2ZM" 1XQ"\)ERYZL1Z@BJ%*4R7J(@]3=P(TILOC@9+J[NOI$G*[$
M]G;Q$QL=T_*TKFEY1O4H,;J4,Z^5I=W0P@+)6H+J9*Y9)"&2NLU\N^,SQQ2$
M'(0B0^K@L,O-I\5$(VIG<=/>4X/!H!EFDJ 38K+1.IEZQQQVA#:F>.;#+S5W
M5-5A>/2:CG#:')R7]06[1#AK4"?"VZ!\B8"Q1C"66ED:%8&4+3DYK*[T+I1R
M=Y1CBH0^'+OV5V WHOU*JQ71UU;GUPK#"RM$X-&'3+%U<N"%50LVX:S%%((U
MB7K?8MP5VT%D<+7.I")%)6FH:%IC)9DA2<=&"9*(H1"5[H5.[X]V3%[N(+R[
M/ D/I-B#3\;3K:DZ-FC(:1 IM6+\2@*66J&2]-68XE#VSH&Y(\0Q><'CH=P]
M57APGGT3#=+>\@1 "8YEP#NB,("A76]%#(4G"<7N9NM]L8[)91X5\_92ZL,L
M=1N'OQ1VV5 A9-=J;6)+-D/T4&)%G6-. A]TL=LU3G,H)WQ4I+N?&OO$;6[$
M>'7L0&;CHPT&%%E>E542@,9$$"@KIIP]QMWB-W=_]IC\[T$I= C=/,ARM4'I
M4I%.1PU.)J9YM!Y0V0PE9V:Z]T%W[PIR5XQC\L5'MUC=68G?09+!Y%**YFC2
M#";R$24:7)9BIU2#G6<(\7S(UA-(U:Y<5ZT@8I#LN>:0T=GJL'>5C4,%:JYY
MPH2,CJI4 YFA@7$N $J/4%2R3A5)-O9V2ZZ!\BA#+'=AS#>)GQU4<IA=^ORT
M_OES*U5PTC]]XDU.5O-&8FW(8"2/''-+95<YVB)-MJYWCLZ]@#[*6,H^W!I>
MG0<[]YM((55)BD#8U@@96YA?"@<D6VZT=@55[T)/#Y((-K$J(9%,(#:%]6QK
M\%@ML;N'(7JK8NJ>''LED#&MQ%W9L=-)TYW4,.PLN':BZNI#$)I'Z02"T<5#
M2)H@4JW.Y2JUZWVI^4X Q[3>'IY!7=0VM%.TZ1.UFK9O6KW Z?(_<79,B_IV
M6WF!3?Q?"DMH6J=XKA##IK=4X5^>RU7GWQT?4=DCW7HP+)U<G\/(JI.W<V53
MG+QX-Y_^BV[ V2J5?9K.9D^OPKNI=Z6#,,EIX!G1KJNQ<1"J:PQ.*$1*LG2O
M?3[04/8*B=X3TY58KK'/OMX1%VSJ*=7J@CLPJ65].B% ^E13=L+(J&^;6@?&
M/*I^LV.8"1="MB/E3I^S@IZ#VX[B_"^V=8.W-^CYKZZY-SE1664KR(%0DLVW
MA!*2Y>W<V4UO5IFU* >?-7L,:%0%H+[K*74HUG5S&GH._FO1K=4DIAK(485@
M1.(5I)4D2#E"DBI@$LX*W3MA;:"AC"F584QS9TP,&N5TV'9NN="K)?HB+!*0
M%^T^EV 1ZR3 D;>%3,Y"];XQ->R(QI1R\;U/CCWY-,HY<E;%>.*%+E%E!.VS
M!Z,K0JP8P0FGI+>61*PCGAIG QE3!LGW/B/NQY[Q^2JO&Q=>UM]7VP]/G.69
M+=NM%T.\]WDO(6:6=XZA)A(Y$>U6/VM(E&/*8!D3T\=%CQ&R_4(KNXF/*936
MQALE(IA ")LK[RQ?K9PH6=3#AZ@N8AQ3):#OF^GWI\8HS9N-J__WQ3R?A 6V
MT[>8F$2V!NQ)XWK*$#!8<,HXE,%K-+WON@\^J#'50AK3%!DGJT8Y65XM%Q]H
MN?[R:H8\J!-'YT,[8IW$8'PM*($]?UX'2DH0;1802>=J;4I5];Y\<)"![3)I
MXK\GS8C8-<J)\^S\.O"U*^)J$LD@&2(@$=@KBA%;T\4 4AJ?<HL0F#$'8:\;
MUTXGA.+?\V8\Y!K_M'FUI \X/6TT<79*<[*UDO7*.<%VJ!$5VIT\B*HDJ#X:
M(80K)/5CF4<W#72GB76HM+W_41.K&_VZS;13.4Y:QJ(LUD()OG7D:?WC:NLX
MJ+7-+B8?<N_*)J?/WHF/ATH"'",?[Z6DH=,"6U1V=7;+YRS9[3?"U?&2-N]O
M>S#Q)%BLUORAW^=+PEE[XV\XG:]^7:SV*[[:&T*G),!!)=.K#=)'_NI&XQ>+
MY1N<T1MB-W/#V>>4UK_A>OOJS73^;D;;UU^>XYHF)$LUF#UD:K<-HFT=:@2!
M\D'&X%+6JGN?I'NCW;L\]8Y/WER??3FGM^^7B^-W[U],/VYN.'Y- IU0KBJ4
MV.Y(L,]NG+<0V_5*;;1R'@L*V?NR:C?P8\KS/Q!SOZF1_2!$Z%=F?4?X_YBN
MWT_GC']S/_<,LT.A2&0'I25H&-WR-82V4&5-1<LD8O<>FOLA'M.]@I$SMH/*
M^YP^-5A?05Z&?VF+G-AB5< 86CML-I?):DB)7\:2C*K9&U?%;0;$W1][L &>
MTN#I;/.E&^_B6X*<56VXN.),4)1F';*-6*)C7X+5&+06D+$01O;;7=KMM.U@
MD,>PQ0S,P@OG:>/DPN$G\FYCVPYK(BDE79K'8TFW("[OG9X716^DBU:8(,)#
M\7H+<0P;S^/F\7UT?7 [Z3HS[X)C-Q%$*K9LUIB*;XE[O(=N"AR&*D-)2=G2
M.S+?=0 /+<VOUH@H0675.A()Q8:0Y7^"E@Y<QM!./866O>L'_(_VGOKS>SB'
MZB[<..P&U^(X^VW>THA*J!*H8GE=KL%#<EXV,2LOB\- N>N&MS?D,6R XV'[
MB.DR5EOONK$Y)[S-OK!#FM@>H*@@19%!Q6P0 ZJ2^TZ%@_@T^E 7\A[97#@L
M7QXVSG91M!*+8JL[@-A4Q6;OK55U\CREL_1)L>_6_8K$_JA'MIV>^A F:W9X
MF:')E"9+C1 4JM;<,@@6)QH7'FC[O(._.#;CL!-Y!]XC[\.!T<3;R5DK<H'D
M [5;D8I]7PJ ,0MMA471/:7K?UZ\O3.-'T#U8S7A3J>>0R]3:U'O?"LDVY+Z
M8\MKR:&4$!R56OP#F6QW6'Y'9Z(]Y/H[+ D&6W\O#>^\S'["U;1E7VD*10C(
M'@NCS &BXI_8@LRMV*&5W8L6W17C0T?C+C)-"Q*R>0#>;^HV2X2D>8,5)>JV
MXQK1O:/[@+'-<1E>7=G:._!V?QJ,R<LB;/V%; 3K/-N"6B9 ;QT(9VK-092"
M#Q50WM7+&I>5-0K.=E+XX:/$$VE)N51;M,((,(P60I8*<DDH7; QVMVZ8=SE
MJ2/UVH.0&+2HX&T,+(M*@-88*$$9HY4O2N"_O?9A.78@Y_PNJGYL9S=9"Y0H
M,_MOQ8%QT4,HH8 .T0MEG8B7+P#_^^SFD=.Z!Q5&D+A_<>BT>K78UK0=-EG_
MUL<>+D'_;A+HE)1_%SZ> GJ:\_%1$\1V,E@AK)0Q MG$WG9HY3R#K:WO7+4Z
M5"5+;[>L ^Q]'8*;(9RTH#E>'*^N!B/529>^E\M?%_-WFZJ-%V0:I5 U\O[4
M.A*#R<26:\P)(I((,F+1A >5Z9X#&H/U\E"<O^Q9C(<YW;SC_8;4&H*\?8]G
M0_M&V%(**JT6O7:M?JD(K5>W;1U5-3D*SI?>CO.@ QJ#S?-]3(:>S#G09+AZ
M()-4$Y)6!:S;-*86&8*UC)E$BD;Z%+M?<;L/SG'MFA-GA!$Q9:#B#;"8)*"N
MK4=&E*JR7>YL[_HM?4?PV/?%._%VV(WP3F08Z<XW22FYJ@1!LLAC0%4AU%2@
M90V84)ST=5R$OCR"Q[ZW/2"A]R+#CB[\]OWV3\(5_?4/_PU02P,$%     @
M"(&I5AX GY'U5@  :>X# !4   !B;F=O+3(P,C,P,S,Q7V1E9BYX;6SLO5MW
M6SF2+OC>OR(GS^M$)>Z76EU]ENVTJ[U.INVQG55GYH4+EX#%4Q3I)BFGW;]^
M A1IZT)))#<V2=&NSI8EBN+^$/$!B A$!/[]?WX^'_WT":>SX63\MY_Y7]C/
M/^$X3?)P_.%O/__Q_@6XG__G?_S;O_W[_P7POY^^_>VG7R?IXAS'\Y^>33',
M,?_TYW!^]M,_,\[^]5.93LY_^N=D^J_AIP#P'XL_>C;Y^&4Z_' V_TDP(6_^
M=OI7YY-'61B8G LHHQ2X@AE8=MHA4T$S_G]_^"MZGXM3#KS($NC5 @$YAR0=
M"X';&+-8?.AH./[77^N7&&;X$PUN/%O\^+>?S^;SCW_]Y9<___SS+Y_C=/27
MR?3#+X(Q^<OJW3\OW_[YUOO_E(MW<^_]+XO??GWK;+CNC?2Q_)?__?MO[](9
MG@<8CF?S,$[?'D"/S_.O?W@5C?[E\I?TUMGPK[/%W_\V26&^4,^#0_CISG?4
MGV#U-J@O 1<@^5\^S_+/__%O/_UT*;DP3=/)"-]B^6GY[1]O7]Y&.AS/?\G#
M\U^6[_DEC$:$>/$)\R\?\6\_SX;G'T>X>NULBN5.]*LA5U"ZPOD?]=-^Z8SI
MC(!,TT5$H%=Q7 G>$..Z3^^.^>MG0<82+D;SAHAO?W93O)/S,&PIX%L?W0#M
MXH/@',\C3EM"O?:Y5W"N0-Y$&&E883SY@./)^3#-_I(FY[\L$#Z;?-H$61Q_
MF$!=3YF\G,'_X_(/KSR:=#P<#^NR\1O]N/SK^HR=0.#G.8XSYI]_&N:__3S$
M%)/F3NK@C<HY!NXQ!V5S<@$+YX/+CZAH5GA&DW3M$T=U49M\?<PH1!PM7AUD
M' Y6N\S+<9E,S\-R&/ARCN>S ;<\H68(&#C2EA$S.",<,-H)/.?%<55N:W*V
M8L8,TU\^3#[]0L\A=0I1OZG"%)>Z?.#IES+N-JKW]-Y!ED7** 70MJ9 Z<0A
M<BDA6.TYHUU/*-ED%/5IUU%_X\:3Z0K_<H[L.(GJSM^#]N:3!L*[U S!__FG
MR33C]&\_LQ9*_'\NPG2.T]&7M_AQ,IT/, N#GH!(YQ*H+"T$;1D$J;6AV<&%
M6[.^[*#/&P\^(=5V$>EM+?,66GZ#T^$D/Q_G7\G8':C G-(HP2@90"7MP6O#
MZ8LKOB21G4E-='SML2>DX=W%>5N_HLE2/ UD9-1!+CE7./,F!(1D"R='0R$$
ME0I(9CR/EFL?;)ME^<:33TC+G81Z6]&RBZ*?C^?#^9<7PQ&^NJCB&'A;'#H=
M(=%80#%##F>BG209&BWM&X5 =5+PS2>>@&(["?&V0E5WA;[%#\/9G'@V?Q7.
M:24A&J62$*)/M)+H;, ;3LADU-XG6D<<:Z#4ZT\]&<5V$.9MY>KNRGTY3I,I
M+1R+0;Z;TU;Q;'(QGD^_/)MD'-B@<O3!01(I@D(TX#+34!@M)-I&#-8WT/6]
M($Y&]>U$?9L)ICL3WH?/+S.-?%B&ES&PY?J3A L,4P*;'0U:10^!3 ?0Y!B8
ME+Q-03?@P!V//QGMMQ#O;;W;[GI_DO,49[/E/W6X?,!,#"*BALRU)&M1$1EC
M3B""(+Q:>=;1^+[ST2>C[ZYBO:UKUTS7S^C;U]/WDS_' ZE8XCD'""X)4,*1
M8Q]*@&Q,*,P[IDQHI^EO#SXU/>\HTMM:]LVTO-AB7D_?3">?AN.$@Z*Y<\%J
ML%AHG,Y$LCI< *&LB76I,::;NW7?TT]-WUV$NR9^TBE,=@W8F\EL'D;_W_#C
MPJK ((71(H/ 2/:E*!F\M1%X$I*7:(Q*+3;O=<\^-8WO+M@U^NX4,*MKS9,I
MA@40K:3B-7#'0Z'5IF0&7A,/7<K!NZARMMVVZJM/.P&=[BR\-5KL%!:K1\VC
M-V>3\<K1USSZK)(!F:0A7S *B%$GD&0U%*.EL:Y;M.3F$T] FYV$N$:CG>)?
M[S!=3(E>7,3WP_F(Z"5<-IGV_Q1L)GL/&00K!&#*2H9D.!D$G31Z\XDGH-%.
M0ERCT4X!L/?34+-SWGTYCY/1 )-CM-J3;Q9<H3U>.7!*28A".60Z1.=S)W5>
M>]P)Z')W\:U19*=@UXI5SS^GLS#^@(O@FV!6I*@U&%5#Y3%HB!H39"99R%EX
M@]VB6^N>>@)J[2S,-=IM$,!Z=C&=TE OST$J[<A$OY@-@B8+G-9]&I:@41:#
MM".8 "B53<+P0H9< Q-X_=-/0-O-A+M&ZPW"5R_'<YR&-!]^PE_#/"QQ#A*M
M*2H;!3%$1G1T%KQ+BLP[,NE*">2%=]MZ[WOZR6B]@7#7:+U!(*N>CTV?D0O^
M83+],HC6%K0^0K))@U*Y9JRB!V.RE3%&YWRK<\:O#ST9'>\NRC6J;1"]>G<>
M1J.G%S,:WFPV$)[G)+D$[;,CJA'?O&0.DI8Q!:TU%M% M=<>>C*JW5V4:U)
M&H2HGI_C] -M'G^?3OZ<GSV;G'\,XR\#C,PR:1$<_0TH:PUX3!YTS,Y(2>A"
M"Q6O??C)J+J[:->HO%.4:DG!,QR-5G"D249YYT%Y[6IN"GD 'B7DP- G H.R
M133RZC-/1L$["W*-7CO%K9;VX.3\O)YB3]*_WIV%*<Y>7\QKY47U]P;%&*-U
M5)"]3[2)> /.\@*6"5=H$3(J-3&Y[\%P,GIO)N@U/.@4[7I" \YUT"]&X<.
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MW-@)OW867+7!O BC]S@E#4H1, 610!;FR:@L!GQB"K+A5EAK BT6Q[)7]"&
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ME(Z#52@S+6A.VM:-7#=#]ICIU:,.UE"E\Y'CF^DRI6R!]TV8OIZ^F]>&Q(O
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M0@;K:<6O]P%:EB%HKT'$D')">C&V[FK^J*\!ZD*35GKH846Y=2D-K9_)H0R
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MMR>.%P;J)>E6)*C?$WS55?WYR3BU;]4:P5OC=)J;G52S$,W2*(E(')LCXUD
M48 9Q#$74"01PB@.1,;%;*=;<H]"D*>Q]#"5#[6)]EHZI87I;BZ?-3$6J\:0
M/%^\2&HCA_G=6A*PFHN;DU:QOYDXMP2JWQFY?,W3<V?&0X%3>TK=*YI://O"
M)4SMI3]=L]3A6?T<:NO#Q;=J<U?\6=8EY$ROX++>#C&S(>XB(.M^YD0*1L(
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MQ8)J6<#F+-:Z"Y8I4U&+^:*OG-?*N6VB\$5_IWJCW/T:O-._V:KBIPD!+2/
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MT<<+U S.X%8D9_C1^B9*/C[..U.$EO<?YLL_-HJ@K([$!Y'>I'(>P2R+M0&
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MXKIJ9].CNZA3A;O\-I-GK/>W#U*\*O%9SJ(L"V+,.12F<B;2_X L(A)*(K-
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MJ2F9%A98R K,S9FO54\0+YU">LR1G3(:EOF!=50''FR@OS)UMT$M -BU=:Y
M*X4_]=6?04]:K0> 495=?X)>Z\ SGM2CW()^M))U$7$Z_R"E*<OY>?E"YR8F
MTD4QB(A(1#*M"%%L2NFE(:22)5#*6$2IWG;AS"IUU7; J:F]3<BFET/C.2HZ
MU Z5"&S8/J[2AN!P^&#1FKX/'7TKP*=C1OUX="CPX)G/D>H]G,VK6QT(!Y*.
MEH6P><YX52(<I-HJ&N%R7T\__Z+*A5'P^;-<G[A^_XW/GX04YMR"22MX:MZR
M6_5Z;7CSLO\!]1Y.9E10E20P,I7#4! F$*>$04[B-(U2*A!*G&("PV&=VF*P
MB72C1H)C_&# N;6,-4QCQH:.2^R?+.^[^Q'8]!6I&!#IN%&-X2G?B8",,&3/
MM<+D<DBQT5>CLX)0('E@&N]F$=&V>X@)I$0D4&%%2!*G,65.3HR#(TU.3S=
M@?QF4N^<%?1!0ED29X$0,>1FP41"9I!@4YTI"&G 19H1JIP26[P0.D*NRU"$
M6JY7/F@:/@I>,[0!<H"$N)-,^%HI#HXSKIX_)>Z.ECYY@]>S NLL[?)0(\^V
M7>?J?/'-HCG#\*IM9_?[3T7.I<G5Q3@(,RBY.5$D)(>8TPB2+"4JQ2@E"?9P
MW& @^%-;#3IP8IR6UGY?!3L-.=T)'ECMVK2I+D_TJ5YUHEZ1 /1[TM"PIR=U
M=Q6HN1BQ&?4@<SA6VVF_X*=P'&3@B7%N)3T,BG[KY<^R>DO+^T_%\CG7VZ,W
M+[]H3#>+MAS8XNZ:ZVU0O3[/XB@1(1$93"(9Z$V*"""3.(,JE#$5,M6O6N!B
M4]L//34C6R,'7$,'CRUVH[=4AQO0%7"W!<MA+NP6FV$8'GBA,.0:U.#3!KE_
M-LBULO\+6($'UZ=I=E;M[HQY4LL. X^J4MT)>:T.>SRA9S+JP^-\^2+E9SDW
M74+V;&+34&#)T@AF"&D-)B,&62@B*$,:!"D*PQB[9:6>&G%J!O:6X=7/17":
M93O=Y)6[@552AQ46#=B!?0?6U/C*7#TYWK@IK+;B[^2R6M]X3E*K.1O1>)$7
M5;YXTAJL;;VA+;<WIL2R;*[[2K\9MW-54#V&5G;%RTTE'\J?-0GZ3DV('NGN
M9J$_>UE6LPRE@A!)H4JR$"+*$DA1'$.2JA#%@H>()"[&U8!8IV:-U77-62V-
MMA#J5-'*R-,GF7:8R;73B!.9LH%U:9O,^V<CYU^:2HMK4<%:UFY&V^MK<:_
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MP\R@W?[OXO/R?9HGIV?:>;\YZ$QXVJ<.@W'4_>V@-+_>%P\[V$#G)0\=[OE
M\\*4P9 ;)3!,<7:N]Y+O<M,X<2$^ZXWEC H9!D)D>NU(0H@23" .50)- =$P
M3#(9)U;G<D9#/+5UI,,(1 L2O.1R+CR?ICQ[GBV#'%.:O:'C(Q8-Q$_T#S=2
MUZ6,MHI678'5.]&)#HSL(Y[B]#5-8QWI/!OOM,YW^J+?^;"GMX'[+5=OG\IJ
M^2"+NF&F&>,^?RS;LWDDQ8FD/(&ABBA$G E(&4%0DC12/&4<1TYIHD?&FMH2
MT4$%Q296MQ7B&+5VNMT380-KY1576S ]GGATH,.3]CLVTJAZRT+DUQK'YI:^
MZ8;70A3&WM9_O2V^+O]8S&@B41@'H=8,<=9$G2G39FE,@XS@D 0\M#)&CXPQ
M-=W0IM>U.*^ 0:IY! :K:^KA+J''-8,GF@;6"+T8ZI&&>)"#,S(1=Y\Y<C+B
M0:%V\Q$/7]JS"\Y/[Z_;!0JE21#'*8:4I@(BAE-(HTQ!E+*0QYF@- Z=VMZL
M'CVYSUDC<^QLLZ;);AWO)_S0'ZD&-< BO2NKK]8TZP>/VXMF1Z"=YC.[5_3[
M_E:!C+8I7[EJ3<O"*(Q9HK\_&F/]!R60I F%/$B$%"AA&:(NG^/!D:;V=:Y#
MCEV?3L=^OX<YM?MVO3 U\*>\)JD#.4A3WY-4>/K2#X\SZH=_4MS7>N#T#1=.
MT6HCHIN_:*ILEI_H2_V,K@MH4\=_X\)9'*694$3  %-FSBV::E )T;/'.$Y#
M@<(,73)_ZPS9)IK<U>$'CXT &PV*:=O48KX6XD().^>\4L<5\)2@3DC7#Q1Q
M;<G9_.456+V!GS;>P+:I<_L&?ORNW\ +Y9.-]"9^W\EF0[Z1ETM'\S#UH^6J
MG8/U^TQD\S [@V6Y^<#6LW?&1BA*H_Q)4E-A6MP:630H;?"^H65>_K)8LE(6
MSP;+S>+QJ3*B+KC&4 O^YJ6^_>V<EF5;/)@0%5&:)3 11-N4@<"0(M,/-8EY
MPE682(R<FFX,!'1JF^(:'Z@!]JP%/=B4VFVJIS!1 ]MI3G/DWO1C8 )]=0L9
M"N:X;48&)GNG/\G0X_5P0WPT14OD@4SKK\LW\A/-1=UGU716_: _HYDT9:)-
MU6A)N-;N@B409T)!'(=9B'&<"B6LZT>[CS\UI?U5+\VR;FGLL%'J0;O%KGI8
M,@=6K WXG<,H6WV6JB5@$A@IMKI(&TF&)=]A0SGL)(RT]QMJ,MPV:/VI/+J7
MZO'8\;8]_67>VJ&<\1BW5:0LJME/^2)_>'IH8Z=!E)%0!1C*E,3F1+" C.((
M2B2R+(TEB^QB6CM/GIKF;\'9:9Y=GHXK]+.D'UA5M[@\1ID/2GO,8-4W;1BK
M^E]K0W7W>:-\P0?%Z+[-PQ?TV\*_+M*\KB-@BCG_1*OV7[_FU7V^N%U(\[5?
M/YANC_]C4E?+:A;+,,Q2C& D5011%"%S[$#"( M5&J9$IDIOUNWKW)\/R>D[
M'Z&^O=&EH+JG"Q""%PW6;4ON88KL-M_C$C^PBK$J8;\"#PSZ*]#*J&V3ZWFM
M:UH_]!>] L[EZM?@G?[-56.M:!K\[=[]S8"G?;H'0*/NR/T1^'KO[?')?<L"
MZI?.6.YUO6BJ]_-TOBJBWZ6N*"%5G*4!#"-)(,I(!$F2"!@K%J2QP'J?&;@5
M!3P]Z-2LJA7FMIIZ@WK5GL(F Z;_!-AI6M^T#JQ+/3#:H_2</47>"L]9##ER
MV3E[$G:+SCG<VS?O__V#+.[TXOACL?RCNC<GF>CB99;%28Q#)J#BIMJP$@G$
M3"LEA@-!9(C3Q*[8W(EQIJ9XVNSV#BMHP((6K>L)@/W4'M<O'@D;6*7TY*K'
M68"C3)QQ'F#_<T<^$W!4N-US <<O[WE0L*Z]6Y>X_$2+VZ+6.Z(.4WR217V&
M<18F.,5)2&&4$ Y1&BC(9&I*4$:$,19@PIUJ%5N,.37E\':K1/&CWCD\UX>-
M345<L9S/:5&:(KE-=5S'XK@V4V!GF'@F=F ETG+ZI>%4 S9GB1K([5%N#;HY
M].WQL*$]1;X.'5J,..[A0WL*=@XA.MS:MX-CTZVE,7JDV7F5/\MJ1M($!S++
M( FS *(HS"#FF81ID$:9_K\D#HB+#CHPSM3TSJW2,,T*6U=!=VV?N)]*.UWB
M@: Q?$0W79GX&J"IH^VA6ITE!]YZ$.X?9>2^@D=%W>T5>/SR_L9(7M6M5:X7
MXNUR86)74N]]9/DN+_E\:1(FUH>G JYHEB50*P,%$8YBR)CD4&5QR"1)" V=
MS1+KT:>F*#; US[/+?A@C;^W_\1M;NSME4$8'\%R\45V+PO&F32/MHS]V*-;
M-<ZT[+-OW!]R9OKM^LD;=>CC%*LLP *2+&(0L5@K-Q)0B%'  A$2I#GJE4.[
M;[2I*3-3M*W<^+XVJCNU67/U[WKFQN[EVTYA>6-Q8 6U0=@&4O#;("7_K4CQ
MG7FZ=ZS+I(\>$_M@#NC1FWPG S2*[&GY5%IU<5ZMXD&4$H'"$!*2((@(#[02
MPJ8*#$$XB",IE'1KBN0=H\M'-T[_I%>-U5W;D_B?115K2SAC#%+*M)W,$P)Q
MA@A4DBB]?<8R)=QE*;GH'(ZQ_-0]',&K>;ST+-HM4!>=FS'V^Z=R0E[-VBK*
M69\Q[ 1L?C6$<3X8_X-GA/3%-Y$$D3/IM<\7.7<@]UCMUX(*O0WY\O+ EEH#
M*"11$A,H$I1"),(48AHP&"0Q1B*EJ0RM'*$[3YZ:%F[!@0:=??QUFZ[3$=?>
M) RL[BSE=XJI[I6U5Q1U^TFCQ4WW"K 9*=U_0=\$B0_Y7/[\5*=KQR)1(4LB
MB -%(5)$VU,,95"@F$:1"!(:IFY9$>N'3^W3:\/[!B!H$+JF/VP0=_H+/(>.
M@3]"!R9Z)#?LBGQ&1L/&PT9.8]@58S=W8<\U/8XK?BJ67$I1?M H]A["KYZ*
MQ:WZI*?_GI92K]5E+NHS,,N%N>=]J47[8R823I2($)0,ZQU1)A-(L0R@E"0+
M0RK3@"KK(XQ^,$U-!;S)E\9%L=1[YA= 30&#SHXN:H%,+N%C*Q+@FS(!\XH
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M&%4''!7SM28X?G$_??!1EJ64*QW^T9R^7J6OM[7>RW=/\C\E+;YJWN6,I)E
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M[1E1X0M]9ZJ4AVTCA^KHIWQ?EH\N6>_KFB]+]^6P+WYF##:9]? 83A' J9&
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M$N$3JG5F,@ UMIZ/<WHH%#F 2N,T316#BH6%"\Z.-3635(N:W"8[89-*VM#
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M'EX_I]:I\/K9:_OY1J]7W[\WA]/5N75Y][@I-[PB:Y\)G4')BP+PE#B^8(@
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M23.I>$HXA4&DO1YC3LU)NW2DT!M;/Z,2&;&!C<M6VJ0E[HT[E4\J@>.=S_2
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M>Y/L!*YP;8L<L\K>'Z!H5?4>0XY<1>\/PG'5?,"]O:K<U@^K-=_HCZN-=BW
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MB@!-[=^(H9*;G!J9D1Z;IQ%5F.C6:R?G"W1GZO$>#'S&-]"T_F7.^FK]DQ8
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M'JH=PI<-7V]&_\ <RAMBKYY+/9SI>J7OY\MJ"R_XPFV\7NR[\FQV,\-HAI
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M=^;=?&GW0G.^V#7F*$^E04O)[.:2(0!YF@)<9 *(E&F@#28I(012$U07$UO
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M5> <8$1RP"62 &.=,TQEQA$).T<_,]+TCM#K..2BRK%<-&(&5X*?P]7/!$3
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MZ]?A#I.#IAP.;SMNW?=S06BQ+#:%J(?5^U9?RJ6ZOM+#;?2+,A,LBB(08D@
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M_@ADK#;]A]R_8>O_[&TG.P 8<JI_###XN9$J;0U_U"5:;TM=$K%(%9OB*$H
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MB+W6M+UVV8.MV7^-*H>1D^&LJ&'L^&-%>Y_(M^[=RVH;NVZJF91AE'% 28(
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MKBCF_N,__ZW[B?I#)VG_Y[_]?U!+ P04    "  (@:E6C?<WF)&+  "#E@8
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M*1[ MV1D%R-N>4+-$#!P)'S'#,X(!XQB.\])0%R5UA[LY>K#X*.Y7])4R)V
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M-3<#Q_/)A.XIU2XP<>T9U\<O),;%N]-E[0-00_A1,<9H'15D[Q.=D]Z L[R
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MW_S<8:_W&JE[#U'UXP)<G7SOEE]P?F&R5"S,*(JPM!$D$S)>7N<,,=O"(NJ
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M48*+R@#ZF+5AI0ALW4#Q7D(&]L,'Q\>LM;+Z0]P?T_%R\>'C'VMFHBPJ"Q6
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MSW^I;MY*K5+=JV$% X5U6%,M5!59&13)<.M;&Z;O3S%Q25,;\=Y=5'<8KSM
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MY\JOR[#MDB1;>:)BIHN[%%!&,@BNOG/+8*TV3C'5VCO:X5C3OLRV!]A8$ND
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M 72 H[;+Z:PG(DVI2V,U*,\0?&8"<K$JL6A#S*W[ZY]_1<T@0(VZAW* =#M
M]OTKTV-&+5)=:+C=T96-)95/%%HFSH)'H?7=X6 '0[3#;?73X6*GO?9#A#1]
M[=8CN]=98(47K4'0Y](%4RHAAD(PD:*WI+I"[];.WN]>^\FAU%8*'1BNO1:I
M2TL.</ <DG(>5%W9&NHK-,]&1$1M?6J]I&^?<TZ;J9@<JT<3<0<P/KC:AX7L
M1$@:BI9T"_""$)!QD$4SE;'VX_+6H<SS+S(\*.8YID@[@/ #7;-EN5J',[SU
MK';]4!%,\(X8"2;'VOHC.7B3.1C'N$Q%1U]:/V?M<<Q>@O-CX&BW5NAF0NT
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M^U.*]BAHW?WW8*'RY3?J'S&L\?_^C_\/4$L#!!0    (  B!J5;%S!AV,P@
M )0H   8    8FYG;RTR,#(S,#,S,7AE>'@S,3$N:'1M[5IM;]LX$OY^OX+K
MX-H$\)OLO-II@#;)[@;8;;-!#L5].M 291&11"U)V?']^GN&E&([=B].7[9N
ML NL&XG#X0SGX3-#4J<_77PXO_WW]25+;):RZW^]^^WJG#5:G<['_GFG<W%[
MP7Z]_?TWMM_N!NQ6\]Q(*U7.TT[G\GV#-1)KBT&G,YU.V]-^6^EQY_:F0ZKV
M.ZE21K0C&S7.3ND-?@6/SOYQ^E.KQ2Y46&8BMRS4@EL1L=+(?,P^1L+<L5:K
MDCI7Q4S+<6)9K]OKLX]*W\D)]^U6VE2<U7I.._[YM.,&.1VI:'9V&LD)D]&;
MAN3'HA?$A]U1KQ?N'QSU^:C/CWNC;A2$87@P.OQ/ ",[$/=]C)VEXDTCDWDK
M$33^8+_7/CHH[' J(YL,@F[WGPTG>G8:J]QB/(W^_D^O9E49UV/HLZI =VBR
MXMZV>"K'^<"YV/"J:O%0I4H/=KKNOR&UM&*>R70V>'TK,V'8>S%E-RKC^>NF
M05A:1F@9>T$C_RO\(.YQ6KD /:G,1>U2T",G+N\3.9*6]8-VL.S!9K:'F'RA
MO[GQ1VN,]V9$(E2:$R@'91X)35*-L_/+F]NKGZ_.W]Y>?7B_J5_?*01737;3
M9I=:WK%?59I!H,E"H:V,9\PFW+[:.3@>;N+#(88K>!1A);52$=M!_[ .EL34
MY';0"HZ_FYM!N_;AKQ]]>5J";ON IN&*)7PBF!83*:;@()M(P_XHN0:BTQF[
M$872EJF<_:QTQH)NZP^F8O:.^"]7[!>1JTR&ILFN\K#=9)Q=B)1/N18,B"PJ
M4+)=FPCV:N>XU^L.M1A+8\&BUKT(AGN([<D+B&UOZV+[CAM$%/.?S=A=KJ:I
MB,:BZ4.L?6 C!1-RA1R$$;C,&<]GK,RM+@4\0%9R"0H1YRS#DY8\93$/\4HS
M1-XRJ[S<BD N0F$,US,2R?B=8 2"!YT&[R(8@R%3E]TP!@F$4B.;02Q'=^;8
MC$T3&2;,E/0S[S\50)E70@YDTJ1(>Y1!I](F<- 4(G0&DMX"IJD(;D[0+6*C
MV>(TO! $]G\<! H62S!(2'"9QQ0$DD,<S7JA7>8QN,<SB<S#M(R@$[A9"& 3
MF)/$5P7"3H@E)*?I')(5&LRCH8'ZR!5S39(H4P@ API@<<,99T_(3<+B5$U-
M#=(YAS%.+[W=L+*Y@#53&[-B[0N!V_[6P>UV*3:47X*CH:D 59431! JCB4>
M7=2N&&4KP@?B+4>IH#@R 5".4FD2$B>Q#.1(!$G/D31AJDSILARX4J4>*(56
MH8CPVK!=X"(2 )H/_N5]F/!\+-A;,-)-F4(BZ/-6<+ K]ES7X"#R3_Y14D&9
M>X"2?D:TM8!;CR.R9>.!XJ6!8@Q$?CY&,R2H'OC\<NNHMT4(E=N#4.R=^C0/
M%\)@RX!@N73V-)*:E&E#7IK-NU#*&PF@HAK))U%5:B@ -4VD<80'*9$[/51@
MSZERD6XUJCD'LRJ+SJ'2K*B8&B5H$[88E<K(;61-.3(RDEQ+<D#Z7.\20$Z:
M2D/YUZU*XY*UHT?LE&$0MK"N4X$*5(9ERHG5X98S8I['T<-7!8O%#/X:"1($
M\:*_B#Z?:+<+QMN#XY/VR>$JC#>FJQ4T;TYT&X,:"V$B(\(J-]BE$*-S YQ3
M14D YCJJP01X2SZ2J;0S2NWKAJ6EY7#G(.57Q9+H0D7J$L=]Y5!18O]C$ 4J
M14+LAB)G@*M-QR)'A9$"V6@1!2T9$D'=[=&+I24+</>+P>_V /BH'9S01%Q.
M>%HZLJ+HBCA&=2@GB(M94^4]5!(;D*]_7%_X.;RB(XC3^/)RI$K[:0LV20_\
M05I0[1P_O=MAH[HJ=TM0^)F /0YN-, +@-QDBQ!797X?S%50T):[JMI<RUKD
M/8,H*9NK,"PUA7XA=:[1FBEC\9X.,*'+A%#TIS_[\6<V:[K$P# H[)%T93BV
M2L*=%M!!0EX^V+7GK4JX>:@SB/P<YD7DLH*;CXJQ9RR5=R*MC@X>R3>_>(J^
M#.=;M0<[V!J8?]D>S!U"1O4*:<XIBAAS$:5SMB*</:/P6*E@7X-+4;]:I<U#
MEG<OH"S+I+5"K&8"=!HI5!#4$DG8Y+KO K^@7$.4CG^I?JX7G?BSE##9+; R
M#]VIPM[?VZMOM;UZFZ(B0X4H 2[:T-+6.)0":*A2\\,V9RKX'>5:7Z&Y;.MJ
M2W>R61\ /0MCU8[$'R>L83(>H:,1#T3V*1ZK*U)TT72Q@^7@$KY!MC=E!GA@
MEIPS50)9>U3VDI+Y]@"MWO^\1<Z.->BBB:@+QVW C3N'K@#6]"E/YA.53@3E
MO9R/J^-T7=&AR(I4S01:IXGR',B7X NX?96BH+T)"!Q]GUJW8ZI:1T"?T"W,
M=,H+(P;U'T-0=9'RV4#F;KY<IV&E:Z2L51FI&TZ([U$G5!>E#E"^N;I%/CEI
M'W6/Z"+9:OP?U0-7=\QM=\?<L=%JV_YQ^Z3[Z>9N._ADVU=2VW$F>[,Q,:;@
M^9M&OU%WJ' SZ!7W+%B^,"8H/9X;/RV+-^I_(<Z=QQ>T'7*IB3'V.Y^]V@D.
MN\.3IOOPX-'-?C4W_\?M+CG]:*IJF7K8"G&;ZWG^D%\[.M\C,*]V]K':W>_J
M+?EUTKZ8+^^G)^G'<)B0M^34$^&LB,I]Q5# 7CJ*9+6A/Y+K?\?WA_?N6J.0
MI*+)U6CGB10QN[P784G'.^R#W_<\(Z+?D-:P7K[=)#F- VDQ5+C!M.U>^W-/
MU"TKL[6W]''9YTQ9QY4H:PJ@1Q^W%<I_W3?P5Q\3L?*YVYQR7)G3G7?A(_!.
M:5>[//&%7/7KO]=S7PZ>_0]02P,$%     @ "(&I5@W,O[<V"   [R@  !@
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MOA;NOPEH[TD"FJ4 TDGA]Q"X8)A)]'Z@O;.&(!1AIJ&>"2JUF^N:#B<)@OE
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M>L,X$I8Q,^%@F4 ;<9FP 8^@IY.Q%@))]EA(!HMG3(V8A5MWF_ &S#43P9K
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M,2YH=&U02P$"% ,4    "  (@:E6L$RA4TP/  !:J@  $0
M@ %'QP( 8FYG;RTR,#(S,#,S,2YX<V102P$"% ,4    "  (@:E6\[0/#4TE
M  !GB@$ %0              @ '"U@( 8FYG;RTR,#(S,#,S,5]C86PN>&UL
M4$L! A0#%     @ "(&I5AX GY'U5@  :>X# !4              ( !0OP"
M &)N9V\M,C R,S S,S%?9&5F+GAM;%!+ 0(4 Q0    (  B!J5;;1&J1@>@
M  3D"0 5              "  6I3 P!B;F=O+3(P,C,P,S,Q7VQA8BYX;6Q0
M2P$"% ,4    "  (@:E6C?<WF)&+  "#E@8 %0              @ $>/ 0
M8FYG;RTR,#(S,#,S,5]P<F4N>&UL4$L! A0#%     @ "(&I5L7,&'8S"
ME"@  !@              ( !XL<$ &)N9V\M,C R,S S,S%X97AX,S$Q+FAT
M;5!+ 0(4 Q0    (  B!J58-S+^W-@@  .\H   8              "  4O0
M! !B;F=O+3(P,C,P,S,Q>&5X>#,Q,BYH=&U02P$"% ,4    "  (@:E6ZFS;
M1IT&  !$)   &               @ &WV 0 8FYG;RTR,#(S,#,S,7AE>'@S
M,C$N:'1M4$L! A0#%     @ "(&I5H/QI(L&$0  >6@  !X
M ( !BM\$ &5X:&EB:70Q,#%A;65N9&UE;G1N;S%T;W-A+FAT;5!+ 0(4 Q0
M   (  B!J5955\WEO0H  ()&   >              "  <SP! !E>&AI8FET
M,C%B;F=O+69I<G-T86UE;F1M92YH=&U02P4&      L "P#T @  Q?L$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
